

0000021665-25-00000810-K COLGATE PALMOLIVE CO 2025021320250213160447160450160450 0 0000021665-25-000008 10-K 134 20241231 20250213 20250213 COLGATE PALMOLIVE CO 0000021665 2844 131815595 DE 1231 10-K 34 001-00644 25620103 300 PARK AVE NEW YORK NY 10022 2123102000 300 PARK AVE NEW YORK NY 10022 10-K 1 cl-20241231.htm 10-K cl-2024123100000216652024FYfalsehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNethhttp://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNethhttp://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNethhttp://fasb.org/us-gaap/2024#NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponenthttp://fasb.org/us-gaap/2024#NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrentis04217:USDxbrii:sharesiso4217:USDxbrii:sharescl:dividendcl:segmentxbrii:purescl:countrycl:planccl:memberStatecl:countryAndTerritorycl:casecl:petitioncl 01-012024-12-310000021665us-gaap:CommonStockMember2024-01-012024-12-310000021665cl:A.500NotesDue2026Member2024-01-012024-12-310000021665cl:A0300NotesDue2029Member2024-01-012024-12-310000021665cl:A1.375NotesDue2034Member2024-01-012024-12-310000021665cl:A0.875NotesDue2039Member2024-01-012024-12-3100000216652024-06-3000000216652025-01-3100000216652024-10-012024-12-3100000216652023-01-012023-12-3100000216652022-01-012022-12-3100000216652024-12-3100000216652023-12-310000021665us-gaap:CommonStockMember2021-12-310000021665us-gaap:AdditionalPaidInCapitalMember2021-12-310000021665cl:UnearnedCompensationMember2021-12-310000021665us-gaap:TreasuryStockCommonMember2021-12-310000021665us-gaap:RetainedEarningsMember2021-12-310000021665us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000021665us-gaap:NoncontrollingInterestMember2021-12-310000021665us-gaap:RetainedEarningsMember2022-01-012022-12-310000021665us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000021665us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000021665us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000021665us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000021665us-gaap:CommonStockMember2022-12-310000021665us-gaap:AdditionalPaidInCapitalMember2022-12-310000021665cl:UnearnedCompensationMember2022-12-310000021665us-gaap:TreasuryStockCommonMember2022-12-310000021665us-gaap:RetainedEarningsMember2022-12-310000021665us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000021665us-gaap:NoncontrollingInterestMember2022-12-310000021665us-gaap:RetainedEarningsMember2023-01-012023-12-310000021665us-gaap:NoncontrollingInterestMember2023-01-012023-12-310000021665us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000021665us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000021665us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000021665cl:UnearnedCompensationMember2023-01-012023-12-310000021665us-gaap:CommonStockMember2023-12-310000021665us-gaap:AdditionalPaidInCapitalMember2023-12-310000021665cl:UnearnedCompensationMember2023-12-310000021665us-gaap:TreasuryStockCommonMember2023-12-310000021665us-gaap:RetainedEarningsMember2023-12-310000021665us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000021665us-gaap:NoncontrollingInterestMember2023-12-310000021665us-gaap:RetainedEarningsMember2024-01-012024-12-310000021665us-gaap:NoncontrollingInterestMember2024-01-012024-12-310000021665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000021665us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310000021665us-gaap:TreasuryStockCommonMember2024-01-012024-12-310000021665us-gaap:CommonStockMember2024-12-310000021665us-gaap:AdditionalPaidInCapitalMember2024-12-310000021665cl:UnearnedCompensationMember2024-12-310000021665us-gaap:TreasuryStockCommonMember2024-12-310000021665us-gaap:RetainedEarningsMember2024-12-310000021665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000021665us-gaap:NoncontrollingInterestMember2024-12-3100000216652022-12-3100000216652021-12-310000021665us-gaap:ProductConcentrationRiskMembercl:OralCareMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310000021665us-gaap:ProductConcentrationRiskMembercl:OralCareMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310000021665us-gaap:ProductConcentrationRiskMembercl:OralCareMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000021665us-gaap:ProductConcentrationRiskMembercl:PersonalCareMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310000021665us-gaap:ProductConcentrationRiskMembercl:PersonalCareMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310000021665us-gaap:ProductConcentrationRiskMembercl:PersonalCareMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000021665us-gaap:ProductConcentrationRiskMembercl:HomeCareMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310000021665us-gaap:ProductConcentrationRiskMembercl:HomeCareMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310000021665us-gaap:ProductConcentrationRiskMembercl:HomeCareMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000021665us-gaap:ProductConcentrationRiskMembercl:PetNutritionMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310000021665us-gaap:ProductConcentrationRiskMembercl:PetNutritionMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310000021665us-gaap:ProductConcentrationRiskMembercl:PetNutritionMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000021665us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000021665us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310000021665us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000021665us-gaap:ShippingAndHandlingMember2022-01-012022-12-310000021665srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000021665srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000021665srt:MaximumMemberus-gaap:BuildingMember2024-12-310000021665cl:LocalBrandsTrademarksCustomerRelationshipsAndNonCompeteAgreementsMembersrt:MinimumMember2024-12-310000021665cl:LocalBrandsTrademarksCustomerRelationshipsAndNonCompeteAgreementsMembersrt:MaximumMember2024-12-310000021665us-gaap:OneTimeTerminationBenefitsMembercl:GlobalGrowthandEfficiencyProgramMember2024-12-310000021665cl:IncrementalDepreciationMembercl:GlobalGrowthandEfficiencyProgramMember2024-12-310000021665us-gaap:AssetImpairmentMembercl:GlobalGrowthandEfficiencyProgramMember2024-12-310000021665us-gaap:OtherRestructuringMembercl:GlobalGrowthandEfficiencyProgramMember2024-12-310000021665cl:GlobalGrowthandEfficiencyProgramMember2024-12-310000021665us-gaap:OneTimeTerminationBenefitsMembercl:GlobalProductivityInitiativeMember2022-01-270000021665cl:AssetRelatedCostsMembercl:GlobalProductivityInitiativeMember2022-01-270000021665us-gaap:OtherRestructuringMembercl:GlobalProductivityInitiativeMember2022-01-270000021665cl:GlobalProductivityInitiativeMembersrt:MinimumMember2022-01-27000

[illegible]

[illegible]

culture is the commitment of all Colgate people to maintain the highest ethical standards and demonstrate ethical leadership, including compliance with Colgate policies and our Code of Conduct. We are committed to getting better every day in all that we do, as individuals and as teams. We seek to foster an inclusive and supportive workplace that promotes the growth and development of all employees, supported by a robust learning culture that aligns with our business needs. We are also committed to listening to our employees and seeing how the company is evolving and growing through regular employee engagement surveys. As a truly global company, with employees in over 100 countries, it is important that our employees reflect the communities in which we live and work. As of December 31, 2024, our global workforce was approximately 58% male and 42% female. Women represented approximately 46% of Colgate’s executives and 35% of senior leadership. In the U.S., approximately 33% of our employees self-identify as racial/ethnic minorities, approximately 45% of our executives self-identify as racial/ethnic minorities and approximately 39% of our senior leadership self-identify as racial/ethnic minorities. In this section, “executives” refers to those employees who are eligible to participate in Colgate’s equity incentive compensation plans and “senior leadership” refers to employees who are Senior Vice Presidents and above. Succession Planning We have a rigorous succession planning process, led by our Global Human Resources function. Our Board is also extensively involved in succession planning and people development, with special focus on CEO succession. As part of the succession planning process, we review and discuss potential successors to key positions and examine backgrounds, capabilities and appropriate developmental assignments. Compensation Philosophy Given the importance of Colgate people to our business success, motivating and retaining critical talent is a key focus. We view compensation as an important tool to motivate leaders at all levels of the organization. For information regarding our compensation philosophy and executive compensation programs, please see our Proxy Statement to be filed with the United States Securities and Exchange Commission (the “SEC”) in connection with the 2025 Annual Meeting of Stockholders. Sustainability and Social Impact Sustainability is critically important to our overall business and growth strategy. Our 2025 Sustainability & Social Impact Strategy is focused on three key ambitions - preserving our environment by accelerating action on climate change and reducing our environmental footprint; helping millions of homes by designing more sustainable products and empowering people to develop healthier habits; and driving social impact with a commitment to helping to ensure the wellbeing of all people and their pets. These ambitions are supported by actionable targets consistent with our continued commitment to building environmental and social consciousness into our decision-making. In 2024, we made progress on the targets set forth in our 2025 Sustainability & Social Impact Strategy. Reduce Plastic Waste: We continue to implement our first-of-its-kind recyclable toothpaste tube across our toothpaste portfolio. We introduced this tube in 2019 and, as of December 31, 2024, we have transitioned approximately 75% of our toothpaste SKUs globally and approximately 95% of our toothpaste SKUs in North America to recyclable tubes. We continue to share the tube technology with third parties and work to encourage recyclability of all tubes in practice and at scale. We are also focused on working with recycling stakeholders and partnering with key third parties to drive tube acceptance and communicating that consumers should check with their local recycling facilities to confirm tube acceptance. We also remain committed to reducing our use of new (virgin) plastic across our portfolio and continue to make progress toward our target to reduce new (virgin) plastic by one-third versus 2019. We are working towards this target with product design changes and by increasing recycled content in our packaging. Accelerate Action on Climate Change: We are taking steps to accelerate action on climate change through science-based near-term, long-term and Net Zero 2040 emissions targets across our operations and value chain, which have been approved by The Science Based Targets initiative. To support our target to become Net Zero carbon in our operations by 2040, we have built a global renewable energy master plan which includes roadmaps by division to cover our manufacturing facilities and owned warehouses, global technology centers and offices. Renewable energy agreements are a valuable part of this renewable energy master plan and are key contributors to achieving our target to have 100% renewable electricity by 2030. As part of these efforts, in 2023 and 2024, we signed long-term virtual power purchase agreements in the United States and Europe, respectively. Lead with Zero Waste Facilities: Our goal is to achieve TRUE certification for zero waste at 100% of our operations, which we define as our manufacturing facilities, owned and operated warehouses, global technology centers and strategic offices, by 2025. In 2024, eight more of our sites achieved TRUE certification. That brings the total number of TRUE certified sites to 44 across six continents in 26 countries, as of December 31, 2024. Social Impact: Colgate Bright Smiles, Bright Futures is our flagship oral health education and well-being initiative. Since the program was established in 1991, we have reached approximately 1.8 billion children and their families with oral health education. Through our Hill’s Food, Shelter & Love program, we have helped over 15 million shelter pets find forever homes since 2002. Additional information about our sustainability targets and efforts, including our 2023 Sustainability & Social Impact Report and our 2024 Climate Transition & Net Zero Action Plan can be found in the Sustainability section of our website at <https://www.colgatepalmolive.com/sustainability>. References to these reports and our website are for informational purposes only and neither the reports nor the other information on our website is incorporated by reference into this Annual Report on Form 10-K. Information about our Executive Officers The following is a list of our executive officers as of February 13, 2025: Name Age Date First Elected Executive Officer Present Title Noel Wallace 60 2009 Chairman of the Board, President and Chief Executive Officer Stanley J. Sutula III 59 2020 Chief Financial Officer Jennifer M. Daniels 61 2014 Chief Legal Officer and Secretary Prabha Parameswaran 66 2019 Group President, Growth and Strategy Panagiotis Tsourapas 60 2019 Group President, Europe and Developing Markets Sally Massey 51 2020 Chief Human Resources Officer Gregory O. Malcolm 57 2022 Executive Vice President, Controller Each of our executive officers listed above has served the Company or our subsidiaries in various executive capacities for the past five years with the exception of Stanley J. Sutula III, Chief Financial Officer. Prior to joining the Company, Mr. Sutula was Executive Vice President and Chief Financial Officer of Pitney Bowes Inc., which he joined in 2017. Under our By-Laws, our officers hold office until their respective successors are chosen and qualified or until they have resigned, retired or been removed by the affirmative vote of a majority of our Board. There are no family relationships between any of our executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was elected. Available Information Our website address is www.colgatepalmolive.com. The information contained on our website is not included as a part of, or incorporated by reference into, this Annual Report on Form 10-K. We make available, free of charge, on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, interactive data files posted pursuant to Rule 405 of Regulation S-T, Current Reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Also available on our website are the Company’s Code of Conduct and Board Guidelines on Significant Corporate Governance Issues, the charters of the Committees of the Board, Specialized Disclosure Reports on Form SD, reports under Section 16 of the Exchange Act of transactions in Company stock by directors and executive officers and our Proxy Statements. ITEM 1A. RISK FACTORS In addition to the risks described elsewhere in this report, set forth below is a summary of the material risks to an investment in our securities. These risks, some of which have occurred and/or are occurring and any of which could occur in the future, are not the only ones we face. Additional risks not presently known to us or that we currently deem immaterial may also have an adverse effect on us. If any of these risks actually occur, our business, results of operations, cash flows and financial condition could be materially and adversely impacted, which might cause the value of our securities to decline. Business and Industry Risks We face risks associated with significant international operations, including exposure to foreign currency fluctuations. We operate on a global basis serving consumers in more than 200 countries and territories with approximately two-thirds of our Net sales originating in markets outside the U.S. While geographic diversity helps to reduce our exposure to risks in any one country or part of the world, it also means that we face risks associated with significant international operations, including, but not limited to: changing macroeconomic conditions in our markets, including as a result of inflationary pressure, economic slowdown or recession, the war in Ukraine, the conflict in the Middle East, major developments in trade relations, volatile commodity prices and increases and/or volatility in the cost of raw and packaging materials, labor, energy and logistics; changes in exchange rates for foreign currencies, which may reduce the U.S. dollar value of revenues, profits and cash flows from non-U.S. markets or increase our supply costs, as measured in U.S. dollars, in those markets; political instability or uncertainty, including as a result of elections, economic instability, geopolitical events and tensions, wars and military conflicts, such as the war in Ukraine, the conflict in the Middle East and tensions between China and Taiwan; changes to trade policies and agreements and other foreign or domestic legal and regulatory requirements, including those resulting in potentially adverse tax consequences or the imposition of and/or the increase in trade restrictions and/or tariffs, sanctions, price controls, labor laws, travel or immigration restrictions, profit controls or other government controls, including as a result of the war in Ukraine, conflict in the Middle East and tensions between China and Taiwan; environmental events, widespread health emergencies, such as pandemics or epidemics, natural disasters or social or labor unrest; exchange controls and other limits on our ability to import or export raw materials or finished product, including as a result of the war in Ukraine and the conflict in the Middle East, or to repatriate earnings from overseas; lack of well-established, reliable and/or impartial legal systems in certain countries where we operate and difficulties in enforcing contractual, intellectual property or other legal rights; and foreign ownership and investment restrictions and the potential for nationalization or expropriation of property or other resources. Any or all of the foregoing risks could have a significant impact on our ability to sell our products on a competitive basis in international markets and may adversely affect our business, results of operations, cash flows and financial condition. In addition, a number of these risks may adversely impact consumer confidence and consumption, which could reduce sales volumes of our products or result in a shift in our product mix from higher margin to lower margin product offerings. We face risks resulting from political and macroeconomic instability and geopolitical events and tensions, such as the war in Ukraine, the conflict in the Middle East and tensions between China and Taiwan. These geopolitical conflicts and tensions may also heighten other risks disclosed in this Annual Report on Form 10-K, any of which could have an adverse impact on our business, results of operations, cash flows or financial condition. The war in Ukraine and the related geopolitical tensions have had and continue to have a significant impact on our operations in Ukraine and Russia, though it has not been material to our Consolidated Financial Statements. We have no manufacturing facilities in Russia. For the year ended December 31, 2024, our business in the Eurasia region constituted approximately 1% of our consolidated net sales and approximately 2% of our consolidated operating profit. We, however, have experienced, and expect to continue to experience, risks related to the impact of the war in Ukraine, including increases in the cost and, in certain cases, limitations on the availability of certain raw and packaging materials and commodities (including oil and natural gas), supply chain and logistics challenges, import restrictions, foreign currency volatility and reputational concerns. We also have faced and continue to face challenges to our ability to repatriate cash from Russia and to identify banking partners to support our Russian operations and may face challenges to our ability to protect our assets in Russia. We also continue to monitor the impact of the sanctions, export controls and import restrictions imposed generally and in response to the war in Ukraine. The conflict in the Middle East has not had a material impact on our Consolidated Financial Statements. Uncertainties and risks remain as to the duration of the conflict and its impact on geopolitical relations and stability in North Africa, the wider Middle East and nearby regions. The conflict has impacted and may continue to impact, among other things, supply chain and logistics, the availability and price of raw and packaging materials and commodities, such as oil, consumer sentiment and consumption and category growth rates in the region. Furthermore, the imposition of tariffs and/or increases in tariffs on various raw materials or products, or threats to impose or increase such tariffs, by the United States and other countries have introduced greater uncertainty with respect to trade policies and government regulations affecting trade between the United States and other countries and new and/or increased tariffs have subjected, and may continue in the future to subject, us to additional costs and expenditure of resources. Major developments in trade relations, including the imposition of new or increased tariffs by the United States and/or other countries, such as China, Mexico and Canada, including those imposed following the United States’ February 2025 executive orders, and any nationalistic trends in specific countries, have altered and could continue to alter the trade environment and consumer purchasing behavior which, in turn, could have a material effect on our business, results of operations, cash flows and financial condition. In an effort to minimize the impact on earnings of foreign currency rate movements, we engage in a combination of selling price increases, where permitted, sourcing strategies, cost containment measures and selective hedging of foreign currency transactions. However, the impact of these measures has not and may not in the future fully offset any negative impact of foreign currency rate movements on our business, results of operations, cash flows and financial condition. Significant competition in our industry could adversely affect our business. We face vigorous competition worldwide, including from strong local competitors (including private label competition) and from other large, multinational companies, some of which have greater resources than we do. In addition, the substantial growth in eCommerce has encouraged the entry of new competitors and business models. We face competition in several aspects of our business, including pricing, promotional activities, new product introductions and expansion into new geographies and channels. Some of our competitors may spend more aggressively on or have more effective advertising and promotional activities than we do, introduce competing products more quickly and/or respond more effectively to business and economic conditions and changing consumer preferences, including by launching innovative new products. Such competition also extends to administrative and legal challenges of product claims and advertising. Our success is and will likely increasingly be dependent on our ability to effectively leverage existing and emerging digital technologies, such as artificial intelligence and data analytics, to gain new commercial insights and develop relevant marketing and advertising to reach customers and consumers. Our ability to compete also depends on the strength of our brands and products and on our ability to enforce and defend our intellectual property, including patent, trademark, copyright, trade secret and trade dress rights, against infringement and legal challenges by competitors. We may be unable to anticipate the timing and scale of such initiatives or challenges by competitors or to successfully respond to them, which could harm our business and/or reputation. In addition, the cost of responding to such initiatives and challenges, including management time, out-of-pocket expenses and price reductions, may affect our performance. A failure to compete effectively could adversely affect our business, results of operations, cash flows and financial condition. Increasing dependence on key retailers in developed markets, changes in the policies of our retail trade customers, the emergence of alternative retail channels and the rapidly changing retail landscape and changing consumer preferences may adversely affect our business. Our products are sold in a highly competitive global marketplace which has experienced increased trade concentration and the growing presence of large-format retailers, discounters and eCommerce retailers. With the growing trend toward retail trade consolidation, the substantial growth of eCommerce and the integration of traditional and digital operations at key retailers, we are increasingly dependent on certain retailers, and some of these retailers have and may continue to have greater bargaining strength than we do. They have used and may continue to use this leverage to demand higher trade discounts, allowances, slotting fees, increased investment, including through display media, paid search and co-op programs, or changes to product assortments, which have led to and could continue to lead to reduced sales or profitability in certain markets. The loss of a key customer or distributor or a significant reduction in sales to a key customer or distributor could adversely affect our business, results of operations, cash flows and financial condition. For additional information regarding our customers, see “Distribution; Raw Materials; Competition; Trademarks and Patents” in Item 1 of our Business. We also have been and may continue to be negatively affected by changes in the policies or practices of our retail trade customers, such as inventory destocking, fulfillment requirements, technology-aided category pricing pressures, limitations on access to shelf space, delisting of our products, or sustainability, supply chain or packaging standards or initiatives. For example, a determination by a key retailer that any of our ingredients should not be used in certain consumer products or that our packaging does not comply with certain requirements and standards could adversely impact our business, results of operations, cash flows and financial condition. In addition, private label products sold by our retail customers, which are typically sold at lower prices than branded products, are a source of competition for certain of our products. Further, the retail landscape in many of our markets continues to evolve as a result of the substantial growth of eCommerce, changing consumer behaviors and preferences (as consumers increasingly shop online, including to compare prices and product availability) and the increased presence of alternative retail channels, such as subscription services and direct-to-customer businesses. The substantial growth in eCommerce and the emergence of alternative retail channels have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers. In addition, consumer preferences continue to evolve due to a number of factors, including evolving consumer concerns or perceptions (whether or not valid) regarding sustainability and social impact practices, including the sourcing and sustainability of raw and packaging materials, a demand for natural or organic products and ingredients and ingredient transparency, consumer concerns or perceptions regarding the effects of ingredients, consumer sentiment toward non-local products or sources and perceptions of and increased focus on labor and human rights and environmental impacts (including responsible sourcing, deforestation, packaging, plastic, energy and water use and waste management). If we are not successful in continuing to adapt or to effectively react to changes in consumer behaviors, preferences or purchasing patterns and/or changing market dynamics, including customer policies or the proliferation of eCommerce and alternative retail channels, our business, results of operations, cash flows and financial condition could be adversely affected. The growth of our business depends on the successful identification, development and launch of innovative new products. Our growth depends on the continued success of existing products, the successful identification,

development and launch of innovative new and differentiated products and the expansion into adjacent categories, channels of distribution or geographies. Our ability to launch new products, to sustain existing products and to expand into adjacent categories, channels of distribution or geographies is affected by whether we can successfully identify, develop and fund technological innovations; obtain and maintain necessary intellectual property protection and avoid infringing intellectual property rights of others; obtain approvals and registrations of regulated products, including from the FDA and other regulatory bodies in the U.S. and abroad; anticipate and quickly respond to the needs and preferences of consumers and customers. The identification, development and introduction of innovative new products that drive incremental sales involves considerable costs and effort, and any new product may not generate sufficient customer and consumer interest and sales to become a profitable product or to cover the costs of its development and promotion. Our ability to achieve a successful launch of a new product could also be adversely affected by preemptive actions taken by competitors in response to the launch, such as increased promotional activities and advertising. In addition, new products may not be accepted quickly or significantly in the marketplace. Our ability to quickly innovate to adapt and market our products and to adapt our packaging or the sustainability profile of our products to meet evolving consumer preferences and/or regulatory requirements is an essential part of our business strategy. The failure to develop and launch successful new products or to adapt our packaging, the sustainability profile of our products or supply chain to meet such preferences could hinder the growth of our business and any delay in the development or launch of a new product could result in us not being the first to market, which could compromise our competitive position and adversely affect our business, results of operations, cash flows and financial condition. In addition, our success in launching new products is also dependent on our ability to deliver effective and efficient marketing in an evolving media landscape (including digital), which is subject to dynamic and increasingly restrictive privacy requirements and emerging regulations. Our ability to launch new products, including our ability to deliver effective and efficient marketing campaigns, is also impacted by our ability to successfully adopt new technologies, such as artificial intelligence, including machine learning and generative artificial intelligence. If, in the course of identifying or developing new products, we are found to have infringed the trademark, trade secret, copyright, patent or other intellectual property rights of others, directly or indirectly, through the use of third-party ideas or technologies, such a finding could adversely affect our ability to develop innovative new products and adversely affect our business, results of operations, cash flows and financial condition. Even if we are not found to infringe a third party's intellectual property rights, claims of infringement could adversely affect us, including by increasing costs and by delaying the launch of new products. Damage to our reputation could have an adverse effect on our business. Maintaining our strong reputation with consumers and our trade partners globally is critical to selling our branded products. Accordingly, we devote significant time and resources to programs designed to protect and preserve our reputation, such as our ethics and compliance, sustainability and social impact, brand protection and product safety, regulatory and quality initiatives and our enterprise risk management program. Negative publicity about us, our brands, our products, our supply chain, our ingredients, our packaging, our sustainability and social impact practices, or our employees, whether or not deserved, could jeopardize our reputation. Such negative publicity could relate to, among other things, health or quality concerns, threatened or pending litigation or regulatory proceedings, animal welfare, labor and human rights and environmental impact (including responsible sourcing, deforestation, packaging, plastic, energy and water use and waste management) or our sustainability and social impact practices. In addition, the proliferation of digital and social media has greatly increased the accessibility of information, the speed of its dissemination and the potential for negative publicity and misinformation. Negative publicity, posts or comments on digital and social media, whether true or untrue, could damage our brands and our reputation. The success of our brands could also suffer if our marketing initiatives do not have the desired impact on a brand's image or its ability to attract consumers. In addition, the legal, regulatory and ethics landscape around the use of artificial intelligence, including machine learning and generative artificial intelligence, is rapidly evolving. Our ability to adapt and use this emerging technology in an effective and ethical manner may impact our reputation and our ability to compete, as outputs from generative artificial intelligence models could be, among other things, false, biased or inconsistent with our values or strategies. Further, the use of generative artificial intelligence tools may compromise our confidential or sensitive information or put our intellectual property at risk or subject us to claims of intellectual property infringement, which could in turn damage our reputation. 10 Additionally, due to the scale and scope of our business, we must rely on relationships with third parties, including our suppliers, distributors, contractors, joint venture partners and other external business partners, for certain functions. While we have policies and procedures for managing these relationships, they inherently involve a lesser degree of control over business operations, compliance and sustainability and social impact practices, thereby potentially increasing our reputational and legal risk. We have taken and in the future may take certain actions to safeguard our reputation and uphold our ethical values, such as changes to how and where we sell, advertise and invest behind our products and operations, which could adversely affect our business, results of operations, cash flows and financial condition. In addition, third parties sell counterfeit versions of our products, which are inferior or may pose safety risks. As a result, consumers of our brands could confuse our products with these counterfeit products, which could cause them to refrain from purchasing our brands in the future and in turn could impair our brand equity and adversely affect our business, results of operations, cash flows and financial condition. Damage to our reputation or loss of consumer confidence in our products for these or any other reasons could adversely affect our business, results of operations, cash flows and financial condition, as well as require resources to rebuild our reputation. We face various risks related to pandemics, epidemics or other widespread public health concerns, which may have a material adverse effect on our business, results of operations, cash flows and financial condition. We face various risks related to pandemics, epidemics or other widespread public health concerns. A pandemic, epidemic or other widespread health concern could have, and COVID-19 has had a variety of impacts on our business, results of operations, cash flows and financial condition, including: our ability to continue to maintain and support the health, safety and well-being of our employees, including key employees; disruptions to our global supply chain, including transportation and logistics challenges; a decrease in our workforce or in the efficiency of such workforce; volatility in the demand for and availability of our products; changes in purchasing patterns of our consumers; significant volatility in demand for certain of our products, which may require us to increase our production capacity or acquire additional capacity at an additional cost and expense; failure of third parties on which we rely to meet their obligations to us, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties; significant changes in the economic and political conditions of the markets in which we operate; disruptions and volatility in the global capital markets, including rising interest rates, which may increase the cost of capital and adversely impact our access to capital; and/or volatility in foreign exchange rates and increases in the cost and availability of raw and packaging materials and transportation and logistics costs. 11 Our success depends upon our ability to recruit, attract and retain key employees and the succession of senior management. Our success largely depends on the performance of our management team and other key employees. If we are unable to recruit, attract and retain talented, highly qualified senior management and other key people, our business, results of operations, cash flows and financial condition could be adversely affected. Successfully executing organizational change, including management transitions at leadership levels of the Company and succession plans for senior management, is critical to our business success. While we follow a disciplined, ongoing succession planning process and have succession plans in place for senior management and other key executives, these do not guarantee that the services of qualified senior executives will continue to be available to us at particular moments in time. Further, changes in immigration laws and government policies have made, in certain circumstances, and may continue to make it more difficult for us to recruit or relocate highly skilled technical, professional and management personnel to meet our business needs. Our ability to attract and retain talent has been and may continue to be impacted by a number of factors, including challenges in the labor market. We continue to embed new ways of working to, among other things, instill a growth mindset to drive innovation. If we do not (or are perceived not to) successfully implement these initiatives, our ability to recruit, attract and retain talent may be adversely impacted. We have pursued and may continue to pursue acquisitions and divestitures, which could adversely impact our business. We have pursued and may continue to pursue acquisitions of brands, businesses, assets or technologies from third parties. Acquisitions and their pursuit have involved, and can involve, numerous potential risks, including, among other things: realizing the full extent of the expected benefits or synergies as a result of a transaction, within the anticipated time frame, or at all; successfully integrating the operations, technologies, services, products and systems of the acquired brands, assets or businesses in an effective, timely and cost-efficient manner; receiving necessary consents, clearances and approvals in connection with a transaction; diverting management's attention from other business priorities; successfully creating in new lines of business, channels of distribution or markets; achieving distribution expansion related to products, categories and markets; retaining key employees, partners, suppliers and customers of the acquired business; conforming standards, controls, procedures and policies of the acquired business with our own; developing or launching products with acquired technologies; and/or other unanticipated problems or liabilities. Moreover, acquisitions have resulted in and could in the future result in substantial additional debt, the assumption of contingent liabilities, such as litigation or earn-out obligations, or transaction costs. In addition, to the extent that the economic benefits associated with an acquisition or investment diminish in the future or the performance of an acquired company or business is less robust than expected, we may be required to record additional impairments of intangible assets, including trademarks and goodwill. Any of these risks could adversely impact our reputation and our business, results of operations, cash flows and financial condition. We have divested and may in the future periodically divest brands or businesses. These divestitures may adversely impact our business, results of operations, cash flows and financial condition if we are unable to offset the dilutive impacts from the loss of revenue associated with the divested brands or businesses, or otherwise achieve the anticipated benefits or 12 cost savings from the divestitures. In addition, businesses under consideration for, or otherwise subject to, divestiture may be adversely impacted prior to the divestiture, which could negatively impact our business, results of operations, cash flows and financial condition. If any planned divestiture is not able to be completed, we may also incur negative business and financial results. Operational Risks Our business results are impacted by our ability to manage disruptions in our global supply chain and/or key office facilities. We are engaged in the manufacture and sourcing of products and materials on a global scale. Our operations and those of our suppliers, contract manufacturers or logistics providers have been and may continue to be disrupted by a number of factors, including, but not limited to: geopolitical events, wars and military conflicts, such as the war in Ukraine and the conflict in Middle East; widespread health emergencies, such as pandemics or epidemics; strikes and other labor disputes; disruptions in logistics; loss or impairment of key manufacturing or distribution sites; loss of key suppliers or contract manufacturers; capacity constraints; raw material and product availability and/or quality or safety issues; industrial accidents or other occupational health and safety issues; the impact on our suppliers of tighter credit or capital markets; the lack of availability of qualified personnel, such as truck drivers and production labor; governmental incentives, regulations and controls (including import and export restrictions, such as new or increased tariffs, sanctions, quotas or trade barriers); and natural disasters, including climatic events (including any potential effects of climate change) and earthquakes, tornadoes, acts of war or terrorism, political unrest or uncertainty, fires or explosions, cybersecurity incidents and other external factors over which we have no control. In addition, we purchase certain key raw and packaging materials from single-source suppliers or a limited number of suppliers and new suppliers may have to be qualified under industry, governmental and/or Colgate standards, which can require additional investment and take a significant period of time. If our existing or new suppliers fail to meet such standards or if we are unable to contract with suppliers on favorable terms, our business, results of operations, cash flows and financial condition could be adversely affected. We believe that the supplies of raw and packaging materials needed to manufacture our products are adequate. In addition, we have business continuity and contingency plans in place for key manufacturing sites and contract manufacturers and the supply of raw and packaging materials. Nonetheless, a significant disruption to the manufacturing or sourcing of products or materials for any reason, including those mentioned above, have at times interrupted and could in the future interrupt product supply and, if not remedied, could have an adverse impact on our business, results of operations, cash flows and financial condition. 13 In addition, as a result of our global shared service organizational model, certain of our functions, such as finance and accounting, customer service and logistics, human resources, global information technology and data analytics are concentrated in key office facilities. A significant disruption to any of our key office facilities for any reason, including those mentioned above, could adversely affect our business, results of operations, cash flows and financial condition. Volatility in material and other costs has in the past and may continue to adversely impact our profitability. Raw and packaging material commodities, such as resins, essential oils, tropical oils, pulp, tallow, corn, poultry and soybeans, are subject to market price variations. Increases in the costs of and/or a reduction in the availability of commodities, energy (including fuel prices), logistics (including trucks and containers) or other necessary services, including as a result of geopolitical conflicts, such as the war in Ukraine and the conflict in the Middle East, and/or the impact of climatic events have affected and are likely to continue to adversely affect our profit margins. While the prices of many commodities and services have retreated from their historical peaks, prices may increase again, which could create year-over-year inflationary pressure. We have taken and may continue to take actions to mitigate these cost increases in the form of price increases and efforts to achieve cost efficiencies in areas such as manufacturing and distribution, or otherwise manage the exposure through sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts. These actions may not, however, fully offset these higher costs and our business, results of operations, cash flows and financial condition have been and may continue to be adversely impacted. In addition, even if we are able to increase the prices of our products in response to commodity and other cost increases, we may not be able to sustain the price increases. If such price increases are sustained, they may negatively impact our sales volume, which can in turn negatively impact our margins and profitability. If competitors do not adjust their prices or if consumers decide not to pay higher prices and forego purchasing certain of our products or switch to a lower-priced product offerings, sales declines, a deterioration in our profitability and loss of market share may occur which could adversely affect our business, results of operations, cash flows and financial condition. See our Business results are impacted by our ability to manage disruptions in our global supply chain and/or key office facilities above for additional information. There is no guarantee that our ongoing efforts to reduce costs will be successful. One way that we generate funds needed to support the growth of our business is through our continuous, Company-wide initiatives to lower costs and increase effective asset utilization, which we refer to as our funding-the-growth initiatives. These initiatives are designed to reduce costs associated with direct materials, indirect expenses, distribution and logistics, and advertising and promotional materials, among other things. The achievement of our funding-the-growth goals depends on our ability to successfully identify and realize additional savings opportunities. Events and circumstances, such as financial or strategic difficulties, delays and unexpected costs may occur that could result in our not realizing any or all of the anticipated benefits or our not realizing the anticipated benefits on our expected timetable. If we are unable to realize the anticipated savings of our funding-the-growth initiatives, our ability to fund other initiatives and achieve our profitability goals may be adversely affected. Any failure to implement our funding-the-growth initiatives in accordance with our expectations could adversely affect our business, results of operations, cash flows and financial condition. For additional information regarding our funding-the-growth initiatives, refer to Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" Executive Overview. A cybersecurity incident, data breach or a failure of key technology systems could adversely impact our business. We rely extensively on information and operational technology systems ("IT/OT Systems"), some of which are managed, hosted, provided and/or used by third parties, including cloud-based service providers, and their vendors, in order to conduct our business. Our uses of these systems include, but are not limited to: communicating within our company and with other parties, including our customers, suppliers and consumers; ordering and managing materials from suppliers; converting materials to finished products; receiving and processing orders from, shipping products to and invoicing our customers, suppliers and consumers; marketing products to consumers; 14 collecting, storing, transferring and/or processing customer, consumer, employee, vendor, investor and other stakeholder information and personal data, including, but not limited to, such data from residents of states, countries and regions with comprehensive data protection laws and regulations; processing transactions, including but not limited to employee payroll, employee and retiree benefits and payments to customers, suppliers and vendors; hosting, processing and sharing confidential and proprietary research, intellectual property, business plans and financial information; summarizing and reporting results of operations, including financial reporting; managing our banking and other cash liquidity systems and platforms; complying with legal, regulatory and tax requirements; providing data security; and handling other processes involved in managing our business. Although we have a broad array of information and operational security measures in place, our IT/OT Systems, including those of third-party service providers with whom we have contracted, have been, and will likely continue to be, subject to computer viruses or other malicious codes, unauthorized access attempts, phishing and other cyberattacks. Cyberattacks and other cyber incidents are occurring more frequently, are constantly evolving in nature, are becoming more sophisticated and are being made by different threat actors including groups, individuals and nation states with a wide range of expertise and motives. Such cyberattacks and cyber incidents can take many forms, including cyber extortion, social engineering, password theft or introduction of viruses or malware, such as ransomware. In addition, the techniques used in cyberattacks and cyber incidents continue to evolve and develop, including through the use of existing and emerging technologies, such

as artificial intelligence. We cannot guarantee that our security efforts will prevent breaches or breakdowns of our or our third-party service providers’ IT/OT Systems because the techniques used in these attacks change frequently and may be difficult to detect for periods of time. In addition, although we have policies and procedures in place to ensure that all personal information collected by us or our third-party service providers is securely maintained, data leakages due to human error or intentional or unintentional conduct have occurred and likely will occur again. Furthermore, we periodically upgrade our IT/OT Systems or adopt new technologies. If such an upgrade or new technology does not function as designed or does not go as planned or if an attacker identifies a vulnerability in our IT/OT Systems, then our exposure to a cyberattack or cyber incident may increase significantly. A cyberattack or cyber incident may adversely impact our business, including our ability to ship products to customers, issue invoices and process payments or order raw and packaging materials. Although we have seen no material impact on our business operations from the cybersecurity incidents we have experienced to date, if we suffer a significant loss or disclosure of confidential business or stakeholder information as a result of a breach of our IT/OT Systems, including those of third-party service providers with whom we have contracted, or otherwise, we may suffer reputational, competitive and/or business harm, incur significant costs and be subject to government investigations, litigation, fines and/or damages, which may adversely impact our business, results of operations, cash flows and financial condition. In addition, the rapid evolution and increased adoption of existing and emerging technologies, such as artificial intelligence, may intensify our cybersecurity risks. Further, while we currently maintain insurance coverage that, subject to its terms and conditions, is intended to address costs associated with certain aspects of cybersecurity incidents and IT/OT System failures, this insurance coverage may not, depending on the specific facts and circumstances surrounding an incident, cover all losses or all types of claims that arise from an incident, or the damage to our business, reputation or brands that may result from an incident. As the frequency and magnitude of cybersecurity incidents increase globally, we may be unable to obtain the insurance coverage that we think is appropriate or necessary to offset the risk. While we have disaster recovery and business continuity plans in place, if our IT/OT Systems are damaged, breached or cease to function properly for any reason, including the poor performance of, failure of or cyberattack on third-party 15service providers, catastrophic events, power outages, cybersecurity breaches, network outages, failed upgrades or other similar events and, if the disaster recovery and business continuity plans do not effectively resolve such issues on a timely basis, we may suffer interruptions in our ability to manage or conduct business as well as reputational harm, and may be subject to governmental investigations and litigation, any of which may adversely impact our business, results of operations, cash flows and financial condition. Climate change and other sustainability matters could have an adverse impact on our business and results of operations. Climate change resulting in the increased frequency and severity of natural disasters and other extreme weather conditions may adversely impact our business, results of operations, cash flows and financial condition. Specifically, the predicted physical effects of climate change may exacerbate challenges regarding the availability and quality of water and the cost, quality and availability of raw and packaging materials, pose physical risks to our facilities and those of our key suppliers, disrupt our global supply chain or impact demand for our products. In addition, the increased concern over climate change has resulted and is likely to continue to result in transition risks, including additional legal and regulatory requirements intended to, among other things, reduce or mitigate the effects of climate change and have related and may relate to, among other things, greenhouse gas emissions (e.g., carbon pricing), alternative energy policy and additional disclosure obligations, such as the Corporate Sustainability Reporting Directive, and extended producer responsibility obligations that relate to our product packaging. Such additional regulations may adversely affect our business, results of operations, cash flows and financial condition by increasing our compliance and manufacturing costs and/or negatively impacting our reputation if we are unable to, or are perceived (whether or not valid) not to, satisfy such requirements or expectations. Achieving our sustainability and social impact targets will require significant efforts from us and our stakeholders, such as our suppliers and other third parties. It will also require capital investment, additional expense (e.g., renewable energy costs) and the development of technology that may not currently exist. Failure to achieve our sustainability and social impact targets or the perception (whether or not valid) that we have failed to act responsibly with respect to such matters or to effectively respond to new or additional legal or regulatory requirements regarding climate change or other sustainability matters, could result in adverse publicity and increased litigation risk and adversely affect our business and reputation. There is also increased focus, including by governmental and non-governmental organizations, investors, customers, consumers, regulators, our employees and other stakeholders on these and other sustainability and social impact matters, including responsible sourcing, deforestation, animal welfare, labor, employment and human rights, the use of plastic, energy and water, the recyclability or recoverability of packaging, including single-use and other plastic packaging. From many of these stakeholders, there is also a growing demand for natural or organic products and ingredient transparency, such as sources of palm oil and palm kernel oil, and an increased focus on reducing our impact on nature. Our reputation could be damaged if we do not (or are perceived not to) act responsibly with respect to sustainability matters, which could adversely affect our business, results of operations, cash flows and financial condition. Our reliance on third parties in many aspects of our business could have an adverse effect on our business and results of operations. We use third parties including, but not limited to, suppliers, contract manufacturers, distributors, commercial banks and other external business partners, to support many aspects of our business including those that provide support across much of the lifespan of our products from the purchasing of ingredients up to and including the sale of our products to consumers. While we maintain robust policies and procedures to govern and manage our interactions with and requirements of these third parties, including building in redundancies and alternatives wherever possible, we inherently have a lesser degree of control over the business operations, governance and compliance of these unrelated entities. As a result, disruptions in these relationships or the failure of these third parties to meet their obligations to us could have an adverse effect on our reputation and our business, results of operations, cash flows and financial condition. Legal and Regulatory Risks Our business is subject to legal and regulatory risks in the U.S. and abroad. Our business is subject to extensive legal and regulatory requirements in the U.S. and abroad. Such legal and regulatory requirements apply to most aspects of our products, including their development, ingredients, formulation, manufacture, packaging, labeling, storage, transportation, distribution, export, import, advertising, sale and environmental impact. U.S. federal authorities, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission, the Consumer Product Safety Commission, the Occupational Safety and Health Administration and the Environmental Protection Agency, regulate different aspects of our business, along with parallel authorities at the state and local levels and comparable authorities overseas. In addition, our selling practices are regulated by competition law authorities in the U.S. and abroad. New or more stringent legal or regulatory requirements, or more restrictive interpretations of existing requirements, could adversely impact our business, results of operations, cash flows and financial condition. For example, from time to time, various regulatory authorities around the world review the use of various ingredients and packaging content in consumer products. While we monitor and seek to mitigate the impact of any emerging information, a decision by a regulatory or governmental authority that any ingredient or packaging content in our products should be restricted or should otherwise be newly regulated could adversely impact our business and reputation, as could negative reactions by our consumers, trade customers or non-governmental organizations to our current or prior use of such ingredients or packaging. Additionally, an inability to develop new or reformulated products containing alternative ingredients, to obtain regulatory approval of such products or ingredients on a timely basis or to effectively market and sell such products could likewise adversely affect our business. Because of our extensive international operations, we could be adversely affected by violations of worldwide anti-bribery laws, including those that prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business, such as the U.S. Foreign Corrupt Practices Act, and laws that prohibit commercial bribery. We are also subject to laws and sanctions imposed by the U.S. (including, without limitation, those imposed by OFAC) and/or by other jurisdictions that may prohibit us or certain of our affiliates from doing business in certain countries, or restrict the kind of business that may be conducted. While our policies mandate compliance with these laws, we cannot provide assurance that our internal control policies and procedures will always protect us from reckless or criminal acts committed by our employees, joint venture partners or agents. Violations of these laws, or allegations of such violations, could disrupt our business and adversely affect our reputation and our business, results of operations, cash flows and financial condition. While it is our policy and practice to comply with all legal and regulatory requirements applicable to our business, findings that we are in violation of, or out of compliance with, applicable laws or regulations have subjected us to, and could subject us to, civil remedies, including fines, damages, injunctions or product recalls, or criminal sanctions, any of which could adversely affect our business, results of operations, cash flows and financial condition. Even if a claim is unsuccessful, is without merit or is not fully pursued, the cost of responding to such a claim, including management time and out-of-pocket expenses, and the negative publicity surrounding such assertions regarding our products, processes or business practices could adversely affect our reputation, brand image and our business, results of operations, cash flows and financial condition. For information regarding our legal and regulatory matters, see Item 3 Legal Proceedings and Note 12, Commitments and Contingencies to the Consolidated Financial Statements. Legal claims and proceedings could adversely impact our business. As a global company serving consumers in more than 200 countries and territories, we are and may continue to be subject to a wide variety of legal claims and proceedings, including disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. Regardless of their merit, these claims can require significant time and expense to investigate and defend. Since litigation is inherently uncertain, there is no guarantee that we will be successful in defending ourselves against such claims or proceedings, or that our assessment of the materiality of these matters, including any reserves taken in connection therewith, will be consistent with the ultimate outcome of such matters. In addition, if one of our products, or an ingredient contained in our products, is perceived or found to be defective, or unsafe or have a quality issue, we have had to and may in the future need to withdraw, recall or reformulate some of our products. Whether or not a legal claim or proceeding is successful, or a withdrawal, recall or reformulation is required or advisable, such assertions could have an adverse effect on our business, results of operations, cash flows and financial condition, and the negative publicity surrounding them could harm our reputation and brand image. The resolution of, or increase in the reserves taken in connection with, one or more of these matters in any reporting period could have a material adverse effect on our business, results of operations, cash flows and financial condition for that period. See Item 3 Legal Proceedings and Note 12, Commitments and Contingencies to the Consolidated Financial Statements for additional information on certain of our legal claims and proceedings. 17 Financial and Economic Risks Uncertain or unfavorable global economic conditions may adversely affect our business. Uncertain or unfavorable global economic conditions could adversely affect our business. Unfavorable global economic conditions, such as a recession, an economic slowdown, inflation, higher interest rates and/or reduced category growth rates, including as a result of the war in Ukraine and the conflict in the Middle East, have negatively impacted and/or could negatively impact our business and result in declining revenues, profitability and/or cash flows. Although we continue to devote significant resources to support our brands and market our products at multiple price points, during periods of economic uncertainty or unfavorable economic conditions, consumers may have less consumer confidence, reduce consumption or discretionary spending and/or change their purchasing patterns by foregoing purchasing certain of our products or by switching to “private label” or lower-priced product offerings. These changes could reduce demand for our products or result in a shift in our product mix, as consumers may choose products that sell at lower prices. Additionally, our retailers may be impacted and they may increase pressure on our selling prices or increase promotional activity for lower-priced or value offerings as they seek to maintain sales volumes and margins. Furthermore, economic conditions can cause our customers, suppliers, distributors, contract manufacturers, logistics providers or other third-party partners to suffer financial or operational difficulties, which may impact their ability to buy our products or provide us with or distribute finished product, raw and packaging materials and/or services in a timely manner or at all. In addition, we could face difficulty collecting or recovering accounts receivables from third parties facing financial or operational difficulties, including bankruptcies. Disruptions in the credit markets or changes to our credit ratings may adversely affect our business. While we currently generate significant cash flows from ongoing operations and have access to global credit markets through our various financing activities, a disruption or volatility in the credit markets, interest rate increases or changes to our credit rating could negatively impact the availability or further increase the cost of funding. Reduced access to credit or increased costs could adversely affect our liquidity and capital resources or significantly increase our cost of capital. In addition, if any financial institutions that hold our cash or other investments or that are parties to our undrawn revolving credit facility supporting our commercial paper programs or other financing arrangements, such as interest rate, foreign exchange or commodity hedging instruments, were to declare bankruptcy or become insolvent, they may be unable to perform under their agreements with us. This could leave us with reduced borrowing capacity or unhedged against certain interest rate, foreign currency or commodity price exposures. In addition, tighter or more volatile credit markets may lead to business disruptions for certain of our suppliers, contract manufacturers or trade customers which could, in turn, adversely impact our business, results of operations, cash flows and financial condition. Tax matters, including changes in tax rates, disagreements with taxing authorities and imposition of new taxes could negatively impact our business. We are subject to taxes in the U.S. and in the foreign jurisdictions where we do business. Due to economic and political conditions, tax rates in the U.S. and various foreign jurisdictions have been and may be subject to significant change. Changes in the mix of our earnings between countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities related to changes in tax rates, changes in tax laws, including how existing tax laws are interpreted or enforced, or contemplated changes in long-standing tax principles, if finalized and adopted, could adversely impact our future effective tax rate and business, results of operations, cash flows and financial condition. For example, long-standing international tax norms that determine each country’s jurisdiction to tax cross-border international trade are evolving as a result of a multilateral project, the Base Erosion and Profit Shifting Project (the “BEPS Project”), that has established new principles and reporting requirements recommended by the member countries of the Organization for Economic Cooperation and Development (the “OECD”). In connection with the BEPS Project, companies are required to disclose more information to tax authorities and the public on operations around the world, which may lead to greater audit scrutiny of profits earned in countries outside of the U.S. Many jurisdictions have already enacted legislation and adopted policies resulting from the BEPS Project. The OECD is also addressing the challenges of the digitization of the global economy with plans to redefine jurisdictional taxation rights in market countries and establish a global minimum tax. The European Union has established the Minimum Tax Directive (the “Pillar II”) that provides for a minimum level of taxation for certain large corporations in every jurisdiction in which they operate. In addition, many other jurisdictions outside of the European Union have also implemented a similar minimum tax regime consistent with the policy of Pillar II. Detailed 18 regulations of these minimum tax regimes are still being considered in certain countries. Other than significant additional time and resources to comply, based on our preliminary evaluation, Pillar II did not have a material impact as of December 31, 2024 and we do not believe it will have a material impact on our business, results of operations, cash flows and financial condition. However, as these and other tax laws and related regulations change, our business, results of operations, cash flows and financial condition could be materially impacted. For more information regarding recent legislation, refer to Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations - Income Taxes.” Furthermore, we are seeing an increase in regular reviews, examinations and audits by the Internal Revenue Service and increasingly aggressive enforcement actions by other taxing authorities with respect to taxes outside of the U.S. Although we believe our tax positions are sustainable, when a taxing authority disagrees with the positions we have taken, we have faced and in the future may face additional tax liabilities, including interest and penalties, in excess of reserves. The payment of such additional amounts upon final adjudication of any disputes could adversely impact our business, results of operations, cash flows and financial condition. 19 ITEM 1B. A. A. A. UNRESOLVED STAFF COMMENTS None. 20 ITEM 1C. A. A. A. CYBERSECURITY Management’s Role in Assessing and Managing Cybersecurity Risk; Processes for assessing, identifying and managing material risks from cybersecurity threats We have a systematic and thorough risk management process, which is designed to identify, assess, prioritize and mitigate the risks that could negatively impact achievement of our strategic and operating objectives. A key component of this process is our Enterprise Risk Management (the “ERM”) Committee, which is led by our Chairman, President and Chief Executive Officer, and includes our Chief Financial Officer, Chief Legal Officer, Chief Information Officer and other members of senior management. The ERM Committee monitors both current and emerging risks facing the Company and meets at least quarterly to review the prioritization of identified risks. The ERM Committee has identified cybersecurity as a critical risk facing the Company. Each of the most critical risks identified is assigned to a member of senior management who oversees the management, mitigation and presentation of the risk to the senior leadership team and throughout the year to our Board of Directors. The risks relating to information technology, including cybersecurity, are overseen by our Chief Information Officer. Our Chief Information Officer then assigns the risks within the Information Technology risk category to others on his team. The cybersecurity risk is managed and overseen by our Chief Information Security Officer (the “CISO”), who reports to our Chief Information Officer. Cybersecurity as a risk is presented to the full ERM Committee annually or more frequently as needed. We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is

possible for assessing and managing material risks to our business.

As of December 31, 2024, we have approximately 22 information security professionals, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company's systems and information. Our Chief Information Officer joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy. The Company's information security organization seeks to employ cybersecurity best practices, including implementing new technologies to proactively identify and monitor new vulnerabilities and reduce risk, conducting due diligence of third-party vendors' information security programs, maintaining security policies and standards and regularly updating and testing our response planning and protocols. The information security organization also works in partnership with our Internal Audit function to identify cybersecurity risks and review cybersecurity-related internal controls with third parties as part of the overall internal controls process. The information security organization also gains valuable information to improve our threat and risk awareness capabilities as a member of an industry information sharing and analysis organization, which provides strategic and tactical information sharing channels. Additionally, employees are provided mandatory cybersecurity awareness training on an annual basis, which includes information about how to identify and report cybersecurity concerns and incidents. The information security organization also conducts phishing simulations and testing scenarios through tabletop exercises and assessment activities, to help ensure compliance with our cyber policies and procedures. We maintain a cybersecurity insurance policy and have retained relevant incident response services. Additionally, we maintain an offensive security team that 21works both independently and with third party cybersecurity professionals to conduct security assessments of our enterprise-wide cybersecurity practices, including penetration testing, and identify areas for continuous improvement within the information security program. The Company is a member of the Retail and Hospitality Information Sharing and Analysis Center, which provides additional intelligence associated with threats pertaining to our industry. We maintain a Data Security Incident Response Plan (the "DSIRP"), which outlines the processes and procedures that we should follow to respond to, remediate and resolve a security incident involving a potential or actual compromise of our proprietary information and/or personal information. It also describes the structure, roles and responsibilities of personnel involved in responding to such incidents and provides a process for alerting senior management of such incidents. The Plan is reviewed on an annual basis and revised as necessary. Our dedicated information security organization leverages various frameworks for managing cybersecurity risks, including the National Institute of Standards and Technology ("NIST") framework. The key pillars of the NIST framework are to (i) develop an organizational understanding to manage cybersecurity risk to systems, people, assets, data and capabilities; (ii) develop and implement appropriate safeguards to ensure delivery of critical services; (iii) develop and implement appropriate activities to identify the occurrence of a cybersecurity event; (iv) develop and implement appropriate activities to maintain plans for resilience and to restore any capabilities or services that were impaired due to a cybersecurity incident; and (v) develop appropriate activities to action an incident. We have a comprehensive third party cybersecurity risk review process, which prioritizes, monitors and assesses the risks associated with our third party service provider interactions. The third party service provider assessment framework follows industry standard practices and allows us to properly understand the risk associated with the services provided which are key to our company's daily operations. For additional information regarding risks faced by the Company from cybersecurity threats, see Item 1A, "Risk Factors - A cybersecurity incident, data breach or a failure of key technology systems could adversely impact our business." Board's Oversight of Cybersecurity RisksOur Board of Directors is focused on cybersecurity. Specific responsibility for cybersecurity oversight is delegated to the Audit Committee. The Board oversees our risk management process to ensure it is properly designed, well-functioning and consistent with our overall corporate strategy. Our Audit Committee oversees the ERM process and the implementation of appropriate risk monitoring and management systems, though all Board members attend Audit Committee meetings and participate in risk management discussions. Our Board of Directors has adopted a written statement, known as the Independent Board Candidate Qualifications and made available on our website, outlining the qualities sought in our directors. This statement, which is refreshed periodically, is used by the Nominating, Governance and Corporate Responsibility Committee (the "NGCR Committee") to evaluate individual director candidates. The NGCR Committee has identified experience with overseeing and managing risk management processes, including with respect to cybersecurity, as being important to creating an effective, well-rounded and diverse Board. Directors with experience overseeing and managing risk management processes play a critical role in the Board's oversight of our enterprise risk management process. Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.

22ITEM 2.A - A PROPERTIESWe own or lease approximately 315 properties, which include manufacturing, distribution, research and development and office facilities worldwide. Our corporate headquarters is located in a leased property at 300 Park Avenue, New York, New York. In the U.S., we operate in approximately 85 properties, of which 17 are owned. Major U.S. manufacturing and warehousing facilities used by the Oral, Personal and Home Care product segment of our business are located in Ohio, South Carolina and Tennessee. The Pet Nutrition segment has major manufacturing and warehousing facilities in Indiana, Kansas, Kentucky, Ohio, Oklahoma and South Carolina. Outside the U.S., we operate in approximately 230 properties, of which 58 are owned, in over 80 countries. Major overseas manufacturing and warehousing facilities used by the Oral, Personal and Home Care product segment of our business are located in Australia, Brazil, China, Colombia, France, Greece, Guatemala, India, Italy, Mexico, Poland, South Africa, Thailand, Turkey and Vietnam. The Pet Nutrition segment has major manufacturing and warehousing facilities in Czech Republic, Italy and the Netherlands. The primary research and development center for Oral Care and Personal Care products is located in New Jersey, the primary research and development center for Home Care products is located in Mexico and the primary research and development center for Pet Nutrition products is located in Kansas. Our global data center is also located in New Jersey. We have shared business service centers in India, Mexico and Poland, which are located in leased properties. All of the facilities we operate are well maintained and adequate for the purpose for which they are intended.

23ITEM 3.A - A LEGAL PROCEEDINGSFor information regarding legal proceedings, refer to Note 12, Commitments and Contingencies to the Consolidated Financial Statements included in Part IV, Item 15 of this report.

ITEM 4. A - A MINE SAFETY DISCLOSURESNot applicable.

PART II ITEM 5.A - A MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIESFor information regarding the market for the Company's common stock, including stock price performance graphs, refer to "Market Information" included in Part IV, Item 15 of this report. For information regarding the securities authorized for issuance under our equity compensation plans, refer to "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" included in Part III, Item 12 of this report. As of December 31, 2024, the number of common shareholders of record was 15,598. Issuer Purchases of Equity SecuritiesOn March 10, 2022, the Board authorized the repurchase of shares of the Company's common stock having an aggregate purchase price of up to \$5 billion under a new share repurchase program (the "2022 Program"), which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company's compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company's discretion, subject to market conditions, customary blackout periods and other factors. The following table shows the share repurchase activity for the three months in the quarter ended December 31, 2024:

	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2)	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs(3)
A (in millions)	October 1 through 31, 2024: 194,671	\$99.07A
B	November 1 through 30, 2024: 554,917	\$92.51A
C	December 1 through 31, 2024: 1,035,383	\$1,183A
D	Total: 795,250	\$94.55A

(1) Includes share repurchases under the 2022 Program and those associated with certain employee elections under the Company's compensation and benefit programs. (2) The difference between the total number of shares purchased and the total number of shares purchased as part of publicly announced plans or programs is 19,302 shares, which represents shares deemed surrendered to the Company to satisfy certain employee elections under the Company's compensation and benefit programs. (3) Includes approximate dollar value of shares that were available to be purchased under the publicly announced plans or programs that were in effect as of December 31, 2024.

ITEM 6.A - A [Reserved]25(Dollars in Millions Except Per Share Amounts)ITEM 7. A - A MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSExecutive OverviewBusiness OrganizationColgate-Palmolive Company (together with its subsidiaries, "Colgate," "we," "us," "our" or "Company") is a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet. We seek to deliver consistent compounded earnings per share growth to help drive superior total shareholder return, as well as to provide Colgate people with an innovative and inclusive work environment. We do this by developing and selling science-led products globally that make people's lives healthier and more enjoyable and by embracing our Sustainability & Social Impact Strategy across our organization. We are tightly focused on two product segments: Oral, Personal and Home Care; and Pet Nutrition. Within these segments, we follow a closely defined business strategy to grow our key product categories and increase our overall market share. Within the categories in which we compete, we prioritize our efforts based on their capacity to maximize the use of the organization's core competencies and strong global equities and to deliver sustainable, profitable long-term growth. Operationally, we are organized along geographic lines with management teams having responsibility for the business and financial results in each region. We compete in more than 200 countries and territories worldwide with established businesses in all regions contributing to our sales and profitability. Approximately two-thirds of our Net sales are generated from markets outside the U.S., with approximately 45% of our Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). This geographic diversity and balance help to reduce our exposure to business and other risks in any one country or part of the world. The Oral, Personal and Home Care product segment is managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of retailers, wholesalers, distributors, dentists and, in some geographies, skin health professionals. Through Hill's Pet Nutrition, we also compete on a worldwide basis in the pet nutrition market, selling products principally through authorized pet supply retailers, veterinarians and e-commerce retailers. We also sell certain of our products direct-to-consumer. We are engaged in manufacturing and sourcing of products and materials on a global scale and have major manufacturing facilities, warehousing facilities and distribution centers in every region around the world. In connection with management changes, we realigned the reporting structure of our skin health business effective July 1, 2024. Accordingly, commencing with the quarter ended September 30, 2024, the results of the skin health business previously reported within the Europe reportable operating segment are reported with our other skin health businesses in the North America reportable operating segment, with no impact on the Company's consolidated results of operations or financial position. The Company has recast its historical geographic segment information to conform to the new reporting structure. On an ongoing basis, management focuses on a variety of key indicators to monitor business health and performance. These indicators include net sales (including volume, pricing and foreign exchange components), organic sales growth (net sales growth excluding the impact of foreign exchange, acquisitions and divestments), a non-GAAP financial measure, and gross profit margin, selling, general and administrative expenses, operating profit, net income and earnings per share, in each case, on a GAAP and a non-GAAP basis, as well as measures used to optimize the management of working capital, capital expenditures, cash flow and return on capital. In addition, we review market share, household penetration and other data to assess how our brands are performing within their categories on a global and regional basis. The monitoring of these indicators and our Code of Conduct and corporate governance practices help to maintain business health and strong internal controls. For additional information regarding non-GAAP financial measures and the Company's use of market share data and the limitations of such data, see "Non-GAAP Financial Measures" and "Market Share Information" below. The War in UkraineThe war in Ukraine, and the related geopolitical tensions, have had and continue to have a significant impact on our operations in Ukraine and Russia, though it has not been material to our Consolidated Financial Statements. We have no manufacturing facilities in Russia. For the year ended December 31, 2024, our business in the Eurasia region constituted approximately 1% of our consolidated net sales and approximately 2% of our consolidated operating profit. 26(Dollars in Millions Except Per Share Amounts)We have experienced, and expect to continue to experience, risks related to the impact of the war in Ukraine, including increases in the costs and, in certain cases, limitations on the availability of certain raw and packaging materials and commodities (including oil and natural gas), supply chain and logistics challenges, import restrictions, foreign currency volatility and reputational concerns. We also have faced and continue to face challenges to our ability to repatriate cash from Russia and identify banking partners to support our Russian operations and we may face challenges to our ability to protect our assets in Russia. We also continue to monitor the impact of sanctions, export controls and import restrictions imposed generally and in response to the war in Ukraine. The Conflict in the Middle EastThe conflict in the Middle East has not had a material impact on our Consolidated Financial Statements. Uncertainties and risks remain as to the duration of the conflict and its impact on geopolitical relations and stability in North Africa, the wider Middle East and nearby regions. The conflict has impacted and may continue to impact, among other things, supply chain and logistics, the availability and price of raw and packaging materials and commodities such as oil, consumer sentiment and consumption and category growth rates in the region. For more information about factors that could impact our business, including due to geopolitical conflicts, such as the war in Ukraine and the conflict in the Middle East, refer to Part I, Item 1A "Risk Factors" of this Annual Report on Form 10-K. Business StrategyTo achieve our business and financial objectives, we are focused on delivering consistent compounded earnings per share growth through driving organic sales growth, operational efficiencies and leveraging the strength of our balance sheet. We believe increased household penetration and improved brand health are the keys to consistent organic sales growth and aim to achieve these through science-led, core and premium innovation, pursuing higher-growth adjacent categories and segments and expanding in faster-growing channels and markets. We aim to deliver margin expansion and cash flow growth through operating leverage and efficiency. We continue to prioritize our investments in high growth segments within our Oral Care, Personal Care and Pet Nutrition businesses. We also seek to lead in the development of human capital and to maximize the impact of our Sustainability & Social Impact Strategy. We are building and scaling our capabilities in areas such as innovation, digital, data, analytics and artificial intelligence, enabling us to be more responsive in today's rapidly changing world. We continue to invest behind our brands, including through advertising, and to develop initiatives to build strong relationships with consumers, retailers and dental, veterinary and skin health professionals. We continue to believe that growth opportunities are greater in those areas of the world in which economic development and rising consumer incomes expand the size and number of markets for our products. The investments needed to drive growth are supported through continuous, Company-wide initiatives to lower costs and increase effective asset utilization. Through these initiatives, which are referred to as our funding-the-growth initiatives, we seek to become even more effective and efficient throughout our businesses. These initiatives are designed to reduce costs associated with direct materials, indirect expenses, distribution and logistics and advertising and promotional materials, among other things, and encompass a wide range of projects, examples of which include raw material substitution, reduction of packaging materials, consolidating suppliers to leverage volumes and increasing manufacturing efficiency through SKU reductions and formulation simplification. Significant Items Impacting ComparabilityDuring the quarter ended June 30, 2023, we reassessed with our legal and tax advisers certain tax deductions taken in prior years by one of our subsidiaries and concluded that it was more likely than not that the deductions would not be sustained by the courts in that jurisdiction. The value of the tax deductions was not material to us in any year in which they were taken. The cumulative effect of the change in tax position of \$148 was reflected as a discrete item in the quarter ended June 30, 2023 income tax expense, partially offset by the reversal of certain prior years' withholding tax reserves of \$22 that were no longer required (hereinafter referred to as the "foreign tax matter"). The tax liability was paid in the quarter ended September 30, 20

Amounts)lawsuit under the Employee Retirement Income Security Act (   ERISA   ) seeking the recalculation of benefits and other relief associated with a 2005 residual annuity amendment to the Colgate-Palmolive Company Employees    Retirement Income Plan (the    Retirement Plan   ). The decision resulted in an increase in the obligations of the Retirement Plan, which based on the current funded status of the Retirement Plan and depending on further developments in the litigation, may require a cash contribution by the Company in 2025. In June 2023, we filed a petition for certiorari to the United States Supreme Court requesting permission for an appeal to that court, which was denied in October 2023. Also, in June 2023, the plaintiffs filed a motion to enter a revised final judgment in the United States District Court for the Southern District of New York (the    District Court   ) to address certain unresolved calculation issues, which we opposed. In March 2024, the District Court granted the plaintiffs    motion and found for the plaintiffs on those calculation issues. We have appealed that decision to the Second Circuit. See Note 12, Commitments and Contingencies to the Consolidated Financial Statements for additional information.

During the quarter ended March 31, 2023, we announced a voluntary recall of select Fabuloso multi-purpose cleaner products sold in the United States and Canada. The costs associated with the voluntary recall had a \$25 impact on our Operating profit in the quarter ended March 31, 2023. On January 27, 2022, the Board approved a targeted productivity program (the    2022 Global Productivity Initiative   ). All initiatives under the program have been implemented and the program concluded on December 31, 2024. The 2022 Global Productivity Initiative resulted in the reallocation of resources towards our strategic priorities and faster growth businesses, efficiencies in our operations and the streamlining of our supply chain to reduce structural costs. Total pretax charges from the implementation of the 2022 Global Productivity Initiative were \$228 (\$186 aftertax). Total annualized pretax savings from the 2022 Global Productivity Initiative were approximately \$125 (\$100 aftertax). See    Restructuring and Related Implementation Charges    below and Note 3, Restructuring and Related Implementation Charges to the Consolidated Financial Statements for additional information. In the years ended December 31, 2024 and 2023, we incurred pretax costs of \$85 (aftertax costs of \$73) and \$32 (aftertax costs of \$25), respectively, resulting from the 2022 Global Productivity Initiative.

OutlookLooking forward, we expect global macroeconomic, political and market conditions to remain challenging, including as a result of inflation, high interest rates, foreign currency volatility and developments in trade relations following the imposition of new and/or additional tariffs by the United States and other countries. We have taken and are taking additional pricing to try to offset the increases in raw and packaging material costs we have seen in recent years. This has negatively impacted consumer demand for our products. Additionally, inflation has impacted the broader economy with consumers around the world facing widespread rising prices as well as high interest rates resulting from measures to address inflation. Recent developments in trade relations and the imposition of new and/or additional tariffs by the United States and other countries, including following the United States    February 2025 executive orders imposing tariffs on imports from Canada, Mexico and China, may contribute to inflationary pressures and, as a result, may impact consumer demand for our products. We are following the dynamic situation closely and evaluating the impact of such tariffs and any retaliatory actions taken by other countries on our business, results of operations, cash flows and financial condition. While we have made and will make efforts to mitigate the impact of these and any additional tariffs imposed by the United States and/or other countries, they could impact the cost and/or price of our products, the cost and availability of raw and packaging materials and commodities and/or consumer demand for our products due to, among other things, the impact of such tariffs on the global economy, inflationary pressures or geopolitical relations. Such inflation and developments in trade relations as well as high interest rates may negatively impact consumer consumption or discretionary spending and/or change their purchasing patterns by foregoing purchasing certain of our products or by switching to    private label    or to our lower-priced product offerings. Although we continue to devote significant resources to support our brands and market our products at multiple price points, these changes could reduce demand for and sales volumes of our products or result in a shift in our product mix from higher margin to lower margin product offerings. In light of this challenging environment, we expect continued volatility across all of our categories and it is therefore difficult to predict category growth rates in the near term.

28(Dollars in Millions Except Per Share Amounts)Given that approximately two-thirds of our Net sales originate in markets outside the U.S., we have experienced and will likely continue to experience volatile foreign currency fluctuations, particularly in Argentina and T   rkiye, which are considered hyper-inflationary economies. Effective January 1, 2025, we designated Nigeria as a hyper-inflationary economy. Consequently, the functional currency for our Nigerian subsidiary will be the U.S. dollar and the impact of all future Nigerian currency fluctuations will be recorded in income. However, this designation is not expected to have a material impact on the Company's Consolidated Financial Statements. As discussed above, we continue to experience higher raw and packaging material costs, including the impact of transactional foreign exchange. While we have taken, and will continue to take, measures to mitigate the effect of these conditions, such as our funding-the-growth and revenue growth management initiatives, in the current environment it may become increasingly difficult to implement certain of these mitigation strategies. Should these conditions persist, they could adversely affect our future results.

While the global marketplace in which we operate has always been highly competitive, we continue to experience heightened competitive activity in certain markets from strong local competitors (including private label competitors), from other large multinational companies, some of which have greater resources than we do, and from new entrants into the market in many of our categories. Such activities have included more aggressive product claims and marketing challenges, as well as increased promotional spending and geographic expansion. We have been negatively affected by changes in the policies and practices of our trade customers in key markets, such as inventory destocking, fulfillment requirements, technology-aided category pricing pressures, limitations on access to shelf space, delisting of our products and sustainability, supply chain and packaging standards or initiatives. In addition, the retail landscape in many of our markets continues to evolve as a result of the continued growth of eCommerce, changing consumer preferences (as consumers increasingly shop online, including to compare prices and product availability) and the increased presence of alternative retail channels, such as subscription services and direct-to-consumer businesses. We are building and scaling our capabilities in areas such as innovation, digital, data, analytics and artificial intelligence and investing behind higher growth businesses. The substantial growth in eCommerce and the emergence of alternative retail channels have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers.

We continue to closely monitor the impact of geopolitical events and tensions, such as the war in Ukraine, the conflict in the Middle East, tensions between China and Taiwan and the developments in trade relations, and the challenging market conditions discussed above, on our business and the related uncertainties and risks. While we have taken, and will continue to take, measures to mitigate the effects of these events and conditions, we cannot estimate with certainty the full extent of their impact on our business, results of operations, cash flows and/or financial condition. For more information about factors that could impact our business, see    Risk Factors    in Part I, Item 1A of this Annual Report on Form 10-K. We believe that we are well prepared to meet the challenges ahead due to our strong financial condition, experience operating in challenging environments, resilient global supply chain, dedicated and diverse global team and focused business strategy. Our strategy is based on delivering consistent compounded earnings per share growth through driving organic sales growth, operational efficiencies and leveraging the strength of our balance sheet. We believe increased household penetration and improved brand health are the keys to consistent organic sales growth and aim to achieve these through science-led, core and premium innovation, pursuing higher-growth adjacent categories and segments and expanding in faster-growing channels and markets. We aim to deliver margin expansion and cash flow growth through operating leverage and efficiency. We also seek to lead in the development of human capital and to maximize our Sustainability & Social Impact Strategy. Our commitment to these priorities, the strength of our brands, the breadth of our global footprint and a commitment to profitability and driving efficiency in cash generation should position us well to manage through the challenges we face and increase shareholder value over time.

29(Dollars in Millions Except Per Share Amounts)Results of OperationsThis section of this Annual Report on Form 10-K generally discusses 2024 and 2023 items and year-to-year comparisons between 2024 and 2023. Discussions of 2022 items and year-to-year comparisons between 2023 and 2022 that are not included in this Annual Report on Form 10-K can be found in    Management   's Discussion and Analysis of Financial Condition and Results of Operations    in Part II, Item 7 of the Company   's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Net SalesWorldwide Net sales were \$20,101 in 2024, up 3.3% from 2023, driven by volume growth of 3.1% and net selling price increases of 4.4%, partially offset by negative foreign exchange of 4.1%. Organic sales (Net sales excluding, as applicable, the impact of foreign exchange, acquisitions and divestments), a non-GAAP financial measure as discussed below, increased 7.4% in 2024. Net sales in the Oral, Personal and Home Care product segment were \$15,618 in 2024, up 3.0% from 2023, driven by volume growth of 3.7% and net selling price increases of 4.4%, partially offset by negative foreign exchange of 5.2%. Organic sales in the Oral, Personal and Home Care product segment increased 8.1% in 2024. The increase in organic sales in 2024 versus 2023 was due to increases in Oral Care, Home Care and Personal Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Home Care was primarily due to organic sales growth in the surface cleaner and fabric softener categories. The increase in Personal Care was primarily due to organic sales growth in the liquid hand soap and body wash categories, partially offset by organic sales declines in the skin health category. The Company   's share of the global toothpaste market was 41.4% for full year 2024, up 0.3 share points from full year 2023, and its share of the global manual toothbrush market was 32.2% for full year 2024, up 0.7 share points versus full year 2023. Full year 2024 market shares in toothpaste were up in Latin America, Europe and Africa/Eurasia, flat in Asia Pacific and down in North America versus full year 2023. In the manual toothbrush category, full year 2024 market shares were up in North America, Latin America and Asia Pacific and flat in Europe and Africa/Eurasia versus full year 2023. For additional information regarding the Company   's use of market share data and limitations of such data, see    Market Share Information    below.

Net sales for Hill   's Pet Nutrition were \$4,483 in 2024, up 4.5% from 2023, driven by volume growth of 0.8% and net selling price increases of 4.1%, partially offset by negative foreign exchange of 0.4%. Organic sales for Hill   's Pet Nutrition increased 4.9% in 2024. The increase in organic sales in 2024 versus 2023 was due to increases in organic sales in the therapeutic and wellness categories.

30(Dollars in Millions Except Per Share Amounts)Gross Profit/MarginWorldwide Gross profit increased 7% to \$12,161 in 2024 from \$11,326 in 2023. Worldwide Gross profit in both periods included charges resulting from the 2022 Global Productivity Initiative. Excluding these charges in both periods, worldwide Gross profit increased to \$12,181 in 2024 compared to \$11,327 in 2023, reflecting an increase of \$482 resulting from higher Gross profit margin and an increase of \$372 resulting from higher Net sales. Worldwide Gross profit margin increased to 60.5% in 2024 from 58.2% in 2023. Excluding charges resulting from the 2022 Global Productivity Initiative in 2024, Gross profit margin increased to 60.6% in 2024 from 58.2% in 2023. This increase in Gross profit margin was due to cost savings from the Company   's funding-the-growth initiatives (280 bps), higher pricing (170 bps) and favorable mix (20 bps), partially offset by higher raw and packaging material costs (230 bps), which included foreign exchange transaction costs.

20242023Gross profit, GAAP\$12,161A \$11,326A 2022 Global Productivity Initiative20A 1A Gross profit, non-GAAP\$12,181A \$11,327A 20242023Basis Point ChangeGross profit margin, GAAP60.5A %58.2A %20A 2022 Global Productivity Initiative0.1A %   A Gross profit margin, non-GAAP60.6A %58.2A %20A 31(Dollars in Millions Except Per Share Amounts)Selling, General and Administrative ExpensesSelling, general and administrative expenses increased 8% to \$7,729 in 2024 from \$7,151 in 2023. Selling, general and administrative expenses in both periods included charges resulting from the 2022 Global Productivity Initiative. Excluding these charges in both periods, Selling, general and administrative expenses increased to \$7,723 in 2024 from \$7,149 in 2023, reflecting increased advertising investment of \$349 and higher overhead expenses of \$225.

Selling, general and administrative expenses as a percentage of Net sales increased to 38.5% in 2024 from 36.8% in 2023. Excluding charges resulting from the 2022 Global Productivity Initiative in both periods, Selling, general and administrative expenses as a percentage of Net sales increased to 38.4% in 2024 from 36.7% in 2023. This increase was due to increased advertising investment (130 bps) and higher overhead expenses (40 bps), both as a percentage of Net sales. In 2024, advertising investment increased as a percentage of Net sales to 13.5% from 12.2% in 2023 and increased by 14.7% in absolute terms to \$2,720 as compared with \$2,371 in 2023.

20242023Selling, general and administrative expenses, GAAP\$7,729A \$7,151A 2022 Global Productivity Initiative(6)(2)Selling, general and administrative expenses, non-GAAP\$7,723A \$7,149A 20242023Basis Point ChangeSelling, general and administrative expenses as a percentage of Net sales, GAAP38.5A %36.8A %17A 2022 Global Productivity Initiative(0.1)(0.1)%Selling, general and administrative expenses as a percentage of Net sales, non-GAAP38.4A %36.7A %17A 32(Dollars in Millions Except Per Share Amounts)Other (Income) Expense, NetOther (income) expense, net was \$164 and \$191 in 2024 and 2023, respectively. Other (income) expense, net in 2024 included charges resulting from the 2022 Global Productivity Initiative. Other (income) expense, net in 2023 included product recall costs and charges resulting from the 2022 Global Productivity Initiative.

20242023Other (income) expense, net, GAAP\$164A \$191A 2022 Global Productivity Initiative(59)(24)Product recall costs   A (25)Other (income) expense, net, non-GAAP\$105A \$142A Excluding the items described above in both periods, as applicable, Other (income) expense, net was \$105 in 2024 and \$142 in 2023, comprised of the following:

20242023Amortization of intangible assets\$75A \$72A Equity income(22)(17)Losses (gains) from marketable securities and other assets\$6A 11A Indirect tax payments (refunds)27A 18A Other, net19A 58A Total Other (income) expense, net, non-GAAP\$105A \$142A 33(Dollars in Millions Except Per Share Amounts)Operating ProfitOperating profit increased 7% to \$4,268 in 2024 from \$3,984 in 2023. In 2024, Operating profit included charges resulting from the 2022 Global Productivity Initiative. In 2023, Operating profit included charges resulting from the 2022 Global Productivity Initiative and product recall costs. Excluding these items in both periods, as applicable, Operating profit increased 8% to \$4,353 in 2024 from \$4,036 in 2023 primarily due to an increase in Gross profit, partially offset by an increase in Selling, general and administrative expenses.

A A A Operating profit margin was 21.2% in 2024, an increase of 70 bps compared with 20.5% in 2023. Excluding the items described above in both periods, as applicable, Operating profit margin was 21.7% in 2024, an increase of 100 bps from 20.7% in 2023, primarily due to an increase in Gross profit (240 bps), partially offset by an increase in Selling, general and administrative expenses (170 bps), both as a percentage of Net sales.

20242023ChangeOperating profit, GAAP\$4,268A \$3,984A 7A %2022 Global Productivity Initiative85A 27A Product recall costs   A 25A Operating profit, non-GAAP\$4,353A \$4,036A 8A %20242023Basis Point ChangeOperating profit margin, GAAP21.2A %20.5A %7A 2022 Global Productivity Initiative0.5A %0.1A %Product recall costs   A %0.1A %Operating profit margin, non-GAAP21.7A %20.7A %10A Non-Service Related Postretirement CostsNon-service related postretirement costs were \$87 in 2024 compared to \$360 in 2023. In 2023, Non-service related postretirement costs included charges related to the ERISA litigation matter and the 2022 Global Productivity Initiative. Excluding these charges in 2023, Non-service related postretirement costs were \$87 in 2024 compared to \$88 in 2023.

20242023Non-service related postretirement costs, GAAP\$87A \$360A ERISA litigation matter   A (267)2022 Global Productivity Initiative   A (5)Non-service related postretirement costs, non-GAAP\$87A \$88A Interest ExpenseInterest expense was \$292 in 2024 as compared to \$287 in 2023. Interest IncomeInterest income was \$67 in 2024 as compared to \$55 in 2023.

34(Dollars in Millions Except Per Share Amounts)Income TaxesThe effective income tax rate was 22.9% in 2024 and 27.6% in 2023.

A As reflected in the table below, the non-GAAP effective income tax rate was 22.7% in 2024 and 23.6% in 2023.

2024Income Before Income TaxesProvision For Income Taxes(1)Effective Income Tax Rate(2)As Reported GAAP\$3,956A \$907A 22.9A %2022 Global Productivity Initiative85A 12A (0.2)%Non-GAAP\$4,041A \$919A 22.7A %2023Income Before Income TaxesProvision For Income Taxes(1)Effective Income Tax Rate(2)As Reported GAAP\$3,392A \$937A 27.6A %ERISA litigation matter267A 55A (0.5)%Foreign tax matter   A (126) (3.4)%2022 Global Productivity Initiative32A 6A (0.1)%Product recall costs25A 6A    A %Non-GAAP\$3,716A \$878A 23.6A %(1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. (2) The impact of non-GAAP items on the Company   's effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes. The effective income tax rate in all years benefited from tax planning associated with the Company   's global business initiatives.

In the third quarter of 2023, the Internal Revenue Service (the    IRS   ) issued a notice giving taxpayers temporary relief from the effects of certain U.S. tax regulations that were issued in December 2021, which place greater restrictions on foreign taxes that are creditable against U.S. taxes on foreign-source income. This notice allowed taxpayers to defer the application of these new regulations through the end of 2023. In December 2023, the IRS issued further guidance modifying this temporary relief period to the date that a notice or other guidance withdrawing or modifying the temporary relief is issued. The Company will recognize the impact, if any, in the period in which the temporary relief is withdrawn or modified. During the quarter ended June 30, 2023, we reassessed with our legal and tax advisers certain tax deductions taken in prior years by one of our subsidiaries and concluded that it was more likely than not that the deductions would not be sustained by the courts in that jurisdiction. The value of the tax deductions was not material to us in any year in which they were taken. The cumulative effect of the change in tax position of \$148 was reflected as a discrete item in the quarter ended June 30, 2023 income tax expense, partially offset by the reversal of certain prior years    withholding tax reserves of \$22 that were no longer required. The tax liability was paid in the quarter ended September 30, 2023.

On August 16, 2022, the Inflation Reduction Act of 2022 (the    IRA   ) was enacted, which among other things, implements a 15% minimum tax on book income of certain large corporations effective for years beginning after December 31, 2022. Based on the Company   's analysis, as well as guidance published by the IRS, the IRA, and in particular the 15% minimum tax, did not have an impact on the Company   's Consolidated Financial Statements. Subsequent to the aforementioned guidance published by the IRS, on

September 12, 2024, the U.S. Treasury Department and IRS released proposed regulations relating to this 15% minimum tax. Based on the Company’s analysis, these proposed regulations, if finalized in their current form, are not expected to have an impact on the Company’s Consolidated Financial Statements. However, the Company will continue to evaluate any additional guidance and clarification that becomes available. Additionally, on December 15, 2022, the 27 member states of the European Union (the “EU”) reached an agreement on a minimum level of taxation for certain large corporations to pay a minimum corporate tax rate of 15% in every jurisdiction in which they operate. This agreement, which is known as the Minimum Tax Directive (part of the Pillar II Model 35(Dollars in Millions Except Per Share Amounts) Rules), was supposed to be transposed into the laws of all EU member states by December 31, 2023. Most member states complied, while some were granted extensions of time. In addition, many other jurisdictions outside the EU have implemented a similar minimum tax regime consistent with the policy of the Pillar II Model Rules. Detailed regulations of these minimum tax regimes are still being considered in certain countries and, in some cases, enactment and timing is still uncertain. Based on current legislation and available guidance, apart from a significant additional compliance burden, Pillar II did not have a material impact as of December 31, 2024 and the Company does not believe it will have a material impact on its Consolidated Financial Statements. However, as these rules and related regulations are revised and implemented, the Company will evaluate the impact, if any, on its Consolidated Financial Statements. The Company has ongoing federal, state and international income tax audits in various jurisdictions and evaluates uncertain tax positions that may be challenged by local tax authorities and not fully sustained. All U.S. federal income tax returns through December 31, 2013 have been audited by the IRS and there are limited matters which the Company plans to appeal for years 2010 through 2013. One such matter relates to the IRS assessment of taxes on the Company by imputing income on certain activities within one of our international operations, which is also under audit for the years 2014 through 2018. There were U.S. Tax Court rulings during 2023 in favor of the IRS against unrelated third parties on similar matters. Despite the U.S. Tax Court rulings, the Company continues to believe that the tax assessment against the Company is without merit. While there can be no assurances, the Company believes this matter will ultimately be decided in favor of the Company. The amount of tax plus interest for the years 2010 through 2018 is estimated to be approximately \$153, which is not included in the Company’s uncertain tax positions. In May 2024, the IRS initiated an audit for the years 2019 through 2021.36(Dollars in Millions Except Per Share Amounts)Net income attributable to Colgate-Palmolive Company and Earnings per shareNet income attributable to Colgate-Palmolive Company was \$2,889, or \$3.51 per share on a diluted basis, in 2024, an increase from \$2,300, or \$2.77 per share on a diluted basis, in 2023. In 2024, Net income attributable to Colgate-Palmolive Company included charges resulting from the 2022 Global Productivity Initiative. In 2023, Net income attributable to Colgate-Palmolive Company included charges resulting from the ERISA litigation matter, the foreign tax matter and the 2022 Global Productivity Initiative and product recall costs. Excluding the items described above in both periods, as applicable, Net income attributable to Colgate-Palmolive Company increased 10% to \$2,962 in 2024 from \$2,682 in 2023, and Earnings per common share on a diluted basis increased 11% to \$3.60 in 2024 from \$3.23 in 2023.2024Income Before Income TaxesProvision For Income Taxes(1)Net Income Including Noncontrolling InterestsLess: Income Attributable To Noncontrolling InterestsNet Income Attributable to Colgate-Palmolive CompanyDiluted Earnings Per Share(2)As Reported GAAP\$3,956A \$907A \$3,049A \$160A \$2,889A \$3,51A 2022 Global Productivity Initiative85A 12A 73A A 73A 0.09A Non-GAAP\$4,041A \$919A \$3,122A \$160A \$2,962A \$3.60A 2023Income Before Income TaxesProvision For Income Taxes(1)Net Income Including Noncontrolling InterestsLess: Income Attributable To Noncontrolling InterestsNet Income Attributable to Colgate-Palmolive CompanyDiluted Earnings Per Share(2)As Reported GAAP\$3,392A \$937A \$2,455A \$155A \$2,300A \$2.77A ERISA litigation matter267A 55A 212A A 212A 0.26A Foreign tax matterA (126)126A A 126A 0.15A 2022 Global Productivity Initiative32A 6A 26A 1A 25A 0.03A Product recall costs25A 6A 19A A 19A 0.02A Non-GAAP\$3,716A \$878A \$2,838A \$156A \$2,682A \$3.23A (1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. (2) The impact of non-GAAP adjustments on diluted earnings per share may not necessarily equal the difference between GAAP and non-GAAP as a result of rounding.37(Dollars in Millions Except Per Share Amounts)Segment ResultsThe Company markets its products in over 200 countries and territories throughout the world in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Company uses Operating profit as a measure of the operating segment performance because it excludes the impact of corporate-driven decisions related to interest expense and income taxes. Oral, Personal and Home CareNorth America20242023% ChangeNet sales\$4,113A \$4,091A 0.5A %Operating profits\$839A \$871A (4)% of Net sales20.4A %21.3A %(90)bpsNet sales in North America increased 0.5% in 2024 to \$4,113, driven by volume growth of 2.6%, partially offset by net selling price decreases of 1.9% and negative foreign exchange of 0.1%. Organic sales in North America increased 0.7% in 2024. The organic sales growth was driven by the United States and Canada. The increase in organic sales in North America in 2024 versus 2023 was due to increases in Home Care and Oral Care organic sales, partially offset by a decrease in Personal Care organic sales. The increase in Home Care was primarily due to organic sales growth in the surface cleaner category, partially offset by an organic sales decline in the hand dish category. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The decrease in Personal Care was primarily due to organic sales declines in the skin health and underarm protection categories, partially offset by organic sales growth in the liquid hand soap category. Operating profit in North America decreased 4% in 2024 to \$839, or 90 bps to 20.4% as a percentage of Net Sales. This decrease in Operating profit as a percentage of Net sales was due to an increase in Gross profit (60 bps), more than offset by an increase in Selling, general and administrative expenses (150 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (210 bps), partially offset by lower pricing and higher raw and packaging material costs (50 bps). This increase in Selling, general and administrative expenses was primarily due to increased advertising investment (140 bps). A A 38(Dollars in Millions Except Per Share Amounts)Latin America20242023% ChangeNet sales\$4,782A \$4,640A 3.1A %Operating profits\$1,526A \$1,417A 8A % of Net sales31.9A %30.5A %140A bpsNet sales in Latin America increased 3.1% in 2024 to \$4,782, driven by volume growth of 3.9% and net selling price increases of 12.9%, partially offset by negative foreign exchange of 13.7%. Organic sales in Latin America increased 16.8% in 2024. Organic sales growth was led by Argentina, Brazil and Mexico. The increase in organic sales in Latin America in 2024 versus 2023 was due to increases in Oral Care, Home Care and Personal Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste, manual toothbrush and mouthwash categories. The increase in Home Care was primarily due to organic sales growth in the surface cleaner and hand dish categories. The increase in Personal Care was primarily due to organic sales growth in the underarm protection category. Operating profit in Latin America increased 8% in 2024 to \$1,526, or 140 bps to 31.9% as a percentage of Net sales. A This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (220 bps), partially offset by an increase in Selling, general and administrative expenses (100 bps), both as a percentage of Net sales. This increase in Gross profit was due to higher pricing and cost savings from the Company’s funding-the-growth initiatives (290 bps), partially offset by significantly higher raw and packaging material costs (540 bps), which included foreign exchange transaction costs. This increase in Selling, general and administrative expenses was due to higher overhead expenses (60 bps) and increased advertising investment (50 bps). 39(Dollars in Millions Except Per Share Amounts)Europe20242023% ChangeNet sales\$2,770A \$2,571A 7.7A %Operating profits\$658A \$573A 15A % of Net sales23.7A %22.3A %140A bpsNet sales in Europe increased 7.7% in 2024 to \$2,770, driven by volume growth of 4.1%, net selling price increases of 2.5% and positive foreign exchange of 1.1%. Organic sales in Europe increased 6.7% in 2024. Organic sales growth was led by Germany, the United Kingdom, France and Poland. The increase in organic sales in Europe in 2024 versus 2023 was primarily due to increases in Oral Care and Personal Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste category. The increase in Personal Care was primarily due to organic sales growth in the body wash category. Operating profit in Europe increased 15% in 2024 to \$658, or 140 bps to 23.7% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (370 bps), partially offset by an increase in Selling, general and administrative expense (230 bps), both as a percentage of Net sales. This increase in Gross profit was due to cost savings from the Company’s funding-the-growth initiatives (290 bps), higher pricing and favorable mix (70 bps), partially offset by higher raw and packaging material costs (100 bps). This increase in Selling, general and administrative expenses was primarily due to increased advertising investment (220 bps). 40(Dollars in Millions Except Per Share Amounts)Asia Pacific20242023% ChangeNet sales\$2,858A \$2,782A 2.7A %Operating profits\$12A \$767A 6A % of Net sales28.4A %27.6A %80A bpsNet sales in Asia Pacific increased 2.7% in 2024 to \$2,858, driven by volume growth of 3.1% and net selling price increases of 1.0%, partially offset by negative foreign exchange of 1.3%. Organic sales in Asia Pacific increased 4.0% in 2024. Organic sales growth was led by India, the Philippines, Australia and the Greater China region. The increase in organic sales in 2024 versus 2023 was primarily due to an increase in Oral Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste category. Operating profit in Asia Pacific increased 6% in 2024 to \$812, or 80 bps to 28.4% as a percentage of Net sales. A This increase in Operating profit as a percentage of Net sales was due to an increase in Gross profit (210 bps) and a decrease in Other (income) expense, net (30 bps), partially offset by an increase in Selling, general and administrative expenses (160 bps), all as a percentage of Net sales. This increase in Gross profit was due to cost savings from the Company’s funding-the-growth initiatives (280 bps) and higher pricing, partially offset by higher raw and packaging material costs (110 bps). A This increase in Selling, general and administrative expenses was due to increased advertising investment (160 bps). A A 41(Dollars in Millions Except Per Share Amounts)Africa/Eurasia20242023% ChangeNet sales\$1,095A \$1,083A 1.2A %Operating profits\$253A \$254A A % of Net sales23.1A %23.5A % (40)bpsNet sales in Africa/Eurasia increased 1.2% in 2024 to \$1,095, driven by volume growth of 7.6% and net selling price increases of 5.7%, partially offset by negative foreign exchange of 12.1%. Organic sales in Africa/Eurasia increased 13.3% in 2024. Organic sales growth was led by TÁrkiye, Nigeria and the North Africa/Middle East region. The increase in organic sales in 2024 versus 2023 was primarily due to increases in Oral Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Home Care was primarily due to organic sales growth in the bleach category. Operating profit in Africa/Eurasia was flat at \$253 versus 2023, and as a percentage of Net sales decreased by 40 bps to 23.1%. A This decrease in Operating profit as a percentage of Net sales was due to an increase in Gross profit (140 bps), more than offset by an increase in Selling, general, and administrative expense (120 bps) and an increase in Other (income) expense, net (60 bps), all as a percentage of Net sales. A This increase in Gross profit was due to cost savings from the Company’s funding-the-growth initiatives (250 bps), higher pricing and favorable mix (30 bps), partially offset by significantly higher raw and packaging material costs (340 bps), which included foreign exchange transaction costs. This increase in Selling, general and administrative expense was due to higher overhead expense (70 bps) and increased advertising investment (50 bps). 42(Dollars in Millions Except Per Share Amounts)Hill20242023% ChangeNet sales\$4,483A \$4,290A 4.5A %Operating profits\$965A \$806A 20A % of Net sales21.5A %18.8A %270A bpsNet sales for Hill2024 increased 4.5% in 2024 to \$4,483, driven by volume growth of 0.8% and net selling price increases of 4.1%, partially offset by negative foreign exchange of 0.4%. Organic sales in Hill2024 increased 4.9% in 2024. Organic sales growth was led by the United States despite a negative impact from lower private label pet nutrition sales of 210 bps. The increase in organic sales in 2024 versus 2023 was due to organic sales growth in the therapeutic and wellness categories. Operating profit in Hill2024 increased 20% in 2024 to \$965, or 270 bps to 21.5% as a percentage of Net sales. A This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (410 bps), partially offset by an increase in Selling, general, and administrative expense (180 bps), both as a percentage of Net sales. This increase in Gross profit was due to cost savings from the Company’s funding-the-growth initiatives (340 bps), higher pricing and favorable mix (50 bps), partially offset by higher raw and packaging material costs (170 bps). This increase in Selling, general and administrative expense was primarily due to increased advertising investment (190 bps). 43(Dollars in Millions Except Per Share Amounts)Corporate20242023% ChangeOperating profit (loss)\$(784)\$(704)11A %Corporate operations include Corporate overhead costs, research and development costs, stock-based compensation expense related to stock options and restricted stock unit awards, restructuring and related implementation costs and gains and losses on sales of non-core product lines. The components of Operating profit (loss) for the Corporate segment are presented as follows:202420232022 Global Productivity Initiative\$(85)\$(27)Product Recall CostsA (25)Corporate overhead costs and other, net(699)(652)Total Corporate Operating profit (loss)\$(784)\$(704)44(Dollars in Millions Except Per Share Amounts)Restructuring and Related Implementation Charges On January 27, 2022, the Board approved the 2022 Global Productivity Initiative. All initiatives under the program have been implemented and the program concluded on December 31, 2024. The 2022 Global Productivity Initiative resulted in the reallocation of resources towards the Company’s strategic priorities and faster growth businesses, efficiencies in the Company’s operations and the streamlining of its supply chain to reduce structural costs. Over the course of the 2022 Global Productivity Initiative, the Company incurred total pretax charges of \$228 (\$186 aftertax) in connection with the implementation of various projects as follows:Total Program Charges as of December 31, 2024Employee-Related Costs\$175A Incremental Depreciation13A Asset Impairments1A Other39A Total\$228A Total pretax charges resulting from the 2022 Global Productivity Initiative were comprised of the following categories: employee-related costs, including severance, pension and other termination benefits (80%); asset-related costs, primarily accelerated depreciation and asset write-downs (5%); and other charges (15%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. Over the course of the 2022 Global Productivity Initiative, approximately 80% of the charges resulted in cash expenditures. Total annualized pretax savings from the 2022 Global Productivity Initiative were approximately \$125 (\$100 aftertax). For the twelve months ended December 31, 2024 and December 31, 2023, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows:Twelve Months Ended December 31, 20242023Gross Profits\$20A \$1A Selling, general and administrative expenses6A 2A Other (income) expense, net59A 24A Non-service related postretirement costsA A Total 2022 Global Productivity Initiative charges, pretax\$85A \$32A Total 2022 Global Productivity Initiative charges, aftertax\$73A \$25A Restructuring and related implementation charges are recorded in the Corporate segment as these initiatives are predominantly centrally directed and controlled and are not included in internal measures of segment operating performance. 45(Dollars in Millions Except Per Share Amounts)Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments:Twelve Months Ended December 31, 2024Total Program ChargesA 20242023North America(1)3A %15A %9A %Latin America A A %A A %9A %Europe(1)89A %19A %44A %Asia PacificA A %20A %7A %Africa/EurasiaA A %65A %6A %Hill’s Pet Nutrition6A %23A %11A %Corporate2A %18A %14A %Total100A %100A %100A % (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals:Twelve Months Ended December 31, 2024Employee-Related CostsA Incremental DepreciationA Asset ImpairmentsOtherTotalBalance at December 31, 2023\$30A \$A \$1A \$34A Charges24A A A A 8A 32A Cash Payments(45)A A A A (10)(55)Charges against assets(5)A A (1)A A (6)Foreign exchange6A A A A 6A Balance at December 31, 2023\$10A \$A A A \$1A \$11A Charges 49A 13A A A 23A 85A Cash Payments (20)A A A A (14)(34)Charges against assetsA A (13)A A A (13)Foreign exchange(5)A A A A A (5)Balance at December 31, 2024\$34A \$A A A \$10A \$44A Employee-Related Costs primarily include severance and other termination benefits and are calculated based on long-standing benefit practices, written severance policies, local statutory requirements and, in certain cases, voluntary termination arrangements. Employee-Related Costs also include pension enhancements which are reflected as Charges against assets within Employee-Related Costs in the preceding table, as the corresponding balance sheet amounts are reflected as a reduction of pension assets or an increase in pension liabilities. Incremental Depreciation is recorded to reflect changes in useful lives and estimated residual values for long-lived assets that will be taken out of service prior to the end of their normal service period. Asset Impairments are recorded to write down inventories and assets held for sale or disposal to their fair value based on amounts expected to be realized. Charges against assets within Asset Impairments are net of cash proceeds pertaining to the sale of certain assets, as applicable. 46(Dollars in Millions Except Per Share Amounts)Non-GAAP Financial MeasuresThis Annual Report on Form 10-K discusses certain financial measures on both a GAAP and a non-GAAP basis. The Company uses the non-GAAP financial measures described below internally in its budgeting process, to evaluate segment and overall operating performance and as a factor in determining compensation. The Company believes that these non-GAAP financial measures are useful in evaluating the Company’s underlying business performance and trends; however, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similar measures presented by other companies. Net sales growth (GAAP) and organic sales growth (Net sales growth excluding the impact of foreign exchange, acquisitions and divestments) (non-GAAP) are discussed in this Annual Report on Form 10-K. Management believes the organic sales growth measure provides investors and analysts with useful supplemental information regarding the Company’s underlying sales trends by presenting sales growth excluding,

the external factor of foreign exchange, as well as the impact of acquisitions and divestments, as applicable. A reconciliation of organic sales growth to Net sales growth for the years ended December 31, 2024 and 2023 is provided below. Gross profit, Gross profit margin, Selling, general and administrative expenses, Selling, general and administrative expenses as a percentage of Net sales, Other (income) expense, net, Operating profit, Operating profit margin, Non-service related postretirement costs, Effective income tax rate, Net income attributable to Colgate-Palmolive Company and Earnings per share on a diluted basis are discussed in this Annual Report on Form 10-K both on a GAAP basis and excluding, as applicable, charges resulting from the ERISA litigation matter, the foreign tax matter and the 2022 Global Productivity Initiative and product recall costs. These non-GAAP financial measures exclude items that, either by their nature or amount, management would not expect to occur as part of the Company's normal business on a regular basis, such as restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. Investors and analysts use these financial measures in assessing the Company's business performance, and management believes that presenting these financial measures on a non-GAAP basis provides them with useful supplemental information to enhance their understanding of the Company's underlying business performance and trends. These non-GAAP financial measures also enhance the ability to compare period-to-period financial results. A reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measures for the years ended December 31, 2024 and 2023 is presented within the applicable section of Results of Operations.

47(Dollars in Millions Except Per Share Amounts)The following tables provide a quantitative reconciliation of Net sales growth to organic sales growth for the years ended December 31, 2024 and 2023 versus the prior year: Year ended December 31, 2024 Net Sales Growth (GAAP) Foreign Exchange Impact Acquisitions and Divestments Impact Organic Sales Growth (Non-GAAP) Oral, Personal and Home Care 1.0% (0.1)% 0.7% Latin America 3.1% (13.7)% 16.8% Europe (1) 7.7% 1.1% 6.7% Asia Pacific 2.7% (1.3)% 4.0% Africa/Eurasia 1.2% (12.1)% 13.3% Total Oral, Personal and Home Care 3.0% (5.2)% 8.1% Pet Nutrition 4.5% (0.4)% 4.9% Total Company 3.3% (4.1)% 7.4% Note: Table may not sum due to rounding. (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. Year ended December 31, 2023 Net Sales Growth (GAAP) Foreign Exchange Impact Acquisitions and Divestments Impact Organic Sales Growth (Non-GAAP) Oral, Personal and Home Care 1.2% (0.2)% 2.4% Latin America 16.5% 1.1% 15.4% Europe (1) 8.9% 2.6% 6.3% Asia Pacific (1.6)% (3.8)% 6.2% 3% Africa/Eurasia 0.1% (17.2)% 17.3% Total Oral, Personal and Home Care 6.4% (1.4)% 7.8% Pet Nutrition 15.5% (0.5)% 10.6% Total Company 8.3% (1.2)% 1.9% 8.4% Note: Table may not sum due to rounding. (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. Market Share Information Management uses market share information as a key indicator to monitor business health and performance. References to market share in this Annual Report on Form 10-K are based on a combination of consumption and market share data provided by third-party vendors, primarily Nielsen, and internal estimates. All market share references represent the percentage of the dollar value of sales of our products, relative to all product sales in the category in the countries in which the Company competes and purchases data (excluding Venezuela from all periods).

48(Dollars in Millions Except Per Share Amounts)Market share data is subject to limitations on the availability of up-to-date information. In particular, market share data is currently not generally available for certain retail channels, such as eCommerce or certain discounters. The Company measures year-to-date market shares from January 1 of the relevant year through the most recent period for which market share data is available, which typically reflects a lag time of one or two months. The Company believes that the third-party vendors we use to provide data are reliable, but we have not verified the accuracy or completeness of the data or any assumptions underlying the data. In addition, market share information calculated by the Company may be different from market share information calculated by other companies due to differences in category definitions, the use of data from different countries, internal estimates and other factors.

49(Dollars in Millions Except Per Share Amounts)Liquidity and Capital ResourcesThe Company expects cash flow from operations and debt issuances will be sufficient to meet foreseeable business operating and recurring cash needs (including for debt service, dividends, capital expenditures, share repurchases and acquisitions). The Company believes its strong cash generation and financial position should continue to allow it broad access to global credit and capital markets. Cash Flow Net cash provided by operations increased 10% to \$4,107 in 2024 as compared to \$3,745 in 2023, primarily due to higher net income, partially offset by changes in working capital. The Company's working capital as a percentage of Net sales was (5.2)% in 2024 and (1.4)% in 2023. This change in working capital as a percentage of Net sales was primarily due to higher accounts payable and accruals. The Company defines working capital as the difference between current assets (excluding Cash and cash equivalents and marketable securities, the latter of which is reported in Other current assets) and current liabilities (excluding short-term debt).

5 Investing activities used \$534 of cash in 2024 compared to \$742 during 2023. Capital expenditures in the year ended December 31, 2024 were \$561, a decrease from \$705 in 2023. Capital expenditures for 2025 are expected to be approximately 3.0% of Net sales. The Company continues to focus its capital spending on projects that are expected to yield high aftertax returns. Financing activities used \$3,389 of cash during the year ended December 31, 2024 compared to \$2,793 during 2023. The increase in cash used was primarily due to higher share repurchases, partially offset by higher proceeds from the exercise of stock options. Long-term debt, including the current portion, decreased to \$7,941 as of December 31, 2024, as compared to \$8,239 as of December 31, 2023, and total debt decreased to \$7,949 as of December 31, 2024 as compared to \$8,549 as of December 31, 2023. During the year ended December 31, 2024, the Company redeemed at maturity \$500 of ten-year Medium-Term Notes with a fixed coupon of 3.25%. The redemption was financed with commercial paper borrowings. In March 2023, the Company issued \$500 of three-year Senior Notes at a fixed coupon rate of 4.800%, \$500 of five-year Senior Notes at a fixed coupon rate of 4.600% and \$500 of ten-year Senior Notes at a fixed coupon rate of 4.600%. The Company's debt issuances support the Company's capital structure objectives of funding its business and growth initiatives while minimizing its risk-adjusted cost of capital. At December 31, 2024, the Company had access to unused domestic and foreign lines of credit of \$3,725 (including under the facility discussed below) and could also issue long-term debt pursuant to an effective shelf registration statement. In November 2022, the Company entered into an amended and restated \$3,000 five-year revolving credit facility with a syndicate of banks for a five-year term expiring November 2027, which replaced, on substantially similar terms, the Company's \$3,000 revolving credit facility that was scheduled to expire in August 2026. In November 2023, the Company extended the term of the credit facility for an additional year, expiring in November 2028. In November 2024, the Company further extended the term of the credit facility for an additional year, expiring in November 2029. Commitment fees related to the credit facility were not material. Domestic and foreign commercial paper outstanding was \$936 and \$906 as of December 31, 2024 and December 31, 2023, respectively. The average daily balances outstanding of commercial paper in 2024 and 2023 were \$1,710 and \$1,800, respectively. The Company classifies commercial paper as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis, including, if necessary, by utilizing its available lines of credit (under the facilities discussed above).

50(Dollars in Millions Except Per Share Amounts)The following is a summary of the Company's commercial paper as of December 31, 2024 and 2023: A 2024 2023 A Weighted Average Interest Rate Maturities Outstanding Weighted Average A Interest Rate Maturities Outstanding Commercial Paper 3.0A % 2025 \$936A 4.0A % 2024 \$906A Certain of the agreements with respect to the Company's bank borrowings contain financial and other covenants as well as cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements and believes the likelihood of noncompliance is remote. Refer to Note 5, Long-Term Debt and Credit Facilities to the Consolidated Financial Statements for further information about the Company's long-term debt and credit facilities. Dividend payments in 2024 were \$1,789, an increase from \$1,749 in 2023. Dividend payments increased to \$1.98 per share in 2024 from \$1.91 per share in 2023. In the first quarter of 2024, the Company increased the quarterly common stock dividend to \$0.50 per share from \$0.48 per share, effective in the second quarter of 2024. The Company repurchases shares of its common stock in the open market and in private transactions to maintain its targeted capital structure and to fulfill certain requirements of its compensation and benefit plans. On March 10, 2022, the Board authorized the repurchase of shares of the Company's common stock having an aggregate purchase price of up to \$5 billion under the 2022 Program, which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company's compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company's discretion, subject to market conditions, customary blackout periods and other factors. Aggregate share repurchases in 2024 consisted of approximately 18.3 million common shares under the 2022 Program and 0.4 million common shares to fulfill the requirements of compensation and benefit plans, for a total purchase price of \$1,739. Aggregate repurchases in 2023 consisted of approximately 14.7 million common shares under the 2022 Program and 0.3 million common shares to fulfill the requirements of compensation and benefit plans, for a total purchase price of \$1,128. Share repurchases, net of proceeds from exercise of stock options, were \$1,101 and \$748 in 2024 and 2023, respectively. Cash and cash equivalents increased \$130 during 2024 to \$1,096 at December 31, 2024, compared to \$966 at December 31, 2023. Cash and cash equivalents held by the Company's foreign subsidiaries was \$1,059 and \$922, respectively, at December 31, 2024 and 2023. The following represents the scheduled maturities of the Company's contractual obligations as of December 31, 2024: A Total 2025 2026 2027 2028 2029 Thereafter Long-term debt including current portion (1) \$7,005A \$652A \$1,035A \$509A \$612A \$519A \$3,678A Net cash interest payments on long-term debt (2) (2) 077A 232A 174A 160A 134A 119A 1,258A Operating Leases 655A 126A 108A 101A 80A 58A 182A Purchase obligations (3) 568A 202A 140A 92A 39A 30A 65A U.S. tax reform payments 77A 77A A A A A A A A Totals 10,382A 1,289A 1,457A 862A 865A 726A \$5,183A (1) The Company classifies commercial paper as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis. The amounts in this table exclude commercial paper. (2) Includes the net interest payments on fixed and variable rate debt. Interest payments associated with floating rate instruments are based on management's best estimate of projected interest rates for the remaining term of variable rate debt. (3) The Company had outstanding contractual obligations with suppliers at the end of 2024 for the purchase of raw, packaging and other materials and services in the normal course of business. These purchase obligation amounts represent only those items which are based on agreements that are legally binding and that specify all significant terms including minimum quantity, price and term and do not represent total anticipated purchases. 51(Dollars in Millions Except Per Share Amounts)Long-term liabilities associated with the Company's postretirement plans are excluded from the table above due to the uncertainty of the timing of these cash disbursements. The amount and timing of cash funding related to these benefit plans will generally depend on the variability of the market value of the assets, changes in the benefit obligations, local regulatory requirements, various economic assumptions (the most significant of which are detailed in Critical Accounting Policies and Use of Estimates below) and voluntary Company contributions. Based on current information, the Company is not required to make a mandatory contribution to its qualified U.S. pension plan in 2025. The Company does not expect to make any voluntary contributions to its U.S. postretirement plans in 2025. In addition, total benefit payments expected to be paid from the Company's assets to participants in unfunded plans are estimated to be approximately \$95 for the year ending December 31, 2025. Additionally, liabilities for unrecognized income tax benefits are excluded from the table above as the Company is unable to reasonably predict the ultimate amount or timing of a settlement of such liabilities. See Note 10, Income Taxes to the Consolidated Financial Statements for more information. As more fully described in Note 12, Commitments and Contingencies to the Consolidated Financial Statements, the Company has commitments and contingencies with respect to lawsuits, environmental matters, taxes and other matters arising in the ordinary course of business. 52(Dollars in Millions Except Per Share Amounts)Off-Balance Sheet ArrangementsThe Company does not have off-balance sheet financing or unconsolidated special purpose entities. Managing Foreign Currency, Interest Rate, Commodity Price and Credit Risk ExposureThe Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a global basis by utilizing a number of techniques, including working capital management, selling price increases, selective borrowings in local currencies and entering into selective derivative instrument transactions, issued with standard features, in accordance with the Company's treasury and risk management policies. The Company's treasury and risk management policies prohibit the use of derivatives for speculative purposes and leveraged derivatives for any purpose. See Note 2, Summary of Significant Accounting Policies and Note 6, Fair Value Measurements and Financial Instruments to the Consolidated Financial Statements for further discussion of derivatives and hedging policies and fair value measurements. Foreign Exchange RiskAs the Company markets its products in over 200 countries and territories, it is exposed to currency fluctuations related to manufacturing and selling its products in currencies other than the U.S. dollar. The Company manages its foreign currency exposures through a combination of cost containment measures, sourcing strategies, selling price increases and the hedging of certain costs in an effort to minimize the impact on earnings of foreign currency rate movements. See Results of Operations above for a discussion of the foreign exchange impact on Net sales in each operating segment. The assets and liabilities of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders' equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year. The Company primarily utilizes foreign currency contracts, including forward and swap contracts, option contracts, foreign and local currency deposits and local currency borrowings to hedge portions of its exposures relating to foreign currency purchases, assets and liabilities created in the normal course of business and the net investment in certain foreign subsidiaries. The duration of foreign currency contracts generally does not exceed 12 months and the contracts are valued using observable market rates. Interest Rate RiskThe Company manages its mix of fixed and floating rate debt against its target with debt issuances and by entering into interest rate swaps in order to mitigate fluctuations in earnings and cash flows that may result from interest rate volatility. The Company utilizes forward-starting interest rate swaps to mitigate the risk of variability in interest rates for future debt issuances. The notional amount, interest payment and maturity date of the swaps generally match the principal, interest payment and maturity date of the related debt, and the swaps are valued using observable benchmark rates. Based on year-end 2024 variable rate debt levels, a 1% increase in interest rates would have increased Interest expense by \$3 in 2024. Commodity Price RiskThe Company is exposed to price volatility related to raw materials used in production, such as resins, essential oils, tropical oils, pulp, tallow, corn, poultry and soybeans. The Company manages its raw material exposures through a combination of cost containment measures, ongoing productivity initiatives and the limited use of commodity hedging contracts. Futures contracts are used on a limited basis, primarily in the Hill's Pet Nutrition segment, to manage volatility related to anticipated raw material inventory purchases of certain traded commodities. 53(Dollars in Millions Except Per Share Amounts)Credit RiskThe Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is the Company's policy to contract with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations. Recent Accounting Pronouncements and Disclosure RulesIn November 2024, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update (ASU) No. 2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments. This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Company's Consolidated Financial Statements. In November 2024, the FASB issued ASU No. 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrants' registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-08, Intangibles Goodwill and Other Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. This ASU improves the accounting for certain crypto assets by requiring companies to measure

them at fair value for each reporting period with changes in fair value recognized in net income. This guidance is effective for the Company for fiscal years beginning after December 15, 2024 and is not expected to have an impact on the Company's Consolidated Financial Statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information to the Consolidated Financial Statements for additional information. In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative. This ASU modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC's regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. 54 (Dollars in Millions Except Per Share Amounts) In August 2023, the FASB issued ASU No. 2023-05, Business Combinations Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement. This ASU requires a joint venture to initially measure all contributions received upon its formation at fair value. This guidance is applicable to joint ventures with a formation date on or after January 1, 2025 and is not expected to have a material impact on the Company's Consolidated Financial Statements. In March 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Company's Consolidated Financial Statements. In September 2022, the FASB issued ASU No. 2022-04, Liabilities Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations. This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programs' key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated roll-forward information. The Company adopted the guidance beginning on January 1, 2023, and with respect to the roll-forward information disclosure, beginning on January 1, 2024. See Note 15, Supplier Finance Programs to the Consolidated Financial Statements for additional information. Critical Accounting Policies and Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Actual results could ultimately differ from those estimates. The accounting policies that are most critical in the preparation of the Company's Consolidated Financial Statements are those that are both important to the presentation of the Consolidated Financial Statements and require significant or complex judgments and estimates on the part of management. The Company's critical accounting policies are reviewed periodically with the Audit Committee of the Board. In certain instances, accounting principles generally accepted in the United States of America allow for the selection of alternative accounting methods. The Company's significant policies that involve the selection of alternative methods are accounting for inventories and handling costs. The Company accounts for inventories using both the first-in, first-out (FIFO) method (approximately 75% of inventories) and the last-in, first-out (LIFO) method (approximately 25% of inventories). There would have been no material impact on reported earnings for 2024 or 2023 had all inventories been accounted for under the FIFO method. Shipping and handling costs (also referred to as logistics costs) may be reported as either a component of Cost of sales or Selling, general and administrative expenses. The Company accounts for such costs, primarily related to warehousing and outbound freight, as fulfillment costs and reports them in the Consolidated Statements of Income as a component of Selling, general and administrative expenses. Accordingly, the Company's Gross profit margin is not comparable with the Gross profit margin of those companies that include shipping and handling charges in Cost of sales. If such costs had been included as a component of Cost of sales, the Company's Gross profit margin would have been lower by 880 bps in 2024, 910 bps in 2023 and 1040 bps in 2022, with no impact on reported earnings. The areas of accounting that involve significant or complex judgments and estimates are pensions and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. In accounting for pension and other postretirement benefit costs, the most significant actuarial assumptions are the discount rate and the expected long-term rate of return on plan assets. The discount rate used to measure the benefit obligation for U.S. defined benefit plans was 5.73% and 5.40% as of December 31, 2024 and 2023, respectively. The discount rate used to measure the benefit obligation for other U.S. postretirement plans was 5.74% and 5.37% as of December 31, 2024 and 2023, respectively. Discount rates used for the U.S. and international defined benefit and other postretirement plans are based on a yield curve constructed from a portfolio of high-quality bonds whose projected cash flows approximate the projected benefit payments of the plans. The assumed expected long-term rate of return on plan assets for U.S. plans was 6.50% as of December 31, 2024 and 2023. In determining the expected long-term rate of return, the Company considers the nature of the Company's investments and the historical rate of return. Average annual rates of return for the U.S. plans for the most recent 1-year, 5-year, 10-year, 15-year and 25-year periods were 5%, 2%, 4%, 6% and 5%, respectively. In addition, the current assumed rate of return for the U.S. plans is based upon the nature of the Company's investments with a target asset allocation of approximately 60% in fixed income securities, 26% in equity securities and 14% in other investments. A 1% change in the assumed rate of return on plan assets of the U.S. pension plans would impact future Net income attributable to Colgate-Palmolive Company by approximately \$11. A 1% change in the discount rate for the U.S. pension plans and the other U.S. retiree benefit plan would impact future Net income attributable to Colgate-Palmolive Company by approximately \$1 and \$2, respectively. A third assumption is the long-term rate of compensation increase for the pension plans, a change in which would partially offset the impact of a change in either the discount rate or the expected long-term rate of return. This rate was 3.50% as of December 31, 2024 and 2023. Refer to Note 9, Retirement Plans and Other Retiree Benefits to the Consolidated Financial Statements for further discussion of the Company's pension and other postretirement plans. The assumption requiring the most judgment in accounting for other postretirement benefits (other than the discount rate noted above) is the medical cost trend rate. The Company reviews external data and its own historical trends for health care costs to determine the medical cost trend rate. The assumed rate of increase for the U.S. postretirement benefit plans is 7.00% for 2025, declining to 5.00% by 2030 and remaining at 4.50% for the years thereafter. A 1% change in the assumed long-term medical cost trend rate would impact future Net income attributable to Colgate-Palmolive Company by \$2. The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant. The Company uses the Black-Scholes-Merton option pricing model to estimate the fair value of stock option awards. The weighted-average estimated fair value of each stock option award granted in the year ended December 31, 2024 was \$22.65. The Black-Scholes model uses various assumptions to estimate the fair value of stock option awards. These assumptions include the expected term of stock option awards, expected volatility rate, risk-free interest rate and expected dividend yield. While these assumptions do not require significant judgment, as the significant inputs are determined from historical experience or independent third-party sources, changes in these inputs could result in significant changes in the fair value of stock option awards. A one-year change in expected term would result in a change in fair value of approximately 7%. A 1% change in volatility would change fair value by approximately 4%. The Company uses a Monte-Carlo simulation to determine the fair value of performance-based restricted stock units at the date of grant. The Monte-Carlo simulation model uses substantially the same inputs as the Black-Scholes model. Goodwill and indefinite-life intangible assets, such as the Company's global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate an asset may be impaired. In assessing impairment, the Company performs either a quantitative or a qualitative analysis. (Dollars in Millions Except Per Share Amounts) Determining the fair value of the Company's reporting units for goodwill and the fair value of its intangible assets requires significant estimates and judgments by management. When a quantitative analysis is performed, the Company generally uses the income approach, which requires several estimates, including future cash flows consistent with management's strategic plans, sales growth rates and the selection of royalty rates and discount rates. Estimating sales growth rates requires significant judgment by management in areas such as future economic conditions, category growth rates, product pricing, consumer tastes and preferences and future expansion expectations. In selecting an appropriate royalty rate, the Company considers the long-term profitability of the brand and recent market transactions for similar brands and products. In determining an appropriate discount rate, the Company considers the current interest rate environment and its estimated cost of capital. Other qualitative factors the Company considers, in addition to those quantitative measures discussed above, include assessments of general macroeconomic conditions, industry-specific considerations and historical financial performance. The Company generally engages a third-party valuation firm to assist it in determining the fair value of intangible assets acquired in business combinations. In determining the fair value of the Company's reporting units, fair value is also determined using the market approach, which is generally derived from metrics of comparable publicly traded companies. As multiple valuation methodologies are used, the Company also performs a qualitative analysis comparing the fair value of a reporting unit under each method to assess its reasonableness and ensure consistency of results. Determining the expected life of a brand requires management judgment and is based on an evaluation of several factors including market share, brand history, future expansion expectations, the level of in-market support anticipated by management, legal or regulatory restrictions and the economic environment in the countries in which the brand is sold. As of the date of the annual goodwill impairment test, the estimated fair value of the Company's reporting units substantially exceeds their carrying value. As of the date of the annual impairment test of indefinite-lived intangible assets, the fair value of one of the Company's indefinite-lived trademark intangible assets exceeded its carrying value by less than 20%. The carrying value of this trademark is \$293 as of December 31, 2024. Given the inherent uncertainties of estimating the future cash flows, the impact of interest rates and inflation on macroeconomic conditions, actual results may differ from management's current estimates, which could potentially result in impairment charges in future periods. The recognition and measurement of uncertain tax positions involves consideration of the amounts and probabilities of various outcomes that could be realized upon ultimate resolution. Tax valuation allowances are established to reduce deferred tax assets, such as tax loss carryforwards, to net realizable value. Factors considered in estimating net realizable value include historical results by tax jurisdiction, carryforward periods, income tax strategies and forecasted taxable income. Legal and other contingency reserves are based on management's assessment of the risk of potential loss, which includes consultation with outside legal counsel and other advisors. Such assessments are reviewed each period and revised based on current facts and circumstances, if necessary. While it is possible that the Company's cash flows and results of operations in a particular quarter or year could be materially affected by the impact of such contingencies, based on current knowledge it is the opinion of management that these matters will not have a material effect on the Company's financial position, or its ongoing results of operations or cash flows. Refer to Note 12, Commitments and Contingencies to the Consolidated Financial Statements for further discussion of the Company's contingencies. 57 (Dollars in Millions Except Per Share Amounts) The Company generates revenue through the sale of well-known consumer products to trade customers under established trading terms. While the recognition of revenue and receivables requires the use of estimates, there is a short time frame (typically less than 60 days) between the shipment of product and cash receipt, thereby reducing the level of uncertainty in these estimates. Refer to Note 2, Summary of Significant Accounting Policies to the Consolidated Financial Statements for further description of the Company's significant accounting policies. 58 (Dollars in Millions Except Per Share Amounts) Cautionary Statement on Forward-Looking Statements This Annual Report on Form 10-K may contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations and releases that set forth anticipated results based on management's current plans and assumptions. Such statements may relate, for example, to sales or volume growth, net selling price increases, organic sales growth, profit or profit margin levels, earnings per share levels, financial goals, the impact of foreign exchange, the impact of additional tariffs, the impact of geopolitical conflicts and tensions, such as the war in Ukraine, the conflict in the Middle East and tensions between China and Taiwan, cost-reduction plans, tax rates, interest rates, new product introductions, digital capabilities, commercial investment levels, acquisitions, divestitures, share repurchases or legal or tax proceedings, among other matters. These statements are made on the basis of the Company's views and assumptions as of this time and the Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Moreover, the Company does not nor does any other person assume responsibility for the accuracy and completeness of those statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Actual events or results may differ materially because of factors that affect international businesses and global economic conditions, as well as matters specific to the Company and the markets it serves, including the uncertain macroeconomic and political environment in different countries, including as a result of inflation and higher interest rates, and its effect on consumer confidence and spending, foreign currency rate fluctuations, exchange controls, import restrictions, tariffs, sanctions, price or profit controls, labor relations, changes in foreign or domestic laws or regulations or their interpretation, political and fiscal developments, including changes in trade, tax and immigration policies, increased competition and evolving competitive practices, the ability to operate and respond effectively during a pandemic, epidemic or widespread public health concern, the ability to manage disruptions in our global supply chain and/or key office facilities, the ability to manage the availability and cost of raw and packaging materials and logistics costs, the ability to maintain or increase selling prices as needed, changes in the policies of retail trade customers, the emergence of alternative retail channels, the growth of eCommerce and the rapidly changing retail landscape, the ability to develop innovative new products and successfully adopt new technologies (such as artificial intelligence), the ability to continue lowering costs and operate in an agile manner, the ability to maintain the security of our information and operational technology systems from a cybersecurity incident or data breach, the ability to address the effects of climate change and achieve our sustainability and social impact goals, the ability to complete acquisitions and divestitures as planned, the ability to successfully integrate acquired businesses, the ability to attract and retain key employees, the uncertainty of the outcome of legal proceedings, whether or not the Company believes they have merit, and the ability to address uncertain or unfavorable global economic conditions, including inflation, disruptions in the credit markets and tax matters. For information about these and other factors that could impact the Company's business and cause actual results to differ materially from forward-looking statements, refer to Part I, Item 1A Risk Factors. ITEM 7A. A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK See Managing Foreign Currency, Interest Rate, Commodity Price and Credit Risk Exposure in Part II, Item 7. 59 ITEM 8. A A FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA See Index to Financial Statements. ITEM 9. A A CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None. ITEM 9A. A A CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures The Company's management, under the supervision and with the participation of the Company's Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of December 31, 2024 (the Evaluation). Based upon the Evaluation, the Company's Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) are effective. Management's Annual Report on Internal Control Over Financial Reporting The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Management, under the supervision and with the participation of the Company's Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the Company's internal control over financial reporting based upon the framework in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and concluded that it was effective as of December 31, 2024. The Company is an independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the Company's internal control over financial reporting as of December 31, 2024, and has expressed an unqualified opinion in their report, which appears under Index to Financial Statements. Report of Independent Registered Public Accounting Firm. Changes in Internal Control Over Financial Reporting The Company is in the process of upgrading its enterprise IT system to SAP S/4 HANA. This change has not had and is not expected to have a material impact on the Company's internal controls over financial reporting. Except as noted above, there were no changes in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. ITEM 9B. A A OTHER INFORMATION (b) Trading Plans During the three months ended December 31, 2024, no director or officer of the Company adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K. ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Not applicable. 60 PART III ITEM 10. A A DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE See Information about our Executive Officers in Part I,

Item 1 of this report.Additional information required by this Item 10 will be included under the headings Governance the Board of Directors, Board Structure and Responsibilities Committees of the Board of Directors Audit Committee and Executive Compensation Compensation Discussion and Analysis Compensation Governance Features Insider Trading Policy and Prohibition on Hedging and Pledging of Company Stock in the Company's Proxy Statement for its 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the year ended December 31, 2024 (the 2025 Proxy Statement) and is incorporated herein by reference.Information on beneficial ownership reporting compliance will be included under the heading Stock Ownership Delinquent Section 16(a) Reports, if applicable, in the 2025 Proxy Statement and is incorporated herein by reference.The Company's Code of Conduct promotes the highest ethical standards in all of the Company's business dealings. The Code of Conduct satisfies the SEC's requirements for a Code of Ethics for senior financial officers and applies to all Company employees, including the Chairman of the Board, President and Chief Executive Officer, the Chief Financial Officer and the Executive Vice President, Controller, and the Company's directors. The Code of Conduct is available on the Company's website at www.colgatepalmolive.com. Any amendment to the Code of Conduct will promptly be posted on the Company's website. It is the Company's policy not to grant waivers of the Code of Conduct. In the extremely unlikely event that the Company grants an executive officer a waiver from a provision of the Code of Conduct, the Company will promptly disclose such information by posting it on its website or by using other appropriate means in accordance with SEC rules.ITEM 11. EXECUTIVE COMPENSATIONInformation required by this Item 11 will be included under the headings Executive Compensation, Governance Compensation of Directors and Governance Compensation Compensation Committee Interlocks and Insider Participation in the 2025 Proxy Statement and is incorporated herein by reference.61ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS(a)Information regarding security ownership of certain beneficial owners and management will be included under the heading Stock Ownership in the 2025 Proxy Statement and is incorporated herein by reference.(b)The Registrant does not know of any arrangements that may at a subsequent date result in a change in control of the Registrant.(c)Equity compensation plan information as of December 31, 2024: (a) (b) (c) Plan CategoryNumber of securities to be issued upon exercise of outstanding options, warrants and rights(in thousands)A Weighted-average exercise price of outstanding options, warrants and rightsA Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))(in thousands)A Equity compensation plans approved by security holders15,798A (1)\$79.00A (2)26,572A (3)Equity compensation plans not approved by security holdersNot applicableA Not applicableA Total15,798A \$79.00A 26,572A (1)Consists of 12,774 options outstanding, 1,987 restricted stock units awarded but not yet vested and 1,037 performance-based restricted stock units outstanding under the Company's 2019 Incentive Compensation Plan, as more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans to the Consolidated Financial Statements.(2)Includes the weighted-average exercise price of stock options outstanding of \$78, restricted stock units of \$88 and performance-based restricted stock units of \$74.(3)Amount includes all of the securities available for future issuances in the form of options, restricted stock units and performance-based awards under the Company's 2019 Incentive Compensation Plan.ITEM 13. A CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCEInformation required by this Item 13 will be included under the headings Governance Certain Relationships and Related Transactions and Governance Director Independence in the 2025 Proxy Statement and is incorporated herein by reference.ITEM 14. A PRINCIPAL ACCOUNTANT FEES AND SERVICESInformation required by this Item 14 will be included under the heading Proposal 2 Ratification of Selection of Independent Registered Public Accounting Firm in the 2025 Proxy Statement and is incorporated herein by reference.62PART IVITEM 15. A EXHIBITS AND FINANCIAL STATEMENT SCHEDULES(a)Financial Statements and Financial Statement SchedulesA A See Index to Financial Statements.A (b) Exhibits:63Exhibit No. DescriptionA 3-A Restated Certificate of Incorporation, as amended. (Registrant hereby incorporates by reference Exhibit 3-A to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, File No. 1-644.)A 3-B Colgate-Palmolive Company By-laws, Amended and Restated as of January 12, 2023. (Registrant hereby incorporates by reference Exhibit 3.01 to its Current Report on Form 8-K filed on January 12, 2023, File No. 1-644.)A 4a) Description of Securities of the Registrant(b) Indenture, dated as of November 15, 1992, between the Company and The Bank of New York Mellon (formerly known as The Bank of New York) as Trustee. (Registrant hereby incorporates by reference Exhibit 4.1 to its Registration Statement on Form S-3 and Post-Effective Amendment No. 1 filed on June 26, 1992, Registration No. 33-48840.) (1) A A A c) Colgate-Palmolive Company Employee Stock Ownership Trust Agreement dated as of June 1, 1989, as amended. (Registrant hereby incorporates by reference Exhibit 4-B (b) to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2000, File No. 1-644.)A A A 10-Aa) Colgate-Palmolive 2019 Incentive Compensation Plan. (Registrant hereby incorporates by reference Annex C to its 2019 Notice of Annual Meeting and Proxy Statement, File No. 1-644.)b) Form of Nonqualified Option Award Agreement used in connection with grants under the Colgate-Palmolive Company 2019 Incentive Compensation Plan. (Registrant hereby incorporates by reference Exhibit 10-B to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, File No. 1-644.)c) Form of Restricted Stock Unit Award Agreement used in connection with grants under the Colgate-Palmolive Company 2019 Incentive Compensation Plan. (Registrant hereby incorporates by reference Exhibit 10-C to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, File No. 1-644.)d) Form of Performance Stock Unit Award Agreement for the 2022-2024 Performance Cycle (Registrant hereby incorporates by reference Exhibit 10-B to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, File No. 1-644.)e) Form of Performance Stock Unit Award Agreement for the 2023-2025 Performance Cycle (Registrant hereby incorporates by reference Exhibit 10-A to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, File No. 1-644.)f) Form of Performance Stock Unit Award Agreement for the 2024-2026 Performance Cycle (Registrant hereby incorporates by reference Exhibit 10-A to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, File No. 1-644.)*10-Ba) Colgate-Palmolive Company Executive Incentive Compensation Plan Trust, as amended. (Registrant hereby incorporates by reference Exhibit 10-B (b) to its Annual Report on Form 10-K for the year ended December 31, 1987, File No. 1-644.)*A A A A b) Amendment, dated as of October 29, 2007, to the Colgate-Palmolive Company Executive Incentive Compensation Plan Trust. (Registrant hereby incorporates by reference Exhibit 10-A (b) to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, File No. 1-644.)*A A A 10-C) Colgate-Palmolive Company Supplemental Salaried Employees Retirement Plan, amended and restated, effective as of January 1, 2021. (Registrant hereby incorporates by reference Exhibit 10-D to its Annual Report on Form 10-K for the year ended December 31, 2021, File No. 1-644.)*10-Da) Colgate-Palmolive Company Executive Severance Plan, as amended and restated through September 13, 2023. (Registrant hereby incorporates by reference Exhibit 10-A to its Current Report on Form 8-K filed on September 15, 2023, File No. 1-644.)*A b) Colgate-Palmolive Company Executive Severance Plan Trust. (Registrant hereby incorporates by reference Exhibit 10-E (b) to its Annual Report on Form 10-K for the year ended December 31, 1987, File No. 1-644.)*64c) Colgate-Palmolive Company Executive Officer Cash Severance Policy. (Registrant hereby incorporates by reference Exhibit 10.1 to its Current Report on Form 8-K filed on April 11, 2022, File No. 1-644.)*A A A 10-EA Colgate-Palmolive Company Pension Plan for Outside Directors, as amended and restated. (Registrant hereby incorporates by reference Exhibit 10-D to its Annual Report on Form 10-K for the year ended December 31, 1999, File No. 1-644.)*A A 10-Fa) Colgate-Palmolive Company Restated and Amended Deferred Compensation Plan for Non-Employee Directors, as amended. (Registrant hereby incorporates by reference Exhibit 10-H to its Annual Report on Form 10-K for the year ended December 31, 1997, File No. 1-644.)*A b) Amendment, effective as of January 1, 2005, to the Colgate-Palmolive Company Restated and Amended Deferred Compensation Plan for Non-Employee Directors. (Registrant hereby incorporates by reference Exhibit 10-F to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, File No. 1-644.)*10-GA Colgate-Palmolive Company Deferred Compensation Plan, amended and restated, effective as of October 28, 2021. (Registrant hereby incorporates by reference Exhibit 10-B to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, File No. 1-644.)*10-H) Amended and Restated Five Year Credit Agreement, dated as of November 4, 2022, by and among Colgate-Palmolive Company, as Borrower, Citibank, N.A., as Administrative Agent and Arranger, and the Lenders party thereto. (Registrant hereby incorporates by reference Exhibit 10-I to its Annual Report on Form 10-K for the year ended December 31, 2022, File No. 1-644.) 10-IColgate-Palmolive Company Supplemental Savings and Investment Plan, amended and restated, effective as of January 1, 2022. (Registrant hereby incorporates by reference Exhibit 10-J to its Annual Report on Form 10-K for the year ended December 31, 2022, File No. 1-644.)*10-J) Form of Indemnification Agreement between Colgate-Palmolive Company and its directors, executive officers and certain key employees. (Registrant hereby incorporates by reference Exhibit 10-K to its Annual Report on Form 10-K for the year ended December 31, 2017, File No. 1-644.)19Colgate-Palmolive Company Insider Trading Policy.*21A Subsidiaries of the Registrant.*A A A 23A Consent of Independent Registered Public Accounting Firm.*A A A 24A Powers of Attorney.*A A A 31-AA Certificate of the Chairman of the Board, President and Chief Executive Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.*31-B Certificate of the Chief Financial Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.*A A A 32A Certificate of the Chairman of the Board, President and Chief Executive Officer and the Chief Financial Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. A 1350.*97Colgate-Palmolive Company Dodd-Frank Clawback Policy for the Recovery of Erroneously Awarded Compensation.*A A 101A The following materials from Colgate-Palmolive Company's Annual Report on Form 10-K for the year ended December 31, 2024, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Changes in Shareholders' Equity, (v) the Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements.*104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*65A A A Indicates a management contract or compensatory plan or arrangement.*A A A Filed herewith.*Furnished herewith.(1)A A A Registrant hereby undertakes to furnish the Commission, upon request, with a copy of any instrument with respect to long-term debt where the total amount of securities authorized thereunder does not exceed 10% of the total assets of the Registrant and its subsidiaries on a consolidated basis.The exhibits indicated above that are not included with the Form 10-K are available upon request and payment of a reasonable fee approximating the registrant's cost of providing and mailing the exhibits. Inquiries should be directed to:Colgate-Palmolive CompanyOffice of the Secretary (10-K Exhibits)300 Park AvenueNew York, NY 10022-74996ITEM 16. A FORM 10-K SUMMARYNone.67 COLGATE-PALMOLIVE COMPANYSIGNATURESPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.A Colgate-Palmolive CompanyA A A A A A (Registrant)A A A A Date: February 13, 2025By:/ Noel WallaceA A Noel Wallace Chairman of the Board, President andChief Executive OfficerPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 13, 2025, by the following persons on behalf of the registrant and in the capacities indicated.A A A (a) A A A A A A Principal Executive OfficerA (d) A A A A A A Directors:/s/ Noel WallaceA/s/ Noel WallaceNoel Wallace Chairman of the Board, President andChief Executive OfficerA Noel Wallace(b) A A A A A A A Principal Financial OfficerA John P. Bilbrey, John T. Cahill, Steven A. Cahillane,Lisa M. Edwards, C. Martin Harris, Martina Hund-Mejean, Kimberly A. Nelson,Brian O. Newman, Lorrie M. NorringtonA A /s/ Stanley J. Sutula IIIA *By: /s/ Jennifer M. DanielsStanley J. Sutula IIIChief Financial OfficerA Jennifer M. DanielsAs Attorney-in-FactA A (c) A A A A A A A Principal Accounting OfficerA A A /s/ Gregory O. MalcolmA Gregory O. MalcolmExecutive Vice President, ControllerA 68Index to Financial StatementsA PageConsolidated Financial StatementsA A Report of Independent Registered Public Accounting Firm (PCAOB ID 2387)70A A Consolidated Statements of Income for the years ended December 31, 2024, 2023 and 202272Consolidated Statements of Comprehensive Income for the years ended December 31, 2024, 2023 and 202273A A Consolidated Balance Sheets as of December 31, 2024 and 202374A A Consolidated Statements of Changes in Shareholders' Equity for the years ended December 31, 2024, 2023 and 202275A A Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 202276A A Notes to Consolidated Financial Statements77A A Market Information121A A All other financial statements and schedules not listed have been omitted since the required information is included in the financial statements or the notes thereto or is not applicable or required.69 Report of Independent Registered Public Accounting FirmTo the Board of Directors and Shareholders of Colgate-Palmolive CompanyOpinions on the Financial Statements and Internal Control over Financial ReportingWe have audited the accompanying consolidated balance sheets of Colgate-Palmolive Company and its subsidiaries (the "Company") as of December 31, 2024 and 2023, and the related consolidated statements of income, of comprehensive income, of changes in shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.Basis for OpinionsThe Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.Definition and Limitations of Internal Control over Financial ReportingA company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.70Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.Critical Audit MattersThe critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.Goodwill Impairment Assessment for a Certain Reporting Unit within the North America Oral, Personal and Home Care Segment Prior to the Reporting Structure RealignmentAs

described in Notes 2, 4 and 13 to the consolidated financial statements, goodwill within the North America Oral, Personal and Home Care segment was \$1,108 million as of December 31, 2024, of which a portion relates to a certain reporting unit. Goodwill is subject to an impairment test at least annually or when events or changes in circumstances indicate that an asset may be impaired. In connection with management changes, the Company realigned the reporting structure of its skin health business effective July 1, 2024, and in conjunction with this reporting structure realignment, management completed a goodwill impairment assessment. As disclosed by management, determining the fair value of the Company's reporting units for goodwill requires significant estimates and judgments by management. When a quantitative analysis is performed, management uses the income approach, which requires several estimates, including future cash flows consistent with management's strategic plans, sales growth rates and discount rates. The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment for a certain reporting unit within the North America Oral, Personal and Home Care segment prior to the reporting structure realignment is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of a certain reporting unit within the North America Oral, Personal and Home Care segment prior to the reporting structure realignment; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to the sales growth rates and the discount rate; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management's goodwill impairment assessment, including controls over the valuation of a certain reporting unit within the North America Oral, Personal and Home Care segment prior to the reporting structure realignment. These procedures also included, among others (i) testing management's process for developing the fair value estimate of a certain reporting unit within the North America Oral, Personal and Home Care segment prior to the reporting structure realignment; (ii) evaluating the appropriateness of the income approach used by management; (iii) testing the completeness and accuracy of underlying data used in the income approach; and (iv) evaluating the reasonableness of the significant assumptions used by management related to the sales growth rates and the discount rate. Evaluating management's assumptions related to the sales growth rates involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of a certain business within the North America Oral, Personal and Home Care segment; (ii) the consistency with external market and industry data; and (iii) whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the income approach and (ii) the reasonableness of the discount rate assumption. PricewaterhouseCoopers LLP New York, New York February 13, 2025 We have served as the Company's auditor since 2002. COLGATE-PALMOLIVE COMPANY Consolidated Statements of Income For the years ended December 31, (Dollars in Millions Except Per Share Amounts) 2024 2023 2022 Net sales \$20,101.1 \$19,457.1 \$17,967.1 Cost of sales \$7,940.8 \$8,131.7 \$7,914.9 Gross profit \$12,161.1 \$11,326.4 \$10,248.4 Selling, general and administrative expenses \$7,729.4 \$7,151.4 \$6,565.4 Other (income) expense, net \$164.4 \$191.4 \$69.4 Goodwill and intangible assets impairment charges \$4.0 \$2.1 \$2.1 Operating profit \$4,268.4 \$3,984.2 \$2,893.4 Non-service related postretirement costs \$87.4 \$360.4 \$80.4 Interest expense \$292.4 \$287.4 \$167.4 Interest income \$67.4 \$55.4 \$14.4 Income before income taxes \$3,956.4 \$3,924.2 \$2,660.4 Provision for income taxes \$907.4 \$937.4 \$693.4 Net income including noncontrolling interests \$3,049.4 \$2,455.4 \$1,967.4 Less: Net income attributable to noncontrolling interests \$160.4 \$152.4 \$182.4 Net income attributable to Colgate-Palmolive Company \$2,889.4 \$2,303.4 \$1,785.4 Earnings per common share, basic \$3.53 \$2.78 \$2.13 Earnings per common share, diluted \$3.51 \$2.77 \$2.13 See Notes to Consolidated Financial Statements. 72 COLGATE-PALMOLIVE COMPANY Consolidated Statements of Comprehensive Income For the years ended December 31, (Dollars in Millions) 2024 2023 2022 Net income including noncontrolling interests \$3,049.4 \$2,455.4 \$1,967.4 Other comprehensive income (loss), net of tax: \$1.4 \$1.4 \$1.4 Cumulative translation adjustments (343) 984 (146) \$1.4 \$1.4 Retirement plan and other retiree benefit adjustments 434 (16) 413 \$1.4 \$1.4 Gains (losses) on cash flow hedges 84 (76) 0 Total Other comprehensive income (loss), net of tax (292) 754 327 Total Comprehensive income including noncontrolling interests 2,757.4 2,530.4 2,294.4 Less: Net income attributable to noncontrolling interests \$160.4 \$152.4 \$182.4 Less: Cumulative translation adjustments attributable to noncontrolling interests (8) (42) (4) Total Comprehensive income attributable to noncontrolling interests \$152.4 \$113.4 \$178.4 Total Comprehensive income attributable to Colgate-Palmolive Company \$2,605.4 \$2,417.4 \$2,116.4 See Notes to Consolidated Financial Statements. 73 COLGATE-PALMOLIVE COMPANY Consolidated Balance Sheets As of December 31, (Dollars in Millions Except Share and Per Share Amounts) 2024 2023 2022 Assets Current Assets \$ Cash and cash equivalents \$1,096.4 \$966.4 Receivables (net of allowances of \$85 and \$80, respectively) \$1,521.4 \$1,586.4 Inventories \$1,987.4 \$1,934.4 Other current assets \$713.4 \$793.4 Total current assets \$5,317.4 \$5,279.4 Property, plant and equipment, net \$4,222.4 \$4,582.4 Goodwill \$3,272.4 \$3,410.4 Other intangible assets, net \$1,756.4 \$1,887.4 Deferred income taxes \$195.4 \$214.4 Other assets \$1,084.4 \$1,021.4 Total assets \$16,046.4 \$16,393.4 Liabilities and Shareholders' Equity Equity \$ Current Liabilities \$ Debt payable within one year \$660.4 \$330.4 Accounts payable \$1,805.4 \$1,698.4 Accrued income taxes \$403.4 \$336.4 Other accruals \$2,891.4 \$2,377.4 Total current liabilities \$5,759.4 \$4,741.4 Long-term debt \$7,289.4 \$8,219.4 Deferred income taxes \$434.4 \$361.4 Other liabilities \$2,111.4 \$2,154.4 Total liabilities \$15,502.4 \$15,436.4 Commitments and contingent liabilities \$4.0 \$4.0 \$4.0 Shareholders' Equity \$ Common stock, \$1 par value (2,000,000,000 shares authorized, 1,465,706,360 shares issued) \$1,466.4 \$1,466.4 Additional paid-in capital \$4,181.4 \$3,808.4 Retained earnings \$26,145.4 \$25,289.4 Accumulated other comprehensive income (loss) \$(4,222.4) \$(3,937.4) Treasury stock, at cost \$(27,358.4) \$(26,017.4) Total Colgate-Palmolive Company shareholders' equity \$2,112.4 \$609.4 Noncontrolling interests \$332.4 \$348.4 Total equity \$2,444.4 \$957.4 Total liabilities and equity \$16,046.4 \$16,393.4 See Notes to Consolidated Financial Statements. 74 COLGATE-PALMOLIVE COMPANY Consolidated Statements of Changes in Shareholders' Equity (Dollars in Millions) \$ Colgate-Palmolive Company Shareholders' Equity \$ Common Stock Additional Paid-In Capital Unearned Compensation Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Noncontrolling Interests Balance, January 1, 2022 \$1,466.4 \$3,269.4 \$(1) \$(24,089) \$24,350.4 \$(4,386) \$362.4 Net income \$2,889.4 \$2,303.4 \$1,785.4 \$1,882.4 Other comprehensive income (loss), net of tax \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Dividends \$(1.86) /per share \$4.0 \$4.0 \$4.0 (1.562) \$4.0 (1.35) Stock-based compensation expense \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Shares issued for stock options \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Shares issued for restricted stock awards \$4.0 (40) \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Treasury stock acquired \$4.0 \$4.0 \$4.0 (1,308) \$4.0 \$4.0 \$4.0 Other \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Balance, December 31, 2022 \$1,466.4 \$3,546.4 \$(1) \$(25,128) \$24,573.4 \$(4,055) \$405.4 Net income \$2,889.4 \$2,303.4 \$1,785.4 \$1,882.4 Other comprehensive income (loss), net of tax \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Dividends \$(1.91) /per share \$4.0 \$4.0 \$4.0 (1.584) \$4.0 (1.70) Stock-based compensation expense \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Shares issued for stock options \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Shares issued for restricted stock awards \$4.0 (34) \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Treasury stock acquired \$4.0 \$4.0 \$4.0 (1,128) \$4.0 \$4.0 \$4.0 Other \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Balance, December 31, 2023 \$1,466.4 \$3,808.4 \$(4) \$(26,017) \$25,289.4 \$(3,937) \$348.4 Net income \$2,889.4 \$2,303.4 \$1,785.4 \$1,882.4 Other comprehensive income (loss), net of tax \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Dividends \$(2.48) /per share \$4.0 \$4.0 \$4.0 (2.034) \$4.0 (1.68) Stock-based compensation expense \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Shares issued for stock options \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Shares issued for restricted stock awards \$4.0 (52) \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Treasury stock acquired \$4.0 \$4.0 \$4.0 (1,739) \$4.0 \$4.0 \$4.0 Other \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 \$4.0 Balance, December 31, 2024 \$1,466.4 \$4,181.4 \$(4) \$(27,358) \$26,145.4 \$(4,222) \$332.4 * Five dividends were declared in 2024. Four dividends were declared in 2023 and 2022. See Notes to Consolidated Financial Statements. 75 COLGATE-PALMOLIVE COMPANY Consolidated Statements of Cash Flows For the years ended December 31, (Dollars in Millions) \$ 2024 2023 2022 Operating Activities \$ Net income including noncontrolling interests \$3,049.4 \$2,455.4 \$1,967.4 Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations: \$ Depreciation and amortization \$605.4 \$567.4 \$545.4 ERISA litigation matter \$267.4 \$267.4 Restructuring and termination benefits, net of cash \$51.4 (23) 494 Stock-based compensation expense \$135.4 \$122.4 \$125.4 Gain on the sale of land \$4.0 \$4.0 (47) Goodwill and intangible assets impairment charges \$4.0 \$2.1 \$2.1 Deferred income taxes (77) (98) (78) Cash effects of changes in: \$ Receivables (56) (37) (22) Inventories (100) 194 (33) Accounts payable and other accruals \$161.4 \$309.4 (115) Other non-current assets and liabilities (16) (11) (51) Net cash provided by operations \$4,107.4 \$3,745.4 \$2,556.4 Investing Activities \$ Capital expenditures (561) (705) (696) Purchases of marketable securities and investments (574) (506) (470) Proceeds from sale of marketable securities and investments \$564.4 \$502.4 \$324.4 Payment for acquisitions, net of cash acquired \$4.0 \$4.0 (809) Proceeds from the sale of land \$4.0 \$4.0 \$4.0 Other investing activities \$37.4 (33) \$5.4 Net cash used in investing activities (524) (742) (1,601) Financing Activities \$ Short-term borrowing (repayment) less than 90 days, net \$93.4 (906) \$40.4 Principal payments on debt (503) (903) (406) Proceeds from issuance of debt \$1,495.4 \$1,513.4 Dividends paid (1,789) (1,749) (1,691) Purchases of treasury shares (1,739) (1,128) (1,308) Proceeds from exercise of stock options \$638.4 \$380.4 \$418.4 Other financing activities (91) 184 (18) Net cash used in financing activities (3,389) (2,793) (952) Effect of exchange rate changes on Cash and cash equivalents (54) (19) (60) Net increase (decrease)

from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit.79COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Income TaxesThe provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return.Á The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes.Financial InstrumentsDerivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Companyæ™™s derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged.Á Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows.The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Companyæ™™s derivative instruments and other financial instruments are more fully described in Note 6, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations.(Stock-Based Compensation)The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period.Á The Company uses the Black-Scholes-Merton (æœBlack-Scholesæ) option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Companyæ™™s stock at the date of grant.Á Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans.Currency TranslationThe assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholdersæ™™ equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year.For subsidiaries operating in highly inflationary environments, local currency-denominated non-monetary assets, including inventories, goodwill and property, plant and equipment, are remeasured at their historical exchange rates, while local currency-denominated monetary assets and liabilities are remeasured at year-end exchange rates. Remeasurement adjustments for these operations are included in Net income attributable to Colgate-Palmolive Company. 80COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Recent Accounting Pronouncements and Disclosure RulesIn November 2024, the Financial Accounting Standards Board (the æœFASBæ) issued Accounting Standards Update (æœASUæ) No. 2024-04, æœDebtæ™™Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments.æ This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Companyæ™™s Consolidated Financial Statements.In November 2024, the FASB issued ASU No. 2024-03, æœIncome Statementæ™™Reporting Comprehensive Incomeæ™™Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.æ This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Companyæ™™s Consolidated Financial Statements. In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrantsæ™™ registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Companyæ™™s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, æœIncome Taxes (Topic 740): Improvements to Income Tax Disclosures.æ This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Companyæ™™s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-08, æœIntangiblesæ™™Goodwill and Otheræ™™Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets.æ This ASU improves the accounting for certain crypto assets by requiring companies to measure them at fair value for each reporting period with changes in fair value recognized in net income. This guidance is effective for the Company for fiscal years beginning after December 15, 2024 and is not expected to have an impact on the Companyæ™™s Consolidated Financial Statements.In November 2023, the FASB issued ASU No. 2023-07, æœSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.æ This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information for additional information.In October 2023, the FASB issued ASU No. 2023-06, æœDisclosure Improvementsæ™™Codification Amendments in Response to the SECæ™™s Disclosure Update and Simplification Initiative.æ This ASU modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SECæ™™s regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Companyæ™™s Consolidated Financial Statements. In August 2023, the FASB issued ASU No. 2023-05, æœBusiness Combinationsæ™™Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement.æ This ASU requires a joint venture to initially measure all contributions received upon its formation at fair value. This guidance is applicable to joint ventures with a formation date on or after January 1, 2025 and is not expected to have a material impact on the Companyæ™™s Consolidated Financial Statements.81COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)In March 2023, the FASB issued ASU No. 2023-01, æœLeases (Topic 842): Common Control Arrangements.æ This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Companyæ™™s Consolidated Financial Statements. In September 2022, the FASB issued ASU No. 2022-04, æœLiabilitiesæ™™Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.æ This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programsæ™™ key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated roll-forward information. The Company adopted the guidance beginning on January 1, 2023, and with respect to the roll-forward information disclosure, beginning on January 1, 2024. See Note 15, Supplier Finance Programs for additional information.ReclassificationsCertain prior year amounts have been reclassified to conform to the current year presentation. 82COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)3.Á Á Á Restructuring and Related Implementation Charges Á On January 27, 2022, the Board approved a targeted productivity program (the æœ2022 Global Productivity Initiativeæ). All initiatives have been implemented and the program concluded on December 31, 2024. The 2022 Global Productivity Initiative resulted in the reallocation of resources towards the Companyæ™™s strategic priorities and faster growth businesses, efficiencies in the Companyæ™™s operations and the streamlining of its supply chain to reduce structural costs.Over the course of the 2022 Global Productivity Initiative, the Company incurred total pretax charges of \$228 (\$186 aftertax) in connection with the implementation of various projects as follows:Total Program Chargesas of DecemberÁ 31, 2024Employee-Related Costs\$175Á Incremental Depreciation13Á Asset Impairments1Á Other39Á Totals\$228Á Total pretax charges resulting from the 2022 Global Productivity Initiative were comprised of the following categories: employee-related costs, including severance, pension and other termination benefits (80%); asset-related costs, primarily accelerated depreciation and asset write-downs (5%); and other charges (15%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. Over the course of the 2022 Global Productivity Initiative, approximately 80% of the charges resulted in cash expenditures. For the twelve months ended December 31, 2024 and December 31, 2023, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows:Twelve Months Ended December 31, 20242023Gross Profit\$20Á \$1Á Selling, general and administrative expenses6Á 2Á Other (income) expense, net59Á 24Á Non-service related postretirement costsæ™™ Á 5Á Total 2022 Global Productivity Initiative charges, pretax\$85Á \$32Á Total 2022 Global Productivity Initiative charges, aftertax\$73Á \$25Á Restructuring and related implementation charges are recorded in the Corporate segment as these initiatives are predominantly centrally directed and controlled and are not included in internal measures of segment operating performance. 83COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments:Twelve Months Ended December 31, Total Program ChargesÁ 20242023North America(1)3Á %15Á %9Á %Latin America æ™™ Á %æ™™ Á %9Á %Europe(1)89Á %19Á %44Á %Asia Pacificæ™™ Á %20Á %7Á %Africa/Eurasiaæ™™ Á %5Á %6Á %Hill's Pet Nutrition6Á %23Á %11Á %Corporateæ™™ Á %18Á %14Á %Total100Á %100Á %100Á %100Á %1) The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. See Note 13, Segment Information for additional details.The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals:Twelve Months Ended December 31, Á Employee-Related CostsÁ Incremental DepreciationÁ Asset ImpairmentsOtherTotalBalance at December 31, 2022\$30Á \$æ™™ Á \$1Á \$3Á \$34Á Charges24Á æ™™ Á \$æ™™ Á 8Á 32Á Cash Payments(45)æ™™ Á \$æ™™ Á (10)(55)Charges against assets(5)æ™™ Á (1)æ™™ Á (6)Foreign exchange6Á æ™™ Á \$æ™™ Á 6Á Balance at DecemberÁ 31, 2023\$10Á \$æ™™ Á \$æ™™ Á \$1Á \$11Á Charges 49Á 13Á æ™™ Á 23Á 85Á Cash Payments (20)æ™™ Á \$æ™™ Á (14)(34)Charges against assetsæ™™ Á (13)æ™™ Á æ™™ Á (13)Foreign exchange(5)æ™™ Á æ™™ Á æ™™ Á æ™™ Á (5)Balance at DecemberÁ 31, 2024\$34Á \$æ™™ Á \$æ™™ Á \$10Á \$44Á Employee-Related Costs primarily include severance and other termination benefits and are calculated based on long-standing benefit practices, written severance policies, local statutory requirements and, in certain cases, voluntary termination arrangements. Employee-Related Costs also include pension enhancements which are reflected as Charges against assets within Employee-Related Costs in the preceding table, as the corresponding balance sheet amounts are reflected as a reduction of pension assets or an increase in pension liabilities. Incremental Depreciation is recorded to reflect changes in useful lives and estimated residual values for long-lived assets that will be taken out of service prior to the end of their normal service period. Asset Impairments are recorded to write down inventories and assets held for sale or disposal to their fair value based on amounts expected to be realized. Charges against assets within Asset Impairments are net of cash proceeds pertaining to the sale of certain assets, as applicable.84COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)4.Á Á Á Goodwill and Other Intangible AssetsThe changes in net carrying value of Goodwill by segment for the years ended DecemberÁ 31, 2024 and 2023 were as follows:2023Á Á Beginning BalanceForeign currency translationEnding BalanceOral, Personal and Home CareÁ North America\$906Á \$2Á \$908Á Latin America168Á 11Á 179Á Europe1,504Á 67Á 1,571Á Asia Pacific179Á æ™™ Á 179Á Africa/Eurasia107Á (19)88Á Total Oral, Personal and Home Care2,864Á 61Á 2,925Á Pet Nutrition488Á (3)485Á Total Goodwill\$3,352Á \$58Á \$3,410Á 2024Á Á Beginning BalanceReallocation (1)Foreign currency translationEnding BalanceOral, Personal and Home CareÁ North America\$908Á \$223Á (23)\$1,108Á Latin America179Á æ™™ Á (34)145Á Europe1,571Á (223)(67)1,281Á Asia Pacific179Á æ™™ Á (11)178Á Africa/Eurasia88Á æ™™ Á (10)78Á Total Oral, Personal and Home Care2,925Á æ™™ Á (135)2,790Á Pet Nutrition485Á æ™™ Á (3)482Á Total Goodwill\$3,410Á \$æ™™ Á \$æ™™ Á (138)\$3,272Á (1) As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reallocation of the goodwill, the Company completed an assessment indicating no goodwill impairment was required as a result of this segment reporting structure realignment. Refer to Note 13, Segment Information for additional information.85COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Other intangible assets as of DecemberÁ 31, 2024 and 2023 were comprised of the following:Á Á 20242023Á Á Gross Carrying AmountAccumulated AmortizationNetGross Carrying AmountAccumulated AmortizationNetTrademarks - finite life\$1,135Á (\$545)\$590Á \$1,167Á (\$519)\$648Á Other finite life intangible assets\$03Á (385)218Á 624Á (363)261Á Indefinite life intangible assets\$48Á æ™™ Á 948Á 978Á æ™™ Á 978Á Total Other intangible assets\$2,686Á (\$930)\$1,756Á \$2,769Á (\$882)\$1,887Á The change in the net carrying amounts of Other intangible assets during 2024 was due to foreign currency translation and amortization expense of \$75. Annual estimated amortization expense for each of the next five years is expected to be approximately \$68. In 2023, the Company re-characterized a certain trademark from an indefinite to a finite life intangible asset based on an assessment of certain macroeconomic conditions, historical performance and demand. The carrying value of this trademark, as of December 31, 2024 is \$234 and is being amortized over its estimated remaining useful life of 24 years.As of the date of the annual impairment test of indefinite-lived intangible assets, the fair value of one of the Companyæ™™s indefinite-lived trademark intangible assets exceeded its carrying value by less than 20%. The carrying value of this trademark is \$293 as of December 31, 2024. Given the inherent uncertainties of estimating the future cash flows, the impact of interest rates and inflation on macroeconomic conditions, actual results may differ from management's current estimates which could potentially result in impairment charges in future periods. 5.Á Á Á Long-Term Debt and Credit FacilitiesLong-term debt consisted of the following at December 31:Á Á Weighted Average Interest RateMaturities20242023Notes3.0%2025-2078\$6,946Á \$7,580Á Commercial paper3.0%2025936Á 606Á Finance Lease ObligationsVarious59Á \$53,794Á1.8,239Á Less: Current portion of long-term debt(652)(20)TotalÁ \$7,289Á \$8,219Á Debt payable within one year consisted of the following at December 31:Á Á 20242023Notes and loans payable\$8Á \$310Á Current portion of long-term debt652Á 20Á Debt payable within one year \$660Á \$330Á 86COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)The Company classifies commercial paper as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis. Excluding commercial paper, scheduled maturities of long-term debt and finance leases outstanding as of DecemberÁ 31, 2024, were as follows: Á Years Ended December 31, 2025\$652Á 20261,035Á 2027509Á 2028612Á 2029519Á Thereafter3,678Á Totals\$7,005Á The Companyæ™™s debt issuances and redemptions support its capital structure strategy objectives of funding its business and growth initiatives while minimizing its risk-adjusted cost of capital. During the year ended December 31, 2024, the Company redeemed at maturity \$500 of ten-year Medium-Term Notes with a fixed coupon of 3.25%. The redemption was financed with commercial paper borrowings. In March 2023, the Company issued \$500 of three-year Senior Notes at a fixed coupon rate of 4.800%, \$500 of five-year Senior Notes at a fixed coupon rate of 4.600% and \$500 of ten-year Senior Notes at a fixed coupon rate of 4.600%. At DecemberÁ 31, 2024, the Company had access to unused domestic and foreign lines of credit of \$3,725 (including under the facility discussed below) and could also issue long-term debt pursuant to an effective shelf registration statement. In November 2022, the Company entered into an amended and restated \$3,000 five-year revolving credit facility with a syndicate of banks for a five-year term expiring November 2027, which replaced, on substantially similar terms, the Companyæ™™s \$3,000 revolving credit facility that was scheduled to expire in August 2026. In November 2023, the Company extended the term of the credit facility for an additional year, expiring in November 2028. In November 2024, the Company further extended the term of the credit facility for an additional year, expiring in November 2029. Commitment fees related to the credit facility are not material. Certain agreements with respect to the Companyæ™™s bank borrowings contain financial and other covenants as well as cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements. 87COLGATE-PALMOLIVE COMPANÝA Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and

Per Share Amounts)6.Â Â Â Â Fair Value Measurements and Financial Instruments The Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates.Â The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material, as it is the Companyâ€™s policy to contract only with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations. The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a global basis by utilizing a number of techniques, including working capital management, sourcing strategies, selling price increases, selective borrowings in local currencies and entering into selective derivative instrument transactions, issued with standard features, in accordance with the Companyâ€™s treasury and risk management policies, which prohibit the use of derivatives for speculative purposes and leveraged derivatives for any purpose.Â It is the Companyâ€™s policy to enter into derivative instrument contracts with terms that match the underlying exposure being hedged.Â Provided below are details of the Companyâ€™s exposures by type of risk and derivative instruments by type of hedge designation. Valuation Considerations The Companyâ€™s derivative instruments include foreign currency contracts and commodity contracts. The fair value of these instruments are classified as follows: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entityâ€™s own assumptions. Foreign Exchange Risk As the Company markets its products in over 200 countries and territories, it is exposed to currency fluctuations related to manufacturing and selling its products in currencies other than the U.S. dollar. The Company manages its foreign currency exposures through a combination of cost containment measures, sourcing strategies, selling price increases and the hedging of certain costs in an effort to minimize the impact on earnings of foreign currency rate movements. The Company primarily utilizes foreign currency contracts, including forward and swap contracts, option contracts, foreign and local currency deposits and local currency borrowings to hedge portions of its foreign currency purchases, assets and liabilities arising in the normal course of business and the net investment in certain foreign subsidiaries. The duration of foreign currency contracts generally does not exceed 12 months and the contracts are valued using observable market rates (Level 2 valuation). Interest Rate Risk The Company manages its targeted mix of fixed and floating rate debt with debt issuances and by entering into interest rate swaps in order to mitigate fluctuations in earnings and cash flows that may result from interest rate volatility. Â The Company utilizes forward-starting interest rate swaps to mitigate the risk of variability in interest rates for future debt issuances. The notional amount, interest payment and maturity date of the swaps generally match the principal, interest payment and maturity date of the related debt, and the swaps are valued using observable benchmark rates (Level 2 valuation). 88COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) Commodity Price Risk The Company is exposed to price volatility related to raw materials used in production, such as resins, essential oils, tropical oils, pulp, tallow, corn, poultry and soybeans. The Company manages its raw material exposures through a combination of cost containment measures, sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts. Â Futures contracts are used on a limited basis, primarily in the Hillâ€™s Pet Nutrition segment, to manage volatility related to raw material inventory purchases of certain traded commodities, and these contracts are measured using quoted commodity exchange prices (Level 1 valuation). The duration of the commodity contracts generally does not exceed 12 months. Credit Risk The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is the Companyâ€™s policy to contract with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations. The following table summarizes the fair value of the Companyâ€™s derivative instruments and other financial instruments which are carried at fair value in the Companyâ€™s Consolidated Balance Sheets as of December 31, 2024 and 2023: Â Assets Liabilities Â Account Fair Value Designated derivative instruments Â December 31, 2024 December 31, 2023 Â December 31, 2024 December 31, 2023 Foreign currency contracts Other current assets 33Â 19A Other accruals 22Â 25A Commodity contracts Other current assets 6Â Â 6Â Other accruals 1A 1A Total designated 33Â 19A 23Â 26A Other financial instruments 1A 1A Marketable securities Other current assets 160A 179A 1A 1A Total other financial instruments 160A 179A 1A 1A The carrying amount of cash, cash equivalents, accounts receivable and short-term debt approximated fair value as of December 31, 2024 and 2023. Â The estimated fair value of the Companyâ€™s long-term debt, including the current portion, as of December 31, 2024 and 2023, was \$7,433 and \$7,862, respectively, and the related carrying value was \$7,941 and \$8,239, respectively. Â The estimated fair value of long-term debt was derived principally from quoted prices on the Companyâ€™s outstanding fixed-term notes (Level 2 valuation). 89COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) The following tables present the notional values as of: Â December 31, 2024 Foreign Currency Contracts Foreign Currency Debt Commodity Contracts Â Total Fair Value Hedges Â 1,669A 6A 6Â Â 1,669A Cash Flow Hedges 1,023A 6Â 18A 1,041A Net Investment Hedges 289A 3,750A 6Â 4,039A Â December 31, 2023 Foreign Currency Contracts Foreign Currency Debt Commodity Contracts Â Total Fair Value Hedges Â 1,625A 6A 6Â Â 1,625A Cash Flow Hedges 869A 6Â 39A 908A Net Investment Hedges 280A 3,908A 6Â 4,188A The amount of gain (loss) recognized in income associated with fair value hedges did not have a material impact on the Companyâ€™s Consolidated Financial Statements during the twelve months ended December 31, 2024. The amount of gain (loss) recognized in income and Accumulated Other Comprehensive Income (AOCI) associated with cash flow hedges did not have a material impact on the Companyâ€™s Consolidated Financial Statements during the twelve months ended December 31, 2024. The following table presents the amount of gain (loss) on net investment hedges recognized in the Companyâ€™s AOCI: Gain (Loss) Recognized in AOCI Twelve Months Ended December 31, Hedging instruments: 2024 2023 Foreign currency contracts 42A \$(34) Foreign currency debt 211A (124) Total gain (loss) on net investment hedges 253A \$(158) 90COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) 7.Â Â Â Â Capital Stock and Stock-Based Compensation Plans Preference Stock The Company has the authority to issue 50,262,150 shares of preference stock. Â Stock Repurchases On March 10, 2022, the Board authorized the repurchase of shares of the Companyâ€™s common stock having an aggregate purchase price of up to \$5A billion under a new share repurchase program, which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Companyâ€™s compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Companyâ€™s discretion, subject to market conditions, customary blackout periods and other factors. The Company repurchased its common stock at a cost of \$1,739 during 2024. The Company may use either authorized and unissued shares or treasury shares to meet share requirements resulting from the exercise of stock options and the vesting of restricted stock unit awards. A summary of common stock and treasury stock activity for the three years ended December 31 is as follows: Â Common Stock Outstanding Treasury Stock Balance, January 1, 2022 840,480,284A 625,226,076A Common stock acquired (17,060,788) 17,060,788A Shares issued for stock options 5,654,692A (5,654,692) Shares issued for restricted stock units and other 1,138,418A (1,138,418) Balance, December 31, 2022 830,212,606A 635,493,754A Common stock acquired (14,735,909) 14,735,909A Shares issued for stock options 5,318,430A (5,318,430) Shares issued for restricted stock units and other 617,642A (617,642) Balance, December 31, 2023 821,412,769A 644,293,591A Common stock acquired (18,321,422) 18,321,422A Shares issued for stock options 8,606,699A (8,606,699) Shares issued for restricted stock units and other 876,652A (876,652) Balance, December 31, 2024 812,574,698A 653,131,662A 91COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units, based on the fair value of those awards at the date of grant. The fair value of restricted stock units, generally based on market price, is amortized ratably over the requisite service period. The estimated fair value of stock options on the date of grant, based on the Black-Scholes value described below, is amortized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company accounts for forfeitures as they occur. Â Awards to employees eligible for retirement prior to the award becoming fully vested are recognized as compensation cost from the grant date through the date that the employee first becomes eligible to retire and is no longer required to provide service to earn the award. The Company has one incentive compensation plan pursuant to which it issues restricted stock units (both performance-based and time-vested) and stock options to employees and shares of common stock and stock options to non-employee directors. The Personnel and Organization Committee of the Board, which is comprised entirely of independent directors, administers the incentive compensation plan. The total stock-based compensation expense charged against pretax income for this plan was \$135, \$122 and \$125 for the years ended December 31, 2024, 2023 and 2022, respectively. The total income tax benefit recognized on stock-based compensation, excluding excess tax benefits, was approximately \$26, \$22 and \$25 for the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is recorded within Selling, general and administrative expenses in the Corporate segment as these amounts are not included in internal measures of segment operating performance. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. Â The weighted-average fair value assumptions are summarized in the following table: Â 2024 2023 2022 Expected term of options 6 years 6 years 6 years Expected volatility rate 20.5A % 19.8A % 21.1A % Risk-free interest rate 3.8A % 4.3A % 3.0A % Expected dividend yield 2.1A % 2.5A % 2.4A % Weighted-average estimated fair value \$ 22.65 \$ 14.89 \$ 14.71 The weighted-average expected term of options granted each year was determined with reference to historical exercise and post-vesting cancellation experience, the vesting period of the awards and the contractual term of the awards, among other factors. Â Expected volatility incorporates implied share-price volatility derived from exchange traded options on the Companyâ€™s common stock. Â The risk-free interest rate for the expected term of the option is based on the yield of a zero-coupon U.S. Treasury bond with a maturity period equal to the optionâ€™s expected term. Stock Options The Company issues non-qualified stock options to non-employee directors, officers and other key employees. Stock options have a contractual term of eight years and generally vest ratably over three years. As of December 31, 2024, approximately 19,248,078 shares of common stock were available for future stock option grants. 92COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) A summary of stock option activity during 2024 is presented below: Â A Shares (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Intrinsic Value of Unexercised In-the-Money Options Options outstanding, January 1, 2024 20,742A \$ 75A Granted 955A 106A A Exercised (8,662) 74A A Forfeited (240) 76A A Expired (21) 73A Options outstanding, December 31, 2024 12,774A 78A 5 176A Options exercisable, December 31, 2024 9,265A 76A 4 136A As of December 31, 2024, there was \$12 of total unrecognized compensation expense related to unvested stock options, which will be recognized over a weighted-average period of 1.3 years. The total intrinsic value of options exercised during the years ended December 31, 2024, 2023 and 2022 was \$150, \$28 and \$47, respectively. The benefits of tax deductions in excess of grant date fair value resulting from the exercise of stock options and vesting of restricted stock unit awards for the years ended December 31, 2024, 2023 and 2022 were \$18, \$4 and \$2, respectively, and are recognized in the provision for income taxes as a discrete item in the quarterly period in which they occur and classified as an operating cash flow. Cash proceeds received from options exercised for the years ended December 31, 2024, 2023 and 2022 were \$638, \$380 and \$418, respectively. Performance-based Restricted Stock Units Under the Companyâ€™s long-term incentive compensation program, the Company grants officers and other key employees a target number of unearned performance-based restricted stock units at the beginning of each three-year performance cycle. Awards are earned and vest following the conclusion of the performance period on the basis of achievement of performance goals established at the commencement of each three-year performance period. A summary of performance-based restricted stock unit activity for the year ended December 31, 2024 is presented below: Â A Shares (in thousands) Weighted Average Grant Date Fair Value Per Award Performance-based restricted stock units as of January 1, 2024 1,069A 68A Activity: Granted 321A 91A Vested (283) 70A Forfeited (89) 72A Change due to performance and/or market condition achievement 19A 57A Performance-based restricted stock units as of December 31, 2024 1,037A 74A As of December 31, 2024, there was \$32 of total unrecognized compensation expense related to unvested performance-based restricted stock unit awards, which will be recognized ratably over the remaining performance period. The Company uses a Monte-Carlo simulation model to estimate the fair value of performance-based restricted stock units at the date of grant. 93COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) Time-Vested Restricted Stock Units The Company also grants time-vested restricted stock unit awards. Awards either vest at the end of the restriction period, which is generally three years from the date of grant, or ratably over the restriction period. As of December 31, 2024, approximately 7,324,623 shares of common stock were available for future restricted stock unit awards. A summary of restricted stock unit activity during 2024 is presented below: Â A Shares (in thousands) Weighted Average Grant Date Fair Value Per Award Restricted stock units as of January 1, 2024 1,174A 76A Activity: Granted 854A 105A Vested (951) 76A Forfeited (90) 77A Restricted stock units as of December 31, 2024 1,987A 88A As of December 31, 2024, there was \$68 of total unrecognized compensation expense related to unvested time-vested restricted stock unit awards, which will be recognized over a weighted-average period of 1.6 years. The total fair value of time-vested restricted stock units vested during the years ended December 31, 2024, 2023 and 2022 was \$72, \$45 and \$40, respectively. 94COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) 8.Â Â Â Â Employee Stock Ownership Plan In 1989, the Company expanded its Employee Stock Ownership Plan (â€œESOPâ€) through the introduction of a leveraged ESOP that funds certain benefits for employees who have met eligibility requirements. As of December 31, 2024 and 2023, there were 7,428,343 and 8,348,104 shares of common stock, respectively, outstanding and issued to the Companyâ€™s ESOP. During 2000, the ESOP entered into a loan agreement with the Company under which the benefits of the ESOP may be extended through 2035. Â As of December 31, 2024, the ESOP had no outstanding borrowings from the Company. Dividends on stock held by the ESOP are paid to the ESOP trust and, together with cash contributions from the Company, are (a) used by the ESOP to repay principal and interest, (b) credited to participant accounts, (c) used for contributions to the Companyâ€™s defined contribution plans or (d) used to pay the Companyâ€™s defined contribution plan expenses. Stock is allocated to participants based upon the ratio of the current yearâ€™s debt service to the sum of total outstanding principal and interest payments over the life of the debt. As of December 31, 2024, 7,334,758 shares of common stock had been released and allocated to participant accounts and 93,585 shares of common stock were available for future release and allocation to participant accounts. Dividends on the stock used to repay principal and interest or credited to participant accounts are deductible for income tax purposes and, accordingly, are reflected net of their tax benefit in the Consolidated Statements of Changes in Shareholdersâ€™ Equity. Annual expense related to the ESOP was \$0 in 2024, 2023 and 2022. The Company paid dividends on the shares held by the ESOP of \$16 in 2024, \$17 in 2023 and \$19 in 2022. The Company did not make any contributions to the ESOP in 2024, 2023 or 2022. 95COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) 9.Â Â Â Â Retirement Plans and Other Retiree Benefits Retirement Plans The Company and certain of its U.S. and foreign subsidiaries maintain defined benefit retirement plans. Benefits under these plans are based primarily on years of service and employeesâ€™ earnings. In the U.S., effective January 1, 2014, the Company provides virtually all future retirement benefits through the Companyâ€™s defined contribution plan. As a result, service after December 31, 2013 is not considered for participants in the Companyâ€™s principal U.S. defined benefit retirement plan. Participants in the Companyâ€™s principal U.S. defined benefit retirement plan whose retirement benefit was determined under the cash balance formula continue to earn interest credits on their vested balances as of December 31, 2013 but no longer receive pay credits. Participants whose retirement benefit was determined under the final average earnings formula or career average earnings formula continue to have their accrued benefit adjusted for pay increases until termination of employment. In the first quarter of 2023, the Company recorded a charge of \$267 as a result of a decision of the United States Court of Appeals for the Second Circuit (the â€œSecond Circuitâ€) affirming a grant of summary judgment to the plaintiffs in a lawsuit under the Employee Retirement Income Security Act seeking the recalculation of benefits and other relief associated with a 2005 residual annuity amendment to the Colgate-Palmolive Company Employeesâ€™ Retirement Income Plan (the â€œRetirement Planâ€). The decision resulted in an increase in the obligations of the Retirement Plan, which based on the current funded status of the Retirement Plan and depending on further developments in the litigation, may require a cash contribution by the Company in 2025. See Note 12, Commitments and Contingencies for additional information. 96COLGATE-PALMOLIVE COMPANYÂ Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) In the Companyâ€™s principal U.S. plans and certain funded foreign plans, funds are contributed to trusts in accordance with regulatory limits to provide for current service and for any unfunded projected benefit obligation over a reasonable period. The target asset allocation for the Companyâ€™s defined benefit plans is as follows: Â United States International Asset Category Equity securities 26A % 17A % Fixed income securities 60A % 63A % Other

investments14Å %20Å %Total100Å %100Å At DecemberÅ 31, 2024, the allocation of the CompanyÅ™s plan assets and the level of valuation input, as applicable, for each major asset category were as follows:Å Level of ValuationInputPension PlansÅ A United StatesInternationalÅ A Å Cash and cash equivalentsLevel 1\$226Å \$21Å U.S. common stocksLevel 11Å 2Å International common stocksLevel 1Å Å 15Å Pooled funds(1)Level 135Å 103Å Fixed income securities(2)Level 262Å 75Å Guaranteed investment contracts(3)Level 2Å Å 30Å Å Å 886Å 246Å Investments valued using NAV per share(4)Å A Domestic, developed and emerging markets equity fundsÅ Å 223Å 28Å Fixed income funds(5)Å Å 68Å 222Å Hedge funds(6)Å Å Å 7Å Multi-asset funds(7)Å Å 157Å 2Å Real estate funds(8)Å Å 27Å Å Å 448Å 286Å Other assets and liabilities, net(9)(39)5Å Total Investments1,295Å \$537Å 97COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)At DecemberÅ 31, 2023, the allocation of the CompanyÅ™s plan assets and the level of valuation input, as applicable, for each major asset category were as follows:Å Level of ValuationInputPension PlansÅ A United StatesInternationalÅ A Å Cash and cash equivalentsLevel 1\$206Å \$14Å U.S. common stocksLevel 1Å Å 2Å International common stocksLevel 1Å Å 20Å Pooled funds(1)Level 120Å 113Å Fixed income securities(2)Level 271Å 71Å Guaranteed investment contracts(3)Level 2Å Å 34Å Å Å 936Å 254Å Investments valued using NAV per share(4)Å A Domestic, developed and emerging markets equity fundsÅ Å 315Å 55Å Fixed income funds(5)Å Å 99Å 219Å Hedge funds(6)Å Å Å 7Å Multi-asset funds(7)Å Å 40Å 1Å Real estate funds(8)Å Å 30Å 454Å 312Å Other assets and liabilities, net(9)(30)Å Å Å Total InvestmentsÅ Å \$1,360Å \$566Å (1)Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities. (2)The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2.Å As of DecemberÅ 31, 2024 and DecemberÅ 31, 2023, approximately 30% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds.(3)The guaranteed investment contracts (ÅœœGICsÅœ) represent contracts with insurance companies measured at the cash surrender value of each contract.Å The Level 2 valuation reflects that the cash surrender value is based principally on a referenced pool of investment funds with active redemption.(4)Investments that are measured at fair value using net asset value (ÅœœNAVÅœ) per share as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the value of the underlying investments owned, minus its liabilities, divided by the number of shares outstanding. There are no unfunded commitments related to these investments. Redemption notice period primarily ranges from 0-3 months and redemption frequency windows range from daily to quarterly.(5)Fixed income funds primarily invest in U.S. government and investment grade corporate bonds.(6)Consists of investments in underlying hedge fund strategies that are primarily implemented through the use of long and short equity and fixed income securities and derivative instruments such as futures and options.(7)Multi-asset funds primarily invest across a variety of asset classes, including global stocks and bonds, as well as alternative strategies.(8)Real estate is valued using the NAV per unit of funds that are invested in real estate property. The investment value of the real estate property is determined quarterly using independent market appraisals as determined by the investment manager. (9)This category primarily includes unsettled trades for investments purchased and sold and interest receivables. 98COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Equity securities in the U.S. defined benefit retirement plans did not include any investment in the CompanyÅ™s common stock at either DecemberÅ 31, 2024 or DecemberÅ 31, 2023.Å No shares of the CompanyÅ™s stock were purchased by the U.S. plans in 2024 or 2023. The plans received no dividends on the CompanyÅ™s common stock in either 2024 or 2023.Other Retiree BenefitsThe Company and certain of its subsidiaries provide, to the extent not otherwise provided by government-sponsored plans, health and life insurance benefits or subsidies for retired employees who meet applicable eligibility requirements. The Company uses a December 31 measurement date for its defined benefit and other retiree benefit plans. Summarized information for the CompanyÅ™s defined benefit and other retiree benefit plans is as follows:99COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Å A Pension PlansOther Retiree Benefit PlansÅ 202420232024202320242023Å A United StatesInternationalÅ A Å Change in Benefit ObligationsÅ Å Å Å Å Benefit obligations at beginning of year\$1,922Å \$1,673Å \$776Å \$675Å \$665Å \$658Å Service cost1Å Å Å 16Å 15Å 7Å 7Å Interest cost99Å 91Å 33Å 33Å 36Å 38Å ParticipantsÅœ™ contributionsÅœ™ Å Å Å 5Å 5Å Å Å Å Å Plan amendmentsÅœ™ Å Å Å Å Å Å Å (33)Actuarial loss (gain)(54)36Å (1)65Å (14)38Å Foreign exchange impactÅœ™ Å Å Å (40)29Å (8)4Å Termination benefits5Å 3Å Å Å Å 2Å Å Å Å Curretilments and settlements1Å Å Å (18)(6)Å Å Å Å Benefit payments(141)(148)(41)(42)(54)(47)ERISA litigation matterrÅœ™ Å 267Å Å Å Å Å Å Å Å Benefit obligations at end of year\$1,831Å \$1,922Å \$720Å \$776Å \$632Å \$665Å Change in Plan AssetsÅ Å Fair value of plan assets at beginning of year\$1,360Å \$1,363Å \$566Å \$516Å \$Åœ™ Å \$Åœ™ Å Actual return on plan assets49Å 115Å 18Å 26Å Å Å Å Å Company contributions29Å 30Å 37Å 39Å 54Å 47Å ParticipantsÅœ™ contributionsÅœ™ Å Å Å 5Å 5Å Å Å Å Å Foreign exchange impactÅœ™ Å Å Å (31)27Å Å Å Å Å Settlements and acquisitions(2)Å Å (17)(5)Åœ™ Å Å Å Benefit payments(141)(148)(41)(42)(54)(47)Fair value of plan assets at end of year\$1,295Å \$1,360Å \$537Å \$566Å \$Åœ™ Å \$Åœ™ Å Funded StatusÅ Å Benefit obligations at end of year\$1,831Å \$1,922Å \$720Å \$776Å \$632Å \$665Å Fair value of plan assets at end of year1,295Å 1,360Å 537Å 566Å Å Å Å Å Net amount recognized\$(536)\$(562)\$(183)\$(632)\$(665)Amounts Recognized in Accumulated Other Comprehensive Income (Loss)Å Å Actuarial loss\$710Å \$767Å \$174Å \$177Å \$109Å \$128Å Transition/prior service cost(credit)Åœ™ Å Å Å 8Å 9Å (159)(180)Å Å \$710Å \$767Å \$182Å \$186Å \$(50)\$(52)Accumulated benefit obligation1,818Å \$1,907Å \$668Å \$719Å \$Åœ™ Å \$Åœ™ Å 100COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Å A Pension PlansOther Retiree Benefit PlansÅ Å 202420232024202320242023Å A United StatesInternationalÅ A Å Weighted-Average Assumptions Used to Determine Benefit ObligationsÅ Å Å Å Å Discount rate5.73Å %5.40Å %4.69Å %4.35Å %5.74Å %5.37Å %Long-term rate of compensation increase3.50Å %3.50Å %3.36Å %3.19Å %Åœ™ Å %Åœ™ Å %ESOP growth rateÅœ™ Å %Åœ™ Å %Åœ™ Å %Åœ™ Å %6.00Å %6.00Å %Medical cost trend rate of increaseÅœ™ Å %Åœ™ Å %Åœ™ Å %7.00Å %6.00Å %Interest Crediting Rate5.58Å %4.99Å %3.23Å %1.13Å %Åœ™ Å %Åœ™ Å %The actuarial gains recorded during 2024 for both the U.S. pension and Other retiree benefit plans were primarily a result of an increase in discount rates applied against future estimated benefit payments that resulted in a decrease in the benefit obligation for both the U.S. pension and Other retiree benefit plans. The actuarial losses recorded during 2023 for both the U.S. pension and Other retiree benefit plans were primarily a result of a decrease in discount rates applied against future estimated benefit payments that resulted in an increase in the benefit obligation for both the U.S. pension and Other retiree benefit plans.The overall investment objective of the plans is to balance risk and return so that obligations to employees are met. The Company evaluates its expected long-term rate of return on plan assets on an annual basis. In determining the expected long-term rate of return, the Company considers the nature of the plansÅœ™ investments and the historical rates of return. The assumed expected long-term rate of return on plan assets for U.S. pension plans was 6.50% as of DecemberÅ 31, 2024 and DecemberÅ 31, 2023. Average annual rates of return on plan assets for the U.S. pension plans for the most recent 1-year, 5-year, 10-year, 15-year and 25-year periods were 5%, 2%, 4%, 6% and 5%, respectively.Å Similar assessments were performed in determining rates of return on international pension plan assets to arrive at the CompanyÅ™s 2024 weighted-average expected long-term rate of return on plan assets of 5.69%.The medical cost trend rate of increase assumed in measuring the expected cost of benefits is projected to decrease from 7.00% in 2025 to 5.00% by 2030, remaining at 4.50% for the years thereafter. Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following:Å Å 20242023Benefit Obligation Exceeds Fair Value of Plan AssetsÅ Å Projected benefit obligation\$2,251Å 2,352Å Fair value of plan assets1,486Å 1,532Å Accumulated benefit obligation2,075Å 2,204Å Fair value of plan assets1,345Å 1,428Å Other Retiree Benefit plans with accumulated postretirement benefit obligation in excess of plan assets as of December 31 consisted of the following:Å Å 20242023Benefit Obligation Exceeds Fair Value of Plan AssetsÅ Å Accumulated postretirement benefit obligation\$632Å \$665Å Fair value of plan assetsÅœ™ Å Å Å 101COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Summarized information regarding the net periodic benefit costs for the CompanyÅ™s defined benefit and other retiree benefit plans is as follows:Å A Pension PlansOther Retiree Benefit PlansÅ Å 202420232022202420232022202420232022Å A United StatesInternationalÅ A Å Components of Net Periodic Benefit CostÅ Å Å Å Å Å Å Å Service cost1Å Å Å \$Åœ™ Å \$Åœ™ Å \$16Å \$15Å \$7Å \$7Å \$18Å Interest cost99Å 91Å 64Å 64Å 33Å 21Å 36Å 38Å 36Å Expected return on plan assets(85)(79)(101)(29)(25)(21)Åœ™ Å Å Å Å Å Amortization of transition and prior service costs (credits)Åœ™ Å Å Å Å 1Å 1Å 1Å 1Å (21)(20)(6)Amortization of actuarial loss39Å 43Å 46Å 5Å 7Å 4Å 14Å Net periodic benefit costs\$44Å \$55Å \$9Å \$26Å \$29Å \$23Å \$26Å \$26Å \$62Å Other postretirement charges\$3Å 13Å Å Å 2Å 4Å Å Å Å 2Å ERISA litigation matterrÅœ™ Å 267Å Å Å Å Å Å Å Å Total pension costs\$59Å \$325Å \$22Å \$26Å \$31Å \$27Å \$26Å \$26Å \$64Å Weighted-Average Assumptions Used to Determine Net Periodic Benefit CostÅ Å Å Å Å Å Å Å Discount rate5.40Å %5.66Å %2.98Å %4.61Å %4.75Å %2.10Å %5.37Å %5.67Å %3.06Å %Expected long-term rate of return on plan assets6.50Å %6.25Å %5.70Å %5.69Å %4.66Å %2.72Å %N/A/N/A/N/A/Long-term rate of compensation increase3.50Å %3.50Å %3.50Å %3.24Å %3.22Å %2.89Å %Åœ™ Å %Åœ™ Å %ESOP growth rateÅœ™ Å %Åœ™ Å %Åœ™ Å %Åœ™ Å %6.00Å %6.00Å %6.00Å %6.00Å %Medical cost trend rate of increaseÅœ™ Å %Åœ™ Å %Åœ™ Å %Åœ™ Å %Åœ™ Å %6.00Å %6.25Å %6.00Å %Interest Crediting Rate4.99Å %5.21Å %2.82Å %0.64Å %2.28Å %0.84Å %Åœ™ Å %Åœ™ Å %102COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)The service related component of pension and other postretirement benefit costs is included in Operating profit. The non-service related components (interest cost, expected return on assets, amortization of transition and prior service costs and credits and amortization of actuarial gains and losses) are included in the line item ÅœœNon-service related postretirement costs,Åœ which is below Operating profit.The Company made no voluntary contributions in 2024, 2023 and 2022. Expected Contributions and Benefit PaymentsAt present, the Company does not expect to make any voluntary contributions to its U.S. postretirement plans for the year ending December 31, 2025. Actual funding may differ from current estimates depending on the variability of the market value of the assets, changes in the benefit obligations and other market or regulatory conditions.Benefit payments expected to be paid from the CompanyÅ™s assets to participants in unfunded plans are estimated to be approximately \$95 for the year ending December 31, 2025. Total benefit payments expected to be paid to participants in both funded and unfunded plans are estimated as follows:Å A Pension PlansYears Ended December 31,United StatesInternationalOther Retiree Benefit PlansTotal2025\$377Å 424Å \$52Å 471Å 2026143Å 41Å 54Å 238Å 2027143Å 43Å 55Å 241Å 2028142Å 45Å 55Å 242Å 2029141Å 46Å 55Å 242Å 20302034653Å 247Å 274Å 1,174Å 103COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)10.Å Å Å Income TaxesThe components of Income before income taxes are as follows for the years ended December 31:Å Å 202420232022United States\$1,084Å \$692Å \$1,169Å International2,872Å 2,700Å 1,491Å Total Income before income taxes\$3,956Å \$3,392Å \$2,660Å The Provision for income taxes consists of the following for the years ended December 31:Å Å 202420232022United States\$188Å \$72Å \$199Å International719Å 865Å 494Å Total Provision for income taxes\$907Å \$937Å \$693Å Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in the current provision for taxes being higher (lower) than the total provision for income taxes as follows:Å Å 202420232022Goodwill and intangible assets\$3Å \$1Å \$106Å Property, plant and equipment12Å (13)2Å Pension and other retiree benefits(6)68Å (1)Stock-based compensation(14)2Å (3)Right-of-use assets/lease liabilities2Å 1Å (5)Tax credits and tax loss carryforwards, net of valuation allowance37Å 29Å 8Å Deferred withholding tax(14)7Å 8Å Research and Experimentation Capitalization21Å 29Å 58Å Other, net(8)11Å (10)Total deferred tax benefit (provision)\$33Å \$135Å \$163Å The difference between the statutory U.S. federal income tax rate and the CompanyÅ™s global effective tax rate as reflected in the Consolidated Statements of Income is as follows:202420232022Percentage of Income before income taxesTax at United States statutory rate21.0Å %21.0Å %21.0Å %State income taxes, net of federal benefit0.5Å (0.1)0.8Å Earnings taxed at other than United States statutory rate4.1Å 5.4Å 5.4Å Non-deductible goodwill impairment chargesÅœ™ Å Å Å 1.9Å Foreign-derived intangible income benefit(2.6)(2.4)(2.6)Foreign tax matterrÅœ™ Å 3.7Å Å Å Å Other, net(0.1)Åœ™ Å (0.4)Effective tax rate22.9Å %27.6Å %26.1Å %104COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)The components of deferred tax assets (liabilities) are as follows at December 31:Å Å 20242023Deferred tax liabilities:Å Goodwill and intangible assets\$(389)\$(412)Property, plant and equipment(397)(420)Right-of-use assets(126)(126)Deferred withholding tax(110)(96)Other(130)(34)Total deferred tax liabilities(1,152)(1,088)Deferred tax assets:Å Pension and other retiree benefits272Å 295Å Tax credits and tax loss carryforwards430Å 356Å Lease liabilities137Å 134Å Accrued liabilities223Å 221Å Stock-based compensation61Å 75Å Research and Experimentation Capitalization108Å 87Å Other101Å 60Å Total deferred tax assets1,332Å 1,228Å Valuation Allowances\$(328)\$(287)Net deferred tax assets1,004Å \$941Å Net deferred income taxes\$(148)\$(147)The changes in valuation allowance for deferred tax assets are as follows: 202420232022Balance, January 1\$287Å \$129Å \$120Å AdditionsÅ Å Å Å Charged to costs and expenses5615814Deductions15Åœ™ Å 5Balance, December 31\$328Å \$287Å \$129Å As of DecemberÅ 31, 2024, the Company had net operating losses (ÅœœNOLsÅœ) and capital loss carryforwards of \$37. Of this amount, capital loss and NOL carryforwards of \$6 will begin to expire in 2025 and NOLs of \$13 can be carried forward indefinitely. The Company believes that it will be able to utilize these capital loss and NOL carryforwards. There is an additional NOL of \$18 which has a full valuation allowance.As of DecemberÅ 31, 2024, the Company has \$393 of tax credits, of which \$66 will begin to expire in 2030 and \$17 can be carried forward indefinitely. The Company believes that it will be able to utilize these tax credits. The remaining credits of \$310 have a full valuation allowance. Applicable U.S. income and foreign withholding taxes have been provided on substantially all of the CompanyÅ™s accumulated earnings of foreign subsidiaries. Net tax expense of \$55, net tax benefit of \$19 and net tax expense of \$164 were recorded directly through equity in 2024, 2023 and 2022 respectively. The net tax expense or benefit in each year predominantly includes current and future tax impacts related to benefit plans and the impact of currency translation adjustments. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return.105COLGATE-PALMOLIVE COMPANYÅ Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Unrecognized tax benefits activity for the years ended December 31, 2024, 2023 and 2022 is summarized below:Å Å 202420232022Unrecognized tax benefits:Å Å Å Balance, January 1\$314Å \$298Å \$245Å Increases as a result of tax positions taken during the current year37Å 73Å 32Å Decreases of tax positions taken during prior years(53)(61)(21)Increases of tax positions taken during prior years10Å 6Å 46Å Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations(3)(2)(2)Effect of foreign currency rate movements(9)Åœ™ Å (2)Balance, December 31\$296Å \$314Å \$298Å If all of the unrecognized tax benefits for 2024 above were recognized, approximately \$286 would impact the effective tax rate. It is reasonably possible that the amount of unrecognized benefits with respect to our uncertain tax positions could change in the next twelve months and such change may or may not be material. The Company recognized expenses of approximately \$22, \$10 and \$8 for interest and penalties related to the above unrecognized tax benefits within income tax expense in 2024, 2023 and 2022, respectively.Å The Company had accrued interest and penalties of approximately \$68, \$45 and \$40 as of December 31, 2024, 2023 and 2022, respectively.In the third quarter of 2023, the Internal Revenue Service (the ÅœœIRSÅœ) issued a notice giving taxpayers temporary relief from the effects of certain U.S. tax regulations that were issued in December 2021, which place greater restrictions on foreign taxes that are creditable against U.S. taxes on foreign-source income. This notice allowed taxpayers to defer the application of these new regulations through the end of 2023. In December 2023, the IRS issued further guidance modifying this temporary relief period to the date that a notice or other guidance withdrawing or modifying the temporary relief is issued. The Company will recognize the impact, if any, in the period in which the temporary relief is withdrawn or modified. During the quarter ended June 30, 2023, the Company reassessed with its legal and tax advisers certain tax deductions taken in prior years by one of our subsidiaries and concluded that it was more likely than not that the deductions would not be sustained by the courts in that jurisdiction. The value of the tax deductions was not material to the Company in any year in which they were taken. The cumulative effect of the change in tax position of \$148 was reflected as a discrete item in the quarter ended June 30, 2023 income tax expense, partially offset by the reversal of certain prior yearsÅœ™ withholding tax reserves of \$22 that were no longer required. The tax liability was paid in the quarter ended September 30, 2023.On August 16, 2022, the Inflation Reduction Act of 2022 (the ÅœœIRAÅœ) was enacted, which among other things, implements a 15% minimum tax on book income of certain large corporations effective for years beginning after December 31, 2022. Based on the CompanyÅ™s s analysis, as well as guidance published by the IRS, the IRA, and in particular the 15% minimum tax, did not have an impact on the CompanyÅ™s s Consolidated Financial Statements. Subsequent to the aforementioned guidance published by the IRS, on September 12, 2024, the U.S. Treasury Department and IRS released proposed regulations relating to this 15% minimum tax. Based on the CompanyÅ™s s analysis, these proposed regulations, if finalized in their current form, are not expected to have an

impact on the Company’s Consolidated Financial Statements. However, the Company will continue to evaluate any additional guidance and clarification that becomes available. Additionally, on December 15, 2022, the 27 member states of the European Union (the EU) reached an agreement on a minimum level of taxation for certain large corporations to pay a minimum corporate tax rate of 15% in every jurisdiction in which they operate. This agreement, which is known as the Minimum Tax Directive (part of the Pillar II Model Rules), was supposed to be transposed into the laws of all EU member states by December 31, 2023. Most member states complied, while some were granted extensions of time. In addition, many other jurisdictions outside the EU have implemented a similar minimum tax regime consistent with the policy of the Pillar II Model Rules. Detailed regulations of these minimum tax regimes are still being considered in certain countries and, in some cases, enactment and timing is still uncertain. COLGATE-PALMOLIVE COMPANY’s Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) uncertain. Based on current legislation and available guidance, apart from a significant additional compliance burden, Pillar II did not have a material impact as of December 31, 2024 and the Company does not believe it will have a material impact on its Consolidated Financial Statements. However, as these rules and related regulations are revised and implemented, the Company will evaluate the impact, if any, on its Consolidated Financial Statements. The Company has ongoing federal, state and international income tax audits in various jurisdictions and evaluates uncertain tax positions that may be challenged by local tax authorities and not fully sustained. All U.S. federal income tax returns through December 31, 2013 have been audited by the IRS and there are limited matters which the Company plans to appeal for years 2010 through 2013. One such matter relates to the IRS assessment of taxes on the Company by imputing income on certain activities within one of our international operations, which is also under audit for the years 2014 through 2018. There were U.S. Tax Court rulings during 2023 in favor of the IRS against unrelated third parties on similar matters. Despite the U.S. Tax Court rulings, the Company continues to believe that the tax assessment against the Company is without merit. While there can be no assurances, the Company believes this matter will ultimately be decided in favor of the Company. The amount of tax plus interest for the years 2010 through 2018 is estimated to be approximately \$153, which is not included in the Company’s uncertain tax positions. In May 2024, the IRS initiated an audit for the years 2019 through 2021. The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income taxes as a current period expense rather than including these amounts in the measurement of deferred taxes. COLGATE-PALMOLIVE COMPANY’s Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) 11. A A Earnings Per Share For the years ended December 31, 2024, 2023 and 2022, earnings per share were as follows: A 2024 2023 2022A Net income attributable to Colgate-Palmolive Company Shares (millions) Per Share Basic EPS\$2,889A \$19.1A \$3.53A \$2,300A \$27.4A \$2.78A \$1,785A \$836.4A \$2.13A Stock options and restricted stock unitsA 1A A 1.8A A 2.4A A Diluted EPS\$2,889A \$23.2A \$3.51A \$2,300A \$29.2A \$2.77A \$1,785A \$838.8A \$2.13A Basic earnings per common share is computed by dividing net income available for common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding stock options and restricted stock units. For the years ended December 31, 2024, 2023 and 2022, the average number of stock options that were anti-dilutive and not included in diluted earnings per share calculations were 295,968, 13,719,286 and 5,236,371, respectively. For the years ended December 31, 2024, 2023 and 2022, the average number of restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 100,191, 1,183 and 155,118, respectively. 10. COLGATE-PALMOLIVE COMPANY’s Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) 12. A A Commitments and Contingencies As of December 31, 2024, the Company has various contractual commitments for future multi-year purchases of raw, packaging and other materials and services totaling approximately \$568. As a global company serving consumers in more than 200 countries and territories, the Company is routinely subject to a wide variety of legal proceedings. These include disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. In addition, management proactively reviews and monitors the Company’s exposure to, and the impact of, environmental matters. The Company is party to various environmental matters and, as such, may be responsible for all or a portion of the cleanup, restoration and post-closure monitoring of several sites. The Company establishes accruals for loss contingencies when it has determined that a loss is probable and that the amount of loss, or range of loss, can be reasonably estimated. Any such accruals are adjusted thereafter as appropriate to reflect changes in circumstances. The Company also determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that a loss is reasonably possible and it is able to determine such estimates. For those matters disclosed below for which the amount of any potential losses can be reasonably estimated, the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is \$0 to approximately \$250 (based on current exchange rates). The estimates included in this amount are based on the Company’s analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate range may not represent the ultimate loss to the Company. Thus, the Company’s exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above. Based on current knowledge, management does not believe that the ultimate resolution of loss contingencies arising from the matters discussed herein will have a material effect on the Company’s consolidated financial position or its ongoing results of operations or cash flows. However, in light of the inherent uncertainties noted above, an adverse outcome in one or more matters could be material to the Company’s results of operations or cash flows for any particular quarter or year. Brazilian Matters There are certain tax and civil proceedings outstanding, as described below, related to the Company’s 1995 acquisition of the Kolynos oral care business from Wyeth (the Seller). The Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company’s Brazilian subsidiary for certain years in connection with the financing of the Kolynos acquisition. The tax assessments with interest, penalties and any court-mandated fees, at the current exchange rate, are approximately \$93. This amount includes additional assessments received from the Brazilian internal revenue authority in April 2016 relating to net operating loss carryforwards used by the Company’s Brazilian subsidiary to offset taxable income that had also been deducted from the authority’s original assessments. The Company has been disputing the disallowances by appealing the assessments since October 2001. COLGATE-PALMOLIVE COMPANY’s Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) In each of September 2015, February 2017, September 2018, April 2019 and August 2020, the Company lost an administrative appeal and subsequently challenged these assessments in the Brazilian federal courts. Currently, there are three lawsuits pending in the Lower Federal Court and two cases have progressed to the Federal Court of Appeals. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the disallowances and that the Company should ultimately prevail. The Company is challenging these disallowances vigorously. In November 2023, based upon changes in Brazilian tax law, the Company filed petitions in three of the actions requesting that the penalty portion of the claim be removed. The Brazilian tax authority agreed with the Company’s position and in August 2024 reduced its claim in two of those actions and in October 2024 reduced its claim in the third. In July 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda. (the Brazilian subsidiary of the Seller) and the Company, as represented by its Brazilian subsidiary, in the 6th. Lower Federal Court in the City of São Paulo, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller’s Brazilian subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company’s Brazilian subsidiary jointly and severally liable for any tax due from the Seller’s Brazilian subsidiary. The case has been pending since 2002, and the Lower Federal Court has not issued a decision. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the action and that the Company should ultimately prevail. The Company is challenging this action vigorously. In December 2005, the Brazilian internal revenue authority issued to the Company’s Brazilian subsidiary a tax assessment with interest, penalties and any court-mandated fees of approximately \$47, at the current exchange rate, based on a claim that certain purchases of U.S. Treasury bills by the subsidiary and their subsequent disposition during the period 2000 to 2001 were subject to a tax on foreign exchange transactions. The Company had been disputing the assessment within the internal revenue authority’s administrative appeals process. However, in November 2015, the Superior Chamber of Administrative Tax Appeals denied the Company’s final administrative appeal, and the Company has filed a lawsuit in the Brazilian federal court. In the event the Company is unsuccessful in this lawsuit, further appeals are available within the Brazilian federal courts. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the tax assessment and that the Company should ultimately prevail. The Company is challenging this assessment vigorously. In addition, in April 2024, based upon changes in Brazilian tax law, the Company filed a petition in this matter requesting that the penalty portion of the claim be removed. The Brazilian tax authority has not yet responded to that petition. 11. COLGATE-PALMOLIVE COMPANY’s Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) Talcum Powder Matters The Company has been named as a defendant in civil actions alleging that certain of its talcum powder products were contaminated with asbestos and/or caused mesothelioma and other cancers. Many of these actions involve a number of co-defendants from a variety of different industries, including suppliers of asbestos and manufacturers of products that, unlike the Company’s products, were designed to contain asbestos. As of December 31, 2024, there were 309 individual cases pending against the Company in state and federal courts throughout the United States, as compared to 279 cases as of December 31, 2023. During the year ended December 31, 2024, 142 new cases were filed and 111 cases were resolved by voluntary dismissal, settlement or dismissal by the court, and one case was removed from the case count when it was established that the claim does not relate to talcum powder. The value of the settlements in the periods presented was not material, either individually or in the aggregate, to such periods’ results of operations. During the three months ended March 31, 2024, one case resulted in a jury verdict in favor of the Company after a trial. Subsequently, the trial court granted plaintiffs’ motion for a new trial in that case. However, during the three months ended September 30, 2024, an appellate court granted the Company’s request to reinstate the jury’s verdict in favor of the Company. Plaintiffs are challenging that ruling and separately are appealing other issues related to the verdict. A significant portion of the Company’s costs incurred in defending and resolving these claims has been, and the Company believes that a portion of the costs will continue to be, covered by insurance policies issued by several primary, excess and umbrella insurance carriers, subject to deductibles, exclusions, retentions, policy limits and insurance carrier insolvencies. While the Company and its legal counsel believe that the Company has strong legal grounds to contest these cases and intends to challenge them vigorously, there can be no assurances regarding the ultimate resolution of these matters. ERISA Matter In June 2016, a lawsuit was filed in the United States District Court for the Southern District of New York (the District Court) against the Retirement Plan, the Company and certain individuals (the Company Defendants) claiming that residual annuity payments associated with a 2005 residual annuity amendment to the Retirement Plan were improperly calculated for certain Retirement Plan participants in violation of ERISA. The relief sought included recalculation of benefits, pre- and post-judgment interest and attorneys’ fees. This action was certified as a class action in July 2017. In July 2020, the District Court dismissed certain claims, and in August 2020 granted the plaintiffs’ motion for summary judgment on the remaining claims. In September 2020, the Company appealed to the Second Circuit. In March 2023, the Second Circuit affirmed the grant of summary judgment to the plaintiffs. In light of the Second Circuit decision, the Company recorded a charge to earnings of \$267 in the quarter ended March 31, 2023, which is comprised of the recalculation of benefits and interest. Possible additional charges associated with this matter are expected to be immaterial and, where estimable, are reflected in the range of reasonably possible losses disclosed above. The decision resulted in an increase in the obligations of the Retirement Plan, which based on the current funded status of the Retirement Plan and depending on further developments in the litigation, may require a cash contribution by the Company in 2025. In June 2023, the Company filed a petition for certiorari to the United States Supreme Court requesting permission for an appeal to that court and that petition was denied in October 2023. Also, in June 2023, the plaintiffs filed a motion to enter a revised final judgment in the District Court to address certain unresolved calculation issues, which the Company opposed. In June 2024, the District Court granted the plaintiffs’ motion and found for the plaintiffs on those calculation issues. The Company has appealed that decision to the Second Circuit. 11. COLGATE-PALMOLIVE COMPANY’s Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) 13. A A Segment Information The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition. The operations of the Oral, Personal and Home Care product segment are managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia. In connection with management changes, the Company realigned the reporting structure of its skin health business effective July 1, 2024. Accordingly, commencing with the quarter ended September 30, 2024, the results of the skin health business previously reported within the Europe reportable operating segment are reported with the other skin health businesses in the North America reportable operating segment, with no impact on the Company’s consolidated results of operations or financial position. The Company has recast its historical geographic segment information to conform to the new reporting structure. The Company evaluates segment performance based on several factors, including Operating Profit. The Company uses Operating Profit as a measure of operating segment performance because it excludes the impact of Corporate-driven decisions related to interest expense and income taxes. The Chairman of the Board, President and Chief Executive Officer has been determined to be the Company’s Chief Operating Decision Maker who uses Operating Profit to assess performance and to allocate resources for each of the reportable operating segments in the budgeting and forecasting process. Asset information by segment is not utilized for purposes of assessing performance or allocating resources, and therefore such information has not been presented. The accounting policies of the operating segments are generally the same as those described in Note 2, Summary of Significant Accounting Policies. An Intercompany sales have been eliminated. A Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets. The Company reports these items within Corporate operations as they relate to Corporate-based responsibilities and decisions and are not included in the internal measures of segment operating performance used by the Company to measure the underlying performance of the operating segments. Approximately two-thirds of the Company’s Net sales are generated from markets outside the U.S., with approximately 45% of the Company’s Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). Oral, Personal and Home Care sales to Walmart, Inc. and its affiliates represent approximately 11% of the Company’s Net sales in each of the years 2024, 2023 and 2022. No other customer represented more than 10% of Net sales in any period presented. In 2024, Corporate Operating Profit included charges resulting from the 2022 Global Productivity Initiative of \$85. In 2023, Corporate Operating Profit included charges resulting from the 2022 Global Productivity Initiative of \$27 and product recall costs of \$25. In 2022, Corporate Operating Profit included goodwill and intangible assets impairment charges of \$721, charges resulting from the 2022 Global Productivity Initiative of \$95, a gain on the sale of land in Asia Pacific of \$47 and acquisition-related costs of \$19. 12. COLGATE-PALMOLIVE COMPANY’s Notes to Consolidated Financial Statements (continued) (Dollars in Millions Except Share and Per Share Amounts) 2024 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America (1)\$4,113A \$1,571A \$1,668A \$36A \$839A Latin America4,782A 1,933A 1,328A (5)1,526A Europe2,770A 1,050A 1,031A 31A 658A Asia Pacific2,858A 1,078A 997A (30)812A Africa/Eurasia1,095A 432A 395A 16A 253A Total Oral, Personal and Home Care15,618A 4,088A Pet Nutrition(2)4,483A 1,869A 1,641A 8A 965A Reconciliation with Total Company Operating Profit Corporate(784)Totals\$20,101A \$4,268A Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were \$3,640 in 2024. (2) Net sales in the U.S. for Pet Nutrition were \$3,059 in 2024. (3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net. 2023 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America(1)\$4,091A \$1,588A \$1,594A \$37A \$871A Latin America4,640A 1,977A 1,241A 51,417A Europe2,571A 1,069A 899A 31A 573A Asia Pacific2,782A 1,108A 925A (18)767A Africa/Eurasia1,083A 442A 377A 9A 254A Total Oral, Personal and Home Care15,167A 3,882A Pet Nutrition(2)4,290A 1,964A 1,493A 2680A Reconciliation with Total Company Operating Profit Corporate(704)Totals\$19,457A \$3,984A Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were \$3,625 in 2023. (2) Net sales in the U.S. for Pet Nutrition were \$2,918 in 2023. (3) Refer to Note 16, Supplemental Income Statement for

information related to Other (income) expense, net.202420232022Capital expenditures\$A Oral, Personal and Home Care\$A North America\$52A \$46A \$66A Latin America126A 146A 121A Europe63A 44A 31A Asia Pacific64A 65A 60A Africa/Eurasia12A 10A 30A Total Oral, Personal and Home Care317A 311A 308A Pet Nutrition143A 301A 297A Corporate101A 93A 91A Total Capital expenditures\$561A \$705A \$696A 114COLGATE-PALMOLIVE COMPANYY Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)2022Net salesCost of SalesSelling, general and administrative expensesOther (income) expense, net (3)Operating ProfitReportable SegmentsOral, Personal and Home CareNorth America(1)\$4,002A \$1,649A \$1,567A \$46A \$741A Latin America3,982A 1,885A 1,059A (71)1,108A Europe2,362A 1,023A 778A 28A 534A Asia Pacific2,826A 1,160A 954A (24)737A Africa/Eurasia1,082A 447A 389A 18A 228A Total Oral, Personal and Home Care14,254A 3,348A Pet Nutrition(2)3,713A 1,569A 1,287A 785A Reconciliation with Total Company Operating ProfitCorporate\$(1,305)Totals\$17,967A \$2,893A Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were \$3,511 in 2022.(2) Net sales in the U.S. for Pet Nutrition were \$2,432 in 2022(3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net.202420232022Capital expenditures\$A Oral, Personal and Home Care\$A North America\$52A \$46A \$66A Latin America126A 146A 121A Europe63A 44A 31A Asia Pacific64A 65A 60A Africa/Eurasia12A 10A 30A Total Oral, Personal and Home Care317A 311A 308A Pet Nutrition143A 301A 297A Corporate101A 93A 91A Total Capital expenditures\$561A \$705A \$696A 114COLGATE-PALMOLIVE COMPANYY Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)202420232022Depreciation and amortization\$A Oral, Personal and Home Care\$A North America\$124A 116A \$128A Latin America100A 98A 93A Europe65A 65A 68A Asia Pacific81A 84A 89A Africa/Eurasia8A 9A 9A Total Oral, Personal and Home Care378A 372A 387A Pet Nutrition132A 101A 65A Corporate95A 94A 93A Total Depreciation and amortization\$605A \$567A \$545A 20242023Long-lived assets(1)United States\$2,728A \$2,733A International2,223A 2,340A Total Long-lived assets\$4,951A \$5,073A (1) Long-lived assets include Property, plant and equipment, net and lease right-of-use assets. 115COLGATE-PALMOLIVE COMPANYY Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)14.ÄÄÄ The Company enters into leases for land, office space, warehouses and equipment. A number of the leases include one or more options to renew the lease terms, purchase the leased property or terminate the lease. The exercise of these options is at the Company's discretion and is therefore recognized on the balance sheet when it is reasonably certain the Company will exercise such options. As the Company's leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Substantially all of the Company's leases are considered operating leases. Finance leases were not material as of December 31, 2024 and 2023. As of December 31, 2024 and 2023, the Company's right-of-use assets and liabilities for operating leases were as follows:20242023Other assets\$529A \$491A Other accruals107A 95A Other liabilities456A 420A Total operating lease liabilities \$563A \$515A Lease liabilities for operating leases as of December 31, 2024 were as follows:2025\$126A 2026108A 2027101A 202880A 202958A Thereafter182A Total lease commitments\$655A Less: Interest(92)Present value of lease liabilities\$563A The components of the Company's operating lease cost for the twelve months ended December 31, 2024 and 2023 were as follows:20242023Operating lease costs144A \$136A Short-term lease costs3A 3A Variable lease costs19A 20A Sublease Income(2)(2)Total lease cost\$164A \$157A Short-term lease cost represents the Company's cost with respect to leases with a duration of 12 months or less and is not reflected on the Company's Consolidated Balance Sheets. Variable lease costs are comprised of costs, such as the Company's proportionate share of actual costs for utilities, common area maintenance, property taxes and insurance, that are not included in the lease liability and are recognized in the period in which they are incurred. 116COLGATE-PALMOLIVE COMPANYY Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Supplemental cash flow information related to operating leases for the twelve months ended December 31, 2024 and 2023 was as follows:ÄÄÄ Payments against amounts included in the measurement of lease liabilities: \$132 and \$171, respectively ÄÄÄ Lease assets obtained in exchange for lease liabilities: \$141 and \$139, respectively. As of December 31, 2024 and 2023, the weighted-average remaining lease term for operating leases was 7 and 8 years, respectively, and the weighted-average discount rate for operating leases was 4.4% and 4.5%, respectively. There were no material operating leases that the Company had entered into or that were yet to commence as of December 31, 2024. 15. Supplier Finance ProgramThe Company has agreements to provide supplier finance programs which facilitate participating suppliers' ability to finance payment obligations of the Company with designated third-party financial institutions. Participating suppliers may, at their sole discretion, elect to finance one or more payment obligations of the Company prior to their scheduled due dates at a discounted price to participating financial institutions. The Company's obligations to its suppliers, including amounts due and scheduled payment dates, are not impacted by suppliers' decisions to finance amounts under these arrangements. The outstanding payment obligations under the Company's supplier finance programs are included in Accounts Payable in the Consolidated Balance Sheets and were not material as of December 31, 2024 or 2023.16.ÄÄÄ Supplemental Income Statement InformationOther (income) expense, net202420232022Amortization of intangible assets\$75A \$72A \$80A Equity income(22)(17)(12)2022 Global Productivity Initiative\$59A 24A 90A Product recall costs\$ÄÄÄ 25A ÄÄÄ Losses (gains) from marketable securities and other assets\$6A 11A (22)Indirect tax payments (refunds)27A 18A (14)Gain on the sale of land in Asia Pacific\$ÄÄÄ (47)Acquisition-related costs\$ÄÄÄ ÄÄÄ 19A Other, net19A \$5A (25)Total Other (income) expense, net\$164A \$191A \$69A ÄÄÄ 202420232022Research and development\$355A \$343A \$320A Advertising\$2,720A \$2,371A \$1,997A 117COLGATE-PALMOLIVE COMPANYY Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)17.ÄÄÄ Supplemental Balance Sheet InformationInventories by major class are as follows at December 31:Inventories20242023Raw materials and supplies\$631A \$606A Work-in-process46A 46A Finished goods1,431A 1,411A Total Inventories, net\$2,108A \$2,063A Non-current inventory, net(121)(129)Current Inventories, net\$1,987A \$1,934A Inventories valued under LIFO amounted to \$453 and \$471 at December 31, 2024 and 2023, respectively. The excess of current cost over FIFO cost at the end of each year was \$105 and \$120, respectively. The liquidations of LIFO inventory quantities had no material effect on income in 2024, 2023 and 2022. Inventory classified as non-current at December 31, 2024 was recorded on the Consolidated Balance Sheets as Other assets.ÄÄÄ Property, plant and equipment, net20242023Land\$226A \$227A Buildings2,056A 2,047A Manufacturing machinery and equipment6,265A 6,365A Other equipment1,580A 1,647A ÄÄÄ 10,127A 10,286A Accumulated depreciation(5,705)(5,704)Total Property, plant and equipment, net\$4,422A \$4,582A Other current assets20242023Marketable securities\$160A \$179A Prepaids520A 595A Derivatives33A 19A Total Other current assets\$713A \$793A 118COLGATE-PALMOLIVE COMPANYY Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)Other accruals20242023Accrued advertising and consumer and trade promotions\$912A \$882A Accrued payroll and employee benefits437A 403A Accrued taxes other than income taxes162A 167A Restructuring accrual\$15A 11A Pension and other retiree benefits93A 96A Lease liabilities due in one year107A 95A Accrued interest72A 78A Derivatives23A 26A Dividend payable408A ÄÄÄ Other662A 619A Total Other accruals\$2,891A \$2,377A Other liabilities20242023Pension and other retiree benefits\$1,306A \$1,390A Long-term lease liabilities456A 420A Restructuring accrual29A ÄÄÄ Other320A 305A Total Other liabilities\$2,111A \$2,115A 119COLGATE-PALMOLIVE COMPANYY Notes to Consolidated Financial Statements (continued)(Dollars in Millions Except Share and Per Share Amounts)18.ÄÄÄ Supplemental Other Comprehensive Income (Loss) InformationOther comprehensive income (loss) components attributable to Colgate-Palmolive Company before tax and net of tax during the years ended December 31 were as follows:ÄÄÄ 202420232022Cumulative translation adjustments: Cumulative translation adjustments, pre-tax\$(298)127A \$(113)Tax amounts(37)13A (29)Cumulative translation adjustments, net of tax (335)140A (142)Pension and other benefits:ÄÄÄ Net actuarial gain (loss), prior service costs and settlementsÄÄÄ during the period31A (49)466A Amortization of net actuarial loss, transition and prior service costs(1)28A 30A 62A Retirement Plan and other retiree benefit adjustments, pre-tax\$59A (19)528A Tax amounts(16)3A (115)Retirement Plan and other retiree benefit adjustments, net of tax 43A (16)413A Cash flow hedges: Gains (losses) on cash flow hedges, pre-tax10A (10)80A Tax amounts(2)3A (20)Gains (losses) on cash flow hedges, net of tax 8A (7)60A Total Other comprehensive income (loss), net of tax\$(284)\$117A \$331A (1)These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details. There were no tax impacts on Other comprehensive income (loss) attributable to Noncontrolling interests. Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive income (loss) is comprised of cumulative foreign currency translation gains and losses, unrecognized pension and other retiree benefit costs and unrealized gains and losses from derivative instruments designated as cash flow hedges. At December 31, 2024 and 2023, Accumulated other comprehensive income (loss) consisted primarily of aftertax unrecognized pension and other retiree benefit costs of \$605 and \$647, respectively, and aftertax cumulative foreign currency translation losses of \$3,687 and \$3,351, respectively. Foreign currency translation adjustments in 2024 primarily reflect losses from the Euro, Brazilian Real and Mexican Peso. Foreign currency translation adjustments in 2023 primarily reflect gains from the Euro, Mexican Peso and Brazilian Real. 120COLGATE-PALMOLIVE COMPANYMarket InformationThe Company's common stock is listed on the New York Stock Exchange, and its trading symbol is CL. Stock Price Performance Graphs The following graphs compare cumulative total shareholder returns on Colgate-Palmolive Company common stock against the S&P Composite-500 Stock Index and a peer company index for the twenty-year, ten-year and five-year periods each ended December 31, 2024. The peer company index is comprised of consumer products companies that have both domestic and international businesses. For 2024, the peer company index consisted of Church & Dwight Co., Inc., The Clorox Company, The Coca-Cola Company, The Estee Lauder Companies, Inc., General Mills, Inc., Haleon plc, Kellanova (formerly known as Kellogg Company), Kenvue Inc. (from and after its spin-off from Johnson & Johnson), Kimberly-Clark Corporation, The Kraft Heinz Company, Mondelez International, Inc., PepsiCo, Inc., The Procter & Gamble Company, Reckitt Benckiser Group plc and Unilever PLC. These performance graphs do not constitute soliciting material, are not deemed filed with the SEC and are not incorporated by reference in any of the Company's filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates these performance graphs by reference therein. 121 EX-4.2 exhibit4a12312024.htm EX-4.4 DocumentEXHIBIT 4(a)DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934As of February 13, 2025, Colgate-Palmolive Company, a Delaware corporation (ÄÄÄ Colgate or the ÄÄÄ Company), had five classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ÄÄÄ Exchange Act): (i) common stock, par value \$1.00 per share (ÄÄÄ Common Stock), (ii) the 0.500% Medium-Term Notes, Series H due 20

interest in arrears on each interest payment date specified in the applicable note on which an installment of interest is due and payable and on the applicable Maturity Date. We will pay interest to the persons in whose names the notes are registered as of the regular record date. However, interest that we pay on the applicable Maturity Date, if any, will be payable to the persons to whom the principal will be payable. If any note is originally issued between a regular record date and the related interest payment date, we will make the first payment of interest on that note on the interest payment date immediately following the next succeeding regular record date to the registered holder on that next succeeding regular record date. The regular record date will be the fifteenth calendar day, whether or not a Business Day (as defined in the applicable Note), immediately preceding the related interest payment date. Issuance in Euro Principal and interest payments in respect of the Notes and additional amounts, if any, will be payable in euro. If euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or the euro is no longer used by the member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions within the international banking community, then all payments in respect of the Notes will be made in U.S. dollars until euro is again available to us or so used. The amount payable on any date in euro will be converted to U.S. dollars on the basis of the Market Exchange Rate (as defined below). Any payment in respect of the Notes so made in U.S. dollars will not constitute an event of default under the Indenture. Neither the Trustee nor the London Paying Agent shall be responsible for obtaining exchange rates, effecting conversions or otherwise handling redenominations. The Market Exchange Rate means the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent euro/U.S. dollar exchange rate available on or prior to the second Business Day prior to the relevant payment date, as reported by Bloomberg. Optional Redemption Prior to the applicable Par Call Date (as defined below), the Notes may be redeemed at our option, at any time, in whole, or from time to time, in part, at a redemption price equal to the greater of: 100% of the principal amount of the Notes to be redeemed; or the sum of the present values of the remaining scheduled payments of principal and interest on the Notes being redeemed assuming that the Notes being redeemed matured on the applicable Par Call Date (not including any portion of any payments of interest accrued to the redemption date), discounted to the redemption date on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 15 basis points, in the case of the 2026 Notes, plus 10 basis points, in the case of the 2029 Notes, plus 20 basis points, in the case of the 2034 Notes or the 2039 Notes. On or after the applicable Par Call Date, the Notes may be redeemed at our option, at any time, in whole, or from time to time, in part, at a redemption price equal to 100% of the principal amount of the Notes being redeemed. In each case, we will pay accrued and unpaid interest on the principal amount being redeemed to, but not including, the redemption date. Notwithstanding the foregoing, installments of interest on Notes being redeemed that are due and payable on interest payment dates falling on or prior to a redemption date will be payable on the interest payment date to the holders as of the close of business on the relevant record date according to the Notes and the Indenture. The Comparable Government Bond Rate will be determined by the Calculation Agent on the third Business Day preceding the redemption date and means, with respect to any date of redemption, the rate per annum equal to the yield to maturity calculated in accordance with customary financial practice in pricing new issues of comparable corporate debt securities paying interest on an annual basis (ACTUAL/ACTUAL (ICMA)) of the applicable Comparable Government Bond, assuming a price for the applicable Comparable Government Bond (expressed as a percentage of its principal amount) equal to the applicable Comparable Government Bond Price for such date of redemption. The Calculation Agent means an independent investment banking or commercial banking institution of international standing appointed by us. The Comparable Government Bond means the Federal Republic of Germany government security or securities selected by one of the Reference Government Bond Dealers appointed by us as having an actual or interpolated maturity comparable with the remaining term of the applicable tranche of Notes assuming such tranche matured on the applicable Par Call Date that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of euro-denominated corporate debt securities of a maturity comparable to the remaining term of such tranche of Notes assuming such tranche matured on the applicable Par Call Date. The Comparable Government Bond Price means, with respect to any redemption date, (A) the arithmetic average of the Reference Government Bond Dealer Quotations for such redemption date, after excluding the highest and lowest such Reference Government Bond Dealer Quotations, or (B) if the Calculation Agent obtains fewer than four such Reference Government Bond Dealer Quotations, the arithmetic average of all such quotations. The Par Call Date means (i) with respect to the 2026 Notes, January 6, 2026 (two months prior to the maturity date of the 2026 Notes), (ii) with respect to the 2029 Notes, August 10, 2029 (three prior to the maturity date of the 2029 Notes), (iii) with respect to the 2034 Notes, December 6, 2033 (three months prior to the maturity date of the 2034 Notes) and (iv) with respect to the 2039 Notes, May 12, 2039 (six months prior to the maturity date of the 2039 Notes). The Reference Government Bond Dealer means each of four banks selected by us, which are (A) primary European government securities dealers, and their respective successors, or (B) market makers in pricing corporate bond issues. The Reference Government Bond Dealer Quotations means, with respect to each Reference Government Bond Dealer and any redemption date, the arithmetic average, as determined by the Calculation Agent, of the bid and offered prices for the applicable Comparable Government Bond (expressed in each case as a percentage of its principal amount) at 11:00 a.m., Central European Time (CET), on the third Business Day preceding such date for redemption quoted in writing to the Calculation Agent by such Reference Government Bond Dealer. Notice of redemption will be mailed at least 15 days (or in the case of the 2029 Notes, 10 days) but not more than 60 days before the redemption date to each holder of record of the applicable Notes to be redeemed at its registered address, provided that while the applicable Notes are represented by one or more global Notes, notice of redemption may, at our option, instead be given to holders of applicable Notes (and beneficial interests therein) in accordance with the applicable rules and regulations of Euroclear and Clearstream. The notice of redemption for the applicable Notes will state, among other things, the amount of the applicable Notes to be redeemed, the redemption date, and the redemption price and the place or places that payment will be made upon presentation and surrender of the applicable Notes to be redeemed. Unless we default in the payment of the redemption price, interest will cease to accrue on any Notes that have been called for redemption at the redemption date. If less than all of the applicable Notes of a tranche are to be redeemed, the Notes of such tranche to be redeemed will be selected in accordance with applicable depositary procedures; provided, however, that no Notes of a principal amount of \$1,000,000 or less shall be redeemed in part. The Notes are also subject to redemption prior to maturity if certain changes in U.S. tax law occur. If such changes occur, the Notes may be redeemed at a redemption price of 100% of their principal amount plus accrued and unpaid interest to the date of redemption. See "Redemption for Tax Reasons." Redemption for Tax Reasons If we have or will become obliged to pay additional amounts (as described below under the heading "Payment of Additional Amounts") as a result of any change in, or amendment to, the laws or regulations of the United States or any political subdivision or taxing authority thereof or therein affecting taxation, or any change in official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment becomes effective on or after the date of the applicable pricing supplement or prospectus supplement, and we determine that such obligation cannot be avoided by the use of reasonable measures then available to us, we may, at our option, at any time, having giving not less than 15 days (or in the case of the 2029 Notes, 10 days) nor more than 60 days' prior written notice to Holders, redeem, in whole, but not in part, the 2026 Notes, the 2029 Notes, the 2034 Notes or the 2039 Notes at a redemption price equal to 100% of their principal amount, together with unpaid interest, if any, on the Notes being redeemed accrued to but excluding the redemption date, provided that no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which we would be obliged to pay such additional amounts if a payment in respect to the applicable tranche of Notes were due on such date. Prior to the transmission or publication of such a notice of redemption, we shall deliver to the Trustee a certificate signed by two executive officers of the Company stating that we are entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to our right to so redeem the Notes has occurred. Payment of Additional Amounts We will, subject to the exceptions and limitations set forth below, pay as additional amounts to a holder of a Note that is a United States Alien (as defined below) such amounts as may be necessary so that every net payment on such Note after deduction or withholding for or on account of any present or future tax, assessment or other governmental charge of whatever nature imposed upon or as a result of such payment by the United States (or any political subdivision or taxing authority thereof or therein), will not be less than the amount provided for in such Note to be then due and payable. However, we will not be required to make any payment of additional amounts for or on account of: a) any tax, assessment or other governmental charge that would not have been imposed but for (i) the existence of any present or former connection between such holder (or between a fiduciary, settlor or beneficiary of, or a person holding a power over, such holder, if such holder is an estate or a trust, or a member or shareholder of such holder, if such holder is a partnership or corporation) and the United States, including, without limitation, such holder (or such fiduciary, settlor, beneficiary, person holding a power, member or shareholder) being or having been a citizen or resident or treated as a resident thereof or being or having been engaged in trade or business or present therein or having or having had a permanent establishment therein, or (ii) the presentation by the holder of a Note for payment more than 15 days after the date on which such payment became due and payable or on which payment thereof was duly provided for, whichever occurs later; b) any estate, inheritance, gift, sales, transfer, personal property or any similar tax, assessment or other governmental charge; c) any tax, assessment or other governmental charge that would not have been imposed but for such holder's past or present status as a controlled foreign corporation, passive foreign investment company (including a qualified election fund) or foreign private foundation or other tax exempt organization with respect to the United States or as a corporation that accumulates earnings to avoid United States Federal income tax; d) any tax, assessment or other governmental charge that is payable otherwise than by deduction or withholding from a payment on a Note; e) any tax, assessment or other governmental charge required to be deducted or withheld by any paying agent from any payment on a Note, if such payment can be made without such deduction or withholding by any other paying agent; f) any tax, assessment or other governmental charge that would not have been imposed but for the holder's failure to comply with any applicable certification, information, documentation or other reporting requirement concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of a Note if, without regard to any tax treaty, such compliance is required by statute or regulation of the United States as a precondition to relief or exemption from such tax, assessment or other governmental charge; g) any tax, assessment or other governmental charge imposed by reason of the holder (i) owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting power of all classes of stock of the Company entitled to vote, (ii) receiving interest described in Section 881(c)(3)(A) of the United States Internal Revenue Code or (iii) being a controlled foreign corporation with respect to the United States that is related to the Company by actual or constructive stock ownership; h) any tax, assessment or other governmental charge that is imposed on a payment pursuant to Sections 1471 through 1474 of the United States Internal Revenue Code (FATCA), any Treasury regulations and official interpretations thereof, and any regulations or official law, agreement or interpretations thereof implementing an intergovernmental approach thereto; or i) any combination of items (a), (b), (c), (d), (e), (f) (g) and (h). nor shall such additional amounts be paid with respect to any payment on a Note to a holder that is a fiduciary or partnership or other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have been entitled to the additional amounts had such beneficiary, settlor, member or beneficial owner been the holder of such Note. For purposes of the foregoing, the holding of or the receipt of any payment with respect to a Note shall not constitute a connection between the holder (or between a fiduciary, settlor, beneficiary, member or shareholder of, or a person having power over, such holder if such holder is an estate, a trust, a partnership or a corporation) and the United States. The term United States Alien means any person who, for United States Federal income tax purposes, is a foreign corporation, a non-resident alien individual, a non-resident alien fiduciary of a foreign estate or trust, or a foreign partnership one or more of the members of which is, for United States Federal income tax purposes, a foreign corporation, a nonresident alien individual or a non-resident alien fiduciary of a foreign estate or trust. Further Issuances We may, from time to time, without the consent of or notice to existing holders of the Notes, create and issue further debt securities having the same terms and conditions as the Notes in all respects, except for issue date, issue price and, to the extent applicable, the first payment of interest and the initial interest accrual date. Additional debt securities issued in this manner will be consolidated with and will form a single tranche or series of debt securities with the related previously outstanding applicable tranche or series of Notes; provided, however, that the issuance of such additional Notes will not be so consolidated for United States federal income tax purposes unless such issuance constitutes a "qualified reopening" within the meaning of the Internal Revenue Code of 1986, as amended (the "Code"), and the Treasury regulations promulgated thereunder. Book-Entry Delivery and Settlement The Notes of each tranche or series will be issued in the form of one or more global Notes in fully registered form, without coupons, and will be deposited with, or on behalf of, a common depositary for, and in respect of interests held through, Euroclear and Clearstream. Except as described herein, certificates will not be issued in exchange for beneficial interests in the global Notes. Except as set forth below, the global Notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees. Beneficial interests in the global Notes will be represented, and transfers of such beneficial interests will be effected, through accounts of financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests will be in denominations of \$1,000,000 and integral multiples of \$1,000 in excess thereof. Investors may hold Notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are participants in such systems. Owners of beneficial interests in the global Notes will not be entitled to have Notes registered in their names, and, except as described herein, will not receive or be entitled to receive physical delivery of Notes in certificated form. So long as the common depositary for Euroclear and Clearstream or its nominee is the registered owner of the global Notes, the common depositary for all purposes will be considered the sole holder of the Notes represented by the global Notes under the Indenture and the global Notes. Except as provided below, beneficial owners will not be considered the owners or holders of the Notes under the Indenture, including for purposes of receiving any reports delivered by us or the Trustee pursuant to the Indenture. Accordingly, each beneficial owner must rely on the procedures of the clearing systems and, if such person is not a participant of the clearing systems, on the procedures of the participant through which such person owns its interest, to exercise any rights of a holder under the Indenture. Under existing industry practices, if we request any action of holders or a beneficial owner desires to give or take any action which a holder is entitled to give or take under the Indenture, the clearing systems would authorize their participants holding the relevant beneficial interests to give or take action and the participants would authorize beneficial owners owning through the participants to give or take such action or would otherwise act upon the instructions of beneficial owners. Conveyance of notices and other communications by the clearing systems to their participants, by the participants to indirect participants and by the participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any statutory or regulatory requirements as may be in effect from time to time. The laws of some jurisdictions require that certain purchasers of securities take physical delivery of such securities in certificated form. These limits and laws may impair the ability to transfer beneficial interests in global Notes. Exchange of Global Notes for Certificated Notes Subject to certain conditions, the Notes represented by the global Notes are exchangeable for certificated Notes in definitive form of like tenor in minimum denominations of \$1,000,000 principal amount and integral multiples of \$1,000 in excess thereof if: (1) we have been notified that both Clearstream and Euroclear have been closed for business for a continuous period of at least 14 days (other than by reason of holiday, statutory or otherwise) or have announced an intention permanently to cease business or have in fact done so and no successor clearing system is available; (2) we, at our option, notify the Trustee in writing that we elect to cause the issuance of certificated Notes in definitive form; or (3) there has occurred and is continuing an Event of Default with respect to the Notes. In all cases, certificated Notes in definitive form delivered in exchange for any global Note or beneficial interest therein will be registered in the names, and issued in any approved denominations, requested by or on behalf of the common depositary (in accordance with its customary procedures). Payments (including principal and interest) and transfers with respect to Notes in certificated form may be executed at the office or office maintained for such purpose in London (initially the corporate trust office of the London Paying Agent) or, at our option, by check mailed to the holders thereof at the respective addresses set forth in the register of holders of the Notes, provided that all payments (including principal and interest) on Notes in certificated form, for which the holders thereof have given wire transfer instructions at least ten calendar days prior to the applicable payment date, will be required to be made by wire transfer of immediately available funds to the accounts specified by the holders thereof. No service charge will be made for any registration of transfer, but payment of a sum sufficient to cover any tax or governmental charge payable in connection with that registration may be required. Indenture Provisions: Merger and Consolidation We may consolidate or merge with or into any other corporation, and we may sell, lease or convey all or substantially all of our assets to any corporation, provided that: (a) the resulting corporation, if other than Colgate, is a corporation organized and existing under the laws of the United States of America or any U.S. state or the District of Columbia and assumes all of our obligations to: (1) pay or deliver the principal of or any premium, interest or additional amounts on the debt securities; and (2) perform and observe all of our other obligations under the Indenture, and (a) we or any successor corporation, as the case may be, are not, immediately after any such

consolidation, merger or sale of assets, in default under the Indenture.Modification and WaiverWe and the trustee may, without the consent of holders, modify provisions of the Indenture for specified purposes, including, among other things, curing ambiguities and correcting inconsistencies. We and the trustee may modify and amend other provisions of the Indenture with the consent of holders of at least a majority in principal amount of each series of debt securities affected. However, the consent of each holder of any debt security affected must be obtained if the amendment or modification:â€ changes the stated maturity of the principal of, or any premium or installment of interest or additional amounts on, any debt security;â€ reduces the principal amount due and payable at maturity or upon acceleration of maturity of, or the rate of interest or additional amounts payable on, or any premium payable on redemption or otherwise on, any debt security;â€ adversely affects any right of repayment at the option of the holders;â€ changes the place of delivery of, or currency of, the payment of principal or any premium, interest or additional amounts on any debt security or impairs the right to institute suit for the enforcement of any such payment or delivery;â€ reduces the percentage in principal amount or aggregate issue price of the outstanding debt securities of any series, the consent of whose holders is required to modify or amend the Indenture; orâ€ modifies the foregoing requirements or reduces the percentage to less than a majority in principal amount of outstanding debt securities necessary to waive certain past defaults by Colgate under the Indenture.The holders of at least a majority in principal amount of the outstanding debt securities of any series may, with respect to that series, waive past defaults under the Indenture and waive our compliance with certain provisions of the Indenture, except as described below under â€Events of Default.â€ Events of DefaultExcept as otherwise provided in the applicable prospectus supplement, each of the following constitutes an event of default with respect to each series of debt securities issued under the Indenture:â€ default in the payment of any interest or additional amounts when due and continuing for 30 days;â€ default in the payment of any principal or premium when due and payable at maturity;â€ default in the payment of any sinking fund payment when due;â€ default in the performance, or breach, of any other obligation of ours under the Indenture, or under provisions of a series of debt securities that are applicable to all series of debt securities, and continuance of the default for 60 days after we are given written notice of the default as provided in the Indenture;â€ specified events of bankruptcy, insolvency or reorganization of Colgate; andâ€ any other event of default with respect to debt securities of that series.If an event of default occurs and is continuing for any series of debt securities, the trustee or the holders of at least 25% in principal amount of the outstanding debt securities of that series may declare the principal of all the debt securities of that series, or any lesser amount provided for in the debt securities of that series, due and payable immediately. At any time after such a declaration of acceleration with respect to the debt securities of any series has been made, but before the trustee has obtained a judgment or decree for payment of the money due, the holders of a majority in principal amount of the outstanding debt securities of that series by written notice may rescind any declaration of acceleration and its consequences, provided that all payments and/or deliveries due, other than those due as a result of acceleration, have been made and all other events of default have been remedied or waived.The holders of at least a majority in principal amount of the outstanding debt securities of any series may waive an event of default with respect to that series, except a default:â€ in the payment of any amounts due and payable or deliverable under the debt securities of that series; orâ€ in respect of an obligation of ours contained in, or a provision of, the Indenture which cannot be modified under the terms of the Indenture without the consent of each holder of outstanding debt securities affected.The holders of a majority in principal amount of the outstanding debt securities of a series may direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to debt securities of that series, provided that the direction is not in conflict with any rule of law, the Indenture or the debt securities of that series. The trustee must, within 90 days after a default occurs, notify the holders of the applicable series of debt securities of the default, unless the default is cured or waived. The trustee may withhold notice of default, except default in payment of principal, any premium, interest or sinking fund payment, if it determines that it is in the interest of the holders to do so. Before proceeding to exercise any right or power under the Indenture at the direction of the holders, the trustee is entitled to receive from those holders reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in complying with any such direction. Unless otherwise stated in the prospectus supplement, any series of debt securities issued under the Indenture will not have the benefit of any cross-default provisions with other indebtedness of our company.We will be required to furnish to the trustee annually a statement as to our performance of all of our obligations and conditions under the Indenture.Legal Defeasance and Covenant DefeasanceWe at any time may terminate as to a series of debt securities all of our obligations (except for certain obligations regarding the defeasance trust and obligations to register the transfer or exchange of a debt security, to replace destroyed, lost or stolen debt securities and any related coupons and to maintain agencies with respect to the debt securities) arising under the Indenture and the debt securities and coupons of that series. This option of ours is called a â€legal defeasance.â€ We at any time may terminate as to a series of debt securities, among other obligations, our obligations arising under the covenant described under â€Limitations Upon Liensâ€ below. This option of ours is called a â€covenant defeasance.â€We may exercise our legal defeasance option with respect to a series of debt securities even if we have previously exercised our covenant defeasance option in regard to that series of debt securities. If we exercise our legal defeasance option with respect to a series of debt securities, that series may not be accelerated because of an Event of Default. If we exercise our covenant defeasance option with respect to a series of debt securities, that series may not be accelerated on the basis of breaches of the defeased covenant.To exercise either option as to a series of debt securities, we must deposit in trust with the trustee cash or United States government obligations sufficient to pay the principal of, premium, if any, and interest on the debt securities of that series at their maturity or redemption and must comply with other specified conditions. In particular, we must obtain an opinion of tax counsel that the defeasance will not result in recognition for United States Federal income tax purposes of any gain or loss to holders of the series of debt securities. The opinion of tax counsel, in the case of legal defeasance, must refer to and be based upon a ruling of the Internal Revenue Service or a change in applicable United States Federal income tax law occurring after the date of the Indenture.Limitations Upon LiensThe debt securities will not be secured by any mortgage, pledge or other lien. Unless a prospectus supplement with respect to a particular series of debt securities states otherwise, the covenants described below will apply to each series of debt securities.We covenant in the Indenture not to create or suffer to exist, or permit any of our Principal Domestic Subsidiaries to create or suffer to exist, any Lien on any Restricted Property, whether owned on the date of the Indenture or thereafter acquired, without making effective provision (and we covenant and agree in the Indenture that we will make or cause to be made effective provision) whereby the debt securities shall be directly secured by such Lien equally and ratably with (or prior to) all other indebtedness secured by such Lien as long as such other indebtedness shall be so secured; provided, however, that there shall be excluded from the foregoing restrictions: â€ Liens securing Debt not exceeding \$10,000,000 which are existing on the date of the Indenture on Restricted Property; and, if any property owned or leased as of the date of the Indenture by us or one of our Principal Domestic Subsidiaries at any time thereafter becomes a Principal Domestic Manufacturing Property, any Liens existing on the date of the Indenture on such property securing the Debt secured or evidenced thereby on the date of the Indenture;â€ Liens on Restricted Property of a Principal Domestic Subsidiary as a security for Debt of such Subsidiary to us or to another Principal Domestic Subsidiary;â€ in the case of any corporation which becomes a Principal Domestic Subsidiary after the date of the Indenture, Liens on Restricted Property of such Principal Domestic Subsidiary which are in existence at the time it becomes a Principal Domestic Subsidiary and which were not incurred in contemplation of it becoming a Principal Domestic Subsidiary;â€ any Lien existing prior to the time of acquisition of any Principal Domestic Manufacturing Property acquired by us or one of our Principal Domestic Subsidiaries after the date of the Indenture through purchase, merger, consolidation or otherwise;â€ any Lien on any Principal Domestic Manufacturing Property (other than a Major Domestic Manufacturing Property) acquired or constructed by our company or a Principal Domestic Subsidiary after the date of the Indenture which is placed on such Property at the time of or within 180 days after the acquisition thereof or prior to, at the time of or within 180 days after completion of construction thereof to secure all or a portion of the price of such acquisition or construction or funds borrowed to pay all or a portion of the price of such acquisition or construction;â€ extensions, renewals or replacements of any Lien referred to in the first, third, fourth or fifth bullet points above to the extent that the principal amount of the Debt secured or evidenced thereby is not increased, provided that the Lien is not extended to any other Restricted Property;â€ Liens imposed by law, such as carriersâ€™, warehousemenâ€™s, mechanicsâ€™, materialmenâ€™s, vendorsâ€™ and landlordsâ€™ liens, and liens arising out of judgments or awards against us or any of our Principal Domestic Subsidiaries with respect to which we or such Subsidiary at the time shall currently be prosecuting an appeal or proceedings for review and with respect to which it shall have secured a stay of execution pending such appeal or proceedings for review;â€ Liens securing the payment of taxes, assessments and governmental charges or levies, either (1) not delinquent or (2) being contested in good faith by appropriate legal or administrative proceedings and as to which we or a Principal Domestic Subsidiary, as the case may be, to the extent required by generally accepted accounting principles applied on a consistent basis, shall have set aside on its books adequate reserves;â€ minor survey exceptions, minor encumbrances, easements or reservations of, or rights of others for, rights of way, sewers, electric lines, telegraph and telephone lines and other similar purposes and zoning or other restrictions as to the use of any Principal Domestic Manufacturing Property, which exceptions, encumbrances, easements, reservations, rights and restrictions do not, in our opinion, in the aggregate materially detract from the value of such Principal Domestic Manufacturing Property or materially impair its use in the operation of our business and that of our Principal Domestic Subsidiaries; andâ€ any Lien on Restricted Property not referred to above if, at the time such Lien is created, incurred, assumed or suffered to be created, incurred or assumed, and after giving effect thereto and to the Debt secured or evidenced thereby, the aggregate amount of all our outstanding Debt together with that of our Principal Domestic Subsidiaries secured or evidenced by Liens on Restricted Property which are not referred to above and which do not equally and ratably secure the debt securities, shall not exceed 15% of Consolidated Net Tangible Assets.â€Codeâ€ means the Internal Revenue Code of 1986, as amended.â€Consolidated Net Tangible Assetsâ€ means the aggregate amount of assets (less applicable reserves and other properly deductible items) after deducting therefrom (1) all current liabilities and (2) all goodwill, trade names, trademarks, patents, unamortized debt discount and expense and other like intangibles of ours and our consolidated subsidiaries, all as set forth on the most recent balance sheet of ours and our consolidated subsidiaries prepared in accordance with generally accepted accounting principles as practiced in the United States.â€Debtâ€ means (1) indebtedness for borrowed money, (2) obligations evidenced by bonds, debentures, notes or other similar instruments, (3) obligations to pay the deferred purchase price of property or services (other than accounts payable in the ordinary course of business), (4) obligations as a lessee under leases which shall have been or should be, in accordance with generally accepted accounting principles, recorded as capital leases, and (5) obligations under direct or indirect guaranties in respect of, and obligations (contingent or otherwise) to purchase or otherwise acquire, or otherwise to assure a creditor against loss in respect of, indebtedness or obligations of others of the kinds referred to in clauses (1) through (4) above.â€Domestic Subsidiaryâ€ means any Subsidiary a majority of the business of which is conducted within the United States of America, or a majority of the properties and assets of which are located within the United States of America, except any Subsidiary whose assets consist substantially of the securities of Subsidiaries which are not Domestic Subsidiaries.â€Instrumentsâ€ of any corporation means and includes (1) all capital stock of all classes of and all other equity interests in such corporation and all rights, options or warrants to acquire the same, and (2) all promissory notes, debentures, bonds and other evidences of Debt of such corporation.â€Lienâ€ means any mortgage, lien, pledge, security interest, encumbrance or charge of any kind, any conditional sale or other title retention agreement or any lease in the nature thereof, provided that the term â€Lienâ€ shall not include any lease involved in a sale and lease-back transaction.â€Major Domestic Manufacturing Propertyâ€ means any Principal Domestic Manufacturing Property the net depreciated book value of which on the date as of which the determination is made exceeds 3% of the Consolidated Net Tangible Assets.â€Principal Domestic Manufacturing Propertyâ€ means any building, structure or facility (including the land on which it is located and the improvements and fixtures constituting a part thereof) used primarily for manufacturing or processing which is owned or leased by us or any of our Subsidiaries, is located in the United States of America and the net depreciated book value of which on the date as of which the determination is made exceeds 1% of Consolidated Net Tangible Assets, except any such building, structure or facility which our Board of Directors by resolution declares is not of material importance to the total business conducted by us and our Subsidiaries as an entirety. â€Principal Domestic Subsidiaryâ€ means (1) each Subsidiary which owns or leases a Principal Domestic Manufacturing Property, (2) each Domestic Subsidiary the consolidated net worth of which exceeds 3% of Consolidated Net Tangible Assets (as set forth in the most recent financial statements delivered pursuant to the Indenture) and (3) each Domestic Subsidiary of each Subsidiary referred to in the foregoing clause (1) or (2) except any such Subsidiary the accounts receivable and inventories of which have an aggregate net book value of less than \$5,000,000.â€Restricted Propertyâ€ means and includes (1) all Principal Domestic Manufacturing Properties, (2) all Instruments of all Principal Domestic Subsidiaries and (3) all inventories and accounts receivable of ours and our Principal Domestic Subsidiaries.â€Subsidiaryâ€ means any Corporation of which at the time of determination we or one or more of our Subsidiaries owns or controls directly or indirectly more than 50% of the shares of Voting Stock.â€Voting Stockâ€ means stock of a Corporation of the class or classes having general voting power under ordinary circumstances to elect at least a majority of the board of directors, managers or trustees of such Corporation, provided that, for this purpose, stock which carries only the right to vote conditionally on the happening of an event shall not be considered voting stock whether or not such event shall have happened.Other capitalized terms used but not defined shall have the meaning given those terms in the Indenture.The Trustee for the NotesThe Bank of New York Mellon serves as trustee under the Indenture and is the security registrar and paying agent with respect to the debt securities.The Indenture contains certain limitations on the right of the trustee, should it become a creditor of ours, to obtain payment of claims in certain cases, or to realize on certain property received in respect of any such claim as security or otherwise. The trustee is permitted to engage in other transactions with us; provided, however, that if the trustee acquires any conflicting interest it must eliminate such conflict or resign. We have banking relationships with The Bank of New York Mellon and certain of its affiliates.Governing LawThe Indenture and the debt securities are governed by, and construed in accordance with, the laws of the State of New York. EX-19 3 exhibit1912312024.htm EX-19 Document EXHIBIT 19COLGATE-PALMOLIVE COMPANY INSIDER TRADING POLICYEffective Date: December 11, 2024PurposeThis Policy provides guidelines with respect to transactions in the securities of Colgate-Palmolive Company (â€Colgate,â€ and together with Colgateâ€™s direct and indirect subsidiaries, the â€Companyâ€), Colgateâ€™s Board of Directors has adopted thisPolicy to promote compliance with applicable laws and regulations that prohibit certain persons who are aware of Material Nonpublic Information (as defined below) about a company from: (i) engaging in transactions in the securities of that company; or (ii) providing Material Nonpublic Information to other persons who may trade on the basis of that information.Persons Subject to the PolicyThis Policy applies to (i) all directors, officers and employees of the Company, (ii) such personsâ€™ Family Members (as defined below) and (iii) any entities, including corporations, partnerships or trusts, that such persons influence or control (collectively, â€Insidersâ€).Key Definitionsâ€Colgate Securitiesâ€ are any securities issued by or related to Colgate, including common stock, bonds, stock options or other derivative securities.â€Family Membersâ€ are any family members of a person, including a spouse, who reside with such person, anyone else who lives in such personâ€™s household, and any family members who do not live in such personâ€™s household but whose transactions in Colgate Securities are directed by such person or are subject to such personâ€™s influence or control (such as parents or children who consult with such person before they trade in Colgate Securities).â€Material Nonpublic Informationâ€ is any information that a reasonable investor would consider important in making a decision to buy, hold or sell securities that has not been disclosed generally to the investing public in a manner that complies with applicable securities laws. Any information that could be expected to affect a companyâ€™s stock price, whether it is positive or negative, should be considered material. While it is not possible to define all categories of material information, some examples of information that ordinarily would be regarded as material are:â€Financial results and projections of future results or other guidance;â€Changes to previously announced guidance;â€Major proposed or pending strategic transactions, including joint ventures, mergers, acquisitions, investments or dispositions;â€A change in dividend policy, stock split, new stock repurchase program or new equity or debt offering;â€Significant project or product developments;â€Changes in top management;â€A change in auditors or notification that the auditorâ€™s reports may no longer be relied upon;â€Pending or threatened significant litigation, or the resolution of such litigation;â€Impending bankruptcy or the existence of severe liquidity problems; orâ€A major cybersecurity breach.Information should be considered nonpublic until the beginning of the second business day after such information has been disseminated widely to the investing public through press releases, filings with the U.S. Securities and Exchange Commission (â€SECâ€) or other means.Policy1.Restrictions Applicable to All Insidersa.Prohibition on Insider Tradingi.Except as otherwise specified below, no Insider may directly or indirectly engage in any transactions involving Colgate Securities while aware of Material Nonpublic Information relating to the Company, including purchases, sales, stock option exercises, bona fide gifts or decisions to invest in or dispose of Colgate Securities within an individual retirement account or Colgateâ€™s Savings & Investment Plan (â€S&I Planâ€).ii.No Insider may directly or indirectly engage in transactions in another companyâ€™s securities while in possession of Material Nonpublic Information concerning that company when the Material Nonpublic Information was obtained in the course of employment with, or the performance of services on behalf of, the Company.iii.It is also the policy of the

Company that the Company will not engage in transactions in Colgate Securities while in possession of Material Nonpublic Information relating to the Company.b.Prohibition on Tipping Information to Others.i.Insiders may not, while in possession of Material Nonpublic Information relating to the Company, make any recommendations or express any opinions to others regarding transacting in Colgate Securities.ii.Insiders may not disclose Material Nonpublic Information relating to the Company to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons, including, but not limited to, family, friends, business associates, investors and expert consulting i-rms, unless any such disclosure is made in accordance with the Companyâ€™s policies regarding the protection or authorized external disclosure of information regarding the Company. This prohibition applies whether or not the Insider receives any benei-t from the use of that information by the other person or entity.If an Insider is unsure whether particular information is material or nonpublic, they should consult with the Global Legal Organization before trading in Colgate Securities or communicating the information to anyone else. In addition, there may be additional restrictions on securities transactions in other countries where a Colgate subsidiary is publicly listed. Insiders located in those countries should consult with the Global Legal Organization in order to ensure compliance with all relevant laws.2.Exceptions for Certain Transactions under Company Plans.a.Restricted Stock Unit Awards. This Policy does not apply to the vesting of restricted stock units, or to the Companyâ€™s withholding of shares of stock to satisfy tax withholding requirements upon the vesting of any restricted stock unit. The Policy does apply, however, to any market sale of restricted stock units upon or after vesting.b.S&I Plan. This Policy does not apply to purchases of Colgate Securities in the Companyâ€™s S&I Plan resulting from the periodic contribution of money to the S&I Plan pursuant to payroll deduction elections. This Policy does apply, however, to certain elections employees may make under the S&I Plan, including: (i) an election to increase or decrease the percentage of the periodic contributions that will be allocated to a Colgate Securities fund; (b) an election to make an intra-plan transfer of an existing account balance into or out of a Colgate Securities fund; or (c) an election to borrow money against an S&I Plan account if the loan could result in a liquidation of some or all of the Colgate Securities fund(s) balance.c.Dividend Reinvestment Plan. This Policy does not apply to purchases of Colgate Securities under the Companyâ€™s dividend reinvestment plan resulting from the reinvestment of dividends paid on Colgate Securities.3.Additional Restrictions and Procedures Applicable to Certain Company Insiders.a.Quarterly Blackout Periods/Trading Restrictions. It is the Companyâ€™s policy that oi-fcers, directors and certain other designated Insiders (together, the â€œDesignated Insidersâ€œ), due to their job responsibilities, are prohibited from conducting any transactions involving Colgate Securities (other than as speci-ed by this Policy) during designated â€œblackout periods.â€œ â€œBlackout periodsâ€œ commence on the i-rst day of the last month of each i-scal quarter and continue until the second business day following a release of quarterly or annual earnings information and may be extended or otherwise adjusted by the Companyâ€™s Chief Legal Oi-fcer following consultation with the Chief Executive Oi-fcer and Chief Financial Oi-fcer.b.Pre-Clearance Procedures. The Designated Insiders, as well as the Family Members of such persons, may only engage in transactions in Colgate Securities outside of blackout periods and must i-rst pre-clear their transaction with the Global Legal Organization. A request for pre-clearance should be submitted to the Global Legal Organization at least one business day in advance of the proposed transaction. When a request for pre-clearance is made, the requestor should carefully consider whether they may be aware of any Material Nonpublic Information about the Company, and should describe fully those circumstances to the Global Legal Organization. Pre-clearance authorizations will be valid only until the close of business on Friday following the approval date (the â€œApproval Weekâ€œ). If a transaction for which clearance has been granted is not executed during the Approval Week and the requestor would still like to execute a transaction, a new pre-clearance request must be submitted. If the requestor becomes aware of Material Nonpublic Information about the Company during the Approval Week after clearance is granted but before the transaction is executed, the pre-clearance shall be void and the transaction must not be completed. If a Designated Insider seeks pre-clearance and permission to engage in the transaction is denied, then they should refrain from initiating any transaction in Colgate Securities, and should not inform any other person of the denial.c.Event-Speci-c Restricted Periods. From time to time, the Company may also require that all or certain Insiders refrain from engaging in transactions in Colgate Securities for a speci-ed period of time due to material information known to the Company and not yet disclosed to the public. In such an event, the Company will notify the impacted Insiders.d.Exceptions. The quarterly trading restrictions, requirement for pre-clearance and event-speci-c trading restrictions do not apply.i.To those transactions to which this Policy does not apply, as described above under the heading â€œExceptions for Certain Transactions Under Company Plans.â€œii.To transactions conducted pursuant to approved Rule 10b5-1 plans. See Exhibit A, â€œImportant Guidance Regarding Rule 10b5-1 Plansâ€œ for more information about Rule 10b5-1 plans.4.Other Prohibited TransactionsIt is the Companyâ€™s policy that oi-fcers, directors and employees who receive equity awards pursuant to Colgateâ€™s incentive compensation plan are prohibited from purchasing any i-nancial instrument that is designed to hedge against or oi-â€œset any decrease in the market value of Colgate Securities. Similarly, employees who do not receive equity awards pursuant to Colgateâ€™s incentive compensation plan are strongly discouraged from entering into such transactions. Examples of transactions covered by this policy include â€œshort salesâ€œ (selling borrowed securities, which the seller hopes can be purchased at a lower price in the future) and â€œputâ€œ and â€œcallâ€œ options (publicly available rights to sell or buy securities within a certain period of time at a speci-ed price). It is also the Companyâ€™s policy that the Companyâ€™s oi-fcers and directors are prohibited from pledging Colgate securities.Personal Responsibility for Compliance With this PolicyPersons subject to this Policy have ethical and legal obligations to maintain the confi-dentiality of information about the Company and to not engage in transactions in Colgate Securities while in possession of Material Nonpublic Information. Persons subject to this Policy must not engage in illegal trading and must avoid the appearance of improper trading. Each individual is responsible for making sure they comply with this Policy, and that any Family Member whose transactions are subject to this Policy also complies with this Policy. In all cases, the responsibility for determining whether an individual is in possession of Material Nonpublic Information rests with that individual, and any action on the part of the Company or any employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. Persons subject to this Policy could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described below in more detail under the heading â€œConsequences of Violations.â€œPost-Termination TransactionsThis Policy continues to apply to transactions in Colgate Securities even after termination of service to the Company. If an individual is in possession of Material Nonpublic Information when their service terminates, that individual may not engage in transactions in Colgate Securities until that information has become public or is no longer material. The pre-clearance procedures speci-ed above, however, will cease to apply to transactions in Colgate Securities upon the expiration of any blackout period or other Company-imposed trading restrictions applicable at the time of the termination of service.Consequences of ViolationsIn addition to Company disciplinary measures, employees violating the U.S. or other securities laws may be subject to severe civil and criminal sanctions, including heavy i-nes and jail sentences, and disgorgement of the proi-ts gained, or losses avoided, by the insider trading.The Company may also be criminally or civilly liable as a controlling person of an insider trading violator if the Company failed to take steps to prevent the action before it occurred. In such cases, Colgate could be forced to pay signi-cant i-nes and restitution.Company AssistanceAny person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the Global Legal Organization.Exhibit AColgate-Palmolive Company Important Guidance Regarding Rule 10b5-1 PlansThis document is intended to address frequently asked questions and practical aspects associated with Rule 10b5-1 plans. As you may know, Rule 10b5-1 plans are a means by which you may purchase or sell Colgate Securities at times when you would otherwise be restricted from trading due to your potential possession of Material Nonpublic Information relating to the Company. Put another way, a Rule 10b5-1 plan allows you to trade during a blackout period. The execution of a transaction in accordance with a valid Rule 10b5-1 plan should provide an ai-firmative defense against allegations of insider trading.If you would like additional information regarding Rule 10b5-1 plans, you may contact the administrator of Colgateâ€™s equity awards, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Any Rule 10b5-1 plan must be in writing and approved by the Global Legal Organization before you may enter into it.What Are the Requirements to Establish a Rule 10b5-1 Plan?To establish a Rule 10b5-1 plan, you must:â€”Enter into the plan when you are not in possession of Material Nonpublic Information relating to the Company and when you are otherwise permitted to trade Colgate Securities (i.e., when we are not in a blackout period);â€”Establish the terms upon which Colgate Securities may be purchased or sold under the plan (e.g., the amount, price and date of the transactions);â€”Not exercise subsequent ini-ence over how, when or whether trades occur under the plan;â€”Comply with SEC rules regarding Rule 10b5-1 plans as detailed below, including with respect to required â€œcooling oi-â€œ periodsâ€œ and prohibitions on multiple plans;â€”Not hedge against transactions under the plan; andâ€”Enter into the plan in good faith, and continue acting in good faith with respect to the plan after entry.How Quickly Can Trades Occur Under a Rule 10b5-1 Plan That I Establish?For directors and Section 16 oi-fcers, under SEC rules, the i-rst trade under the plan may not occur until the later of (i) 90 days following the date the plan is executed by you and(ii) two business days following the i-ling of a Form 10-Q or 10-K covering the period in which the plan is adopted.If you are not a director or a Section 16 oi-fcer, under SEC rules, the i-rst trade under the plan may not occur until at least 30 days following the date the plan is executed by you.What Types of Terms May I Establish For Trades Under a Rule 10b5-1 Plan?At the time you enter into the plan you must specify the amount, price and date of the transactions to occur under the plan. The terms of the plan may provide for the number of shares to be purchased or sold in any one transaction or in the aggregate under the plan, and the time period over which the purchases or sales may occur. In addition, you may specify that vested stock options will be exercised and the underlying shares sold under the plan. Please note, however, that â€œlimit orderâ€œ plans, directing that shares be sold only when and if Colgateâ€™s stock price exceeds or falls below a certain amount, are not permissible because such plans are less likely to provide an ai-firmative defense to insider trading allegations. Please consult the Global Legal Organization with any questions regarding the interpretation of this policy.In addition, under SEC rules, only one â€œsingle-tradeâ€œ plan (i.e., a Rule 10b5-1 plan designed to execute in a single transaction) is permitted in a 12-month period.Can I have multiple Rule 10b5-1 Plans at one time?Generally, no. Under SEC rules, overlapping Rule 10b5-1 plans are not permitted. However, there is a limited exception that would allow you to enter into a second plan as long as trades under the second plan do not start until trades under the i-rst plan have i-nished plus the required â€œcooling oi-â€œâ€œ period is observed following the end date of the i-rst plan.If I Decide I Donâ€™t Like The Terms of a Rule 10b5-1 Plan I Established, What Can I Do?Modi-cation and termination of the plan should be avoided as they could create the perception that you are exerting subsequent ini-ence over the plan and could call into question your good faith in entering into the plan. As a result, you should consult withthe Global Legal Organization before seeking to modify or terminate your plan. A modi-cation is considered to be a termination of the existing plan and entry into a new plan on the modi-ed terms. Therefore, any modi-cation must occur when we are not in a blackout period and when you are not in possession of Material Nonpublic Information relating to the Company. If you modify your plan, a new â€œcooling oi-â€œâ€œ period (of the same applicable length described above) must be observed before trades under the modi-ed plan may start. As noted above, this â€œcooling oi-â€œâ€œ period, which is required by SEC rules, is intended to help avoid any question that the modi-cation was not made in good faith.If I Establish a Rule 10b5-1 Plan, May I Trade Outside of the Plan?Generally yes, however your trades outside of the plan may not involve shares that were designated to be traded under the plan. For example, if you have established a plan that directs Merrill to exercise a tranche of stock options, you may not seek to exercise that tranche of stock options yourself outside of the plan. However, you are free to sell any other shares of Colgate Securities you own outside of the plan during an open trading period.Please consult with the Global Legal Organization before undertaking any transactions outside of the plan.Do Trades Under a 10b5-1 Plan Need to Comply with Section 16?Yes. Entering into a plan does not exempt Colgateâ€™s oi-fcers and directors from compliance with Section 16.What Disclosure is Required Regarding my Rule 10b5-1 Plans?Section 16 oi-fcers and directors are required to disclose in Form 4 whether a transaction was pursuant to a Rule 10b5-1 plan and, if so, the date that the Rule 10b5-1 plan was entered into. In addition, Colgate is required to disclose in Form 10-Qs and Form 10-Ks any trading plans adopted, modi-ed or terminated by any Section 16 oi-fcer or director during the previous quarter, including the following information:â€”Name and titleâ€”Date of Rule 10b5-1 plan adoption or terminationâ€”Duration of the Rule 10b5-1 planâ€”Aggregate amount of securities to be sold or purchased under the Rule 10b5-1 plan EX-21 4 exhibit2112312024.htm EX-21 DocumentEXHIBIT 21COLGATE-PALMOLIVE COMPANYSUBSIDIARIES OF THE REGISTRANTName of CompanyJurisdiction of OrganizationCleaning Dimensions, Inc.DelawareColgate (BVI) LimitedBritish Virgin IslandsColgate (Guangzhou) Company LimitedChinaColgate Business Services of the Americas, S.C.MexicoColgate Flavors and Fragrances, Inc.DelawareColgate Global Business Services Private LimitedIndiaColgate Holdings United KingdomColgate Oral Pharmaceuticals, Inc.DelawareColgate Palmolive Ghana LimitedGhanaColgate Palmolive Holding S.Com.P.A.SpainColgate Palmolive LLCUnited Arab EmiratesColgate Palmolive Nouvelle Caledonie SarlNew CaledoniaColgate Palmolive Tanzania LimitedTanzaniaColgate Sanxiao Company LimitedChinaColgate Tolaram Pte. Ltd.*SingaporeColgate Venture Company, Inc.DelawareColgate, Inc.DelawareColgate-Palmolive (America), Inc.DelawareColgate-Palmolive (Asia) Pte, LtdSingaporeColgate-Palmolive (Blantyre) LimitedMalawiColgate-Palmolive (Brunei) Sdn BhdBruneiColgate-Palmolive (Central America) Inc. y CompaÃ±ia LimitadaGuatemalaColgate-Palmolive (Central America), Inc.DelawareColgate-Palmolive (Centro America) S.A.GuatemalaColgate-Palmolive (China) Co. LtdChinaColgate-Palmolive (Costa Rica), S.A.Costa RicaColgate-Palmolive (Dominica), Inc.DelawareColgate-Palmolive (Dominican Republic), Inc.DelawareColgate-Palmolive (East Africa) LimitedKenyaColgate-Palmolive (Eastern) Pte. Ltd.SingaporeColgate-Palmolive (Egypt) S.A.E.Delaware/EgyptColgate-Palmolive (Fiji) Pte LimitedFijiColgate-Palmolive (Gabon), S.A.GabonColgate-Palmolive (Gulf States) Ltd. *United Arab EmiratesColgate-Palmolive (Guyana) Ltd.GuyanaColgate-Palmolive (Hellas) S.A. I.C.GreeceColgate-Palmolive (H.K.) LimitedHong KongColgate-Palmolive (India) Limited *IndiaColgate-Palmolive (Kazakhstan), L.L.P.KazakhstanColgate-Palmolive (Latvia) Ltd.LatviaColgate-Palmolive (Malaysia) Sdn BhdMalaysiaColgate-Palmolive (Middle East Exports) Ltd.British Virgin IslandsColgate-Palmolive (Myanmar) LimitedMyanmarColgate-Palmolive (New York), Inc.DelawareColgate-Palmolive (Poland) Sp. z o.o.PolandColgate-Palmolive (Proprietary) LimitedSouth AfricaColgate-Palmolive (Research & Development), Inc.DelawareColgate-Palmolive (Romania) SRLRomaniaColgate-Palmolive (Thailand) LimitedThailandColgate-Palmolive (Uganda) LimitedUgandaColgate-Palmolive (UK) LimitedUnited KingdomColgate-Palmolive (Vietnam) Ltd.VietnamColgate-Palmolive (Zambia) Inc.DelawareColgate-Palmolive (Zimbabwe), Inc.DelawareColgate-Palmolive A.B.SwedenColgate-Palmolive ACI Bangladesh Pvt. Limited *BangladeshColgate-Palmolive A/SDenmarkColgate-Palmolive Adria Ltd.SloveniaColgate-Palmolive Arabia Ltd. *Saudi ArabiaColgate-Palmolive Argentina S.A.ArgentinaColgate-Palmolive Asia Pacific LimitedHong KongColgate-Palmolive Asia Pacific Treasury Services LimitedHong KongColgate-Palmolive Belgium S.A.BelgiumColgate-Palmolive Bolivia, Ltda.BoliviaColgate-Palmolive Cameroun S.A. *CamerounColgate-Palmolive Canada, Inc.CanadaColgate-Palmolive Caribbean Business LLCPuerto RicoColgate-Palmolive Caricom Service Co., Inc.Puerto RicoColgate-Palmolive Central European Management Inc.DelawareColgate-Palmolive ÃƒEspaÃ±a republika s.r.o.Czech RepublicColgate-Palmolive Chile S.A.ChileColgate-Palmolive Cia.DelawareColgate-Palmolive Comercial Ltda.BrazilColgate-Palmolive Commercial (Hellas) SP LLCGreeceColgate-Palmolive S.A.S.FranceColgate-Palmolive Commercale S.r.l.ItalyColgate-Palmolive Compania AnonimaVenezuelaColgate-Palmolive Company, Distr. LLCPuerto RicoColgate-Palmolive de Paraguay Sociedad AnonimaParaguayColgate-Palmolive de Puerto Rico, Inc.DelawareColgate-Palmolive del Ecuador, S.A.I.C.EcuadorColgate-Palmolive del Peru (Delaware) Inc.DelawareColgate-Palmolive Development Corp.DelawareColgate-Palmolive East West Africa Region (Pty) LtdSouth AfricaColgate-Palmolive Enterprises, Inc.DelawareColgate-Palmolive Espana, S.A.SpainColgate-Palmolive Europe SarlSwitzerlandandColgate-Palmolive Global Trading CompanyDelawareColgate-Palmolive Holding Argentina S.A.ArgentinaColgate-Palmolive Hungary Kft, Limited Liability CompanyHungaryColgate-Palmolive IHQ Services (Thailand) LimitedThailandColgate-Palmolive Inc.DelawareColgate-Palmolive Inc. S.A.UruguayColgate-Palmolive Industrial Ltda.BrazilColgate-Palmolive Industriel S.A.S.FranceColgate-Palmolive International Holding LLCDelawareColgate-Palmolive International LLCDelawareColgate-Palmolive Investment Co., Inc.DelawareColgate-Palmolive Investments (BVI) Ltd.British Virgin IslandsColgate-Palmolive Investments (PNG) Ltd.Papua New GuineaColgate-Palmolive Investments, (UK) LimitedUnited KingdomColgate-Palmolive Investments, Inc.DelawareColgate-Palmolive Israel Ltd.IsraelColgate-Palmolive Italia, S.r.l.ItalyColgate-Palmolive JSCRussiaColgate-Palmolive Lanka (Private) LimitedSri LankaColgate-Palmolive Latin America Inc.DelawareColgate-Palmolive LimitedNew ZealandColgate-Palmolive Manufacturing (Poland) Sp. z o.o.PolandColgate-Palmolive Marketing Sdn BhdMalaysiaColgate-Palmolive Maroc, S.A.MoroccoColgate-Palmolive Mocambique LimitadaMozambiqueColgate-Palmolive Nederland B.V.NetherlandsColgate-Palmolive Norge A/SNorwayColgate-Palmolive Peru S.A.PeruColgate-Palmolive Philippines, Inc.PhilippinesColgate-Palmolive Pty LtdAustraliaColgate-Palmolive Retirement Trustee LimitedNew ZealandColgate-Palmolive S.r.l.ItalyColgate-Palmolive Services (Hellas) LLCGreeceColgate-Palmolive Services (Poland) Sp. z o.o.PolandColgate-Palmolive Services CEW GmbHGermanyColgate-Palmolive Services, S.A.FranceColgate-Palmolive Slovensko, s.r.o.SlovakiaColgate-Palmolive Support Services UCIRElandColgate-Palmolive Temizlik Urunleri Sanayi ve Ticart S.A.TurkeyColgate-Palmolive Transnational Inc.DelawareColgate-Palmolive UK Group LimitedUnited KingdomColgate-Palmolive Ukraine LLCUkraineColgate-Palmolive, LdaPortugalColgate-Palmolive, S.A. de C.V.MexicoColpal CBS, S de R. L. de C. V.MexicoConsumer Viewpoint Center, Inc.New JerseyCotelle S.A.FranceCP GABA GmbHGermanyCP International Holding C.V.NetherlandsCP Skin Health Group, Inc.DelawareDimac Development Corp.DelawareEKIB, Inc.DelawareELM Company LimitedBermudaElta MD Holdings, Inc.DelawareElta MD (Shanghai) Trade Co.,

Ltd.ChinaFilorga Benelux SASBelgiumFilorga Mexico Cosmetic, S.A. de C.V.MexicoFilorga Portugal, Unipessoal, Lda.PortugalFilorga RU, Limited Liability CompanyRussiaFZG Holdings LimitedHong KongGABA Europe Holding GmbHSwitzerlandGABA International Holding LLCDelawareGABA Schweiz AGSwitzerlandGABA Therwil GmbHSwitzerlandGamma Development Co., Ltd.ThailandGlobal Trading and Supply LLCDelawareHamol, Ltd.DelawareHawley & Hazel (BVI) Company Ltd. *British Virgin IslandsHillacé™'s Funding CompanyDelawareHillacé™'s Pet Nutrition (NZ) LimitedNew ZealandHillacé™'s Pet Nutrition (Thailand) Co., Ltd.ThailandHillacé™'s Pet Nutrition Asia LimitedHong KongHillacé™'s Pet Nutrition B.V.NetherlandsHillacé™'s Pet Nutrition Canada Inc.CanadaHillacé™'s Pet Nutrition de Mexico, S.A. de C.V.MexicoHillacé™'s Pet Nutrition de Puerto Rico, Inc.Puerto RicoHillacé™'s Pet Nutrition Denmark ApSDenmarkHillacé™'s Pet Nutrition Espana, S.L.SpainHillacé™'s Pet Nutrition GmbHGermanyHillacé™'s Pet Nutrition Holding B.V.NetherlandsHillacé™'s Pet Nutrition Indiana, Inc.DelawareHillacé™'s Pet Nutrition Italia, S.r.l.ItalyHillacé™'s Pet Nutrition Korea Ltd.KoreaHillacé™'s Pet Nutrition Ltd.United KingdomHillacé™'s Pet Nutrition Manufacturing, B.V.NetherlandsHillacé™'s Pet Nutrition Manufacturing srlItalyHillacé™'s Pet Nutrition Manufacturing, s.r.oCzech RepublicHillacé™'s Pet Nutrition Norway ASNorwayHillacé™'s Pet Nutrition OORussiaHillacé™'s Pet Nutrition (OAC) LimitedUnited KingdomHillacé™'s Pet Nutrition Pty. LimitedAustraliaHillacé™'s Pet Nutrition s.r.o.Czech RepublicHillacé™'s Pet Nutrition Sales, Inc.DelawareHillacé™'s Pet Nutrition SNCFranceHillacé™'s Pet Nutrition South Africa Proprietary LimitedSouth AfricaHillacé™'s Pet Nutrition Sweden ABSwedenHillacé™'s Pet Nutrition Switzerland GmbHSwitzerlandHillacé™'s Pet Nutrition Taiwan, LtdTaiwanHillacé™'s Pet Nutrition Trading (GZ) Co., LtdChinaHillacé™'s Pet Nutrition, Inc.DelawareHillacé™'s Pet Products (Benelux) S.A.BelgiumHillacé™'s Pet Products, Inc.DelawareHillacé™'s Veterinary Companies of America, Inc.DelawareHillacé™'s-Colgate (Japan) Ltd.JapanHPN Manufacturing Holdings, Inc.DelawareHPN Manufacturing, LLCDelawareHygiene Systemes et Services SATunisiaIES Enterprises, Inc.MassachusettsInmobiliaria Colpal, S. de R.L. de C.V.MexicoInmobiliaria Hills, S.A. de C.V.MexicoInnovacion Creativa, S.A. de C.V.MexicoKolynos CorporationDelawareLaboratoires Filorga Cosmetiques Espana S.L.U.SpainLaboratoires Filorga Cosmetiques Italia S.R.L.ItalyLaboratoires Filorga Cosma&tiques S.A.FranceLournay Sales, Inc.DelawareMennen de Chile, Ltd.DelawareMennen de Nicaragua, S.A.DelawareMennen Interamerica, Ltd.DelawareMennen LimitedDelawareMennen South Africa, Ltd.DelawareMission Hills Property CorporationDelawareMission Hills, S.A. de C.V.MexicoNorwood International, IncorporatedDelawareOlive Music Publishing CorporationDelawareP.T. Colgate Palmolive Indonesia *IndonesiaParamount Research, Inc.DelawarePenny, LLCDelawarePet Chemicals Inc.FloridaProductos Halogenados Copalven, C.A.VenezuelaPurity Holding CompanyDelawarePurity Music Publishing CorporationDelawareSamuel Taylor Holdings B.V.NetherlandsSanxiao Company LimitedHong KongServices Development Co., Ltd.ThailandSociete Generale de Negoce et de Services (GENESE) S.A.TunisiaThe GDN - The Global Distributive Network SASFranceThe Lournay Company, Inc.DelawareThe MPDP - The Medical and Pharmaceutic Distributive Platform SASFranceThe Murphy-Phoenix CompanyOhioTomaé™'s of Maine Holdings, Inc.DelawareTomaé™'s of Maine, Inc.MaineVipont Pharmaceutical, Inc.DelawareWeda (Beijing) Co. Ltd.China* Indicates a company that is not wholly owned, directly or indirectly, by Colgate-Palmolive Company. EX-23 5 exhibit2312312024.htm EX-23 DocumentEXHIBIT 23CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMWe hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-275201) and Form S-8 (Nos. 33-58746, 33-64753, 333-45679, 333-132038, 333-171448, and 333-231380) of Colgate-Palmolive Company of our report dated February 13, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K. /s/ PricewaterhouseCoopers LLPNew York, New YorkFebruary 13, 2025 EX-24 6 exhibit2412312024.htm EX-24 DocumentEXHIBIT 24POWER OF ATTORNEYKNOW ALL PERSONS BY THESE PRESENTS:Á Á Á Á I, John P. Bilbrey, do hereby make, constitute and appoint Jennifer M. Daniels and Kristine Hutchinson, and each of them, as my attorneys-in-fact and agents with full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf the Annual Report of Colgate-Palmolive Company on Form 10-K for the year ended December 31, 2024, and any and all amendments thereto and any other documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents and/or either of them may lawfully do or cause to be done by virtue hereof.Á Á Á Á In witness whereof, I have executed this Power of Attorney this 12th day of February, 2025. /s/ John P. BilbreyName: John P. BilbreyEXHIBIT 24POWER OF ATTORNEYKNOW ALL PERSONS BY THESE PRESENTS:Á Á Á Á I, John T. Cahill, do hereby make, constitute and appoint Jennifer M. Daniels and Kristine Hutchinson, and each of them, as my attorneys-in-fact and agents with full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf the Annual Report of Colgate-Palmolive Company on Form 10-K for the year ended December 31, 2024, and any and all amendments thereto and any other documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents and/or either of them may lawfully do or cause to be done by virtue hereof.Á Á Á Á In witness whereof, I have executed this Power of Attorney this 12th day of February, 2025. /s/ John T. CahillName: John T. CahillEXHIBIT 24POWER OF ATTORNEYKNOW ALL PERSONS BY THESE PRESENTS:Á Á Á Á I, Steven A. Cahillane, do hereby make, constitute and appoint Jennifer M. Daniels and Kristine Hutchinson, and each of them, as my attorneys-in-fact and agents with full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf the Annual Report of Colgate-Palmolive Company on Form 10-K for the year ended December 31, 2024, and any and all amendments thereto and any other documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents and/or either of them may lawfully do or cause to be done by virtue hereof.Á Á Á Á In witness whereof, I have executed this Power of Attorney this 12th day of February, 2025. /s/ Steven A. CahillaneName: Steven A. CahillaneEXHIBIT 24POWER OF ATTORNEYKNOW ALL PERSONS BY THESE PRESENTS:Á Á Á Á I, Lisa M. Edwards, do hereby make, constitute and appoint Jennifer M. Daniels and Kristine Hutchinson, and each of them, as my attorneys-in-fact and agents with full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf the Annual Report of Colgate-Palmolive Company on Form 10-K for the year ended December 31, 2024, and any and all amendments thereto and any other documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents and/or either of them may lawfully do or cause to be done by virtue hereof.Á Á Á Á In witness whereof, I have executed this Power of Attorney this 12th day of February, 2025. /s/ Lisa M. EdwardsName: Lisa M. EdwardsEXHIBIT 24POWER OF ATTORNEYKNOW ALL PERSONS BY THESE PRESENTS:Á Á Á Á I, C. Martin Harris, do hereby make, constitute and appoint Jennifer M. Daniels and Kristine Hutchinson, and each of them, as my attorneys-in-fact and agents with full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf the Annual Report of Colgate-Palmolive Company on Form 10-K for the year ended December 31, 2024, and any and all amendments thereto and any other documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents and/or either of them may lawfully do or cause to be done by virtue hereof.Á Á Á Á In witness whereof, I have executed this Power of Attorney this 12th day of February, 2025./s/ C. Martin HarrisName: C. Martin HarrisEXHIBIT 24POWER OF ATTORNEYKNOW ALL PERSONS BY THESE PRESENTS:Á Á Á Á I, Martina Hund-Mejean, do hereby make, constitute and appoint Jennifer M. Daniels and Kristine Hutchinson, and each of them, as my attorneys-in-fact and agents with full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf the Annual Report of Colgate-Palmolive Company on Form 10-K for the year ended December 31, 2024, and any and all amendments thereto and any other documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents and/or either of them may lawfully do or cause to be done by virtue hereof.Á Á Á Á In witness whereof, I have executed this Power of Attorney this 12th day of February, 2025./s/ Brian O. NewmanName: Brian O. NewmanEXHIBIT 24POWER OF ATTORNEYKNOW ALL PERSONS BY THESE PRESENTS:Á Á Á Á I, Lorrie M. Norrington, do hereby make, constitute and appoint Jennifer M. Daniels and Kristine Hutchinson, and each of them, as my attorneys-in-fact and agents with full power of substitution for me and in my name, place and stead, in any and all capacities, to execute for me and on my behalf the Annual Report of Colgate-Palmolive Company on Form 10-K for the year ended December 31, 2024, and any and all amendments thereto and any other documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents and/or either of them may lawfully do or cause to be done by virtue hereof.Á Á Á Á In witness whereof, I have executed this Power of Attorney this 12th day of February, 2025./s/ Lorrie M. NorringtonName: Lorrie M. NorringtonEX-31.A 7 exhibit31a12312024.htm EX-31.A DocumentEXHIBIT 31-AI, Noel Wallace, certify that:1.I have reviewed this Annual Report on Form 10-K of Colgate-Palmolive Company;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: February 13, 2025 /s/ Noel WallaceNoel WallaceChairman of the Board, President andChief Executive Officer EX-31.B 8 exhibit31b12312024.htm EX-31.B DocumentEXHIBIT 31-BI, Stanley J. Sutula III, certify that:1.I have reviewed this Annual Report on Form 10-K of Colgate-Palmolive Company;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: February 13, 2025 /s/ Stanley J. Sutula IIIStanley J. Sutula IIIChief Financial Officer EX-32 9 exhibit3212312024.htm EX-32 DocumentEXHIBIT 32The undersigned Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer of Colgate-Palmolive Company each certify, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. § 1350, that:(1)the Annual Report on Form 10-K for the year ended December 31, 2024 (the "Annual Report") which this statement accompanies, fully complies with the requirements of Sections 13(a) and 15(d) of the Securities Exchange Act of 1934; and(2)information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of Colgate-Palmolive Company.Date:

February 13, 2025 /s/ Noel WallaceNoel WallaceChairman of the Board, President andChief Executive Officer/s/ Stanley J. Sutula IIStanley J. Sutula IIChief Financial OfficerA signed original of this written statement has been provided to Colgate-Palmolive Company and will be retained by Colgate-Palmolive Company and furnished to the Securities and Exchange Commission or its staff upon request. EX-97 10 exhibit9712312024.htm EX-97 DocumentEXHIBIT 97COLGATE-PALMOLIVE COMPANY DODD-FRANK CLAWBACK POLICY FOR THERECOVERY OF ERRONEOUSLY AWARDED COMPENSATION1.Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to the Company. This Policy is intended to comply with, and shall be construed and interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act and Section 303A.14 of the NYSE Listing Company Manual.2.Administration. This Policy shall be administered by the P&O Committee. Any determinations made by the P&O Committee shall be final and binding on all affected individuals.3.Definitions. For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.a.Accounting Restatement means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial restatements that is material to the previously issued financial statements (a "Big R&E restatement"), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a "celitelle r&E restatement").b.Board means the Board of Directors of the Company.c.Clawback Eligible Incentive Compensation means all Incentive-based Compensation Received by an Executive Officer (i) on or after the Effective Date, (ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (v) during the applicable Clawback Period.d.Clawback Period means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date, and if the Company changes its fiscal year, any transition period of less than nine months within or immediately following those three completed fiscal years.e.Company means Colgate-Palmolive Company, a Delaware corporation.f.Effective Date means October 2, 2023.g.Erroneously Awarded Compensation means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.h.Exchange Act means the Securities Exchange Act of 1934, as amended.i.Executive Officer means each individual who is currently or was previously designated as a Section 16 officer of the Company within the meaning of Rule 16a-1(f) under the Exchange Act.j.Financial Reporting Measures means measures that are determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall for purposes of this Policy be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company's financial statements or included in a filing with the SEC.k.Incentive-based Compensation means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.l.NYSE means the New York Stock Exchange.m.P&O Committee means the Personnel and Organization Committee of the Board.n.Policy means this Dodd-Frank Clawback Policy for the Recovery of Erroneously Awarded Compensation, as the same may be amended and/or restated from time to time.o.Received means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company's fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if payment, grant or vesting of the Incentive-based Compensation occurs after the end of that period.p.Restatement Date means the earlier to occur of (i) the date the Board, a committee of the Board or the Officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement, in each case regardless of if or when the restated financial statements are issued.q.SEC means the United States Securities and Exchange Commission.4.Repayment of Erroneously Awarded Compensation.a. In the event of an Accounting Restatement, the Company shall reasonably promptly recover the Erroneously Awarded Compensation as follows:(i) After an Accounting Restatement, the P&O Committee shall determine the amount of any Erroneously Awarded Compensation Received by each Executive Officer and shall promptly thereafter provide each Executive Officer with written notice containing the amount of any Erroneously Awarded Compensation and a demand for repayment or return of such compensation, as applicable. For Incentive-based Compensation based on (or derived from) the Company's stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount to be repaid or returned shall be determined by the P&O Committee based on a reasonable estimate of the effect of the Accounting Restatement on the Company's stock price or total shareholder return upon which the Incentive-based Compensation was Received (and the Company shall maintain documentation of such determination of such reasonable estimate and provide such documentation to the NYSE).(ii) The P&O Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously Awarded Compensation based on all applicable facts and circumstances, including set-off, reducing future compensation or such other means or combination of means as the P&O Committee, in its sole discretion, determines to be appropriate. Notwithstanding the foregoing, except as set forth in Section 4(b) below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer's obligations hereunder.(iii) To the extent that the Executive Officer has already reimbursed the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by the Company or applicable law, any such reimbursed amount shall be credited toward the amount of Erroneously Awarded Compensation that is subject to recovery under this Policy.(iv) To the extent that an Executive Officer fails to repay all Erroneously Awarded Compensation to the Company when due, the Company shall take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer. The applicable Executive Officer shall be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.b. Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section 4(a) above if the P&O Committee determines that recovery would be impracticable and any of the following conditions are met:(i) The direct expenses paid to a third party to assist in enforcing the Policy against an Executive Officer would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously Awarded Compensation, documented such attempts and provided such documentation to the NYSE;(ii) Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel acceptable to the NYSE that recovery would result in such a violation and a copy of the opinion is provided to the NYSE; or (iii) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or 411(a) of the U.S. Internal Revenue Code of 1986, as amended, and regulations thereunder.5.Reporting and Disclosure. The Company shall file all disclosures with respect to this Policy in accordance with the requirement of the federal securities laws, including the disclosure required by the applicable SEC filings.6.Indemnification Prohibitions. The Company shall not be permitted to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company's enforcement of its rights under this Policy. In addition, the Company shall not enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the Company's right to recovery of any Erroneously Awarded Compensation and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).7.Acknowledgement. Each Executive Officer shall be required to sign and return to the Company, within thirty (30) calendar days following the later of (i) the Effective Date or (ii) the date the individual becomes an Executive Officer, the Acknowledgement Form attached hereto as Exhibit A, pursuant to which such Executive Officer agrees to be bound by, and comply with, the terms and conditions of this Policy.8.Effective Date. This Policy shall be effective as of the Effective Date.9.Amendments; Termination. The P&O Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when it determines that it is legally required by any federal securities laws, SEC or NYSE rule. The P&O Committee may terminate this Policy at any time. Notwithstanding anything in this Section 9 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC or NYSE rule.10.Other Recoupment Rights; No Additional Payments. The P&O Committee intends that this Policy will be applied to the fullest extent of the law. Any employment agreement, equity award agreement, compensatory plan or any other agreement entered into with an Executive Officer on or after the Effective Date shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. For the avoidance of doubt, in the case of any inconsistency between the provisions of this Policy and the provisions of any other clawback policy the Company has adopted or may in the future adopt, the provisions and requirements of this Policy shall prevail.11.Successors. This Policy shall be binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.*A A A *A A A *Exhibit A COLGATE-PALMOLIVE COMPANY DODD-FRANK CLAWBACK POLICY FOR THERECOVERY OF ERRONEOUSLY AWARDED COMPENSATION ACKNOWLEDGEMENT FORMBy signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Colgate-Palmolive Company (the "Company") Dodd-Frank Clawback Policy for the Recovery of Erroneously Awarded Compensation (the "Policy"). By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned's employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy. Signature Print Name Date EX-101.SCH 11 cl-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link: presentationLink link: calculationLink link: definitionLink 0000002 - Document - Audit Information link: presentationLink link: calculationLink link: definitionLink 9952151 - Statement - Consolidated Statements of Income link: presentationLink link: calculationLink link: definitionLink 9952152 - Statement - Consolidated Statements of Comprehensive Income link: presentationLink link: calculationLink link: definitionLink 9952153 - Statement - Consolidated Balance Sheets link: presentationLink link: calculationLink link: definitionLink 9952154 - Statement - Consolidated Balance Sheets (Parenthetical) link: presentationLink link: calculationLink link: definitionLink 9952155 - Statement - Consolidated Statements of Changes in Shareholders' Equity link: presentationLink link: calculationLink link: definitionLink 9952156 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) link: presentationLink link: calculationLink link: definitionLink 9952157 - Statement - Consolidated Statements of Cash Flows link: presentationLink link: calculationLink link: definitionLink 9952158 - Disclosure - Nature of Operations link: presentationLink link: calculationLink link: definitionLink 9952159 - Disclosure - Summary of Significant Accounting Policies link: presentationLink link: calculationLink link: definitionLink 9952160 - Disclosure - Restructuring and Related Implementation Charges link: presentationLink link: calculationLink link: definitionLink 9952161 - Disclosure - Goodwill and Other Intangible Assets link: presentationLink link: calculationLink link: definitionLink 9952162 - Disclosure - Long-Term Debt and Credit Facilities link: presentationLink link: calculationLink link: definitionLink 9952163 - Disclosure - Fair Value Measurements and Financial Instruments link: presentationLink link: calculationLink link: definitionLink 9952164 - Disclosure - Capital Stock and Stock-Based Compensation Plans link: presentationLink link: calculationLink link: definitionLink 9952165 - Disclosure - Employee Stock Ownership Plan link: presentationLink link: calculationLink link: definitionLink 9952166 - Disclosure - Retirement Plans and Other Retiree Benefits link: presentationLink link: calculationLink link: definitionLink 9952167 - Disclosure - Income Taxes link: presentationLink link: calculationLink link: definitionLink 9952168 - Disclosure - Earnings Per Share link: presentationLink link: calculationLink link: definitionLink 9952169 - Disclosure - Commitments and Contingencies link: presentationLink link: calculationLink link: definitionLink 9952170 - Disclosure - Segment Information link: presentationLink link: calculationLink link: definitionLink 9952171 - Disclosure - Leases link: presentationLink link: calculationLink link: definitionLink 9952172 - Disclosure - Supplier Finance Program link: presentationLink link: calculationLink link: definitionLink 9952173 - Disclosure - Supplemental Income Statement Information link: presentationLink link: calculationLink link: definitionLink 9952174 - Disclosure - Supplemental Balance Sheet Information link: presentationLink link: calculationLink link: definitionLink 9952175 - Disclosure - Supplemental Other Comprehensive Income (Loss) Information link: presentationLink link: calculationLink link: definitionLink 995511 - Disclosure - Summary of Significant Accounting Policies (Policies) link: presentationLink link: calculationLink link: definitionLink 995512 - Disclosure - Nature of Operations (Tables) link: presentationLink link: calculationLink link: definitionLink 995513 - Disclosure - Restructuring and Related Implementation Charges (Tables) link: presentationLink link: calculationLink link: definitionLink 995514 - Disclosure - Goodwill and Other Intangible Assets (Tables) link: presentationLink link: calculationLink link: definitionLink 995515 - Disclosure - Long-Term Debt and Credit Facilities (Tables) link: presentationLink link: calculationLink link: definitionLink 995516 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) link: presentationLink link: calculationLink link: definitionLink 995517 - Disclosure - Capital Stock and Stock-Based Compensation Plans (Tables) link: presentationLink link: calculationLink link: definitionLink 995518 - Disclosure - Retirement Plans and Other Retiree Benefits (Tables) link: presentationLink link: calculationLink link: definitionLink 995519 - Disclosure - Income Taxes (Tables) link: presentationLink link: calculationLink link: definitionLink 995520 - Disclosure - Earnings Per Share (Tables) link: presentationLink link: calculationLink link: definitionLink 995521 - Disclosure - Segment Information (Tables) link: presentationLink link: calculationLink link: definitionLink 995522 - Disclosure - Leases (Tables) link: presentationLink link: calculationLink link: definitionLink 995523 - Disclosure - Supplemental Income Statement Information (Tables) link: presentationLink link: calculationLink link: definitionLink 995524 - Disclosure - Supplemental Balance Sheet Information (Tables) link: presentationLink link: calculationLink link: definitionLink 995525 - Disclosure - Supplemental Other Comprehensive Income (Loss) Information (Tables) link: presentationLink link: calculationLink link: definitionLink 995526 - Disclosure - Nature of Operations (Details) link: presentationLink link: calculationLink link: definitionLink 995527 - Disclosure - Summary of Significant Accounting Policies - Principles of Consolidation, Inventories (Details) link: presentationLink link: calculationLink link: definitionLink 995528 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment (Details) link: presentationLink link: calculationLink link: definitionLink 995529 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangibles (Details) link: presentationLink link: calculationLink link: definitionLink 995530 - Disclosure - Restructuring and Related Implementation Charges - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 995531 - Disclosure - Restructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date (Details) link: presentationLink link: calculationLink link: definitionLink 995532 - Disclosure - Restructuring and Related Implementation Charges - Summary of Restructuring and Related Costs (Details) link: presentationLink link: calculationLink link: definitionLink 995533 - Disclosure - Restructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment (Details) link: presentationLink link: calculationLink link: definitionLink 995534 - Disclosure - Restructuring and Related Implementation Charges - Restructuring Activity and Related Accruals (Details) link: presentationLink link: calculationLink link: definitionLink 995535 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) link: presentationLink link: calculationLink link: definitionLink 995536 - Disclosure - Goodwill and Other Intangible Assets - Summary of Other Intangible Assets (Details) link: presentationLink link: calculationLink link: definitionLink 995537 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 995538 - Disclosure - Long-Term Debt and Credit Facilities - Components of Long-term Debt (Details) link: presentationLink link: calculationLink link: definitionLink 995539 - Disclosure - Long-Term Debt and Credit Facilities - Debt Payable within One Year (Details) link: presentationLink link: calculationLink link: definitionLink 995540 - Disclosure - Long-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance

Lease Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Long-Term Debt and Credit Facilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Fair Value Measurements and Financial Instruments - Fair Value of Derivative Instruments and Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Notional Values (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Gain (Loss) Included in OCI (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Performance Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Employee Stock Ownership Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - Retirement Plans and Other Retiree Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - Retirement Plans and Other Retiree Benefits - Schedule of Target Asset Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - Retirement Plans and Other Retiree Benefits - Allocation of Plan Assets and Level of Valuation Input, by Major Asset Category (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - Retirement Plans and Other Retiree Benefits - Benefit Obligation Exceeds Fair Value of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Other Retiree Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Net Periodic Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - Retirement Plans and Other Retiree Benefits - Expected Contributions and Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - Income Taxes - Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - Income Taxes - Income Tax Provision Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - Income Taxes - Change in Valuation Allowance for Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9955569 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 9955570 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955571 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955572 - Disclosure - Segment Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955573 - Disclosure - Segment Information - Schedule of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955574 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - Leases - Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9955576 - Disclosure - Leases - Schedule of Minimum Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9955577 - Disclosure - Leases - Schedule of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9955578 - Disclosure - Supplemental Income Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventories by Major Class (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventories by Major Class (Details) link:presentationLink link:calculationLink link:definitionLink 9955580 - Disclosure - Supplemental Balance Sheet Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955581 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9955582 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955583 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Accruals (Details) link:presentationLink link:calculationLink link:definitionLink 9955584 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955585 - Disclosure - Supplemental Other Comprehensive Income (Loss) Information - Schedule of Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955586 - Disclosure - Supplemental Other Comprehensive Income (Loss) Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 cl-20241231.cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 cl-20241231.def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 cl-20241231.lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Property, plant and equipment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation, Amount 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] 1.375% Notes due 2034 1.375% Notes Due 2034 [Member] 1.375% Notes Due 2034 [Member] Total debt Long-Term Debt and Lease Obligation, Including Current Maturities Cover page. Cover [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net increase (decrease) in Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] International Foreign Plan [Member] Trading Symbol Trading Symbol Net operating loss and capital loss carryforwards, set to begin expiring Net Operating Loss and Capital Loss Carryforwards, Set to Begin Expiring Net Operating Loss and Capital Loss Carryforwards, Set to Begin Expiring Fair Value Hedges Fair Value Hedging [Member] Other Other Accrued Liabilities Current Other Carrying value as of the balance sheet date of other obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Total Comprehensive income including noncontrolling interests Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Non-NEOs Non-NEOs [Member] Total income tax benefit from stock compensation Share-Based Payment Arrangement, Expense, Tax Benefit Supplemental Income Statement Information Supplemental Information [Text Block] This element is used to disclose supplemental income statement information for the periods disclosed. Dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Personal Care Personal Care [Member] Personal Care products include bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants and other similar items. 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Brazilian internal revenue authority, matter 2 Tax Assessments With Interest And Penalties The amount of tax assessment with estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations related to investments held by a foreign subsidiary. Allowance for doubtful accounts receivable, current Accounts Receivable, Allowance for Credit Loss, Current Schedule Of Finite And Indefinite Lived Intangible Assets By Major Class [Table] Schedule Of Finite And Indefinite Lived Intangible Assets By Major Class [Table] Disclosure of the carrying value of amortizable intangible assets by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Disclosure of the details of intangible assets not subject to amortization, excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company. Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Shares issued for restricted stock and other (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Hedging Relationship [Domain] Hedging Relationship [Domain] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Other comprehensive income (loss), pretax Other Comprehensive Income (Loss), before Tax Award Timing Disclosures [Line Items] Net Investment Hedges Net Investment Hedging [Member] Deferred withholding tax Effective Income Tax Rate Reconciliation, Deferred Withholding Tax, Amount Effective Income Tax Rate Reconciliation, Deferred Withholding Tax, Amount Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Proceeds from sale of marketable securities and investments Proceeds from Sale and Maturity of Marketable Securities Loss contingency, pending claims, number (in cases) Loss Contingency, Pending Claims, Number Total long lived assets Total Long Lived Assets Amount of total long-lived assets, primarily property, plant and equipment and goodwill and other intangibles. Plan Name [Domain] Plan Name [Domain] Inventories Inventory, Net [Abstract] United States UNITED STATES Other assets Other Assets, Noncurrent Leases [Abstract] Leases [Abstract] Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Schedule of Common and Treasury Stock Activity Schedule Of Common And Treasury Stock Activity [Table Text Block] Schedule Of Common And Treasury Stock Activity [Table Text Block] Operating Segments Operating Segments [Member] Net cash provided by operations Net Cash Provided by (Used in) Operating Activities Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Restructuring and related cost, expected cost, percentage Restructuring and Related Cost, Expected Cost, Percentage Restructuring and Related Cost, Expected Cost, Percentage Other Stockholders' Equity, Other Prepaids Prepaid Expense, Current Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Goodwill and intangible assets Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount Restructuring Type [Axis] Restructuring Type [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other current assets Prepaid Expense and Other Assets, Current [Abstract] Insider Trading Policies and Procedures [Line Items] Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Other accruals Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Investments accounted for using the equity method, maximum interest Equity Method Investment Ownership Percentage Maximum The maximum percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Tabular List, Table Tabular List [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Expected long-term rate of return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Medical cost trend rate of increase Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Medical Cost Trend Rate Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Medical Cost Trend Rate for next fiscal. Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Pooled funds Defined Benefit Plan, Pooled Funds [Member] Defined Benefit Plan, Pooled Funds [Member] Investment redemption notice period Investment Redemption Notice Period Investment Redemption Notice Period Inventories valued under LIFO LIFO Inventory Amount Goodwill and intangible assets Deferred Tax Liabilities, Goodwill and Intangible Assets Supplemental Income Statement Elements [Abstract] Supplemental Income Statement Elements [Abstract] Credit Facility [Domain] Credit Facility [Domain] Home Care Home Care [Member] Home Care products include laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches and other similar items. Goodwill Beginning Balance Ending Balance Goodwill Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Fixed income securities Fixed Income Securities [Member] Entity Information [Line Items] Entity Information [Line Items] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Total gain (loss) on investment hedges Other Comprehensive Income (Loss), Hedged Item In Net Investment Hedge, Gain (Loss), Before Reclassification And Tax Other Comprehensive Income (Loss), Hedged Item In Net Investment Hedge, Gain (Loss), Before Reclassification And Tax 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other financing activities Proceeds from (Payments for) Other Financing Activities Charges against assets Restructuring Reserve, Charges Against Assets Restructuring Reserve, Charges Against Assets Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total Comprehensive income attributable to Colgate-Palmolive Company Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension Plans Pension Plan [Member] Accrued income taxes Accrued Income Taxes, Current Real estate funds Employee Benefit Plan, Real Estate [Member] Other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Incentive Stock Plans Incentive Stock Plans Member The Company has plans that provide for grants of restricted stock awards for officers and other employees. A committee of independent members of the Board of Directors administers the plan. Award Type [Axis] Award Type [Axis] Net deferred income taxes Deferred Tax Liabilities, Net Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Schedule of Finite and Indefinite Lived Intangible Assets By Major Class Schedule Of Finite And Indefinite Lived Intangible Assets By Major Class [Table Text Block] Disclosure of amortizable intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization. Disclosure of the carrying value of intangible assets not subject to amortization, excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company. Less: Cumulative translation adjustments attributable to noncontrolling interests Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest Foreign tax matter Effective Income Tax Rate Reconciliation, Foreign Tax Matter, Percent Effective Income Tax Rate Reconciliation, Foreign Tax Matter, Percent Work-in-process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Options exercisable - end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock par value (in dollars per share) Common Stock, Par or Stated Value Per Share Percent of total restructuring charges related to segment Percent Of Total Restructuring Charges Related To Segment For The Period Percent Of Total Restructuring Charges Related To Segment For The Period Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Other accruals Lease liabilities due in one year Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Loss contingency, cases removed from case count Loss Contingency, Cases Removed from Case Count Loss Contingency, Cases Removed from Case Count Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Other, net Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Unrecognized pension and other retiree benefit costs, aftertax Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Property, plant and equipment, gross Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by

Share-Based Payment Award, Options, Exercises in Period Participantsâ€™ contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Goodwill and Other Intangibles Goodwill and Intangible Assets, Policy [Policy Text Block] Diluted EPS (in shares) Weighted Average Number of Shares Outstanding, Diluted Domestic, developed and emerging markets equity funds Defined Benefit Plan, Domestic, Developed and Emerging Markets Equity Funds [Member] Domestic, Developed and Emerging Markets Equity Funds [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total Colgate-Palmolive Company shareholdersâ€™ equity Equity, Attributable to Parent Total deferred tax assets Deferred Tax Assets, Gross Fair Value Measurements and Financial Instruments Financial Instruments Disclosure [Text Block] Restructuring accrual Restructuring Reserve, Noncurrent Derivatives Derivative Asset, Current Schedule of Goodwill by Segment Schedule of Goodwill [Table Text Block] Unearned Compensation Unearned Compensation [Member] Amount corresponds to the amount of leveraged ESOP debt guaranteed by the company. When the debt is recorded on the company's books, the equity reserve for unearned compensation is also recorded. Concentration Risk Type [Domain] Concentration Risk Type [Domain] Selling, general and administrative expenses Selling, general and administrative expenses Selling, General and Administrative Expense Product Product [Member] Cash and cash equivalents Defined Benefit Plan, Cash and Cash Equivalents [Member] Document Fiscal Period Focus Document Fiscal Period Focus Acquisition-related costs Business Combination, Acquisition Related Costs 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Annual estimated amortization expense, year 2 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Average annual rates of return for the most recent 15-year period Average Annual Rate Of Return For Most Recent Fifteen Year Period The average annual rate of return on pension plan assets for the most recent 15 year period. Weighted average remaining contractual life, options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Additions Additions [Member] Additions Total Other comprehensive income (loss), net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Derivative Contract Type [Domain] Derivative Contract [Domain] Actuarial loss (gain) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Net Sales and Operating Profit by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Amended Foreign Revolving Credit Facility 3000 Million Capacity Amended Domestic Revolving Credit Facility 3000 Million Capacity [Member] Amended Domestic Revolving Credit Facility 1500 Million Capacity [Member] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Purchases of marketable securities and investments Payments to Acquire Marketable Securities ESOP growth rate Defined Benefit Plan Assumptions Used Calculating Benefit Obligation ESOP Growth Rate Expected growth rate of company stock held by the employee stock ownership plans used to determine benefit obligations for defined benefit plans. Weighted average remaining contractual life, options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring and related cost incurred cost to date after tax Restructuring And Related Cost Incurred Cost To Date After Tax Restructuring And Related Cost Incurred Cost To Date After Tax Defined Benefit Plan [Table] Defined Benefit Plan [Table] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Finite-lived intangible assets, net Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Options - shares expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total lease cost Lease, Cost International common stocks Defined Benefit Plan, International Common Stock [Member] This category includes information about ownership interests in international corporations and other legal entities for which ownership interest is represented by shares of common stock. Statistical Measurement [Axis] Statistical Measurement [Axis] Loss contingency, number of cases on appeal Loss Contingency, Number Of Cases On Appeal Loss Contingency, Number of Cases On Appeal Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name Variable lease cost Variable Lease, Cost Oral, Personal and Home Care Total Oral, Personal and Home Care Oral, Personal and Home Care [Member] Oral, Personal and Home Care Other (income) expense, net Other (Income) Expense, Net [Member] Other (Income) Expense, Net [Member] Schedule of Right-of-use Assets and Liabilities for Operating Leases Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Schedule of Percent of Total Restructuring Charges Related To Segment for the period Schedule Of Percent Of Total Restructuring Charges Related To Segment For The Period [Table Text Block] Schedule of Percent Of Total Restructuring Charges Related To Segment for the period Award Timing Predetermined Award Timing Predetermined [Flag] Right-of-use assets/lease liabilities Effective Income Tax Rate Reconciliation, Nondeductible Expense, Leases, Amount Amortization of transition and prior service costs (credits) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Earnings per common share, diluted (in dollars per share) Diluted EPS (in dollars per share) Earnings Per Share, Diluted Total benefit payments [Abstract] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Fixed income securities Defined Benefit Plan, Fixed Income Securities [Member] Defined Benefit Plan, Fixed Income Securities [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Customer [Axis] Customer [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Receivables Increase (Decrease) in Receivables Other Deferred Tax Liabilities, Other Total fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Net income including noncontrolling interests Net income including noncontrolling interests Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Expected benefit payments from company assets Expected Benefit Payments From Company Assets Expected Benefit Payments From Company's Assets to be paid in year one. Provision for income taxes Total Provision for income taxes Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Notional value of derivative Derivative, Notional Amount Components of Net Periodic Benefit Cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Derivative asset Derivative Asset Unrecognized compensation expense, weighted-average period of recognition in years Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net sales Net sales Revenue from Contract with Customer, Excluding Assessed Tax Other equipment Property, Plant and Equipment, Other, Gross Global Productivity Initiative Global Productivity Initiative [Member] Global Productivity Initiative Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Pretax charges related to the Restructuring Program to date Restructuring and Related Cost, Cost Incurred to Date All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued payroll and employee benefits Employee-related Liabilities, Current Additional paid-in capital Additional Paid in Capital Accrued advertising and consumer and trade promotions Accrued Advertising And Coupon Redemption Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for advertising of the entity's goods and services as well as for coupon redemption. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Charges Restructuring Charges Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net operating loss and capital loss carryforwards Net Operating Loss and Capital Loss Carryforwards Net Operating Loss and Capital Loss Carryforwards Commodity contracts Commodity Contract [Member] Shares issued for restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Gains (losses) on cash flow hedges, pre-tax Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Non-service related postretirement costs Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Guaranteed investment contracts Defined Benefit Plan, Guaranteed Investment Contracts [Member] This element represents investments in contracts with insurance companies measured at the cash surrender value of each contract. Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Transition/prior service cost(credit) Defined Benefit Plan Accumulated Other Comprehensive Income Net Transition Assets Obligations And Net Prior Service Cost Credit Before Tax The portion of accumulated other comprehensive income comprised of net prior service cost/credit and net transition assets (obligations), before tax. Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities And Lapse Of Applicable Statute Of Limitations The gross amount of decreases in unrecognized tax benefits resulting from settlements with taxing authorities and lapses of the applicable statutes of limitations. Restricted stock awards - beginning of period (in dollars per share) Restricted stock awards - end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Shareholdersâ€™ Equity Liabilities and Equity [Abstract] Tax plus interest for years 2010 through 2018 Income Tax Examination, Estimate of Possible Loss Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Foreign Currency Debt Debt [Member] Loss contingency, new claims filed, number (in cases) Loss Contingency, New Claims Filed, Number Total 2022 Global Productivity Initiative charges, pretax Restructuring and related cost, incurred cost Restructuring and Related Cost, Incurred Cost Restatement Determination Date Restatement Determination Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating Profit Operating Income (Loss) [Member] Interest Crediting Rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Options - beginning of period (in dollars per share) Options - end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Other assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Options - beginning balance (in shares) Options - ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Property, plant and equipment, net Property, Plant and Equipment [Abstract] Schedule of Other Accruals Other Accruals [Table Text Block] Other Accruals [Table Text Block] Stock Repurchases [Abstract] Payments for Repurchase of Equity [Abstract] Earnings Per Share Earnings Per Share [Text Block] Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Shares issued for stock options Stock Issued During Period, Value, Stock Options Exercised Proceeds from the sale of land Proceeds from Sale, Land, Held-for-Use Restricted stock awards - shares granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Segments [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Tax amounts Other Comprehensive Income (Loss), Tax Percentage of investments in Company's common stock Defined Benefit Plan Percentage Of Equity Securities Invested In Employer Securities The percentage of equity securities of the defined benefit plan invested in the Company's common stock. Unrecognized tax benefits: Unrecognized Tax Benefits [Roll Forward] PEO PEO [Member] Asset Related Costs Asset Related Costs [Member] Asset Related Costs Charged to costs and expenses Charged to Costs and Expenses [Member] Charged to Costs and Expenses Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Name Trading Arrangement, Individual Name Net amount recognized Defined Benefit Plan, Funded (Unfunded) Status of Plan Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Ten year notes at 3.250 percent number Ten Year Notes at 3.250 Percent Number [Member] Ten Year Notes at 3.250 Percent Number Property, Plant and Equipment by Type [Axis] Long-Lived Tangible Asset [Axis] Amounts recognized in accumulated other comprehensive income Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Entity Public Float Entity Public Float Incremental DepreciationÂ Incremental Depreciation [Member] Incremental Depreciation [Member] Total 2022 Global Productivity Initiative charges, aftertax Restructuring And Related Cost, Incurred Cost, After Tax Restructuring And Related Cost, Incurred Cost, After Tax Equity income Income (Loss) from Equity Method Investments Treasury stock, at cost Treasury Stock, Common, Value Benefit obligations at beginning of year Benefit obligations at end of year Defined Benefit Plan, Benefit Obligation Tax credit carryforward, subject to expiration Tax Credit Carryforward, Subject to Expiration Tax Credit Carryforward, Subject to Expiration Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Pension and other retiree benefits Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Dividend payable Dividends Payable Approximate percentage of inventories determined using the first-in, first-out (FIFO) method Percentage of FIFO Inventory Tax benefit from exercise of stock options and vesting of restricted stock unit awards Employee Service Share-Based Compensation, Tax Benefit From Exercise Of Stock Options And Vesting Of Restricted Stock Unit Awards Employee Service Share-Based Compensation, Tax Benefit From Exercise Of Stock Options And Vesting Of Restricted Stock Unit Awards Dividends paid Payments of Ordinary Dividends Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Finite & indefinite lived intangibles, gross Intangible Assets, Gross (Excluding Goodwill) Valuation Allowance Balance, January 1 Balance, December 31 Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Other Charges Other Other Restructuring [Member] Cash effects of changes in: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Percentage of consolidated Net sales represented by sales outside US Percentage Of Consolidated Net Sales Represented By Sales Outside US Percentage of Consolidated Net Sales represented by sales outside US Product recall costs Product Recall Costs Product Recall Costs Program-to-date accumulated charges (percent) Restructuring and Related Cost, Incurred Cost, Percent Restructuring and Related Cost, Incurred Cost, Percent Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Accrued interest Interest Payable, Current Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Segment Reporting [Abstract] Segment Reporting [Abstract] Pension and other retiree benefits Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent Entity Central Index Key Entity Central Index Key Research and development and Advertising Research And Development And Advertising [Table Text Block] This element is used to disclose supplemental income statement information related to research and development and advertising expense. Schedule of Inventories by Major Class Schedule of Inventory, Current [Table Text Block] Cumulative translation adjustments, pre-tax Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Corporate Corporate Segment [Member] Accounts payable and other accruals Increase (Decrease) in Accounts Payable and Accrued Liabilities Loss contingency, number of cases resulting in verdict for the Company Loss Contingency, Number of Cases Resulting in Verdict for the Company Loss Contingency, Number of Cases Resulting in Verdict for the Company Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Segment Information Segment Reporting Disclosure [Text Block] Debt payable within one year Less: Current portion of long-term debt Current portion of long-term debt Long-Term Debt, Current Maturities Finite and indefinite-lived intangible assets [Line Items] Finite And Indefinite Lived Intangible Assets [Line

Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Fair Value, Inputs, Level 1, 2 and 3 Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] Loss contingency, pending claims, number (in cases) Loss Contingency, Number of Cases Pending in Lower Federal Count Loss Contingency, Number of Cases Pending in Lower Federal Count Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Measurement Basis [Axis] Measurement Basis [Axis] Title Trading Arrangement, Individual Title Schedule of Components of Income Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Balance, January 1 Balance, December 31 Unrecognized Tax Benefits Total Comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Minimum number of countries and territories serving consumers (more than) (in countries and territories) Minimum Number Of Countries And Territories Serving Consumers Minimum Number Of Countries And Territories Serving Consumers City Area Code City Area Code Current Liabilities Liabilities, Current [Abstract] Auditor Location Auditor Location Accrued liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Number of countries in which entity operates (more than) Number of Countries in which Entity Operates Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Ten Year Notes at 4.600 Percent Number Ten Year Notes at 4.60 Percent Number [Member] Ten Year Notes at 4.60 Percent Number Local Brands, Trademarks, Customer Relationships, and Non-Compete Agreements Local Brands, Trademarks, Customer Relationships And Non Compete Agreements Member Finite-lived intangible assets consisting of: Payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time, an asset acquired in a business combination representing a customer relationship that exists between an entity and its customer, rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and local brand value. Unused borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Purchases of treasury shares Repurchased stock Payments for Repurchase of Common Stock Designated derivative instruments Summary of Derivative Instruments [Abstract] Long-term debt Total Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Weighted Average Grant Date Fair Value Per Award Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Stock-Based Compensation [Abstract] Share-Based Payment Arrangement, Recognized Amount [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Outstanding borrowings in the ESOP Employee Stock Ownership Plan ESOP Debt Structure Employer Loan Amount The amount of advances from the Company to the ESOP which remain outstanding as of the balance sheet date. Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Inventories Increase (Decrease) in Inventories Effect of foreign currency rate movements Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Deferred income taxes Deferred Income Taxes and Tax Credits 2026 Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Short-Term Debt Schedule of Short-Term Debt [Table Text Block] Equity Awards Adjustments Equity Awards Adjustments [Member] Total operating lease liabilities Present value of lease liabilities Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Principal payments on debt Repayments of Other Debt Preference Stock [Abstract] Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Notes and loans payable Notes and Loans Payable, Current Amendment Flag Amendment Flag Carrying Value Reported Value Measurement [Member] Participantsâ€™ contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Foreign currency translation losses Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Defined Benefit Plan, Plan Assets, Allocations [Abstract] Defined Benefit Plan, Plan Assets, Allocations [Abstract] Machinery and equipment Machinery and Equipment [Member] Schedule of Components of Deferred Income Tax Benefit Schedule of Components of Deferred Income Tax Benefit (Provision) [Table Text Block] Disclosure of the temporary differences between accounting for financial statement purposes and accounting for tax purposes that result in the current provision for taxes being higher (lower) than the total provision for income taxes. Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Long-Term Debt and Credit Facilities Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face amount Debt Instrument, Face Amount Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising Advertising Expense Notes Notes Payable, Other Payables [Member] Land Land Annual ESOP expense Employee Stock Ownership Plan (ESOP), Compensation Expense Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other investing activities Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years that are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Restricted stock awards - shares forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Other liabilities Other Liabilities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Estimated useful life Property, Plant and Equipment, Useful Life Percentage of consolidated Net sales coming from emerging markets Percentage Of Consolidated Net Sales Coming From Emerging Markets Percentage of Consolidated Net Sales coming from Emerging Markets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Deferred Tax Asset, Valuation Allowance [Roll Forward] Deferred Tax Asset, Valuation Allowance [Roll Forward] Deferred Tax Asset, Valuation Allowance Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Basic EPS Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Other (income) expense, net Other Income Expense Net Abstract Foreign exchange impact Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Manufacturing machinery and equipment Machinery and Equipment, Gross Shares (millions) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Reporting unit, impairment analysis carrying amount Reporting Unit, Impairment Analysis, Carrying Amount Reporting Unit, Impairment Analysis, Carrying Amount Total assets Assets Filorga Reporting Unit Filorga Reporting Unit [Member] Filorga Reporting Unit Marketing Costs Advertising Cost [Policy Text Block] Net operating loss carryforward, valuation allowance Operating Loss Carryforwards, Valuation Allowance Other liabilities Total Other liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingent liabilities Commitments and Contingencies Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Schedule of Effective Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Supplemental Balance Sheet Information Supplemental Balance Sheet Information [Text Block] This element is used to disclose supplemental balance sheet information for the periods disclosed. Termination Date Trading Arrangement Termination Date Nature of Operations Nature of Operations [Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Long-Term Debt, Maturity, Year One Company contributions to the ESOP Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP Debt Instrument [Axis] Debt Instrument [Axis] Funded Status Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract] Net income attributable to Colgate-Palmolive Company Net Income (Loss) Net Income (Loss) Attributable to Parent Other (income) expense, net Total Other (income) expense, net Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] 2030-2034 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Net investment hedges [Abstract] Summary of Net Investment Hedge Activity [Abstract] Entity File Number Entity File Number Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Schedule of Entity-Wide Information, Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Foreign exchange Restructuring Reserve, Foreign Currency Translation Gain (Loss) Effect of exchange rate changes on Cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Dividends Dividends, Common Stock Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Intrinsic value of unexercised in-the-money options, options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Deferred withholding tax Deferred Tax Liabilities, Deferred Withholding Tax Deferred Tax Liabilities, Deferred Withholding Tax Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Non-deductible goodwill impairment charges Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Buildings Buildings and Improvements, Gross Withholding tax reserves, prior year reversals Decreases of tax positions taken during prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Change due to performance and/or market condition achievement (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Tax credits and tax loss carryforwards Deferred Tax Assets Tax Loss And Tax Credit Carryforwards The tax effect as of the balance sheet date of the amount of future tax deductions arising from all unused tax loss and tax credit carryforwards which have been reduced by a valuation allowance. Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Derivative and Financial Instruments, Fair Value [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Other postretirement charges Defined Benefit Plan, Other Cost (Credit) Cost of sales Cost of Revenue Adjustment to Compensation: Adjustment to Compensation [Axis] Less: Net income attributable to noncontrolling interests Less: Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Pension Adjustments Service Cost Pension Adjustments Service Cost Cost [Member] Basic EPS (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Non-current inventory, net Inventory, Noncurrent Other investments Real Estate and Other Investments [Member] Real Estate and Other Investments Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Target asset allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage North America North America [Member] Name Awards Close in Time to MNPI Disclosures, Individual Name Year which ultimate medical cost trend rate is reached Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate Sales Revenue, Net Revenue Benchmark [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Number of member states of the European Union Number of Member States of the European Union Number of Member States of the European Union Loss Contingencies [Line Items] Loss Contingencies [Line Items] Restructuring accrual Restructuring Reserve, Current Voluntary contributions to postretirement plans Defined Benefit Plan Voluntary Contributions By Employer Voluntary contributions made by the Company to its postretirement plans. Statistical Measurement [Domain] Statistical Measurement [Domain] Capital expenditures Segment, Expenditure, Addition to Long-Lived Assets Schedule of Components of Operating Lease Expense Lease, Cost [Table Text Block] Additional disclosures pertaining to stock based compensation [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Research and Experimentation Capitalization Effective Income Tax Rate Reconciliation, Research and Experimentation, Capitalization Effective Income Tax Rate Reconciliation, Research and Experimentation, Capitalization Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Tax credit carryforward Tax Credit Carryforward, Amount Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Equity method investments included in other assets Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Schedule of Other Liabilities Other Liabilities [Table Text Block] Excess of current cost over LIFO cost Excess of Replacement or Current Costs over Stated LIFO Value Schedule of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Interest Crediting Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Other non-current assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Shareholdersâ€™ Equity Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Long-term rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Annual estimated amortization expense, year 3 Finite-Lived Intangible Asset, Expected Amortization, Year Three Common stock balance, January 1 (in shares) Common stock balance, December 31 (in shares) Common Stock, Shares, Outstanding Goodwill [Line Items] Goodwill [Line Items] Leases Lessee, Operating Leases [Text Block] International Foreign Income Tax Expense (Benefit), Continuing Operations Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Operating lease cost Operating Lease, Cost Multi-Asset funds Defined Benefit Plan, Multi-Asset Funds [Member] Multi-Asset Funds [Member] Debt payable within one-year Debt payable within one year Short-Term Bank Loans and Notes Payable Other liabilities Long-term lease liabilities Operating Lease, Liability, Noncurrent Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Benefit payments Defined Benefit Plan, Benefit Obligation, Benefits Paid Change due to performance and/or market condition achievement (in dollars per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Change, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Change, Weighted Average Grant Date Fair Value Cash Flow Hedges Cash Flow Hedging [Member] Dividends paid by the Company on shares held by the ESOP Employee Stock Ownership Plan (ESOP), Dividends Paid to ESOP Cumulative effect of change in tax position Unrecognized Tax Benefits, Cumulative Effect of change in Tax Position Unrecognized Tax Benefits, Cumulative Effect of change in Tax Position United States Federal Income Tax Expense (Benefit), Continuing Operations Service cost Defined Benefit Plan, Service Cost Entity Tax Identification Number Entity Tax Identification Number Equity securities Defined Benefit Plan, Equity Securities [Member] Schedule of Finite-Lived Intangible Assets by Major Class [Table] Intangible Asset, Finite-Lived [Table] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Increases of tax positions taken during prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Common stock acquired (in shares) Treasury Stock, Shares, Acquired Retirement Plan Type [Axis] Retirement Plan Type [Axis] Ultimate medical cost trend rate Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Selling, general and administrative expenses Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Long-term rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase ERISA litigation matter Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change Treasury Stock Treasury Stock, Common [Member] Deferred tax assets: Deferred Tax Assets, Net [Abstract] Other Other Cost and Expense, Operating Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Restructuring and termination benefits, net of cash Restructuring, net of cash The amount of noncash restructuring costs net of cash payments. Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) For Plan Amendment And Business Combination Defined Benefit Plan, Benefit Obligation, Increase (Decrease) For Plan Amendment And Business Combination Other current assets Total Other current assets Other Assets, Current Defined Benefit Plan, Health Care Cost

Trend Rate Assumed Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Fiscal Year Four Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Fiscal Year Four Actuarial loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Intrinsic value of unexercised in-the-money options, options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Geographical [Axis] Geographical [Axis] Schedule of Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Valuation allowance, deferred tax asset, additions (deductions) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Cash Payments Payments for Restructuring Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Weighted average interest rate Debt, Weighted Average Interest Rate Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current Assets Assets, Current [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Treasury stock balance, January 1 (in shares) Treasury stock balance, December 31 (in shares) Treasury Stock, Common, Shares Accrued interest related to unrecognized tax benefits Unrecognized Tax Benefits, Interest on Income Taxes Accrued Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Short-term lease cost Short-Term Lease, Cost Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Restricted stock awards - shares vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Marketable securities Marketable Securities, Current Raw materials and supplies Inventory, Raw Materials and Supplies, Net of Reserves Security Exchange Name Security Exchange Name Average annual rates of return for the most recent 25-year period Average Annual Rate Of Return For Most Recent Twenty Five Year Period The average annual rate of return on pension plan assets for the most recent 25 year period. Options - shares exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Expected long-term rate of return on plan assets Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Long Term Return On Plan Assets Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Long Term Return On Plan Assets Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Gain on the sale of land Gain on the sale of land in Asia Pacific Gain (Loss) on Sale of Properties Common stock issued (in shares) Common Stock, Shares, Issued Three Year Notes at 4.800 Percent Number Three Year Notes at 4.80 Percent Number [Member] Three Year Notes at 4.80 Percent Number Treasury Stock Summary Of Treasury Stock Activity [Roll Forward] A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Oral Care Oral Care [Member] Oral Care products include toothpaste, toothbrushes, mouth rinses and other similar items. Average annual rates of return for the most recent 5-year period Average Annual Rate Of Return For Most Recent Five Year Period The average annual rate of return on pension plan assets for the most recent 5 year period. Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Percent of net sales Percentage of consolidated sales represented by one customer Concentration Risk, Percentage Walmart, Inc. Walmart, Inc. [Member] Walmart, Inc. Derivative liability Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Performance Shares Performance Based Restricted Stock Units [Member] Performance Based Restricted Stock Units [Member] Europe Europe Europe [Member] Common stock authorized (in shares) Common Stock, Shares Authorized Goodwill and intangible assets impairment charges Goodwill and Intangible Asset Impairment 0.875% Notes due 2039 0.875% Notes due 2039 [Member] 0.875% Notes due 2039 [Member] Payment for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Time-Vested Stock Time-Vested Restricted Stock Units [Member] Time-Vested Restricted Stock Units [Member] Restructuring costs 2022 Global Productivity Initiative Restructuring Costs Settlements and acquisitions Defined Benefit Plan, Plan Assets, Payment for Settlement Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Entity Voluntary Filers Entity Voluntary Filers Termination benefits Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Actuarial gain Amortization of actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense Interest Expense, Nonoperating Total deferred tax benefit (provision) Deferred Income Tax Expense (Benefit) Non-service related postretirement costs Non-Service Related Postretirement Costs [Member] Non-Service Related Postretirement Costs [Member] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Total pension cost Pension and Other Postretirement Benefits Cost (Reversal of Cost) Proceeds from issuance of debt Proceeds from Other Debt Receivables (net of allowances of \$85 and \$80, respectively) Accounts Receivable, after Allowance for Credit Loss, Current Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Total Long-Term Debt Global Growth and Efficiency Program Global Growth and Efficiency Program [Member] Global Growth and Efficiency Program [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of plan assets Fair value of plan assets at beginning of year Fair value of plan assets at end of year Defined Benefit Plan, Plan Assets, Amount Thereafter Long-Term Debt, Maturity, after Year Five Total Inventories, net Inventory, Net, Including Noncurrent Inventory, Net, Including Noncurrent Commercial paper Commercial paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Document Annual Report Document Annual Report Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of geographically reportable operating segments (in segments) Number Of Geographically Reportable Operating Segments Number Of Geographically Reportable Operating Segments Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Indefinite-lived intangible assets (excluding goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Amortization of intangible assets Amortization of Intangible Assets Other (income) expense, net Other (income) expense, net [Table Text Block] Other (income) expense, net [Table Text Block] Non-US Non-US [Member] Indefinite life intangible assets Unclassified Indefinite-Lived Intangible Assets [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Finance Lease Obligations Finance Lease Obligation [Member] Finance Lease Obligation [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Investments accounted for using the equity method, minimum interest Equity Method Investment Ownership Percentage Minimum The minimum percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. PEO Name PEO Name Award Type [Domain] Award Type [Domain] Contractual commitments, amount Long-Term Purchase Commitment, Amount Shares issued for stock options (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Curtailments and settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease For Curtailment And Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease For Curtailment And Settlements Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Loss contingency, petitions approved for removal of penalty portion of claim Loss Contingency, Petitions Approved for Removal of Penalty Portion of Claim Loss Contingency, Petitions Approved for Removal of Penalty Portion of Claim Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Deferred income taxes Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Estimated useful life of finite-lived intangible assets Finite-Lived Intangible Asset, Useful Life Stock-based compensation, additional disclosures [Abstract] Share-Based Payment Arrangement, Additional Disclosure [Abstract] Investments fair value Investments, Fair Value Disclosure Additional Paid-In Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Gain on sale of land Gain (Loss) on Sale of Land Gain (Loss) on Sale of Land Retirement Plans and Other Retiree Benefits Retirement Benefits [Text Block] U.S. plans assets purchased to Company (in shares) Defined Benefit Plan, Plan Assets, Purchases, Shares Defined Benefit Plan, Plan Assets, Purchases, Shares Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Restructuring and related Cost, estimated to settle through cash, percentage Restructuring and Related Cost, Estimated to Settle Through Cash, Percentage Restructuring and Related Cost, Estimated to Settle Through Cash, Percentage Schedule of Defined Benefit Plans Disclosures Schedule of Defined Benefit Plans Disclosures [Table Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Number of operating segments (in segments) Number of Operating Segments Income taxes paid Income Taxes Paid Foreign-derived intangible income benefit Effective Income Tax Rate Reconciliation, FDII, Percent Restructuring and Related Implementation Charges Restructuring and Related Activities Disclosure [Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Fair Value Measured at Net Asset Value Per Share Fair Value Measured at Net Asset Value Per Share [Member] Retirement Plan and other retiree benefit adjustments, pre-tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Fixed interest rate Debt Instrument, Interest Rate, Stated Percentage Corporate Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Supplemental Cash Flow Information Supplemental Cash Flow Information [Abstract] Diluted EPS Net Income (Loss) Available to Common Stockholders, Diluted Research and Experimentation Capitalization Deferred Tax Asset, In-Process Research and Development Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Auditor Firm ID Auditor Firm ID Effective tax rate Effective Income Tax Rate Reconciliation, Percent Operating profit Operating Income (Loss) Projected benefit obligation Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Total liabilities and equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Program 2022 Program 2022 [Member] Program 2022 Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Derivatives Derivative Liability, Current Pet Nutrition Pet Nutrition [Member] Pet Nutrition Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Share-based Compensation, Performance Restricted Stock and Time-based Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Shipping and Handling Shipping and Handling [Member] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Common Stock Outstanding Summary Of Common Stock Activity [Roll Forward] Summary Of Common Stock Activity [Roll Forward] Individual: Individual [Axis] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Options - shares forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected term of options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Inventories Current Inventories, net Inventory, Net Schedule of Provision for Income Taxes Provision for Income Taxes [Table Text Block] Disclosure of the domestic and foreign components of the provision for income Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Income tax expense (benefit) allocated directly to equity Income Tax Effects Allocated Directly to Equity Shares in ESOP (in shares) Employee Stock Ownership Plan (ESOP), Shares in ESOP Benefit payments Defined Benefit Plan, Plan Assets, Benefits Paid Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Sublease Income Sublease Income Financial Instruments Derivatives, Policy [Policy Text Block] Range of reasonably possible losses Loss Contingency, Estimate of Possible Loss Asia Pacific Asia Pacific [Member] Minimum Minimum [Member] Adoption Date Trading Arrangement Adoption Date ESOP growth rate Defined Benefit Plan Assumptions Used Calculating Net Periodic Cost ESOP Growth Rate Expected growth rate of company stock held by the employee stock ownership plans used to determine benefit obligations for defined benefit plans. Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Tax at United States statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Exercise Price Award Exercise Price Number of stockholder approved plans, current Number of Stockholder Approved Plans, Current Number of Stockholder Approved Plans, Current Schedule of Components of Deferred Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Medical cost trend rate assumed for next fiscal year Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Arrangement Duration Trading Arrangement Duration Schedule of Comprehensive Income (Loss) Comprehensive Income (Loss) [Table Text Block] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Indirect tax payments (refunds) Indirect Tax Payments (Refunds) Indirect Tax Payments (Refunds) Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Africa/Eurasia Africa Eurasia [Member] A specified group of foreign regions about which segment information is provided by the entity. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument term Debt Instrument, Term Annual estimated amortization expense, year 4 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Reporting Unit [Axis] Reporting Unit [Axis] Buildings Building [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entities [Table] Entities [Table] Estimated fair value of long-term debt Debt Instrument, Fair Value Disclosure Foreign exchange impact Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Other Retiree Benefit Plans Other Postretirement Benefits Plan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other intangible assets, net Intangible assets, net (excluding goodwill) Intangible Assets, Net (Excluding Goodwill) Gain (loss) on net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Employee-Related Costs A One-time Termination Benefits [Member] Acquisition-related costs Business Combination, Acquisition Related Costs, Net Business Combination, Acquisition Related Costs, Net Change in Plan Assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Current liabilities Pension and other retiree benefits Liability, Defined Benefit Plan, Current tax credit carryforward, valuation allowance Tax Credit Carryforward, Valuation Allowance Net operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Losses (gains) from marketable securities and other assets Gain (Loss) on Marketable Securities and Other Assets Gain (Loss) on Marketable Securities and Other Assets Deferred income taxes Deferred Income Tax Liabilities, Net Expected volatility rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Earnings taxed at other than United States statutory rate Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Investments accounted for using the cost method, maximum interest Cost Method Investment Ownership Percentage Maximum The maximum percentage of ownership of common stock or equity participation in the investee accounted for under the cost method of accounting. This maximum is up to, but not including, the maximum value. Retirement plan and other retiree benefit adjustments Other Comprehensive Income (Loss), Defined Benefit Plan, after Reclassification Adjustment, after Tax Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash and Cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Change in Benefit Obligations Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Measure: Measure [Axis] Increases as a result of tax positions taken during the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Common shares released and allocated to participant accounts (in

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

ML1U=159-1ASJ>VNCUF,LS6UW2#6Z,MKH/H1VWQ|Q|ISY2?C7SSU1Q0%>5Q1A1M,YB4Q0%<0W-0W-DFZLNF4UJ=J-
ML2U=160412DQI9J>2G/1-0H3KE\$4<0+<4+0%#0811W>K M- #NVCQ&0&K M.TDX,NQ,4847J-1K3ZA,JM-#ETK?KJ03JCT98G9D8GCLQUA@>#J617QG M->#B3?@3U>JH3-
J3\$PAA1LUUBQ(W1%2)>J3(4%>L6K5AY29(C2)BA* M#52I2<4?=>C) (8QC%>H(ZWO>+JUD6>?<X>6<->2ZE%MKLSI>?>2J@<+3<5V>3<8(92%)R5N0F28IH\$R5R5J>A4K6D-MZ\$>0' A1(#0&C&G
6+0MSRQC&A,616/PW>24=78J MF-1R.2J2825B69.5#MIA3C(W2683N,M2D3HR+FOQBS@<RPFJ M#(H1M5%>C&TCNA1*IC<+LHP Q1R3V3+U+V+VO=>+S54 7U03&
MX75S=V2,L0N4H(Y/IB,V4L96641UNK&AS/6 F2QUXJ MLHCQ&8;OOH,CN6ZPD2T>SVCJ/JJL B'51= M5-1HSA9ZU8=019HJZFN+2J0YJ1VRV4U RETS@>+F1 C- SV\$=5J M
R69,J27YNB(QQ2R)<CJ90K<XZ94B1(0)(W6CBMCGDGTKTQ17U+37 MH2P1QF>J 7Q05-W=5#156%002V97Y0NMNMTX6,6LJF#P(FRUCU997.MVQQ?2PQ@>4ABAW+57
6+5\$H00@<AU+>#& M8RL317V9IQU<K7<Z/ZA5&M M 8893DL3LM4M&A5J21<+<5L=B4(F1N/QPPE,2C\$F&VR6(S\$<R%>+ MC4FCSPE,16M37Q0+>10,8XJ@<F%>F&F,
M,UOQ(XPSNWDRO,N+X2A,RLE MZMINOR+OLVIFQDEQJ(B0M0K\$>+<XRV41+>#7\$E3F,1H8ZFN&1<@4U1,M\$>U>V27AGG<+>?2YNL\$ Q,H-1J\$S\$KXG,GD7J+VYVRZP\$M<A
(2CD3Q6<6> MJ1,J4Y=8\$YR+Y1J+2P(HWVK6J2C,9#4L#1T#XTX)XDXZ=>W&B%<MCDN#>28KE6NS<9>4UZZK=>24 VYRJ,S(J7JIRD<5JIDJ=>+>#8E,K)8PQ11HDD0=>R\$<
MD10)FZ(TBCL,6:GTCQ@%N=>?>YDWM=>T1 C-1JM58+V7+GS&8>3?7\$ISK@T MRDP6UMFPEBAUNO,1JBE,NLJ MKJNZ7ZN)Y#H8DL%<C96FBNA[2\$5Q%>?<L<2.AKU4 43U@0&?>96E7A5#HI9K
M1U/E+&6,7&Q9K?7H)JW7J W-GS.LXZURR<3C3>15>H86J72J?&I> M82,U8P\$M-&K0/L-1GP%>@Y40Q>#<
M085R>M3Y31E(AA4UHD041BH047MY3ZYR M=S/S05?>E72.U?ZF,2=>5S,WC76 MPFZ48A+8X%9FTHB>@>5JX0Z?5(SO*U0K,<+0 P0I>ARPZR[8Y2X6K@<=L
M=>7HJ1A1<F>U5\$522>2=6C #B5ML&A1+D2>J07<+>(6K+1,1LK M6M1W85+H0(K3U)6G/E+>10@2IWC&C,%2I3HDZ48L45\$B0U+2J53Z2R0M+06(TJ0H<IY0B<DH.Q#<+>@A#K>J |
|<+10Y|HJYQ@<L5YLDWFVWXXY?>HJH2D6<+>=<9D4C|P+2X&Y5 8W\$K2M1L*990@<48DN59I8T?R&E&MD7C7E1L8,H8J6%6%0N(CN0)Q0+7?>2>@,1+>IY0B-UQZ2
<=182JBKKI&XZNLF22@<H MJ05,J7QJQA.ZCT6V+>SZZKIEZLV,VIP0Q<R5-E4E "96F">+>PIOVZF<@<M12P|KJ>XGRMI1/8<KE,5:FBDK M#M0BQ?C\$>216G.%5=AVU\$P+>#1*PY,
M0/6MB#84Y1=2XJ|>O?P0T1 20<1-E67&4&HLV1Q T13H'KU+<1DK<Q1M @M<+>65<+>5987V2F<B\$*55C<+>Q099@<62XQCQ,1%J\$TWR,2L ZJZ>F9
M=>T5V54F>YU,C622R04+>VK\$508TAVF\$>LTADS8H8=65.0 E\$B4""<KX<+>KJW? 2JN?Y8J5W4Q|H1J VHW%<QJ0I+>#<J\$NBH3<XJ\$U#M<57I8M1Q<M+>P#8E\$>A|XJLPWY?
E+>J|W#K/TXAX6;61QZRZ,KFES9.\$TR+QZ0.\$M MTCJ|H<TG/4Q:XXPB29Y)4B>20I4J\$H4M+>+>\$>A#<H U>W>W>J?>T-1>J|,MN<VTFYOE>=>?>K,K<@>EER:0YH73H%4V3|HK>7RQ?U+<G7
M\$>TZPA#<K<D>2<+>1<4FQ?>2716RP&#19MC6,&QFAJ|W#XW5JW10G+03K M+>?J\$HBKFR|U>729.6IATJ.&<+>7 RAD5D&1WUE+0C>=>SR\$B M-S M?
<5\$5\$2+>1LY>1F1PS5<@<EZ<+>07F+1A>8T|C|F#2'23@<@>D5ZROE9&K5 0(EGLF1XW9R1N,1J6F.74F&NZJ\$>+>9EYVE7&J8ZHS5.5281R1J0XJH.VG\$<Y2J 2H) MB#6\$T|QJ|5IRD
Q|JX4,THYSN&J|K|KOGRD<KBRYF3>1UJ5J #M2=613X|T@<E E4HJ04J+> MPO,3&J1 H1 HFX&54J2>+>HCZWR<KJ|U.SZSEOM,Y%OR&M\$Q4L4&6K73WR\$YJ MPKI2P+>HJ|U>FEZ3>9Q?>
1+M(\$W3Q/2P%L664?>T>K75U0 MBZ+<+>1YLMRYM2?0C9CV0J0GCH\$S,D2R<C2R\$M+>42.9 WTBT8B4RLQJ MPT TFSB5-MV(2S4) H4|HJOY>=>PEVY/3B1>57328?>HTU32
N1AJP+<4J9\$82ZL2Q>@/J=>+>6DGFCA7M3P+YCLL0P&N,TEZMUIB<B<S,D>=>=<K&H4+>#2QJ M5JN0E7J7?DJ(DJ25J|QJWEE+H|H|Q P+>RSG7-RJ\$2J026C75N9I2 M+YBEL02ZH*
<7G-R,40CTN\$ Q613MW<Q&A>=<S\$JPV>BYQJW7JW4Y14R7,J6MS8<2YHF+>P=>60AJ8V79DG.DJ M+>T=M&JWH0=>
M|>E2EFJ?E3D\$>JXJZQ&R&Q&R&44XD077JM<+>000U|RV|<G0+>U|PSTCDX,NJ MN>+>X JXR-DB,1+>W5TLR4H7J>G 4>8I083L7T#>@>P M#A57^RQ_P J
M0E,D,*>KJED0(HCKJ).UL=H-1A^KY3,>DD,D0<4JN7CJ4LQ31=>#FV@+>W M00M,<+>B7&8566<XIRI8P>=>7%PIVLX(R6S9CNGYRHK<LULBC(CCU,XW<+>
M+>98H72>7DH@P1,6TTR440J,GT7K8 BV+>@>=>=<99R&RD4U+>A|NBJ MKY<+>ZQJ831(BZ2,=>J92D.TT=FUB&IHG<XU\$X\$>BG 4>0<@>LTF.S1+>1& M|ABPY9G0A=>#T=P480|H7Q WT-
S,RX>M9+>+>BJ@<C5B68JUN71D\$J MJN,OL&K\$F WA9\$8J6UA+>1+V40P FYKWHMHSJ>+>@J&5AQ0E8J8+>BAD<K7>+>D O F7P177,XM5 I&F810R|TZF1E@>Y,MY>2(W74
Y3YEDB03<19E2Q3GNEXUS5Q&C\$VW178%=>=<1MKA,W5>=>JHXTX MDJ9J, C-1L1L2Y%CFM2QCNHHR0 MZ/<W=>G<,<7>PND?04XJ8J8X+T+7.5162 M3HNO-1B2BR\$S216X>
X0KBP@>W1?J024CYG@<CM(G9 \$RY,E1J\$>J|B<+>M,GMW<OG>=>8JVTXN45K2RI M-RISQ55N06 M4B7H55W\$>=<(3&IV?)9JTF@24K+>U1906 W1J9U9JHJ8C+T+7.5162 M3HNO-1B2BR\$S216X>
2NU9J)ZMSM,SVZL3ETJ>U,01753Q3M3,1+>FV=>G M+>E2P+6A7C14Q6J)PPDXE024H3FEGD6E<+>@<J&STDXT ADFF& V(A9@>+>U M56M1M06O CKTQC&C<R\$R|H<+>Y|>5>416<8J>+
(Q56I8Q7449<+>@<JNB M3F+>F18424J<Z>N9H

Q3#7E7E2C#C7R5NT9TFPIV(M,D33&J9U91<0>)>37UYAR6K&BNL7CT67JZ MHY<NXT+T+H+V>Y>XZKH<IKK,YIYU&SL4RL59M2R.RYI?>OJ9S/B&8QFJ=ZVM7/2/L1QQQJZ M4R9AJ7@>
J37HRG69/Q04H10Q1JQR82MJYQWQZ&571R6P5>U>Z28M&A<L-MBIQ5AYUP-U3>W+H+6+Q9N9/DJVB<H1U+H+IES6/LTFD?>4<M&F&E51J1X#61ZVDS5>\$(M"E@KS=,0U@BEV=
DDJ+14QHT-JK-4/1 X1FV18QC=<IS-PA3C3M P"R/R) JFJT,71>E2Y+M7+13IQKBR9&N9NB&QS=TK+H1U+H+IES6/LTFD?>4<M&F&E51J1X#61ZVDS5>\$(M"E@KS=,0U@BEV=
3JBES+7<=7<B1,QAUMQ#<N9NQC&TIAZP7J MJB DSRU1U+5F&R50KXKWA4V=>IP6+1<7F721FF74<722.LWJB5M_XE
M3E1,GXD,P6U,IR=9I0H9L5>GUB<4JWVY<E.LI+ND7M,DGR,J1>OK<FZBE92 MS6T NDZ2=EQBL:0WVW<EAE<EB>+B7B1G1_XHM*EJU05_?GQK(H-?<C^M;BWS,R#<
<?+H+V5Y5<0NU7R&E<SS3BK&F<8LT6<1G<GLKY?>F&HYZ2R@<M+U1P@BSE.S82AEZ<H JD4_N&FSS9R2/4?<K1>334V587Y<6R/Y+15UW/MJ%S12@<T^M*2
TLOCY55<6KVDYU9<ASIKK36<1TSTNTOH1LD7?>F&HPEB8X&333M0PQ&M,IV MAV.7L01Z5T&C,94 Z1<L7>=>1AU81Q3 9YV1PT 71-7<3>1ZNX<68J-6 MX(BJ?>#TAB).>P+?B#&OERS?>
V4D<T39-W1 MSCU1M2DTR4=>1<M1?260>L.WZ2?6Y2M>5R-IBVXN<4-HBIVBZ5UWDRD_OE=WL/H+V10.0 B.M6 MPF&67G/BV7V,Q2PMT85&H1BDQ9YIU@<E+ZPMU1=>NCG?<M/?>
LI-1VFN&S RS+NDH<V8QJ8K7F<#82>=>NM3+2DZ3&E1L/0-NMNC.1#8R M4+5<?>XDXHCAF&C9O-K18<X?>07HOVJP PI9WJN_XE ZEA6V0E7VZ5X3Y78 M
B2ES&CDE&Q&16W098.<5PI,H>5A:YF-U3>W>3?/H+6<4<1<8RH,U3J9J MOIX #JPCBF SSM2 @.B.N4<DJS'H-6U1+6B/5 MK5B/5>V1#52\$8=<6+5?>1<6U@YJYZ+L MZI+@.W4 M22Q1S/2(A
P,4<?>F&E51J1X#61ZVDS5>\$(M"E@KS=,0U@BEV=<3JBES+7<=7<B1,QAUMQ#<N9NQC&TIAZP7J MJB DSRU1U+5F&R50KXKWA4V=>IP6+1<7F721FF74<722.LWJB5M_XE
M3E1,GXD,P6U,IR=9I0H9L5>GUB<4JWVY<E.LI+ND7M,DGR,J1>OK<FZBE92 MS6T NDZ2=EQBL:0WVW<EAE<EB>+B7B1G1_XHM*EJU05_?GQK(H-?<C^M;BWS,R#<
<?+H+V5Y5<0NU7R&E<SS3BK&F<8LT6<1G<GLKY?>F&HYZ2R@<M+U1P@BSE.S82AEZ<H JD4_N&FSS9R2/4?<K1>334V587Y<6R/Y+15UW/MJ%S12@<T^M*2
TLOCY55<6KVDYU9<ASIKK36<1TSTNTOH1LD7?>F&HPEB8X&333M0PQ&M,IV MAV.7L01Z5T&C,94 Z1<L7>=>1AU81Q3 9YV1PT 71-7<3>1ZNX<68J-6 MX(BJ?>#TAB).>P+?B#&OERS?>
V4D<T39-W1 MSCU1M2DTR4=>1<M1?260>L.WZ2?6Y2M>5R-IBVXN<4-HBIVBZ5UWDRD_OE=WL/H+V10.0 B.M6 MPF&67G/BV7V,Q2PMT85&H1BDQ9YIU@<E+ZPMU1=>NCG?<M/?>
LI-1VFN&S RS+NDH<V8QJ8K7F<#82>=>NM3+2DZ3&E1L/0-NMNC.1#8R M4+5<?>XDXHCAF&C9O-K18<X?>07HOVJP PI9WJN_XE ZEA6V0E7VZ5X3Y78 M
B2ES&CDE&Q&16W098.<5PI,H>5A:YF-U3>W>3?/H+6<4<1<8RH,U3J9J MOIX #JPCBF SSM2 @.B.N4<DJS'H-6U1+6B/5 MK5B/5>V1#52\$8=<6+5?>1<6U@YJYZ+L MZI+@.W4 M22Q1S/2(A
P,4<?>F&E51J1X#61ZVDS5>\$(M"E@KS=,0U@BEV=<3JBES+7<=7<B1,QAUMQ#<N9NQC&TIAZP7J MJB DSRU1U+5F&R50KXKWA4V=>IP6+1<7F721FF74<722.LWJB5M_XE
M3E1,GXD,P6U,IR=9I0H9L5>GUB<4JWVY<E.LI+ND7M,DGR,J1>OK<FZBE92 MS6T NDZ2=EQBL:0WVW<EAE<EB>+B7B1G1_XHM*EJU05_?GQK(H-?<C^M;BWS,R#<
<?+H+V5Y5<0NU7R&E<SS3BK&F<8LT6<1G<GLKY?>F&HYZ2R@<M+U1P@BSE.S82AEZ<H JD4_N&FSS9R2/4?<K1>334V587Y<6R/Y+15UW/MJ%S12@<T^M*2
TLOCY55<6KVDYU9<ASIKK36<1TSTNTOH1LD7?>F&HPEB8X&333M0PQ&M,IV MAV.7L01Z5T&C,94 Z1<L7>=>1AU81Q3 9YV1PT 71-7<3>1ZNX<68J-6 MX(BJ?>#TAB).>P+?B#&OERS?>
V4D<T39-W1 MSCU1M2DTR4=>1<M1?260>L.WZ2?6Y2M>5R-IBVXN<4-HBIVBZ5UWDRD_OE=WL/H+V10.0 B.M6 MPF&67G/BV7V,Q2PMT85&H1BDQ9YIU@<E+ZPMU1=>NCG?<M/?>
LI-1VFN&S RS+NDH<V8QJ8K7F<#82>=>NM3+2DZ3&E1L/0-NMNC.1#8R M4+5<?>XDXHCAF&C9O-K18<X?>07HOVJP PI9WJN_XE ZEA6V0E7VZ5X3Y78 M
B2ES&CDE&Q&16W098.<5PI,H>5A:YF-U3>W>3?/H+6<4<1<8RH,U3J9J MOIX #JPCBF SSM2 @.B.N4<DJS'H-6U1+6B/5 MK5B/5>V1#52\$8=<6+5?>1<6U@YJYZ+L MZI+@.W4 M22Q1S/2(A
P,4<?>F&E51J1X#61ZVDS5>\$(M"E@KS=,0U@BEV=<3JBES+7<=7<B1,QAUMQ#<N9NQC&TIAZP7J MJB DSRU1U+5F&R50KXKWA4V=>IP6+1<7F721FF74<722.LWJB5M_XE
M3E1,GXD,P6U,IR=9I0H9L5>GUB<4JWVY<E.LI+ND7M,DGR,J1>OK<FZBE92 MS6T NDZ2=EQBL:0WVW<EAE<EB>+B7B1G1_XHM*EJU05_?GQK(H-?<C^M;BWS,R#<
<?+H+V5Y5<0NU7R&E<SS3BK&F<8LT6<1G<GLKY?>F&HYZ2R@<M+U1P@BSE.S82AEZ<H JD4_N&FSS9R2/4?<K1>334V587Y<6R/Y+15UW/MJ%S12@<T^M*2
TLOCY55<6KVDYU9<ASIKK36<1TSTNTOH1LD7?>F&HPEB8X&333M0PQ&M,IV MAV.7L01Z5T&C,94 Z1<L7>=>1AU81Q3 9YV1PT 71-7<3>1ZNX<68J-6 MX(BJ?>#TAB).>P+?B#&OERS?>
V4D<T39-W1 MSCU1M2DTR4=>1<M1?260>L.WZ2?6Y2M>5R-IBVXN<4-HBIVBZ5UWDRD_OE=WL/H+V10.0 B.M6 MPF&67G/BV7V,Q2PMT85&H1BDQ9YIU@<E+ZPMU1=>NCG?<M/?>
LI-1VFN&S RS+NDH<V8QJ8K7F<#82>=>NM3+2DZ3&E1L/0-NMNC.1#8R M4+5<?>XDXHCAF&C9O-K18<X?>07HOVJP PI9WJN_XE ZEA6V0E7VZ5X3Y78 M
B2ES&CDE&Q&16W098.<5PI,H>5A:YF-U3>W>3?/H+6<4<1<8RH,U3J9J MOIX #JPCBF SSM2 @.B.N4<DJS'H-6U1+6B/5 MK5B/5>V1#52\$8=<6+5?>1<6U@YJYZ+L MZI+@.W4 M22Q1S/2(A
P,4<?>F&E51J1X#61ZVDS5>\$(M"E@KS=,0U@BEV=<3JBES+7<=7<B1,QAUMQ#<N9NQC&TIAZP7J MJB DSRU1U+5F&R50KXKWA4V=>IP6+1<7F721FF74<722.LWJB5M_XE
M3E1,GXD,P6U,IR=9I0H9L5>GUB<4JWVY<E.LI+ND7M,DGR,J1>OK<FZ

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

6Y>T.Z!\$ZM+JB5-KHUN24A<MW.3

03M371WH004IK=5@OBH3VMW6"JS:7A6.WK62K5T5+M+T%:W58+W-M>%9#4%IA:RMQ=S9Q.FU76G8W94.7.6AM)B-X03LK=7H004%W
M=G9(2DEV2*9V>/%T5.4TLW8FOX5E%)A5U5S17ER2D9)=*5J5F1UE9915I4=7%3:S.WES.FUZ.CIK.71C)B-X03M7+5.33U(O
M5510>G=E3U1L7C3.GA63EBT<7R6E=DDP>6IM<2IX-V1X)B-X03LO=1%W7A636-69&ER.V5W<5U\$535153MK.FM:5V=)2\$IQ24K4'O3'0X47A61UEQ-T95
M=3AY+SA)B-X03M+3V%R+W=1=V1X+WEA8D95>'A6.DMU>%8R2W5X5DOT5BIS MOC=T2'U<O'F-A6.DMU>%8R2W5X5C)=7A6.DMU>%8R2W5X)B-X
M03M6.DMU>%8R2W5X5C)=7A6.DMU>%8R2W5X5D-853Z>D-Z-<U-F53&S;B.WDX66%9T1.5W>R>F1E45AF8G2%>0:4-#0T*65E)B-X03LO:6E46EDP
M0592.SI).GA69FE'X'86C&57AX5C)=7A6.DMU.M>%9=>80.W4P9CAI-6I(4T%:TIT>%9>B-X03MC5F1H%95=)72S)J6DDK5D=D.M-
4=35="6C).3G5X4&W10PITMO=4MU>%8R2W6D-6PO-5)Z5F8K64I+S5.M3FEQ631O)B-
X03LW1EA9<3=&6%EQ.#Q+5%8R2W5X5C)=7A6.DMU>%8R2W5X5C)=7A6.DMU>%8R2W5X)B-X M03M6.DMQ5C-CIS-T<5IX1DI/)&%K6UE5C-9<3+=<3A%2BM3F%\$-
FMG9*MP.WA6)B-X03M6>%8R2W5X M5C)=<8Q.U4G16GR203550Q=T-45%EQ:4I+=7A6.DMT339+5D1-1DQ6.6I'M<%4P%9N8C5+<6=S>%19059(2W-4&5)>A9+V%:3C%7
M65EQ-T9867W1EA9<6PS:5@00412E9F.<M1'50'U1467%6MTMU>%8R)B-X
M03M+&A69GEG.<%81G1C4&8=5%&PK8E5PX4&AO-U1#5).5DP5C1B<5)9:5H2W)7.D)B-X03M53FAI#<J2DU.93&Y3T=AM85-153W)B-X03MX65-
)GA19VM-4BM-5@R3DMG5GA61EEQ-T9867W1EA9 M<6IS:5%3A.FI.7AD4T+1E-030T=70-65DA1UEG041C)F&5D.S=#>M0B-X M03M7-QS940P<%EJ3\$A'1\$9+
U(K:W5:3=4R4E9A46A196Y.W4E'FMO:5+S-M6%EQ-T9867W1EA9 M1.8G1H-35&:5+1B+VOP12MO-G1B.U1\$)B-X03M62EE956YH.M.E%):S=5>5-F=215-
3)Q<6ML9C)Q92D65V53C5T6KX16QM<2W14U)B(XV8X M:6UX5DUC5FH1A6.DMU>%8R M2W5X5C)=7A6.DMR6D19)B-X03M0.<133W%+5U915TE3\$U1<6IF=5-A1\$95
M3%2.E.9Q.XC(V5U.S:6QJ0VUX85)84TQC.CEGRU.U0A.9&=+554P.T9037A6 M6DY4U1=V1E3&J66EQ0T14-O>%9#>31E.EE2 M.V).5A:V1B5V33DEZ6U1A1905610K5TY+<
<579>49&5TE64E4Y>7A1T(M093)1=4&:54.5+M-T123HX.6%4G1'F&X10E8R54Q88YAE9S<K<6IV1EA9)B-X03M0.T9516GR M=&D%<5%#>3-K=8D5Y'=F-
%55>5144U516E1548S8C)567%127-.8S*8H71 M3%96<=I.D3DHH.T@Q.55E1C-01U-&6'IDB-X03M16G8Y6C)2S1Q:C%R83Q(O M=&C)X.C%R16M=&D-
Q4TM32%2V10VE9K04)I<7J><5A6F6R5K56.T6'IM150 M'U1467%6MTMU>%8R2W5X)B-X03M6.DMP9%>5DR.BH4&U9+W=5.<4S1TMP.M.FERC52.SQ5 M8F)4=5%DO4T
Y=CJW03T)T-DM31VM53G<=(1V%9)1.9M2%5EPE4'S M=UDR55)4=5A-59A&F-6:1L.R1A9)1T8-X03MI<4TP.GDU6C)Y=S.PE4W M=4MU>%8R2W6D-6PO M=T-
58S%<T>P%95+J+VLP)B-X0321RWJ)7)S5FLIEA=S-P.F1L M0T5P.#A1B-X03M1.#Q2DA18G-X2592=7A1>8U)'M74&Q4.#8Y1D1O>F5B M4U533A.FO:O:4A+3 T.75&
M6'U.&QZ.&(O-U)O-C%U C=&=13DX8C)O.C5.BU>B<FXV2E)7<71B>T9FM6)X M.S-6<=K1.YM#=&EB.35S)B-X03LR.KA5'YJZ1'MA5YV46G16-W%:61S M37-9864X)B-X03MT-
S97272E.%2)D)B0S9%>T-T=3A:IT7'S9N9D-R6&QB M.#&03S=<086QK.TYB.65R.&E3.&(05'H3HT.HW'OWIO3&51YUK4C5)B-X M03LR.MELED87M%:S.U>X>21%W
Q=SIQ.#D5321R23=A.W5>=513=>58V) M9E1G5D=F.&DQ1U0095AY+V%W%:6Y:6D1&87=>4MY>G)1+Y)B-X03M=#CA127A6 M%9T.U)3'5W5D9&E8M9T5>6-64&5(V33)H)B-
X03M6-'A8:54'7191%8R2W5X5DH6CAW1S)U1C1Z5%2E9F5 M36Y33S4UE8DT:S9E=&+Y04P.#8Y4Y1M-DM5=&E66G)B-X03MK46-BMP M-
FA'VIA=DU'VLS9Y73E.4T0V5U1G1%6.2&5P.DET4U1G)U=IT.953534E(R-&K=<#%K=E)B-X03M19\$XY<71'ITDU2#E70D5+ M8T=K1F6M=E(W2W)*R15-
T=W:E8W=552.IX.6H33>33C&T>A01V9R-WE6 M0D1+T581W0V9T(Y6&DQ)B-X03M29\$3S>5H3SE3#G<3DW8TXV2U2S1C68590>5 Y060U449N2W9+5&E14T.T)B-X
M03M6.MBBI1E4K.G0W9313159X16LP5&9A.FM537 K64Y2.7%+W=Z.WDQ.T9T.M50W31)B-X03M13)S>=H3SE+WSW4C&K.Q989FTE.FHQ.U7O55=)B-X03M11W%X4#95 M>6HR3%-
X=DM2+W.X5EDQ8E=0-7)(<G1D4UA-UR-55K=&MG9TU+=&8V>613 M+W)M1GDV<71L>6IF1W=O1DY-5EI.<VEI1.&A03W9R>3&X9E5L-78X06H<5EG
M04%10V=>=1%X5C)+&A6)B-X03M=>DUV+TM/87(O)D(52')<=65&A6&E.M-T9867W1EA9)B-X03M5U5E.5U0&93=2+W=5;4UF.\$&Y95=I1E5X>%8R2W5X5FHRV\$U9#>Q.M.TOP5V=>)B-
X03MNS8)<#5'55%>'W4K85AK&8.D5C'AL40.YU1.M.BLO>=U2W(L-58Q>GHS-6=N.6%731.SAT5W<7=5)B-X03M.L=5.6'3'M-8R2W5X5C)=7A6
M.DMU>%8R2W5X5C)=7A6.DMU>%8R2W6D-6PO-5)Z5F8K64I+W=4#519-6+U1.M2W5X5C)=U153F&P.F18)B-X03MT:SE1=EEB4C=Y45%7.7132VAK.TE0151K
M4E4T<71F6&14U@P6%#>.F=997%41S.P66(I>9.7.M=<#Q5:YAI.M2S=M57%96D8G640W%65F5TK6%W4C(O<'X3FO.5SADB-X03MY.E-8&EL.M3G-Y9V=E.F(R-
\$O=\$>T>E1Z<51807%9.E%=>4(O=51U<#DPO>6IM<2IX)B-X03MW9@>O>6%B1E5X>%8R2W5X5F@O-6@K43=J
M2EG=>E95.7>A67%3=3G1E.)A2S)1UT84G5F4U9+4T'4B18155M.M9D919EUF>FEE>3AS'17.&58.4=M=5A1U'5AF5'3E3&544U=X6C508G%)B-
M03MU4Y>591.<Q3U1A407>A'U90'U9+>G0Y.M1F.662K4C@U939-3FE)B-X03LO55)(<D93 M>79T'@Q089D95.#1.4P)436&8R2W5X5C)1)B-X
X03MU>%8R2W5X5C)=7A6.DMU M>%8R2W5X5C)=7A6.DMU>%8R2W5X5DQV378X07EL.7%U=O-T1-2&F.&UM>=9-M8U9D)7)S5F1A6.DMU>%8R
M2W5X5C)=7A6.DMU>%8R2W5X5C)=7A6.DMU>%8R2W5X5C)=7A6.DMU>%8R M2W5X5C)1)B-X03MU>%9=>DUV+T%#>FU.O'<SA134AC9AM>7A636-
69&ER'1Y86)&57AX5C)=7A6.DMU)B-X03MX5DOT5BIS M=3'IF.\$&U:D@004J03S1X5DUC5FH2I1W1\$M/87(O04UW9'@O M>6%B1E5X)B-
X03MX5C)=7A6.DMU>=9=>80.W4P9B1M36

Q1Q2/%NBA418FF%Q1%R=>PX.7&QU1U&QG4#22#FOGJMN.150-MB6;0W4J81Z=I.716QNF(YOC%)(HH40DB+93K&Q29FR05C+@KW.ON.AB.XVU.MPEW?
UTQ19.0/@X2B7#?1JH1.P1%W&#TE2/2A8X1%6&#JHM(1%K.M0%5.KXNTOJRD991F21MOHKN9E7ASS=(H.RH7XZ?1QVBYXJ.M.F:JAG.MV).XVQL%Y)MO?<?>
GR0#10E6RJ02>HW.BTWD.P.=>7<3>.RMV1V.W&#W1U%09H1TNG.M-9+JFEDHW.G2O:OCHIFR?T.C.P.R+D.F.M7V5N7UFA.XM.Y6E1
%SS&DV513E=8NC=6Y8V750V?F4+J\$W%K%R=M.HO.M.YL.WX.H20BP/MDT3%XYU9V5R640.M\$?M.49S=>?%RLU?L?AN.~^N^KXG-GJ/<=8LM+I&#>.ESMR.MB^8KFA
M6:6UJ).W5:1&S1V1.OH1DSTVNZ.L.F1X6X0YR/L.1.285244.C.M.F:2DNDZDYVAB.Z.1&10J2.D.YS.RGKI.NJVW.40DEE.YWRIS7F9A1<X90+>1.3W1X&MKN3YV
M-E.P.4.4.K2KUBM0Q1%UDHYH(G-1%)1.==0G<+>1\$N:671[S2807H(XB1B)1=1<0.R#H.HJMHXK3V3>OD4L<=>F/MJ5.M&(VU1V1=7Z)AQ:
(86X.14.QS<64KU+P=>07G0/3YD/G.IV.P#A.M514.MX54)7LF>8GBY<HGCZ%>ORYMU.==3&D50?G2&1H?3.A2@JA3NTE<JYUZU70>=&0B1.MVIT=2.H.Y-V=WX.VI
JGAKS9<21OC.R=C%>+SY=57NRYVCY.52M.VP51.2VAF1+5K614YH&.HEK&XWQ:666H790.M?JIGR4YW5KAAAOV?V?<6RGH%>EDHY.O?>HITS&E6:
M38PPE2.MMM(4F4B25%Q.57Y?P%>.RWE.A(24B83K9Y&=>+5HR.6XK.M2.3K>6<+>W.M.95TH1+>K3>:GK.UC1F9.5UBR=>74WMZP7H615MKNK.S.MUJ9?G6:Z1H
0.8.S.#CWRJ+1KR1=EP.VYRXV1+1+Q8R9<+>L4H1N1NR679L.M&H+2X19./Q9VL%<5.56163%66V?S+JH7NL0.1>P5.SHYG.7OZM.M2?TXX.HORJ4H1
U.DTDF6M<S>.G51<5.C.J&LZ41>LB2F%Q=8B29.FL.M.FE&N.RP1D/3ZD.JMX%>G.Y.Z.I.CT&.=>F.Y.MIA.L.1+O7&D.56+7W1.M.WQ161+>+P10JM)2SRIE.%\$04MCO6W?
81S9.HH.VW&K2D>80M.B-R.M7EX<+>(3QR27M)TPTD4TJME<+>I3.ZR=VB(RH0-KKA#F=)@DKZ0.-M.R55JK=L3).2?X4F1+
K4XWGXX?CM1=370+5P&C=>0.6A1D5.RG?P=P.M.+D9.%PEVTF=7?PE21E.NT3?S&SO=1N0H1.K49QGL+HYX+1K#J3Y9Y7KW&Z12>S/G1E?J
%KFWY?C.G0J41>2+T90L.KY2.M2#B.WV+VQB50/EJ1UTJ.6&7+2G.>N(C.S:NDGDMBK?LBH27B.M&25#R+R?QJ.P#M.VHXSZFL?DF7Z
4QBK21O93+OE=5R2N.GHD.Y0K3Q8RM.VW.N.ZLRTY>+W=M.SQJF51FJ00J1?7GCDVQIC7XUUVT?2.MJ9?1EMBBF=3S16LL?SZL2V%>C.45(6)&W?ZSD<5?
G4DFU?>BFYR5.H&01.M7.YQ1F==.E.<R3J2.F2T.KRD?J1UYUUC<8NG18<+>QSN26G1DPG4IRDKK?R&M+80?1.SANZ=0CT41C6H%>G.YOQU+XP3+U+Y>?<+>.9H<+>141U4P5
MBZU10R7.5P1K?>+2+K5+75.Y0.P4JO.KB=31A0ML\$Y.F+L+VRESG.2L5.M.+&S.DG.L7>1\$1O./6E.N2.S%?<2K\$SACT?UD2>=>CUUT2+GLI.M06ZK&NFB5%KHF441Z
1.80OC7?<33.N.#S?%IRSSYGQU0Q.0?>+1.MQ9811.1.2%U9LFK9V.BT.B?>F51+DOX.9.M=M.B.TTSKOE.UO.L4J4?M.ZL.XHY(D1.3)EBJ82.<+>A(FB5NUPF0FX4K?
T8G3D/1V.B9MJZE.ME<GTF.FX?>G.LU3JGCOYNXZKJ.VK3R/5NK=>P.VXVOV16T?+1+0H829?F1.M?>H792C9?+T2)61+&>3-1<=>XQC.TCUTB7X/H1YWG=W3-1)<X)M
MLZ5V4P.VXJ.H1N?T513.H.UEUDR?>1D2541V0=BE?L7&S.LU+VR7XHK&.W=518585+OAG?CFLT11=LLV?S%>FV.RX.H.MK.
1.UJUTU?>W9C5M81H52Q?>YTA=5D0?<0LPE651D5?>+1A?>2.WK1T.MYQ37?1H&RV.8?7RIOM?T?BVI9.B&1.U7ZK?>UD2<93%>G0H&PJ0-JQ.K3.M?Y0?>2R19.
3KF21.YR.R.3&1+51&JGX<+>JZ40.2DU.CTGD.<05<0?F1.MSA.F?7P16.LZL?XIGD7?>(1%<L.WGWSOIXX?+BZ+Z863%>NKK=U2?
M5\$515<+43Y)TSL1.#%K8W&#GIVP19G9WV49S2=352M.L.P=>F120BBIA54A.MM-X?>7L10M9G91UFUXHVN5661.4DD1MC<+>U21LFHG>\$.S.1?U?>7.1ROP4Y
MW(SL5G.OF?FW?>Y.N.1=1&KM2.D480258.2M.80J5U=<=6Q-3177&17R?>MORF3.C.83<+>H3L1?P&K.V5%<+>IDD7215G?>+&1Q1T7F04HWA)44S1.<+>31M
M4&5MTLZ.Y.DK=21+R2K+1A=6BZ)2EL2TE?>R%6N.1<+>JUVQ6.1=1P30=?>M#?+1=Q2Y1?>LFOHRCV.U.S%<+>C2YK0DK.OA=X3L&G.W&?>7V.MC<+>@<C
CAOX2URE.DLZ40TR1H.W22M5<=>D.N%<+>0JFEFO?>WIGC?>+W.MLP?>3&V.L1=MO3C.M.M.FH1Z.13H4.F40)9H7CIAF?<K?>GALC?>3&0L.O141+J9<=>2
M2&J@<+>A1K@<+>DUW2140Q&S.9MW.L40&AIB?<+>M.W.-0.5L<+>3JWMZ=6VE1.HDXUXOX2D0.Z1P.P#HDH4Q&Q&K?<+>N2S)U.M.MUPID10HBLF)2RUOR&M&0?>Y.PY&D&I
VR?G18J5.8VQIG/E>0%OPM<=<=OF.LMS719.(=4TAKOQZ2FT3EK/L@-3?>MMM.M*1@<+>H1LV+5?>KR=5?>1.C#0.7#>5185Y&.<+>U.MAAJ817/?>1NPZ61+<+>M@<+>3V1.P1\$13.-S.T
7.QL1<+>2RYG7Y%>0T0?>U.H.30X7?>L&(KC10H&SYE.MRQC3&Z2+Z1D1WQ&G&V)=91GZ?<+>C?<+>F1D1VQ<+>R?>4.H.VY2?>IV.M00@<+>MOTB=>6?>P22.IB2?>DF.996V.M=
<=>WY?>S.M&X?<+>10N.<+>46%<+>Y1Z8?>8.M.J3+3B&F.YXWV.HIUB=GJ53Q5B-77J2=>+>J9?>N.SHL.2&S.23.2Q.M<+>IZ=B=>#1<+>X.N.2P1&24E&C&F1P7)PGUGE
L631XB26?>T39#>M5?>7?>16Y?>F&R+UBMW.401.FR.MHVC=>==2-2?>1\$X=Z2.8?>V1+130A?>V.M.2%<+>XN9%>ZBZ?<+>C311+6S.UCHVZK6B2?>2URMN?>MBJBH0KZ?<+>210<+>N.O.M@<+>C.M
M&M.E4N&F.D1?<+>L<+>N.N?>1.SESQ.NMP+9K6+91=>)>ORP.IG1?<+>K?>7.D16M+1.M+FY@EMKPEHVS.HSSE&#?>2.H2HR&M.#568R1?>K06N?>T9D19F&MCPHY3&HRC=>L
LXJZC=F-1>+>JG1.W?>6.<+>(M.YL8IM.TRI.BYK6HWE-8.Z)IGZ?<+>F.C.X94+FC.SKKOJH1%>=>S&#<+>I?<+>O1.M<+>3V1.T0?<+>E/.S00+1#F1+<+>6.1&0.951-M*31@<+>61W01&K.M)3K90&T?
M1HSY.PJ.L1\$Y?<+>SK.FQ019?>D?>+>1?<+>C.#M&G&N)16XN42Y?<+>INXJYJ

Q-1R+7R1PC0HH#M5J3.3IG/34 MU067XYOF-2SA6.GNSD5A98)+>L5.AHM+H06<(>71L.B>+>WY>(<P1+2&L'M20L(K0J)6L+>+>ESU+4%;J\$VNI)Q?>
>7P.59F7YSZQO;5H0>N>KJ<@<M.9/C6S)AHE5)UUA-X2U7P23R1<7<Q<CFAN)H+K4J3Q1Z53-HL9P.6-2AD.MJ006GDZIH+R20KBN<
HJ3J.VXNHV5J5L&4VFYJ2.0GRGHJ.564H/85J)MHS4.CLPW2.OE6H+<F>S88<UK.FTPBVVWVWTVXV7JQK6LVI+9W.VE<56.M-BN6Z52HES/M0UJ+8WB.NC7M)I<
(9>+L+2H+G+37790<4J)J.BJ9&49W(V%#1%OD3(H.3&XBTG)M)3M5<H/V23>2>J.H.09H830MKOK9TGX.7YUO+>V.WG055U+UQ096DEIA)MF.ANN6<=<D>V/H.I255YK(O)<
(RMZ=>E+<=>2&F0E0H10.(MPFZ+VYVZ+V8)Q78H>D9C3ZUW+6V)PKH2XU(K1BYA+<6I6AF.MKKN:4JYUTV-5&FDJ.BJVPXVVS9E5QGS/06)<=>QD=<@<V3J6H+SF.M%<
IXRQ4H.6<NG.UFF.ZI5)IA)S+>BWVYSD.P+&&4.1%<M+H6.MYVQ<NO>NYGVMQX<H>+>LX+MN<KXJBF&+W+TDDAMO.R6G7YIE+<FQ>0WWMR<
M&E2.D5&E19+<ZML69K1ZOC7VU.MG&K+KB&NJS.VW-M27&E+<U5&UAI2N+<L>+>X2W%6U20>2D(G10ITF7R0I2H)M<H.FM-B-X-W3>_D.665<^JH+<+<
(+<+<F1T9<+<MBS*>0=<E83JH9?>MHER5JMTCT<+<E+W50W&G&FZ)W-(D<IC40QISDE7H0XCLN+<I>P(C)PAX<H+HMY3?=>R/GN56HJAG?<
?0I=<+<1D1JUVJF2.>M4WA4RWYU.W+2+<5+<D80.M+7(2VYV)ENB&0Z%<F&NCPQ4.40Q+<1.QWF+U+9+<I+D4ZD107+1+8H)Y5(O).MRLR?<
F-CZA)A+<A-Z9C<@<A1-9VLD102F.7FC(F&FZ=>LHRR+UL0BQZ?>M+<42U+K-F.RB<L+<E.NU+4CIV039J+<+<D4T10:1FHK13RRO82A.GS9&9Z#34.MMM4.Q&325&.G8UT+V<
FA2.1Y5+3JZ2.70&H)J+YOYNZ&E&+<2+>V&CLB7.M+T5020Q2.GJUS.ZO+N1+>K+<GM<6U0B4>2%<M&A1S5BKX&8/S<
M8C5+<6NUK6=>T=IRJ?>E.NE2+<G20B2M54.9BK>0V%<C&8LM9KCLM2L+P.U4UBU80843GOY?R7YVT+R1)+<AWC5G+>_KBR.5UJFE?W1WE.M1+<85-
9K&VY2XN15U+1070M&63=>57N?J9?<FC3&+<RLHKXG;LH5?<?<U.MEU?ZN7X(2+<EAY?>?<O&X454ZIDE>
M<4Q>4+<YAT5&FE0URJ4H15+<0M.LP+H1+<5VS.J&X1R0H0VZ.INAFF.MY"=M&51R0+1F+H1P/NP)QIEB<0B+<V1N+Q+<MB)EC(G+<31R?I?B2M=>=<XQ<??>B>2?Q?<
55YH+<905110S6F&K4HY.M9ZTK&4.4613DR)E?>D4;Y&W0+3?T.M7&=>P.KG68LTKVQNBV?>_I3ZK&=R8(L.GMOG&3.2MG.ZID?AN7+<4&D/L+<XQ?<
3ANK5Z9XWBR<R9?M.%)<(6XOX&S+<5&1&7H?>MRS716.WTP<I2FUVOL+>27MIG.1=>C&N9LX.M&BEB36-V1=>6I?2%<ZZKZNF&4F5V7?>YVVO1F?=>551D4J+<F?9>6DHW<
MW>OZ3.ZE?>X3J&C<YO.-SVL+<?>JMWFAN?M><@<K&0.(SKE)2.ME8.B%<BNG&8H1TCA.GX9=>R=2M.6FN+DW<
M=<0>XJ+2Y%+<4N>_V1QW&AD@<E=EDE43FHWA+?<L2&+<1+<S7N7M.OHOHR=<VZ6)8G&+<R&B+<ZC.MSA:1R8>+>2F1N.N.YT<X8YVW+<H4A8.Y.E<NAD5JVF.F>S.SVZ.\$F%Z<
M&F.S)<=<D1U.1">0<+<25+<I&SZ7M.<L56)SNY2B6N&5V.MBE716889&E+<K1T4.I&S6G&J.S&UMJ+<4X+<+>@DG7?I.XSKD107&E2DZ5E7.MPC5=>N+<2&FM=M&+<
H8G9AL.D150IZE>9RDR?<=>0N+<1?WR1GBL+7I2I1.MTRB+<2EYV15R16G&W82BL(DK<3P)UHYH5.9?HKLBI3PLC&+<S.EY?3PAQ.M+<8Y&J?750<46?>1S.P#IC5+7I7Z+<1<
M4&GJ&#<831U+P2+3M?Q7T9&CM6B+<CHW&HU#0D7+<+<H1.C+M.=>MHHJL.H.M+<XSM&MMMMH&G&=>=<81N+<5+6H<=>@<(M.M+<1+<0+Q.M+<U1?I2C.XH1+<1J?M)BNZG<
M7(BJX+<H+<H5+<E&Y&E&W3C?<+<I+<V4E?<?>6Y35?<=>(M5)<10JITL5D5U&FRM8DB.S&G+<1+<7.24.C+<C6L.G&FEGNME?8U&F+<W1P8400>2I6<
YD68ZP9&E+<K+<K.LK7F4.QO9=0=9%<H1-ZL&HH6Y.LN+<WO.MPN5&NI+<2/3IS&=>@?=>P.J?J5?>7?<1?>SARTQOZIN=PO#MB.M1U1UB62&?<P.9+<#1<
B2H&L&H1S7?DNU=<5<=<ZQ(O)<U4QJO=>O.K+<IBC.Y+<H0R+<RPVU&+<W.K+<N1108J+<W7?<PD2=>8RU0&XL+<5HXR.HF)7LRT&A254.MDC58U-6FR8N)?<
Z2951.92N<NS66?<6J3GJN(S4+<UQ#<G&K&H=6.P.L#<2&X.MZU5>+<W.YOA+<+<YD&S+<E?<VORL4+<W?<M1ON<=<88.OOOG?P@<JRI1+<OY(M&E?<CRJ@<6_0HA=>1?<
Y=>7?<K&#<R&S&P.M.U2YH?X3150+<4+<YZM.ANH12=>=>17.LCK&H0?N1?>6SWH&6N73&W1.M6=>5ZJG&OE.MTU8Y&N1J4H&
L.GJ5YV4N<+<+<V36?>7H1+<?<G+<JA.BDBI293R+<43Z8.MK&F8H.M3&FY&USL7HIDOC#M3G7QZA(ST&S%>TAXN0?<0N+<JRVRE&R1K?2<
M/T?<G1..W716..B1C=0C.IN&#<SR@<A4GW/I4R@<W.P.=6=WES/M4W5=>=<3R2<+<+<E&C&SLE&X646%<LE=VF?Q5A>9.XS6I?MFAIS&B*HAA5&(EC.MAL5A>D)-<
T3Z78(4%#<L&K%<9IR&B+<D+<1+<M+<4+<+<J4W+<2+<PB.8HJC52=>N.5.HR5)FQNA>_JL9J1-5NP>V>7<M?<+<+<OZLMV.U.T.OB5MV=SS3&G+<6&X&M5(YK&E>N=<(VY>+84<
M&KN>=<I&6.6IQMSOR+<7.P?<85DHWQ?<?<+<1+<@<E.BUGI&S&8+<L+<F&S8.MHHM:<GN+<1P+<H&3UJ3C+<P+<I6MVT+<H&N1ZLK+W7?<J1XJ+<10Q?<XJ&S+<UQ&1.MK.Z5/M?<?<
+<E+<4&B.JOR.M759B9L+<#<C<8&U&W5=>M+<R.C7KD605F7YZR2210M7?<62>=<G94XN+<K.M=0&K4L+>SV8OL<0O7=>U&4.TRWJ+<WJ?>O9+<Y6&U+<P.0K=>
M3I2/3&S&X6F71.VS.GF&L2CIT4N.WWZT.4K&3YFV=>79IQP5Y.N9Q<CL=KJ.M2+<5MX.L+<5V1FZIR?<+<P=PKXO

[illegible]

[illegible]

ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float	
Entity Common Stock, Shares Outstanding	811,536,437
Documents Incorporated by Reference	
	Documents Portions of Proxy Statement for the 2025 Annual Meeting of Stockholders Form 10-K Reference Part III, Items 10 through 14
Entity Central Index Key	0000021665
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock	
Entity Information [Line Items]	
Title of 12(b) Security	Common Stock, \$1.00 par value
Trading Symbol	CL
Security Exchange Name	NYSE
0.500% Notes due 2026	
Entity Information [Line Items]	
Title of 12(b) Security	0.500% Notes due 2026
Trading Symbol	CL26
Security Exchange Name	NYSE
0.300% Notes due 2029	
Entity Information [Line Items]	
Title of 12(b) Security	0.300% Notes due 2029
Trading Symbol	CL29
Security Exchange Name	NYSE
1.375% Notes due 2034	
Entity Information [Line Items]	
Title of 12(b) Security	1.375% Notes due 2034
Trading Symbol	CL34
Security Exchange Name	NYSE
0.875% Notes due 2039	
Entity Information [Line Items]	
Title of 12(b) Security	0.875% Notes due 2039
Trading Symbol	CL39
Security Exchange Name	NYSE

~~XML 22-R2.htm IDEA: XBRL DOCUMENT~~

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]	
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	New York, New York
Auditor Firm ID	238

~~XML 23-R3.htm IDEA: XBRL DOCUMENT~~

Consolidated	12 Months Ended		
Statements of Income			
- USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Millions			
Income Statement [Abstract]			
Net sales	\$ 20,101	\$ 19,457	\$ 17,967
Cost of sales	7,940	8,131	7,719
Gross profit	12,161	11,326	10,248
Selling, general and administrative expenses	7,729	7,151	6,565
Other (income) expense, net	164	191	69
Goodwill and intangible assets impairment charges	0	0	721
Operating profit	4,268	3,984	2,893
Non-service related postretirement costs	87	360	80
Interest expense	292	287	167
Interest income	67	55	14
Income before income taxes	3,956	3,392	2,660
Provision for income taxes	907	937	693
Net income including noncontrolling interests	3,049	2,455	1,967
Less: Net income attributable to noncontrolling interests	160	155	182
Net income attributable to Colgate-Palmolive Company	\$ 2,889	\$ 2,300	\$ 1,785
Earnings per common share, basic (in dollars per share)	\$ 3.53	\$ 2.78	\$ 2.13
Earnings per common share, diluted (in dollars per share)	\$ 3.51	\$ 2.77	\$ 2.13

~~XML 24-R4.htm IDEA: XBRL DOCUMENT~~

Consolidated	12 Months Ended		
Statements of			
Comprehensive			
Income - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Millions			
Statement of Comprehensive Income [Abstract]			
Net income including noncontrolling interests	\$ 3,049	\$ 2,455	\$ 1,967
Other comprehensive income (loss), net of tax:			
Cumulative translation adjustments	(343)	98	(146)
Retirement plan and other retiree benefit adjustments	43	(16)	413
Gains (losses) on cash flow hedges	8	(7)	60
Total Other comprehensive income (loss), net of tax	(292)	75	327
Total Comprehensive income including noncontrolling interests	2,757	2,530	2,294
Less: Net income attributable to noncontrolling interests	160	155	182
Less: Cumulative translation adjustments attributable to noncontrolling interests	(8)	(42)	(4)
Total Comprehensive income attributable to noncontrolling interests	152	113	178
Total Comprehensive income attributable to Colgate-Palmolive Company	\$ 2,605	\$ 2,417	\$ 2,116

~~XML 25-R5.htm IDEA: XBRL DOCUMENT~~

Consolidated Balance	Dec. 31, 2024		Dec. 31, 2023
Sheets - USD (\$)			
\$ in Millions			
Current Assets			
Cash and cash equivalents	\$ 1,096	\$ 966	
Receivables (net of allowances of \$85 and \$80, respectively)	1,521	1,586	
Inventories	1,987	1,934	
Other current assets	713	793	
Total current assets	5,317	5,279	
Property, plant and equipment, net	4,422	4,582	
Goodwill	3,272	3,410	
Other intangible assets, net	1,756	1,887	
Deferred income taxes	195	214	
Other assets	1,084	1,021	

Total assets	16,046	16,393
Current Liabilities		
Debt payable within one-year	660	330
Accounts payable	1,805	1,698
Accrued income taxes	403	336
Other accruals	2,891	2,377
Total current liabilities	5,759	4,741
Long-term debt	7,289	8,219
Deferred income taxes	343	361
Other liabilities	2,111	2,115
Total liabilities	15,502	15,436
Commitments and contingent liabilities	0	0
Shareholders' Equity		
Common stock, \$1 par value (2,000,000,000 shares authorized, 1,465,706,360 shares issued)	1,466	1,466
Additional paid-in capital	4,181	3,808
Retained earnings	26,145	25,289
Accumulated other comprehensive income (loss)	(4,222)	(3,937)
Treasury stock, at cost	(27,358)	(26,017)
Total Colgate-Palmolive Company shareholders' equity	212	609
Noncontrolling interests	332	348
Total equity	544	957
Total liabilities and equity	\$ 16,046	\$ 16,393

~~XML 26 R6.htm IDEA: XBRL DOCUMENT~~

Consolidated Balance Sheets		
(Parenthetical) - USD	Dec. 31, 2024	Dec. 31, 2023
(\$)		
\$ in Millions		

Current Assets		
Allowance for doubtful accounts receivable, current	\$ 85	\$ 80
Shareholders' Equity		
Common stock par value (in dollars per share)	\$ 1	\$ 1
Common stock authorized (in shares)	2,000,000,000	2,000,000,000
Common stock issued (in shares)	1,465,706,360	1,465,706,360
Debt payable within one year	\$ 652	\$ 20

~~XML 27 R7.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Changes in Shareholders' Equity - USD (\$)	Total	Common Stock	Additional Paid-In Capital	Unearned Compensation	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
\$ in Millions								
Beginning balance at Dec. 31, 2021	\$ 1,466	\$ 3,269	\$ (1)	\$ (24,089)	\$ 24,350	\$ (4,386)		\$ 362
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Net income	\$ 1,967					1,785		182
Other comprehensive income (loss), net of tax	327						331	(4)
Dividends	[1]					(1,562)		(135)
Stock-based compensation expense			125					0
Shares issued for stock options			190		226			
Shares issued for restricted stock awards			(40)		40			
Treasury stock acquired					(1,308)			
Other			2		3			
Ending balance at Dec. 31, 2022	1,466	3,546	(1)	(25,128)	24,573	(4,055)		405
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Net income	2,455					2,300		155
Other comprehensive income (loss), net of tax	75						117	(42)
Dividends	[1]					(1,584)		(170)
Stock-based compensation expense			122					
Shares issued for stock options			170		212			
Shares issued for restricted stock awards			(34)		34			
Treasury stock acquired					(1,128)			
Other			4	1	(7)		1	
Ending balance at Dec. 31, 2023	957	1,466	3,808	0	(26,017)	25,289	(3,937)	348
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Net income	3,049					2,889		160
Other comprehensive income (loss), net of tax	(292)						(284)	(8)
Dividends	[1]					(2,034)		(168)
Stock-based compensation expense			135					
Shares issued for stock options			284		354			
Shares issued for restricted stock awards			(52)		52			
Treasury stock acquired					(1,739)			
Other			6		(8)	1	(1)	
Ending balance at Dec. 31, 2024	\$ 544	\$ 1,466	\$ 4,181	\$ 0	\$ (27,358)	\$ 26,145	\$ (4,222)	\$ 332

[1] * Five dividends were declared in 2024. Four dividends were declared in 2023 and 2022.

~~XML 28 R8.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)	12 Months Ended			
	Dec. 31, 2024 dividend \$ / shares	Dec. 31, 2023 dividend \$ / shares	Dec. 31, 2022 dividend \$ / shares	
Statement of Stockholders' Equity [Abstract]				
Dividends declared per common share (in dollars per share) \$ / shares	\$ 2.48	\$ 1.91	\$ 1.86	[1]
Number of dividends declared per quarter dividend	5	4	4	

[1] * Five dividends were declared in 2024. Four dividends were declared in 2023 and 2022.

~~XML 29 R9.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Cash Flows - USD (\$)	12 Months Ended		
\$ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Activities			
Net income including noncontrolling interests	\$ 3,049	\$ 2,455	\$ 1,967
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations:			
Depreciation and amortization	605	567	545
ERISA litigation matter	0	267	0
Restructuring and termination benefits, net of cash	51	(23)	49
Stock-based compensation expense	135	122	125

Gain on the sale of land	0	0	(47)
Goodwill and intangible assets impairment charges	0	0	721
Deferred income taxes	(77)	(98)	(78)
Cash effects of changes in:			
Receivables	(56)	(37)	(227)
Inventories	(100)	194	(333)
Accounts payable and other accruals	516	309	(115)
Other non-current assets and liabilities	(16)	(11)	(51)
Net cash provided by operations	4,107	3,745	2,556
Investing Activities			
Capital expenditures	(561)	(705)	(696)
Purchases of marketable securities and investments	(574)	(506)	(470)
Proceeds from sale of marketable securities and investments	564	502	322
Payment for acquisitions, net of cash acquired	0	0	(809)
Proceeds from the sale of land	0	0	47
Other investing activities	37	(33)	5
Net cash used in investing activities	(534)	(742)	(1,601)
Financing Activities			
Short-term borrowing (repayment) less than 90 days, net	93	(906)	540
Principal payments on debt	(503)	(903)	(406)
Proceeds from issuance of debt	2	1,495	1,513
Dividends paid	(1,789)	(1,749)	(1,691)
Purchases of treasury shares	(1,739)	(1,128)	(1,308)
Proceeds from exercise of stock options	638	380	418
Other financing activities	(91)	18	(18)
Net cash used in financing activities	(3,389)	(2,793)	(952)
Effect of exchange rate changes on Cash and cash equivalents	(54)	(19)	(60)
Net increase (decrease) in Cash and cash equivalents	130	191	(57)
Cash and cash equivalents at beginning of year	966	775	832
Cash and cash equivalents at end of year	1,096	966	775
Supplemental Cash Flow Information			
Income taxes paid	933	937	945
Interest paid	\$ 302	\$ 280	\$ 151

[XML 30 R10.htm-IDEA: XBRL DOCUMENT](#)

Nature of Operations

12 Months Ended
Dec. 31, 2024

[Organization, Consolidation and Presentation of Financial Statements \[Abstract\]](#)

Nature of Operations

Nature of Operations

The Company manufactures and markets a wide variety of products in the U.S. and around the world in two product segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners and other similar items. These products are sold primarily to a variety of retailers, wholesalers, distributors, dentists and, in some geographies, skin health professionals. Pet Nutrition products include specialty pet nutrition products manufactured and marketed by Hill's Pet Nutrition. The principal customers for Pet Nutrition products are authorized pet supply retailers, veterinarians and eCommerce retailers. Some of our products are also sold direct-to-consumer. Principal global and regional trademarks include Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet.

The Company's principal classes of products accounted for the following percentages of worldwide Net sales for the past three years:						
	2024		2023		2022	
Oral Care	43	%	42	%	43	%
Personal Care	18	%	19	%	19	%
Home Care	17	%	17	%	17	%
Pet Nutrition	22	%	22	%	21	%
Total	100	%	100	%	100	%

[XML 31 R11.htm-IDEA: XBRL DOCUMENT](#)

[Summary of Significant Accounting Policies \[Abstract\]](#)

[Summary of Significant Accounting Policies](#)

12 Months Ended
Dec. 31, 2024

Summary of Significant Accounting Policies
Principles of Consolidation

The Consolidated Financial Statements include the accounts of Colgate-Palmolive Company and its majority-owned or controlled subsidiaries. Intercompany transactions and balances have been eliminated. The Company's investments in consumer products companies with interests ranging between 20% and 50%, where the Company has significant influence over the investee, are accounted for using the equity method. Net income (loss) from such investments is recorded in Other (income) expense, net in the Consolidated Statements of Income. As of December 31, 2024 and 2023, equity method investments included in Other assets in the Consolidated Balance Sheets were \$81 and \$83, respectively. Unrelated third parties hold the remaining ownership interests in these investments. Investments with less than a 20% interest are recorded at cost and periodically adjusted based on observable price changes or quoted market prices in active markets, if applicable.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Company's assumptions and estimates involved in preparing the financial statements includes pension and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. Additionally, the Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments and retirement plan assets. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. Actual results could ultimately differ from those estimates.

Revenue Recognition

The Company's revenue contracts represent a single performance obligation to sell its products to trade customers. Sales are recorded at the time control of the products is transferred to trade customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the products. Control is the ability of trade customers to "direct the use of" and "obtain the benefit from" our products. In evaluating the timing of the transfer of control of products to trade customers, the Company considers several control indicators, including significant risks and rewards of products, the Company's right to payment and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to trade customers.

Net sales reflect the transaction prices for contracts, which include units shipped at selling list prices reduced by variable consideration. Variable consideration includes expected sales returns and the cost of current and continuing promotional programs. Current promotional programs primarily include product listing allowances and co-operative advertising arrangements. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements. The cost of promotional programs is estimated using the expected value method considering all reasonably available information, including the Company's historical experience and its current expectations, and is reflected in the transaction price when sales are recorded. Adjustments to the cost of promotional programs in subsequent periods are generally not material, as the Company's promotional programs are typically of short duration, thereby reducing the uncertainty inherent in such estimates.

Sales returns are generally accepted at the Company's discretion and are not material to the Company's Consolidated Financial Statements. The Company's contracts with trade customers do not have significant financing components or non-cash consideration and the Company does not have unbilled revenue or significant amounts of prepayments from customers. The Company records Net sales excluding taxes collected on its sales to its trade customers. Shipping and handling activities are accounted for as contract fulfillment costs and classified as Selling, general and administrative expenses.

Shipping and Handling Costs

Shipping and handling costs (also referred to as logistics costs) are classified as Selling, general and administrative expenses and were \$1,777, \$1,771 and \$1,874 for the years ended December 31, 2024, 2023 and 2022, respectively.

Marketing Costs

The Company markets its products through advertising and other promotional activities. Advertising costs are included in Selling, general and administrative expenses and are expensed as incurred. Certain consumer and trade promotional programs, such as consumer coupons, are recorded as a reduction of sales.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

Inventories

The cost of approximately 75% of inventories is determined using the FIFO method, which is stated at the lower of cost or net realizable value. The cost of the remaining inventories, in the U.S. and Mexico, is determined using the LIFO method, which is stated at the lower of cost or market. Inventories in excess of one year of forecasted sales are classified in the Consolidated Balance Sheets as non-current "Other assets."

Property, Plant and Equipment

Land, buildings and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over the estimated useful lives ranging from 3 to 15 years for machinery and equipment and up to 40 years for buildings. Depreciation attributable to manufacturing operations is included in Cost of sales. The remaining component of depreciation is included in Selling, general and administrative expenses.

Goodwill and Other Intangibles

Goodwill and indefinite-life intangible assets, such as the Company’s global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate that an asset may be impaired. In assessing impairment, the Company performs either a quantitative or a qualitative analysis.

Determining the fair value of the Company’s reporting units for goodwill and the fair value of its intangible assets requires significant estimates and judgments by management. When a quantitative analysis is performed, the Company generally uses the income approach, which requires several estimates, including future cash flows consistent with management’s strategic plans, sales growth rates and the selection of royalty rates and discount rates. The Company generally engages a third-party valuation firm to assist in determining the fair value of intangible assets acquired in business combinations.

As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reporting structure realignment, the Company completed an assessment indicating no goodwill impairment was required. Refer to Note 13, Segment Information for additional information.

Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit.

Income Taxes

The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes.

Financial Instruments

Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company’s derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows.

The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company’s derivative instruments and other financial instruments are more fully described in Note 6, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations.

Stock-Based Compensation

The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period. The Company uses the Black-Scholes-Merton (“Black-Scholes”) option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company’s stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans.

Currency Translation

The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders’ equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year.

For subsidiaries operating in highly inflationary environments, local currency-denominated non-monetary assets, including inventories, goodwill and property, plant and equipment, are remeasured at their historical exchange rates, while local currency-denominated monetary assets and liabilities are remeasured at year-end exchange rates. Remeasurement adjustments for these operations are included in Net income attributable to Colgate-Palmolive Company.

Recent Accounting Pronouncements and Disclosure Rules

In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2024-04, “Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments.” This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Company’s Consolidated Financial Statements.

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements.

In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrants’ registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements.

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements.

In December 2023, the FASB issued ASU No. 2023-08, “Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets.” This ASU improves the accounting for certain crypto assets by requiring companies to measure them at fair value for each reporting period with changes in fair value recognized in net income. This guidance is effective for the Company for fiscal years beginning after December 15, 2024 and is not expected to have an impact on the Company’s Consolidated Financial Statements.

In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information for additional information.

In October 2023, the FASB issued ASU No. 2023-06, “Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.” This ASU modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements.

In August 2023, the FASB issued ASU No. 2023-05, “Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement.” This ASU requires a joint venture to initially measure all contributions received upon its formation at fair value. This guidance is applicable to joint ventures with a formation date on or after January 1, 2025 and is not expected to have a material impact on the Company’s Consolidated Financial Statements.

In March 2023, the FASB issued ASU No. 2023-01, “Leases (Topic 842): Common Control Arrangements.” This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Company’s Consolidated Financial Statements.

In September 2022, the FASB issued ASU No. 2022-04, “Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programs’ key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated roll-forward information. The Company adopted the guidance beginning on January 1, 2023, and with respect to the roll-forward information disclosure, beginning on January 1, 2024. See Note 15, Supplier Finance Programs for additional information.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

[XML 32-R12.htm IDEA: XBRL DOCUMENT](#)

Restructuring and Related Implementation Charges
[Restructuring and Related Activities \[Abstract\]](#)
[Restructuring and Related Implementation Charges](#)

12 Months Ended

Dec. 31, 2024

Restructuring and Related Implementation Charges

On January 27, 2022, the Board approved a targeted productivity program (the “2022 Global Productivity Initiative”). All initiatives have been implemented and the program concluded on December 31, 2024. The 2022 Global Productivity Initiative resulted in the reallocation of resources towards the Company’s strategic priorities and faster growth businesses, efficiencies in the Company’s operations and the streamlining of its supply chain to reduce structural costs.

Over the course of the 2022 Global Productivity Initiative, the Company incurred total pretax charges of \$228 (\$186 aftertax) in connection with the implementation of various projects as follows:		
Total Program Charges as of December 31, 2024		
Employee-Related Costs	\$	175
Incremental Depreciation		13
Asset Impairments		1
Other		39
Total	\$	228

Total pretax charges resulting from the 2022 Global Productivity Initiative were comprised of the following categories: employee-related costs, including severance, pension and other termination benefits (80%); asset-related costs, primarily accelerated depreciation and asset write-downs (5%); and other charges (15%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. Over the course of the 2022 Global Productivity Initiative, approximately 80% of the charges resulted in cash expenditures.

For the twelve months ended December 31, 2024 and December 31, 2023, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows:

	Twelve Months Ended December 31,	
	2024	2023
Gross Profit	\$ 20	\$ 1
Selling, general and administrative expenses	6	2
Other (income) expense, net	59	24
Non-service related postretirement costs	—	5
Total 2022 Global Productivity Initiative charges, pretax	\$ 85	\$ 32
Total 2022 Global Productivity Initiative charges, aftertax	\$ 73	\$ 25

Restructuring and related implementation charges are recorded in the Corporate segment as these initiatives are predominantly centrally directed and controlled and are not included in internal measures of segment operating performance.
Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments:

	Twelve Months Ended December 31,		Total Program Charges
	2024	2023	
North America ⁽¹⁾	3 %	15 %	9 %
Latin America	— %	— %	9 %
Europe ⁽¹⁾	89 %	19 %	44 %
Asia Pacific	— %	20 %	7 %
Africa/Eurasia	— %	5 %	6 %
Hill's Pet Nutrition	6 %	23 %	11 %
Corporate	2 %	18 %	14 %
Total	100 %	100 %	100 %

⁽¹⁾ The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. See Note 13, Segment Information for additional details.

The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals:

	Twelve Months Ended December 31,				Total
	Employee-Related Costs	Incremental Depreciation	Asset Impairments	Other	
Balance at December 31, 2022	\$ 30	\$ —	\$ 1	\$ 3	\$ 34
Charges	24	—	—	8	32
Cash Payments	(45)	—	—	(10)	(55)
Charges against assets	(5)	—	(1)	—	(6)
Foreign exchange	6	—	—	—	6
Balance at December 31, 2023	\$ 10	\$ —	\$ —	\$ 1	\$ 11
Charges	49	13	—	23	85
Cash Payments	(20)	—	—	(14)	(34)
Charges against assets	—	(13)	—	—	(13)
Foreign exchange	(5)	—	—	—	(5)
Balance at December 31, 2024	\$ 34	\$ —	\$ —	\$ 10	\$ 44

Employee-Related Costs primarily include severance and other termination benefits and are calculated based on long-standing benefit practices, written severance policies, local statutory requirements and, in certain cases, voluntary termination arrangements. Employee-Related Costs also include pension enhancements which are reflected as Charges against assets within Employee-Related Costs in the preceding table, as the corresponding balance sheet amounts are reflected as a reduction of pension assets or an increase in pension liabilities.

Incremental Depreciation is recorded to reflect changes in useful lives and estimated residual values for long-lived assets that will be taken out of service prior to the end of their normal service period. Asset Impairments are recorded to write down inventories and assets held for sale or disposal to their fair value based on amounts expected to be realized. Charges against assets within Asset Impairments are net of cash proceeds pertaining to the sale of certain assets, as applicable.

[XML 33 R13.htm IDEA: XBRL DOCUMENT](#)

Goodwill and Other Intangible Assets

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

The changes in net carrying value of Goodwill by segment for the years ended December 31, 2024 and 2023 were as follows:

	2023		
	Beginning Balance	Foreign currency translation	Ending Balance
Oral, Personal and Home Care			
North America	\$ 906	\$ 2	\$ 908
Latin America	168	11	179
Europe	1,504	67	1,571
Asia Pacific	179	—	179
Africa/Eurasia	107	(19)	88
Total Oral, Personal and Home Care	2,864	61	2,925
Pet Nutrition	488	(3)	485
Total Goodwill	\$ 3,352	\$ 58	\$ 3,410

	2024		
	Beginning Balance	Reallocation ⁽¹⁾	Ending Balance
Oral, Personal and Home Care			
North America	\$ 908	\$ 223	\$ 1,108
Latin America	179	—	145
Europe	1,571	(223)	1,281
Asia Pacific	179	—	178
Africa/Eurasia	88	—	78
Total Oral, Personal and Home Care	2,925	—	2,790
Pet Nutrition	485	—	482
Total Goodwill	\$ 3,410	\$ —	\$ 3,272

⁽¹⁾ As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reallocation of the goodwill, the Company completed an assessment indicating no goodwill impairment was required as a result of this segment reporting structure realignment. Refer to Note 13, Segment Information for additional information.

Other intangible assets as of December 31, 2024 and 2023 were comprised of the following:

	2024			2023		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Trademarks - finite life	\$ 1,135	\$ (545)	\$ 590	\$ 1,167	\$ (519)	\$ 648
Other finite life intangible assets	603	(385)	218	624	(363)	261
Indefinite life intangible assets	948	—	948	978	—	978
Total Other intangible assets	\$ 2,686	\$ (930)	\$ 1,756	\$ 2,769	\$ (882)	\$ 1,887

The change in the net carrying amounts of Other intangible assets during 2024 was due to foreign currency translation and amortization expense of \$75. Annual estimated amortization expense for each of the next five years is expected to be approximately \$68. In 2023, the Company re-characterized a certain trademark from an indefinite to a finite life intangible asset based on an assessment of certain macroeconomic conditions, historical performance and demand. The carrying value of this trademark as of December 31, 2024 is \$234 and is being amortized over its estimated remaining useful life of 24 years.

As of the date of the annual impairment test of indefinite-lived intangible assets, the fair value of one of the Company's indefinite-lived trademark intangible assets exceeded its carrying value by less than 20%. The carrying value of this trademark is \$293 as of December 31, 2024. Given the inherent uncertainties of estimating the future cash flows, the impact of interest rates and inflation on macroeconomic conditions, actual results may differ from management's current estimates which could potentially result in impairment charges in future periods.

[XML 34 R14.htm IDEA: XBRL DOCUMENT](#)

Long-Term Debt and Credit Facilities

Debt Disclosure [Abstract]

Long-Term Debt and Credit Facilities

Long-Term Debt and Credit Facilities

Long-term debt consisted of the following at December 31:

	Weighted Average Interest Rate	Maturities	2024	2023
Notes	3.0%	2025 - 2078	\$ 6,946	\$ 7,580
Commercial paper	3.0%	Various	936	606
Finance Lease Obligations			59	53
			7,941	8,239
Less: Current portion of long-term debt			(652)	(20)
Total			\$ 7,289	\$ 8,219

Debt payable within one year consisted of the following at December 31:

	2024	2023
Notes and loans payable	\$ 8	\$ 310
Current portion of long-term debt	652	20
Debt payable within one year	<u>\$ 660</u>	<u>\$ 330</u>

The Company classifies commercial paper as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis. Excluding commercial paper, scheduled maturities of long-term debt and finance leases outstanding as of December 31, 2024, were as follows:

Years Ended December 31,	
2025	\$ 652
2026	1,035
2027	509
2028	612
2029	519
Thereafter	3,678
Total	<u>\$ 7,005</u>

The Company's debt issuances and redemptions support its capital structure strategy objectives of funding its business and growth initiatives while minimizing its risk-adjusted cost of capital. During the year ended December 31, 2024, the Company redeemed at maturity \$500 of ten-year Medium-Term Notes with a fixed coupon of 3.25%. The redemption was financed with commercial paper borrowings. In March 2023, the Company issued \$500 of three-year Senior Notes at a fixed coupon rate of 4.800%, \$500 of five-year Senior Notes at a fixed coupon rate of 4.600% and \$500 of ten-year Senior Notes at a fixed coupon rate of 4.600%.

At December 31, 2024, the Company had access to unused domestic and foreign lines of credit of \$3,725 (including under the facility discussed below) and could also issue long-term debt pursuant to an effective shelf registration statement. In November 2022, the Company entered into an amended and restated \$3,000 five-year revolving credit facility with a syndicate of banks for a five-year term expiring November 2027, which replaced, on substantially similar terms, the Company's \$3,000 revolving credit facility that was scheduled to expire in August 2026. In November 2023, the Company extended the term of the credit facility for an additional year, expiring in November 2028. In November 2024, the Company further extended the term of the credit facility for an additional year, expiring in November 2029. Commitment fees related to the credit facility are not material.

Certain agreements with respect to the Company's bank borrowings contain financial and other covenants as well as cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements.

~~XML 35 R15.htm IDEA: XBRL DOCUMENT~~

**Fair Value
Measurements and
Financial Instruments**

[Fair Value
Disclosures
\[Abstract\]](#)

[Fair Value
Measurements and
Financial Instruments](#)

**12 Months Ended
Dec. 31, 2024**

Fair Value Measurements and Financial Instruments

The Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material, as it is the Company's policy to contract only with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations.

The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a global basis by utilizing a number of techniques, including working capital management, sourcing strategies, selling price increases, selective borrowings in local currencies and entering into selective derivative instrument transactions, issued with standard features, in accordance with the Company's treasury and risk management policies, which prohibit the use of derivatives for speculative purposes and leveraged derivatives for any purpose. It is the Company's policy to enter into derivative instrument contracts with terms that match the underlying exposure being hedged. Provided below are details of the Company's exposures by type of risk and derivative instruments by type of hedge designation.

Valuation Considerations

The Company's derivative instruments include foreign currency contracts and commodity contracts. The fair value of these instruments are classified as follows:

- Level 1: Quoted market prices in active markets for identical assets or liabilities.
- Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
- Level 3: Unobservable inputs reflecting the reporting entity's own assumptions.

Foreign Exchange Risk

As the Company markets its products in over 200 countries and territories, it is exposed to currency fluctuations related to manufacturing and selling its products in currencies other than the U.S. dollar. The Company manages its foreign currency exposures through a combination of cost containment measures, sourcing strategies, selling price increases and the hedging of certain costs in an effort to minimize the impact on earnings of foreign currency rate movements.

The Company primarily utilizes foreign currency contracts, including forward and swap contracts, option contracts, foreign and local currency deposits and local currency borrowings to hedge portions of its foreign currency purchases, assets and liabilities arising in the normal course of business and the net investment in certain foreign subsidiaries. The duration of foreign currency contracts generally does not exceed 12 months and the contracts are valued using observable market rates (Level 2 valuation).

Interest Rate Risk

The Company manages its targeted mix of fixed and floating rate debt with debt issuances and by entering into interest rate swaps in order to mitigate fluctuations in earnings and cash flows that may result from interest rate volatility. The Company utilizes forward-starting interest rate swaps to mitigate the risk of variability in interest rates for future debt issuances. The notional amount, interest payment and maturity date of the swaps generally match the principal, interest payment and maturity date of the related debt, and the swaps are valued using observable benchmark rates (Level 2 valuation).

Commodity Price Risk

The Company is exposed to price volatility related to raw materials used in production, such as resins, essential oils, tropical oils, pulp, tallow, corn, poultry and soybeans. The Company manages its raw material exposures through a combination of cost containment measures, sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts. Futures contracts are used on a limited basis, primarily in the Hill's Pet Nutrition segment, to manage volatility related to raw material inventory purchases of certain traded commodities, and these contracts are measured using quoted commodity exchange prices (Level 1 valuation). The duration of the commodity contracts generally does not exceed 12 months.

Credit Risk

The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is the Company's policy to contract with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations.

The following table summarizes the fair value of the Company's derivative instruments and other financial instruments which are carried at fair value in the Company's Consolidated Balance Sheets as of December 31, 2024 and 2023:

	Assets				Liabilities			
	Account	Fair Value			Account	Fair Value		
		December 31, 2024	December 31, 2023			December 31, 2024	December 31, 2023	
Designated derivative instruments								
Foreign currency contracts	Other current assets	33	19		Other accruals	22	25	
Commodity contracts	Other current assets	—	—		Other accruals	1	1	
Total designated		<u>\$ 33</u>	<u>\$ 19</u>			<u>\$ 23</u>	<u>\$ 26</u>	
Other financial instruments								
Marketable securities	Other current assets	160	179					
Total other financial instruments		<u>\$ 160</u>	<u>\$ 179</u>					

The carrying amount of cash, cash equivalents, accounts receivable and short-term debt approximated fair value as of December 31, 2024 and 2023. The estimated fair value of the Company's long-term debt, including the current portion, as of December 31, 2024 and 2023, was \$7,433 and \$7,862, respectively, and the related carrying value was \$7,941 and \$8,239, respectively. The estimated fair value of long-term debt was derived principally from quoted prices on the Company's outstanding fixed-term notes (Level 2 valuation). The following tables present the notional values as of:

December 31, 2024						
	Foreign Currency Contracts	Foreign Currency Debt	Commodity Contracts		Total	
Fair Value Hedges	\$ 1,669	\$ —	\$ —	\$	1,669	
Cash Flow Hedges	1,023	—	18		1,041	
Net Investment Hedges	289	3,750	—		4,039	

December 31, 2023						
	Foreign Currency Contracts	Foreign Currency Debt	Commodity Contracts		Total	
Fair Value Hedges	\$ 1,625	\$ —	\$ —	\$	1,625	
Cash Flow Hedges	869	—	39		908	
Net Investment Hedges	280	3,908	—		4,188	

The amount of gain (loss) recognized in income associated with fair value hedges did not have a material impact on the Company's Consolidated Financial Statements during the twelve months ended December 31, 2024.

The amount of gain (loss) recognized in income and Accumulated Other Comprehensive Income (AOCI) associated with cash flow hedges did not have a material impact on the Company's Consolidated Financial Statements during the twelve months ended December 31, 2024.

The following table presents the amount of gain (loss) on net investment hedges recognized in the Company's AOCI:

	Gain (Loss) Recognized in AOCI		
	Twelve Months Ended December 31,		
	2024		2023
Hedging instruments:			
Foreign currency contracts	\$	42	\$ (34)
Foreign currency debt		211	(124)
Total gain (loss) on net investment hedges	\$	253	\$ (158)

[XML 36 R16.htm IDEA: XBRL DOCUMENT](#)

[Capital Stock and Stock-Based Compensation Plans](#)
[Share-Based Payment Arrangement](#)
[\[Abstract\]](#)
[Capital Stock and Stock-Based Compensation Plans](#)

12 Months Ended
Dec. 31, 2024

Capital Stock and Stock-Based Compensation Plans Preference Stock

The Company has the authority to issue 50,262,150 shares of preference stock.

Stock Repurchases

On March 10, 2022, the Board authorized the repurchase of shares of the Company’s common stock having an aggregate purchase price of up to \$5 billion under a new share repurchase program, which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company’s compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company’s discretion, subject to market conditions, customary blackout periods and other factors. The Company repurchased its common stock at a cost of \$1,739 during 2024.

The Company may use either authorized and unissued shares or treasury shares to meet share requirements resulting from the exercise of stock options and the vesting of restricted stock unit awards.

A summary of common stock and treasury stock activity for the three years ended December 31 is as follows:

	Common Stock Outstanding	Treasury Stock
Balance, January 1, 2022	840,480,284	625,226,076
Common stock acquired	(17,060,788)	17,060,788
Shares issued for stock options	5,654,692	(5,654,692)
Shares issued for restricted stock units and other	1,138,418	(1,138,418)
Balance, December 31, 2022	830,212,606	635,493,754
Common stock acquired	(14,735,909)	14,735,909
Shares issued for stock options	5,318,430	(5,318,430)
Shares issued for restricted stock units and other	617,642	(617,642)
Balance, December 31, 2023	821,412,769	644,293,591
Common stock acquired	(18,321,422)	18,321,422
Shares issued for stock options	8,606,699	(8,606,699)
Shares issued for restricted stock units and other	876,652	(876,652)
Balance, December 31, 2024	812,574,698	653,131,662

Stock-Based Compensation

The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units, based on the fair value of those awards at the date of grant. The fair value of restricted stock units, generally based on market price, is amortized ratably over the requisite service period. The estimated fair value of stock options on the date of grant, based on the Black-Scholes value described below, is amortized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company accounts for forfeitures as they occur. Awards to employees eligible for retirement prior to the award becoming fully vested are recognized as compensation cost from the grant date through the date that the employee first becomes eligible to retire and is no longer required to provide service to earn the award.

The Company has one incentive compensation plan pursuant to which it issues restricted stock units (both performance-based and time-vested) and stock options to employees and shares of common stock and stock options to non-employee directors. The Personnel and Organization Committee of the Board, which is comprised entirely of independent directors, administers the incentive compensation plan. The total stock-based compensation expense charged against pretax income for this plan was \$135, \$122 and \$125 for the years ended December 31, 2024, 2023 and 2022, respectively. The total income tax benefit recognized on stock-based compensation, excluding excess tax benefits, was approximately \$26, \$22 and \$25 for the years ended December 31, 2024, 2023 and 2022, respectively.

Stock-based compensation expense is recorded within Selling, general and administrative expenses in the Corporate segment as these amounts are not included in internal measures of segment operating performance.

The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The weighted-average fair value assumptions are summarized in the following table:

	2024	2023	2022
Expected term of options	6 years	6 years	6 years
Expected volatility rate	20.5 %	19.8 %	21.1 %
Risk-free interest rate	3.8 %	4.3 %	3.0 %
Expected dividend yield	2.1 %	2.5 %	2.4 %
Weighted-average estimated fair value	\$ 22.65	\$ 14.89	\$ 14.71

The weighted-average expected term of options granted each year was determined with reference to historical exercise and post-vesting cancellation experience, the vesting period of the awards and the contractual term of the awards, among other factors. Expected volatility incorporates implied share-price volatility derived from exchange traded options on the Company’s common stock. The risk-free interest rate for the expected term of the option is based on the yield of a zero-coupon U.S. Treasury bond with a maturity period equal to the option’s expected term.

Stock Options

The Company issues non-qualified stock options to non-employee directors, officers and other key employees. Stock options have a contractual term of eight years and generally vest ratably over three years. As of December 31, 2024, approximately 19,248,078 shares of common stock were available for future stock option grants.

A summary of stock option activity during 2024 is presented below:

	Shares (in thousands)	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (in years)	Intrinsic Value of Unexercised In-the-Money Options
Options outstanding, January 1, 2024	20,742	\$ 75		
Granted	955	106		
Exercised	(8,662)	74		
Forfeited	(240)	76		
Expired	(21)	73		
Options outstanding, December 31, 2024	12,774	78	5	\$ 176
Options exercisable, December 31, 2024	9,265	\$ 76	4	\$ 136

As of December 31, 2024, there was \$12 of total unrecognized compensation expense related to unvested stock options, which will be recognized over a weighted-average period of 1.3 years. The total intrinsic value of options exercised during the years ended December 31, 2024, 2023 and 2022 was \$150, \$28 and \$47, respectively.

The benefits of tax deductions in excess of grant date fair value resulting from the exercise of stock options and vesting of restricted stock unit awards for the years ended December 31, 2024, 2023 and 2022 were \$18, \$4 and \$2, respectively, and are recognized in the provision for income taxes as a discrete item in the quarterly period in which they occur and classified as an operating cash flow. Cash proceeds received from options exercised for the years ended December 31, 2024, 2023 and 2022 were \$638, \$380 and \$418, respectively.

Performance-based Restricted Stock Units

Under the Company’s long-term incentive compensation program, the Company grants officers and other key employees a target number of unearned performance-based restricted stock units at the beginning of each three-year performance cycle. Awards are earned and vest following the conclusion of the performance period on the basis of achievement of performance goals established at the commencement of each three-year performance period.

A summary of performance-based restricted stock unit activity for the year ended December 31, 2024 is presented below:

	Shares (in thousands)	Weighted Average Grant Date Fair Value Per Award
Performance-based restricted stock units as of January 1, 2024	1,069	\$ 68
Activity:		
Granted	321	91
Vested	(283)	70
Forfeited	(89)	72
Change due to performance and/or market condition achievement	19	57
Performance-based restricted stock units as of December 31, 2024	1,037	\$ 74

As of December 31, 2024, there was \$32 of total unrecognized compensation expense related to unvested performance-based restricted stock unit awards, which will be recognized ratably over the remaining performance period.

The Company uses a Monte-Carlo simulation model to estimate the fair value of performance-based restricted stock units at the date of grant.

Time-Vested Restricted Stock Units

The Company also grants time-vested restricted stock unit awards. Awards either vest at the end of the restriction period, which is generally three years from the date of grant, or ratably over the restriction period. As of December 31, 2024, approximately 7,324,623 shares of common stock were available for future restricted stock unit awards.

A summary of restricted stock unit activity during 2024 is presented below:

	Shares (in thousands)	Weighted Average Grant Date Fair Value Per Award	
Restricted stock units as of January 1, 2024	2,174	\$	76
Activity:			
Granted	854		105
Vested	(951)		76
Forfeited	(90)		77
Restricted stock units as of December 31, 2024	1,987	\$	88

As of December 31, 2024, there was \$68 of total unrecognized compensation expense related to unvested time-vested restricted stock unit awards, which will be recognized over a weighted-average period of 1.6 years. The total fair value of time-vested restricted stock units vested during the years ended December 31, 2024, 2023 and 2022 was \$72, \$45 and \$40, respectively.

[XML 37-R17.htm](#) **IDEA: XBRL DOCUMENT**

**Employee Stock
Ownership Plan**
**Share-Based Payment
Arrangement**
[Abstract]
**Employee Stock
Ownership Plan**

**12 Months Ended
Dec. 31, 2024**

Employee Stock Ownership Plan

In 1989, the Company expanded its Employee Stock Ownership Plan ("ESOP") through the introduction of a leveraged ESOP that funds certain benefits for employees who have met eligibility requirements. As of December 31, 2024 and 2023, there were 7,428,343 and 8,348,104 shares of common stock, respectively, outstanding and issued to the Company's ESOP.

During 2000, the ESOP entered into a loan agreement with the Company under which the benefits of the ESOP may be extended through 2035. As of December 31, 2024, the ESOP had no outstanding borrowings from the Company.

Dividends on stock held by the ESOP are paid to the ESOP trust and, together with cash contributions from the Company, are (a) used by the ESOP to repay principal and interest, (b) credited to participant accounts, (c) used for contributions to the Company's defined contribution plans or (d) used to pay the Company's defined contribution plan expenses. Stock is allocated to participants based upon the ratio of the current year's debt service to the sum of total outstanding principal and interest payments over the life of the debt. As of December 31, 2024, 7,334,758 shares of common stock had been released and allocated to participant accounts and 93,585 shares of common stock were available for future release and allocation to participant accounts.

Dividends on the stock used to repay principal and interest or credited to participant accounts are deductible for income tax purposes and, accordingly, are reflected net of their tax benefit in the Consolidated Statements of Changes in Shareholders' Equity.

Annual expense related to the ESOP was \$0 in 2024, 2023 and 2022.

The Company paid dividends on the shares held by the ESOP of \$16 in 2024, \$17 in 2023 and \$19 in 2022. The Company did not make any contributions to the ESOP in 2024, 2023 or 2022.

[XML 38-R18.htm](#) **IDEA: XBRL DOCUMENT**

**Retirement Plans and
Other Retiree
Benefits**
Retirement Benefits
[Abstract]
**Retirement Plans and
Other Retiree Benefits**

**12 Months Ended
Dec. 31, 2024**

Retirement Plans and Other Retiree Benefits

Retirement Plans

The Company and certain of its U.S. and foreign subsidiaries maintain defined benefit retirement plans. Benefits under these plans are based primarily on years of service and employees' earnings.

In the U.S., effective January 1, 2014, the Company provides virtually all future retirement benefits through the Company's defined contribution plan. As a result, service after December 31, 2013 is not considered for participants in the Company's principal U.S. defined benefit retirement plan. Participants in the Company's principal U.S. defined benefit retirement plan whose retirement benefit was determined under the cash balance formula continue to earn interest credits on their vested balances as of December 31, 2013 but no longer receive pay credits. Participants whose retirement benefit was determined under the final average earnings formula or career average earnings formula continue to have their accrued benefit adjusted for pay increases until termination of employment.

In the first quarter of 2023, the Company recorded a charge of \$267 as a result of a decision of the United States Court of Appeals for the Second Circuit (the "Second Circuit") affirming a grant of summary judgment to the plaintiffs in a lawsuit under the Employee Retirement Income Security Act seeking the recalculation of benefits and other relief associated with a 2005 residual annuity amendment to the Colgate-Palmolive Company Employees' Retirement Income Plan (the "Retirement Plan"). The decision resulted in an increase in the obligations of the Retirement Plan, which based on the current funded status of the Retirement Plan and depending on further developments in the litigation, may require a cash contribution by the Company in 2025. See Note 12, Commitments and Contingencies for additional information.

In the Company's principal U.S. plans and certain funded foreign plans, funds are contributed to trusts in accordance with regulatory limits to provide for current service and for any unfunded projected benefit obligation over a reasonable period. The target asset allocation for the Company's defined benefit plans is as follows:

Asset Category	United States		International	
Equity securities	26	%	17	%
Fixed income securities	60	%	63	%
Other investments	14	%	20	%
Total	100	%	100	%

At December 31, 2024, the allocation of the Company's plan assets and the level of valuation input, as applicable, for each major asset category were as follows:

	Level of Valuation Input	Pension Plans	
		United States	International
Cash and cash equivalents	Level 1	\$ 226	\$ 21
U.S. common stocks	Level 1	1	2
International common stocks	Level 1	—	15
Pooled funds ⁽¹⁾	Level 1	35	103
Fixed income securities ⁽²⁾	Level 2	624	75
Guaranteed investment contracts ⁽³⁾	Level 2	—	30
		886	246
Investments valued using NAV per share ⁽⁴⁾			
Domestic, developed and emerging markets equity funds		223	28
Fixed income funds ⁽⁵⁾		68	222
Hedge funds ⁽⁶⁾		—	7
Multi-asset funds ⁽⁷⁾		157	2
Real estate funds ⁽⁸⁾		—	27
		448	286
Other assets and liabilities, net ⁽⁹⁾		(39)	5
Total Investments		\$ 1,295	\$ 537

At December 31, 2023, the allocation of the Company's plan assets and the level of valuation input, as applicable, for each major asset category were as follows:

	Level of Valuation Input	Pension Plans	
		United States	International
Cash and cash equivalents	Level 1	\$ 206	\$ 14
U.S. common stocks	Level 1	—	2
International common stocks	Level 1	—	20
Pooled funds ⁽¹⁾	Level 1	20	113
Fixed income securities ⁽²⁾	Level 2	710	71
Guaranteed investment contracts ⁽³⁾	Level 2	—	34
		936	254
Investments valued using NAV per share ⁽⁴⁾			
Domestic, developed and emerging markets equity funds		315	55
Fixed income funds ⁽⁵⁾		99	219
Hedge funds ⁽⁶⁾		—	7
Multi-asset funds ⁽⁷⁾		40	1
Real estate funds ⁽⁸⁾		—	30
		454	312
Other assets and liabilities, net ⁽⁹⁾		(30)	—
Total Investments		\$ 1,360	\$ 566

⁽¹⁾ Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities.

⁽²⁾ The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2. As of December 31, 2024 and December 31, 2023, approximately 30% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds.

⁽³⁾ The guaranteed investment contracts ("GICs") represent contracts with insurance companies measured at the cash surrender value of each contract. The Level 2 valuation reflects that the cash surrender value is based principally on a referenced pool of investment funds with active redemption.

⁽⁴⁾ Investments that are measured at fair value using net asset value ("NAV") per share as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the value of the underlying investments owned, minus its liabilities, divided by the number of shares outstanding. There are no unfunded commitments related to these investments. Redemption notice period primarily ranges from 0-3 months and redemption frequency windows range from daily to quarterly.

⁽⁵⁾ Fixed income funds primarily invest in U.S. government and investment grade corporate bonds.

⁽⁶⁾ Consists of investments in underlying hedge fund strategies that are primarily implemented through the use of long and short equity and fixed income securities and derivative instruments such as futures and options.

⁽⁷⁾ Multi-asset funds primarily invest across a variety of asset classes, including global stocks and bonds, as well as alternative strategies.

⁽⁸⁾ Real estate is valued using the NAV per unit of funds that are invested in real estate property. The investment value of the real estate property is determined quarterly using independent market appraisals as determined by the investment manager.

⁽⁹⁾ This category primarily includes unsettled trades for investments purchased and sold and interest receivables.

Equity securities in the U.S. defined benefit retirement plans did not include any investment in the Company's common stock at either December 31, 2024 or December 31, 2023. No shares of the Company's stock were purchased by the U.S. plans in 2024 or 2023. The plans received no dividends on the Company's common stock in either 2024 or 2023.

Other Retiree Benefits

The Company and certain of its subsidiaries provide, to the extent not otherwise provided by government-sponsored plans, health and life insurance benefits or subsidies for retired employees who meet applicable eligibility requirements.

The Company uses a December 31 measurement date for its defined benefit and other retiree benefit plans. Summarized information for the Company's defined benefit and other retiree benefit plans is as follows:

	Pension Plans				Other Retiree Benefit Plans	
	2024	2023	2024	2023	2024	2023
	United States		International			
Change in Benefit Obligations						
Benefit obligations at beginning of year	\$ 1,922	\$ 1,673	\$ 776	\$ 675	\$ 665	\$ 658
Service cost	1	—	16	15	7	7
Interest cost	99	91	33	33	36	38
Participants' contributions	—	—	5	5	—	—
Plan amendments	—	—	—	—	—	(33)
Actuarial loss (gain)	(54)	36	(11)	65	(14)	38
Foreign exchange impact	—	—	(40)	29	(8)	4
Termination benefits	5	3	—	2	—	—
Curtailments and settlements	(1)	—	(18)	(6)	—	—
Benefit payments	(141)	(148)	(41)	(42)	(54)	(47)
ERISA litigation matter	—	267	—	—	—	—
Benefit obligations at end of year	\$ 1,831	\$ 1,922	\$ 720	\$ 776	\$ 632	\$ 665
Change in Plan Assets						
Fair value of plan assets at beginning of year	\$ 1,360	\$ 1,363	\$ 566	\$ 516	\$ —	\$ —
Actual return on plan assets	49	115	18	26	—	—
Company contributions	29	30	37	39	54	47
Participants' contributions	—	—	5	5	—	—
Foreign exchange impact	—	—	(31)	27	—	—
Settlements and acquisitions	(2)	—	(17)	(5)	—	—
Benefit payments	(141)	(148)	(41)	(42)	(54)	(47)
Fair value of plan assets at end of year	\$ 1,295	\$ 1,360	\$ 537	\$ 566	\$ —	\$ —
Funded Status						
Benefit obligations at end of year	\$ 1,831	\$ 1,922	\$ 720	\$ 776	\$ 632	\$ 665
Fair value of plan assets at end of year	1,295	1,360	537	566	—	—
Net amount recognized	\$ (536)	\$ (562)	\$ (183)	\$ (210)	\$ (632)	\$ (665)
Amounts Recognized in Balance Sheet						
Noncurrent assets	\$ 1	\$ 1	\$ 47	\$ 48	\$ —	\$ —
Current liabilities	(27)	(28)	(15)	(15)	(51)	(53)
Noncurrent liabilities	(510)	(535)	(215)	(243)	(581)	(612)
Net amount recognized	\$ (536)	\$ (562)	\$ (183)	\$ (210)	\$ (632)	\$ (665)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)						
Actuarial loss	\$ 710	\$ 767	\$ 174	\$ 177	\$ 109	\$ 128
Transition/prior service cost(credit)	—	—	8	9	(159)	(180)
	\$ 710	\$ 767	\$ 182	\$ 186	\$ (50)	\$ (52)
Accumulated benefit obligation	\$ 1,818	\$ 1,907	\$ 668	\$ 719	\$ —	\$ —
	Pension Plans				Other Retiree Benefit Plans	
	2024	2023	2024	2023	2024	2023
	United States		International			
Weighted-Average Assumptions Used to Determine Benefit Obligations						
Discount rate	5.73 %	5.40 %	4.69 %	4.35 %	5.74 %	5.37 %
Long-term rate of compensation increase	3.50 %	3.50 %	3.36 %	3.19 %	— %	— %
ESOP growth rate	— %	— %	— %	— %	6.00 %	6.00 %
Medical cost trend rate of increase	— %	— %	— %	— %	7.00 %	6.00 %
Interest Crediting Rate	5.58 %	4.99 %	3.23 %	1.13 %	— %	— %

The actuarial gains recorded during 2024 for both the U.S. pension and Other retiree benefit plans were primarily a result of an increase in discount rates applied against future estimated benefit payments that resulted in a decrease in the benefit obligation for both the U.S. pension and Other retiree benefit plans. The actuarial losses recorded during 2023 for both the U.S. pension and Other retiree benefit plans were primarily a result of a decrease in discount rates applied against future estimated benefit payments that resulted in an increase in the benefit obligation for both the U.S. pension and Other retiree benefit plans.

The overall investment objective of the plans is to balance risk and return so that obligations to employees are met. The Company evaluates its expected long-term rate of return on plan assets on an annual basis. In determining the expected long-term rate of return, the Company considers the nature of the plans' investments and the historical rates of return. The assumed expected long-term rate of return on plan assets for U.S. pension plans was 6.50% as of December 31, 2024 and December 31, 2023. Average annual rates of return on plan assets for the U.S. pension plans for the most recent 1-year, 5-year, 10-year, 15-year and 25-year periods were 5%, 2%, 4%, 6% and 5%, respectively. Similar assessments were performed in determining rates of return on international pension plan assets to arrive at the Company's 2024 weighted-average expected long-term rate of return on plan assets of 5.69%.

The medical cost trend rate of increase assumed in measuring the expected cost of benefits is projected to decrease from 7.00% in 2025 to 5.00% by 2030, remaining at 4.50% for the years thereafter.

Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following:

	2024	2023
Benefit Obligation Exceeds Fair Value of Plan Assets		
Projected benefit obligation	\$ 2,251	\$ 2,352
Fair value of plan assets	1,486	1,532
Accumulated benefit obligation	2,075	2,204
Fair value of plan assets	1,345	1,428

Other Retiree Benefit plans with accumulated postretirement benefit obligation in excess of plan assets as of December 31 consisted of the following:

	2024	2023
Benefit Obligation Exceeds Fair Value of Plan Assets		
Accumulated postretirement benefit obligation	\$ 632	\$ 665
Fair value of plan assets	—	—

Summarized information regarding the net periodic benefit costs for the Company's defined benefit and other retiree benefit plans is as follows:

	Pension Plans						Other Retiree Benefit Plans		
	2024	2023	2022	2024	2023	2022	2024	2023	2022
	United States			International					
Components of Net Periodic Benefit Cost									
Service cost	\$ 1	\$ —	\$ —	\$ 16	\$ 15	\$ 15	\$ 7	\$ 7	\$ 18
Interest cost	99	91	64	33	33	21	36	38	36
Expected return on plan assets	(85)	(79)	(101)	(29)	(25)	(21)	—	—	—
Amortization of transition and prior service costs (credits)	—	—	—	1	1	1	(21)	(20)	(6)
Amortization of actuarial loss	39	43	46	5	5	7	4	1	14
Net periodic benefit cost	\$ 54	\$ 55	\$ 9	\$ 26	\$ 29	\$ 23	\$ 26	\$ 26	\$ 62
Other postretirement charges	5	3	13	—	2	4	—	—	2
ERISA litigation matter	—	267	—	—	—	—	—	—	—
Total pension cost	\$ 59	\$ 325	\$ 22	\$ 26	\$ 31	\$ 27	\$ 26	\$ 26	\$ 64
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost									
Discount rate	5.40 %	5.66 %	2.98 %	4.61 %	4.75 %	2.10 %	5.37 %	5.67 %	3.06 %
Expected long-term rate of return on plan assets	6.50 %	6.25 %	5.70 %	5.69 %	4.66 %	2.72 %	N/A	N/A	N/A
Long-term rate of compensation increase	3.50 %	3.50 %	3.50 %	3.24 %	3.22 %	2.89 %	— %	— %	— %
ESOP growth rate	— %	— %	— %	— %	— %	— %	6.00 %	6.00 %	6.00 %
Medical cost trend rate of increase	— %	— %	— %	— %	— %	— %	6.00 %	6.25 %	6.00 %
Interest Crediting Rate	4.99 %	5.21 %	2.82 %	0.64 %	2.28 %	0.84 %	— %	— %	— %

The service related component of pension and other postretirement benefit costs is included in Operating profit. The non-service related components (interest cost, expected return on assets, amortization of transition and prior service costs and credits and amortization of actuarial gains and losses) are included in the line item "Non-service related postretirement costs," which is below Operating profit.

The Company made no voluntary contributions in 2024, 2023 and 2022.

Expected Contributions and Benefit Payments

At present, the Company does not expect to make any voluntary contributions to its U.S. postretirement plans for the year ending December 31, 2025. Actual funding may differ from current estimates depending on the variability of the market value of the assets, changes in the benefit obligations and other market or regulatory conditions.

Benefit payments expected to be paid from the Company's assets to participants in unfunded plans are estimated to be approximately \$95 for the year ending December 31, 2025.

Total benefit payments expected to be paid to participants in both funded and unfunded plans are estimated as follows:

Years Ended December 31,	Pension Plans		Other Retiree Benefit Plans	Total
	United States	International		
2025	\$ 377	\$ 42	\$ 52	471
2026	143	41	54	238
2027	143	43	55	241
2028	142	45	55	242
2029	141	46	55	242
2030-2034	653	247	274	1,174

XML 39 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended Dec. 31, 2024

[Income Tax Disclosure \[Abstract\]](#) [Income Taxes](#)

Income Taxes

The components of Income before income taxes are as follows for the years ended December 31:

	2024	2023	2022
United States	\$ 1,084	\$ 692	\$ 1,169
International	2,872	2,700	1,491
Total Income before income taxes	\$ 3,956	\$ 3,392	\$ 2,660

The Provision for income taxes consists of the following for the years ended December 31:

	2024	2023	2022
United States	\$ 188	\$ 72	\$ 199
International	719	865	494
Total Provision for income taxes	\$ 907	\$ 937	\$ 693

Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in the current provision for taxes being higher (lower) than the total provision for income taxes as follows:

	2024	2023	2022
Goodwill and intangible assets	\$ 3	\$ 1	\$ 106
Property, plant and equipment	12	(13)	2
Pension and other retiree benefits	(6)	68	(1)
Stock-based compensation	(14)	2	(3)
Right-of-use assets/lease liabilities	2	1	(5)
Tax credits and tax loss carryforwards, net of valuation allowance	37	29	8
Deferred withholding tax	(14)	7	8
Research and Experimentation Capitalization	21	29	58
Other, net	(8)	11	(10)
Total deferred tax benefit (provision)	\$ 33	\$ 135	\$ 163

The difference between the statutory U.S. federal income tax rate and the Company's global effective tax rate as reflected in the Consolidated Statements of Income is as follows:

	2024	2023	2022
Percentage of Income before income taxes			
Tax at United States statutory rate	21.0 %	21.0 %	21.0 %
State income taxes, net of federal benefit	0.5	(0.1)	0.8
Earnings taxed at other than United States statutory rate	4.1	5.4	5.4
Non-deductible goodwill impairment charges	—	—	1.9
Foreign-derived intangible income benefit	(2.6)	(2.4)	(2.6)
Foreign tax matter	—	3.7	—
Other, net	(0.1)	—	(0.4)
Effective tax rate	22.9 %	27.6 %	26.1 %

The components of deferred tax assets (liabilities) are as follows at December 31:

	2024	2023
Deferred tax liabilities:		
Goodwill and intangible assets	\$ (389)	\$ (412)
Property, plant and equipment	(397)	(420)
Right-of-use assets	(126)	(126)
Deferred withholding tax	(110)	(96)
Other	(130)	(34)
Total deferred tax liabilities	(1,152)	(1,088)
Deferred tax assets:		
Pension and other retiree benefits	272	295
Tax credits and tax loss carryforwards	430	356
Lease liabilities	137	134
Accrued liabilities	223	221
Stock-based compensation	61	75
Research and Experimentation Capitalization	108	87
Other	101	60
Total deferred tax assets	1,332	1,228
Valuation Allowance	\$ (328)	\$ (287)
Net deferred tax assets	\$ 1,004	\$ 941
Net deferred income taxes	\$ (148)	\$ (147)

The changes in valuation allowance for deferred tax assets are as follows:

	2024	2023	2022
Balance, January 1	\$ 287	\$ 129	\$ 120
Additions			
Charged to costs and expenses	56	158	14
Deductions	15	—	5
Balance, December 31	\$ 328	\$ 287	\$ 129

As of December 31, 2024, the Company had net operating losses ("NOLs") and capital loss carryforwards of \$37. Of this amount, capital loss and NOL carryforwards of \$6 will begin to expire in 2025 and NOLs of \$13 can be carried forward indefinitely. The Company believes that it will be able to utilize these capital loss and NOL carryforwards. There is an additional NOL of \$18 which has a full valuation allowance.

As of December 31, 2024, the Company has \$393 of tax credits, of which \$66 will begin to expire in 2030 and \$17 can be carried forward indefinitely. The Company believes that it will be able to utilize these tax credits. The remaining credits of \$310 have a full valuation allowance.

Applicable U.S. income and foreign withholding taxes have been provided on substantially all of the Company's accumulated earnings of foreign subsidiaries.

Net tax expense of \$55, net tax benefit of \$19 and net tax expense of \$164 were recorded directly through equity in 2024, 2023 and 2022 respectively. The net tax expense or benefit in each year predominantly includes current and future tax impacts related to benefit plans and the impact of currency translation adjustments.

The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return.

Unrecognized tax benefits activity for the years ended December 31, 2024, 2023 and 2022 is summarized below:

	2024	2023	2022
Unrecognized tax benefits:			
Balance, January 1	\$ 314	\$ 298	\$ 245
Increases as a result of tax positions taken during the current year	37	73	32
Decreases of tax positions taken during prior years	(53)	(61)	(21)
Increases of tax positions taken during prior years	10	6	46
Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations	(3)	(2)	(2)
Effect of foreign currency rate movements	(9)	—	(2)
Balance, December 31	\$ 296	\$ 314	\$ 298

If all of the unrecognized tax benefits for 2024 above were recognized, approximately \$286 would impact the effective tax rate. It is reasonably possible that the amount of unrecognized benefits with respect to our uncertain tax positions could change in the next twelve months and such change may or may not be material.

The Company recognized expenses of approximately \$22, \$10 and \$8 for interest and penalties related to the above unrecognized tax benefits within income tax expense in 2024, 2023 and 2022, respectively. The Company had accrued interest and penalties of approximately \$68, \$45 and \$40 as of December 31, 2024, 2023 and 2022, respectively.

In the third quarter of 2023, the Internal Revenue Service (the "IRS") issued a notice giving taxpayers temporary relief from the effects of certain U.S. tax regulations that were issued in December 2021, which place greater restrictions on foreign taxes that are creditable against U.S. taxes on foreign-source income. This notice allowed taxpayers to defer the application of these new regulations through the end of 2023. In December 2023, the IRS issued further guidance modifying this temporary relief period to the date that a notice or other guidance withdrawing or modifying the temporary relief is issued. The Company will recognize the impact, if any, in the period in which the temporary relief is withdrawn or modified.

During the quarter ended June 30, 2023, the Company reassessed with its legal and tax advisers certain tax deductions taken in prior years by one of our subsidiaries and concluded that it was more likely than not that the deductions would not be sustained by the courts in that jurisdiction. The value of the tax deductions was not material to the Company in any year in which they were taken. The cumulative effect of the change in tax position of \$148 was reflected as a discrete item in the quarter ended June 30, 2023 income tax expense, partially offset by the reversal of certain prior years' withholding tax reserves of \$22 that were no longer required. The tax liability was paid in the quarter ended September 30, 2023.

On August 16, 2022, the Inflation Reduction Act of 2022 (the "IRA") was enacted, which among other things, implements a 15% minimum tax on book income of certain large corporations effective for

years beginning after December 31, 2022. Based on the Company’s analysis, as well as guidance published by the IRS, the IRA, and in particular the 15% minimum tax, did not have an impact on the Company’s Consolidated Financial Statements. Subsequent to the aforementioned guidance published by the IRS, on September 12, 2024, the U.S. Treasury Department and IRS released proposed regulations relating to this 15% minimum tax. Based on the Company’s analysis, these proposed regulations, if finalized in their current form, are not expected to have an impact on the Company’s Consolidated Financial Statements. However, the Company will continue to evaluate any additional guidance and clarification that becomes available.

Additionally, on December 15, 2022, the 27 member states of the European Union (“EU”) reached an agreement on a minimum level of taxation for certain large corporations to pay a minimum corporate tax rate of 15% in every jurisdiction in which they operate. This agreement, which is known as the Minimum Tax Directive (part of the “Pillar II Model Rules”), was supposed to be transposed into the laws of all EU member states by December 31, 2023. Most member states complied, while some were granted extensions of time. In addition, many other jurisdictions outside the EU have implemented a similar minimum tax regime consistent with the policy of the Pillar II Model Rules. Detailed regulations of these minimum tax regimes are still being considered in certain countries and, in some cases, enactment and timing is still uncertain. Based on current legislation and available guidance, apart from a significant additional compliance burden, Pillar II did not have a material impact as of December 31, 2024 and the Company does not believe it will have a material impact on its Consolidated Financial Statements. However, as these rules and related regulations are revised and implemented, the Company will evaluate the impact, if any, on its Consolidated Financial Statements.

The Company has ongoing federal, state and international income tax audits in various jurisdictions and evaluates uncertain tax positions that may be challenged by local tax authorities and not fully sustained. All U.S. federal income tax returns through December 31, 2013 have been audited by the IRS and there are limited matters which the Company plans to appeal for years 2010 through 2013. One such matter relates to the IRS assessment of taxes on the Company by imputing income on certain activities within one of our international operations, which is also under audit for the years 2014 through 2018. There were U.S. Tax Court rulings during 2023 in favor of the IRS against unrelated third parties on similar matters. Despite the U.S. Tax Court rulings, the Company continues to believe that the tax assessment against the Company is without merit. While there can be no assurances, the Company believes this matter will ultimately be decided in favor of the Company. The amount of tax plus interest for the years 2010 through 2018 is estimated to be approximately \$153, which is not included in the Company’s uncertain tax positions. In May 2024, the IRS initiated an audit for the years 2019 through 2021.

The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.

[XML 40 R20.htm IDEA: XBRL DOCUMENT](#)

Earnings Per Share

**12 Months Ended
Dec. 31, 2024**

[Earnings Per Share](#)

[\[Abstract\]](#)

[Earnings Per Share](#)

Earnings Per Share

For the years ended December 31, 2024, 2023 and 2022, earnings per share were as follows:

	2024			2023			2022		
	Net income attributable to Colgate-Palmolive Company	Shares (millions)	Per Share	Net income attributable to Colgate-Palmolive Company	Shares (millions)	Per Share	Net income attributable to Colgate-Palmolive Company	Shares (millions)	Per Share
Basic EPS	\$ 2,889	819.1	\$ 3.53	\$ 2,300	827.4	\$ 2.78	\$ 1,785	836.4	\$ 2.13
Stock options and restricted stock units		4.1			1.8			2.4	
Diluted EPS	\$ 2,889	823.2	\$ 3.51	\$ 2,300	829.2	\$ 2.77	\$ 1,785	838.8	\$ 2.13

Basic earnings per common share is computed by dividing net income available for common stockholders by the weighted-average number of shares of common stock outstanding for the period.

Diluted earnings per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding stock options and restricted stock units.

For the years ended December 31, 2024, 2023 and 2022, the average number of stock options that were anti-dilutive and not included in diluted earnings per share calculations were 295,968, 13,719,286 and 5,236,371, respectively. For the years ended December 31, 2024, 2023 and 2022, the average number of restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 100,191, 1,183 and 155,118, respectively.

[XML 41 R21.htm IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies

**12 Months Ended
Dec. 31, 2024**

[Commitments and Contingencies](#)

[Disclosure \[Abstract\]](#)

[Commitments and Contingencies](#)

[Commitments and Contingencies](#)

Commitments and Contingencies

As of December 31, 2024, the Company has various contractual commitments for future multi-year purchases of raw, packaging and other materials and services totaling approximately \$568.

As a global company serving consumers in more than 200 countries and territories, the Company is routinely subject to a wide variety of legal proceedings. These include disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. In addition, management proactively reviews and monitors the Company’s exposure to, and the impact of, environmental matters. The Company is party to various environmental matters and, as such, may be responsible for all or a portion of the cleanup, restoration and post-closure monitoring of several sites.

The Company establishes accruals for loss contingencies when it has determined that a loss is probable and that the amount of loss, or range of loss, can be reasonably estimated. Any such accruals are adjusted thereafter as appropriate to reflect changes in circumstances.

The Company also determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that a loss is reasonably possible and it is able to determine such estimates. For those matters disclosed below for which the amount of any potential losses can be reasonably estimated, the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is \$0 to approximately \$250 (based on current exchange rates). The estimates included in this amount are based on the Company’s analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate range may not represent the ultimate loss to the Company. Thus, the Company’s exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above.

Based on current knowledge, management does not believe that the ultimate resolution of loss contingencies arising from the matters discussed herein will have a material effect on the Company’s consolidated financial position or its ongoing results of operations or cash flows. However, in light of the inherent uncertainties noted above, an adverse outcome in one or more matters could be material to the Company’s results of operations or cash flows for any particular quarter or year.

Brazilian Matters

There are certain tax and civil proceedings outstanding, as described below, related to the Company’s 1995 acquisition of the Kolynos oral care business from Wyeth (the “Seller”).

The Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company’s Brazilian subsidiary for certain years in connection with the financing of the Kolynos acquisition. The tax assessments with interest, penalties and any court-mandated fees, at the current exchange rate, are approximately \$93. This amount includes additional assessments received from the Brazilian internal revenue authority in April 2016 relating to net operating loss carryforwards used by the Company’s Brazilian subsidiary to offset taxable income that had also been deducted from the authority’s original assessments. The Company has been disputing the disallowances by appealing the assessments since October 2001.

In each of September 2015, February 2017, September 2018, April 2019 and August 2020, the Company lost an administrative appeal and subsequently challenged these assessments in the Brazilian federal courts. Currently, there are three lawsuits pending in the Lower Federal Court and two cases have progressed to the Federal Court of Appeals. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the disallowances and that the Company should ultimately prevail. The Company is challenging these disallowances vigorously. In November 2023, based upon changes in Brazilian tax law, the Company filed petitions in three of the actions requesting that the penalty portion of the claim be removed. The Brazilian tax authority agreed with the Company’s position and in August 2024 reduced its claim in two of those actions and in October 2024 reduced its claim in the third.

In July 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda. (the Brazilian subsidiary of the Seller) and the Company, as represented by its Brazilian subsidiary, in the 6th. Lower Federal Court in the City of São Paulo, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller’s Brazilian subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company’s Brazilian subsidiary jointly and severally liable for any tax due from the Seller’s Brazilian subsidiary. The case has been pending since 2002, and the Lower Federal Court has not issued a decision. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the action and that the Company should ultimately prevail. The Company is challenging this action vigorously.

In December 2005, the Brazilian internal revenue authority issued to the Company’s Brazilian subsidiary a tax assessment with interest, penalties and any court-mandated fees of approximately \$47, at the current exchange rate, based on a claim that certain purchases of U.S. Treasury bills by the subsidiary and their subsequent disposition during the period 2000 to 2001 were subject to a tax on foreign exchange transactions. The Company had been disputing the assessment within the internal revenue authority’s administrative appeals process. However, in November 2015, the Superior Chamber of Administrative Tax Appeals denied the Company’s final administrative appeal, and the Company has filed a lawsuit in the Brazilian federal court. In the event the Company is unsuccessful in this lawsuit, further appeals are available within the Brazilian federal courts. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the tax assessment and that the Company should ultimately prevail. The Company is challenging this assessment vigorously. In addition, in April 2024, based upon changes in Brazilian tax law, the Company filed a petition in this matter requesting that the penalty portion of the claim be removed. The Brazilian tax authority has not yet responded to that petition.

Talcum Powder Matters

The Company has been named as a defendant in civil actions alleging that certain of its talcum powder products were contaminated with asbestos and/or caused mesothelioma and other cancers. Many of these actions involve a number of co-defendants from a variety of different industries, including suppliers of asbestos and manufacturers of products that, unlike the Company’s products, were designed to contain asbestos.

As of December 31, 2024, there were 309 individual cases pending against the Company in state and federal courts throughout the United States, as compared to 279 cases as of December 31, 2023. During the year ended December 31, 2024, 142 new cases were filed and 111 cases were resolved by voluntary dismissal, settlement or dismissal by the court, and one case was removed from the case count when it was established that the claim does not relate to talcum powder. The value of the settlements in the periods presented was not material, either individually or in the aggregate, to such periods’ results of operations. During the three months ended March 31, 2024, one case resulted in a jury verdict in favor of the Company after a trial. Subsequently, the trial court granted plaintiffs’ motion for a new trial in that case. However, during the three months ended September 30, 2024, an appellate court granted the Company’s request to reinstate the jury’s verdict in favor of the Company. Plaintiffs are challenging that ruling and separately are appealing other issues related to the verdict.

A significant portion of the Company’s costs incurred in defending and resolving these claims has been, and the Company believes that a portion of the costs will continue to be, covered by insurance policies issued by several primary, excess and umbrella insurance carriers, subject to deductibles, exclusions, retentions, policy limits and insurance carrier insolvencies.

While the Company and its legal counsel believe that the Company has strong legal grounds to contest these cases and intends to challenge them vigorously, there can be no assurances regarding the ultimate resolution of these matters.

ERISA Matter

In June 2016, a lawsuit was filed in the United States District Court for the Southern District of New York (the “District Court”) against the Retirement Plan, the Company and certain individuals (the “Company Defendants”) claiming that residual annuity payments associated with a 2005 residual annuity amendment to the Retirement Plan were improperly calculated for certain Retirement Plan participants in violation of ERISA. The relief sought included recalculation of benefits, pre- and post-judgment interest and attorneys’ fees. This action was certified as a class action in July 2017. In July 2020, the District Court dismissed certain claims, and in August 2020 granted the plaintiffs’ motion for summary judgment on the remaining claims. In September 2020, the Company appealed to the Second Circuit. In March 2023, the Second Circuit affirmed the grant of summary judgment to the plaintiffs.

In light of the Second Circuit decision, the Company recorded a charge to earnings of \$267 in the quarter ended March 31, 2023, which is comprised of the recalculation of benefits and interest. Possible additional charges associated with this matter are expected to be immaterial and, where estimable, are reflected in the range of reasonably possible losses disclosed above. The decision resulted in an increase in the obligations of the Retirement Plan, which based on the current funded status of the Retirement Plan and depending on further developments in the litigation, may require a cash contribution by the Company in 2025. In June 2023, the Company filed a petition for certiorari to the United States Supreme Court requesting permission for an appeal to that court and that petition was denied in October 2023. Also, in June 2023, the plaintiffs filed a motion to enter a revised final judgment in the District Court to address certain unresolved calculation issues, which the Company opposed. In March 2024, the District Court granted the plaintiffs' motion and found for the plaintiffs on those calculation issues. The Company has appealed that decision to the Second Circuit.

[XML 42 R22.htm IDEA: XBRL DOCUMENT](#)

Segment Information

[Segment Reporting](#)
[\[Abstract\]](#)
[Segment Information](#)

Segment Information

The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition.

The operations of the Oral, Personal and Home Care product segment are managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

In connection with management changes, the Company realigned the reporting structure of its skin health business effective July 1, 2024. Accordingly, commencing with the quarter ended September 30, 2024, the results of the skin health business previously reported within the Europe reportable operating segment are reported with the other skin health businesses in the North America reportable operating segment, with no impact on the Company's consolidated results of operations or financial position. The Company has recast its historical geographic segment information to conform to the new reporting structure.

The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of operating segment performance because it excludes the impact of Corporate-driven decisions related to interest expense and income taxes. The Chairman of the Board, President and Chief Executive Officer has been determined to be the Company's Chief Operating Decision Maker who uses Operating Profit to assess performance and to allocate resources for each of the reportable operating segments in the budgeting and forecasting process. Asset information by segment is not utilized for purposes of assessing performance or allocating resources, and therefore such information has not been presented.

The accounting policies of the operating segments are generally the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany sales have been eliminated. Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets. The Company reports these items within Corporate operations as they relate to Corporate-based responsibilities and decisions and are not included in the internal measures of segment operating performance used by the Company to measure the underlying performance of the operating segments.

Approximately two-thirds of the Company's Net sales are generated from markets outside the U.S., with approximately 45% of the Company's Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). Oral, Personal and Home Care sales to Walmart, Inc. and its affiliates represent approximately 11% of the Company's Net sales in each of the years 2024, 2023 and 2022. No other customer represented more than 10% of Net sales in any period presented.

In 2024, Corporate Operating profit included charges resulting from the 2022 Global Productivity Initiative of \$85. In 2023, Corporate Operating profit included charges resulting from the 2022 Global Productivity Initiative of \$27 and product recall costs of \$25. In 2022, Corporate Operating profit included goodwill and intangible assets impairment charges of \$721, charges resulting from the 2022 Global Productivity Initiative of \$95, a gain on the sale of land in Asia Pacific of \$47 and acquisition-related costs of \$19.

	2024				
	Net sales	Cost of Sales	Selling, general and administrative expenses	Other (income) expense, net ⁽³⁾	Operating Profit
Reportable Segments					
Oral, Personal and Home Care					
North America ⁽¹⁾	\$ 4,113	\$ 1,571	\$ 1,668	\$ 36	\$ 839
Latin America	4,782	1,933	1,328	(5)	1,526
Europe	2,770	1,050	1,031	31	658
Asia Pacific	2,858	1,078	997	(30)	812
Africa/Eurasia	1,095	432	395	16	253
Total Oral, Personal and Home Care	15,618				4,088
Pet Nutrition ⁽²⁾	4,483	1,869	1,641	8	965
Reconciliation with Total Company Operating Profit					
Corporate					(784)
Total	\$ 20,101				\$ 4,268

Note: Table may not sum due to rounding.

⁽¹⁾ Net sales in the U.S. for Oral, Personal and Home Care were \$3,640 in 2024.

⁽²⁾ Net sales in the U.S. for Pet Nutrition were \$3,059 in 2024.

⁽³⁾ Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net.

	2023				
	Net sales	Cost of Sales	Selling, general and administrative expenses	Other (income) expense, net ⁽³⁾	Operating Profit
Reportable Segments					
Oral, Personal and Home Care					
North America ⁽¹⁾	\$ 4,091	\$ 1,588	\$ 1,594	\$ 37	\$ 871
Latin America	4,640	1,977	1,241	5	1,417
Europe	2,571	1,069	899	31	573
Asia Pacific	2,782	1,108	925	(18)	767
Africa/Eurasia	1,083	442	377	9	254
Total Oral, Personal and Home Care	15,167				3,882
Pet Nutrition ⁽²⁾	4,290	1,964	1,493	26	806
Reconciliation with Total Company Operating Profit					
Corporate					\$ (704)
Total	\$ 19,457				\$ 3,984

Note: Table may not sum due to rounding.

⁽¹⁾ Net sales in the U.S. for Oral, Personal and Home Care were \$3,625 in 2023.

⁽²⁾ Net sales in the U.S. for Pet Nutrition were \$2,918 in 2023.

⁽³⁾ Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net.

	2022				
	Net sales	Cost of Sales	Selling, general and administrative expenses	Other (income) expense, net ⁽³⁾	Operating Profit
Reportable Segments					
Oral, Personal and Home Care					
North America ⁽¹⁾	\$ 4,002	\$ 1,649	\$ 1,567	\$ 46	\$ 741
Latin America	3,982	1,885	1,059	(71)	1,108
Europe	2,362	1,023	778	28	534
Asia Pacific	2,826	1,160	954	(24)	737
Africa/Eurasia	1,082	447	389	18	228
Total Oral, Personal and Home Care	14,254				3,348
Pet Nutrition ⁽²⁾	3,713	1,569	1,287	7	850
Reconciliation with Total Company Operating Profit					
Corporate					\$ (1,305)
Total	\$ 17,967				\$ 2,893

Note: Table may not sum due to rounding.

⁽¹⁾ Net sales in the U.S. for Oral, Personal and Home Care were \$3,511 in 2022.

⁽²⁾ Net sales in the U.S. for Pet Nutrition were \$2,432 in 2022.

⁽³⁾ Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net.

	2024		2023		2022	
Capital expenditures						
Oral, Personal and Home Care						
North America	\$	52	\$	46	\$	66
Latin America		126		146		121
Europe		63		44		31
Asia Pacific		64		65		60
Africa/Eurasia		12		10		30
Total Oral, Personal and Home Care		317		311		308
Pet Nutrition		143		301		297
Corporate		101		93		91
Total Capital expenditures	\$	561	\$	705	\$	696

	2024		2023		2022	
Depreciation and amortization						
Oral, Personal and Home Care						
North America	\$	124	\$	116	\$	128
Latin America		100		98		93
Europe		65		65		68
Asia Pacific		81		84		89
Africa/Eurasia		8		9		9
Total Oral, Personal and Home Care		378		372		387
Pet Nutrition		132		101		65
Corporate		95		94		93
Total Depreciation and amortization	\$	605	\$	567	\$	545

	2024	2023
Long-lived assets⁽¹⁾		
United States	\$ 2,728	\$ 2,733
International	2,223	2,340
Total Long-lived assets	<u>\$ 4,951</u>	<u>\$ 5,073</u>

⁽¹⁾ Long-lived assets include Property, plant and equipment, net and lease right-of-use assets.

[XML 43 R23.htm IDEA: XBRL DOCUMENT](#)

Leases
[Leases \[Abstract\]](#)
[Leases](#)

**12 Months Ended
Dec. 31, 2024**

Leases

The Company enters into leases for land, office space, warehouses and equipment. A number of the leases include one or more options to renew the lease terms, purchase the leased property or terminate the lease. The exercise of these options is at the Company's discretion and is therefore recognized on the balance sheet when it is reasonably certain the Company will exercise such options. As the Company's leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date.

Substantially all of the Company's leases are considered operating leases. Finance leases were not material as of December 31, 2024 and 2023.

As of December 31, 2024 and 2023, the Company's right-of use assets and liabilities for operating leases were as follows:

	2024	2023
Other assets	\$ 529	\$ 491
Other accruals	107	95
Other liabilities	456	420
Total operating lease liabilities	<u>\$ 563</u>	<u>\$ 515</u>

Lease liabilities for operating leases as of December 31, 2024 were as follows:

2025	\$ 126
2026	108
2027	101
2028	80
2029	58
Thereafter	182
Total lease commitments	<u>\$ 655</u>
Less: Interest	(92)
Present value of lease liabilities	<u>\$ 563</u>

The components of the Company's operating lease cost for the twelve months ended December 31, 2024 and 2023 were as follows:

	2024	2023
Operating lease cost	\$ 144	\$ 136
Short-term lease cost	3	3
Variable lease cost	19	20
Sublease Income	(2)	(2)
Total lease cost	<u>\$ 164</u>	<u>\$ 157</u>

Short-term lease cost represents the Company's cost with respect to leases with a duration of 12 months or less and is not reflected on the Company's Consolidated Balance Sheets. Variable lease costs are comprised of costs, such as the Company's proportionate share of actual costs for utilities, common area maintenance, property taxes and insurance, that are not included in the lease liability and are recognized in the period in which they are incurred.

Supplemental cash flow information related to operating leases for the twelve months ended December 31, 2024 and 2023 was as follows:

- Payments against amounts included in the measurement of lease liabilities: \$132 and \$171, respectively
- Lease assets obtained in exchange for lease liabilities: \$141 and \$139, respectively.

As of December 31, 2024 and 2023, the weighted-average remaining lease term for operating leases was 7 and 8 years, respectively, and the weighted-average discount rate for operating leases was 4.4% and 4.5%, respectively.

There were no material operating leases that the Company had entered into or that were yet to commence as of December 31, 2024.

[XML 44 R24.htm IDEA: XBRL DOCUMENT](#)

Supplier Finance Program
[Other Liabilities Disclosure \[Abstract\]](#)
[Supplier Finance Program](#)

**12 Months Ended
Dec. 31, 2024**

Supplier Finance Program

The Company has agreements to provide supplier finance programs which facilitate participating suppliers' ability to finance payment obligations of the Company with designated third-party financial institutions. Participating suppliers may, at their sole discretion, elect to finance one or more payment obligations of the Company prior to their scheduled due dates at a discounted price to participating financial institutions. The Company's obligations to its suppliers, including amounts due and scheduled payment dates, are not impacted by suppliers' decisions to finance amounts under these arrangements. The outstanding payment obligations under the Company's supplier finance programs are included in Accounts Payable in the Consolidated Balance Sheets and were not material as of December 31, 2024 or 2023.

[XML 45 R25.htm IDEA: XBRL DOCUMENT](#)

Supplemental Income Statement Information
[Supplemental Income Statement Elements \[Abstract\]](#)
[Supplemental Income Statement Information](#)

**12 Months Ended
Dec. 31, 2024**

	2024	2023	2022
Other (income) expense, net			
Amortization of intangible assets	\$ 75	\$ 72	\$ 80
Equity income	(22)	(17)	(12)
2022 Global Productivity Initiative	59	24	90
Product recall costs	—	25	—
Losses (gains) from marketable securities and other assets	6	11	(22)
Indirect tax payments (refunds)	27	18	(14)
Gain on the sale of land in Asia Pacific	—	—	(47)
Acquisition-related costs	—	—	19
Other, net	19	58	(25)
Total Other (income) expense, net	<u>\$ 164</u>	<u>\$ 191</u>	<u>\$ 69</u>
	2024	2023	2022
Research and development	\$ 355	\$ 343	\$ 320
Advertising	\$2,720	\$2,371	\$1,997

[XML 46 R26.htm IDEA: XBRL DOCUMENT](#)

Supplemental Balance Sheet Information
[Balance Sheet Related Disclosures \[Abstract\]](#)
[Supplemental Balance Sheet Information](#)

**12 Months Ended
Dec. 31, 2024**

Supplemental Balance Sheet Information

Inventories by major class are as follows at December 31:

	2024	2023
Inventories		
Raw materials and supplies	\$ 631	\$ 606
Work-in-process	46	46
Finished goods	1,431	1,411
Total Inventories, net	<u>\$ 2,108</u>	<u>\$ 2,063</u>
Non-current inventory, net	(121)	(129)
Current Inventories, net	<u>\$ 1,987</u>	<u>\$ 1,934</u>

Inventories valued under LIFO amounted to \$453 and \$471 at December 31, 2024 and 2023, respectively. The excess of current cost over LIFO cost at the end of each year was \$105 and \$120, respectively. The liquidations of LIFO inventory quantities had no material effect on income in 2024, 2023 and 2022. Inventory classified as non-current at December 31, 2024 was recorded on the Consolidated Balance Sheets as "Other assets."

Property, plant and equipment, net	2024	2023
Land	\$ 226	\$ 227
Buildings	2,056	2,047
Manufacturing machinery and equipment	6,265	6,365
Other equipment	1,580	1,647
	10,127	10,286
Accumulated depreciation	(5,705)	(5,704)
Total Property, plant and equipment, net	\$ 4,422	\$ 4,582

Other current assets	2024	2023
Marketable securities	\$ 160	\$ 179
Prepays	520	595
Derivatives	33	19
Total Other current assets	\$ 713	\$ 793

Other accruals	2024	2023
Accrued advertising and consumer and trade promotions	\$ 912	\$ 882
Accrued payroll and employee benefits	437	403
Accrued taxes other than income taxes	162	167
Restructuring accrual	15	11
Pension and other retiree benefits	93	96
Lease liabilities due in one year	107	95
Accrued interest	72	78
Derivatives	23	26
Dividend payable	408	—
Other	662	619
Total Other accruals	\$ 2,891	\$ 2,377

Other liabilities	2024	2023
Pension and other retiree benefits	\$ 1,306	\$ 1,390
Long-term lease liabilities	456	420
Restructuring accrual	29	—
Other	320	305
Total Other liabilities	\$ 2,111	\$ 2,115

[XML 47 R27.htm IDEA: XBRL DOCUMENT](#)

Supplemental Other Comprehensive Income (Loss) Information

[Equity \[Abstract\]](#)

[Supplemental Other Comprehensive Income \(Loss\) Information](#)

12 Months Ended

Dec. 31, 2024

Supplemental Other Comprehensive Income (Loss) Information

Other comprehensive income (loss) components attributable to Colgate-Palmolive Company before tax and net of tax during the years ended December 31 were as follows:

	2024	2023	2022
Cumulative translation adjustments:			
Cumulative translation adjustments, pre-tax	\$ (298)	\$ 127	\$ (113)
Tax amounts	(37)	13	(29)
Cumulative translation adjustments, net of tax	(335)	140	(142)
Pension and other benefits:			
Net actuarial gain (loss), prior service costs and settlements during the period	31	(49)	466
Amortization of net actuarial loss, transition and prior service costs ⁽¹⁾	28	30	62
Retirement Plan and other retiree benefit adjustments, pre-tax	59	(19)	528
Tax amounts	(16)	3	(115)
Retirement Plan and other retiree benefit adjustments, net of tax	43	(16)	413
Cash flow hedges:			
Gains (losses) on cash flow hedges, pre-tax	10	(10)	80
Tax amounts	(2)	3	(20)
Gains (losses) on cash flow hedges, net of tax	8	(7)	60
Total Other comprehensive income (loss), net of tax	\$ (284)	\$ 117	\$ 331

⁽¹⁾ These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details.

There were no tax impacts on Other comprehensive income (loss) attributable to Noncontrolling interests.

Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income (loss) is comprised of cumulative foreign currency translation gains and losses, unrecognized pension and other retiree benefit costs and unrealized gains and losses from derivative instruments designated as cash flow hedges. At December 31, 2024 and 2023, Accumulated other comprehensive income (loss) consisted primarily of aftertax unrecognized pension and other retiree benefit costs of \$605 and \$647, respectively, and aftertax cumulative foreign currency translation losses of \$3,687 and \$3,351, respectively. Foreign currency translation adjustments in 2024 primarily reflect losses from the Euro, Brazilian Real and Mexican Peso. Foreign currency translation adjustments in 2023 primarily reflect gains from the Euro, Mexican Peso and Brazilian Real.

[XML 48 R28.htm IDEA: XBRL DOCUMENT](#)

Pay vs Performance Disclosure - USD (\$) \$ in Millions

[Pay vs Performance Disclosure](#)

Net Income (Loss)	\$ 2,889	\$ 2,300	\$ 1,785

[XML 49 R29.htm IDEA: XBRL DOCUMENT](#)

Insider Trading Arrangements 3 Months Ended Dec. 31, 2024

[Trading Arrangements, by Individual](#)

Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

[XML 50 R30.htm IDEA: XBRL DOCUMENT](#)

Insider Trading Policies and Procedures 12 Months Ended Dec. 31, 2024

[Insider Trading Policies and Procedures \[Line Items\]](#)

Insider Trading Policies and Procedures Adopted	true

[XML 51 R31.htm IDEA: XBRL DOCUMENT](#)

Cybersecurity Risk Management and Strategy Disclosure

[Cybersecurity Risk Management, Strategy, and Governance \[Line Items\]](#)

[Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats \[Text Block\]](#)

12 Months Ended

Dec. 31, 2024

Management's Role in Assessing and Managing Cybersecurity Risk; Processes for assessing, identifying and managing material risks from cybersecurity threats

We have a systematic and thorough risk management process, which is designed to identify, assess, prioritize and mitigate the risks that could negatively impact achievement of our strategic and operating objectives. A key component of this process is our Enterprise Risk Management ("ERM") Committee, which is led by our Chairman, President and Chief Executive Officer, and includes our Chief Financial Officer, Chief Legal Officer, Chief Information Officer and other members of senior management. The ERM Committee monitors both current and emerging risks facing the Company and meets at least quarterly to review the prioritization of identified risks. The ERM Committee has identified cybersecurity as a critical risk facing the Company. Each of the most critical risks identified is assigned to a member of senior management who oversees the management, mitigation and presentation of the risk to the senior leadership team and throughout the year to our Board of Directors. The risks relating to information technology, including cybersecurity, are overseen by our Chief Information Officer. Our Chief Information Officer then assigns the risks within the Information Technology risk category to others on his team. The cybersecurity risk is managed and overseen by our Chief Information Security Officer ("CISO"), who reports to our Chief Information Officer. Cybersecurity as a risk is presented to the full ERM Committee annually or more frequently as needed.

We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats. Our Chief Information Officer reports to our Group President, Growth and Strategy, a member of our senior leadership team who reports to our Chairman of the Board, President and Chief Executive Officer.

Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized

worldwide, enabling him to guide his organization to protect the Company’s systems and information.

Our Chief Information Officer joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.

The Company’s information security organization seeks to employ cybersecurity best practices, including implementing new technologies to proactively identify and monitor new vulnerabilities and reduce risk, conducting due diligence of third-party vendors’ information security programs, maintaining security policies and standards and regularly updating and testing our response planning and protocols. The information security organization also works in partnership with our Internal Audit function to identify cybersecurity risks and review cybersecurity-related internal controls with third parties as part of the overall internal controls process. The information security organization also gains valuable information to improve our threat and risk awareness capabilities as a member of an industry information sharing and analysis organization, which provides strategic and tactical information sharing channels. Additionally, employees are provided mandatory cybersecurity awareness training on an annual basis, which includes information about how to identify and report cybersecurity concerns and incidents. The information security organization also conducts phishing simulations and testing scenarios through tabletop exercises and assessment activities, to help ensure compliance with our cyber policies and procedures. We maintain a cybersecurity insurance policy and have retained relevant incident response services. Additionally, we maintain an offensive security team that works both independently and with third party cybersecurity professionals to conduct security assessments of our enterprise-wide cybersecurity practices, including penetration testing, and identify areas for continuous improvement within the information security program. The Company is a member of the Retail and Hospitality Information Sharing and Analysis Center, which provides additional intelligence associated with threats pertaining to our industry.

We maintain a Data Security Incident Response Plan (the “Plan”), which outlines the processes and procedures that we should follow to respond to, remediate and resolve a security incident involving a potential or actual compromise of our proprietary information and/or personal information. It also describes the structure, roles and responsibilities of personnel involved in responding to such incidents and provides a process for alerting senior management of such incidents. The Plan is reviewed on an annual basis and revised as necessary.

Our dedicated information security organization leverages various frameworks for managing cybersecurity risks, including the National Institute of Standards and Technology (“NIST”) framework. The key pillars of the NIST framework are to (i) develop an organizational understanding to manage cybersecurity risk to systems, people, assets, data and capabilities; (ii) develop and implement appropriate safeguards to ensure delivery of critical services; (iii) develop and implement appropriate activities to identify the occurrence of a cybersecurity event; (iv) develop and implement appropriate activities to maintain plans for resilience and to restore any capabilities or services that were impaired due to a cybersecurity incident; and (v) develop appropriate activities to action an incident.

We have a comprehensive third party cybersecurity risk review process, which prioritizes, monitors and assesses the risks associated with our third party service provider interactions. The third party service provider assessment framework follows industry standard practices and allows us to properly understand the risk associated with the services provided which are key to our company’s daily operations.

For additional information regarding risks faced by the Company from cybersecurity threats, see Item 1A, “Risk Factors - A cybersecurity incident, data breach or a failure of key technology systems could adversely impact our business.”

[Cybersecurity Risk Management Processes Integrated \[Flag\]](#)

true

[Cybersecurity Risk Management Processes Integrated \[Text Block\]](#)

We have a systematic and thorough risk management process, which is designed to identify, assess, prioritize and mitigate the risks that could negatively impact achievement of our strategic and operating objectives. A key component of this process is our Enterprise Risk Management (“ERM”) Committee, which is led by our Chairman, President and Chief Executive Officer, and includes our Chief Financial Officer, Chief Legal Officer, Chief Information Officer and other members of senior management.

[Cybersecurity Risk Management Third Party Engaged \[Flag\]](#)

true

[Cybersecurity Risk Third Party Oversight and Identification Processes \[Flag\]](#)

true

[Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant \[Flag\]](#)

false

[Cybersecurity Risk Board of Directors Oversight \[Text Block\]](#)

Our Board of Directors is focused on cybersecurity. Specific responsibility for cybersecurity oversight is delegated to the Audit Committee. The Board oversees our risk management process to ensure it is properly designed, well-functioning and consistent with our overall corporate strategy. Our Audit Committee oversees the ERM process and the implementation of appropriate risk monitoring and management systems, though all Board members attend Audit Committee meetings and participate in risk management discussions.

Our Board of Directors has adopted a written statement, known as the Independent Board Candidate Qualifications and made available on our website, outlining the qualities sought in our directors. This statement, which is refreshed periodically, is used by the Nominating, Governance and Corporate Responsibility Committee (“NGCR Committee”) to evaluate individual director candidates. The NGCR Committee has identified experience with overseeing and managing risk management processes, including with respect to cybersecurity, as being important to creating an effective, well-rounded and diverse Board. Directors with experience overseeing and managing risk management processes play a critical role in the Board’s oversight of our enterprise risk management process.

Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.

[Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight \[Text Block\]](#)

Specific responsibility for cybersecurity oversight is delegated to the Audit Committee.

[Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight \[Text Block\]](#)

Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.

[Cybersecurity Risk Role of Management \[Text Block\]](#)

We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats. Our Chief Information Officer reports to our Group President, Growth and Strategy, a member of our senior leadership team who reports to our Chairman of the Board, President and Chief Executive Officer.

Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company’s systems and information.

Our Chief Information Officer joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.

[Cybersecurity Risk Management Positions or Committees Responsible \[Flag\]](#)

true

[Cybersecurity Risk Management Positions or Committees Responsible \[Text Block\]](#)

Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.

[Cybersecurity Risk Management Expertise of Management Responsible \[Text Block\]](#)

Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company’s systems and information.

Our Chief Information Officer joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.

[Cybersecurity Risk Process for Informing Management or Committees Responsible \[Text Block\]](#)

We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats.

[Cybersecurity Risk Management Positions or Committees Responsible Report to Board \[Flag\]](#)

true

[XML 52-R32.htm IDEA: XBRL DOCUMENT](#)

Summary of Significant Accounting Policies (Policies)
[Accounting Policies](#)

12 Months Ended

Dec. 31, 2024

[Abstract]	
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of Colgate-Palmolive Company and its majority-owned or controlled subsidiaries. Intercompany transactions and balances have been eliminated. The Company’s investments in consumer products companies with interests ranging between 20% and 50%, where the Company has significant influence over the investee, are accounted for using the equity method. Net income (loss) from such investments is recorded in Other (income) expense, net in the Consolidated Statements of Income. As of December 31, 2024 and 2023, equity method investments included in Other assets in the Consolidated Balance Sheets were \$81 and \$83, respectively. Unrelated third parties hold the remaining ownership interests in these investments. Investments with less than a 20% interest are recorded at cost and periodically adjusted based on observable price changes or quoted market prices in active markets, if applicable. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Company’s assumptions and estimates involved in preparing the financial statements includes pension and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. Additionally, the Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments and retirement plan assets. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. Actual results could ultimately differ from those estimates.
Use of Estimates	Revenue Recognition The Company’s revenue contracts represent a single performance obligation to sell its products to trade customers. Sales are recorded at the time control of the products is transferred to trade customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the products. Control is the ability of trade customers to “direct the use of” and “obtain the benefit from” our products. In evaluating the timing of the transfer of control of products to trade customers, the Company considers several control indicators, including significant risks and rewards of products, the Company’s right to payment and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to trade customers. Net sales reflect the transaction prices for contracts, which include units shipped at selling list prices reduced by variable consideration. Variable consideration includes expected sales returns and the cost of current and continuing promotional programs. Current promotional programs primarily include product listing allowances and co-operative advertising arrangements. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements. The cost of promotional programs is estimated using the expected value method considering all reasonably available information, including the Company’s historical experience and its current expectations, and is reflected in the transaction price when sales are recorded. Adjustments to the cost of promotional programs in subsequent periods are generally not material, as the Company’s promotional programs are typically of short duration, thereby reducing the uncertainty inherent in such estimates. Sales returns are generally accepted at the Company’s discretion and are not material to the Company’s Consolidated Financial Statements. The Company’s contracts with trade customers do not have significant financing components or non-cash consideration and the Company does not have unbilled revenue or significant amounts of prepayments from customers. The Company records Net sales excluding taxes collected on its sales to its trade customers. Shipping and handling activities are accounted for as contract fulfillment costs and classified as Selling, general and administrative expenses.
Revenue Recognition	Shipping and Handling Costs Shipping and handling costs (also referred to as logistics costs) are classified as Selling, general and administrative expenses and were \$1,777, \$1,771 and \$1,874 for the years ended December 31, 2024, 2023 and 2022, respectively. Marketing Costs The Company markets its products through advertising and other promotional activities. Advertising costs are included in Selling, general and administrative expenses and are expensed as incurred. Certain consumer and trade promotional programs, such as consumer coupons, are recorded as a reduction of sales. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Inventories The cost of approximately 75% of inventories is determined using the FIFO method, which is stated at the lower of cost or net realizable value. The cost of the remaining inventories, in the U.S. and Mexico, is determined using the LIFO method, which is stated at the lower of cost or market. Inventories in excess of one year of forecasted sales are classified in the Consolidated Balance Sheets as non-current “Other assets.” Property, Plant and Equipment Land, buildings and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over the estimated useful lives ranging from 3 to 15 years for machinery and equipment and up to 40 years for buildings. Depreciation attributable to manufacturing operations is included in Cost of sales. The remaining component of depreciation is included in Selling, general and administrative expenses. Goodwill and Other Intangibles Goodwill and indefinite-life intangible assets, such as the Company’s global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate that an asset may be impaired. In assessing impairment, the Company performs either a quantitative or a qualitative analysis. Determining the fair value of the Company’s reporting units for goodwill and the fair value of its intangible assets requires significant estimates and judgments by management. When a quantitative analysis is performed, the Company generally uses the income approach, which requires several estimates, including future cash flows consistent with management’s strategic plans, sales growth rates and the selection of royalty rates and discount rates. The Company generally engages a third-party valuation firm to assist in determining the fair value of intangible assets acquired in business combinations. As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reporting structure realignment, the Company completed an assessment indicating no goodwill impairment was required. Refer to Note 13, Segment Information for additional information. Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit.
Marketing Costs	Income Taxes The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes.
Cash and Cash equivalents	Financial Instruments Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company’s derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows. The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company’s derivative instruments and other financial instruments are more fully described in Note 6, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations. Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period. The Company uses the Black-Scholes-Merton (“Black-Scholes”) option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company’s stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans.
Inventories	Currency Translation The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders’ equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year. For subsidiaries operating in highly inflationary environments, local currency-denominated non-monetary assets, including inventories, goodwill and property, plant and equipment, are remeasured at their historical exchange rates, while local currency-denominated monetary assets and liabilities are remeasured at year-end exchange rates. Remeasurement adjustments for these operations are included in Net income attributable to Colgate-Palmolive Company. Recent Accounting Pronouncements and Disclosure Rules In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2024-04, “Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments.” This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Company’s Consolidated Financial Statements. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrants’ registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-08, “Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets.” This ASU improves the accounting for certain crypto assets by requiring companies to measure them at fair value for each reporting period with changes in fair value recognized in net income. This guidance is effective for the Company for fiscal years beginning after December 15, 2024 and is not expected to have an impact on the Company’s Consolidated Financial Statements. In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information for additional information. In October 2023, the FASB issued ASU No. 2023-06, “Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.” This ASU modified the
Property, Plant and Equipment	
Goodwill and Other Intangibles	
Income Taxes	
Financial Instruments	
Stock-Based Compensation	
Currency Translation	
Recent Accounting Pronouncements	

disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC's regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements.

In August 2023, the FASB issued ASU No. 2023-05, "Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement." This ASU requires a joint venture to initially measure all contributions received upon its formation at fair value. This guidance is applicable to joint ventures with a formation date on or after January 1, 2025 and is not expected to have a material impact on the Company's Consolidated Financial Statements.

In March 2023, the FASB issued ASU No. 2023-01, "Leases (Topic 842): Common Control Arrangements." This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Company's Consolidated Financial Statements.

In September 2022, the FASB issued ASU No. 2022-04, "Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations." This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programs' key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated roll-forward information. The Company adopted the guidance beginning on January 1, 2023, and with respect to the roll-forward information disclosure, beginning on January 1, 2024.

Reclassifications

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

[XML 53 R33.htm IDEA: XBRL DOCUMENT](#)

Nature of Operations
(Tables)

12 Months Ended
Dec. 31, 2024

Organization, Consolidation and Presentation of Financial
Statements [Abstract]

Percentage of Worldwide Sales

The Company's principal classes of products accounted for the following percentages of worldwide Net sales for the past three years:

	2024		2023		2022
Oral Care	43	%	42	%	43
Personal Care	18	%	19	%	19
Home Care	17	%	17	%	17
Pet Nutrition	22	%	22	%	21
Total	100	%	100	%	100

[XML 54 R34.htm IDEA: XBRL DOCUMENT](#)

Restructuring and
Related
Implementation
Charges (Tables)

12 Months Ended
Dec. 31, 2024

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs

Over the course of the 2022 Global Productivity Initiative, the Company incurred total pretax charges of \$228 (\$186 aftertax) in connection with the implementation of various projects as follows:

	Total Program Charges as of December 31, 2024	
Employee-Related Costs	\$	175
Incremental Depreciation		13
Asset Impairments		1
Other		39
Total	\$	228

For the twelve months ended December 31, 2024 and December 31, 2023, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows:

	Twelve Months Ended December 31,	
	2024	2023
Gross Profit	\$	20
Selling, general and administrative expenses		6
Other (income) expense, net		59
Non-service related postretirement costs		—
Total 2022 Global Productivity Initiative charges, pretax	\$	85
		\$
Total 2022 Global Productivity Initiative charges, aftertax	\$	73
		\$

The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals:

	Twelve Months Ended December 31,					
	Employee-Related Costs	Incremental Depreciation	Asset Impairments	Other		Total
Balance at December 31, 2022	\$	30	\$	—	\$	1
Charges		24		—		8
Cash Payments		(45)		—		(10)
Charges against assets		(5)		(1)		—
Foreign exchange		6		—		—
Balance at December 31, 2023	\$	10	\$	—	\$	1
Charges		49		13		23
Cash Payments		(20)		—		(14)
Charges against assets		—		(13)		—
Foreign exchange		(5)		—		—
Balance at December 31, 2024	\$	34	\$	—	\$	10

Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments:

	Twelve Months Ended December 31,		Total Program Charges
	2024	2023	
North America ⁽¹⁾	3	15	9
Latin America	—	—	9
Europe ⁽¹⁾	89	19	44
Asia Pacific	—	20	7
Africa/Eurasia	—	5	6
Hill's Pet Nutrition	6	23	11
Corporate	2	18	14
Total	100	100	100

⁽¹⁾ The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. See Note 13, Segment Information for additional details.

[XML 55 R35.htm IDEA: XBRL DOCUMENT](#)

Goodwill and Other
Intangible Assets
(Tables)

12 Months Ended
Dec. 31, 2024

Goodwill and Intangible Assets

Disclosure [Abstract]

Schedule of Goodwill by Segment

The changes in net carrying value of Goodwill by segment for the years ended December 31, 2024 and 2023 were as follows:

	Beginning Balance		2023 Foreign currency translation		Ending Balance	
Oral, Personal and Home Care						
North America	\$	906	\$	2	\$	908
Latin America		168		11		179
Europe		1,504		67		1,571
Asia Pacific		179		—		179
Africa/Eurasia		107		(19)		88
Total Oral, Personal and Home Care		2,864		61		2,925
Pet Nutrition		488		(3)		485
Total Goodwill	\$	3,352	\$	58	\$	3,410

	Beginning Balance		2024 Reallocation ⁽¹⁾		Foreign currency translation		Ending Balance	
Oral, Personal and Home Care								
North America	\$	908	\$	223	\$	(23)	\$	1,108
Latin America		179		—		(34)		145
Europe		1,571		(223)		(67)		1,281
Asia Pacific		179		—		(1)		178
Africa/Eurasia		88		—		(10)		78
Total Oral, Personal and Home Care		2,925		—		(135)		2,790
Pet Nutrition		485		—		(3)		482
Total Goodwill	\$	3,410	\$	—	\$	(138)	\$	3,272

⁽¹⁾ As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reallocation of the goodwill, the Company completed an assessment indicating no goodwill impairment was required as a result of this segment reporting structure realignment. Refer to Note 13, Segment Information for additional information.

Other intangible assets as of December 31, 2024 and 2023 were comprised of the following:

Schedule of Finite and Indefinite
Lived Intangible Assets By Major
Class

	2024			2023		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Trademarks - finite life	\$ 1,135	\$ (545)	\$ 590	\$ 1,167	\$ (519)	\$ 648
Other finite life intangible assets	603	(385)	218	624	(363)	261
Indefinite life intangible assets	948	—	948	978	—	978
Total Other intangible assets	\$ 2,686	\$ (930)	\$ 1,756	\$ 2,769	\$ (882)	\$ 1,887

[XML 56 R36.htm IDEA: XBRL DOCUMENT](#)

[Long-Term Debt and Credit Facilities \(Tables\)](#)
[Debt Disclosure \[Abstract\]](#)
[Schedule of Long-term Debt Instruments](#)

[Schedule of Short-Term Debt](#)

[Schedule of Maturities of Long-term Debt](#)

[XML 57 R37.htm IDEA: XBRL DOCUMENT](#)

[Fair Value Measurements and Financial Instruments \(Tables\)](#)
[Fair Value Disclosures \[Abstract\]](#)
[Schedule of Derivative Instruments](#)

[Schedule of Notional Amounts of Outstanding Derivative Positions](#)

[Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income \(Loss\)](#)

[XML 58 R38.htm IDEA: XBRL DOCUMENT](#)

[Capital Stock and Stock-Based Compensation Plans \(Tables\)](#)
[Share-Based Payment Arrangement \[Abstract\]](#)
[Schedule of Common and Treasury Stock Activity](#)

[Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions](#)

[Schedule of Share-based Compensation, Stock Options, Activity](#)

12 Months Ended
Dec. 31, 2024

Long-term debt consisted of the following at December 31:

	Average Weighted Interest Rate		Maturities		2024	2023
	2025	2028	2025	2028		
Notes	3.0%				\$ 6,946	\$ 7,580
Commercial paper	3.0%		2025		936	606
Finance Lease Obligations			Various		59	53
					7,941	8,239
Less: Current portion of long-term debt					(652)	(20)
Total					\$ 7,289	\$ 8,219

Debt payable within one year consisted of the following at December 31:

	2024	2023
Notes and loans payable	\$ 8	\$ 310
Current portion of long-term debt	652	20
Debt payable within one year	\$ 660	\$ 330

Excluding commercial paper, scheduled maturities of long-term debt and finance leases outstanding as of December 31, 2024, were as follows:

Years Ended December 31,	
2025	\$ 652
2026	1,035
2027	509
2028	612
2029	519
Thereafter	3,678
Total	\$ 7,005

12 Months Ended
Dec. 31, 2024

The following table summarizes the fair value of the Company’s derivative instruments and other financial instruments which are carried at fair value in the Company’s Consolidated Balance Sheets as of December 31, 2024 and 2023:

	Assets			Liabilities		
	Account	Fair Value		Account	Fair Value	
		December 31, 2024	December 31, 2023		December 31, 2024	December 31, 2023
Designated derivative instruments						
Foreign currency contracts	Other current assets	33	19	Other accruals	22	25
Commodity contracts	Other current assets	—	—	Other accruals	1	1
Total designated		\$ 33	\$ 19		\$ 23	\$ 26
Other financial instruments						
Marketable securities	Other current assets	160	179			
Total other financial instruments		\$ 160	\$ 179			

The following tables present the notional values as of:

	December 31, 2024			
	Foreign Currency Contracts	Foreign Currency Debt	Commodity Contracts	Total
Fair Value Hedges	\$ 1,669	\$ —	\$ —	\$ 1,669
Cash Flow Hedges	1,023	—	18	1,041
Net Investment Hedges	289	3,750	—	4,039

	December 31, 2023			
	Foreign Currency Contracts	Foreign Currency Debt	Commodity Contracts	Total
Fair Value Hedges	\$ 1,625	\$ —	\$ —	\$ 1,625
Cash Flow Hedges	869	—	39	908
Net Investment Hedges	280	3,908	—	4,188

The following table presents the amount of gain (loss) on net investment hedges recognized in the Company’s AOCI:

	Gain (Loss) Recognized in AOCI	
	Twelve Months Ended December 31,	
	2024	2023
Hedging instruments:		
Foreign currency contracts	\$ 42	\$ (34)
Foreign currency debt	211	(124)
Total gain (loss) on net investment hedges	\$ 253	\$ (158)

12 Months Ended
Dec. 31, 2024

A summary of common stock and treasury stock activity for the three years ended December 31 is as follows:

	Common Stock Outstanding	Treasury Stock
Balance, January 1, 2022	840,480,284	625,226,076
Common stock acquired	(17,060,788)	17,060,788
Shares issued for stock options	5,654,692	(5,654,692)
Shares issued for restricted stock units and other	1,138,418	(1,138,418)
Balance, December 31, 2022	830,212,606	635,493,754
Common stock acquired	(14,735,909)	14,735,909
Shares issued for stock options	5,318,430	(5,318,430)
Shares issued for restricted stock units and other	617,642	(617,642)
Balance, December 31, 2023	821,412,769	644,293,591
Common stock acquired	(18,321,422)	18,321,422
Shares issued for stock options	8,606,699	(8,606,699)
Shares issued for restricted stock units and other	876,652	(876,652)
Balance, December 31, 2024	812,574,698	653,131,662

The weighted-average fair value assumptions are summarized in the following table:

	2024	2023	2022
Expected term of options	6 years	6 years	6 years
Expected volatility rate	20.5 %	19.8 %	21.1 %
Risk-free interest rate	3.8 %	4.3 %	3.0 %
Expected dividend yield	2.1 %	2.5 %	2.4 %
Weighted-average estimated fair value	\$ 22.65	\$ 14.89	\$ 14.71

A summary of stock option activity during 2024 is presented below:

	Shares (in thousands)	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (in years)	Intrinsic Value of Unexercised In-the-Money Options
Options outstanding, January 1, 2024	20,742	\$ 75		
Granted	955	106		
Exercised	(8,662)	74		
Forfeited	(240)	76		
Expired	(21)	73		
Options outstanding, December 31, 2024	12,774	78	5	\$ 176
Options exercisable, December 31, 2024	9,265	\$ 76	4	\$ 136

[Schedule of Share-based Compensation, Performance Restricted Stock and Time-based Restricted Stock Units Activity](#)

A summary of performance-based restricted stock unit activity for the year ended December 31, 2024 is presented below:

	Shares (in thousands)	Weighted Average Grant Date Fair Value Per Award
Performance-based restricted stock units as of January 1, 2024	1,069	\$ 68
Activity:		
Granted	321	91
Vested	(283)	70
Forfeited	(89)	72
Change due to performance and/or market condition achievement	19	57
Performance-based restricted stock units as of December 31, 2024	1,037	\$ 74

A summary of restricted stock unit activity during 2024 is presented below:

	Shares (in thousands)	Weighted Average Grant Date Fair Value Per Award
Restricted stock units as of January 1, 2024	2,174	\$ 76
Activity:		
Granted	854	105
Vested	(951)	76
Forfeited	(90)	77
Restricted stock units as of December 31, 2024	1,987	\$ 88

[XML 59 R39.htm IDEA: XBRL DOCUMENT](#)

**Retirement Plans and
Other Retiree
Benefits (Tables)**

[Retirement Benefits \[Abstract\]](#)

[Schedule of Allocation of Plan
Assets](#)

12 Months Ended

Dec. 31, 2024

The target asset allocation for the Company's defined benefit plans is as follows:

Asset Category	United States	International
Equity securities	26 %	17 %
Fixed income securities	60 %	63 %
Other investments	14 %	20 %
Total	100 %	100 %

At December 31, 2024, the allocation of the Company's plan assets and the level of valuation input, as applicable, for each major asset category were as follows:

	Level of Valuation Input	Pension Plans	
		United States	International
Cash and cash equivalents	Level 1	\$ 226	\$ 21
U.S. common stocks	Level 1	1	2
International common stocks	Level 1	—	15
Pooled funds ⁽¹⁾	Level 1	35	103
Fixed income securities ⁽²⁾	Level 2	624	75
Guaranteed investment contracts ⁽³⁾	Level 2	—	30
		886	246
Investments valued using NAV per share ⁽⁴⁾			
Domestic, developed and emerging markets equity funds		223	28
Fixed income funds ⁽⁵⁾		68	222
Hedge funds ⁽⁶⁾		—	7
Multi-asset funds ⁽⁷⁾		157	2
Real estate funds ⁽⁸⁾		—	27
		448	286
Other assets and liabilities, net ⁽⁹⁾		(39)	5
Total Investments		\$ 1,295	\$ 537

At December 31, 2023, the allocation of the Company's plan assets and the level of valuation input, as applicable, for each major asset category were as follows:

	Level of Valuation Input	Pension Plans	
		United States	International
Cash and cash equivalents	Level 1	\$ 206	\$ 14
U.S. common stocks	Level 1	—	2
International common stocks	Level 1	—	20
Pooled funds ⁽¹⁾	Level 1	20	113
Fixed income securities ⁽²⁾	Level 2	710	71
Guaranteed investment contracts ⁽³⁾	Level 2	—	34
		936	254
Investments valued using NAV per share ⁽⁴⁾			
Domestic, developed and emerging markets equity funds		315	55
Fixed income funds ⁽⁵⁾		99	219
Hedge funds ⁽⁶⁾		—	7
Multi-asset funds ⁽⁷⁾		40	1
Real estate funds ⁽⁸⁾		—	30
		454	312
Other assets and liabilities, net ⁽⁹⁾		(30)	—
Total Investments		\$ 1,360	\$ 566

⁽¹⁾ Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities.

⁽²⁾ The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2. As of December 31, 2024 and December 31, 2023, approximately 30% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds.

⁽³⁾ The guaranteed investment contracts ("GICs") represent contracts with insurance companies measured at the cash surrender value of each contract. The Level 2 valuation reflects that the cash surrender value is based principally on a referenced pool of investment funds with active redemption.

⁽⁴⁾ Investments that are measured at fair value using net asset value ("NAV") per share as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the value of the underlying investments owned, minus its liabilities, divided by the number of shares outstanding. There are no unfunded commitments related to these investments. Redemption notice period primarily ranges from 0-3 months and redemption frequency windows range from daily to quarterly.

⁽⁵⁾ Fixed income funds primarily invest in U.S. government and investment grade corporate bonds.

⁽⁶⁾ Consists of investments in underlying hedge fund strategies that are primarily implemented through the use of long and short equity and fixed income securities and derivative instruments such as futures and options.

⁽⁷⁾ Multi-asset funds primarily invest across a variety of asset classes, including global stocks and bonds, as well as alternative strategies.

⁽⁸⁾ Real estate is valued using the NAV per unit of funds that are invested in real estate property. The investment value of the real estate property is determined quarterly using independent market appraisals as determined by the investment manager.

⁽⁹⁾ This category primarily includes unsettled trades for investments purchased and sold and interest receivables.

The Company uses a December 31 measurement date for its defined benefit and other retiree benefit plans. Summarized information for the Company's defined benefit and other retiree benefit plans is as follows:

[Schedule of Defined Benefit Plans
Disclosures](#)

	Pension Plans				Other Retiree Benefit Plans	
	2024	2023	2024	2023	2024	2023
	United States		International			
Change in Benefit Obligations						
Benefit obligations at beginning of year	\$ 1,922	\$ 1,673	\$ 776	\$ 675	\$ 665	\$ 658
Service cost	1	—	16	15	7	7
Interest cost	99	91	33	33	36	38
Participants' contributions	—	—	5	5	—	—
Plan amendments	—	—	—	—	—	(33)
Actuarial loss (gain)	(54)	36	(11)	65	(14)	38
Foreign exchange impact	—	—	(40)	29	(8)	4
Termination benefits	5	3	—	2	—	—
Curtailments and settlements	(1)	—	(18)	(6)	—	—
Benefit payments	(141)	(148)	(41)	(42)	(54)	(47)
ERISA litigation matter	—	267	—	—	—	—
Benefit obligations at end of year	\$ 1,831	\$ 1,922	\$ 720	\$ 776	\$ 632	\$ 665
Change in Plan Assets						
Fair value of plan assets at beginning of year	\$ 1,360	\$ 1,363	\$ 566	\$ 516	\$ —	\$ —
Actual return on plan assets	49	115	18	26	—	—
Company contributions	29	30	37	39	54	47
Participants' contributions	—	—	5	5	—	—
Foreign exchange impact	—	—	(31)	27	—	—
Settlements and acquisitions	(2)	—	(17)	(5)	—	—
Benefit payments	(141)	(148)	(41)	(42)	(54)	(47)
Fair value of plan assets at end of year	\$ 1,295	\$ 1,360	\$ 537	\$ 566	\$ —	\$ —
Funded Status						
Benefit obligations at end of year	\$ 1,831	\$ 1,922	\$ 720	\$ 776	\$ 632	\$ 665
Fair value of plan assets at end of year	1,295	1,360	537	566	—	—
Net amount recognized	\$ (536)	\$ (562)	\$ (183)	\$ (210)	\$ (632)	\$ (665)
Amounts Recognized in Balance Sheet						
Noncurrent assets	\$ 1	\$ 1	\$ 47	\$ 48	\$ —	\$ —
Current liabilities	(27)	(28)	(15)	(15)	(51)	(53)
Noncurrent liabilities	(510)	(535)	(215)	(243)	(581)	(612)
Net amount recognized	\$ (536)	\$ (562)	\$ (183)	\$ (210)	\$ (632)	\$ (665)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)						
Actuarial loss	\$ 710	\$ 767	\$ 174	\$ 177	\$ 109	\$ 128
Transition/prior service cost(credit)	—	—	8	9	(159)	(180)
	\$ 710	\$ 767	\$ 182	\$ 186	\$ (50)	\$ (52)
Accumulated benefit obligation	\$ 1,818	\$ 1,907	\$ 668	\$ 719	\$ —	\$ —

	Pension Plans				Other Retiree Benefit Plans	
	2024	2023	2024	2023	2024	2023
	United States		International			
Weighted-Average Assumptions Used to Determine Benefit Obligations						
Discount rate	5.73 %	5.40 %	4.69 %	4.35 %	5.74 %	5.37 %
Long-term rate of compensation increase	3.50 %	3.50 %	3.36 %	3.19 %	— %	— %
ESOP growth rate	— %	— %	— %	— %	6.00 %	6.00 %
Medical cost trend rate of increase	— %	— %	— %	— %	7.00 %	6.00 %
Interest Crediting Rate	5.58 %	4.99 %	3.23 %	1.13 %	— %	— %

Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following:			
Benefit Obligation Exceeds Fair Value of Plan Assets	2024		2023
Projected benefit obligation	\$	2,251	\$ 2,352
Fair value of plan assets		1,486	1,532
Accumulated benefit obligation		2,075	2,204
Fair value of plan assets		1,345	1,428

Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following:

	2024	2023
Benefit Obligation Exceeds Fair Value of Plan Assets		
Projected benefit obligation	\$ 2,251	\$ 2,352
Fair value of plan assets	1,486	1,532
Accumulated benefit obligation	2,075	2,204
Fair value of plan assets	1,345	1,428

Other Retiree Benefit plans with accumulated postretirement benefit obligation in excess of plan assets as of December 31 consisted of the following:

	2024	2023
Benefit Obligation Exceeds Fair Value of Plan Assets		
Accumulated postretirement benefit obligation	\$ 632	\$ 665
Fair value of plan assets	—	—

Summarized information regarding the net periodic benefit costs for the Company's defined benefit and other retiree benefit plans is as follows:

Components of Net Periodic Benefit Cost	Pension Plans						Other Retiree Benefit Plans											
	2023			2022	2023			2022	2024			2023	2022					
	United States				International													
Service cost	\$ 1	\$ —	\$ —	\$ 16	\$ 15	\$ 15	\$ 7	\$ 7	\$ 18									
Interest cost	99	91	64	33	33	21	36	38	36									
Expected return on plan assets	(85)	(79)	(101)	(29)	(25)	(21)	—	—	—									
Amortization of transition and prior service costs (credits)	—	—	—	1	1	1	(21)	(20)	(6)									
Amortization of actuarial loss	39	43	46	5	5	7	4	1	14									
Net periodic benefit cost	\$ 54	\$ 55	\$ 9	\$ 26	\$ 29	\$ 23	\$ 26	\$ 26	\$ 62									
Other postretirement charges	5	3	13	—	2	4	—	—	2									
ERISA litigation matter	—	267	—	—	—	—	—	—	—									
Total pension cost	\$ 59	\$ 325	\$ 22	\$ 26	\$ 31	\$ 27	\$ 26	\$ 26	\$ 64									
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost																		
Discount rate	5.40	%	5.66	%	2.98	%	4.61	%	4.75	%	2.10	%	5.37	%	5.67	%	3.06	%
Expected long-term rate of return on plan assets	6.50	%	6.25	%	5.70	%	5.69	%	4.66	%	2.72	%	N/A		N/A		N/A	
Long-term rate of compensation increase	3.50	%	3.50	%	3.50	%	3.24	%	3.22	%	2.89	%	—	%	—	%	—	%
ESOP growth rate	—	%	—	%	—	%	—	%	—	%	—	%	6.00	%	6.00	%	6.00	%
Medical cost trend rate of increase	—	%	—	%	—	%	—	%	—	%	—	%	6.00	%	6.25	%	6.00	%
Interest Crediting Rate	4.99	%	5.21	%	2.82	%	0.64	%	2.28	%	0.84	%	—	%	—	%	—	%

Total benefit payments expected to be paid to participants in both funded and unfunded plans are estimated as follows:

Years Ended December 31,	Pension Plans		Other Retiree Benefit Plans		Total
	United States	International			
2025	\$ 377	\$ 42	\$ 52		471
2026	143	41	54		238
2027	143	43	55		241
2028	142	45	55		242
2029	141	46	55		242
2030-2034	653	247	274		1,174

[XML 60 R40.htm IDEA: XBRL DOCUMENT](#)

Income Taxes (Tables)

[Income Tax Disclosure \[Abstract\]](#)

[Schedule of Components of Income Before Income Taxes](#)

12 Months Ended Dec. 31, 2024

The components of Income before income taxes are as follows for the years ended December 31:

	2024	2023	2022
United States	\$ 1,084	\$ 692	\$ 1,169
International	2,872	2,700	1,491
Total Income before income taxes	\$ 3,956	\$ 3,392	\$ 2,660

The Provision for income taxes consists of the following for the years ended December 31:

[Schedule of Provision for Income Taxes](#)

Schedule of Components of
Deferred Income Tax Benefit

	2024	2023	2022
United States	\$ 188	\$ 72	\$ 199
International	719	865	494
Total Provision for income taxes	\$ 907	\$ 937	\$ 693

Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in the current provision for taxes being higher (lower) than the total provision for income taxes as follows:

	2024	2023	2022
Goodwill and intangible assets	\$ 3	\$ 1	\$ 106
Property, plant and equipment	12	(13)	2
Pension and other retiree benefits	(6)	68	(1)
Stock-based compensation	(14)	2	(3)
Right-of-use assets/lease liabilities	2	1	(5)
Tax credits and tax loss carryforwards, net of valuation allowance	37	29	8
Deferred withholding tax	(14)	7	8
Research and Experimentation Capitalization	21	29	58
Other, net	(8)	11	(10)
Total deferred tax benefit (provision)	\$ 33	\$ 135	\$ 163

Schedule of Effective Tax Rate
Reconciliation

	2024	2023	2022
Percentage of Income before income taxes			
Tax at United States statutory rate	21.0 %	21.0 %	21.0 %
State income taxes, net of federal benefit	0.5	(0.1)	0.8
Earnings taxed at other than United States statutory rate	4.1	5.4	5.4
Non-deductible goodwill impairment charges	—	—	1.9
Foreign-derived intangible income benefit	(2.6)	(2.4)	(2.6)
Foreign tax matter	—	3.7	—
Other, net	(0.1)	—	(0.4)
Effective tax rate	22.9 %	27.6 %	26.1 %

Schedule of Components of
Deferred Tax Assets (Liabilities)

	2024	2023
The components of deferred tax assets (liabilities) are as follows at December 31:		
Deferred tax liabilities:		
Goodwill and intangible assets	\$ (389)	\$ (412)
Property, plant and equipment	(397)	(420)
Right-of-use assets	(126)	(126)
Deferred withholding tax	(110)	(96)
Other	(130)	(34)
Total deferred tax liabilities	(1,152)	(1,088)
Deferred tax assets:		
Pension and other retiree benefits	272	295
Tax credits and tax loss carryforwards	430	356
Lease liabilities	137	134
Accrued liabilities	223	221
Stock-based compensation	61	75
Research and Experimentation Capitalization	108	87
Other	101	60
Total deferred tax assets	1,332	1,228
Valuation Allowance	\$ (328)	\$ (287)
Net deferred tax assets	\$ 1,004	\$ 941
Net deferred income taxes	\$ (148)	\$ (147)

Schedule of Unrecognized Tax
Benefits Activity

	2024	2023	2022
The changes in valuation allowance for deferred tax assets are as follows:			
Balance, January 1	\$ 287	\$ 129	\$ 120
Additions			
Charged to costs and expenses	56	158	14
Deductions	15	—	5
Balance, December 31	\$ 328	\$ 287	\$ 129
Unrecognized tax benefits activity for the years ended December 31, 2024, 2023 and 2022 is summarized below:			
Unrecognized tax benefits:			
Balance, January 1	\$ 314	\$ 298	\$ 245
Increases as a result of tax positions taken during the current year	37	73	32
Decreases of tax positions taken during prior years	(53)	(61)	(21)
Increases of tax positions taken during prior years	10	6	46
Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations	(3)	(2)	(2)
Effect of foreign currency rate movements	(9)	—	(2)
Balance, December 31	\$ 296	\$ 314	\$ 298

~~XML 61-R41.htm-IDEA: XBRL DOCUMENT~~

Earnings Per Share
(Tables)

12 Months Ended
Dec. 31, 2024

Earnings Per Share
[Abstract]

Schedule of Earnings Per
Share, Basic and Diluted

For the years ended December 31, 2024, 2023 and 2022, earnings per share were as follows:

	2024			2023			2022		
	Net income attributable to Colgate-Palmolive Company	Shares (millions)	Per Share	Net income attributable to Colgate-Palmolive Company	Shares (millions)	Per Share	Net income attributable to Colgate-Palmolive Company	Shares (millions)	Per Share
Basic EPS	\$ 2,889	819.1	\$ 3.53	\$ 2,300	827.4	\$ 2.78	\$ 1,785	836.4	\$ 2.13
Stock options and restricted stock units		4.1			1.8			2.4	
Diluted EPS	\$ 2,889	823.2	\$ 3.51	\$ 2,300	829.2	\$ 2.77	\$ 1,785	838.8	\$ 2.13

~~XML 62-R42.htm-IDEA: XBRL DOCUMENT~~

Segment Information
(Tables)

12 Months Ended
Dec. 31, 2024

Segment Reporting [Abstract]

Net Sales and Operating Profit by
Segment

	2024				
	Net sales	Cost of Sales	Selling, general and administrative expenses	Other (income) expense, net ⁽³⁾	Operating Profit
Reportable Segments					
Oral, Personal and Home Care					
North America ⁽¹⁾	\$ 4,113	\$ 1,571	\$ 1,668	\$ 36	\$ 839
Latin America	4,782	1,933	1,328	(5)	1,526
Europe	2,770	1,050	1,031	31	658
Asia Pacific	2,858	1,078	997	(30)	812
Africa/Eurasia	1,095	432	395	16	253
Total Oral, Personal and Home Care	15,618				4,088
Pet Nutrition ⁽²⁾	4,483	1,869	1,641	8	965
Reconciliation with Total Company Operating Profit					
Corporate					(784)
Total	\$ 20,101				\$ 4,268

Note: Table may not sum due to rounding.

⁽¹⁾ Net sales in the U.S. for Oral, Personal and Home Care were \$3,640 in 2024.

⁽²⁾ Net sales in the U.S. for Pet Nutrition were \$3,059 in 2024.

⁽³⁾ Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net.

2023					
	Net sales	Cost of Sales	Selling, general and administrative expenses	Other (income) expense, net ⁽³⁾	Operating Profit
Reportable Segments					
Oral, Personal and Home Care					
North America ⁽¹⁾	\$ 4,091	\$ 1,588	\$ 1,594	\$ 37	\$ 871
Latin America	4,640	1,977	1,241	5	1,417
Europe	2,571	1,069	899	31	573
Asia Pacific	2,782	1,108	925	(18)	767
Africa/Eurasia	1,083	442	377	9	254
Total Oral, Personal and Home Care	15,167				3,882
Pet Nutrition ⁽²⁾	4,290	1,964	1,493	26	806
Reconciliation with Total Company Operating Profit					
Corporate					(704)
Total	\$ 19,457				\$ 3,984

Note: Table may not sum due to rounding.

⁽¹⁾ Net sales in the U.S. for Oral, Personal and Home Care were \$3,625 in 2023.

⁽²⁾ Net sales in the U.S. for Pet Nutrition were \$2,918 in 2023.

⁽³⁾ Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net.

2022					
	Net sales	Cost of Sales	Selling, general and administrative expenses	Other (income) expense, net ⁽³⁾	Operating Profit
Reportable Segments					
Oral, Personal and Home Care					
North America ⁽¹⁾	\$ 4,002	\$ 1,649	\$ 1,567	\$ 46	\$ 741
Latin America	3,982	1,885	1,059	(71)	1,108
Europe	2,362	1,023	778	28	534
Asia Pacific	2,826	1,160	954	(24)	737
Africa/Eurasia	1,082	447	389	18	228
Total Oral, Personal and Home Care	14,254				3,348
Pet Nutrition ⁽²⁾	3,713	1,569	1,287	7	850
Reconciliation with Total Company Operating Profit					
Corporate					(1,305)
Total	\$ 17,967				\$ 2,893

Note: Table may not sum due to rounding.

⁽¹⁾ Net sales in the U.S. for Oral, Personal and Home Care were \$3,511 in 2022.

⁽²⁾ Net sales in the U.S. for Pet Nutrition were \$2,432 in 2022

⁽³⁾ Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net.

	2024	2023	2022
Capital expenditures			
Oral, Personal and Home Care			
North America	\$ 52	\$ 46	\$ 66
Latin America	126	146	121
Europe	63	44	31
Asia Pacific	64	65	60
Africa/Eurasia	12	10	30
Total Oral, Personal and Home Care	317	311	308
Pet Nutrition	143	301	297
Corporate	101	93	91
Total Capital expenditures	\$ 561	\$ 705	\$ 696
Depreciation and amortization			
Oral, Personal and Home Care			
North America	\$ 124	\$ 116	\$ 128
Latin America	100	98	93
Europe	65	65	68
Asia Pacific	81	84	89
Africa/Eurasia	8	9	9
Total Oral, Personal and Home Care	378	372	387
Pet Nutrition	132	101	65
Corporate	95	94	93
Total Depreciation and amortization	\$ 605	\$ 567	\$ 545

	2024	2023
Long-lived assets⁽¹⁾		
United States	\$ 2,728	\$ 2,733
International	2,223	2,340
Total Long-lived assets	\$ 4,951	\$ 5,073

⁽¹⁾ Long-lived assets include Property, plant and equipment, net and lease right-of-use assets.

~~XML 63 R43.htm IDEA: XBRL DOCUMENT~~

Leases (Tables)

[Leases \[Abstract\]](#)

[Schedule of Right-of-use Assets and Liabilities for Operating Leases](#)

[Schedule of Operating Lease Liabilities](#)

[Schedule of Components of Operating Lease Expense](#)

~~XML 64 R44.htm IDEA: XBRL DOCUMENT~~

Supplemental Income

Statement

Information (Tables)

[Supplemental Income Statement Elements \[Abstract\]](#)

[Other \(income\) expense, net](#)

12 Months Ended

Dec. 31, 2024

Other (income) expense, net	2024	2023	2022
Amortization of intangible assets	\$ 75	\$ 72	\$ 80
Equity income	(22)	(17)	(12)
2022 Global Productivity Initiative	59	24	90
Product recall costs	—	25	—
Losses (gains) from marketable securities and other assets	6	11	(22)
Indirect tax payments (refunds)	27	18	(14)
Gain on the sale of land in Asia Pacific	—	—	(47)
Acquisition-related costs	—	—	19
Other, net	19	58	(25)
Total Other (income) expense, net	\$ 164	\$ 191	\$ 69
	2024	2023	2022
Research and development	\$ 355	\$ 343	\$ 320
Advertising	\$2,720	\$2,371	\$1,997

[Research and development and Advertising](#)

[XML 65 R45.htm IDEA: XBRL DOCUMENT](#)

Supplemental
Balance Sheet
Information (Tables)
[Balance Sheet Related Disclosures \[Abstract\]](#)
[Schedule of Inventories by Major Class](#)

12 Months Ended
Dec. 31, 2024

Inventories by major class are as follows at December 31:

Inventories	2024	2023
Raw materials and supplies	\$ 631	\$ 606
Work-in-process	46	46
Finished goods	1,431	1,411
Total inventories, net	\$ 2,108	\$ 2,063
Non-current inventory, net	(121)	(129)
Current inventories, net	\$ 1,987	\$ 1,934

[Schedule of Property, Plant and Equipment](#)

Property, plant and equipment, net	2024	2023
Land	\$ 226	\$ 227
Buildings	2,056	2,047
Manufacturing machinery and equipment	6,265	6,365
Other equipment	1,580	1,647
	10,127	10,286
Accumulated depreciation	(5,705)	(5,704)
Total Property, plant and equipment, net	\$ 4,422	\$ 4,582

[Schedule of Other Current Assets](#)

Other current assets	2024	2023
Marketable securities	\$ 160	\$ 179
Prepays	520	595
Derivatives	33	19
Total Other current assets	\$ 713	\$ 793

[Schedule of Other Accruals](#)

Other accruals	2024	2023
Accrued advertising and consumer and trade promotions	\$ 912	\$ 882
Accrued payroll and employee benefits	437	403
Accrued taxes other than income taxes	162	167
Restructuring accrual	15	11
Pension and other retiree benefits	93	96
Lease liabilities due in one year	107	95
Accrued interest	72	78
Derivatives	23	26
Dividend payable	408	—
Other	662	619
Total Other accruals	\$ 2,891	\$ 2,377

[Schedule of Other Liabilities](#)

Other liabilities	2024	2023
Pension and other retiree benefits	\$ 1,306	\$ 1,390
Long-term lease liabilities	456	420
Restructuring accrual	29	—
Other	320	305
Total Other liabilities	\$ 2,111	\$ 2,115

[XML 66 R46.htm IDEA: XBRL DOCUMENT](#)

Supplemental Other
Comprehensive
Income (Loss)
Information (Tables)
[Equity \[Abstract\]](#)
[Schedule of Comprehensive Income \(Loss\)](#)

12 Months Ended
Dec. 31, 2024

Other comprehensive income (loss) components attributable to Colgate-Palmolive Company before tax and net of tax during the years ended December 31 were as follows:

	2024	2023	2022
Cumulative translation adjustments:			
Cumulative translation adjustments, pre-tax	\$ (298)	\$ 127	\$ (113)
Tax amounts	(37)	13	(29)
Cumulative translation adjustments, net of tax	(335)	140	(142)
Pension and other benefits:			
Net actuarial gain (loss), prior service costs and settlements during the period	31	(49)	466
Amortization of net actuarial loss, transition and prior service costs ⁽¹⁾	28	30	62
Retirement Plan and other retiree benefit adjustments, pre-tax	59	(19)	528
Tax amounts	(16)	3	(115)
Retirement Plan and other retiree benefit adjustments, net of tax	43	(16)	413
Cash flow hedges:			
Gains (losses) on cash flow hedges, pre-tax	10	(10)	80
Tax amounts	(2)	3	(20)
Gains (losses) on cash flow hedges, net of tax	8	(7)	60
Total Other comprehensive income (loss), net of tax	\$ (284)	\$ 117	\$ 331

⁽¹⁾ These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details.

[XML 67 R47.htm IDEA: XBRL DOCUMENT](#)

Nature of Operations
(Details) - Sales
Revenue, Net -
Product
Concentration Risk

12 Months Ended

Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022

[Oral Care](#)

[Entity-Wide Information, Revenue from External Customer \[Line Items\]](#)

[Percent of net sales](#) 43.00% 42.00% 43.00%

[Personal Care](#)

[Entity-Wide Information, Revenue from External Customer \[Line Items\]](#)

[Percent of net sales](#) 18.00% 19.00% 19.00%

[Home Care](#)

[Entity-Wide Information, Revenue from External Customer \[Line Items\]](#)

[Percent of net sales](#) 17.00% 17.00% 17.00%

[Pet Nutrition](#)

[Entity-Wide Information, Revenue from External Customer \[Line Items\]](#)

[Percent of net sales](#) 22.00% 22.00% 21.00%

[Product](#)

[Entity-Wide Information, Revenue from External Customer \[Line Items\]](#)

[Percent of net sales](#) 100.00% 100.00% 100.00%

[XML 68 R48.htm IDEA: XBRL DOCUMENT](#)

Summary of

Accounting Policies [Abstract]		
Investments accounted for using the equity method, minimum interest	20.00%	
Investments accounted for using the equity method, maximum interest	50.00%	
Equity method investments included in other assets	\$ 81	\$ 83
Investments accounted for using the cost method, maximum interest	20.00%	
Approximate percentage of inventories determined using the first-in, first-out (FIFO) method	75.00%	

~~XML 69 R49.htm~~ ~~IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Property, Plant and Equipment [Line Items]			
Selling, general and administrative expenses	\$ 7,729	\$ 7,151	\$ 6,565
Minimum Machinery and equipment			

[Property, Plant and Equipment \[Line Items\]](#)

Estimated useful life	3 years
Maximum Machinery and equipment	

[Property, Plant and Equipment \[Line Items\]](#)

Estimated useful life	15 years
Maximum Buildings	

[Property, Plant and Equipment \[Line Items\]](#)

Estimated useful life	40 years
Shipping and Handling	

Property, Plant and Equipment [Line Items]			
Selling, general and administrative expenses	\$ 1,777	\$ 1,771	\$ 1,874

~~XML 70 R50.htm~~ ~~IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies - Goodwill and Other Intangibles (Details) - Local Brands, Trademarks, Customer Relationships, and Non-Compete Agreements	Dec. 31, 2024

Minimum	
Finite-Lived Intangible Assets [Line Items]	
Estimated useful life of finite-lived intangible assets	5 years
Maximum	
Finite-Lived Intangible Assets [Line Items]	
Estimated useful life of finite-lived intangible assets	40 years

~~XML 71 R51.htm~~ ~~IDEA: XBRL DOCUMENT~~

Restructuring and Related Implementation Charges - Narrative (Details) - USD (\$) \$ in Millions	Dec. 31, 2024	Jan. 27, 2022

Restructuring Cost and Reserve [Line Items]		
Pretax charges related to the Restructuring Program to date	\$ 228	
Restructuring and related cost incurred cost to date after tax	\$ 186	
Global Productivity Initiative Employee-Related Costs		
Restructuring Cost and Reserve [Line Items]		
Restructuring and related cost, expected cost, percentage	80.00%	
Global Productivity Initiative Asset Related Costs		
Restructuring Cost and Reserve [Line Items]		
Restructuring and related cost, expected cost, percentage	5.00%	
Global Productivity Initiative Other Charges		
Restructuring Cost and Reserve [Line Items]		
Restructuring and related cost, expected cost, percentage	15.00%	
Global Productivity Initiative Minimum		
Restructuring Cost and Reserve [Line Items]		
Restructuring and related Cost, estimated to settle through cash, percentage	80.00%	

~~XML 72 R52.htm~~ ~~IDEA: XBRL DOCUMENT~~

Restructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date (Details) \$ in Millions	Dec. 31, 2024
	USD (\$)

Restructuring Cost and Reserve [Line Items]	
Pretax charges related to the Restructuring Program to date	\$ 228
Global Growth and Efficiency Program	
Restructuring Cost and Reserve [Line Items]	
Pretax charges related to the Restructuring Program to date	228
Global Growth and Efficiency Program Employee-Related Costs	
Restructuring Cost and Reserve [Line Items]	
Pretax charges related to the Restructuring Program to date	175
Global Growth and Efficiency Program Incremental Depreciation	
Restructuring Cost and Reserve [Line Items]	
Pretax charges related to the Restructuring Program to date	13
Global Growth and Efficiency Program Asset Impairments	
Restructuring Cost and Reserve [Line Items]	
Pretax charges related to the Restructuring Program to date	1
Global Growth and Efficiency Program Other	
Restructuring Cost and Reserve [Line Items]	
Pretax charges related to the Restructuring Program to date	\$ 39

XML 73 R53.htm IDEA: XBRL DOCUMENT

Restructuring and Related Implementation Charges - Summary of Restructuring and Related Costs (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]			
Total 2022 Global Productivity Initiative charges, pretax	\$ 20	\$ 1	
Global Productivity Initiative			
Restructuring Cost and Reserve [Line Items]			
Total 2022 Global Productivity Initiative charges, pretax	85	32	\$ 95
Total 2022 Global Productivity Initiative charges, aftertax	73	25	
Global Productivity Initiative Selling, general and administrative expenses			
Restructuring Cost and Reserve [Line Items]			
Total 2022 Global Productivity Initiative charges, pretax	\$ 6	\$ 2	
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses	
Global Productivity Initiative Other (income) expense, net			
Restructuring Cost and Reserve [Line Items]			
Total 2022 Global Productivity Initiative charges, pretax	\$ 59	\$ 24	
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Operating Income (Expense), Net	Other Operating Income (Expense), Net	
Global Productivity Initiative Non-service related postretirement costs			
Restructuring Cost and Reserve [Line Items]			
Total 2022 Global Productivity Initiative charges, pretax	\$ 0	\$ 5	
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Non-service related postretirement costs	Non-service related postretirement costs	

XML 74 R54.htm IDEA: XBRL DOCUMENT

Restructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment (Details) - Global Productivity Initiative	12 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	100.00%	100.00%
Program-to-date accumulated charges (percent)	100.00%	
Pet Nutrition		
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	6.00%	23.00%
Program-to-date accumulated charges (percent)	11.00%	
Corporate		
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	2.00%	18.00%
Program-to-date accumulated charges (percent)	14.00%	
North America		
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	3.00%	15.00%
Program-to-date accumulated charges (percent)	9.00%	
Latin America		
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	0.00%	0.00%
Program-to-date accumulated charges (percent)	9.00%	
Europe		
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	89.00%	19.00%
Program-to-date accumulated charges (percent)	44.00%	
Asia Pacific		
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	0.00%	20.00%
Program-to-date accumulated charges (percent)	7.00%	
Africa/Eurasia		
Restructuring Cost and Reserve [Line Items]		
Percent of total restructuring charges related to segment	0.00%	5.00%
Program-to-date accumulated charges (percent)	6.00%	

XML 75 R55.htm IDEA: XBRL DOCUMENT

Restructuring and Related Implementation Charges - Restructuring Activity and Related Accruals (Details) - Global Productivity Initiative - USD (\$) \$ in Millions	12 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023
Restructuring Reserve [Roll Forward]		
Beginning balance	\$ 11	\$ 34
Charges	85	32
Cash Payments	(34)	(55)
Charges against assets	(13)	(6)
Foreign exchange	(5)	6
Ending balance	44	11
Employee-Related Costs		
Restructuring Reserve [Roll Forward]		
Beginning balance	10	30
Charges	49	24
Cash Payments	(20)	(45)
Charges against assets	0	(5)
Foreign exchange	(5)	6
Ending balance	34	10
Incremental Depreciation		
Restructuring Reserve [Roll Forward]		
Beginning balance	0	0
Charges	13	0
Cash Payments	0	0

Charges against assets	(13)	0
Foreign exchange	0	0
Ending balance	0	0
Asset Impairments		
Restructuring Reserve [Roll Forward]		
Beginning balance	0	1
Charges	0	0
Cash Payments	0	0
Charges against assets	0	(1)
Foreign exchange	0	0
Ending balance	0	0
Other		
Restructuring Reserve [Roll Forward]		
Beginning balance	1	3
Charges	23	8
Cash Payments	(14)	(10)
Charges against assets	0	0
Foreign exchange	0	0
Ending balance	\$ 10	\$ 1

~~XML 76 R56.htm IDEA: XBRL DOCUMENT~~

Goodwill and Other	12 Months Ended	
Intangible Assets -		
Schedule of Goodwill		
(Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023
\$ in Millions		

Goodwill [Roll Forward]

Beginning Balance	\$ 3,410	\$ 3,352
Reallocation	0	
Foreign currency translation	(138)	58
Ending Balance	3,272	3,410
Oral, Personal and Home Care		

Goodwill [Roll Forward]

Beginning Balance	2,925	2,864
Reallocation	0	
Foreign currency translation	(135)	61
Ending Balance	2,790	2,925
Pet Nutrition		

Goodwill [Roll Forward]

Beginning Balance	485	488
Foreign currency translation	(3)	(3)
Ending Balance	482	485

North America | Oral, Personal and Home Care

Goodwill [Roll Forward]

Beginning Balance	908	906
Reallocation	223	
Foreign currency translation	(23)	2
Ending Balance	1,108	908
Latin America Oral, Personal and Home Care		

Goodwill [Roll Forward]

Beginning Balance	179	168
Foreign currency translation	(34)	11
Ending Balance	145	179

Europe | Oral, Personal and Home Care

Goodwill [Roll Forward]

Beginning Balance	1,571	1,504
Reallocation	(223)	
Foreign currency translation	(67)	67
Ending Balance	1,281	1,571
Asia Pacific Oral, Personal and Home Care		

Goodwill [Roll Forward]

Beginning Balance	179	179
Foreign currency translation	(1)	0
Ending Balance	178	179

Africa/Eurasia | Oral, Personal and Home Care

Goodwill [Roll Forward]

Beginning Balance	88	107
Foreign currency translation	(10)	(19)
Ending Balance	\$ 78	\$ 88

~~XML 77 R57.htm IDEA: XBRL DOCUMENT~~

Goodwill and Other		
Intangible Assets -		
Summary of Other		
Intangible Assets	Dec. 31, 2024	Dec. 31, 2023
(Details) - USD (\$)		
\$ in Millions		

Finite and indefinite-lived intangible assets [Line Items]

Finite & indefinite lived intangibles, gross	\$ 2,686	\$ 2,769
Finite-lived intangible assets, accumulated amortization	(930)	(882)
Intangible assets, net (excluding goodwill)	1,756	1,887
Indefinite life intangible assets		

Finite and indefinite-lived intangible assets [Line Items]

Indefinite-lived intangible assets (excluding goodwill)	948	978
Trademarks		

Finite and indefinite-lived intangible assets [Line Items]

Finite-lived intangible assets, gross	1,135	1,167
Finite-lived intangible assets, accumulated amortization	(545)	(519)
Finite-lived intangible assets, net	590	648
Other finite life intangible assets		

Finite and indefinite-lived intangible assets [Line Items]

Finite-lived intangible assets, gross	603	624
Finite-lived intangible assets, accumulated amortization	(385)	(363)
Finite-lived intangible assets, net	\$ 218	\$ 261

~~XML 78 R58.htm IDEA: XBRL DOCUMENT~~

Goodwill and Other	12 Months Ended		
Intangible Assets -			
Narrative (Details) -			
USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Millions			
Goodwill [Line Items]			

Amortization of intangible assets	\$ 75	\$ 72	\$ 80
Annual estimated amortization expense, year 1	68		
Annual estimated amortization expense, year 2	68		
Annual estimated amortization expense, year 3	68		
Annual estimated amortization expense, year 4	68		
Annual estimated amortization expense, year 5	68		
Indefinite life intangible assets			
Goodwill [Line Items]			
Indefinite-lived Intangible Assets (Excluding Goodwill)	948	\$ 978	
Trademarks			
Goodwill [Line Items]			
Indefinite-lived Intangible Assets (Excluding Goodwill)	\$ 234		
Estimated remaining useful life (in years)	24 years		
Filorga Reporting Unit Trademarks			
Goodwill [Line Items]			
Reporting unit, impairment analysis carrying amount	\$ 293		
~~XML 79-R59.htm-IDEA: XBRL DOCUMENT~~			
Long-Term Debt and Credit Facilities - Components of Long-term Debt (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	
\$ in Millions			
Debt Instrument [Line Items]			
Total debt	\$ 7,941	\$ 8,239	
Less: Current portion of long-term debt	(652)	(20)	
Total	\$ 7,289	8,219	
Notes			
Debt Instrument [Line Items]			
Weighted average interest rate	3.00%		
Total debt	\$ 6,946	7,580	
Commercial paper			
Debt Instrument [Line Items]			
Weighted average interest rate	3.00%		
Total debt	\$ 936	606	
Finance Lease Obligations			
Debt Instrument [Line Items]			
Total debt	\$ 59	\$ 53	
~~XML 80-R60.htm-IDEA: XBRL DOCUMENT~~			
Long-Term Debt and Credit Facilities - Debt Payable within One Year (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	
\$ in Millions			
Debt Disclosure [Abstract]			
Notes and loans payable	\$ 8	\$ 310	
Current portion of long-term debt	652	20	
Debt payable within one year	\$ 660	\$ 330	
~~XML 81-R61.htm-IDEA: XBRL DOCUMENT~~			
Long-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance Lease Maturities (Details) - USD (\$)	Dec. 31, 2024		
\$ in Millions			
Debt Disclosure [Abstract]			
2025	\$ 652		
2026	1,035		
2027	509		
2028	612		
2029	519		
Thereafter	3,678		
Total	\$ 7,005		
~~XML 82-R62.htm-IDEA: XBRL DOCUMENT~~			
Long-Term Debt and Credit Facilities - Narrative (Details) - USD (\$)	1 Months Ended	12 Months Ended	
	Mar. 31, 2023	Nov. 30, 2022	Dec. 31, 2024
Revolving Credit Facility			
Debt Instrument [Line Items]			
Unused borrowing capacity			\$ 3,725,000,000
Amended Foreign Revolving Credit Facility 3000 Million Capacity			
Debt Instrument [Line Items]			
Debt instrument term	5 years		
Maximum borrowing capacity	\$ 3,000,000,000		
Ten year notes at 3.250 percent number			
Debt Instrument [Line Items]			
Face amount			\$ 500,000,000
Debt instrument term			10 years
Fixed interest rate			3.25%
Three Year Notes at 4.800 Percent Number			
Debt Instrument [Line Items]			
Face amount			\$ 500,000,000
Debt instrument term			3 years
Fixed interest rate			4.80%
Five Year Notes at 4.600 Percent Number			
Debt Instrument [Line Items]			
Face amount			\$ 500,000,000
Debt instrument term			5 years
Fixed interest rate			4.60%
Ten Year Notes at 4.600 Percent Number			
Debt Instrument [Line Items]			
Face amount			\$ 500,000,000
Debt instrument term			10 years
Fixed interest rate			4.60%
~~XML 83-R63.htm-IDEA: XBRL DOCUMENT~~			
Fair Value Measurements and Financial Instruments	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	

- Narrative (Details) \$ in Millions	USD (\$) country	USD (\$)
Debt Instrument [Line Items]		
Minimum number of countries and territories serving consumers (more than) (in countries and territories) country	200	
Total	\$ 7,005	
Carrying Value		
Debt Instrument [Line Items]		
Total	7,941	\$ 8,239
Fair Value, Inputs, Level 2		
Debt Instrument [Line Items]		
Estimated fair value of long-term debt	\$ 7,433	\$ 7,862
XML 84 R64.htm IDEA: XBRL DOCUMENT		
Fair Value		
Measurements and		
Financial Instruments		
- Fair Value of		
Derivative		
Instruments and	Dec. 31, 2024	Dec. 31, 2023
Other Financial		
Instruments (Details)		
- USD (\$)		
\$ in Millions		
Designated derivative instruments		
Derivative asset	\$ 33	\$ 19
Derivative liability	23	26
Other financial instruments		
Investments fair value	\$ 160	\$ 179
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other accruals	Other accruals
Foreign currency contracts		
Designated derivative instruments		
Derivative asset	\$ 33	\$ 19
Derivative liability	22	25
Commodity contracts		
Designated derivative instruments		
Derivative asset	0	0
Derivative liability	1	1
Other current assets		
Other financial instruments		
Marketable securities	\$ 160	\$ 179
XML 85 R65.htm IDEA: XBRL DOCUMENT		
Fair Value		
Measurements and		
Financial Instruments		
- Schedule of	Dec. 31, 2024	Dec. 31, 2023
Notional Values		
(Details) - USD (\$)		
\$ in Millions		
Fair Value Hedges		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	\$ 1,669	\$ 1,625
Fair Value Hedges Foreign currency contracts		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	1,669	1,625
Fair Value Hedges Foreign Currency Debt		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	0	0
Fair Value Hedges Commodity contracts		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	0	0
Cash Flow Hedges		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	1,041	908
Cash Flow Hedges Foreign currency contracts		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	1,023	869
Cash Flow Hedges Foreign Currency Debt		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	0	0
Cash Flow Hedges Commodity contracts		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	18	39
Net Investment Hedges		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	4,039	4,188
Net Investment Hedges Foreign currency contracts		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	289	280
Net Investment Hedges Foreign Currency Debt		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	3,750	3,908
Net Investment Hedges Commodity contracts		
Derivative Instruments, Gain (Loss) [Line Items]		
Notional value of derivative	\$ 0	\$ 0
XML 86 R66.htm IDEA: XBRL DOCUMENT		
Fair Value	12 Months Ended	
Measurements and		
Financial Instruments		
- Schedule of Gain		
(Loss) Included in		
OCI (Details) - Net	Dec. 31, 2024	Dec. 31, 2023
Investment Hedges -		
USD (\$)		
\$ in Millions		
Net investment hedges [Abstract]		
Total gain (loss) on investment hedges	\$ 253	\$ (158)
Foreign currency contracts		
Net investment hedges [Abstract]		
Gain (loss) on net investment hedges	42	(34)
Foreign Currency Debt		
Net investment hedges [Abstract]		

Gain (loss) on net investment hedges \$ 211 \$ (124)

[XML-87-R67.htm-IDEA: XBRL DOCUMENT](#)

Capital Stock and Stock-Based Compensation Plans - Narrative (Details)	12 Months Ended			
	Dec. 31, 2024 USD (\$) plan shares	Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)	Mar. 10, 2022 USD (\$)
Preference Stock [Abstract]				
Shares authorized (in shares) shares	50,262,150			
Stock Repurchases [Abstract]				
Repurchased stock	\$ 1,739,000,000	\$ 1,128,000,000	\$ 1,308,000,000	
Stock-Based Compensation [Abstract]				
Number of stockholder approved plans, current plan	1			
Total stock-based compensation expense charged against pretax income	\$ 135,000,000	122,000,000	125,000,000	
Total income tax benefit from stock compensation	\$ 26,000,000	22,000,000	25,000,000	
Additional disclosures pertaining to stock based compensation [Abstract]				
Contractual term (in years)	8 years			
Vesting period (in years)	3 years			
Stock-based compensation, additional disclosures [Abstract]				
Tax benefit from exercise of stock options and vesting of restricted stock unit awards	\$ 18,000,000	4,000,000	2,000,000	
Proceeds from exercise of stock options	\$ 638,000,000	380,000,000	418,000,000	
Stock Option Plans				
Additional disclosures pertaining to stock based compensation [Abstract]				
Number of shares available for grant (in shares) shares	19,248,078			
Unrecognized compensation expense	\$ 12,000,000			
Unrecognized compensation expense, weighted-average period of recognition in years	1 year 3 months 18 days			
Stock-based compensation, additional disclosures [Abstract]				
Total intrinsic value of options exercised	\$ 150,000,000	28,000,000	47,000,000	
Performance Shares Incentive Stock Plans				
Additional disclosures pertaining to stock based compensation [Abstract]				
Vesting period (in years)	3 years			
Unrecognized compensation expense	\$ 32,000,000			
Time-Vested Stock Incentive Stock Plans				
Additional disclosures pertaining to stock based compensation [Abstract]				
Vesting period (in years)	3 years			
Number of shares available for grant (in shares) shares	7,324,623			
Unrecognized compensation expense	\$ 68,000,000			
Unrecognized compensation expense, weighted-average period of recognition in years	1 year 7 months 6 days			
Stock-based compensation, additional disclosures [Abstract]				
Total fair value of shares vested	\$ 72,000,000	\$ 45,000,000	\$ 40,000,000	
Program 2022				
Stock Repurchases [Abstract]				
Stock repurchase program, authorized amount				\$ 5,000,000,000
Repurchased stock	\$ 1,739,000,000			

[XML-88-R68.htm-IDEA: XBRL DOCUMENT](#)

Capital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity (Details) - shares	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Common Stock Outstanding			
Common stock balance, January 1 (in shares)	821,412,769	830,212,606	840,480,284
Common stock acquired (in shares)	18,321,422	14,735,909	17,060,788
Shares issued for stock options (in shares)	8,606,699	5,318,430	5,654,692
Shares issued for restricted stock and other (in shares)	876,652	617,642	1,138,418
Common stock balance, December 31 (in shares)	812,574,698	821,412,769	830,212,606
Treasury Stock			
Treasury stock balance, January 1 (in shares)	644,293,591	635,493,754	625,226,076
Common stock acquired (in shares)	18,321,422	14,735,909	17,060,788
Shares issued for stock options (in shares)	8,606,699	5,318,430	5,654,692
Shares issued for restricted stock and other (in shares)	876,652	617,642	1,138,418
Treasury stock balance, December 31 (in shares)	653,131,662	644,293,591	635,493,754

[XML-89-R69.htm-IDEA: XBRL DOCUMENT](#)

Capital Stock and Stock-Based Compensation Plans - Fair Value Assumptions (Details) - \$ / shares	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]			
Expected term of options	6 years	6 years	6 years
Expected volatility rate	20.50%	19.80%	21.10%
Risk-free interest rate	3.80%	4.30%	3.00%
Expected dividend yield	2.10%	2.50%	2.40%
Weighted-average estimated fair value (in dollars per share)	\$ 22.65	\$ 14.89	\$ 14.71

[XML-90-R70.htm-IDEA: XBRL DOCUMENT](#)

Capital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) \$ / shares in Units, shares in Thousands, \$ in Millions	12 Months Ended	
	Dec. 31, 2024 USD (\$) \$ / shares shares	
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]		
Options - beginning balance (in shares) shares	20,742	
Granted (in shares) shares	955	
Exercised (in shares) shares	(8,662)	
Forfeited (in shares) shares	(240)	
Expired (in share) shares	(21)	
Options - ending balance (in shares) shares	12,774	
Options exercisable (in shares) shares	9,265	
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]		
Options - beginning of period (in dollars per share) \$ / shares	\$ 75	
Options - shares granted (in dollars per share) \$ / shares	106	
Options - shares exercised (in dollars per share) \$ / shares	74	
Options - shares forfeited (in dollars per share) \$ / shares	76	

Options - shares expired (in dollars per share) \$ / shares	73
Options - end of period (in dollars per share) \$ / shares	78
Options exercisable - end of period (in dollars per share) \$ / shares	\$ 76
Weighted average remaining contractual life, options outstanding (in years)	5 years
Weighted average remaining contractual life, options exercisable (in years)	4 years
Intrinsic value of unexercised in-the-money options, options outstanding \$	\$ 176
Intrinsic value of unexercised in-the-money options, options exercisable \$	\$ 136

[XML 91-R71.htm IDEA: XBRL DOCUMENT](#)

Capital Stock and Stock-Based Compensation Plans - Summary of Performance Restricted Stock Activity (Details) - Performance Shares shares in Thousands	12 Months Ended
Shares (in thousands)	
Restricted stock awards - beginning balance (in shares) shares	1,069
Granted (in shares) shares	321
Vested (in shares) shares	(283)
Forfeited (in shares) shares	(89)
Change due to performance and/or market condition achievement (in shares) shares	19
Restricted stock awards - ending balance (in shares) shares	1,037
Weighted Average Grant Date Fair Value Per Award	
Restricted stock awards - beginning of period (in dollars per share) \$ / shares	\$ 68
Restricted stock awards - shares granted (in dollars per share) \$ / shares	91
Restricted stock awards - shares vested (in dollars per share) \$ / shares	70
Restricted stock awards - shares forfeited (in dollars per share) \$ / shares	72
Change due to performance and/or market condition achievement (in dollars per share \$ / shares	57
Restricted stock awards - end of period (in dollars per share) \$ / shares	\$ 74

[XML 92-R72.htm IDEA: XBRL DOCUMENT](#)

Capital Stock and Stock-Based Compensation Plans - Summary of Restricted Stock Activity (Details) - Time-Vested Stock shares in Thousands	12 Months Ended
Shares (in thousands)	
Restricted stock awards - beginning balance (in shares) shares	2,174
Granted (in shares) shares	854
Vested (in shares) shares	(951)
Forfeited (in shares) shares	(90)
Restricted stock awards - ending balance (in shares) shares	1,987
Weighted Average Grant Date Fair Value Per Award	
Restricted stock awards - beginning of period (in dollars per share) \$ / shares	\$ 76
Restricted stock awards - shares granted (in dollars per share) \$ / shares	105
Restricted stock awards - shares vested (in dollars per share) \$ / shares	76
Restricted stock awards - shares forfeited (in dollars per share) \$ / shares	77
Restricted stock awards - end of period (in dollars per share) \$ / shares	\$ 88

[XML 93-R73.htm IDEA: XBRL DOCUMENT](#)

Employee Stock Ownership Plan (Details) - USD (\$)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]			
Shares in ESOP (in shares)	7,428,343	8,348,104	
Outstanding borrowings in the ESOP	\$ 0		
Common shares released and allocated to participant accounts (in shares)	7,334,758		
Common shares available for future allocation to participant accounts (in shares)	93,585		
Annual ESOP expense	\$ 0	\$ 0	\$ 0
Dividends paid by the Company on shares held by the ESOP	16,000,000	17,000,000	19,000,000
Company contributions to the ESOP	\$ 0	\$ 0	\$ 0

[XML 94-R74.htm IDEA: XBRL DOCUMENT](#)

Retirement Plans and Other Retiree Benefits - Narrative (Details) - USD (\$) \$ in Millions	3 Months Ended	12 Months Ended			
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]					
ERISA litigation matter	\$ 267		\$ 0	\$ 267	\$ 0
Expected benefit payments from company assets			95		
Pension Plans United States					
Defined Benefit Plan Disclosure [Line Items]					
ERISA litigation matter	\$ 267	0	267	0	
Actuarial gain		\$ (39)	\$ (43)	(46)	
Percentage of investments in Company's common stock		0.00%	0.00%		
U.S. plans assets purchased to Company (in shares)		0	0		
Defined benefit plan dividends received on employer securities		\$ 0	\$ 0		
Expected long-term rate of return on plan assets		6.50%			
Average annual rates of return for the most recent 1-year period		5.00%			
Average annual rates of return for the most recent 5-year period		2.00%			
Average annual rates of return for the most recent 10-year period		4.00%			
Average annual rates of return for the most recent 15-year period		6.00%			
Average annual rates of return for the most recent 25-year period		5.00%			
Other postretirement charges		\$ 5	3	13	
Voluntary contributions to postretirement plans		0	0	0	
Pension Plans International					
Defined Benefit Plan Disclosure [Line Items]					
ERISA litigation matter		0	0	0	
Actuarial gain		\$ (5)	(5)	(7)	
Expected long-term rate of return on plan assets		5.69%			
Other postretirement charges		\$ 0	2	4	
Other Retiree Benefit Plans					
Defined Benefit Plan Disclosure [Line Items]					
ERISA litigation matter		0	0	0	
Actuarial gain		\$ (4)	(1)	(14)	
Medical cost trend rate assumed for next fiscal year		7.00%			
Ultimate medical cost trend rate		4.50%			

Year which ultimate medical cost trend rate is reached	2030			
Other postretirement charges	\$ 0	\$ 0	\$ 2	
Defined Benefit Plan, Health Care Cost Trend Rate Assumed	5.00%			
~~XML 95-R75.htm-IDEA: XBRL DOCUMENT~~				
Retirement Plans and Other Retiree				
Benefits - Schedule of Target Asset	Dec. 31, 2024			
Allocation (Details)				
United States				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	100.00%			
International				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	100.00%			
Equity securities United States				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	26.00%			
Equity securities International				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	17.00%			
Fixed income securities United States				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	60.00%			
Fixed income securities International				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	63.00%			
Other investments United States				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	14.00%			
Other investments International				
Defined Benefit Plan, Plan Assets, Allocations [Abstract]				
Target asset allocation	20.00%			
~~XML 96-R76.htm-IDEA: XBRL DOCUMENT~~				
Retirement Plans and Other Retiree		12 Months Ended		
Benefits - Allocation of Plan Assets and Level of Valuation				
Input, by Major Asset Category (Details) - USD (\$)		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Millions				
Defined Benefit Plan Disclosure [Line Items]				
Percent of fixed income assets invested in US treasury or agency securities			30.00%	
Minimum				
Defined Benefit Plan Disclosure [Line Items]				
Investment redemption notice period	0 months			
Maximum				
Defined Benefit Plan Disclosure [Line Items]				
Investment redemption notice period	3 months			
United States Pension Plans				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	\$ 1,295	\$ 1,360	\$ 1,363	
United States Pension Plans Fair Value, Inputs, Level 1, 2 and 3				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	886	936		
United States Pension Plans Fair Value Measured at Net Asset Value Per Share				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	448	454		
United States Pension Plans Cash and cash equivalents Fair Value, Inputs, Level 1				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	226	206		
United States Pension Plans U.S. common stocks Fair Value, Inputs, Level 1				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	1	0		
United States Pension Plans International common stocks Fair Value, Inputs, Level 1				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	0	0		
United States Pension Plans Pooled funds Fair Value, Inputs, Level 1				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	35	20		
United States Pension Plans Fixed income securities Fair Value, Inputs, Level 2				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	624	710		
United States Pension Plans Guaranteed investment contracts Fair Value, Inputs, Level 2				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	0	0		
United States Pension Plans Domestic, developed and emerging markets equity funds Fair Value Measured at Net Asset Value Per Share				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	223	315		
United States Pension Plans Fixed income funds Fair Value Measured at Net Asset Value Per Share				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	68	99		
United States Pension Plans Hedge funds Fair Value Measured at Net Asset Value Per Share				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	0	0		
United States Pension Plans Multi-Asset funds Fair Value Measured at Net Asset Value Per Share				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	157	40		
United States Pension Plans Real estate funds Fair Value Measured at Net Asset Value Per Share				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	0	0		
United States Pension Plans Other assets and liabilities, net				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	(39)	(30)		
International Pension Plans				
Defined Benefit Plan Disclosure [Line Items]				
Fair value of plan assets	537	566	\$ 516	

International Pension Plans Fair Value, Inputs, Level 1, 2 and 3		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	246	254
International Pension Plans Fair Value Measured at Net Asset Value Per Share		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	286	312
International Pension Plans Cash and cash equivalents Fair Value, Inputs, Level 1		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	21	14
International Pension Plans U.S. common stocks Fair Value, Inputs, Level 1		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	2	2
International Pension Plans International common stocks Fair Value, Inputs, Level 1		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	15	20
International Pension Plans Pooled funds Fair Value, Inputs, Level 1		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	103	113
International Pension Plans Fixed income securities Fair Value, Inputs, Level 2		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	75	71
International Pension Plans Guaranteed investment contracts Fair Value, Inputs, Level 2		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	30	34
International Pension Plans Domestic, developed and emerging markets equity funds Fair Value Measured at Net Asset Value Per Share		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	28	55
International Pension Plans Fixed income funds Fair Value Measured at Net Asset Value Per Share		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	222	219
International Pension Plans Hedge funds Fair Value Measured at Net Asset Value Per Share		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	7	7
International Pension Plans Multi-Asset funds Fair Value Measured at Net Asset Value Per Share		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	2	1
International Pension Plans Real estate funds Fair Value Measured at Net Asset Value Per Share		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	27	30
International Pension Plans Other assets and liabilities, net		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	\$ 5	\$ 0

~~XML 97-R77.htm~~ ~~IDEA: XBRL DOCUMENT~~

Retirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Amounts Recognized in Balance Sheet			
Current liabilities	\$ (93)	\$ (96)	
Pension Plans			
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)			
Accumulated benefit obligation	2,075	2,204	
Other Retiree Benefit Plans			
Change in Benefit Obligations			
Benefit obligations at beginning of year	665	658	
Service cost	7	7	\$ 18
Interest cost	36	38	36
Participants' contributions	0	0	
Plan amendments	0	(33)	
Actuarial loss (gain)	(14)	38	
Foreign exchange impact	(8)	4	
Termination benefits	0	0	
Curtailments and settlements	0	0	
Benefit payments	(54)	(47)	
ERISA litigation matter	0	0	
Benefit obligations at end of year	632	665	658
Change in Plan Assets			
Fair value of plan assets at beginning of year	0	0	
Actual return on plan assets	0	0	
Company contributions	54	47	
Participants' contributions	0	0	
Foreign exchange impact	0	0	
Settlements and acquisitions	0	0	
Benefit payments	(54)	(47)	
Fair value of plan assets at end of year	0	0	0
Funded Status			
Benefit obligations at end of year	632	665	658
Fair value of plan assets at end of year	0	0	0
Net amount recognized	(632)	(665)	
Amounts Recognized in Balance Sheet			
Noncurrent assets	0	0	
Current liabilities	(51)	(53)	
Noncurrent liabilities	(581)	(612)	
Net amount recognized	(632)	(665)	
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)			
Actuarial loss	109	128	
Transition/prior service cost(credit)	(159)	(180)	
Amounts recognized in accumulated other comprehensive income	(50)	(52)	
Accumulated benefit obligation	632	665	
Accumulated benefit obligation	\$ 0	\$ 0	
Weighted-Average Assumptions Used to Determine Benefit Obligations			
Discount rate	5.74%	5.37%	
Long-term rate of compensation increase	0.00%	0.00%	
ESOP growth rate	6.00%	6.00%	
Medical cost trend rate of increase	7.00%	6.00%	

Interest Crediting Rate	0.00%	0.00%	
United States Pension Plans			
Change in Benefit Obligations			
Benefit obligations at beginning of year	\$ 1,922	\$ 1,673	
Service cost	1	0	0
Interest cost	99	91	64
Participants' contributions	0	0	
Plan amendments	0	0	
Actuarial loss (gain)	(54)	36	
Foreign exchange impact	0	0	
Termination benefits	5	3	
Curtailments and settlements	(1)	0	
Benefit payments	(141)	(148)	
ERISA litigation matter	0	267	
Benefit obligations at end of year	1,831	1,922	1,673
Change in Plan Assets			
Fair value of plan assets at beginning of year	1,360	1,363	
Actual return on plan assets	49	115	
Company contributions	29	30	
Participants' contributions	0	0	
Foreign exchange impact	0	0	
Settlements and acquisitions	(2)	0	
Benefit payments	(141)	(148)	
Fair value of plan assets at end of year	1,295	1,360	1,363
Funded Status			
Benefit obligations at end of year	1,831	1,922	1,673
Fair value of plan assets at end of year	1,295	1,360	1,363
Net amount recognized	(536)	(562)	
Amounts Recognized in Balance Sheet			
Noncurrent assets	1	1	
Current liabilities	(27)	(28)	
Noncurrent liabilities	(510)	(535)	
Net amount recognized	(536)	(562)	
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)			
Actuarial loss	710	767	
Transition/prior service cost(credit)	0	0	
Amounts recognized in accumulated other comprehensive income	710	767	
Accumulated benefit obligation	\$ 1,818	\$ 1,907	
Weighted-Average Assumptions Used to Determine Benefit Obligations			
Discount rate	5.73%	5.40%	
Expected long-term rate of return on plan assets	6.50%		
Long-term rate of compensation increase	3.50%	3.50%	
ESOP growth rate	0.00%	0.00%	
Medical cost trend rate of increase	0.00%	0.00%	
Interest Crediting Rate	5.58%	4.99%	
International Pension Plans			
Change in Benefit Obligations			
Benefit obligations at beginning of year	\$ 776	\$ 675	
Service cost	16	15	15
Interest cost	33	33	21
Participants' contributions	5	5	
Plan amendments	0	0	
Actuarial loss (gain)	(11)	65	
Foreign exchange impact	(40)	29	
Termination benefits	0	2	
Curtailments and settlements	(18)	(6)	
Benefit payments	(41)	(42)	
ERISA litigation matter	0	0	
Benefit obligations at end of year	720	776	675
Change in Plan Assets			
Fair value of plan assets at beginning of year	566	516	
Actual return on plan assets	18	26	
Company contributions	37	39	
Participants' contributions	5	5	
Foreign exchange impact	(31)	27	
Settlements and acquisitions	(17)	(5)	
Benefit payments	(41)	(42)	
Fair value of plan assets at end of year	537	566	516
Funded Status			
Benefit obligations at end of year	720	776	675
Fair value of plan assets at end of year	537	566	\$ 516
Net amount recognized	(183)	(210)	
Amounts Recognized in Balance Sheet			
Noncurrent assets	47	48	
Current liabilities	(15)	(15)	
Noncurrent liabilities	(215)	(243)	
Net amount recognized	(183)	(210)	
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)			
Actuarial loss	174	177	
Transition/prior service cost(credit)	8	9	
Amounts recognized in accumulated other comprehensive income	182	186	
Accumulated benefit obligation	\$ 668	\$ 719	
Weighted-Average Assumptions Used to Determine Benefit Obligations			
Discount rate	4.69%	4.35%	
Expected long-term rate of return on plan assets	5.69%		
Long-term rate of compensation increase	3.36%	3.19%	
ESOP growth rate	0.00%	0.00%	
Medical cost trend rate of increase	0.00%	0.00%	
Interest Crediting Rate	3.23%	1.13%	

~~XML 99-R78.htm IDEA: XBRL DOCUMENT~~

Defined Benefit Plan Disclosure [Line Items]

Projected benefit obligation	\$ 2,251	\$ 2,352
Fair value of plan assets	1,486	1,532
Accumulated benefit obligation	2,075	2,204
Fair value of plan assets	1,345	1,428

Other Retiree Benefit Plans

Defined Benefit Plan Disclosure [Line Items]

Accumulated benefit obligation	0	0
Fair value of plan assets	\$ 0	\$ 0

~~XML 99 R79.htm IDEA: XBRL DOCUMENT~~

Retirement Plans and

Other Retiree

Benefits - Summary

of Other Retiree

Benefit Plans

(Details) - Other

Retiree Benefit Plans

- USD (\$)

\$ in Millions

Defined Benefit Plan Disclosure [Line Items]

Accumulated benefit obligation	\$ 632	\$ 665
Fair value of plan assets	\$ 0	\$ 0

~~XML 100 R80.htm IDEA: XBRL DOCUMENT~~

Retirement Plans and

Other Retiree

Benefits - Summary

of Net Periodic

Benefit Costs

(Details) - USD (\$)

\$ in Millions

Components of Net Periodic Benefit Cost

	3 Months Ended		12 Months Ended	
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Dec. 31, 2023				
Dec. 31, 2022				

Components of Net Periodic Benefit Cost

ERISA litigation matter	\$ 267	\$ 0	\$ 267	\$ 0

Other Retiree Benefit Plans

Components of Net Periodic Benefit Cost

Service cost	7	7	18
Interest cost	36	38	36
Expected return on plan assets	0	0	0
Amortization of transition and prior service costs (credits)	(21)	(20)	(6)
Amortization of actuarial loss	4	1	14
Net periodic benefit cost	26	26	62
Other postretirement charges	0	0	2
ERISA litigation matter	0	0	0
Total pension cost	\$ 26	\$ 26	\$ 64

Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost

Discount rate	5.37%	5.67%	3.06%
Long-term rate of compensation increase	0.00%	0.00%	0.00%
ESOP growth rate	6.00%	6.00%	6.00%
Medical cost trend rate of increase	6.00%	6.25%	6.00%
Interest Crediting Rate	0.00%	0.00%	0.00%

United States | Pension Plans

Components of Net Periodic Benefit Cost

Service cost	\$ 1	\$ 0	\$ 0
Interest cost	99	91	64
Expected return on plan assets	(85)	(79)	(101)
Amortization of transition and prior service costs (credits)	0	0	0
Amortization of actuarial loss	39	43	46
Net periodic benefit cost	54	55	9
Other postretirement charges	5	3	13
ERISA litigation matter	\$ 267	0	0
Total pension cost	\$ 59	\$ 325	\$ 22

Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost

Discount rate	5.40%	5.66%	2.98%
Expected long-term rate of return on plan assets	6.50%	6.25%	5.70%
Long-term rate of compensation increase	3.50%	3.50%	3.50%
ESOP growth rate	0.00%	0.00%	0.00%
Medical cost trend rate of increase	0.00%	0.00%	0.00%
Interest Crediting Rate	4.99%	5.21%	2.82%

International | Pension Plans

Components of Net Periodic Benefit Cost

Service cost	\$ 16	\$ 15	\$ 15
Interest cost	33	33	21
Expected return on plan assets	(29)	(25)	(21)
Amortization of transition and prior service costs (credits)	1	1	1
Amortization of actuarial loss	5	5	7
Net periodic benefit cost	26	29	23
Other postretirement charges	0	2	4
ERISA litigation matter	0	0	0
Total pension cost	\$ 26	\$ 31	\$ 27

Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost

Discount rate	4.61%	4.75%	2.10%
Expected long-term rate of return on plan assets	5.69%	4.66%	2.72%
Long-term rate of compensation increase	3.24%	3.22%	2.89%
ESOP growth rate	0.00%	0.00%	0.00%
Medical cost trend rate of increase	0.00%	0.00%	0.00%
Interest Crediting Rate	0.64%	2.28%	0.84%

~~XML 101 R81.htm IDEA: XBRL DOCUMENT~~

Retirement Plans and

Other Retiree

Benefits - Expected

Contributions and

Benefit Payments

(Details)

\$ in Millions

Total benefit payments [Abstract]

2025	\$ 471
2026	238
2027	241
2028	242
2029	242
2030-2034	1,174

Other Retiree Benefit Plans

Total benefit payments [Abstract]	
2025	52
2026	54
2027	55
2028	55
2029	55
2030-2034	274
United States Pension Plans	

Total benefit payments [Abstract]	
2025	377
2026	143
2027	143
2028	142
2029	141
2030-2034	653
International Pension Plans	

Total benefit payments [Abstract]	
2025	42
2026	41
2027	43
2028	45
2029	46
2030-2034	\$ 247

~~[XML 102 R82.htm IDEA: XBRL DOCUMENT](#)~~

Income Taxes - Components of Income Before Income Taxes	12 Months Ended		
(Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Millions			

[Income Tax Disclosure \[Abstract\]](#)

United States	\$ 1,084	\$ 692	\$ 1,169
International	2,872	2,700	1,491
Income before income taxes	\$ 3,956	\$ 3,392	\$ 2,660

~~[XML 103 R83.htm IDEA: XBRL DOCUMENT](#)~~

Income Taxes - Provision for Income Taxes (Details) - USD (\$)	12 Months Ended		
\$ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Income Tax Disclosure \[Abstract\]](#)

United States	\$ 188	\$ 72	\$ 199
International	719	865	494
Total Provision for income taxes	\$ 907	\$ 937	\$ 693

~~[XML 104 R84.htm IDEA: XBRL DOCUMENT](#)~~

Income Taxes - Income Tax Provision Reconciliation (Details) - USD (\$)	12 Months Ended		
\$ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Income Tax Disclosure \[Abstract\]](#)

Goodwill and intangible assets	\$ 3	\$ 1	\$ 106
Property, plant and equipment	12	(13)	2
Pension and other retiree benefits	(6)	68	(1)
Stock-based compensation	(14)	2	(3)
Right-of-use assets/lease liabilities	2	1	(5)
Tax credits and tax loss carryforwards, net of valuation allowance	37	29	8
Deferred withholding tax	(14)	7	8
Research and Experimentation Capitalization	21	29	58
Other, net	(8)	11	(10)
Total deferred tax benefit (provision)	\$ 33	\$ 135	\$ 163

~~[XML 105 R85.htm IDEA: XBRL DOCUMENT](#)~~

Income Taxes - Effective Tax Rate Reconciliation (Details)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Income Tax Disclosure \[Abstract\]](#)

Tax at United States statutory rate	21.00%	21.00%	21.00%
State income taxes, net of federal benefit	0.50%	(0.10%)	0.80%
Earnings taxed at other than United States statutory rate	4.10%	5.40%	5.40%
Non-deductible goodwill impairment charges	0.00%	0.00%	1.90%
Foreign-derived intangible income benefit	(2.60%)	(2.40%)	(2.60%)
Foreign tax matter	0.00%	3.70%	0.00%
Other, net	(0.10%)	0.00%	(0.40%)
Effective tax rate	22.90%	27.60%	26.10%

~~[XML 106 R86.htm IDEA: XBRL DOCUMENT](#)~~

Income Taxes - Components of Deferred Tax Assets (Liabilities) (Details) - USD (\$)	12 Months Ended			
\$ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021

[Deferred tax liabilities:](#)

Goodwill and intangible assets	\$ (389)	\$ (412)		
Property, plant and equipment	(397)	(420)		
Right-of-use assets	(126)	(126)		
Deferred withholding tax	(110)	(96)		
Other	(130)	(34)		
Total deferred tax liabilities	(1,152)	(1,088)		

[Deferred tax assets:](#)

Pension and other retiree benefits	272	295		
Tax credits and tax loss carryforwards	430	356		
Lease liabilities	137	134		
Accrued liabilities	223	221		
Stock-based compensation	61	75		
Research and Experimentation Capitalization	108	87		
Other	101	60		
Total deferred tax assets	1,332	1,228		
Valuation Allowance	(328)	(287)	\$ (129)	\$ (120)
Net deferred tax assets	1,004	941		
Net deferred income taxes	\$ (148)	\$ (147)		

XML 107 R87.htm IDEA: XBRL DOCUMENT

Income Taxes - Change in Valuation Allowance for Deferred Tax Assets (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Deferred Tax Asset, Valuation Allowance [Roll Forward]

Balance, January 1	\$ 287	\$ 129	\$ 120
Balance, December 31	328	287	129

Charged to costs and expenses

Deferred Tax Asset, Valuation Allowance [Roll Forward]

Valuation allowance, deferred tax asset, additions (deductions)	56	158	14

Deductions

Deferred Tax Asset, Valuation Allowance [Roll Forward]

Valuation allowance, deferred tax asset, additions (deductions)	\$ (15)	\$ 0	\$ (5)

XML 108 R88.htm IDEA: XBRL DOCUMENT

Income Taxes - Narrative (Details) \$ in Millions	3 Months Ended		12 Months Ended		
	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 15, 2022
	USD (\$)	USD (\$)	USD (\$)	USD (\$)	memberState

Income Tax Disclosure [Abstract]

Net operating loss and capital loss carryforwards		\$ 37			
Net operating loss and capital loss carryforwards, set to begin expiring		6			
Net operating loss carryforwards, not subject to expiration		13			
Net operating loss carryforward, valuation allowance		18			
Tax credit carryforward		393			
Tax credit carryforward, subject to expiration		66			
Tax credit carryforward, not subject to expiration		17			
tax credit carryforward, valuation allowance		310			
Income tax expense (benefit) allocated directly to equity		55	\$ (19)	\$ 164	
Unrecognized tax benefits that would impact effective tax rate		286			
Interest (income) expense recognized related to unrecognized tax benefits		22	10	8	
Accrued interest related to unrecognized tax benefits		68	45	40	
Cumulative effect of change in tax position	\$ 148				
Withholding tax reserves, prior year reversals	\$ 22	53	\$ 61	\$ 21	
Number of member states of the European Union memberState					27
Tax plus interest for years 2010 through 2018		\$ 153			

XML 109 R89.htm IDEA: XBRL DOCUMENT

Income Taxes - Unrecognized Tax Benefits (Details) - USD (\$) \$ in Millions	3 Months Ended		12 Months Ended		
	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	

Unrecognized tax benefits:

Balance, January 1		\$ 314	\$ 298	\$ 245
Increases as a result of tax positions taken during the current year		37	73	32
Decreases of tax positions taken during prior years	\$ (22)	(53)	(61)	(21)
Increases of tax positions taken during prior years		10	6	46
Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations		(3)	(2)	(2)
Effect of foreign currency rate movements		(9)	0	(2)
Balance, December 31		\$ 296	\$ 314	\$ 298

XML 110 R90.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD (\$) \$ / shares in Units, shares in Millions, \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Net income attributable to Colgate-Palmolive Company

Basic EPS	\$ 2,889	\$ 2,300	\$ 1,785
Diluted EPS	\$ 2,889	\$ 2,300	\$ 1,785
Shares (millions)			
Basic EPS (in shares)	819.1	827.4	836.4
Stock options and restricted stock units (in shares)	4.1	1.8	2.4
Diluted EPS (in shares)	823.2	829.2	838.8
Per Share			
Basic EPS (in dollars per share)	\$ 3.53	\$ 2.78	\$ 2.13
Diluted EPS (in dollars per share)	\$ 3.51	\$ 2.77	\$ 2.13

XML 111 R91.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Narrative (Details) - shares	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Employee Stock Option

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)	295,968	13,719,286	5,236,371

Restricted Stock Units (RSUs)

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares)	100,191	1,183	155,118

XML 112 R92.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) \$ in Millions	1 Months Ended		3 Months Ended	12 Months Ended			
	Aug. 31, 2024	Nov. 30, 2023	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2005
	petition	petition	USD (\$) case	USD (\$) case	USD (\$) case	USD (\$)	USD (\$)
				countryAndTerritory			

Loss Contingencies [Line Items]

Contractual commitments, amount \$				\$ 568			
Number of countries in which entity operates (more than) countryAndTerritory				200			
Brazilian internal revenue authority, matter 1 \$				\$ 93			
Loss contingency, pending claims, number (in cases)				3			
Loss contingency, number of cases on appeal				2			
Loss contingency, petitions for removal of penalty portion of claim petition		3					
Loss contingency, petitions approved for removal of penalty portion of claim petition	2						
Brazilian internal revenue authority, matter 2 \$							\$ 47
Loss contingency, pending claims, number (in cases)				309	279		
Loss contingency, new claims filed, number (in cases)				142			
Loss contingency, claims dismissed or settled, number (in cases)				111			
Loss contingency, cases removed from case count				1			

Loss contingency, number of cases resulting in verdict for the Company	1			
ERISA litigation matter \$	\$ 267	\$ 0	\$ 267	\$ 0
Minimum				
Loss Contingencies [Line Items]				
Range of reasonably possible losses \$		0		
Maximum				
Loss Contingencies [Line Items]				
Range of reasonably possible losses \$		\$ 250		
~~XML 113 R93.htm IDEA XBRL DOCUMENT~~				

Segment Information - Narrative (Details) \$ in Millions	Dec. 31, 2024 USD (\$) segment	12 Months Ended	
		Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)
Segment Reporting Information [Line Items]			
Number of operating segments (in segments) segment	2		
Number of geographically reportable operating segments (in segments) segment	5		
Restructuring costs	\$ 59	\$ 24	\$ 90
Restructuring and related cost, incurred cost	\$ 20	1	
Goodwill and intangible assets impairment charges			721
Gain on sale of land			47
Corporate			
Segment Reporting Information [Line Items]			
Acquisition-related costs			\$ 19
Global Growth and Efficiency Program			
Segment Reporting Information [Line Items]			
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Operating Income (Loss)		Operating Income (Loss)
Restructuring and related cost, incurred cost		27	
Global Productivity Initiative			
Segment Reporting Information [Line Items]			
Restructuring and related cost, incurred cost	\$ 85	32	\$ 95
Operating Profit Global Growth and Efficiency Program			
Segment Reporting Information [Line Items]			
Restructuring and related cost, incurred cost		\$ 25	
Operating Profit Global Productivity Initiative Corporate			
Segment Reporting Information [Line Items]			
Restructuring costs	\$ 85		
Sales Revenue, Net			
Segment Reporting Information [Line Items]			
Percentage of consolidated Net sales represented by sales outside US	66.70%		
Percentage of consolidated Net sales coming from emerging markets	45.00%		
Sales Revenue, Net Customer Concentration Risk Walmart, Inc.			
Segment Reporting Information [Line Items]			
Percentage of consolidated sales represented by one customer	11.00%		

Segment Information - Schedule of Segment Information (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]			
Net sales	\$ 20,101	\$ 19,457	\$ 17,967
Cost of sales	7,940	8,131	7,719
Selling, general and administrative expenses	7,729	7,151	6,565
Operating profit	4,268	3,984	2,893
Capital expenditures	561	705	696
Depreciation and amortization	605	567	545
Total long lived assets	4,951	5,073	
United States			
Segment Reporting Information [Line Items]			
Total long lived assets	2,728	2,733	
Non-US			
Segment Reporting Information [Line Items]			
Total long lived assets	2,223	2,340	
Total Oral, Personal and Home Care United States			
Segment Reporting Information [Line Items]			
Net sales	3,640	3,625	3,511
Pet Nutrition United States			
Segment Reporting Information [Line Items]			
Net sales	3,059	2,918	2,432
Operating Segments Total Oral, Personal and Home Care			
Segment Reporting Information [Line Items]			
Net sales	15,618	15,167	14,254
Operating profit	4,088	3,882	3,348
Capital expenditures	317	311	308
Depreciation and amortization	378	372	387
Operating Segments Total Oral, Personal and Home Care North America			
Segment Reporting Information [Line Items]			
Net sales	4,113	4,091	4,002
Cost of sales	1,571	1,588	1,649
Selling, general and administrative expenses	1,668	1,594	1,567
Other	36	37	46
Operating profit	839	871	741
Capital expenditures	52	46	66
Depreciation and amortization	124	116	128
Operating Segments Total Oral, Personal and Home Care Latin America			
Segment Reporting Information [Line Items]			
Net sales	4,782	4,640	3,982
Cost of sales	1,933	1,977	1,885
Selling, general and administrative expenses	1,328	1,241	1,059
Other	(5)	5	(71)
Operating profit	1,526	1,417	1,108
Capital expenditures	126	146	121
Depreciation and amortization	100	98	93
Operating Segments Total Oral, Personal and Home Care Europe			
Segment Reporting Information [Line Items]			
Net sales	2,770	2,571	2,362
Cost of sales	1,050	1,069	1,023
Selling, general and administrative expenses	1,031	899	778

Other	31	31	28
Operating profit	658	573	534
Capital expenditures	63	44	31
Depreciation and amortization	65	65	68
Operating Segments Total Oral, Personal and Home Care Asia Pacific			
Segment Reporting Information [Line Items]			
Net sales	2,858	2,782	2,826
Cost of sales	1,078	1,108	1,160
Selling, general and administrative expenses	997	925	954
Other	(30)	(18)	(24)
Operating profit	812	767	737
Capital expenditures	64	65	60
Depreciation and amortization	81	84	89
Operating Segments Total Oral, Personal and Home Care Africa/Eurasia			
Segment Reporting Information [Line Items]			
Net sales	1,095	1,083	1,082
Cost of sales	432	442	447
Selling, general and administrative expenses	395	377	389
Other	16	9	18
Operating profit	253	254	228
Capital expenditures	12	10	30
Depreciation and amortization	8	9	9
Operating Segments Pet Nutrition			
Segment Reporting Information [Line Items]			
Net sales	4,483	4,290	3,713
Cost of sales	1,869	1,964	1,569
Selling, general and administrative expenses	1,641	1,493	1,287
Other	8	26	7
Operating profit	965	806	850
Capital expenditures	143	301	297
Depreciation and amortization	132	101	65
Corporate			
Segment Reporting Information [Line Items]			
Operating profit	(784)	(704)	(1,305)
Capital expenditures	101	93	91
Depreciation and amortization	\$ 95	\$ 94	\$ 93

~~XML 115 R95.htm IDEA: XBRL DOCUMENT~~

Leases - Narrative (Details) \$ in Millions	12 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023
	USD (\$) leaseRenewalOption	USD (\$)
Leases [Abstract]		
Number of lease renewal options (one or more) leaseRenewalOption 1		
Operating lease, payments	\$ 132	\$ 171
Right-of-use asset obtained in exchange for operating lease liability	\$ 141	\$ 139
Operating lease, weighted average remaining lease term	7 years	8 years
Operating lease, weighted average discount rate	4.40%	4.50%

~~XML 116 R96.htm IDEA: XBRL DOCUMENT~~

Leases - Balance Sheet (Details) - USD (\$)		
	Dec. 31, 2024	Dec. 31, 2023
\$ in Millions		
Leases [Abstract]		
Other assets	\$ 529	\$ 491
Other accruals	107	95
Other liabilities	456	420
Total operating lease liabilities	\$ 563	\$ 515
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other accruals	Other accruals
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other liabilities	Other liabilities

~~XML 117 R97.htm IDEA: XBRL DOCUMENT~~

Leases - Schedule of Minimum Lease Commitments (Details) - USD (\$)		
	Dec. 31, 2024	Dec. 31, 2023
\$ in Millions		
Leases [Abstract]		
2025	\$ 126	
2026	108	
2027	101	
2028	80	
2029	58	
Thereafter	182	
Total lease commitments	655	
Less: Interest	(92)	
Present value of lease liabilities	\$ 563	\$ 515

~~XML 118 R98.htm IDEA: XBRL DOCUMENT~~

Leases - Schedule of Lease Cost (Details) - USD (\$)		
	Dec. 31, 2024	Dec. 31, 2023
\$ in Millions		
Leases [Abstract]		
Operating lease cost	\$ 144	\$ 136
Short-term lease cost	3	3
Variable lease cost	19	20
Sublease Income	(2)	(2)
Total lease cost	\$ 164	\$ 157

~~XML 119 R99.htm IDEA: XBRL DOCUMENT~~

Supplemental Income Statement			
12 Months Ended			
Information (Details)			
- USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Millions			
Other (income) expense, net			
Amortization of intangible assets	\$ 75	\$ 72	\$ 80
Equity income	(22)	(17)	(12)
2022 Global Productivity Initiative	59	24	90
Product recall costs	0	25	0
Losses (gains) from marketable securities and other assets	6	11	(22)
Indirect tax payments (refunds)	27	18	(14)
Gain on the sale of land in Asia Pacific	0	0	(47)

Acquisition-related costs	0	0	19
Other, net	19	58	(25)
Total Other (income) expense, net	164	191	69
Research and development	355	343	320
Advertising	\$ 2,720	\$ 2,371	\$ 1,997

~~XML 120 R100.htm IDEA: XBRL DOCUMENT~~

Supplemental
Balance Sheet
Information -
Schedule of
Inventories by Major
Class (Details) - USD
(\$)
\$ in Millions

Inventories		
Raw materials and supplies	\$ 631	\$ 606
Work-in-process	46	46
Finished goods	1,431	1,411
Total Inventories, net	2,108	2,063
Non-current inventory, net	(121)	(129)
Current Inventories, net	\$ 1,987	\$ 1,934

~~XML 121 R101.htm IDEA: XBRL DOCUMENT~~

Supplemental
Balance Sheet
Information -
Narrative (Details) -
USD (\$)
\$ in Millions

Balance Sheet Related Disclosures [Abstract]

Inventories valued under LIFO	\$ 453	\$ 471
Excess of current cost over LIFO cost	\$ 105	\$ 120

~~XML 122 R102.htm IDEA: XBRL DOCUMENT~~

Supplemental
Balance Sheet
Information -
Schedule of Property,
Plant and Equipment
(Details) - USD (\$)
\$ in Millions

Property, plant and equipment, net

Land	\$ 226	\$ 227
Buildings	2,056	2,047
Manufacturing machinery and equipment	6,265	6,365
Other equipment	1,580	1,647
Property, plant and equipment, gross	10,127	10,286
Accumulated depreciation	(5,705)	(5,704)
Property, plant and equipment, net	\$ 4,422	\$ 4,582

~~XML 123 R103.htm IDEA: XBRL DOCUMENT~~

Supplemental
Balance Sheet
Information -
Schedule of Other
Current Assets
(Details) - USD (\$)
\$ in Millions

Other current assets

Marketable securities	\$ 160	\$ 179
Prepays	520	595
Derivatives	33	19
Total Other current assets	\$ 713	\$ 793

~~XML 124 R104.htm IDEA: XBRL DOCUMENT~~

Supplemental
Balance Sheet
Information -
Schedule of Other
Accruals (Details) -
USD (\$)
\$ in Millions

Other accruals

Accrued advertising and consumer and trade promotions	\$ 912	\$ 882
Accrued payroll and employee benefits	437	403
Accrued taxes other than income taxes	162	167
Restructuring accrual	15	11
Pension and other retiree benefits	93	96
Lease liabilities due in one year	107	95
Accrued interest	72	78
Derivatives	23	26
Dividend payable	408	0
Other	662	619
Other accruals	\$ 2,891	\$ 2,377

~~XML 125 R105.htm IDEA: XBRL DOCUMENT~~

Supplemental
Balance Sheet
Information -
Schedule of Other
Liabilities (Details) -
USD (\$)
\$ in Millions

Other liabilities

Pension and other retiree benefits	\$ 1,306	\$ 1,390
Long-term lease liabilities	456	420
Restructuring accrual	29	0
Other	320	305
Total Other liabilities	\$ 2,111	\$ 2,115

~~XML 126 R106.htm IDEA: XBRL DOCUMENT~~

Supplemental Other
Comprehensive
Income (Loss)
Information -
Schedule of
Comprehensive
Income (Loss)
(Details) - USD (\$)
\$ in Millions

12 Months Ended

Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022

0-1HXZ)3AJG2K4K~01OT;#(2%:D:ZO)2ASWDJIBS MNJS@W.BNH/H#@((QY=<7.2 FFNXL UOD') T#OBJPK'6Z'27%:ATKS M46D;'BW\$HOFEWOD'I'7<-1NN-
G#7#IC#1!>\$SADP>>ITTSBY;#=#5A MJFE1P-SCJ@Wl@e~!!~ULR56BH@=(JSALE>;@TYY46@V+@O+4-38Y-PY M,P%L(SN2,@CYKI@R-ZB'@TEQ4FH=^OFFE!:=?
DC0'T9D6I2SDP>M Z~CE9A@;@&U&=+1H2MOU+UM'H'Y=S=0<?I15U4M@ MP~C&Y'4H'2WU&5;U)@BWSH045YVD@H(JLZ'KV9VB=@D)=67FK%
146BRM1UT#(>@F#RAXMIK@QB#P0014Q MLIK>UT-G'676 @FD3A1-CZ6F5RRW H@C41ETFO=6^4L%:@03/W8?GO M1019>=RZZ37-7 ~4TV@.KKG+L
22>4IS3YVZLS<4%WZBDVDF02<6-M+B-S<~1%~!H/JGS5FS.W_4J~2<W(HH)4DA<(R J/AE=X+13Y-62M4\$1M0 L)~35H/P\$ _T) B>=VSS-W:
H965TSULK59D==JHP/TK5C9M[30]1DHS&0J7H>.E5%VOZJ/9CD0JPF.M_4~>7^<%TI(0-4B;U);OISG7IUS=G_Q09U_1HYR->~!JQ\$157MF64
M0\$9EBZ@OYDP%OE5.1+6ZXST-B LMIVV+U SBC+K;O-6&VI(\$@A4H8K.&S:2DLIEW%>5AU2-M W3P6 -IRIUSF5,XCI'9K%'M:16I8T')5-VSS#-R.HOXJD7I'P-L6
MB0HJ>~!<049RN6/E0ZJ I_P6 6P^4P%~!~(W L'0 /ZIS3H4YJ+MA'~!~5ABRC@>IOIS8W'QO'A09%>TRY#H'HK%G>6.F<I8A3H4CGDN>L!@ MB.E.88.
HDG~242TPDKB>+&S~NHID MI3/HKHIM+SJO3~VZ7>F>R~WI~K3KR16-8&~<29JK~%/IQS@0.7H72 MDFFSRJFIHOJUXOIGL.O_ Y>8IS(KS:2Q MG1.GXUMF6.^<PU;
W99_T2NTN<@=W>7YOQ_O'Q&SZ=IGI/FI@OQGWF MVZRTJTG:QEUM@ IBZ~!~1~UROC@G4HJ=~>P~ NZA=&7>3LO;H+I8J7IRB>@L:M:355PMZY@Q2W.A2IRHJ@&I&K 6-X
%2E@7YV.PFGP3YR>~F.XG.FS.9_M+X>~&BR=ZNWBQUOF>5&XT'RH'B+W9S;G'JI'MSWOO@=..~@7&T.D@J@O@O_EI+ P04 '~2@U>ZMIX(X'#2' M&
'AL+U@O.GGC<@)5' NIC3\FKLI.KD512E50-187XNPNXLDHHJ9_K7B7F. E MT7=BK'R4'FE+W97H IDQC@V3C16 30-MMWDP L^EN%YOVS6;Y&BO@O)KO@I>P7I3-O-
3-Q4Y6JIESPYM&@HNRM4MM4MKB7K2R.3_YR(BCN_N_48>~!~MJA@6&7>.49Q@L'A9J~!~4Q@C'@)(@V2>0Z.SFY.'L\$SF2'VWUM;@<= MMPPI'&=E.T4FLGZ '30I'X'&?
A*0153D7XA+RST(R'=O+XOXHG JBRI/Y6YVRQLC<@>I78'S'G+H4Y'O_U_AI8K(ML:45%)GX~8M'PTKM@I.V.ZO.F83TL61/EVF.FXNFPLC;30BB0416\$FfI>B
MGKLU_VJIS7V7@{33CLUO@O<~%7^G-JHR_L D5=@O.IYU63QI@{(E)FISM7T M4CT'UC-3_ 9Y%;I20YW_H'5HU-MN-ELOY@Q@YYSVNFIWVG.8UHHBG<@>MEIG7R7I
IYX=>KDD.2>6SI>P'0'G09S_M_2'N'@PV H7>2%Z3E8M X67@2WT_UAWYVGIYTQSP_#IK-G96HA4K696 MUOT'9C@S#IW'MNPXPS16S(OAT/GFTYRB4I'PW'K+>Z>ZA4'6-L'
(F3#H-HS'36PH0JHLH5V.E#2FE MRNY.2YTR TDW7# BD_K4'EZ#YR4)IG3T&S@=>@IB3RWVEJ+I&V>PB+PP2U_MZW<~!H1LB-2+M 820 KH-63;50B89UIVTVITX%M?<
XOF>I'RD=>9H_MR.FB16NR@2W3EUOWA4TRB4.WQSM'99?7~>L'(B'@~>342L(QV'15ZP6Y MGSS;@3;@=B'TVKIAHSU&U&S&# T HOIC#0(<H9IKM-4IOT.IO@KKI;
MDH153YJQCAIT'Y&GL44L(C)>.\$X&YAV3OHJ7BF8HE>I8MHY@OJEP.CUGM.LDMP3'LHQ@OTQOGSS5%I@B/L5+/8TIMHTI4@T+WPV<
M_BGI'77+J41IU>FfM%>~ZIQP'33>K+E+&K4YCO=IX-C6'JB8THBI8BN6-M0D0F6GHGXNM.1%2(KR5IK.WL-A@PDX9Z6)ADO=>2RO:0SUITR M=>S(SVTF%AV3DH21+>D-
~2>IHXY5+9YF7OS.K494AA_XAFES@J7B3D MP_'80IUEH79I>+>0WQ2FE(GDR9_-0U3RR1A2&K/
PO.T8OT7JDM788~4U(I4ONEJ'92'\$KL&XJOUTX@7^3^~B1>A4UG6-TT6ZNPSG.NPYA.3.VK-JS16PGQ/(1 M412ZK'7XPOSXITLXNZW8~!<~#-
F3B8>K'8046BV%1%~Z7%~2%FO/IONE M%'MP3(Z'Z'Z)1%4P@ (LXHFF)HOM7_CZ7B9=F Y' ^E^T>Y&OT^MM2K F MJ&M L%(BPZ%@X;
YTAAY TB.FBFCFF+9U;SG.OZ%)='IKDH@GS+1/2ML MV05CNTM&4@OY^C-BST0SBTN:XXYF)LSG&8(KA';JB'BT8VOU5/>@<
609+BN0\$5%P<=<F.CUC3GJ'CR@M'BM'>~\$VIT30GHI MBX'>BD_K4'EZ#YR4)IG3T&S@=>@IB3RWVEJ+I&V>PB+PP2U_MZW<~!H1LB-2+M 820 KH-63;50B89UIVTVITX%M?<
7B'M6%6BM(63P90IHX&K.T#4 'K6KCIZM5%6L VUWC@FM'M_L5=56L_S_W&XS_L_P%Q2I@P% @ DH-6BB9H_7WJ IOH ID IX M'W.WK&ULE5.;UWPK2EYP_RN/6:G
MWDAJ.YZ'MHWRO K3.BJ.S.13P).EZ'G&S23Y:6WLCDHC@Q*(#>~!~1~Z'6MSYGV008'SVL5Z(F5O=WQQ_6WR:XL^2'97 IE_V;M:RBLU2=OV MM_X%WNY-
2&U:KV5'69&-1DD5Y.VP.E&K^K'L<~G%^<1~UK.Q*77M129@*IZ.(Rf RK=6 M3CLKTYIF4S5I6UB%=2.IN;BWJ(D)IS'P<= MPJ%~T/I'WP924Z'~)P8SZ@Y?
6Z('Z&S<@>~TY71=10U5Z7I'7Q04X'~NXIRITPDL M'96CD+D03>=>B47'004C>I5K2E4 M IQXG^P8_75A ID'~PY2('CKMKFDV;4.VLQ2BWB39P_8!<6U'D3W^< MB1K4JF
3&0NLX19&5<X26&NEW92P5-F76'17M0Z>.(RK;LPf<~D M'DH IT0>2>P>~Y'6#8H4D'~!~IOS8HM=F'01S)Z>(VF3#EKCS 14 M30
10'~!~1WX5CHGQI@I(P7K/M'F~!>>KCA8I2<#5 MA'Y0P<~!~1 Q MS&R@QIORYG+3%5% MOI.OPI<@I(D-UW'1'~\$E^T'~OZIGX\$2 MR@C18.W^B@.\$46B=W.JI3-
US\$~!~00.FBP>@ CJFN .<=< MYVP6EIJOU_HGRH'>#G9>Z@<66LJ(03)UDN:79&KA4 M05L.SID:C9Y-S7=(KR+ID@V(7%)5H8W7B-RB>~!~P'ZB7>>6BL9\$NSPDWPOI'M(M)?
<@/MS9'57%O:2 M4LHJE0O(<~>7H16(IB6(H'YI98R'5'+~!~OC& G!@! OIW A102P.%@ <MDH1-6HK;M@L&%DT ID IX;~!~IW.W)K&U!
MU3Q9VQZ MD&W.9TM~%~U>~>T/C1@16MFHJ-G3 FS~Y\$M WIWHZZIO.UK3>~NU>~!~7>UOOLCQ'0'20'V6JY>~!~#Z<NOBN97KWY>~!~M/C M MO=REF<NZM?F<
8MOCNX/GF<3FMYP5.5_ZERWYQO.G<~>~T7ZORNX-GL&S MKNAHJO KMVEYF@O>~\$3JUG>@'AP2SLGM+YAIV&S WG+GWIKXKL51!=>#DP MIS08H>I'P~I'NM,N7G@U7^~!~K?<
1B_K#T_S#%T5'K0~>@G675R/VDIHA>#) M9X3064ZF9'FQOI>P2T3UJF=78C7Y65OEI\$S@QI3TH~> GL07GQVU/M3LXUW_2KS&KH2E>~W@
OB_KU:YZ>=WIOB1XLYXIC>I>@ C-RH&ZC2W=>PLOO1 AVT'RTYV.N6R3UJF=EQE MQGLFZL>~!~<~!~@7HHG FGVLHNE>I0+~!~I9>8<KVENLIGX^>)I07= <
<#NA@0EKS~;U_MY5#@0SE.1'13J2NL 0%XHC.X?SDBG+O^ADX7X\$'_P^&S<@/~!~A9'8'9E M.LEEU UBWIPH_X.YQ'2X46YV&ME&\$\$ %0V@P=G46KW^#9&76KEIY/63
MHUJ I3/W MHUVB16NK(B5F0'KO M_18E_JEM>~!~>G'NSIP'U_G@I M3IRANR8<~>O+~!~S<@< P8>~>HJM&A\$S'~!~#V60.18ZT65IR.F57'.F6I<= MEYL5X2N J2IE^7G/H?<
WV'2>ZV1<L'6D6MNWTF>~!~M+GG6SUPOQY&S2K7>IMDSR4>~ZGEW00&<Z& JL~>~!~#2MAPWX^P.P0= MH@HJZL0A'4 A2J PL6XDATOR+XQ?<
D1H8N>U_ Y58'2 YDLRR~!~GA: M'WO

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|VI>F=>LW.^=<1L5G.R!BO=B M>=>WHN?EBX|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|XSHZ.W*M*G.M^T#121UC878EK-H <O5.&6D=>P=>F!>S68%FQMR@.0L?#7#&10+X! MNY^<3%<1B!>2#0.ZABBN#<N=#>21HJO14VX56=3LK5\$+^TL5 YR-P.M.TL> RC1A<(XFPH6&#*SR1@4K>+?>E.FFR!>G&S269Q.B16JVH M.P&3+>+BMMH!2PK6T6W51+ZF^G&1@>IP02/00JN1HD=<G=<0YQ&C2Y15>B7Z M0A.&#1=>+>^>P&C&PKL1A3K!>X3Q+0YV!>(<S8BDC&A>+5?Q? 1TF M^W=>W+BD(TOD.<4!>H&F<1W).2-4DY>A&B3V/&YZ)GK!&C>M4YPI(6&M2D)M1L-OS91H0!>P2.T.MSX&BF3J2)F8B2=>U&97WT+>W.TPA5>EC87*HN<=>=>=>4N1X M&59.4<1B.H1XJH1?2\$%#X810Q#X&F5S=6TJH1XQY0C%#Y%#4816HM.M1X.DUX\$5%AGRE!Dj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

[illegible]

\$2F D<7E/7AU/ F+Z 90DH5/U77(=FD0_K_OXA\$TUNE/VS(=5*P& &ULI5=M3_X\$AK MHVZUBB5\$F_2%4I/2<(<HX&>6*GO:29S;3LI&R68*7N<ZGH9*5)ARIFG7/ M<R*V/OC:2 LI>J3\$C5F9WXXO1LS_LI2Y27*(P_VSS)AGLXPU=O33M/I-FIE M.G&T9N=>0;#I/LI.DQI-KK<OR0V6E5F!P=>J9I/L
 <8IRRH8(ME:4\$MDA6;KZKA8=-8ED*BPN=M BECEYO/AVI<27RU_WJ54HD09*(53 &S_ MS_*12(72X*?<>Y:EP8G6B9;2Y.U70A003;DXH RITS="DSITNA#3P

020204PA4#FQND#L#1.0L5P(950B1017Z)KKZ<[L-V-98KVRTG/D7-VTHM-7V%-MK-7Ts(5UJYO.)0*LX18>:-1AQ7ZLW/GQ7.#F-0l\$8#X<H-WJ-Rl-MO<[V3B7-DHU)377-EQ4\$<KLMZ+DL-TD#174;D2\$IOVJ<HOF\$3N5SY<M6>AL(133T3T.3.#@ME0M4+981539.1@57-MN.Y-P#1L@L@
(8B33JL-0F5-N545961S(6CC3)1\$16\$>Z4LBE+1368;8D-MOO6%11#-BPMY9%OTFOE<FDH<C1Y>E8.&2UJPM<M7>XWCV510=O=P8?
MDJ&149L49LPE7T1615%4PK5/9W/>#HPRY P5%Y+<Y>L5(80CCAW-MF8Z>1>SVYX7#1P600HUFUXI<H#O.1DM;MYS9QVQ
MBE:NE49<WVDH6;BW+G1X-786-#EB(M#5=AJ1936GL0JR)315Q4I<K16OP.M8U<SHYKOBOT>=>X2SF5SUIHIDJA<GHI<N<NE0>V7(D%IX8IO=>1D+M18C6I)?
>KA.L4\$05YV<T16F&XWQ1<2B-QT5<=>A7#EQ0G0D%60H3LJ#IY.M.Y8>+<G5I\$0D82N=HYK=HX.SL6Y10SJ7F269I2\$B#BSNHP81+G<1)1#1#MVNE?<
MMOQM#YXULX.X+X20%HE+V-S2F4LGO\$G6%#D5XKNFW-MMOK<I0.87P03&FV?Z-YW&IOI=>#@A+IG=>6<C>4R+GFOZ79A&=>MO<PRZIB=>N#<
+8<T?Z-OK6AP<#C6GBKKD7<#9VLC1X-0-9JWWM<N1#6P3KW7.GA?CXI-X.B13Z77@+>2X(M7?P2U)W.M16+TOL?3ZUHI4+OZ-M+8>=>A1L6K7MA1>MB1A102P.\$%<@<
HBL-6N3N<B2W10-RQ-1D-M1X<1W.WJ&KLS&AM<ILY\$XKZ1J<SDVU>K=>M-2MPPX<IU6+&5=1D-LPSI08FT3T8M+4G&R7K1C<SEAI?TWJAI<<57.57323&RG-M&
HBUOIVPE<#G8U+3D0625Y7W/(R1/1W)N=>07H6?>9LZW<X&9U?>7MWRK.M(31=N<H@5KL.0124?W2L6165H1F7&UUCOHMM>#1W<WOB.088H=>1U87G
M-GT22D.0LR5M<655-VWGK3<AUT5A32.L&W7NB&JGJLA5<T1Z-Y2-L?P-M5@2AIGCMW(6F7<GHI\$246A<Z-V03-N&JDT3A<Z1<=>X%2?HABX?HJH@JWUTHE6.05F=Y*
M4.51<1C7;FUA(4J9-FW#B9H<V1Z8P<X<W1P<+IG-%>#I&X&AW1M.JNWU2RNL05+H8845.7F&E8K9L9.SQ=2<032/X>1MH#PHU<4WEAF&L=(35M<VFX8Z9+SIYD?
OK<51;WDPFUV<6<P6>=>JF35F7BRYOLXUE(OHLYUW7#U<CZ0?VYK9IWM<JANU52PU05+1Z09N715I0QJ76#7A8H#J#=>ITMLG+11#84N
Q-6V1K<GG54.6C1)115NP.058P.7<(18P10M0&6V102)1M7=>7(L6=C51)12M(R1WV.AUXBOYAMT8#<D&B<741ML8+U1E>(A<JPL?44O)<?
#X<1L-E>?0P1E51121.V&E.CT&S3Y21A1M.GBUIVXO4IU/<OKF52=RCXIT&2VXG#X%G-B7&5F&H<J17<H1K0-MOW<X01B#84H0C.P8I0/B350<^>TWM1L
<=>43H166D<H<A-M816P<+(<S-PE<#>85H1H#76A<1#>8X<1P?7QO.MUAF61W5V7<1Y<L<=>0BPI1#<61L-91YH<6ML3?>T55=67HPE<+GFE<Z?1M#9<IARF&B-L-
T1EY13Z2Q4YXB9I44-UGP<1JBI->@<MMWCM<Q067MV<FYFKYX&3L10<H0BWRP<QCI<F77WAI.2>CLPS<YIP5.1CAQC=>M9S<IY?4&M1H#1=>X<(>H0%<7C)/4F-O<
11Y1H5H509/6<CG-M-M-W1.V1PNO><?L%N3LPID.HM)M&1%<9?L=I(5N%=>B7.1A'D.58M)C'N-MD8SERIY<OV?Z=>6JSISMT<=>Z<XW0GWS)X
+>?>F<=>=>CBK7Z1BX&41.MHLOG&8IG<N-WY<H1H46<=>(<S-NH56QI?1T321UBD(2@>9.THR5B8GN<MQ?#SBZ9>.<J5L3<QNI.TBI#K<23FY1PIA<=>3V1SLS.O-
+>@0?T.MS1&H131<ZXMCE>1DCZ.TMOTZX<@<GKBK74<18<C'UW&9Q6.8&5SM>Z61.0Q-OW<=>N<S&S0X<UQ.6I.FM9E8C<MLZ7V.V9QM1+X4P.F<N#N#<9Y2\$<A1>1E+<
?PGH-2W4ULB<H2N<V7FO<1BA52?O1LB+N.<=>BKL1YVH<E.NJX.M-MX<77>=>YBSH16>=>JF<=>O1S<X&45L#10<1>35K<1JLK1PTM+1&L9+>PQ=VIR-W.H965F3
MEZ?<GBWU1Y.F9S121U75R5<67544KU0<6+73JYV1LMA21A543<=>7K59I5U20->B<H16W4OC1.D148H4C.967.HL(T)JL<H<A-MY&E&H&W1W?<
4WI+LD&4.5>JRR15J9F/(J1<INXCHS<X053Z1IQR<Z29%5M?16K9NSX2<1U98P1.OD<+1NV-BNT<C1LAF<F2+14+Y>08Q.>17.52GL(R5>J5S=>M%<1)XT-O-
%5R8LS<Y51F6GQ1+<KB1WK1J1<I<S;P2.1419LS&SL1QI<L1M<7X&U1NK91<1U30&7&19D<1L.MX0A%FR<NJD19.HC1P1V0.S94P<3E#1+(B1A<C7M1.F8A+HO%L1O?<@NDDIX
MO<1754347E021M2.0?LS1.%7U3S.M<=>8R.0.58EWN15ESEF3CS<(K+O)<O
M53WXLXMO3C.WHE)76J<C53P&XG0A4+BIU7<O.HS<N<C?B&X&B15F5\$1\$@MHC3VM(2QEO5?5L13.1LGZ<W)MUW?1J.MG<
VYMLZ3W3DE3<3+1.83J1V35J?PSD1<=>XJMB806.Q.O.DP1Q1A0&C<?5WKH1UA&A1C<2<75Y1U2\$?Y1&M1S<F&KD+JZ+P.9.6<C<1Y1>UL01ANWOTENU0+1LMB=>
719Q&6-U'M-N+CC(V4\$QQ5U<3EPOR<B&1(RO+8V1V3J2N'B-MBUAB<27M%#42>R2B-9BIC<Y8=>1@A.27LOH0.H934'R<DJKIRE6NFD=(6.M-
B9Y9/11A10.1736=>0ADHH.YB>A=080AQ/BKH&BQAI&MG.MT7JN<ZMGY<3P3M<?P1E.OU=>L4Y102QV.3.H7O.<6OEZ>=>43GRTOAL.M#81<D.8<C-
A1\$<MOM<MOC<Y=>+27@11=1Y<G<S&4A.1Q#<M#<QX2<1+11MBN<XQOI<0R07B9?>+>#<3PZ?11A<8Y<5>E1F683QD?O&A<S0&=>MFI<L<37VYV5VBLV=IZI+W<
Q-O551#2953PV->1<46%OQ(CWG6+TS1Z.MH.W17@>2P16E4AI<DL.D0<K&VKT1<E.TY.TK1<H1329&?>Y=>H2V71<132DQP=>=>M9<6WS0.31<(<=>Z95&K1+<D&BZ<
M+1L1R<Z<M#NNN?>H&1P2ZV1MHHE.GT.64M1H0'KFGUA<+<4?M1E.C>1VRJ4GG6BK0I?>D&M.MRKA.Y0<6B00&X4D=62G<21HD<R>VYCS<+>=>Q05N<
4P514LO16WFAQV>1L1H1H119&1LRN.M#101<=>GH(1L1T&ZB.EB.UTY1&C&X6*U46DQF.HC'Q'BDB.M1<4LF.T.R124O4&G.HI4C<A1<?1R>=>X'Q7ZW<TC=>IZ=9L1C/<3F%<(M2<1
17V1L1D1+>VSK1D<N%>1+Z<X+1O-F-M6B%1A<1S+L1T&RZXP.M1<JL1T.28IEQ04CZ6>=>=>1HYZX1R'Q(BY:HYHU9S7T#0<XPC>=>@U0<#8)M+>D1NBC.O0<VWJLAE<LY>
N2YW>RWTHL<8N1A&XW91L.D&6&9D161M1ZPF6Q<SKC'J1@0E1NOJAF<K526L0=>=>90LYVM<633BY1E.NW<1C10&6.Y30<7&K9P1J1P1YQ?=>=&

[illegible]

WOPU12>YD AZ22@IGC%>H^0%U/VZ MY-AW.VMTL<32RUM1:M7QOBA=U%SZ:(W25Z)>RJ=N@UVB<X*>20V MFYGW<15N83UU&&G WCOI2>.P/<#VOA
MPI=5Y<5MAI<JL>#XAR2%N%A%>61GN+FM&EZ97IZS.Y.15=57&S<3CFMGBV@OUNCH V)=IB.W>-H\$59P6GO?FUP_X\$3SI.F./2U+ITE<?%L#.MI3/F2F&<+IZ.VR
WG=>U.X0A7YOIN<#Z#22.KG IZ6.9TVFS-Q2T?=>JO+Z M3PNR>K.N=>%XOL1_2_YRFI+H5D.P>P+U8GR67.DY4+E60J9D%.M&LM1+D7FCIG.FISC?
IVB1>H.Q&ULMSAM.HLV&AKA#>+1% MHFS+<68+>.P&#>1@08.YXH6.GS3BD02?>RDWI_4E+TBLNWCM.MBYPNFBV-Y5#HJ6>G#E/I7BWKBNC+
<1\$705/>K/I+FHNN#(24+U2NI)5 MAYSOU>P(T)390PFKUFL+&HXKL16.FSD<\$>X?P29+YVNEVI9NM.B>M<+HG+W@>16WW"/3(+556>94IX<=>N9IPG?
S/<.&66WRD<9.T9&21+SL- MNXUXU_1/@H3.I5D123<4.2 M=57FB%BY&80PL/(U/WA)=B6#FZ?5/<@/AA# A/OUS:<BSUY F/>@.M2/E/KR(FI#>R<.(XOS)
IS3XW?@..F2ME QUCUF7- SUCHEIL.J&KR&DG=>79319.12.M3XO#VFPO>LHM%<3/LBI/(61<55?JOF6 XZY5IF4IT7T1KFEXC)EGCM-M8IM76C.#2V?2.C.R'LAUZ+
MS:E3W=>fjwN/>IG7@-3-7XPI->96 JPS f8KACF/8H24=PIOHYR<<7T MA-D7&D1/P1?LB?>1.0SHHS004=>=>46WGAFA=E-OOP6IU:896:1L#R6=M.R8XFLLAVTHH3>Z5
ML IVN2? Q+/>HEHD:EWZ:64/G:6DPXBNRXHCIO.P.Z-YYSI38PIQPE257XU+U P04 M="#2@8&#>H1>1>S">1/>Q0'AL+W=QO0-XMSEXCT32FE WC&T(S<AZE.9I&R&SV-V'
M/QUN287Y-MR27-I:4956C1H-L-9810"R2LC2430C.YSPDQ22/(9A.ZSVF2 MBT<C<+?L/OOGJT.VWBX-6&SIEZ(I0XGRRQO0R1.27I2.35VC%EDPRDO.
MYH1HU33X?ZH2Z%***<)N3<+16LHS1=40UR&D27((2A5.06+HLR9RD MJ4?2=Q=@>5<K?OL71MBJ7(QSYB3.4W.29BU.PL 5B2Z=>ZEEXC?I?3F
MO&HT.F373TOPAS(I-LIBOP7-RF1999:DQU1022BEA#W+L.B3.<=>K&S'A.AB MZ+R&EFWE.6#2A.<=>8#LDHBW13=>MEO.DJVL@DFIR8R35N<+5YSN#@
MF.18D3T2.L">Z2>+>+?@/N>"f8YW?/%4DO+74H 78"?>J&#>DP.+BZ M0(G*7KXIXW8*K-V.<Y&YDX"%4OG))Z&09:L0#Q=FEB>^/<(+)=Z2Q35 M3LE
(IAK2)< /AV9Z>SDJV(L.SHS)I 7SMALER3QA59=(1AX908). G: MXMX3M23#>=>X\$W.M#V/B.9J4.5.5CB<RQ9(532TN@G2@/IPAP-4GRF6G M_PDD1/HIG ID.Y.)3V
&V?<VCIUZ97BJ7BT97BT3U<=>S B4OLFMR N M9 .@>Z&+?FHH@OPHRNUA2A>=>K<7+7BWM+<C5QDB<+ \$6-1=JL-K.B.N<=>YAYAO?B8M YV< <R?>9JI
OK.@>A7F6SUG@W37T34ICZ1+>U ML P17 =>29J(M4L7.M5)+P PXXOA+XIZU.9)AB&SJZNS.<A MNJ80LR.HXJ=M3NG64.7B6C9>=>WKMM64G.RH/U2##M7?>S52/E".PG15BJV
MFA-W.VY=>15#>SURBGMT+>C.0:2.OAI.AR-1A5.YK8.FE.U>KL=>SWHSWSA.R MH6U3U1?>REHIDRTO DMH&KW&7KAIRFIN8SKYI&H47F7\$<I&VCW-Q8I MMW1>
J3SO.<3FDF\$=>E PIES%T*N5H5F&E(<=>EG3XJ+N%LSL&8LI#0ZT M&YP&+>2-JIG:O5Q9 C.>@>IW+UZOAH5F&J(-%K2/HYSEVS_2A>=>G<CV/
M09=V8&UL8(OQ(4?>X=X4 VSS7?>ICH1IHWFKUA&#K07JU<7X00>52J&P-B/MCGK=72FO5Z53N=D35 O2(CAMKAP:TZ1990=L O+G G40?>+2+&H T+>
MKX->XYD&R4RZ2?AR KQZDQ?<Q KHJL.KTR-G5B LQW=N?>+M.L73M A.<WO'5L7U/LH.X7L&5<(9-6/S7J3U.791->+H7KG&N#M?J4I MMJ1ZZ+FF1+2U@IU?
P2?Q+HN7Y<F=IUG(GI<G<25<.<#X3.YD&98 U5?<6-M5@<FZR3G64KFI=>=>Z5 YV1E'+<H-HOBZYG*G<3-BK<=>@F6I?>7U5J7B14 M RG5 TBS?>02P.%>
DH1-6A&ULM5M=>M-/5&5&H2?>2<+<B4VHI>10P6 M4=>=>08D6>=>#OK/PHLYO5.5 WHDY228R&3?>I&MVKNZ44FCJGG15M SLIC#1A04 W+JOB MHJ
O'DD.Z4.QD) 9ZE9C+QCCZ0PHSDW7<3Z"D1"78N7 M2?=>+UF7MH%DEP.F97.&.\$&1%/V1\$:#F\$>V</0+1VZCF@1 ME.UH8:&0R771EKI1+>+EOQG6R8L6.PI0?>
J9<-(RI>XISX<-6Y JRI MT82&EPP047?70AN5%<=>OWY+7 UNF&<82U4U7(#4.MH) A?>+1+C&MS.<'(W\$A4M H\$A1<=>#G%)2B3.8 Y(DX&.23=I)V@IC7 M\$>
#XWIV1+1567J.KSN.W@V?>PQXLBS7..JE@8215+JGL0.PU(K<=>+7J M.<+IAPU @UJH?HJ0Z?ITU6PKD<15Y?OTL OTL OTJTWJD&L?13?>#2E MIH JVK3?>
O'E5M&GX5<710Q.ABL&G(C7.5 I(P)FT MTQ.3?>04Q 4WA185Y.GV.-HO?>L&BK80S MISWR1+85RCYX<+>+R<=>K&K30.<P3.8) HU V?>EMS2@9JH8WC TO?>ZX
M.E+GE8AJC@<CG?>S.SJZ<=>+1H@>L23A)OE'H'>H=>V Y3.PO=VJR.W.H9657FR3+HUL+>W?>78?>+EA M(QN>9)GZ9<9.92162 M2?>V0A2.1CIBFKI@OI-SIS3.N.
I>+Q1C.X2B9QQAX#RE=I2L77Y.PS7W+M.VY7?(CG'UD1:C OEG3.GICM'P4ZIJZOXGBE&5YS#>DV.R<I<+>?ZHR?>3 M2?(Q)FI5">O5KK/+>80N8TD3 MI'1Y<
71+>JOKA1+1G<1%2URQJ313FN7H&KYKMN"700J8)+&2JZKBUS M60K\$=EBHJZ?+SIP7?<C=SR3BO&N+>+?>+I6E=C5I&H&X=B+>S Y?>72< MP5WT6Z KWY<C9.JT?>
4&2R2RSGITZ&R4Z2?AR KQZDQ?<Q KHJL.KTR-G5B LQW=N?>+M.L73M A.<WO'5L7U/LH.X7L&5<(9-6/S7J3U.791->+H7KG&N#M?J4I MMJ1ZZ+FF1+2U@IU?
P2?Q+HN7Y<F=IUG(GI<G<25<.<#X3.YD&98 U5?<6-M5@<FZR3G64KFI=>=>Z5 YV1E'+<H-HOBZYG*G<3-BK<=>@F6I?>7U5J7B14 M RG5 TBS?>02P.%>
DH1-6A&ULM5M=>M-/5&5&H2?>2<+<B4VHI>10P6 M4=>=>08D6>=>#OK/PHLYO5.5 WHDY228R&3?>I&MVKNZ44FCJGG15M SLIC#1A04 W+JOB MHJ
O'DD.Z4.QD) 9ZE9C+QCCZ0PHSDW7<3Z"D1"78N7 M2?=>+UF7MH%DEP.F97.&.\$&1%/V1\$:#F\$>V</0+1VZCF@1 ME.UH8:&0R771EKI1+>+EOQG6R8L6.PI0?>
J9<-(RI>XISX<-6Y JRI MT82&EPP047?70AN5%<=>OWY+7 UNF&<82U4U7(#4.MH) A?>+1+C&MS.<'(W\$A4M H\$A1<=>#G%)2B3.8 Y(DX&.23=I)V@IC7 M\$>
#XWIV1+1567J.KSN.W@V?>PQXLBS7..JE@8215+JGL0.PU(K<=>+7J M.<+IAPU @UJH?HJ0Z?ITU6PKD<15Y?OTL OTL OTJTWJD&L?13?>#2E MIH JVK3?>
O'E5M&GX5<710Q.ABL&G(C7.5 I(P)FT MTQ.3?>04Q 4WA185Y.GV.-HO?>L&BK80S MISWR1+85RCYX<+>+R<=>K&K30.<P3.8) HU V?>EMS2@9JH8WC TO?>ZX
M.E+GE8AJC@<CG?>S.SJZ<=>+1H@>L23A)OE'H'>H=>V Y3.PO=VJR.W.H9657FR3+HUL+>W?>78?>+EA M(QN>9)GZ9<9.92162 M2?>V0A2.1CIBFKI@OI-SIS3

S:BJQ9EHJ3BY,NF8"1.H+D2A2Q1J#9.M4#2"01.%+SUB+L%QFLT"1C%.U%#ZBL2T6:L6JXV"1+I1OZOMYGSJ9.M#M%TX@+1%I%LSA%QYF9M8E
50P4C+09%6J%BG7TRR#1LOB(=9ZB3QOMJ.M. MWQ 0E1=V<1%7 ML^XFLTKL100ZY+P.D0:12LXWGF8+Q2%.MKVH"157+17W+@-1..3")M7C.
H#6A2.W+2.EFC60N5+H2@+3.96"07"018DF5(=VJ).M+53 MW.BVE:1Y>957YEF+P.7D:1HJH4G=X8005Y9GYH+U+40-(D2D52+2%MMVM9*+T3BU-2M?>
Z1.3%16%-WH<1?>=QH291Y4+D#1L%G:LSW10+U<5G>+Q51P15%>HDL G5XG65X?E5A+PYM.2.C2W>X1\$5789IH51=D6C%226671+P%O.N:QCRG/F66 M%?>
+YNIHQ7JBYIEHJ=>D0>HEH.VY19JZKIVB+KH2GT.F3:CP<=XILU MB EO0%HR<TF5JA>WR<68Y4484+201%1+ISK%>X)S.YLAU84149D<=M\$<+<?>F+U<G:
GM.5+5.E.G<U"2A"2AZU=7U(C.D.H01<0)VZ(H"0DVF.M7<Q88.NKT"A=NKEY.HM+H93Z."/Q.MCAT4FG(GL"122N.BADH&D6AR=0".1.15MUJYD5=\$L.BC)6.75-140Q(RP
MI<1\$>12&Y.40S-T%1+1<@NA?T\$SM7TQ"FF(=2%)E.K)S)T(M&V%7416.MV1.O4)51PQK3Q82VS4)KAJMT92.1H<E/KO/P15Z.C"DNW-B670K/>K+UJ+MB#H%<4F4RL4CQ0T7X5=>1?>
=WENE".UMT 180K.9P4F+0<7R-W3?K&C&P.MH0L.U#2Y3X2."LYZR\$H"8B412.3.W4U+<+K.P.Q\$129U9C?2%.Z4151X\$<7E.H1RF.TA"2\$SIK1(4A)@D130LK51\$=<Y
M%G419FV1+1HHJH<1A%<DN.Z&9V9P>1YOP(2XN%0)>Y1N1BHRR-TR+H+ML.MBD91+1P%0QM80&1B"1FM2.16Z11.4TT?=@72D269?1514A.6X\$5(7=M.MHLO.MG-PZ.M%17C.
10XD=W%197RD1H756=7>N@+A)YVS>1>701?2YVOFV).EB18D5=MHJ1SG<?>1@N+1J8-1245L#H0 (<35K%>=>1A.<?>M>PO-VIR:W.H965TB M'G-P3QX"S.HG:
(C"MK94W.06GR<JM\$<+QOFTV1P.WZL%UE1=7.3K1J-ZIPEHRC.WIR5U39K.MVF<K^XOZL1+9.7.0=G.1YURL>1BRR%5XFI.MUV27H56G.(HHZ)C=2.5KKXOE.NO^HW70^?>
>>ER<1L.FVLN*6^WYD?4WOY7PGLC.G6715W.MHWLAX=7WGVL5DA:@<7/1<0/<%TV6:>P6C?2.KCWXH>201<0/<?>YVM.M.P+JRXNF?>
SZF(1@YTFWMO<6>+HGFH05^6W\$F1HJH(I&S&A)V"MTB(7ZY>=R/H7X0QOMJIA)<H7S2B<1#3ATFD>=W0A\$707VW7M.7MHUB7 MHT7<G.9EM?
E7FD689V4H.8\$G2X&UPHUV-ZW716%WZLIV3+>ZHLXN.KQ.MRSPQ242YM(8=V1LE.SHP.9D192UPJ.M.HJKBQY.GG2).WN41+YVAAO&K1P.MKLZ715%>XHN8#STR1C#2=>L0PU?>
(HUDH1.-57<PL7Y1L-01X(M<V+ILE+D.M6V9Q>5VO5IOMKM.UHC=7%5.MN.M.E=8OPW4A?K\$<S+B>P.(PM)C)MXQO)JD19.3PNC7Q)QD9?>XEE<4E>1N^K1@7<-P2.#0
M3T.3>29H=<N.G.W2V9P?CSXK.M^Z1R?H<SHELB+<PX4OXNL0R.MH1=DNGC7(R.<?>KJ2E.MHIFP2(HF9A)O68MXU<HJ49X.#E=C24PG1<2%1J.M8#(181<#Z71
NOZN.N2X.NIP.P+<QTYQ\$>.\$6DG.W\$F9J?WQ71JR=7Y.M418<=7.L0RQ.MZ<JIM(\$53Y9W1R.KP.JB19)1PVC4(2=9E.SPYMW00.O1.M:1OMWMSP?>
SG"IR.H92F.01).HRF<605XWNZ\$XVW-0>?W2Y96?28:=M43.LTB.(CA4Y101B&2B=ATL1L1Y?>+>G4\$=N.AE<@>OYH4<-3K.MT191BO1CM\$DIX>HMGG1/SP.)<FO
MVGL19J.LQ^K<6>.6BCA<+V08M.8N1%>L9.91<1N%8CL1E6B@B1<M.XD?B401C42?>QW<@<UUSPH1(C2V=>9+&8.P@W<L2D52CMCVADGX?FGZ.M&S(1+1+@+X#
DXZ1CPBT(F18Z+X1%>@H\$R.H.600<H0LZ0Q-MP\$)>+>M&CBQOEUE9&=<0XEE XIG.<+1+1EJH1H1@<C2Y.R1@<9655N.NVE.HJEF.M2WB.WZ3=>A.0.MERF?>C2%3
NDA@7-18WQ6>78T2.IMOV7?H6.NR.LZXL.R2G(H<B.WY1H=19?>B6S#8.1.W.XPZCG89?>EQ.MT21+G6JH5DM3/373NRMHXK9)OY=>Z5OISCK34CAT=>OCNH<6A>+>6&J
MST@=<X\$XZK13MDG6DELCFEM+80HXV12%W1<=>2.610Y7&0.O.B6R&L% MW02NL2.DH90N.1.B4M4&2.GLX.VWAS4OT.Z6E.OTM?KE2.L.V.06V.M1
>86H1H1W+>SNB6ICB>1N1F8PIGG3K5<U4MMMO?>P_N?ZOFA.9:B3+MFG+U1U5017WSA/>V.8K"3?>7.3D3?>VHO7Z1Y?>MIRO13JUQ51&N92D&M?>
A#FYWC=V^AD8H1X^YOC67X1C6XFF41).PP<+<6.M&A.H1B?>2+>?S6F6S00/9P?>=<1C18QH131QN.U.M9K.1TW18QBEL+291.W+1>SOEP1D10Z7LG<.(HE-C\$042PWKSJ
F+Q.R1J9P.MVA<+>7)31323X3?>H/IO\$<2B.RH+H9VR&E1B7IAW.L%0Q@LW3Z5%#3C%>M.E.PTC+PQW.S1Z?RW71M.P=PDN<2R6B)P3VPY8<-0Q0B.&0D\$5X\$P1
18E\$M12&MM.M+1?<1C&G.TLC.M&L.TF0#>+1N%<8E.9.K@<1C\$%<X.LC.PZ?R721633%6.Y8I>+>TLX.M19EM1)+G4HK3N#7%<1H+H"6\$<HY"R5%>2.YUB.M5%<G3C<+<6J
N1(AWGZ?ZNIHLH<C43LR1Q>+X.MG@<141.9N0H<@<HMM9=NU3MNTS530>6A1&K1QO?>7T.T7PU=<P+IH0M0HON.M0N0>+>W6S.WB4-0<H?QXLZ.G2.M+1?>C25\$R.A"C@<#
<2(C\$>IT:150>1H13 MO1P#<+>HJUF5U<+1%<1%<@<RBL/HV0=KL>^<8B0QD.G#>B100 F?1L\$1.M6PKIOE7JU00-[AB?RR<+10^<CRY%V%26R061+OU3@<DID&GZRC5C-1@<UK
MVB=<+1>S#>=25?Y1L1H1Q25191QUM<C53T3>YAV#<+>E%?31B.UA\$K.M.TC1-J=0.VP#V<6S1<=<ZK2B-B'D-KEP<K+PGI=<1D1.V&+1K6110JN@1+1MECVE?>
Z19Z%<C1L">6TES\$22+>L?>2W1?>+>0ZANZ\$P660A.MT@DPPEZEM<1J0R&CK&G%0231G\$>W.B3A>XMNFI1WUSX799QW/ATQ30>=>EY=1V<78?>OYV&0.M<?>
B-7%T-M.C.SMIUEU67ABXV.TWJ9.610%<X%>KN>?7.XIBD?V1C.O.IEY3?>LLD=V1JA.TOHK.MR^P32<OL57IW.51#45L#H0 (<35K%>=>1A.<?>M>PO-VIR:W.H965TB M'G-P3QX"S.HG:
H965T4M1.62.C.W1&M1.G7F6E.607V811+>+516<0<<Q.41QOQ?>2.M9441VIR\$U9(2C3124VYU@MM88KH051V^\$E&K.DT-1ZWR-97.
<NX800.B>5J.HTM%\$>."RKOV>8+M5D->.\$1#"?%>A:~B%96H&5<H1D3Y=>18QH-S@<K.Y.7X%>VB.MI3?3U@<Q+>XVVR"NHQ6:AAO#%IE0S)IC
12FUVB=<#1?TDXF1.1\$YQJA.M.M8G60511N073C(B)3HXW.(4A+1+8YAH0\$41T4F#U5A6<BB>=>6T?
M@AW0&)<Q8DB>NRH<C\$W242QN"6"0DQ1J31>1NRH49YQJ08.D1(1.M1P.R"HH@5?>1>1OPFWE7YVB5YOH&1@<-1NM&P.9L.N&Z4L1%CB.86H4M1?>
U6.1<10=266T1D.YGZ=>+87HE.B"=>9T1E5F1.K456VC.M&PFI+&

!090G9>3W214!@:YMNRIKN.MQ3UL/PHUBUS(HH.DYOS)&UUVIG:PS<@%9C3IH:3!3!WLN3BSEY%6UV.M-N:*
(!90&G9P.SW~+8%.6K<@%!(LJ<@%P>P>4IRY>WHR22)CS<#-.U.Y.M.F@%#8DC=4G0OL5BAL&KV00S+IBW9YW7&@&U4!X4P3H\$LKR<2!E(B#M.#1!\$N.5=Z!P7BH!JP*
(G&P.P."A06 T9&41&PRMH<ZRLH!>D=I4.MJ7T2HK96.P<9KBQ.#5E!F7FZ5T+ 2G660+7Z.1!@AC6Z&4MBM8H7P7B#P+TGLQ?A1+DM7MT5A#8L~.WTS.722>161R&
<11"WQSONQ.A.L%NGAU79A-ID%AH&2U.F.M<L.WIR+CGRRIG662\$Y3PLD)C!N%\$>7=+6\$SUL<T!HUM<MB&F.A6.M.QO:2B7T17V5+5!P!R.W)
(C:GAY78A2.Q@&F%N4!T70IMG.MYK1L(OR)51/21R8#F.KL@YX171G!A&V1AJO1(1%#1JDB<@%X1ZD'G6D~.RC'AU01&F.=Z.C.Q.P!<SCKCZ2
=>QT.4+OY+L4!7V(GE.2Y=MRBLD-8CB.M.EK:67TY8~<K&YK7Y.YY.B.#6&5&4ZV258X&BL.GA4AZ=<6&GDW&E.MUYS<Q.4RT~#B!S(FQCQ:QDVA+M-1@RGNUV7ZS>1%
LMZ.W.9T-2O.DYXR+LW!KC3YU.S3C+Y3M<=56A719M<=F1K4&5.0G3H1Y<@AXN8HBWUMFBX3YD15E=J59K<GJ9G165X9JHH.M~+3J84769<0R>@&B.5B>&CIG?2
5K2M55\$UHKK!/>@VTPV&=K=X.WV.MKZN5.19~#2H5@<177N5PH6P598?>=J5-7Z-B.H\$JD-46C'TSA'~M~7H!151'9R5E'T3'6A.A.9!11~&ZG/@DY3>D15
E=15Y12P2.9UW.M3!65>B'9CWNHONJH6Q@EOTYTL7!8M!M.Y:084!747U!TFLYU!5ZS!MG-Y>#X!YVNSMS8XB8U+1+7+1P-G@QN6.6JKWHM=0#.H#6.KTZ@&H
MGN!>1X.MHLD3<@XUB2CV(KU'XGP.VHN):&Q&87EQ2.VGL.E.MHHI(2)JO2(4T@Q@Y'X24V19V6W7+14M'Y33!1V1'FN14+M!M!OQMCG.IW<C.R+&B!U.135CP@&TQY<
66DXICQ.M.I(VN35.MF.16N!>1&W&4!K(FESCR316WY9Z#5)>1JGAID&F3P100ZXA5RIG.MDD&YDV.VU!P04~"2@%U:UH0L<4!<#D#M@&A!W=0>9!01#
1.67H1W1Q0=>9.M6FP(KP)1.BD>1!>IV6<=&MNS&#PEFJ.P.MLLXP83<@JARIIBT3X<=<M&X5Z<1D7YUOK=<J+<X&#<UE&KX~5.M@&X&Q9L0)JH8!U+!E19Y)
<8>YR7O.2E.G\$D0!<W<H\$45.0GQ'T'D&Q.M>B?>0K02!2P.2V~!Y=>@MN.75=<#1XD'DB48WVW16S7R8MPDR1.6~>A.M3L<^!D3D0/ZD+Z#(#7G)21BRIF.L#59X<
DPKIG&IFK).73!3PORI<G.MH\$P3A78E&4JXF0L3.<U4!JMN=EV1&MGOD07~>#K+D.U@H?>=<C#1J1
M1STC>1.QC\$H<0~>WX>D>GTD41!7U!AKE'TA01Z5+RZ7!QSRY>7R!<KGTZ.MG07KG?SIR06.N.'IKF<Y&YIV:~A'PPOS.M>YHMWM.
14Y4TQ/2KR>DW~4<F.L!<@>DVC+4W152ZK(CHKIKY!TFOHS.HL.U0LS3.2P>DPTFW&+1T04S=A!>V.CUN=OODTFAK.MQ.1A(XK&K%=(BUA&~&N?
2.0YV4!(#DHIMR=E@LZGB&CIMG+MDS:6!AT9P~P#P<=<#69#HGT!>D'M)YWG>2.3IMK>5.FINMS.T%:0!>A.48(58P=>07VIE.A\$!<H!<0.C!>3512(P.M.\$!>9>&PO=VIR:W
H965TK-BOS!2-G:Q07~#>D.M@GK0IX=>@4C1!/>3~2)A&TE)26>FD.MOFENP'EFFG/5VEJ5G12X%(25@.5U/D@~.R9.O5-1-MIXZO!<49U>+!7WAA!O15D)Q2%(<JTW13!O-
=>BLOK1P<C!X/N@Q.MG<@&1.5ZA!>97VXK:@P.M%&1&H!<#>8=>2O>D6R97915141ZW.TLTESA@.M3Q!<O@X!H0G2'5%\$!\$!>U!<BDYG:BLE&B1B1ISM~>H!873#
(-6JBDG1HW.MA>3J+5!E3PA2DR1<=<1<#8!<1!1!0U950!9918X!YV&S!>D.G.0&S3!>M~>W9>4<G!V~>+!<S>W(\$X&A'0!<0SKR41(K!3L1+>@T!<@<
M0:>#R&FAA9>3H-GW3CS(=<S!>SRAIY!<4B9L0!<@>4GRZUS2\$6XD<@L6I9!<MXHIS!M&U014!<46!RE~Y4.B.#MF.HM-G!U&A!<S!<M0!S!<PDWS\$QZCGV9P
M0R8>B60<@Q&7<C<@<D!>A>Y@M.R&KFR!R~!<U!<ORGP<=>3!RVR:BHLH!<W!KT!M2.2@8Q8.6=1&ZHU!<#>T>0!<S>@DN.MH.<C!<G&@Q!<VQ!<506B7PACBZBV=I
MN+9&ZS9!<IEEY)!<UHS9UHM~%MRIA>=>D.WIV6'H#>P<3!Y<UXV&!<P.MY\$!<K#<!<PFS'=F.E.LW\$9!TL.M>~.OT*4*8!4Y4.M@4MDT6&MB\$8R.MHOAZ!<7D%84-
=>J80.B@K\$<4-WYUOZKO'XU!F!<1+@&E+1!WY@=>63.MZYRT!<S7YLBW!.V!S!EVUO<~>RHZ.X'0790B9V\$>R!3'W5>D9!3=12!0%~>M2?K2V.YO>Z!U.W'K>.>75!<1!<?F<~
2!NAK>1J.8DSN&.#H!H!R'0U02P!<S.M~>D.HH!<6DPU!<2.P~<P!<D.IX'!<W.W!<K&U!S5==>JOPX.KT35B9.K-U0?7U!TBVEV!<1ZX9-WZ?C!<P!<F=FI
MT!H!<V!<OYHD+0%~#<1/1.K!<S!<Q2!<218Y2>.<4N.7MBW6-618.M7+V!<PD!<VL6(V!<CN2>10<1N!<4G&E!<@<A1B!H!<P!<MK~<3DEIN'<TXK!H<=>P2.MHB.F!<A5+!<8P!<5+?&br/>Y\$K!<6=<S&EKA!<QOMOT!<53U.SQ2P3YA.M'UO'Q6&A.M.HL!<@<13!QH<5&GL<5!<@<1J!<PCH!<QX%<0<1D!<B.M=>MSNF!<1!<Q@<@<X'Y&E!<6A2!<Z
#_19X!YX=RG.O!X'W~#UCU!<U!<P!<O.M.M!<1T!<1<@<T2!<S'=>1=VX%#F.86R!<B'!<1!<O'<GLZG-HFZ!<1Z!<F!<O!<U!<ZOE.MZOEY.XA5U22A*2%>+!<B.M.)<UV!<CM%<O#<2TYR!<UR~>8E-
KVI!<U!<O?<MWQO!<N!<0B3!<MZO>Z5+!<1!<@<GLH.Z.5K!<1G'V!<U?<1#?<17YQ!<P4S!<7ZNR.M!<L!<X!<K0<=>9OX!<1<4+<DFTFW~#<1O!<F!<7!<69ZP.(ND.F.BG6V70QUQ!<72!<K?<
15==DD4>D35D-0R.M!<MY\$2<@<Z5+!<1!<@<GLH.Z8.U!<@<192.GR9!XIC!<M!<MY!<EGXQ!<M5>29>GY0!Y7G!<4Z40!<BK!<+!<H!<Q5!<1J!<Q!<5!<1J!<6&7!<OYBE!<4E@!<M2N=BH'H<
+W/O!<R5!<V>=<16N!<1<=<G!<F!<O!<1'U'X!<H!<P04.M~>2@<S!<U>@<D.P&#<B.0!<A!<W!<O!<M2>O!<1!<L!<4E9DRY89>WN0FT!<14!<H!<J0>Z!<WOCY!<AW!<HPLGW.G476.A1?<F
MY523!<4N!<1>6~<G!<G9D!<F!<M=6!<H

```

0=OVDH07$EY@N" H2Z2NT"$S5 (M-ESK)I#E#^+^C%GEX$ODF2%=@Q1RWZFW%+^@0L&QULX#P-3U=2U XI=PW<I= M9_X;K%8$281A:66>5<#O=1%71?7<6+ZCHXD?I
CE4ST0J0$R?K7-D7&T1-MYH9LACBWU+L P04 " "2@S;U;V9:D8D" #U@& @ "AL+W=OC< "Z=$ $ #J2?QOS $YU 9U0?RHW 35X+7JQDVM"
MW>NN2G;HJ?H$3$90XL0?RHJHJL& &7L3F= MDDP&#SOV;19J AE215;12 -1V/G2L R6%ZZQ?XIM Z&AB157-DOV6P MGD/26FEM&144+ "R<=7-@ "IP/A" T@ "I@+ %A
9HH5:FE" DUB">9$F M&E,P & #HMS &T+N<K3688XG2SJN" VZ(0J0?9D?6=CSU@/VA11D?9 X-MX/G) @Y$K @/G8.DTU@Q$14 KCR1L FLF)BH VXX(RX&2W)/0 D<+ICWPZ2
0AHS<QX?XWTO(SNNI@C7B-W<^B MOKFS&BK+L5U<^C M Z6$P:GDGBIHHJDBH<1=1%23.0$M->15-7RSAB>B;H-MXH)41HBBY1?BG.Y7LOZB9>I-
Z(478$W.7GHAT?XJ2>1#P_X9I0B?M<^MVQS:E4V1.3L5+9+.87&JF>^Y+1($T.SJ<$T/N<^7W=2Y2I+U+ P04 M" "2@S;U;I3?2%7# "3"P&@
^AL+W=O&ULK991JL;V> "J$50PMLD23QDHW: HH80PNL6?CZS.MG6VB?F1E)U<M^Y4HC@2P1A+18HW? XNSN2Q051R1HJ#Z#146X6@9IK>0%3%BJB;D0-
MW$S9?ED1.9BR9ZL2F_BF=I&A$5161?>WSAWCWZ?<S2B?X&4F&1M$1=EL7%KXFM?V19@<K>#>A0H8.THJ#W4M<N<M<^PG;9?WHICQ J<M0;4CNKD&=E0-
D+1L6.OY3?<1&S?+1UOZL>O)H/ABBX&^PL+25<E1W=0U.U73IHB(XSP.M<+1 00?TE-MM HK590K?7M (DM<D?200?/126.PA1Z0P).%7C-FW10H?
-2L3R+Z+51EF+G+CGKPV8= "1MPFGU$1<JL5;59<^EH9. KD 8+1HHP&GW1?< 7L3M<^FESRGKNJOHEM<M=0HJAP0425?P10V?V) @2D(5)40K<#M-YJ:QAI DAG<X$1Y:
QW:MS&G+Q X)SW_X^K<FCQ+P9G&A:IFXAD.8#?#EHHO<1V/L6&9?F UV,3)7I<M<^I08I7DPR=02+&B10?>F U3B K:ISI>Z8@&A^EPFRV_>Z87>1H<=D4
MNI%N9;1PL>6CNI>#O10MAE15FV46ZAZH?VJWN92@JPO%Z;1QSP9HFL M4C JK<=743I&SWB0R226544U@%I@&H:ZIFJ?OAF+AHMTM?>?^E'G M>KJJC5*N09SXF@?
V7PT.S9?2Q=IAK<A0! MZL Y4UMFE:Q92YZH?5P=P21#0/O<8<1AW=H@&WVLEWPO012MC.O43R; M+T=^CXC#> #1FV.6^1^16B1?>=H<19#.8Y5DPOT/O+DOV>OJ5R)WE"O$
M6&MMD4UF3D19W@&#&1:UNT1MA970?>X+I=FD; 2^H$K&1E16W)SGU!+ M P04 " "2@S;U=60WK" "JP @& ^AL+W=O&ULK95=YLP@& (BL61J976160M2-
CZHE55MTA#M;MVH#1&L MPOIND<=>$6&T(GDO=U/8<HJXSW8Q &6BV=9 "CT4E(FTTZA5?CNC(MH,3R MBET)DNY2>26+1<^Q2F=>#8+&1=EEC
MO@?7MU?U=W8?LFZ4L1F057L2U?U<K^F=BH9?8M)PAD2D$<S L1<+B M<1<E09&R&C9.7VJXG<95?T L(55K>N #&D<^EZY MR9J@>^SYORIM?7L NA(OM F1&I^<
N&TILMR&RM.58XB077F&6BM9H9V-K8 M.V&15ETKH3T3GJ619504% 5D4IN@64I020SN1?Y8LTE.M2 14N^N^K? M>Z(J201N^1OZGX" A.H+?>
FTG?S&PMTA@A#X12+21C5VE/LZ; MMF2F5P&EAP&Z14? 0H+H(10/LK1>GAZW17UZ@K5<5%KZX1&10G/IZWG?M2 142.O&8BP) ^&5GB7@< G 2Q>2= Y_VZ/O$!# OZ3V^NW8>+
ISBEFS MN40N1$0!@& "I=ITZC& &IGUL&S THMC=&1T<15U?I?> MWK&@&S)J> 19 M^2<^10?>J9D.LB?&K08PL$&E(C;SIFDX=>7%2^OX&PO=VIR-W.H965T4%&D2<Z<Z<Z<Z<
MSEUFENZ<C<GTO/VL10P?+&TTFIM9CES<ZS0SHN<IREY&X#>1= KJ?K@&G1ON M^2<^10?>A^<WTFB3YOPB@&A^8MH" C&RUEO7L FK63(17ZL M1RX=7-7Y8G2<_F
IQ:0QD1B4G 1006 YDD12Q1H Q?U<N^6M5G12L2ZU?T MFW+R@L P39F1X$<C&K FUL0?<5GA702H1QOH51M35DN@L<M^M^AHI<5NPZ?7<2>A1?>
2.10X3A3VMJ1A2N0XZM-M1L Q?U<9E;HJDE8B0L @-IPUY @P3S>P)KY<^MIN<T1=0H&0JF.R6+9 M^<@>7D9.HL6<^2P3<YRRN&ABN1BI (MWH...D.P4U<=GV1^3V?
Z&KX$ 2<=>IQ GV1^3V?> AK5Z?>UJ19C M492858<3EH.HJ<^VJ0B @<7W/P@>O&HWT?>F K@< "T(W41X>=>Z^6<^U<SJA+1^6^K&4< 7%1L5.9T?>BQ03@ M499?
0+U+L1$ T1S6E1L1L" GDA$5A>=>H0! #45N155>1<G1G6LE)@&IX, M6V@41R<7H4TOR<A9H10>XO<@IGXB^YH1TO^V&UVU&C3 M1J.K1HJG=21Y+&DEY2BQ(VY4Z<T<97H
US6Z;K4+1 MWR9QW#Z1?T3Q (H04GU+1F1G&9<#>2JUBI=KDLI<6B81DZ @C(G@>1?>1<XWJ M:77X?IT>12>6>W1 KOSA^J^V&S^HIG^WE&(I2D<1=1=V7%5(5E2D&DV59Z
MHIS3+<S1R23J(IRM>=>N<^HJ1+U?I P04 " "2@S;U:DE1+Y8@& M #1010<^AL+W=O&ULK51131LP&K MPO<1 @&DHI1+<T$12Q0H:HVIZF&C)M.%PI&^I+>S7YR&J+>
1+XK0 M+W$2>=>Z2K<^WID?T1#>29>86UZOZLF1DHYEA5?EDJ73)<^EZY9M&AMK M4^GL&A2FLX1<DWK06<165G^UEOK.NBR2QOHL83<^I=>SP56=ARF
M%50A^UM=>W1CN6G)MV5F#4I0ZLX9E G$ M^UQ<^SCH1X3%1141CW1:777>F N^LGI B^U=M^R8 .G2OSDN2TFWHD" M.2I96M@&M:W
15 065F7VH+V18W) &Z&O%DP1E1P1?>0YF$<100M MC(P@&H142VTR:R6 6.618E661#&FJX?MJO<^U$Y7Z=>18559?>Q0U%$ A60(4U.C M^N<^>1=>B@WJ?7OPP&67<03H)
D6J1>206>WHK 69P2D25?>FV1?>1 M<AHM&XUPB@&B+&3OH&8$N1YK<^M0XITXK<^10C72C8)CXFXU&V3ION+Y
MOB3NA10!>1?>ITZG01&H1P>@1Y&M^4M<^M0I2C1?>I1=>C%<5V<4^0M/O2NE5UP+&1<D6+1GJ@FUG3&95=>LNE7FFKY<@&C67&SH.ETK9 M1<=>@&I@W141&H10<^H10<^
35KOD9H1P_03<=>KPOG<1HML&5F5<=>C@CS3K HAJIS9&N<^1<MJOF<K02Y4R11J14?>F7JYV5D:3?DBB%>17AP6&ESLR&AP<T1V2C13P.E<7&RTOH/9Q?7R<6G71
MOJ PY0N$45E<Z1V?LHM)7N1+UXZ=6R1%>=K0019.B9T?>B)61I+V+8 MK.IDE^G9+6A$7 JFX(CU2.R90%M<6IDMN%BI "L>7P/V3 (<B-3@&+C 9E=08IN6=I=0/U1$G M4-
"TH>E=9AKNB1+DEJ&V4SIE.DV31H0L18:G8T3Q?P.VH<0%3&78 M1LHK82M6P8318?>1E V5N@G:8H&C&PR?2A1)3T>=>KFRWZT&W&QV&R91>PFDX?T
M&38>0>81B>=>T$8&N<N-R33<Z>O&L$S TWB&Z&@&3AR&F&M 20R<=>Z?>0?>3&4Q1B3;1?>1U L680?>200F?>=>C&8D?>T?&gt
```

[falsefalseR7.htm9952155 - Statement - Consolidated Statements of Changes in Shareholders' EquitySheethhttp://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityConsolidated Statements of Changes in Shareholders' EquityStatements7](#)
[falsefalseR8.htm9952156 - Statement - Consolidated Statements of Changes in Shareholders' Equity \(Parenthetical\)Sheethhttp://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParentheticalConsolidated Statements of Changes in Shareholders' Equity \(Parenthetical\)Statements8](#) [falsefalseR9.htm9952157 - Statement - Consolidated Statements of Cash FlowsSheethhttp://www.colgate.com/role/ConsolidatedStatementsOfCashFlowsConsolidated Statements of Cash FlowsStatements9](#) [falsefalseR10.htm9952158 - Disclosure - Nature of OperationsSheethhttp://www.colgate.com/role/NatureOfOperationsNature of OperationsNotes10](#) [falsefalseR11.htm9952159 - Disclosure - Summary of Significant Accounting PoliciesSheethhttp://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11](#) [falsefalseR12.htm9952160 - Disclosure - Restructuring and Related Implementation ChargesSheethhttp://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuring and Related Implementation ChargesNotes12](#) [falsefalseR13.htm9952161 - Disclosure - Goodwill and Other Intangible AssetsSheethhttp://www.colgate.com/role/GoodwillandOtherIntangibleAssetsGoodwill and Other Intangible AssetsNotes13](#) [falsefalseR14.htm9952162 - Disclosure - Long-Term Debt and Credit FacilitiesSheethhttp://www.colgate.com/role/LongTermDebtandCreditFacilitiesLong-Term Debt and Credit FacilitiesNotes14](#) [falsefalseR15.htm9952163 - Disclosure - Fair Value Measurements and Financial InstrumentsSheethhttp://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFair Value Measurements and Financial InstrumentsNotes15](#) [falsefalseR16.htm9952164 - Disclosure - Capital Stock and Stock-Based Compensation PlansSheethhttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansCapital Stock and Stock-Based Compensation PlansNotes16](#) [falsefalseR17.htm9952165 - Disclosure - Employee Stock Ownership PlanSheethhttp://www.colgate.com/role/EmployeeStockOwnershipPlanEmployee Stock Ownership PlanNotes17](#) [falsefalseR18.htm9952166 - Disclosure - Retirement Plans and Other Retiree BenefitsSheethhttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsRetirement Plans and Other Retiree BenefitsNotes18](#) [falsefalseR19.htm9952167 - Disclosure - Income TaxesSheethhttp://www.colgate.com/role/IncomeTaxesIncome TaxesNotes19](#) [falsefalseR20.htm9952168 - Disclosure - Earnings Per ShareSheethhttp://www.colgate.com/role/EarningsPerShareEarnings Per ShareNotes20](#) [falsefalseR21.htm9952169 - Disclosure - Commitments and ContingenciesSheethhttp://www.colgate.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes21](#) [falsefalseR22.htm9952170 - Disclosure - Segment InformationSheethhttp://www.colgate.com/role/SegmentInformationSegment InformationNotes22](#) [falsefalseR23.htm9952171 - Disclosure - LeasesSheethhttp://www.colgate.com/role/LeasesLeasesNotes23](#) [falsefalseR24.htm9952172 - Disclosure - Supplier Finance ProgramSheethhttp://www.colgate.com/role/SupplierFinanceProgramSupplier Finance ProgramNotes24](#) [falsefalseR25.htm9952173 - Disclosure - Supplemental Income Statement InformationSheethhttp://www.colgate.com/role/SupplementalIncomeStatementInformationSupplemental Income Statement InformationNotes25](#) [falsefalseR26.htm9952174 - Disclosure - Supplemental Balance Sheet InformationSheethhttp://www.colgate.com/role/SupplementalBalanceSheetInformationSupplemental Balance Sheet InformationNotes26](#) [falsefalseR27.htm9952175 - Disclosure - Supplemental Other Comprehensive Income \(Loss\) InformationSheethhttp://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationSupplemental Other Comprehensive Income \(Loss\) InformationNotes27](#) [falsefalseR28.htm9952180 - Disclosure - Pay vs Performance DisclosureSheethhttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes28](#) [falsefalseR29.htm995445 - Disclosure - Insider Trading ArrangementsSheethhttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes29](#) [falsefalseR30.htm995447 - Disclosure - Insider Trading Policies and ProceduresSheethhttp://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProcInsider Trading Policies and ProceduresNotes30](#) [falsefalseR31.htm995530 - Disclosure - Cybersecurity Risk Management and Strategy DisclosureSheethhttp://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementandStrategyDisclosureCybersecurity Risk Management and Strategy DisclosureNotes31](#) [falsefalseR32.htm9955511 - Disclosure - Summary of Significant Accounting Policies \(Policies\)Sheethhttp://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies \(Policies\)Policieshttp://www.colgate.com/role/SummaryOfSignificantAccountingPolicies32](#) [falsefalseR33.htm9955512 - Disclosure - Nature of Operations \(Tables\)Sheethhttp://www.colgate.com/role/NatureOfOperationsTablesNature of Operations \(Tables\)Tableshttp://www.colgate.com/role/NatureOfOperations33](#) [falsefalseR34.htm9955513 - Disclosure - Restructuring and Related Implementation Charges \(Tables\)Sheethhttp://www.colgate.com/role/RestructuringandRelatedImplementationChargesTablesRestructuring and Related Implementation Charges \(Tables\)Tableshttp://www.colgate.com/role/RestructuringandRelatedImplementationCharges34](#) [falsefalseR35.htm9955514 - Disclosure - Goodwill and Other Intangible Assets \(Tables\)Sheethhttp://www.colgate.com/role/GoodwillandOtherIntangibleAssetsTablesGoodwill and Other Intangible Assets \(Tables\)Tableshttp://www.colgate.com/role/GoodwillandOtherIntangibleAssets35](#) [falsefalseR36.htm9955515 - Disclosure - Long-Term Debt and Credit Facilities \(Tables\)Sheethhttp://www.colgate.com/role/LongTermDebtandCreditFacilitiesTablesLong-Term Debt and Credit Facilities \(Tables\)Tableshttp://www.colgate.com/role/LongTermDebtandCreditFacilities36](#) [falsefalseR37.htm9955516 - Disclosure - Fair Value Measurements and Financial Instruments \(Tables\)Sheethhttp://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsTablesFair Value Measurements and Financial Instruments \(Tables\)Tableshttp://www.colgate.com/role/FairValueMeasurementsandFinancialInstruments37](#) [falsefalseR38.htm9955517 - Disclosure - Capital Stock and Stock-Based Compensation Plans \(Tables\)Sheethhttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansTablesCapital Stock and Stock-Based Compensation Plans \(Tables\)Tableshttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlans38](#) [falsefalseR39.htm9955518 - Disclosure - Retirement Plans and Other Retiree Benefits \(Tables\)Sheethhttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsTablesRetirement Plans and Other Retiree Benefits \(Tables\)Tableshttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefits39](#) [falsefalseR40.htm9955519 - Disclosure - Income Taxes \(Tables\)Sheethhttp://www.colgate.com/role/IncomeTaxesTablesIncome Taxes \(Tables\)Tableshttp://www.colgate.com/role/IncomeTaxes40](#) [falsefalseR41.htm9955520 - Disclosure - Earnings Per Share \(Tables\)Sheethhttp://www.colgate.com/role/EarningsPerShareTablesEarnings Per Share \(Tables\)Tableshttp://www.colgate.com/role/EarningsPerShare41](#) [falsefalseR42.htm9955521 - Disclosure - Segment Information \(Tables\)Sheethhttp://www.colgate.com/role/SegmentInformationTablesSegment Information \(Tables\)Tableshttp://www.colgate.com/role/SegmentInformation42](#) [falsefalseR43.htm9955522 - Disclosure - Leases \(Tables\)Sheethhttp://www.colgate.com/role/LeasesTablesLeases \(Tables\)Tableshttp://www.colgate.com/role/Leases43](#) [falsefalseR44.htm9955523 - Disclosure - Supplemental Income Statement Information \(Tables\)Sheethhttp://www.colgate.com/role/SupplementalIncomeStatementInformationTablesSupplemental Income Statement Information \(Tables\)Tableshttp://www.colgate.com/role/SupplementalIncomeStatementInformation44](#) [falsefalseR45.htm9955524 - Disclosure - Supplemental Balance Sheet Information \(Tables\)Sheethhttp://www.colgate.com/role/SupplementalBalanceSheetInformationTablesSupplemental Balance Sheet Information \(Tables\)Tableshttp://www.colgate.com/role/SupplementalBalanceSheetInformation45](#) [falsefalseR46.htm9955525 - Disclosure - Supplemental Other Comprehensive Income \(Loss\) Information \(Tables\)Sheethhttp://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationTablesSupplemental Other Comprehensive Income \(Loss\) Information \(Tables\)Tableshttp://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformation46](#) [falsefalseR47.htm9955526 - Disclosure - Nature of Operations \(Details\)Sheethhttp://www.colgate.com/role/NatureOfOperationsDetailsNature of Operations \(Details\)Detailshttp://www.colgate.com/role/NatureOfOperationsTables47](#) [falsefalseR48.htm9955527 - Disclosure - Summary of Significant Accounting Policies - Principles of Consolidation, Inventories \(Details\)Sheethhttp://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesPrinciplesofConsolidationInventoriesDetailsSummary of Significant Accounting Policies - Principles of Consolidation, Inventories \(Details\)Details48](#) [falsefalseR49.htm9955528 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment \(Details\)Sheethhttp://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetailsSummary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment \(Details\)Details49](#) [falsefalseR50.htm9955529 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangibles \(Details\)Sheethhttp://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetailsSummary of Significant Accounting Policies - Goodwill and Other Intangibles \(Details\)Details50](#) [falsefalseR51.htm9955530 - Disclosure - Restructuring and Related Implementation Charges - Narrative \(Details\)Sheethhttp://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetailsRestructuring and Related Implementation Charges - Narrative \(Details\)Details51](#) [falsefalseR52.htm9955531 - Disclosure - Restructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date \(Details\)Sheethhttp://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesCumulativeToDateDetailsRestructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date \(Details\)Details52](#) [falsefalseR53.htm9955532 - Disclosure - Restructuring and Related Implementation Charges - Summary of Restructuring and Related Costs \(Details\)Sheethhttp://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetailsRestructuring and Related Implementation Charges - Summary of Restructuring and Related Costs \(Details\)Details53](#) [falsefalseR54.htm9955533 - Disclosure - Restructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment \(Details\)Sheethhttp://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetailsRestructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment \(Details\)Details54](#) [falsefalseR55.htm9955534 - Disclosure - Restructuring and Related Implementation Charges - Restructuring Activity and Related Accruals \(Details\)Sheethhttp://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetailsRestructuring and Related Implementation Charges - Restructuring Activity and Related Accruals \(Details\)Details55](#) [falsefalseR56.htm9955535 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Goodwill \(Details\)Sheethhttp://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetailsGoodwill and Other Intangible Assets - Schedule of Goodwill \(Details\)Details56](#) [falsefalseR57.htm9955536 - Disclosure - Goodwill and Other Intangible Assets - Summary of Other Intangible Assets \(Details\)Sheethhttp://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetailsGoodwill and Other Intangible Assets - Summary of Other Intangible Assets \(Details\)Details57](#) [falsefalseR58.htm9955537 - Disclosure - Goodwill and Other Intangible Assets - Narrative \(Details\)Sheethhttp://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetailsGoodwill and Other Intangible Assets - Narrative \(Details\)Details58](#) [falsefalseR59.htm9955538 - Disclosure - Long-Term Debt and Credit Facilities - Components of Long-term Debt \(Details\)Sheethhttp://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetailsLong-Term Debt and Credit Facilities - Components of Long-term Debt \(Details\)Details59](#) [falsefalseR60.htm9955539 - Disclosure - Long-Term Debt and Credit Facilities - Debt Payable within One Year \(Details\)Sheethhttp://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetailsLong-Term Debt and Credit Facilities - Debt Payable within One Year \(Details\)Details60](#) [falsefalseR61.htm9955540 - Disclosure - Long-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance Lease Maturities \(Details\)Sheethhttp://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetailsLong-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance Lease Maturities \(Details\)Details61](#) [falsefalseR62.htm9955541 - Disclosure - Long-Term Debt and Credit Facilities - Narrative \(Details\)Sheethhttp://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetailsLong-Term Debt and Credit Facilities - Narrative \(Details\)Details62](#) [falsefalseR63.htm9955542 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative \(Details\)Sheethhttp://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetailsFair Value Measurements and Financial Instruments - Narrative \(Details\)Details63](#) [falsefalseR64.htm9955543 - Disclosure - Fair Value Measurements and Financial Instruments - Fair Value of Derivative Instruments and Other Financial Instruments \(Details\)Sheethhttp://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetailsFair Value Measurements and Financial Instruments - Fair Value of Derivative Instruments and Other Financial Instruments \(Details\)Details64](#) [falsefalseR65.htm9955544 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Notional Values \(Details\)Sheethhttp://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetailsFair Value Measurements and Financial Instruments - Schedule of Notional Values \(Details\)Details65](#) [falsefalseR66.htm9955545 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Gain \(Loss\) Included in OCI \(Details\)Sheethhttp://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetailsFair Value Measurements and Financial Instruments - Schedule of Gain \(Loss\) Included in OCI \(Details\)Details66](#) [falsefalseR67.htm9955546 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Narrative \(Details\)Sheethhttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetailsCapital Stock and Stock-Based Compensation Plans - Narrative \(Details\)Details67](#) [falsefalseR68.htm9955547 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity \(Details\)Sheethhttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetailsCapital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity \(Details\)Details68](#) [falsefalseR69.htm9955548 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Fair Value Assumptions](#)

[\(Details\)Sheethttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetailsCapital Stock and Stock-Based Compensation Plans - Summary of Performance Restricted Stock Activity \(Details\)Details69 falsefalseR70.htm9955549 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity \(Details\)Sheethttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetailsCapital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity \(Details\)Details70 falsefalseR71.htm9955550 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Performance Restricted Stock Activity](#)

[\(Details\)Sheethttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetailsCapital Stock and Stock-Based Compensation Plans - Summary of Performance Restricted Stock Activity \(Details\)Details71 falsefalseR72.htm9955551 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Restricted Stock Activity](#)

[\(Details\)Sheethttp://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetailsCapital Stock and Stock-Based Compensation Plans - Summary of Restricted Stock Activity \(Details\)Details72 falsefalseR73.htm9955552 - Disclosure - Employee Stock Ownership Plan](#)

[\(Details\)Sheethttp://www.colgate.com/role/EmployeeStockOwnershipPlanDetailsEmployee Stock Ownership Plan](#)

[\(Details\)Detailshttp://www.colgate.com/role/EmployeeStockOwnershipPlan73 falsefalseR74.htm9955553 - Disclosure - Retirement Plans and Other Retiree Benefits - Narrative](#)

[\(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetailsRetirement Plans and Other Retiree Benefits - Narrative](#)

[\(Details\)Details74 falsefalseR75.htm9955554 - Disclosure - Retirement Plans and Other Retiree Benefits - Schedule of Target Asset Allocation](#)

[\(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetailsRetirement Plans and Other Retiree Benefits - Schedule of Target Asset Allocation \(Details\)Details75 falsefalseR76.htm9955555 - Disclosure - Retirement Plans and Other Retiree Benefits - Allocation of Plan Assets and Level of Valuation Input, by Major Asset Category](#)

[\(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetailsRetirement Plans and Other Retiree Benefits - Allocation of Plan Assets and Level of Valuation Input, by Major Asset Category \(Details\)Details76 falsefalseR77.htm9955556 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans](#)

[\(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetailsRetirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans \(Details\)Details77 falsefalseR78.htm9955557 - Disclosure - Retirement Plans and Other Retiree Benefits - Benefit Obligation Exceeds Fair Value of Plan Assets](#)

[\(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueofPlanAssetsDetailsRetirement Plans and Other Retiree Benefits - Benefit Obligation Exceeds Fair Value of Plan Assets \(Details\)Details78 falsefalseR79.htm9955558 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Other Retiree Benefit Plans](#)

[\(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetailsRetirement Plans and Other Retiree Benefits - Summary of Other Retiree Benefit Plans \(Details\)Details79 falsefalseR80.htm9955559 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Net Periodic Benefit Costs \(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetailsRetirement Plans and Other Retiree Benefits - Summary of Net Periodic Benefit Costs \(Details\)Details80 falsefalseR81.htm9955560 - Disclosure - Retirement Plans and Other Retiree Benefits - Expected Contributions and Benefit Payments](#)

[\(Details\)Sheethttp://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetailsRetirement Plans and Other Retiree Benefits - Expected Contributions and Benefit Payments \(Details\)Details81 falsefalseR82.htm9955561 - Disclosure - Income Taxes - Components of Income Before Income Taxes \(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetailsIncome Taxes - Components of Income Before Income Taxes \(Details\)Details82 falsefalseR83.htm9955562 - Disclosure - Income Taxes - Provision for Income Taxes](#)

[\(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetailsIncome Taxes - Provision for Income Taxes \(Details\)Details83 falsefalseR84.htm9955563 - Disclosure - Income Taxes - Income Tax Provision Reconciliation](#)

[\(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetailsIncome Taxes - Income Tax Provision Reconciliation \(Details\)Details84 falsefalseR85.htm9955564 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation](#)

[\(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetailsIncome Taxes - Effective Tax Rate Reconciliation \(Details\)Details85 falsefalseR86.htm9955565 - Disclosure - Income Taxes - Components of Deferred Tax Assets \(Liabilities\)](#)

[\(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetailsIncome Taxes - Components of Deferred Tax Assets \(Liabilities\) \(Details\)Details86 falsefalseR87.htm9955566 - Disclosure - Income Taxes - Change in Valuation Allowance for Deferred Tax Assets](#)

[\(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesChangeinValuationAllowanceforDeferredTaxAssetsDetailsIncome Taxes - Change in Valuation Allowance for Deferred Tax Assets \(Details\)Details87 falsefalseR88.htm9955567 - Disclosure - Income Taxes - Narrative](#)

[\(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesNarrativeDetailsIncome Taxes - Narrative \(Details\)Details88 falsefalseR89.htm9955568 - Disclosure - Income Taxes - Unrecognized Tax Benefits \(Details\)Sheethttp://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetailsIncome Taxes - Unrecognized Tax Benefits \(Details\)Details89 falsefalseR90.htm9955569 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted](#)

[\(Details\)Sheethttp://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetailsEarnings Per Share - Schedule of Earnings Per Share, Basic and Diluted \(Details\)Details90 falsefalseR91.htm9955570 - Disclosure - Earnings Per Share - Narrative](#)

[\(Details\)Sheethttp://www.colgate.com/role/EarningsPerShareNarrativeDetailsEarnings Per Share - Narrative \(Details\)Details91 falsefalseR92.htm9955571 - Disclosure - Commitments and Contingencies \(Details\)Sheethttp://www.colgate.com/role/CommitmentsandContingenciesDetailsCommitments and Contingencies \(Details\)Details92 falsefalseR93.htm9955572 - Disclosure - Segment Information - Narrative](#)

[\(Details\)Sheethttp://www.colgate.com/role/SegmentInformationNarrativeDetailsSegment Information - Narrative \(Details\)Details93 falsefalseR94.htm9955573 - Disclosure - Segment Information - Schedule of Segment Information \(Details\)Sheethttp://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetailsSegment Information - Schedule of Segment Information \(Details\)Details94 falsefalseR95.htm9955574 - Disclosure - Leases - Narrative](#)

[\(Details\)Sheethttp://www.colgate.com/role/LeasesNarrativeDetailsLeases - Narrative \(Details\)Details95 falsefalseR96.htm9955575 - Disclosure - Leases - Balance Sheet](#)

[\(Details\)Sheethttp://www.colgate.com/role/LeasesBalanceSheetDetailsLeases - Balance Sheet \(Details\)Details96 falsefalseR97.htm9955576 - Disclosure - Leases - Schedule of Minimum Lease Commitments \(Details\)Sheethttp://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetailsLeases - Schedule of Minimum Lease Commitments \(Details\)Details97 falsefalseR98.htm9955577 - Disclosure - Leases - Schedule of Lease Cost](#)

[\(Details\)Sheethttp://www.colgate.com/role/LeasesScheduleofLeaseCostDetailsLeases - Schedule of Lease Cost \(Details\)Details98 falsefalseR99.htm9955578 - Disclosure - Supplemental Income Statement Information \(Details\)Sheethttp://www.colgate.com/role/SupplementalIncomeStatementInformationDetailsSupplemental Income Statement Information \(Details\)Details99 falsefalseR100.htm9955579 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventories by Major Class](#)

[\(Details\)Sheethttp://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetailsSupplemental Balance Sheet Information - Schedule of Inventories by Major Class \(Details\)Details100 falsefalseR101.htm9955580 - Disclosure - Supplemental Balance Sheet Information - Narrative](#)

[\(Details\)Sheethttp://www.colgate.com/role/SupplementalBalanceSheetInformationNarrativeDetailsSupplemental Balance Sheet Information - Narrative \(Details\)Details101 falsefalseR102.htm9955581 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment](#)

[\(Details\)Sheethttp://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetailsSupplemental Balance Sheet Information - Schedule of Property, Plant and Equipment \(Details\)Details102 falsefalseR103.htm9955582 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Current Assets \(Details\)Sheethttp://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherCurrentAssetsDetailsSupplemental Balance Sheet Information - Schedule of Other Current Assets \(Details\)Details103 falsefalseR104.htm9955583 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Accruals \(Details\)Sheethttp://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetailsSupplemental Balance Sheet Information - Schedule of Other Accruals \(Details\)Details104 falsefalseR105.htm9955584 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Liabilities](#)

[\(Details\)Sheethttp://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetailsSupplemental Balance Sheet Information - Schedule of Other Liabilities \(Details\)Details105 falsefalseR106.htm9955585 - Disclosure - Supplemental Other Comprehensive Income \(Loss\) Information - Schedule of Comprehensive Income \(Loss\)](#)

[\(Details\)Sheethttp://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLossDetailsSupplemental Other Comprehensive Income \(Loss\) Information - Schedule of Comprehensive Income \(Loss\)](#)

[\(Details\)Detailshttp://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationTables106 falsefalseR107.htm9955586 - Disclosure - Supplemental Other Comprehensive Income \(Loss\) Information - Narrative](#)

[\(Details\)Sheethttp://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationNarrativeDetailsSupplemental Other Comprehensive Income \(Loss\) Information - Narrative \(Details\)Detailshttp://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationTables107 falsefalseAll ReportsBookAll Reports cl-20241231.htmlcl-20241231.xsdcl-20241231-cal.xmlcl-20241231-def.xmlcl-20241231-lab.xmlcl-20241231-pre.xmlcl-20241231-g1.jpgcl-20241231-g2.jpgcl-20241231-g3.jpg http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/cyd/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024trueJSON135MetaLinks.jsonIDEA: XBRL DOCUMENT { "version": "2.2", "instance": "{ "cl-20241231.htm", "nsPrefix": "cl", "nsuri": "http://www.colgate.com/role/20241231", "dts": { "inline": { "local": { "cl-20241231.htm" } }, "schema": { "local": { "cl-20241231.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/cl-2003-12-31.xsd", "http://www.xbrl.org/2003/slink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/rctf-2006-02-27.xsd", "http://www.xbrl.org/rrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/rrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/rrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "calculationLink": { "local": { "cl-20241231-cal.xml" } }, "definitionLink": { "local": { "cl-20241231-def.xml" } }, "labelLink": { "local": { "cl-20241231-lab.xml](#)

```
"html": "http://www.colgate.com/role/NatureofOperations", "longName": "9952158 - Disclosure - Nature of Operations", "shortName": "Nature of Operations", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "10", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:NatureOfOperations"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:NatureOfOperations"}, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R11": { "role": "http://www.colgate.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952159 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "11", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R12": { "role": "http://www.colgate.com/role/RestructuringandRelatedImplementationCharges", "longName": "9952160 - Disclosure - Restructuring and Related Implementation Charges", "shortName": "Restructuring and Related Implementation Charges", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "12", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R13": { "role": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssets", "longName": "9952161 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "13", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R14": { "role": "http://www.colgate.com/role/LongTermDebtandCreditFacilities", "longName": "9952162 - Disclosure - Long-Term Debt and Credit Facilities", "shortName": "Long-Term Debt and Credit Facilities", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "14", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R15": { "role": "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstruments", "longName": "9952163 - Disclosure - Fair Value Measurements and Financial Instruments", "shortName": "Fair Value Measurements and Financial Instruments", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "15", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R16": { "role": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlans", "longName": "9952164 - Disclosure - Capital Stock and Stock-Based Compensation Plans", "shortName": "Capital Stock and Stock-Based Compensation Plans", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "16", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R17": { "role": "http://www.colgate.com/role/EmployeesStockOwnershipPlan", "longName": "9952165 - Disclosure - Employee Stock Ownership Plan", "shortName": "Employee Stock Ownership Plan", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "17", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R18": { "role": "http://www.colgate.com/role/PensionandOtherPostretirementBenefits", "longName": "9952166 - Retirement Plans and Other Retiree Benefits", "shortName": "Retirement Plans and Other Retiree Benefits", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "18", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R19": { "role": "http://www.colgate.com/role/IncomeTaxes", "longName": "9952167 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "19", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R20": { "role": "http://www.colgate.com/role/EarningsPerShare", "longName": "9952168 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "20", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R21": { "role": "http://www.colgate.com/role/CommitmentsandContingencies", "longName": "9952169 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "21", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R22": { "role": "http://www.colgate.com/role/SegmentInformation", "longName": "9952170 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "22", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R23": { "role": "http://www.colgate.com/role/Leases", "longName": "9952171 - Disclosure - Leases", "shortName": "Leases", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "23", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:LesseesOperatingLeasesTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"span": "div", "body": "html"}], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }}, "R24": { "role": "http://www.colgate.com/role/SupplierFinanceProgram", "longName": "9952172 - Disclosure - Supplier Finance Program", "shortName": "Supplier Finance Program", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "24", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:SupplierFinanceProgramTextBlock"}, "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": [{"span": "div", "body": "html"}]
```



```
"reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplierFinanceProgramTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Supplemental Income Statement Information", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": 25, "firstAnchor": { "contextRef": "c-1", "name": "SupplementalIncomeStatementInformationTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "SupplementalBalanceSheetInformation", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": 26, "firstAnchor": { "contextRef": "c-1", "name": "SupplementalBalanceSheetInformationTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "SupplementalOtherComprehensiveIncomeLossInformation", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": 27, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-9", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Insider Trading Policies and Procedures", "isDefault": false, "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": 30, "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Summary of Significant Accounting Policies (Policies)", "isDefault": false, "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": 32, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Nature of Operations (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 33, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Goodwill and Other Intangible Assets (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 35, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Fair Value Measurements and Financial Instruments (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 37, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Capital Stock and Stock-Based Compensation Plans (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 38, "firstAnchor": { "contextRef": "c-1", "name": "cl:ScheduleOfCommonAndTreasuryStockActivityTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Retirement Plans and Other Retiree Benefits (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 39, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Income Taxes (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 40, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Earnings Per Share (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 41, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Segment Information (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 42, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "Leases (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 43, "firstAnchor": { "contextRef": "c-1", "name": "cl:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "div", "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-1", "name": "cl:AssetsAndLiabilitiesLessee
```

"ix:continuation", "body", "html" }], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cl-OtherIncomeExpenseNetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }], "R45": { "role": "http://www.colgate.com/role/SupplementalBalanceSheetInformationTables", "longName": "9955524 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationTables", "longName": "9955525 - Disclosure - Supplemental Other Comprehensive Income (Loss) Information (Tables)", "shortName": "Supplemental Other Comprehensive Income (Loss) Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.colgate.com/role/NatureofOperationsDetails", "longName": "9955526 - Disclosure - Nature of Operations (Details)", "shortName": "Nature of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-60", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPrinciplesofConsolidationInventoriesDetails", "longName": "9955527 - Disclosure - Summary of Significant Accounting Policies - Principles of Consolidation, Inventories (Details)", "shortName": "Summary of Significant Accounting Policies - Principles of Consolidation, Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-12", "name": "cl:EquityMethodInvestmentOwnershipPercentageMinimum", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails", "longName": "9955528 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails", "longName": "9955529 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangibles (Details)", "shortName": "Summary of Significant Accounting Policies - Goodwill and Other Intangibles (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-81", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails", "longName": "9955530 - Disclosure - Restructuring and Related Implementation Charges - Narrative (Details)", "shortName": "Restructuring and Related Implementation Charges - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesCumulativeToDateDetails", "longName": "9955531 - Disclosure - Restructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date (Details)", "shortName": "Restructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesRelatedToSegmentForThePeriod", "longName": "9955532 - Disclosure - Restructuring and Related Implementation Charges - Summary of Restructuring and Related Costs (Details)", "shortName": "Restructuring and Related Implementation Charges - Summary of Restructuring and Related Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredBySegmentDetails", "longName": "9955533 - Disclosure - Restructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment (Details)", "shortName": "Restructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-98", "name": "cl:PercentOfTotalRestructuringChargesRelatedToSegmentForThePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails", "longName": "9955534 - Disclosure - Restructuring and Related Implementation Charges - Restructuring Activity and Related Accruals (Details)", "shortName": "Restructuring and Related Implementation Charges - Restructuring Activity and Related Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-135", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails", "longName": "9955535 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Goodwill (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails", "longName": "9955536 - Disclosure - Goodwill and Other Intangible Assets - Summary of Other Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets - Summary of Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "longName": "9955537 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails", "longName": "9955538 - Disclosure - Long-Term Debt and Credit Facilities - Components of Long-term Debt (Details)", "shortName": "Long-Term Debt and Credit Facilities - Components of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails", "longName": "9955539 - Disclosure - Long-Term Debt and Credit Facilities - Debt Payable within One Year (Details)", "shortName": "Long-Term Debt and Credit Facilities - Debt Payable within One Year (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:NotesAndLoansPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails", "longName": "9955539 - Disclosure - Long-Term Debt and Credit Facilities - Debt Payable within One Year (Details)", "shortName": "Long-Term Debt and Credit Facilities - Debt Payable within One Year (Details)", "isDefault": "false", "groupType": "disclosure",

```

"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShortTermDebtTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:NotesAndLoansPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShortTermDebtTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleOfLongTermDebtandFinanceLeaseMaturitiesDetails", "longName": "9955540 - Disclosure - Long-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance Lease Maturities (Details)", "shortName": "Long-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance Lease Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails", "longName": "9955541 - Disclosure - Long-Term Debt and Credit Facilities - Narrative (Details)", "shortName": "Long-Term Debt and Credit Facilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-201", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-201", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "longName": "9955542 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "cl:MinimumNumberOfCountriesAndTerritoriesServingConsumers", "unitRef": "country", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cl:MinimumNumberOfCountriesAndTerritoriesServingConsumers", "unitRef": "country", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "longName": "9955543 - Disclosure - Fair Value Measurements and Financial Instruments - Fair Value of Derivative Instruments and Other Financial Instruments (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Fair Value of Derivative Instruments and Other Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "longName": "9955544 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Notional Values (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Notional Values (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-217", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-217", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails", "longName": "9955545 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Gain (Loss) Included in OCI (Details)", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Gain (Loss) Included in OCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-242", "name": "cl:OtherComprehensiveIncomeLossHedgedItemInNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-242", "name": "cl:OtherComprehensiveIncomeLossHedgedItemInNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "longName": "9955546 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Narrative (Details)", "shortName": "Capital Stock and Stock-Based Compensation Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails", "longName": "9955547 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity (Details)", "shortName": "Capital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "cl:ScheduleOfCommonAndTreasuryStockActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "cl:ScheduleOfCommonAndTreasuryStockActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails", "longName": "9955548 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Fair Value Assumptions (Details)", "shortName": "Capital Stock and Stock-Based Compensation Plans - Fair Value Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "longName": "9955549 - Disclosure - Capital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)", "shortName": "Capital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "
```

"uniqueAnchor": {"c": "contextRef", "c-1": "name", "c": "ExpectedBenefitPaymentsFromCompanyAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "div", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "unique": true }, "R75": {"role": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleOfTargetAssetAllocationDetails", "longName": "9955554 - Disclosure - Retirement Plans and Other Retiree Benefits - Schedule of Target Asset Allocation (Details)", "shortName": "Retirement Plans and Other Retiree Benefits - Schedule of Target Asset Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": {"contextRef": "c-269", "name": "us-gaap:DefinedBenefitPlanAssetsTargetAllocationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "td", "tr": "table", "ix:continuation": "div", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "c-269", "name": "us-gaap:DefinedBenefitPlanAssetsTargetAllocationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "td", "tr": "table", "ix:continuation": "div", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R76": {"role": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails", "longName": "9955555 - Disclosure - Retirement Plans and Other Retiree Benefits - Allocation of Plan Assets and Level of Valuation Input by Major Asset Category (Details)", "shortName": "Retirement Plans and Other Retiree Benefits - Allocation of Plan Assets and Level of Valuation Input by Major Asset Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": {"contextRef": "c-13", "name": "cl:PercentageOfFixedIncomePortfolioInvestedInUSTreasuryOrAgencySecurities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "div", "ix:continuation": "ix:continuation" "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "c-13", "name": "cl:PercentageOfFixedIncomePortfolioInvestedInUSTreasuryOrAgencySecurities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": {"span": "div", "ix:continuation": "ix:continuation" "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R77": {"role": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryOfDefinedBenefitandOtherRetireeBenefitPlansDetails", "longName": "9955556 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans (Details)", "shortName": "Retirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": {"contextRef": "c-12", "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "cl:OtherAccrualsTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "c-341", "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R78": {"role": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueofPlanAssetsDetails", "longName": "9955557 - Disclosure - Retirement Plans and Other Retiree Benefits - Benefit Obligation Exceeds Fair Value of Plan Assets (Details)", "shortName": "Retirement Plans and Other Retiree Benefits - Benefit Obligation Exceeds Fair Value of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": {"contextRef": "c-344", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "c-344", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R79": {"role": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryOfOtherRetireeBenefitPlansDetails", "longName": "9955558 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Other Retiree Benefit Plans (Details)", "shortName": "Retirement Plans and Other Retiree Benefits - Summary of Other Retiree Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": {"contextRef": "c-343", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "c-343", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R80": {"role": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryOfNetPeriodicBenefitCostsDetails", "longName": "9955559 - Disclosure - Retirement Plans and Other Retiree Benefits - Summary of Net Periodic Benefit Costs (Details)", "shortName": "Retirement Plans and Other Retiree Benefits - Summary of Net Periodic Benefit Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": {"contextRef": "c-368", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "div", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {"contextRef": "c-341", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "ix:continuation": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "unique": true }, "R81": {"role": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails", "longName": "9955560 - Disclosure - Retirement Plans and Other Retiree Benefits - Expected Contributions and Benefit Payments (Details)", "shortName": "Retirement Plans and Other Retiree Benefits - Expected Contributions and Benefit Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": {"contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R82": {"role": "http://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetails", "longName": "9955561 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details)", "shortName": "Income Taxes - Components of Income Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R83": {"role": "http://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetails", "longName": "9955562 - Disclosure - Income Taxes - Provision for Income Taxes (Details)", "shortName": "Income Taxes - Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "cl:ProvisionForIncomeTaxesTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R84": {"role": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "longName": "9955563 - Disclosure - Income Taxes - Income Tax Provision Reconciliation (Details)", "shortName": "Income Taxes - Income Tax Provision Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {"span": "td", "tr": "table", "div": "cl:ScheduleOfComponentsOfDeferredIncomeTaxBenefitProvisionTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R85": {"role": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "longName": "9955564 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)", "shortName": "Income Taxes - Effective Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": {"contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": {"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "R86": {"role": "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails", "longName": "9955565 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Liabilities) (Details)", "shortName": "Income Taxes - Components of Deferred Tax Assets (Liabilities) (

```

reportCount": 1, "baseRef": "cl-20241231.htm", "unique": true } }, "R90": { "role": "http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails", "longName": "9955569 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.colgate.com/role/EarningsPerShareNarrativeDetails", "longName": "9955570 - Disclosure - Earnings Per Share - Narrative (Details)", "shortName": "Earnings Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-357", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-357", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.colgate.com/role/CommitmentsandContingenciesDetails", "longName": "9955571 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.colgate.com/role/SegmentInformationNarrativeDetails", "longName": "9955572 - Disclosure - Segment Information - Narrative (Details)", "shortName": "Segment Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails", "longName": "9955573 - Disclosure - Segment Information - Schedule of Segment Information (Details)", "shortName": "Segment Information - Schedule of Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.colgate.com/role/LeasesNarrativeDetails", "longName": "9955574 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-12", "name": "cl:LesseesOperatingLeaseNumberOfRenewalOptions", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-12", "name": "cl:LesseesOperatingLeaseNumberOfRenewalOptions", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.colgate.com/role/LeasesBalanceSheetDetails", "longName": "9955575 - Disclosure - Leases - Balance Sheet (Details)", "shortName": "Leases - Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cl:AssetsAndLiabilitiesLesseesTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cl:AssetsAndLiabilitiesLesseesTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails", "longName": "9955576 - Disclosure - Leases - Schedule of Minimum Lease Commitments (Details)", "shortName": "Leases - Schedule of Minimum Lease Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:LesseesOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LesseesOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:LesseesOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LesseesOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.colgate.com/role/LeasesScheduleofLeaseCostDetails", "longName": "9955577 - Disclosure - Leases - Schedule of Lease Cost (Details)", "shortName": "Leases - Schedule of Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails", "longName": "9955578 - Disclosure - Supplemental Income Statement Information (Details)", "shortName": "Supplemental Income Statement Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cl:OtherIncomeExpenseNetTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cl:OtherIncomeExpenseNetTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails", "longName": "9955579 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventories by Major Class (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Inventories by Major Class (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "cl-20241231.htm",
```



```
"id": "table", "div": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "body": "html", "reportCount": 1, "baseRef": "cl-20241231.htm", "unique": true }, {"role": "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationNarrativeDetails", "longName": "995586-Disclosure - Supplemental Other Comprehensive Income (Loss) Information - Narrative (Details)", "shortName": "Supplemental Other Comprehensive Income (Loss) Information - Narrative (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "order", "107": "firstAnchor", "contextRef": "c-12", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOffTax", "unitRef": "usd", "xsiNil": false, "lang": "en-US", "decimals": 6, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cl-20241231.htm", "first": true, "unique": true }, {"role": "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "0.500% Notes due 2026", "label": "0.500% Notes Due 2026 [Member]", "documentation": "0.500% Notes Due 2026 [Member]", "auth ref": [ "r1", "cl A0.875NotesDue2039Member", "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "A0.500NotesDue2026Member", "presentation": "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "0.875% Notes due 2039", "label": "0.875% Notes Due 2039 [Member]", "documentation": "0.875% Notes Due 2039 [Member]", "auth ref": [ "r1", "cl A0.300NotesDue2029Member", "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "A0.300NotesDue2029Member", "presentation": "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "0.300% Notes due 2029", "label": "0.300% Notes Due 2029 [Member]", "documentation": "0.000% Notes due 2021 [Member]", "auth ref": [ "r1", "cl A1.375NotesDue2034Member", "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "A1.375NotesDue2034Member", "presentation": "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "1.375% Notes due 2034", "label": "1.375% Notes Due 2034 [Member]", "documentation": "1.375% Notes Due 2034 [Member]", "auth ref": [ "r1", "us-gaap:AccountingPoliciesAbstract", "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": "en-us", "role": "terseLabel", "Accounting Policies Abstract", "label": "Accounting Policies Abstract", "auth ref": [ "r1", "us-gaap:AccountsPayableCurrent", "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, {"presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth ref": [ "r92", "r1038" ], "us-gaap:AccountsReceivableNetCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap:AssetsCurrent", "weight": 1.0, "order": 2.0 }, {"presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Receivables (net of allowances of $65 and $80, respectively)", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "auth ref": [ "r1234" ], "us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "crdr": "credit", "calculation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleOfOtherAccrualsDetails", "parentTag": "us-gaap:OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, {"presentation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleOfOtherAccrualsDetails", "lang": "en-us", "role": "terseLabel", "Accrued taxes other than income taxes", "label": "Accrual for Taxes Other than Income Taxes, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth ref": [ "r95", "r971", "r1320" ], "cl AccruedAdvertisingAndCouponRedemptionCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "AccruedAdvertisingAndCouponRedemptionCurrent", "crdr": "credit", "calculation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleOfOtherAccrualsDetails", "parentTag": "us-gaap:OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, {"presentation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleOfOtherAccrualsDetails", "lang": "en-us", "role": "terseLabel", "Accrued advertising and consumer and trade promotions", "label": "Accrued Advertising And Coupon Redemption Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for advertising of the entity's goods and services as well as for coupon redemption. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth ref": [ "r1", "us-gaap:AccruedIncomeTaxesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, {"presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Accrued income taxes", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "auth ref": [ "r95", "r162" ], "us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleOfComprehensiveIncomeLossDetails", "lang": "en-us", "role": "terseLabel", "Retirement Plan and other retiree benefit adjustments, pre-tax", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "auth ref": [ "r3", "r4", "r14", "r25", "r19", "r104", "r105", "r1206" ], "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails", "parentTag": "us-gaap:PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 }, {"presentation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails", "lang": "en-us", "role": "negatedTerseLabel", "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "auth ref": [ "r42", "r240", "r798" ], "us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleOfComprehensiveIncomeLossDetails", "lang": "en-us", "role": "terseLabel", "Gains (losses) on cash flow hedges, pre-tax", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "auth ref": [ "r264", "r272", "r273", "r679", "r976", "r1204" ], "us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOffTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOffTax", "crdr": "debit", "presentation": "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationNarrativeDetails", "lang": "en-us", "role": "verboseLabel", "Unrecognized pension and other retiree benefit costs, aftertax", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, After Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "auth ref": [ "r3", "r4", "r25", "r119", "r1287" ], "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOffTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOffTax", "crdr": "credit", "presentation": "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationNarrativeDetails", "lang": "en-us", "role": "negatedTerseLabel", "Foreign currency translation losses", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "auth ref": [ "r260", "r262", "r263", "r264", "r707" ], "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOffTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOffTax", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 4.0 }, {"presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "auth ref": [ "r24", "r25", "r120", "r250", "r793", "r838", "r839" ], "us-gaap:AccumulatedOtherComprehensiveIncomeMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity", "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleOfComprehensiveIncomeLossDetails", "lang": "en-us", "role": "terseLabel", "Accumulated Other Comprehensive Income (Loss)", "label": "AOI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "auth ref": [ "r1", "r14", "r25", "r686", "r689", "r740", "r834", "r835", "r1204", "r1205", "r1206", "r1220", "r1221", "r1222", "r1223" ], "us-gaap:AccumulatedTranslationAdjustmentMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleOfComprehensiveIncomeLossDetails", "lang": "en-us", "role": "terseLabel", "Cumulative translation adjustments, pre-tax", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [
```

```

"XBRLBlockItemType": "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AdjToNonPeeNeoCompFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Adjustment To Non-PEO NEO Compensation Footnote", "label": "Adjustment To Non-PEO NEO Compensation Footnote [Text Block]", "auth_ref": "r1131", "ecd AdjToPeeCompFnTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AdjToPeeCompFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "auth_ref": "r1131", "us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "lang": "en-us", "role": "terseLabel", "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "auth_ref": "r56", "r57", "r580", "us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "auth_ref": "us-gaap AdvertisingCostsPolicyTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": "http://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "Marketing Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost.", "auth_ref": "r181", "us-gaap AdvertisingExpense": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails", "lang": "en-us", "role": "terseLabel", "Advertising", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "auth_ref": "r624", "r1022", "AfricaEurasiaMember": "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231/", "localname": "AfricaEurasiaMember", "presentation": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails", "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails", "lang": "en-us", "role": "terseLabel", "Africa/Eurasia", "label": "Africa Eurasia [Member]", "documentation": "A specified group of foreign regions about which segment information is provided by the entity.", "auth_ref": "ecd AggtChngPnsnValInSummryCompstnTblForApblyrMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AggtChngPnsnValInSummryCompstnTblForApblyrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "auth_ref": "r1176", "ecd AggtErrCompAmt": "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AggtErrCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount", "auth_ref": "r1089", "r1100", "r1110", "ecd AggtErrCompNotYetDeterminedTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "auth_ref": "r1092", "r1103", "r1113", "r1146", "ecd AggtPnsnAdjsSvcCstMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]", "auth_ref": "r1177", "ecd AllAdjToCompMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AllAdjToCompMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]", "auth_ref": "r1131", "ecd AllExecutiveCategoriesMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AllExecutiveCategoriesMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "All Executive Categories", "label": "All Executive Categories [Member]", "auth_ref": "r1138", "ecd AllIndividualsMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AllIndividualsMember", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "All Individuals", "label": "All Individuals [Member]", "auth_ref": "r1093", "r1104", "r1114", "r1138", "r1147", "r1151", "r1159", "ecd AllTradingArrangementsMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "AllTradingArrangementsMember", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "terseLabel", "All Trading Arrangements", "label": "All Trading Arrangements [Member]", "auth_ref": "r1157", "us-gaap AllocatedShareBasedCompensationExpense": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Total stock-based compensation expense charged against pretax income", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "auth_ref": "r613", "r622", "us-gaap AllowanceForDoubtfulAccountsReceivableCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Allowance for doubtful accounts receivable, current", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "auth_ref": "r251", "r369", "r374", "cl AmendedDomesticRevolvingCreditFacility3000MillionCapacityMember": "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231/", "localname": "AmendedDomesticRevolvingCreditFacility3000MillionCapacityMember", "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Amended Foreign Revolving Credit Facility 3000 Million Capacity", "label": "Amended Domestic Revolving Credit Facility 3000 Million Capacity [Member]", "documentation": "Amended Domestic Revolving Credit Facility 1500 Million Capacity [Member]", "auth_ref": "dei AmendmentFlag": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "AmendmentFlag", "presentation": "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "auth_ref": "us-gaap AmortizationOfIntangibleAssets": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails", "parentTag": "us-gaap OtherOperatingIncomeExpenseNet", "weight": -1.0, "order": 1.0, "presentation": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails", "lang": "en-us", "role": "terseLabel", "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "auth_ref": "r10", "r394", "r401", "r993", "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": "http://www.colgate.com/role/EarningsPerShareNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "auth_ref": "r326", "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": "http://www.colgate.com/role/EarningsPerShareNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security.", "auth_ref": "r32", "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": "http://www.colgate.com/role/EarningsPerShareNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "us-gaap AntidilutiveSecuritiesNameDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": "http://www.colgate.com/role/EarningsPerShareNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "auth_ref": "r32", "srt AsiaPacificMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024/", "localname": "AsiaPacificMember", "presentation": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails", "http://www.colgate.com/role/SegmentInformationNarrativeDetails", "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails", "lang": "en-us", "role": "terseLabel", "Asia Pacific", "label": "
```

"Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r235", "r257", "r288", "r371", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r675", "r680", "r709", "r1038", "r1278", "r1358" } } }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets", "http://www.colgate.com/role/ConsolidatedBalanceSheetsParentetical" } } }, "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current [Abstract]" } } } }, "auth_ref": { } }, "cl_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } } }, "auth_ref": { } }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": { "http://www.colgate.com/role/AuditInformation" } } }, "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } } }, "auth_ref": { "r1072", "r1073", "r1096" } } }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": { "http://www.colgate.com/role/AuditInformation" } } }, "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } } }, "auth_ref": { "r1072", "r1073", "r1096" } } }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": { "http://www.colgate.com/role/AuditInformation" } } }, "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } } }, "auth_ref": { "r1072", "r1073", "r1096" } } }, "cl_AverageAnnualRateOfReturnForMostRecentFifteenYearPeriod": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "AverageAnnualRateOfReturnForMostRecentFifteenYearPeriod", "presentation": { "http://www.colgate.com/role/RetirementPlansAndOtherRetireeBenefitsNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Average annual rates of return for the most recent 15-year period", "label": "Average Annual Rate Of Return For Most Recent Fifteen Year Period", "documentation": "The average annual rate of return on pension plan assets for the most recent 15 year period." } } } }, "auth_ref": { } }, "cl_AverageAnnualRateOfReturnForMostRecentFiveYearPeriod": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "AverageAnnualRateOfReturnForMostRecentFiveYearPeriod", "presentation": { "http://www.colgate.com/role/RetirementPlansAndOtherRetireeBenefitsNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Average annual rates of return for the most recent 5-year period", "label": "Average Annual Rate Of Return For Most Recent Five Year Period", "documentation": "The average annual rate of return on pension plan assets for the most recent 5 year period." } } } }, "auth_ref": { } }, "cl_AverageAnnualRateOfReturnForMostRecentOneYearPeriod": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "AverageAnnualRateOfReturnForMostRecentOneYearPeriod", "presentation": { "http://www.colgate.com/role/RetirementPlansAndOtherRetireeBenefitsNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Average annual rates of return for the most recent 1-year period", "label": "Average Annual Rate Of Return For Most Recent One Year Period", "documentation": "The average annual rate of return on pension plan assets for the most recent 1 year period." } } } }, "auth_ref": { } }, "cl_AverageAnnualRateOfReturnForMostRecentTenYearPeriod": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "AverageAnnualRateOfReturnForMostRecentTenYearPeriod", "presentation": { "http://www.colgate.com/role/RetirementPlansAndOtherRetireeBenefitsNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Average annual rates of return for the most recent 10-year period", "label": "Average Annual Rate Of Return For Most Recent Ten Year Period", "documentation": "The average annual rate of return on pension plan assets for the most recent 10 year period." } } } }, "auth_ref": { } }, "cl_AverageAnnualRateOfReturnForMostRecentTwentyFiveYearPeriod": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "AverageAnnualRateOfReturnForMostRecentTwentyFiveYearPeriod", "presentation": { "http://www.colgate.com/role/RetirementPlansAndOtherRetireeBenefitsNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Average annual rates of return for the most recent 25-year period", "label": "Average Annual Rate Of Return For Most Recent Twenty Five Year Period", "documentation": "The average annual rate of return on pension plan assets for the most recent 25 year period." } } } }, "auth_ref": { } }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } } }, "auth_ref": { "r1154" } } }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } } }, "auth_ref": { "r1155" } } }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } } }, "auth_ref": { "r1150" } } }, "ecd_AwardTmgHwMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHwMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } } }, "auth_ref": { "r1150" } } }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } } }, "auth_ref": { "r1150" } } }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } } }, "auth_ref": { "r1150" } } }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } } }, "auth_ref": { "r1150" } } }, "ecd_AwardTmgPredtrmdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } } }, "auth_ref": { "r1150" } } }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } } }, "auth_ref": { "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r612" } } }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } } }, "auth_ref": { "r1153" } } }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } } }, "auth_ref": { "r1152" } } }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }, "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } } }, "auth_ref": { "r1151" } } }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } } }, "auth_ref": { "r415", "r1372", "r1373" } } }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } } }, "auth_ref": { "r77", "r80", "r415", "r1372", "r1373" } } }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Related Disclosures [Abstract]", "label": "Balance Sheet Related Disclosures [Abstract]" } } } }, "auth_ref": { } }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "BuildingMember", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } } }, "auth_ref": { "r140" } } }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails" } } }, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } } }, "auth_ref": { "r140" } } }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees, advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } } }, "auth_ref": { "r61" } } }, "cl_BusinessCombinationAcquisitionRelatedCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "BusinessCombinationAcquisitionRelatedCostsNet", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails" } } }, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0, "order": 8.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related costs", "label": "Business Combination, Acquisition Related Costs, Net", "documentation": "Business Combination, Acquisition Related Costs, Net" } } } }, "auth_ref": { } }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } } }, "auth_ref": { "r86", "r87" } } }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets" } } }, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets" } } }, "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } }, "auth_ref": { "r29", "r238", "r668" } } }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPolicies" } } }, "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents; (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk; (3) the classification of any negative balance accounts (overdrafts); and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } } }, "auth_ref": { "r30" } } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" }

"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "periodStartLabel", "Cash and cash equivalents at beginning of year", "periodEndLabel": "Cash and cash equivalents at end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }, "auth_ref": "r29", "r131", "r285" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "totalLabel", "Net increase (decrease) in Cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }, "auth_ref": "r0", "r131" }, "us-gaap_CashFlowHedgingMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": "en-us", "role": "terseLabel", "Cash Flow Hedges", "label": "Cash Flow Hedging {Member}", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." }, "auth_ref": "r74" }, "ecd_ChangedPeerGroupFnTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote {Text Block}", "auth_ref": "r1129" }, "cd_ChargedToCostsAndExpensesMember", "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ChargedToCostsAndExpensesMember", "presentation": "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceforDeferredTaxAssetsDetails", "lang": "en-us", "role": "terseLabel", "Charged to costs and expenses", "label": "Charged to Costs and Expenses {Member}", "documentation": "Charged to Costs and Expenses" }, "auth_ref": " " }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year {Member}", "auth_ref": "r1126" }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested {Member}", "auth_ref": "r1124" }, "dei_CityAreaCode", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "City Area Code", "label": "City Area Code", "documentation": "Area code of city" }, "auth_ref": " " }, "us-gaap_ClassOfStockDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Class of Stock {Domain}", "label": "Class of Stock {Domain}", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." }, "auth_ref": "r192", "r247", "r248", "r249", "r288", "r312", "r316", "r323", "r325", "r332", "r333", "r371", "r443", "r446", "r447", "r448", "r452", "r453", "r482", "r483", "r484", "r485", "r486", "r709", "r844", "r845", "r846", "r847", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r884", "r906", "r924", "r944", "r945", "r946", "r947", "r948", "r1101", "r1214", "r1224" }, "ecd_CoSelectedMeasureAmt", "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Company Selected Measure Amount", "label": "Company Selected Measure Amount" }, "auth_ref": "r1130" }, "ecd_CoSelectedMeasureName", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Company Selected Measure Name", "label": "Company Selected Measure Name" }, "auth_ref": "r1130" }, "us-gaap_CommercialPaperMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails", "lang": "en-us", "role": "terseLabel", "Commercial paper", "label": "Commercial Paper {Member}", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." }, "auth_ref": "r145", "r442", "r1060", "r1061", "r1062", "r1063" }, "us-gaap_CommitmentsAndContingencies", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Commitments and contingent liabilities", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." }, "auth_ref": "r101", "r166", "r791", "r883" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": "en-us", "role": "terseLabel", "Commitments and Contingencies Disclosure {Abstract}", "label": "Commitments and Contingencies Disclosure {Abstract}" }, "auth_ref": " " }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": "http://www.colgate.com/role/CommitmentsandContingencies", "lang": "en-us", "role": "verboseLabel", "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure {Text Block}", "documentation": "The entire disclosure for commitments and contingencies." }, "auth_ref": "r143", "r432", "r433", "r952", "r1263", "r1271" }, "us-gaap_CommodityContractMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommodityContractMember", "presentation": "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": "en-us", "role": "terseLabel", "Commodity contracts", "label": "Commodity Contract {Member}", "documentation": "Derivative instrument whose primary underlying risk is tied to commodity prices." }, "auth_ref": "r1009", "r1028" }, "us-gaap_CommonStockDividendsPerShareDeclared", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical", "lang": "en-us", "role": "terseLabel", "Dividends declared per common share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." }, "auth_ref": "r148" }, "us-gaap_CommonStockMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.colgate.com/role/Cover", "lang": "en-us", "role": "terseLabel", "Common Stock", "label": "Common Stock {Member}", "documentation": "Stock that is subordinate to all other stock of the issuer." }, "auth_ref": "r1056", "r1057", "r1058", "r1060", "r1061", "r1062", "r1063", "r1220", "r1221", "r1223", "r1338", "r1403", "r1406" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Shareholders'2019 Equity", "label": "Common Stock, Number of Shares, Par Value and Other Disclosure {Abstract}" }, "auth_ref": " " }, "us-gaap_CommonStockParOrStatedValuePerShare", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Common stock par value (in dollars per share)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." }, "auth_ref": "r106", "r894" }, "us-gaap_CommonStockSharesIssued", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Common stock issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." }, "auth_ref": "r106" }, "us-gaap_CommonStockSharesOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails", "lang": "en-us", "role": "periodStartLabel", "Common stock balance, January 1 (in shares)", "periodEndLabel": "Common stock balance, December 31 (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." }, "auth_ref": "r15", "r106", "r884", "r903", "r1406", "r1407" }, "us-gaap_CommonStockValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Common stock, \$1 par value (2,000,000,000 shares authorized, 1,465,706,360 shares issued)", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." }, "auth_ref": "r106", "r792", "r1038" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure {Text Block}", "auth_ref": "r1135" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income {Text Block}", "auth_ref": "r1134" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure {Text Block}", "auth_ref": "r1136" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return {Text Block}", "auth_ref": "r1133" }, "us-gaap_CompensationAndRetirementDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": "en-us", "role": "terseLabel", "Retirement Benefits {Abstract}", "label": "Retirement Benefits {Abstract}" }, "auth_ref": " " }, "us-gaap_ComprehensiveIncomeNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfComprehensiveIncome", "parentTag": null,

"weight": null, "order": null, "root": true }}, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "lang": { "en-us": { "role": { "totalLabel": "Total Comprehensive income attributable to Colgate-Palmolive Company", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r26": "r267", "r269": "r277", "r785": "r806", "r808" } }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "lang": { "en-us": { "role": { "totalLabel": "Total Comprehensive income attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r8": "r65", "r69": "r267", "r269": "r276", "r784": "r806", "r807" } }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "lang": { "en-us": { "role": { "totalLabel": "Total Comprehensive income including noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r69": "r156", "r267": "r269", "r275": "r783", "r806" } }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformation": { "lang": { "en-us": { "role": { "terseLabel": "Supplemental Other Comprehensive Income (Loss) Information", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": { "r115": "r274", "r782": "r805" } }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.colgate.com/role/NatureOfOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": { "r33": "r34", "r88": "r89", "r367": "r951" } }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.colgate.com/role/NatureOfOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": { "r33": "r34", "r88": "r89", "r367": "r951", "r1187" } }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.colgate.com/role/NatureOfOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percent of net sales", "label": "Percent of net sales", "documentation": "Percentage of consolidated sales represented by one customer." } } }, "auth_ref": { "r33": "r34", "r88": "r89", "r367": "r951", "r1187" } }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.colgate.com/role/NatureOfOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the denominator in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": { "r33": "r34", "r88": "r89", "r367" } }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": { "r33": "r34", "r88": "r89", "r367": "r951" } }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": { "r174": "r193", "r219": "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r293", "r330", "r340", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r443", "r444", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r986", "r987", "r1193", "r1194", "r1278", "r1279" } }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": { "r174": "r193", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r293", "r330", "r340", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r443", "r444", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r986", "r987", "r1193", "r1194", "r1278", "r1279" } }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": { "r66": "r977" } }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": { "r1227" } }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": { "r20": "r355", "r356", "r357", "r358", "r361", "r1230" } }, "cl_CostMethodInvestmentOwnershipPercentageMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "CostMethodInvestmentOwnershipPercentageMaximum", "presentation": { "http://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesPrinciplesOfConsolidationInventoriesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investments accounted for using the cost method, maximum interest", "label": "Cost Method Investment Ownership Percentage Maximum", "documentation": "The maximum percentage of ownership of common stock or equity participation in the investee accounted for under the cost method of accounting. This maximum is up to, but not including, the maximum value." } } }, "auth_ref": { "r1230" } }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "http://www.colgate.com/role/SegmentInformationScheduleOfSegmentInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsOfIncome": { "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": { "r124": "r288", "r371", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r709", "r986", "r1278" } }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { "r1276": "r1277" } }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": { "r442": "r1276" } }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": { "r442": "r1276", "r1277" } }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.colgate.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, "auth_ref": { "r1276": "r1277" } }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": { "r136": "r367" } }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure": { "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": { "r1081": "r1170" } }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure": { "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": { "r1081": "r1170" } }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure": { "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": { "r1083": "r1172" } }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure": { "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": { "r1083": "r1172" } }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": { "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure": { "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": { "r1085": "r1174" } }


```

"cybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth ref": { "r1083": "r1172" } ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth ref": { "r1076": "r1163" } ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth ref": { "r1077": "r1166" } ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth ref": { "r1077": "r1166" } ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth ref": { "r1075": "r1164" } ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth ref": { "r1075": "r1164" } ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth ref": { "r1075": "r1164" } ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth ref": { "r1078": "r1167" } ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth ref": { "r1080": "r1169" } ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth ref": { "r1080": "r1169" } ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth ref": { "r1081": "r1170" } ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth ref": { "r1084": "r1173" } ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth ref": { "r1082": "r1171" } ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth ref": { "r1079": "r1168" } ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth ref": [ ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.colgate.com/role/LongTermDebtandCreditFacilities", "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt and Credit Facilities", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth ref": { "r144": "r207", "r410": "r411", "r412": "r413", "r414": "r441", "r442": "r454", "r460": "r461", "r462": "r463", "r464": "r465", "r470": "r477", "r478": "r480", "r719" } ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth ref": { "r22": "r94", "r95": "r161", "r165": "r293", "r455": "r456", "r457": "r458", "r459": "r461", "r466": "r467", "r468": "r469", "r471", "r472": "r473", "r474": "r475", "r476": "r1000", "r1001": "r1002", "r1003": "r1004", "r1036": "r1215", "r1264": "r1265", "r1266": "r1354", "r1355" } ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth ref": { "r455": "r719", "r720": "r1001", "r1002": "r1036" } ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value of long-term debt", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth ref": { "r468": "r708", "r1001": "r1002", "r1340": "r1341", "r1342": "r1343", "r1350" } ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth ref": { "r97": "r456" } ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": { "r293": "r455", "r456": "r457", "r458": "r459", "r461", "r466": "r467", "r468", "r469", "r471", "r472": "r473", "r474": "r475", "r476": "r477", "r478": "r1000", "r1001": "r1002", "r1003": "r1004", "r1036": "r1215", "r1354", "r1355" } ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth ref": { "r22": "r293", "r455": "r456", "r457", "r458": "r459", "r461", "r466": "r467", "r468", "r469
```

deferred tax liabilities, "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }
"auth_ref": "r102", "r103", "r163", "r650" } } }
"us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } } }
"presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } } }
"auth_ref": "r630", "r631", "r790" } } }
"us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } } }
"presentation": { "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } } }
"auth_ref": "r134" } } }
"us-gaap_DeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetDomain", "presentation": { "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceForDeferredTaxAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset Domain", "label": "Deferred Tax Asset Domain", "documentation": "Identification of the deferred tax asset for which a valuation reserve exists." } } } }
"auth_ref": "r1328" } } }
"cl_DeferredTaxAssetValuationAllowanceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DeferredTaxAssetValuationAllowanceRollForward", "presentation": { "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceForDeferredTaxAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset, Valuation Allowance [Roll Forward]", "label": "Deferred Tax Asset, Valuation Allowance [Roll Forward]", "documentation": "Deferred Tax Asset, Valuation Allowance" } } } }
"auth_ref": { "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } } }
"auth_ref": "r651" } } }
"us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Research and Experimentation Capitalization", "label": "Deferred Tax Asset, In-Process Research and Development", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } } }
"auth_ref": "r1331" } } }
"us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } } }
"auth_ref": "r1327" } } }
"us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Tax Assets, Net [Abstract]", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } } }
"auth_ref": "r1331" } } }
"us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } } }
"auth_ref": "r1331" } } }
"cl_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensionsAndOtherRetireeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensionsAndOtherRetireeBenefits", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Pension and other retiree benefits", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions And Other Retiree Benefits", "documentation": "The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from pension costs and other retiree benefits, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken." } } } }
"auth_ref": { "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } } }
"auth_ref": "r1331" } } }
"us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } } }
"auth_ref": "r1331" } } }
"cl_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Lease Liabilities", "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Lease Liabilities" } } } }
"auth_ref": { "cl_DeferredTaxAssetsTaxLossAndTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DeferredTaxAssetsTaxLossAndTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Tax credits and tax loss carryforwards", "label": "Deferred Tax Assets Tax Loss And Tax Credit Carryforwards", "documentation": "The tax effect as of the balance sheet date of the amount of future tax deductions arising from all unused tax loss and tax credit carryforwards which have been reduced by a valuation allowance." } } } }
"auth_ref": { "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceForDeferredTaxAssetsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation Allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } } }
"auth_ref": "r652" } } }
"us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Net deferred income taxes", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } } }
"auth_ref": "r1327" } } }
"us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross [Abstract]", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } } }
"auth_ref": { "cl_DeferredTaxLiabilitiesDeferredWithholdingTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DeferredTaxLiabilitiesDeferredWithholdingTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred withholding tax", "label": "Deferred Tax Liabilities, Deferred Withholding Tax", "documentation": "Deferred Tax Liabilities, Deferred Withholding Tax" } } } }
"auth_ref": { "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "crdr": "credit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Goodwill and intangible assets", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill." } } } }
"auth_ref": { "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Right-of-use assets", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } } }
"auth_ref": { "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } } }
"auth_ref": { "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Property, plant and equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } } }
"auth_ref": "r1331" } } }
"us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } } }
"presentation": { "http://www.colgate.com/role/IncomeTaxesComponentsofDeferredTaxAssetsLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Defined benefit plan accumulated benefit obligation", "label": "Deferred Tax Liabilities, Defined Benefit Plan Accumulated Benefit Obligation", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from defined benefit plan accumulated benefit obligation." } } } }
"auth_ref": "r1331" } } }

"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": { "r532" } }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "crdr": "debit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "lang": { "en-us": { "role": { "totalLabel": "Amounts recognized in accumulated other comprehensive income", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": { "r3", "r4", "r25", "r119", "r1287" } }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amounts Recognized in Accumulated Other Comprehensive Income (Loss)", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss before Tax [Abstract]", "auth_ref": { "r1" } }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "lang": { "en-us": { "role": { "negatedLabel": "Actuarial loss", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": { "r25", "r544" } }, "cl_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsAndNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsAndNetPriorServiceCostCreditBeforeTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "lang": { "en-us": { "role": { "negatedLabel": "Transition/prior service cost(credit)", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income Net Transition Assets Obligations And Net Prior Service Cost Credit Before Tax", "documentation": "The portion of accumulated other comprehensive income comprised of net prior service cost/credit and net transition assets (obligations), before tax." } } }, "auth_ref": { "r1" } }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": { "r514", "r1011" } }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial loss (gain)", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": { "r507" } }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails", "lang": { "en-us": { "role": { "terseLabel": "Actuarial gain", "negatedLabel": "Amortization of actuarial loss", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": { "r501", "r539", "r564", "r1011", "r1012" } }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails", "lang": { "en-us": { "role": { "terseLabel": "Amortization of transition and prior service costs (credits)", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": { "r501", "r540", "r565", "r1011", "r1012" } }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "crdr": "debit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "lang": { "en-us": { "role": { "totalLabel": "Net amount recognized", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": { "r49", "r50" } }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amounts Recognized in Balance Sheet", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "auth_ref": { "r1" } }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0, "order": 1.0 } }, "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": { "r159", "r499", "r500", "r522", "r896", "r1011", "r1367" } }, "us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsTargetAllocationsAbstract", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Allocations [Abstract]", "label": "Defined Benefit Plan, Plan Assets, Allocations [Abstract]", "auth_ref": { "r1" } }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": { "r545" } }, "cl_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationESOPGrowthRate": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationESOPGrowthRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "ESOP growth rate", "label": "Defined Benefit Plan Assumptions Used Calculating Benefit Obligation ESOP Growth Rate", "documentation": "Expected growth rate of company stock held by the employee stock ownership plans used to determine benefit obligations for defined benefit plans." } } }, "auth_ref": { "r1" } }, "cl_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedLongTermReturnOnPlanAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedLongTermReturnOnPlanAssets", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Expected long-term rate of return on plan assets", "label": "Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Long Term Return On Plan Assets", "documentation": "Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Long Term Return On Plan Assets" } } }, "auth_ref": { "r1" } }, "cl_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationMedicalCostTrendRate": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationMedicalCostTrendRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Medical cost trend rate of increase", "label": "Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Medical Cost Trend Rate", "documentation": "Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Medical Cost Trend Rate for next fiscal." } } }, "auth_ref": { "r1" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-term rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": { "r546" } }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest Crediting Rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": { "r548" } }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Discount

rate","label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate","documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": { "r545" } }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Expected long-term rate of return on plan assets" }, "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": { "r547", "r569" } }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Long-term rate of compensation increase" }, "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": { "r546" } }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Interest Crediting Rate" }, "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": { "r548" } }, "cl_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicCostEsoPGrowthRate": { "xbrltype": "percentItem", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicCostEsoPGrowthRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "ESOP growth rate" }, "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Cost Eso PGrowth Rate", "documentation": "Expected growth rate of company stock held by the employee stock ownership plans used to determine benefit obligations for defined benefit plans." } } }, "auth_ref": { } }, "cl_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicMedicalCostTrendRate": { "xbrltype": "percentItem", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicMedicalCostTrendRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Medical cost trend rate of increase" }, "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Medical Cost Trend Rate", "documentation": "Defined Benefit Plan Assumptions Used Calculating Net Periodic Medical Cost Trend Rate" } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": { "1.0", "order": { "1.0" } }, "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "periodStartLabel": "Benefit obligations at beginning of year", "periodEndLabel": "Benefit obligations at end of year" }, "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": { "r502" } }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "negatedTerseLabel": "Benefit payments", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": { "r509", "r572" } }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Participants vs 2019 contributions", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation." } } }, "auth_ref": { "r506" } }, "cl_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentAndSettlements": { "xbrltype": "monetaryItem", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentAndSettlements", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "negatedLabel": "Curtailments and settlements", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease For Curtailment And Settlements", "documentation": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease For Curtailment And Settlements" } } }, "auth_ref": { } }, "cl_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForPlanAmendmentAndBusinessCombination": { "xbrltype": "monetaryItem", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForPlanAmendmentAndBusinessCombination", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "role": { "terseLabel": "Plan amendments", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) For Plan Amendment And Business Combination", "documentation": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) For Plan Amendment And Business Combination" } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": { "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r550", "r1009", "r1010", "r1011" } }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails" }, "lang": { "en-us" }, "role": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested." } } }, "auth_ref": { "r1009" } }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Change in Benefit Obligations", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Change in Plan Assets", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "verboseLabel": "Company contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": { "r516", "r526", "r568", "r1009", "r1010", "r1011", "r1012" } }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "cl_DefinedBenefitPlanDividendsReceivedOnEmployerSecurities": { "xbrltype": "monetaryItem", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanDividendsReceivedOnEmployerSecurities", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Defined benefit plan dividends received on employer securities", "label": "Defined Benefit Plan Dividends Received On Employer Securities", "documentation": "The amount of dividends received by the defined benefit plan on the company's common stock." } } }, "auth_ref": { } }, "cl_DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember": { "xbrltype": "domainItem", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Domestic, developed and emerging markets equity funds", "label": "Defined Benefit Plan, Domestic, Developed and Emerging Markets Equity Funds [Member]", "documentation": "Domestic, Developed and Emerging Markets Equity Funds [Member]" } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Equity securities", "label": "Defined Benefit Plan, Equity Securities [Member]", "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": { "r1009", "r1011" } }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "Total benefit payments [Abstract]", "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails" }, "lang": { "en-us" }, "role": { "terseLabel": "2030-2034", "label": "Defined Benefit Plan, Expected Future Benefit Payment, After Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan

expected to be paid in five fiscal years after fifth fiscal year following current fiscal year."}}, {"auth_ref": "r533"}}, {"us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year."}}}}, {"auth_ref": "r533"}}, {"us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2029", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year."}}}}, {"auth_ref": "r533"}}, {"us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year."}}}}, {"auth_ref": "r533"}}, {"us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year."}}}}, {"auth_ref": "r533"}}, {"us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year."}}}}, {"auth_ref": "r533"}}, {"us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"lang": {"en-us": {"role": {"negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."}}}}, {"auth_ref": "r501", "r538", "r563", "r1011", "r1012"}}, {"us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 2.0}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair value of plan assets", "periodStartLabel": "Fair value of plan assets at beginning of year", "periodEndLabel": "Fair value of plan assets at end of year", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."}}}}, {"auth_ref": "r513", "r524", "r526", "r527", "r1009", "r1010", "r1011"}}, {"cl_DefinedBenefitPlanFixedIncomeFundsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanFixedIncomeFundsMember", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fixed income securities", "label": "Defined Benefit Plan, Fixed Income Securities [Member]", "documentation": "Defined Benefit Plan, Fixed Income Securities [Member]"}}, {"auth_ref": "r513", "r524", "r526", "r527", "r1009", "r1010", "r1011"}}, {"us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Foreign exchange impact", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan."}}}}, {"auth_ref": "r508"}}, {"us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"lang": {"en-us": {"role": {"totalLabel": "Net amount recognized", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status."}}}}, {"auth_ref": "r499", "r522", "r1011"}}, {"us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"lang": {"en-us": {"role": {"terseLabel": "Funded Status", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]"}}, {"auth_ref": "r11"}}, {"cl_DefinedBenefitPlanGuaranteedInvestmentContractsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanGuaranteedInvestmentContractsMember", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Guaranteed investment contracts", "label": "Defined Benefit Plan, Guaranteed Investment Contracts [Member]", "documentation": "This element represents investments in contracts with insurance companies measured at the cash surrender value of each contract."}}}}, {"auth_ref": "r11"}}, {"cl_DefinedBenefitPlanHealthCareCostTrendRateAssumedFiscalYearFour": {"xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedFiscalYearFour", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Fiscal Year Four", "documentation": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Fiscal Year Four"}}, {"auth_ref": "r11"}}, {"us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Medical cost trend rate assumed for next fiscal year", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "documentation": "Assumed rate for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status."}}}}, {"auth_ref": "r549"}}, {"cl_DefinedBenefitPlanHedgeFundsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanHedgeFundsMember", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Hedge funds", "label": "Defined Benefit Plan, Hedge Funds [Member]", "documentation": "Defined Benefit Plan, Hedge Funds [Member]"}}, {"auth_ref": "r11"}}, {"us-gaap_DefinedBenefitPlanInterestCost": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."}}}}, {"auth_ref": "r501", "r505", "r537", "r562", "r1011", "r1012"}}, {"cl_DefinedBenefitPlanInternationalCommonStockMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanInternationalCommonStockMember", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"lang": {"en-us": {"role": {"terseLabel": "International common stocks", "label": "Defined Benefit Plan, International Common Stock [Member]", "documentation": "This category includes information about ownership interests in international corporations and other legal entities for which ownership interest is represented by shares of common stock."}}}}, {"auth_ref": "r11"}}, {"cl_DefinedBenefitPlanMultiAssetFundsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanMultiAssetFundsMember", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Multi-Asset funds", "label": "Defined Benefit Plan, Multi-Asset Funds [Member]", "documentation": "Multi-Asset Funds [Member]"}}, {"auth_ref": "r11"}}, {"us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"parentTag": "us-gaap_PensionAndOtherPostretirementBenefitExpense", "weight": 1.0, "order": 3.0}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"lang": {"en-us": {"role": {"totalLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan."}}}}, {"auth_ref": "r535", "r560", "r1011", "r1012"}}, {"us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Components of Net Periodic Benefit Cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]"}}, {"auth_ref": "r11"}}, {"us-gaap_DefinedBenefitPlanOtherChanges": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanOtherChanges", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"lang": {"en-us": {"role": {"terseLabel": "ERISA litigation matter", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other."}}}}, {"auth_ref": "r11"}}, {"us-gaap_DefinedBenefitPlanOtherCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanOtherCosts", "crdr": "debit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"parentTag": "us-gaap_PensionAndOtherPostretirementBenefitExpense", "weight": 1.0, "order": 2.0}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails":


```

    "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other postretirement charges." }, "label": "Defined Benefit Plan, Other Cost (Credit)", "documentation": "Amount of defined benefit plan cost (credit), classified as other." } } }, "auth_ref": [1] }, "us-gaap-DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueOfPlanAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets." }, "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": ["r557", "r1011"] }, "us-gaap-DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueOfPlanAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation." }, "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": ["r557", "r1011"] }, "us-gaap-DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueOfPlanAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation." }, "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": ["r557", "r558", "r1011"] }, "us-gaap-DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueOfPlanAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets." }, "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": ["r557", "r558", "r1011"] }, "cl-DefinedBenefitPlanPercentageOfEquitySecuritiesInvestedInEmployerSecurities": { "xbrlType": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanPercentageOfEquitySecuritiesInvestedInEmployerSecurities", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of investments in Company's common stock." }, "label": "Defined Benefit Plan Percentage Of Equity Securities Invested In Employer Securities", "documentation": "The percentage of equity securities of the defined benefit plan invested in the Company's common stock." } } }, "auth_ref": [1] }, "us-gaap-DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsPlanSummaryOfDefinedBenefitAndOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Negated Terse Label.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to: pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to: prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": ["r518", "r1290"] }, "us-gaap-DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryOfDefinedBenefitAndOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Participants' contributions." }, "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": ["r517"] }, "us-gaap-DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryOfDefinedBenefitAndOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange impact." }, "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": ["r515"] }, "cl-DefinedBenefitPlanPlanAssetsPurchasesShares": { "xbrlType": "sharesItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanPlanAssetsPurchasesShares", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "U.S. plans assets purchased to Company (in shares).", "label": "Defined Benefit Plan, Plan Assets, Purchases, Shares", "documentation": "Defined Benefit Plan, Plan Assets, Purchases, Shares" } } }, "auth_ref": [1] }, "us-gaap-DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Target asset allocation." }, "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": ["r523", "r1011"] }, "cl-DefinedBenefitPlanPooledFundsMember": { "xbrlType": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanPooledFundsMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Pooled funds.", "label": "Defined Benefit Plan, Pooled Funds [Member]", "documentation": "Defined Benefit Plan, Pooled Funds [Member]" } } }, "auth_ref": [1] }, "us-gaap-DefinedBenefitPlanRealEstateMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRealEstateMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Real estate funds.", "label": "Employee Benefit Plan, Real Estate [Member]", "documentation": "Property composed of building, land, and land improvement; in which employee benefit plan asset is invested." } } }, "auth_ref": ["r1009", "r1011"] }, "us-gaap-DefinedBenefitPlanServiceCost": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap-DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitAndOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Service cost." }, "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": ["r503", "r536", "r561", "r1011", "r1012"] }, "us-gaap-DefinedBenefitPlanSettlementsPlanAssets": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitAndOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements and acquisitions.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": ["r521"] }, "us-gaap-DefinedBenefitPlanSpecialTerminationBenefits": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSpecialTerminationBenefits", "crdr": "credit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitAndOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Termination benefits.", "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits", "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement." } } }, "auth_ref": ["r504"] }, "cl-DefinedBenefitPlanUSCommonStocksMember": { "xbrlType": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanUSCommonStocksMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "U.S. common stocks.", "label": "Defined Benefit Plan, US Common Stocks [Member]", "documentation": "This category includes information about ownership interests in United States corporations and other legal entities for which ownership interest is represented by shares of common stock." } } }, "auth_ref": [1] }, "us-gaap-DefinedBenefitPlanUltimateHealthCareCostTrendRate": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ultimate medical cost trend rate.", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan." } } }, "auth_ref": ["r549"] }, "cl-DefinedBenefitPlanVoluntaryContributionsByEmployer": { "xbrlType": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "DefinedBenefitPlanVoluntaryContributionsByEmployer", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Voluntary contributions to postretirement plans.", "label": "Defined Benefit Plan Voluntary Contributions By Employer", "documentation": "Voluntary contributions made by the Company to its postretirement plans." } } }, "auth_ref": [1] }, "us-gaap-DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitAndOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Assumptions Used to Determine Benefit Obligations.", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation Abstract", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r10", "r330", "r343", "r360", "r986", "r987"] }, "us-gaap-DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrlType
```

"DerivativeAssetStatementOffFinancialPositionExtensibleEnumeration", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": { "r682" } }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r258", "r259", "r695", "r696", "r703", "r708", "r864", "r865", "r866", "r867", "r868", "r870", "r871", "r872", "r873", "r874", "r890", "r891", "r934", "r937", "r938", "r939", "r940", "r941", "r975", "r1029", "r1032", "r1058", "r1341", "r1342", "r1343", "r1404" } }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherCurrentAssetsDetails", "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": "I"
"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherCurrentAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r258" } }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract Type [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": { "r872", "r874", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r898", "r899", "r900", "r901", "r912", "r913", "r914", "r915", "r918", "r919", "r920", "r921", "r934", "r935", "r938", "r940", "r1056", "r1058", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1351", "r1352" } }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": { "en-us": { "role": { "verboseLabel": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": { "r78", "r81", "r82", "r158", "r872", "r874", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r898", "r899", "r900", "r901", "r912", "r913", "r914", "r915", "r918", "r919", "r920", "r921", "r934", "r935", "r938", "r940", "r1056", "r1058", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1351", "r1352" } }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": { "r16", "r78", "r81" } }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": { "r16", "r78", "r81", "r82", "r84", "r85", "r684" } }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r684" } }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r258", "r259", "r695", "r696", "r703", "r708", "r864", "r865", "r866", "r867", "r870", "r871", "r872", "r873", "r874", "r898", "r900", "r901", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r975", "r1341", "r1342", "r1343", "r1404" } }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails", "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": "I"
"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r258" } }, "us-gaap_DerivativeLiabilityStatementOffFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityStatementOffFinancialPositionExtensibleEnumeration", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": { "r682" } }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": "I"
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Notional value of derivative", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": { "r1335", "r1336" } }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": "I"
"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": { "r16", "r70", "r71", "r76", "r83", "r292", "r307" } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": "I"
"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlans", "lang": { "en-us": { "role": { "terseLabel": "Capital Stock and Stock-Based Compensation Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r578", "r583", "r614", "r615", "r617", "r1020" } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": { "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": "I"
"http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity", "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment in-kind (PIK)." } } }, "auth_ref": { "r7", "r148" } }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails", "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": "I"
"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails", "lang": { "en-us": { "role": { "terseLabel": "Dividend payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": { "r95", "r100", "r164", "r1064", "r1368" } }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": { "r1072", "r1073", "r1096" } }, "dei_DocumentFinStmntErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmntErrorCorrectionFlag", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": { "r1072", "r1073", "r1096", "r1139" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { "dei_DocumentFiscalYearFocus": { "xbrltype": "qYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document period in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r1117" } }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": { "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": "I"
"http://www.colgate.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated

by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference.", "auth_ref": "r1070"}, {"tag": "us-gaap_DomesticPlanMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticPlanMember", "presentation": "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails", "lang": "en-us", "role": "terseLabel", "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "auth_ref": "r1291", "r1292", "r1293"}, {"tag": "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRfctdInTHCompForCvrdYrMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRfctdInTHCompForCvrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "auth_ref": "r1128"}, {"tag": "us-gaap_EarningsPerShareAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": "en-us", "role": "terseLabel", "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]", "auth_ref": "r278", "r299", "r300", "r301", "r302", "r303", "r304", "r309", "r312", "r323", "r324", "r325", "r329", "r670", "r673", "r692", "r693", "r786", "r809", "r979"}, {"tag": "cl_EarningsPerShareBasicAndDilutedEPSAbstract", "xbrltype": "stringItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": "http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails", "lang": "en-us", "role": "terseLabel", "Per Share", "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]", "documentation": "Earnings Per Share, Basic and Diluted EPS", "auth_ref": "r278", "r299", "r300", "r301", "r302", "r303", "r304", "r312", "r323", "r324", "r325", "r329", "r670", "r673", "r692", "r693", "r786", "r809", "r979"}, {"tag": "us-gaap_EarningsPerShareDiluted", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfIncome", "http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails", "lang": "en-us", "role": "verboseLabel", "Earnings per common share, diluted (in dollars per share)", "label": "Diluted EPS (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "auth_ref": "r278", "r299", "r300", "r301", "r302", "r303", "r304", "r312", "r323", "r324", "r325", "r329", "r670", "r673", "r692", "r693", "r786", "r809", "r979"}, {"tag": "us-gaap_EarningsPerShareTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": "http://www.colgate.com/role/EarningsPerShare", "lang": "en-us", "role": "terseLabel", "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share.", "auth_ref": "r309", "r326", "r327", "r328"}, {"tag": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0}, {"tag": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": "r711"}, {"tag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "parentTag": null, "weight": null, "order": null, "root": true}, {"tag": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "auth_ref": "r635", "r1024"}, {"tag": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Tax at United States statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "auth_ref": "r291", "r635", "r659", "r1024"}, {"tag": "cl_EffectiveIncomeTaxRateReconciliationDeferredWithholdingTaxAmount", "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDeferredWithholdingTaxAmount", "crdr": "debit", "calculation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Deferred withholding tax", "label": "Effective Income Tax Rate Reconciliation, Deferred Withholding Tax, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Deferred Withholding Tax, Amount", "auth_ref": "r291", "r635", "r659", "r1024"}, {"tag": "us-gaap_EffectiveIncomeTaxRateReconciliationFdiIPercent", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationFdiIPercent", "calculation": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Foreign-derived intangible income benefit", "label": "Effective Income Tax Rate Reconciliation, FDI, Percent", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDI).", "auth_ref": "r1024", "r1321", "r1323"}, {"tag": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Earnings taxed at other than United States statutory rate", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "auth_ref": "r636", "r639", "r1024", "r1218", "r1321"}, {"tag": "cl_EffectiveIncomeTaxRateReconciliationForeignTaxMatterPercent", "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationForeignTaxMatterPercent", "calculation": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Foreign tax matter", "label": "Effective Income Tax Rate Reconciliation, Foreign Tax Matter, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "auth_ref": "r636", "r639", "r1024", "r1218", "r1321"}, {"tag": "cl_EffectiveIncomeTaxRateReconciliationResearchAndExperimentationCapitalization", "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationResearchAndExperimentationCapitalization", "crdr": "debit", "calculation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Research and Experimentation Capitalization", "label": "Effective Income Tax Rate Reconciliation, Research and Experimentation, Capitalization", "documentation": "Effective Income Tax Rate Reconciliation, Research and Experimentation, Capitalization", "auth_ref": "r1024", "r1218", "r1321"}, {"tag": "cl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "lang": "en-us", "role": "terseLabel", "State income taxes, net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "auth_ref": "r638", "r1024", "r1218", "r1321"}, {"tag": "cl_EffectiveIncomeTaxRateReconciliationTaxLossAndTaxCreditCarryforwards", "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationTaxLossAndTaxCreditCarryforwards", "crdr": "credit", "calculation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0}, {"tag": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "lang": "en-us", "role": "terseLabel", "Tax credits and tax loss carryforwards, net of valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Tax Loss And Tax Credit Carryforwards", "documentation": "The sum of the differences between total income tax expense (benefit) as reported in the Income Statement for the period and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to tax loss and tax credit carryforwards.", "auth_ref": "r1024", "r1218", "r1321"}, {"tag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails", "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0}, {"tag": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails", "lang": "en-us", "role": "terseLabel", "Accrued payroll and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred

through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."} } }, "auth_ref": {"r35"} } }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"}, {"presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Stock-based compensation, additional disclosures [Abstract]"}, {"label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"} } }, {"auth_ref": {"I"} } }, {"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"}, {"crdr": "debit", "presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Unrecognized compensation expense"}, {"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, {"auth_ref": {"r616"} } }, {"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"}, {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"}, {"presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Unrecognized compensation expense, weighted-average period of recognition in years"}, {"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in PnYnMnDnTnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": {"r616"} } }, {"us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"}, {"crdr": "credit", "presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Total income tax benefit from stock compensation"}, {"label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, {"auth_ref": {"r613"} } }, {"cl_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptionsAndVestingOfRestrictedStockUnitAwards"}, {"xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptionsAndVestingOfRestrictedStockUnitAwards"}, {"crdr": "credit", "presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Tax benefit from exercise of stock options and vesting of restricted stock unit awards"}, {"label": "Employee Service Share-Based Compensation, Tax Benefit From Exercise Of Stock Options And Vesting Of Restricted Stock Unit Awards"} } } }, {"auth_ref": {"I"} } }, {"us-gaap_EmployeeStockOptionMember"}, {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember"}, {"presentation": {"http://www.colgate.com/role/EarningsPerShareNarrativeDetails"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Employee Stock Option"}, {"label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } }, {"auth_ref": {"I"} } }, {"us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPCashContributionsToESOP"}, {"crdr": "debit", "presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlanDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Company contributions to the ESOP"}, {"label": "Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP", "documentation": "This item represents the amount of cash contributions during the period made by the entity to the Employee Stock Ownership Plan (ESOP)."} } } }, {"auth_ref": {"r58"} } }, {"us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense"}, {"crdr": "debit", "presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlanDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Annual ESOP expense"}, {"label": "Employee Stock Ownership Plan (ESOP), Compensation Expense", "documentation": "The amount of plan compensation cost recognized during the period." } } } }, {"auth_ref": {"r59"} } }, {"cl_EmployeeStockOwnershipPlanESOPDebtStructureEmployerLoanAmount"}, {"xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EmployeeStockOwnershipPlanESOPDebtStructureEmployerLoanAmount"}, {"crdr": "debit", "presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlanDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Outstanding borrowings in the ESOP"}, {"label": "Employee Stock Ownership Plan ESOP Debt Structure Employer Loan Amount", "documentation": "The amount of advances from the Company to the ESOP which remain outstanding as of the balance sheet date." } } } }, {"auth_ref": {"I"} } }, {"cl_EmployeeStockOwnershipPlanESOPDisclosuresTextBlock"}, {"xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresTextBlock"}, {"presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlan"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Employee Stock Ownership Plan"}, {"label": "Employee Stock Ownership Plan ESOP Disclosures [Text Block]", "documentation": "Employee Stock Ownership Plan ESOP Disclosures [Text Block]"} } } }, {"auth_ref": {"I"} } }, {"us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPDividendsPaidToESOP"}, {"crdr": "debit", "presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlanDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Dividends paid by the Company on shares held by the ESOP"}, {"label": "Employee Stock Ownership Plan (ESOP), Dividends Paid to ESOP", "documentation": "Dividends paid on stock held by an employee stock ownership plan." } } } }, {"auth_ref": {"r58"} } }, {"us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"}, {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"}, {"presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlanDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Common shares released and allocated to participant accounts (in shares)"}, {"label": "Employee Stock Ownership Plan (ESOP), Number of Allocated Shares", "documentation": "The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested." } } } }, {"auth_ref": {"r60"} } }, {"us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares"}, {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares"}, {"presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlanDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Common shares available for future allocation to participant accounts (in shares)"}, {"label": "Employee Stock Ownership Plan (ESOP), Number of Suspense Shares", "documentation": "Shares contributed to the ESOP that have not yet been released, committed to be released, or allocated to participant accounts. Suspense shares generally collateralize ESOP debt." } } } }, {"auth_ref": {"r60"} } }, {"us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP"}, {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPSharesInESOP"}, {"presentation": {"http://www.colgate.com/role/EmployeeStockOwnershipPlanDetails"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Shares in ESOP (in shares)"}, {"label": "Employee Stock Ownership Plan (ESOP), Shares in ESOP", "documentation": "Sum of the allocated, committed-to-be-released and suspense shares of the entity held by the plan." } } } }, {"auth_ref": {"r60"} } }, {"dei_EntitiesTable"}, {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entities [Table]"}, {"label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityAddressAddressLine1"}, {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Address, Address Line One"}, {"label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityAddressCityOrTown"}, {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Address, City or Town"}, {"label": "Entity Address, City or Town", "documentation": "Name of the City or Town." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityAddressPostalZipCode"}, {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Address, Postal Zip Code"}, {"label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityAddressStateOrProvince"}, {"xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Address, State or Province"}, {"label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityCentralIndexKey"}, {"xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Central Index Key"}, {"label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } }, {"auth_ref": {"r1069"} } }, {"dei_EntityCommonStockSharesOutstanding"}, {"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Common Stock, Shares Outstanding"}, {"label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock/items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityCurrentReportingStatus"}, {"xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Current Reporting Status"}, {"label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (i) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityEmergingGrowthCompany"}, {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Emerging Growth Company"}, {"label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } } }, {"auth_ref": {"r1069"} } }, {"dei_EntityFileNumber"}, {"xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity File Number"}, {"label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityFilerCategory"}, {"xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Filer Category"}, {"label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }, {"auth_ref": {"r1069"} } }, {"dei_EntityIncorporationStateCountryCode"}, {"xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Incorporation, State or Country Code"}, {"label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityInformationLineItems"}, {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Information [Line Items]"}, {"label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, {"auth_ref": {"I"} } }, {"dei_EntityInteractiveDataCurrent"}, {"xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent"}, {"presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Interactive Data Current"}, {"label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."} } } }, {"auth_ref": {"r1179"} } }, {"dei_EntityPublicFloat"}, {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat"}, {"crdr": "credit", "presentation": {"http://www.colgate.com/role/Cover"}, {"lang": {"en-us"}, {"role": {"terseLabel": "Entity Public Float"}, {"label": "Entity Public Float",

"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": { "r1069" } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.colgate.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r1069" } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.colgate.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r1069" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.colgate.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r1069" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.colgate.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r1069" } }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": { "http://www.colgate.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": { "r1069" } }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": { "http://www.colgate.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": { "r1180" } }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": { "http://www.colgate.com/role/NatureOfOperationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Entity-Wide Information, Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r1180" } }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": { "r1122" } }, "ecd_EqtyAwrdsAdjExclgValRprtInSummaryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummaryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": { "r1175" } }, "ecd_EqtyAwrdsAdjMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments [Member]", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": { "r1175" } }, "ecd_EqtyAwrdsInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r1175" } }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": { "r115" } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r15", "r231", "r274", "r272", "r273", "r294", "r295", "r296", "r298", "r303", "r305", "r307", "r331", "r372", "r373", "r407", "r487", "r657", "r658", "r667", "r668", "r669", "r671", "r672", "r673", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r712", "r714", "r715", "r716", "r717", "r718", "r721", "r724", "r740", "r805", "r834", "r835", "r836", "r852", "r924" } }, "cl_EquityMethodInvestmentOwnershipPercentageMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EquityMethodInvestmentOwnershipPercentageMaximum", "presentation": { "http://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesPrinciplesOfConsolidationInventoriesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investments accounted for using the equity method, maximum interest", "label": "Equity Method Investment Ownership Percentage Maximum", "documentation": "The maximum percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": { "r115" } }, "cl_EquityMethodInvestmentOwnershipPercentageMinimum": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "EquityMethodInvestmentOwnershipPercentageMinimum", "presentation": { "http://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesPrinciplesOfConsolidationInventoriesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investments accounted for using the equity method, minimum interest", "label": "Equity Method Investment Ownership Percentage Minimum", "documentation": "The minimum percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": { "r115" } }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": { "http://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesPrinciplesOfConsolidationInventoriesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Equity method investments included in other assets", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": { "r330", "r348", "r360", "r370", "r1197", "r1236" } }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": { "r1132" } }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": { "r1089", "r1100", "r1110", "r1143" } }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": { "r1086", "r1097", "r1107", "r1140" } }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": { "http://www.colgate.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" }, "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredBySegmentDetails", "http://www.colgate.com/role/SegmentInformationScheduleOfSegmentInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe", "documentation": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": { "r1189", "r1190", "r1191", "r1192", "r1408", "r1409", "r1410", "r1411" } }, "us-gaap_ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue", "crdr": "debit", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Excess of current cost over LIFO cost", "label": "Excess of Replacement or Current Costs over Stated LIFO Value", "documentation": "The excess of replacement or current cost over the stated LIFO (last in first out) inventory value when the LIFO inventory method is utilized." } } }, "auth_ref": { "r253" } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis]" } } }, "auth_ref": { "r1138" } }, "cl_ExpectedBenefitPaymentsFromCompanyAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ExpectedBenefitPaymentsFromCompanyAssets", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expected benefit payments from company assets", "label": "Expected Benefit Payments From Company Assets", "documentation": "Expected Benefit Payments From Company's Assets to be paid in year one." } } }, "auth_ref": { "r115" } }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative and Financial Instruments, Fair Value [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r115" } }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": { "r468", "r526", "r527", "r528", "r529", "r530", "r531", "r694", "r696", "r697", "r698", "r699", "r702", "r703", "r705", "r741", "r742", "r743", "r1001", "r1002", "r1009", "r1010", "r1011", "r1029", "r1032" } }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": { "r468", "r1001", "r1002" } }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": { "r468", "r1001", "r1002" } }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": { "r115" } }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleOfNotionalValuesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedges", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": { "r73" } }, "us-gaap_FairValueInputsLevel1and2and3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1and2and3Member", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3", "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)."} } } }, "auth_ref": { "r1029", "r1286", "r1340", "r1351" } }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": {

"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value, Inputs, Level 1","label":"Fair Value, Inputs, Level 1 [Member]","documentation":"Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."}}},"auth_ref":{"r468","r526","r531","r696","r703","r741","r1009","r1010","r1011","r1029"}},"us-gaap_FairValueInputsLevel2Member":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueInputsLevel2Member","presentation":{"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"},"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value, Inputs, Level 2","label":"Fair Value, Inputs, Level 2 [Member]","documentation":"Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."}}},"auth_ref":{"r468","r526","r531","r696","r697","r703","r742","r1001","r1002","r1009","r1010","r1011","r1029"}},"us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Fair Value Measured At Net Asset Value Per Share Member","presentation":{"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails"},"http://www.colgate.com/role/Fair Value Measured at Net Asset Value Per Share","label":"Fair Value Measured at Net Asset Value Per Share [Member]","documentation":"Fair value measured at net asset value per share as practical expedient."}}},"auth_ref":{"r526","r694","r705","r1029"}},"us-gaap_FairValueMeasurementsFairValueHierarchyDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Fair Value Measurements Fair Value Hierarchy Domain","presentation":{"http://www.colgate.com/role/Fair Value Measurements and Financial Instruments Narrative Details"},"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value Hierarchy and NAV [Domain]","label":"Fair Value Hierarchy and NAV [Domain]","documentation":"Categories used to prioritize the inputs to valuation techniques to measure fair value."}}},"auth_ref":{"r468","r526","r527","r528","r529","r530","r531","r694","r696","r697","r698","r699","r702","r703","r705","r741","r742","r743","r1001","r1002","r1009","r1010","r1011","r1029","r1032"}},"us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation Table","presentation":{"http://www.colgate.com/role/Fair Value Measurements and Financial Instruments Narrative Details"},"http://www.colgate.com/role/Fair Value Measurements and Financial Instruments Fair Value of Derivative Instruments and Other Financial Instruments Details"},"lang":{"en-us":{"role":{"terseLabel":"Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]","label":"Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]","documentation":"Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument."}}},"auth_ref":{"r77","r79","r84"}},"us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Federal Income Tax Expense Benefit Continuing Operations","crdr":{"debit"},"calculation":{"http://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetails":{"parentTag":"us-gaap_IncomeTaxExpenseBenefit","weight":1.0,"order":1.0}}},"presentation":{"http://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"},"lang":{"en-us":{"role":{"verboseLabel":"United States","label":"Federal Income Tax Expense (Benefit), Continuing Operations","documentation":"Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."}}},"auth_ref":{"r289","r632","r634"}},"cl_FilorgaReportingUnitMember":{"xbrltype":"domainItemType","nsuri":"http://www.colgate.com/20241231","localname":"FilorgaReportingUnitMember","presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Filorga Reporting Unit","label":"Filorga Reporting Unit [Member]","documentation":"Filorga Reporting Unit"}}}},"auth_ref":{"r1}}},"cl_FinanceLeaseObligationMember":{"xbrltype":"domainItemType","nsuri":"http://www.colgate.com/20241231","localname":"FinanceLeaseObligationMember","presentation":{"http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails"},"lang":{"en-us":{"role":{"terseLabel":"Finance Lease Obligations","label":"Finance Lease Obligation [Member]","documentation":"Finance Lease Obligation [Member]"}}}},"auth_ref":{"r1}}},"us-gaap_FinancialInstrumentsDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Financial Instruments Disclosure Text Block","presentation":{"http://www.colgate.com/role/Fair Value Measurements and Financial Instruments"},"lang":{"en-us":{"role":{"verboseLabel":"Fair Value Measurements and Financial Instruments","label":"Financial Instruments Disclosure [Text Block]","documentation":"The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."}}},"auth_ref":{"r1}}},"us-gaap_FinancialInstrumentsOwnedAtFairValueByTypeAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Financial Instruments Owned At Fair Value By Type Abstract","presentation":{"http://www.colgate.com/role/Fair Value Measurements and Financial Instruments Fair Value of Derivative Instruments and Other Financial Instruments Details"},"lang":{"en-us":{"role":{"verboseLabel":"Other financial instruments","label":"Financial Instruments, Owned, at Fair Value, by Type, Alternative [Abstract]"}}}},"auth_ref":{"r1}}},"cl_FiniteAndIndefiniteLivedIntangibleAssetsLineItems":{"xbrltype":"stringItemType","nsuri":"http://www.colgate.com/20241231","localname":"FiniteAndIndefiniteLivedIntangibleAssetsLineItems","presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Finite and indefinite-lived intangible assets [Line Items]","label":"Finite And Indefinite Lived Intangible Assets [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":{"r1}}},"us-gaap_FiniteLivedIntangibleAssetUsefulLife":{"xbrltype":"durationItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetUsefulLife","presentation":{"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Estimated useful life of finite-lived intangible assets","label":"Finite-Lived Intangible Asset, Useful Life","documentation":"Useful life of finite-lived intangible assets, in PnYnMnDTnHnMnS format, for example, P1Y3M13D represents the reported fact of one year, five months, and thirteen days."}}},"auth_ref":{"r1}}},"us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsAccumulatedAmortization","crdr":{"credit"},"calculation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails":{"parentTag":"us-gaap_FiniteLivedIntangibleAssetsNet","weight":1.0,"order":2.0},"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails":{"parentTag":"us-gaap_IntangibleAssetsNetExcludingGoodwill","weight":1.0,"order":2.0}}},"presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Finite-lived intangible assets, accumulated amortization","label":"Finite-Lived Intangible Assets, Accumulated Amortization","documentation":"Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."}}},"auth_ref":{"r242","r380","r400","r993"}},"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths","crdr":{"debit"},"presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Annual estimated amortization expense, year 1","label":"Finite-Lived Intangible Asset, Expected Amortization, Year One","documentation":"Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}}},"auth_ref":{"r402","r964","r993"}},"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsAmortizationExpenseYearFive","crdr":{"debit"},"presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Annual estimated amortization expense, year 5","label":"Finite-Lived Intangible Asset, Expected Amortization, Year Five","documentation":"Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}}},"auth_ref":{"r402","r964","r993"}},"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour","crdr":{"debit"},"presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Annual estimated amortization expense, year 4","label":"Finite-Lived Intangible Asset, Expected Amortization, Year Four","documentation":"Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}}},"auth_ref":{"r402","r964","r993"}},"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree","crdr":{"debit"},"presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Annual estimated amortization expense, year 3","label":"Finite-Lived Intangible Asset, Expected Amortization, Year Three","documentation":"Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}}},"auth_ref":{"r402","r964","r993"}},"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo","crdr":{"debit"},"presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Annual estimated amortization expense, year 2","label":"Finite-Lived Intangible Asset, Expected Amortization, Year Two","documentation":"Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}}},"auth_ref":{"r402","r964","r993"}},"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsByMajorClassAxis","presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails"},"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Finite-Lived Intangible Assets by Major Class [Axis]","label":"Finite-Lived Intangible Assets by Major Class [Axis]","documentation":"Information by major type or class of finite-lived intangible assets."}}},"auth_ref":{"r393","r395","r396","r397","r399","r400","r404","r405","r749","r750","r964"}},"us-gaap_FiniteLivedIntangibleAssetsGross":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsGross","crdr":{"debit"},"calculation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails":{"parentTag":"us-gaap_FiniteLivedIntangibleAssetsNet","weight":1.0,"order":1.0}}},"presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Finite-lived intangible assets, gross","label":"Finite-Lived Intangible Assets, Gross","documentation":"Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."}}},"auth_ref":{"r380","r400","r750","r993"}},"us-gaap_FiniteLivedIntangibleAssetsLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsLineItems","presentation":{"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Finite-Lived Intangible Assets [Line Items]","label":"Finite-Lived Intangible Assets [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":{"r393","r400","r404","r405","r406","r749","r964","r993"}},"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FiniteLivedIntangibleAssetsMajorClassNameDomain","presentation":{"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails"},"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Finite-Lived Intangible Assets, Major Class Name [Domain]","label":"Finite-Lived Intangible Assets, Major Class Name [Domain]","documentation":"The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."}}},"auth_ref":{"r393","r395","r396","r397","r399","r400","r404","r405","r964"}},"us-

gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Finite-lived intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r749", "r1257" } }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Estimated remaining useful life (in years)", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r749" } } }, "cl_FiveYearNotesAt460PercentNumberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "FiveYearNotesAt460PercentNumberMember", "presentation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Five Year Notes at 4.60 Percent Number", "label": "Five Year Notes at 4.60 Percent Number [Member]", "documentation": "Five Year Notes at 4.60 Percent Number" } } }, "auth_ref": { } }, "us-gaap_FixedIncomeSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixedIncomeSecuritiesMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fixed income securities", "label": "Fixed Income Securities [Member]", "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity." } } }, "auth_ref": { "r1011", "r1056", "r1057", "r1205" } } }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": { "r710" } } }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": { "r975", "r1009", "r1027", "r1029" } }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "International", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations." } } }, "auth_ref": { "r289", "r634" } }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": { "r1291", "r1292", "r1293" } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": { "r1093", "r1104", "r1114", "r1147" } }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": { "r1093", "r1104", "r1114", "r1147" } }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": { "r1093", "r1104", "r1114", "r1147" } }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": { "r1093", "r1104", "r1114", "r1147" } }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": { "r1093", "r1104", "r1114", "r1147" } }, "ecd_FrValAsOffPrYrEndOfEqtyAwrdsGrntdInPrYrsFldYstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOffPrYrEndOfEqtyAwrdsGrntdInPrYrsFldYstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PypDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": { "r1127" } }, "cl_GainLossOnMarketableSecuritiesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "GainLossOnMarketableSecuritiesAndOtherAssets", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Losses (gains) from marketable securities and other assets", "label": "Gain (Loss) on Marketable Securities and Other Assets", "documentation": "Gain (Loss) on Marketable Securities and Other Assets" } } }, "auth_ref": { } }, "cl_GainLossOnSaleOfLand": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "GainLossOnSaleOfLand", "crdr": "credit", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of land", "label": "Gain (Loss) on Sale of Land", "documentation": "Gain (Loss) on Sale of Land" } } }, "auth_ref": { } }, "us-gaap_GainLossOnSaleOfProperties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfProperties", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0, "order": 7.0 } }, "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on the sale of land", "negatedLabel": "Gain on the sale of land in Asia Pacific", "label": "Gain (Loss) on Sale of Properties", "documentation": "The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method." } } }, "auth_ref": { "r1212", "r1261", "r1262" } }, "cl_GlobalGrowthandEfficiencyProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "GlobalGrowthandEfficiencyProgramMember", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesCumulativeToDateDetails": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Global Growth and Efficiency Program", "label": "Global Growth and Efficiency Program [Member]", "documentation": "Global Growth and Efficiency Program [Member]" } } }, "auth_ref": { } }, "cl_GlobalProductivityInitiativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "GlobalProductivityInitiativeMember", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Global Productivity Initiative", "label": "Global Productivity Initiative [Member]", "documentation": "Global Productivity Initiative" } } }, "auth_ref": { } }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": { "r1241", "r1381", "r1781", "r1987", "r1992", "r1030", "r1038", "r1240", "r1247" } }, "cl_GoodwillAndIndefiniteLivedIntangiblesImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "GoodwillAndIndefiniteLivedIntangiblesImpairmentCharges", "crdr": "debit", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and intangible assets impairment charges", "label": "Goodwill and Indefinite-Lived Intangibles Impairment Charges", "documentation": "Goodwill and Indefinite-Lived Intangibles Impairment Charges" } } }, "auth_ref": { } }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 } }, "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "lang": { "en-us": { "role": { "verboseLabel": "Goodwill and intangible assets impairment charges", "label": "Goodwill and Intangible Asset Impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": { } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssets": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": { "r1238", "r1250" } }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangibles", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for

goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": f
"r1238", "r1250" } } }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails"
"l": "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of
foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from
joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": f "r388" } } }, "us-gaap_GoodwillLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails"
"l": "lang": { "en-us": { "role": { "terseLabel": "Goodwill Line Items", "label": "Goodwill Line Items", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": f "r382",
"r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r992" } } }, "cl_GoodwillReallocatedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.colgate.com/20241231", "localname": "GoodwillReallocatedDuringPeriod", "crdr": "debit", "presentation": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails": "l": "lang": { "en-us": { "role": { "terseLabel": "Reallocation", "label": "Goodwill,
Reallocated During Period", "documentation": "Goodwill, Reallocated During Period" } } }, "auth_ref": f } } }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails": "l": "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label":
"Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": f } } }, "us-
gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": {
"http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } } }, "presentation": {
"http://www.colgate.com/role/ConsolidatedStatementsofIncome": "l": "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation":
"Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": f "r124", "r124",
"r175", "r289", "r371", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r709", "r981", "r986", "r1226", "r1229", "r1231", "r1232", "r1233", "r1278" } } },
"us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": {
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOGIDetails":
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofNotionalValuesDetails": "l": "lang": { "en-us": { "role": { "terseLabel": "Hedging
Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": f "r16" } } }, "cl_HomeCareMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "HomeCareMember", "presentation": {
"http://www.colgate.com/role/NatureofOperationsDetails": "l": "lang": { "en-us": { "role": { "terseLabel": "Home Care", "label": "Home Care [Member]", "documentation": "Home
Care products include laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches and other similar items." } } }, "auth_ref": f } } },
"dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": {
"http://www.colgate.com/role/Cover": "l": "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": f
"r1072", "r1073", "r1096" } } }, "cl_IncentiveStockPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname":
"IncentiveStockPlansMember", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails": "l": "lang": { "en-us": { "role": {
"terseLabel": "Incentive Stock Plans", "label": "Incentive Stock Plans Member", "documentation": "The Company has plans that provide for grants of restricted stock awards
for officers and other employees. A committee of independent members of the Board of Directors administers the plan." } } }, "auth_ref": f } } }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": {
"http://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } } }, "presentation": {
"http://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetails": "l": "lang": { "en-us": { "role": { "verboseLabel": "United States", "label": "Income
(Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is
attributable to domestic operations." } } }, "auth_ref": f "r290", "r633" } } }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } } },
"http://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": {
"http://www.colgate.com/role/ConsolidatedStatementsofIncome": "http://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetails": "l": "lang": { "en-
us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense
(benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": f "r122", "r171", "r175", "r787", "r801", "r981", "r986", "r1226", "r1229", "r1231",
"r1232", "r1233" } } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": {
"http://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } } }, "presentation": {
"http://www.colgate.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesDetails": "l": "lang": { "en-us": { "role": { "verboseLabel": "International", "label": "Income
(Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is
attributable to foreign operations, which is defined as income or loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": f "r290",
"r633" } } }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": {
"parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0, "order": 2.0 } } }, "presentation": {
"http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": "l": "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity income", "label": "Income (Loss)
from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": f "r10",
"r123", "r170", "r330", "r345", "r360", "r370", "r800" } } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": f } } },
"us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis",
"presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails":
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails":
"http://www.colgate.com/role/SegmentInformationNarrativeDetails": "l": "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label":
"Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } },
"auth_ref": f "r408", "r415", "r424", "r700", "r701", "r704", "r831", "r833", "r909", "r964", "r1031", "r1374" } } }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails":
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails":
"http://www.colgate.com/role/SegmentInformationNarrativeDetails": "l": "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label":
"Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": f
"r415", "r424", "r700", "r701", "r704", "r831", "r833", "r909", "r964", "r1031", "r1374" } } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income
Tax Disclosure [Abstract]" } } }, "auth_ref": f } } }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.colgate.com/role/IncomeTaxes": "l": "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes",
"label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": f "r291", "r626", "r635", "r640", "r641", "r642",
"r647", "r654", "r660", "r662", "r665", "r666", "r849", "r1024" } } }, "us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquity": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxEffectsAllocatedDirectlyToEquity", "crdr": "debit", "presentation": {
"http://www.colgate.com/role/IncomeTaxesNarrativeDetails": "l": "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit) allocated directly to equity", "label":
"Income Tax Effects Allocated Directly to Equity", "documentation": "The sum of the tax effects of all items occurring during the period that have been charged or credited
directly to other comprehensive income or to related components of shareholders' equity." } } }, "auth_ref": f "r632" } } }, "us-
gaap_IncomeTaxExaminationEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExaminationEstimateOfPossibleLoss", "crdr": "debit", "presentation": { "http://www.colgate.com/role/IncomeTaxesNarrativeDetails": "l": "lang": { "en-us": { "role": {
"terseLabel": "Tax plus interest for years 2010 through 2018", "label": "Income Tax Examination, Estimate of Possible Loss", "documentation": "Estimated amount of loss
resulting from an adverse tax position." } } }, "auth_ref": f "r1325" } } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-
gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } } }, "http://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null,
"root": true } } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": "http://www.colgate.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
"l": "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "totalLabel": "Total Provision for income taxes", "label": "Income Tax Expense (Benefit)",
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": f "r178",
"r189", "r306", "r307", "r330", "r346", "r360", "r632", "r635", "r661", "r811", "r1024" } } }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies": "l":
"lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income
taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax
credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization
of interest and penalties in the financial statements." } } }, "auth_ref": f "r270", "r628", "r629", "r647", "r648", "r653", "r656", "r843" } } }, "us-
gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationNondeductibleExpenseAmortization", "crdr": "debit", "calculation": {
"http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0
"l": "presentation": { "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails": "l": "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill and
intangible assets", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount", "documentation": "Amount of the difference between
reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income
(loss) from continuing operations attributable to nondeductible amortization." } } }, "auth_ref": f "r1321", "r1323" } } }, "us-
gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationNondeductibleExpenseDepreciation", "crdr": "debit", "calculation": {
"http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0
"l": "presentation": { "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails": "l": "lang": { "en-us": { "role": { "negatedTerseLabel": "Property,
plant and equipment", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation, Amount", "documentation": "Amount of the difference
between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax
income (loss) from continuing operations attributable to nondeductible depreciation." } } }, "auth_ref": f "r1321", "r1323" } } }, "us-

```

"gaap": "IncomeTaxReconciliationNondeductibleExpenseLeases", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseLeases", "crd": "debit", "calculation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0, "presentation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "lang": "en-us", "role": "negatedTerseLabel", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Leases, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible lease expense", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crd": "debit", "calculation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0, "presentation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "lang": "en-us", "role": "negatedTerseLabel", "label": "Pension and other retiree benefits", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crd": "debit", "calculation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0, "presentation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "lang": "en-us", "role": "negatedTerseLabel", "label": "Stock-based compensation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherReconcilingItems", "crd": "debit", "calculation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0, "presentation": "http://www.colgate.com/role/IncomeTaxesIncomeTaxProvisionReconciliationDetails", "lang": "en-us", "role": "negatedTerseLabel", "label": "Other, net", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crd": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "label": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crd": "debit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0, "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "label": "Accounts payable and other accruals", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crd": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0, "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "label": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "xbrl": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "label": "Cash effects of changes in", "label": "Increase (Decrease) in Operating Capital [Abstract]", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crd": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0, "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "label": "Other non-current assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crd": "debit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0, "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "label": "Receivables", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "xbrl": "http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "lang": "en-us", "role": "role", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "crd": "debit", "calculation": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails", "parentTag": "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0, "presentation": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails", "lang": "en-us", "role": "role", "verboseLabel": "Stock options and restricted stock units (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share-based payment arrangements using the treasury stock method", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IncrementalDepreciationMember", "xbrl": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails", "parentTag": "us-gaap-IndefiniteLivedIntangibleAssetsByMajorClassAxis", "weight": 1.0, "order": 3.0, "presentation": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails", "lang": "en-us", "role": "role", "terseLabel": "Indefinite-lived intangible assets (excluding goodwill)", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crd": "debit", "calculation": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails", "parentTag": "us-gaap-IndefiniteLivedIntangibleAssetsByMajorClassAxis", "weight": 1.0, "order": 2.0, "presentation": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails", "lang": "en-us", "role": "role", "verboseLabel": "Indefinite-lived intangible assets (excluding goodwill)", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "xbrl": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails", "parentTag": "us-gaap-IndefiniteLivedIntangibleAssetsByMajorClassAxis", "weight": 1.0, "order": 1.0, "presentation": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails", "lang": "en-us", "role": "role", "terseLabel": "Indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IndirectTaxPaymentsRefunds", "xbrl": "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails", "parentTag": "us-gaap-IndirectTaxPaymentsRefunds", "weight": 1.0, "order": 6.0, "presentation": "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails", "lang": "en-us", "role": "role", "terseLabel": "Indirect tax payments (refunds)", "label": "Indirect Tax Payments (Refunds)", "documentation": "Indirect Tax Payments (Refunds)", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "ecd_IndividualAxis", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "xbrl": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "xbrl": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "xbrl": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Individual", "label": "Individual [Axis]", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "ecd_InsiderTradingArrLineItems", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": "en-us", "role": "role", "label": "Insider Trading Arrangements [Line Items]", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "ecd_InsiderTradingPoliciesProcLineItems", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": "en-us", "role": "role", "label": "Insider Trading Policies and Procedures [Line Items]", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "crd": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "lang": "en-us", "role": "role", "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "xbrl": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "lang": "en-us", "role": "role", "terseLabel": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "xbrl": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crd": "debit", "calc
```

"http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 },
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true },
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true },
"presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets",
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Other intangible assets, net", "totalLabel": "Intangible assets, net (excluding goodwill)", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth ref": { "r393", "r1257", "r1258" } }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth ref": { "r342", "r1209" } }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth ref": { "r280", "r293", "r294" } }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of accrued interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": { "r95" } }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails_1": { "parentTag": "cl_InventoryNetIncludingNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth ref": { "r139", "r973" } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "parentTag": "cl_InventoryNetIncludingNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_InventoryNetIncludingNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "terseLabel": "Current Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth ref": { "r254", "r969", "r1038" } }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNetAbstract", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net [Abstract]", "documentation": "Inventory, Net, Including Noncurrent." } } }, "auth ref": { "r139", "r973" } }, "us-gaap_InventoryNetIncludingNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "InventoryNetIncludingNoncurrent", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total Inventories, net", "label": "Inventory, Net, Including Noncurrent", "documentation": "Inventory, Net, Including Noncurrent." } } }, "auth ref": { "r139", "r973" } }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "parentTag": "cl_InventoryNetIncludingNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Non-current inventory, net", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth ref": { "r199" } }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth ref": { "r179", "r237", "r252", "r375", "r376", "r377", "r477", "r979" } }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails_1": { "parentTag": "cl_InventoryNetIncludingNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments." } } }, "auth ref": { "r139", "r1203" } }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails_1": { "parentTag": "cl_InventoryNetIncludingNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth ref": { "r139", "r974" } }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth ref": { "r330", "r341", "r360", "r986", "r1207" } }, "cl_InvestmentRedemptionNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "InvestmentRedemptionNoticePeriod", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment redemption notice period", "label": "Investment Redemption Notice Period", "documentation": "Investment Redemption Notice Period." } } }, "auth ref": { "r139", "r1203" } }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investments fair value", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth ref": { "r1339", "r1340", "r1350" } }, "us-gaap_LIFOInventoryAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LIFOInventoryAmount", "crdr": "debit", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Inventories valued under LIFO", "label": "LIFO Inventory Amount", "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods." } } }, "auth ref": { "r972" } }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Land", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantandEquipmentGross", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth ref": { "r1196" } }, "srt_LatinAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LatinAmericaMember", "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails",
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails",
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails",
"http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Latin America", "label": "Latin America [Member]", "documentation": "Region of Latin America." } } }, "auth ref": { "r1189", "r1190", "r1191", "r1192", "r1408", "r1409", "r1410", "r1411" } }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth ref": { "r729", "r1037" } }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://www.colgate.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Operating Lease Expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth ref": { "r1356" } }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth ref": { "r738" } }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.colgate.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth ref": { "r1357" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease commitments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth ref": { "r738" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0,

"order": 6.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r738" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r738" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r730" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r738" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r738" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r738" } }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": { "r738" } }, "cl_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": { "http://www.colgate.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of lease renewal options (one or more)", "label": "Lessee, Operating Lease, Number of Renewal Options", "documentation": "Lessee, Operating Lease, Number of Renewal Options" } } }, "auth_ref": { "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": { "http://www.colgate.com/role/Leases": { "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": { "r723" } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r22", "r94", "r95", "r96", "r99", "r100", "r101", "r104", "r288", "r371", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r676", "r680", "r681", "r709", "r882", "r980", "r1067", "r1278", "r1358", "r1359" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r111", "r168", "r796", "r1038", "r1216", "r1237", "r1353" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders' 2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": { "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r96", "r236", "r288", "r371", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r676", "r680", "r681", "r709", "r1038", "r1278", "r1358", "r1359" } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": { "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": { "r93", "r98" } }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unused borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": { "r93", "r98", "r442" } }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "calculation": { "http://www.colgate.com/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_PensionAndOtherPostretirementBenefitExpense", "weight": 1.0, "order": 1.0 } }, "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://www.colgate.com/role/CommitmentsandContingenciesDetails": { "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "ERISA litigation matter", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": { "r1188" } }, "cl_LocalBrandsTrademarksCustomerRelationshipsandNonCompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LocalBrandsTrademarksCustomerRelationshipsandNonCompeteAgreementsMember", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Local Brands, Trademarks, Customer Relationships, and Non-Compete Agreements", "label": "Local Brands, Trademarks, Customer Relationships and Non-Compete Agreements Member", "documentation": "Finite-lived intangible assets consisting of: Payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time, an asset acquired in a business combination representing a customer relationship that exists between an entity and its customer, rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and local brand value." } } }, "auth_ref": { "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.colgate.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": { "r22", "r165", "r467", "r481", "r1001", "r1002", "r1036", "r1370" } }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt and Lease Obligation, Including Current Maturities", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current." } } }, "auth_ref": { "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 1.0 } }, "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails": { "parentTag": "us-gaap_ShortTermBankLoansAndNotesPayable", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheetsParenthetical": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt payable within one year", "negatedLabel": "Less: Current portion of long-term debt", "verboseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": { "r245" } }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": {

"lang": "en-us", "role": "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r12", "r293", "r293", "r1281", "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "parentTag": "us-gaap:LongTermDebt", "weight": 1.0, "order": 1.0, "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "lang": "en-us", "role": "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r12", "r293", "r472", "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "parentTag": "us-gaap:LongTermDebt", "weight": 1.0, "order": 5.0, "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "lang": "en-us", "role": "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r12", "r293", "r472", "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "parentTag": "us-gaap:LongTermDebt", "weight": 1.0, "order": 4.0, "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "lang": "en-us", "role": "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r12", "r293", "r472", "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "parentTag": "us-gaap:LongTermDebt", "weight": 1.0, "order": 3.0, "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "lang": "en-us", "role": "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r12", "r293", "r472", "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "parentTag": "us-gaap:LongTermDebt", "weight": 1.0, "order": 2.0, "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesScheduleofLongTermDebtandFinanceLeaseMaturitiesDetails": "lang": "en-us", "role": "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r12", "r293", "r472", "us-gaap:LongTermDebtNoncurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedBalanceSheets": "parentTag": "us-gaap:Liabilities", "weight": 1.0, "order": 2.0, "gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": "weight": 1.0, "order": 2.0, "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": "parentTag": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 2.0, "presentation": "http://www.colgate.com/role/ConsolidatedBalanceSheets": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": "lang": "en-us", "role": "verboseLabel": "Long-term debt", "terseLabel": "Total", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "auth_ref": "r246", "us-gaap:LongTermPurchaseCommitmentAmount": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Contractual commitments, amount", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "auth_ref": "us-gaap:LongtermDebtTypeAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": "lang": "en-us", "role": "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt.", "auth_ref": "r22", "r1264", "r1265", "r1266", "us-gaap:LongtermDebtTypeDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails": "lang": "en-us", "role": "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "auth_ref": "r22", "r44", "r1264", "r1265", "r1266", "us-gaap:LossContingenciesLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r434", "r435", "r436", "r440", "r623", "r999", "r1272", "r1273", "us-gaap:LossContingenciesTable": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation.", "auth_ref": "r434", "r435", "r436", "r440", "r623", "r999", "r1272", "r1273", "cl:LossContingencyCasesRemovedFromCaseCount": "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LossContingencyCasesRemovedFromCaseCount", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, cases removed from case count", "label": "Loss Contingency, Cases Removed from Case Count", "documentation": "Loss Contingency, Cases Removed from Case Count", "auth_ref": "us-gaap:LossContingencyClaimsSettledAndDismissedNumber": "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyClaimsSettledAndDismissedNumber", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, claims dismissed or settled, number (in cases)", "label": "Loss Contingency, Claims Settled and Dismissed, Number", "documentation": "The number of claims settled and dismissed during the period.", "auth_ref": "r1272", "r1273", "us-gaap:LossContingencyEstimateOfPossibleLoss": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Range of reasonably possible losses", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "auth_ref": "r435", "r436", "r439", "r440", "r623", "r999", "us-gaap:LossContingencyNewClaimsFiledNumber": "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNewClaimsFiledNumber", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, new claims filed, number (in cases)", "label": "Loss Contingency, New Claims Filed, Number", "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "auth_ref": "r1272", "r1273", "cl:LossContingencyNumberOfCasesOnAppeal": "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LossContingencyNumberOfCasesOnAppeal", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, number of cases on appeal", "label": "Loss Contingency, Number of Cases On Appeal", "documentation": "Loss Contingency, Number of Cases On Appeal", "auth_ref": "cl:LossContingencyNumberOfCasesPendingInLowerFederalCourt": "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LossContingencyNumberOfCasesPendingInLowerFederalCourt", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, pending claims, number (in cases)", "label": "Loss Contingency, Number of Cases Pending in Lower Federal Court", "documentation": "Loss Contingency, Number of Cases Pending in Lower Federal Court", "auth_ref": "cl:LossContingencyNumberOfCasesResultingInVerdictForTheCompany": "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LossContingencyNumberOfCasesResultingInVerdictForTheCompany", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, number of cases resulting in verdict for the Company", "label": "Loss Contingency, Number of Cases Resulting in Verdict for the Company", "documentation": "Loss Contingency, Number of Cases Resulting in Verdict for the Company", "auth_ref": "us-gaap:LossContingencyPendingClaimsNumber": "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, pending claims, number (in cases)", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency.", "auth_ref": "r1272", "r1273", "cl:LossContingencyPetitionsApprovedForRemovalOfPenaltyPortionOfClaim": "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LossContingencyPetitionsApprovedForRemovalOfPenaltyPortionOfClaim", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, petitions approved for removal of penalty portion of claim", "label": "Loss Contingency, Petitions Approved for Removal of Penalty Portion of Claim", "documentation": "Loss Contingency, Petitions Approved for Removal of Penalty Portion of Claim", "auth_ref": "cl:LossContingencyPetitionsApprovedForRemovalOfPenaltyPortionOfClaim": "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "LossContingencyPetitionsApprovedForRemovalOfPenaltyPortionOfClaim", "presentation": "http://www.colgate.com/role/CommitmentsandContingenciesDetails": "lang": "en-us", "role": "terseLabel": "Loss contingency, petitions for removal of penalty portion of claim", "label": "Loss Contingency, Petitions for Removal of Penalty Portion of Claim", "documentation": "Loss Contingency, Petitions for Removal of Penalty Portion of Claim", "auth_ref": "us-gaap:MachineryAndEquipmentGross": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": "parentTag": "us-gaap:PropertyPlantandEquipmentGross", "weight": 1.0, "order": 4.0, "presentation": "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": "lang": "en-us", "role": "terseLabel": "Manufacturing machinery and equipment", "label": "Machinery and Equipment, Gross", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "auth_ref": "r140", "us-gaap:MachineryAndEquipmentMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": "lang": "en-us", "role": "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "auth_ref": "srt:MajorCustomersAxis": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": "http://www.colgate.com/role/SegmentInformationNarrativeDetails": "lang": "en-us", "role": "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers.", "auth_ref": "r367", "r1008", "r1040", "r1053", "r1283", "r1371", "r1375", "r1376", "r1378", "r1379", "r1380", "r1381", "r1382",

"r1384", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402" }, {"us-gaap_MarketableSecurities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": {"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueOfDerivativeInstrumentsandOtherFinancialInstrumentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } }}, "auth_ref": {"r169", "r1200"}}, "us-gaap_MarketableSecuritiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": {"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherCurrentAssetsDetails": {"parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 }}, "presentation": {"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherCurrentAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } }}, "auth_ref": {"r1200"}}, "srt_MaximumMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": {"http://www.colgate.com/role/CommitmentsandContingenciesDetails": {"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails": {"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": {"lang": {"en-us": {"role": {"terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } }}, "auth_ref": {"r194", "r196", "r198", "r199", "r201", "r229", "r230", "r435", "r436", "r437", "r438", "r576", "r623", "r699", "r746", "r830", "r832", "r840", "r873", "r874", "r927", "r929", "r931", "r932", "r942", "r962", "r963", "r991", "r1005", "r1019", "r1032", "r1033", "r1034", "r1035", "r1049", "r1280", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365"}}, "ecd_MeasureAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Measure", "label": "Measure [Axis]", "documentation": "MeasureName", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Name", "label": "Measure Name", "documentation": "MinimumMember", "presentation": {"http://www.colgate.com/role/CommitmentsandContingenciesDetails": {"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails": {"http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": {"lang": {"en-us": {"role": {"terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } }}, "auth_ref": {"r194", "r196", "r198", "r199", "r201", "r229", "r230", "r435", "r436", "r437", "r438", "r576", "r623", "r699", "r746", "r830", "r832", "r840", "r873", "r874", "r927", "r929", "r931", "r932", "r942", "r962", "r963", "r991", "r1005", "r1019", "r1032", "r1033", "r1034", "r1035", "r1049", "r1280", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365"}}, "cl_MinimumNumberOfCountriesAndTerritoriesServingConsumers": {"xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "MinimumNumberOfCountriesAndTerritoriesServingConsumers", "presentation": {"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Minimum number of countries and territories serving consumers (more than) (in countries and territories)", "label": "Minimum Number Of Countries And Territories Serving Consumers", "documentation": "Minimum Number Of Countries And Territories Serving Consumers", "auth_ref": {"us-gaap_MinorityInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }}, "presentation": {"http://www.colgate.com/role/ConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } }}, "auth_ref": {"r110", "r167", "r288", "r371", "r443", "r446", "r447", "r448", "r452", "r453", "r709", "r795", "r886"}}, "ecd_MnpiDiscTimedForCompValFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "auth_ref": {"r1150"}}, "ecd_MtrTermsOffrdArrTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOffrdArrTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]", "auth_ref": {"r1158"}}, "srt_NameOfMajorCustomerDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": {"http://www.colgate.com/role/SegmentInformationNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } }}, "auth_ref": {"r367", "r1008", "r1048", "r1053", "r1283", "r1371", "r1375", "r1376", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402"}}, "ecd_NamedExecutiveOfficersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]", "auth_ref": {"r1131"}}, "us-gaap_NatureOfOperations": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": {"http://www.colgate.com/role/NatureOfOperations": {"lang": {"en-us": {"role": {"terseLabel": "Nature of Operations", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } }}, "auth_ref": {"r180", "r190"}}, "us-gaap_NetCashProvidedByUsedInFinancingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 }}, "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed; or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } }}, "auth_ref": {"r282"}}, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "auth_ref": {"us-gaap_NetCashProvidedByUsedInInvestingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 }}, "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } }}, "auth_ref": {"r282"}}, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "auth_ref": {"us-gaap_NetCashProvidedByUsedInOperatingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }}, "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "Net cash provided by operations", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } }}, "auth_ref": {"r131", "r132", "r134"}}, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "auth_ref": {"us-gaap_NetIncomeLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofIncome": {"parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }}, "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofIncome": {"lang": {"en-us": {"role": {"totalLabel": "Net income attributable to Colgate Palmolive Company", "label": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } }}, "auth_ref": {"r125", "r134", "r172", "r234", "r265", "r268", "r273", "r288", "r297", "r299", "r300", "r301", "r302", "r303", "r306", "r307", "r321", "r371", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r670", "r673", "r693", "r709", "r804", "r905", "r922", "r923", "r1065", "r1278"}}, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": {"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }}, "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": {"parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }}, "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofIncome": {"lang": {"en-us": {"role": {"terseLabel": "Less: Net income attributable to noncontrolling interests", "label": "Less: Net income attributable to noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } }}, "auth_ref": {"r69", "r157", "r265", "r268", "r303", "r306", "r307", "r803", "r1206"}}, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": {"http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }}, "presentation": {"http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {"lang": {"en-us": {"role": {"terseLabel": "Basic EPS", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } }}, "auth_ref": {"r279", "r299", "r300", "r301", "r302", "r309", "r310", "r322", "r325", "r673"}}, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": {"http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {"parentTag": null, "weight": null, "order": null, "root": true }}, "presentation": {"http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {"lang": {"en-us": {"role": {"totalLabel": "Diluted EPS", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } }}, "auth_ref": {"r279", "r311", "r317", "r318", "r319", "r320", "r322", "r325"}}, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": {"

```

http://www.colgate.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Net income attributable to Colgate-Palmolive Company", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "auth_ref": "f", "us-gaap": "NetInvestmentHedgingMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": "f", "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Net Investment Hedges", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation.", "auth_ref": "r75", "cl_NetOperatingLossAndCapitalLossCarryforwards": "f", "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "NetOperatingLossAndCapitalLossCarryforwards", "crdr": "debit", "presentation": "f", "http://www.colgate.com/role/IncomeTaxNarrativeDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Net operating loss and capital loss carryforwards", "label": "Net Operating Loss and Capital Loss Carryforwards", "documentation": "Net Operating Loss and Capital Loss Carryforwards", "auth_ref": "f", "cl_NetOperatingLossAndCapitalLossCarryforwardsSetToBeginExpiring": "f", "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "NetOperatingLossAndCapitalLossCarryforwardsSetToBeginExpiring", "crdr": "debit", "presentation": "f", "http://www.colgate.com/role/IncomeTaxNarrativeDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Net operating loss and capital loss carryforwards, set to begin expiring", "label": "Net Operating Loss and Capital Loss Carryforwards, Set to Begin Expiring", "documentation": "Net Operating Loss and Capital Loss Carryforwards, Set to Begin Expiring", "auth_ref": "f", "us-gaap": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "crdr": "debit", "calculation": "f", "http://www.colgate.com/role/ConsolidatedStatementsofIncome", "parentTag": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0, "presentation": "f", "http://www.colgate.com/role/ConsolidatedStatementsofIncome", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-service related postretirement costs", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "documentation": "Amount of expense (reversal of expense) for net-periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.", "auth_ref": "r501", "us-gaap": "NewAccountingPronouncementsPolicyPolicyTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": "f", "http://www.colgate.com/role/SummaryofSignificantAccountingPolicies", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "auth_ref": "f", "ecd_NonGaapMeasureDescriptionTextBlock": "f", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": "f", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]", "auth_ref": "r1130", "ecd_NonNeosMember": "f", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": "f", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]", "auth_ref": "r1093", "r1104", "r1114", "r1138", "r1147", "ecd_NonPeoNeoAvgCompActuallyPaidAmt": "f", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": "f", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "auth_ref": "r1121", "ecd_NonPeoNeoAvgTotalCompAmt": "f", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": "f", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount", "auth_ref": "r1120", "ecd_NonPeoNeoMember": "f", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": "f", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]", "auth_ref": "r1138", "ecd_NonRule10b51ArrAdoptedFlag": "f", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": "f", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": "r1158", "ecd_NonRule10b51ArrTrmndFlag": "f", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": "f", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": "r1158", "cl_NonServiceRelatedPostretirementCostsMember": "f", "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "NonServiceRelatedPostretirementCostsMember", "presentation": "f", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-service related postretirement costs", "label": "Non-Service Related Postretirement Costs [Member]", "documentation": "Non-Service Related Postretirement Costs [Member]", "auth_ref": "f", "us-gaap": "NonUsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": "f", "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Non-US", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US).", "auth_ref": "r1408", "r1409", "r1410", "r1411", "us-gaap": "NoncontrollingInterestMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": "f", "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "auth_ref": "r63", "r487", "r1220", "r1221", "r1222", "r1223", "r1406", "srt_NorthAmericaMember": "f", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NorthAmericaMember", "presentation": "f", "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails", "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "North America", "label": "North America [Member]", "documentation": "Continent of North America.", "auth_ref": "r1189", "r1190", "r1191", "r1192", "r1408", "r1409", "r1410", "r1411", "us-gaap": "NotesAndLoansPayableCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansPayableCurrent", "crdr": "credit", "calculation": "f", "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails", "parentTag": "us-gaap:ShortTermBankLoansAndNotesPayable", "weight": 1.0, "order": 1.0, "presentation": "f", "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Notes and loans payable", "label": "Notes and Loans Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "auth_ref": "r94", "r95", "us-gaap": "NotesPayableOtherPayablesMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableOtherPayablesMember", "presentation": "f", "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesComponentsofLongtermDebtDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Notes", "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party.", "auth_ref": "f", "us-gaap": "NumberOfCountriesInWhichEntityOperates", "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfCountriesInWhichEntityOperates", "presentation": "f", "http://www.colgate.com/role/CommitmentsandContingenciesDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "The number of countries in which the entity operates (more than)", "label": "Number of Countries in which Entity Operates", "documentation": "The number of countries in which the entity operates as of balance sheet date.", "auth_ref": "f", "cl_NumberOfDividendsDeclaredPerQuarter": "f", "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "NumberOfDividendsDeclaredPerQuarter", "presentation": "f", "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquityParenthetical", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Number of dividends declared per quarter", "label": "Number of Dividends Declared Per Quarter", "documentation": "Number of Dividends Declared Per Quarter", "auth_ref": "f", "cl_NumberOfGeographicallyReportableOperatingSegments": "f", "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "NumberOfGeographicallyReportableOperatingSegments", "presentation": "f", "http://www.colgate.com/role/SegmentInformationNarrativeDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Number of geographically reportable operating segments (in segments)", "label": "Number Of Geographically Reportable Operating Segments", "documentation": "Number Of Geographically Reportable Operating Segments", "auth_ref": "f", "cl_NumberOfMemberStatesOfTheEuropeanUnion": "f", "xbrltype": "integerItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "NumberOfMemberStatesOfTheEuropeanUnion", "presentation": "f", "http://www.colgate.com/role/IncomeTaxNarrativeDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Number of member states of the European Union", "label": "Number of Member States of the European Union", "documentation": "Number of Member States of the European Union", "auth_ref": "f", "us-gaap": "NumberOfOperatingSegments": "f", "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": "f", "http://www.colgate.com/role/SegmentInformationNarrativeDetails", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "Number of operating segments (in segments
```

"OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "http://www.colgate.com/role/LeasesScheduleofMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r726": { "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "presentation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other accruals", "verboseLabel": "Lease liabilities due in one year", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r726": { "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": { "r727": { "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "terseLabel": "Long-term lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r726": { "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": { "r727": { "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.colgate.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease, payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": { "r728": { "r734": { "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r725": { "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.colgate.com/role/LeasesBalanceSheetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": { "r727": { "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.colgate.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r737": { "r1037": { "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.colgate.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in PnYnMnDtnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r736": { "r1037": { "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsValuationAllowance", "crdr": "credit", "presentation": { "http://www.colgate.com/role/IncomeTaxNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforward, valuation allowance", "label": "Operating Loss Carryforwards, Valuation Allowance", "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": { "r1328": { "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r354": { "r355": { "r356": { "r357": { "r358": { "r361": { "r986": { "r987": { "cl_OralCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OralCareMember", "presentation": { "http://www.colgate.com/role/NatureOfOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Oral Care", "label": "Oral Care [Member]", "documentation": "Oral Care products include toothpaste, toothbrushes, mouth rinses and other similar items." } } }, "auth_ref": { "l": { "cl_OralPersonalAndHomeCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OralPersonalAndHomeCareMember", "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails": { "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Oral, Personal and Home Care", "terseLabel": "Total Oral, Personal and Home Care", "label": "Oral, Personal and Home Care [Member]", "documentation": "Oral, Personal and Home Care" } } }, "auth_ref": { "l": { "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "documentation": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "auth_ref": { "l": { "cl_OtherAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherAccrualsTableTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationTables": { "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Other Accruals", "label": "Other Accruals [Table Text Block]", "documentation": "Other Accruals [Table Text Block]", "auth_ref": { "l": { "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other accruals", "totalLabel": "Other accruals", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r95": { "cl_OtherAccruedLiabilitiesCurrentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherAccruedLiabilitiesCurrentOther", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 10.0 }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities Current Other", "documentation": "Carrying value as of the balance sheet date of other obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "l": { "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherCurrentAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "totalLabel": "Total Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": { "r256": { "r1038": { "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r243": { "cl_OtherAssetsandLiabilitiesNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherAssetsandLiabilitiesNetMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other assets and liabilities, net", "label": "Other Assets and Liabilities, Net [Member]", "documentation": "Other Assets and Liabilities, Net [Member]", "auth_ref": { "l": { "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Less: Cumulative translation adjustments attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to noncontrolling interests." } } }, "auth_ref": { "r8": { "r14": { "r156": { "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLossDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), before reclassifications, pretax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r25": { "r272": { "r712": { "r715": { "r718": { "r805": { "r1204": { "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": {

"http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLossDetails" |, "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), pretax", "label": "Other Comprehensive Income (Loss), before Tax", "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "auth_ref": { "r274", "r712", "r713", "r718", "r782", "r805", "r1204", "r1205" } }, "us-gaap": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) on cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } }, "auth_ref": { "r261", "r262", "r805" } }, "us-gaap": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } }, "auth_ref": { "r2", "r805" } }, "cl": "OtherComprehensiveIncomeLossHedgedItemInNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherComprehensiveIncomeLossHedgedItemInNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOGIDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total gain (loss) on investment hedges", "label": "Other Comprehensive Income (Loss), Hedged Item In Net Investment Hedge, Gain (Loss), Before Reclassification And Tax", "documentation": "Other Comprehensive Income (Loss), Hedged Item In Net Investment Hedge, Gain (Loss), Before Reclassification and Tax" } }, "auth_ref": { "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOGIDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } }, "auth_ref": { "r683" } }, "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLossDetails" |, "lang": { "en-us": { "role": { "totalLabel": "Total Other comprehensive income (loss), net of tax", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "auth_ref": { "r15", "r21", "r266", "r269", "r274", "r303", "r712", "r713", "r718", "r782", "r805", "r1204", "r1205" } }, "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } }, "auth_ref": { "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "lang": { "en-us": { "role": { "negatedLabel": "Retirement plan and other retiree benefit adjustments", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } }, "auth_ref": { "r3", "r4", "r119", "r120", "r805" } }, "us-gaap:OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLossDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Tax amounts", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "auth_ref": { "r5", "r271", "r274", "r632", "r663", "r664", "r712", "r716", "r718", "r782", "r805" } }, "us-gaap:OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails": { "parentTag": "us-gaap:OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } }, "auth_ref": { "r126", "r810", "r986" } }, "us-gaap:OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } }, "auth_ref": { "r77", "r84" } }, "cl:OtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherIncomeExpenseNet", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "parentTag": "us-gaap:OtherOperatingIncomeExpenseNet", "weight": -1.0, "order": 9.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other (income) expense, net", "documentation": "Other operating income, not previously categorized, from items that are associated with the entity's normal revenue producing operation, and the amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } }, "auth_ref": { "cl:OtherIncomeExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherIncomeExpenseNetAbstract", "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "label": "Other Income Expense Net Abstract" } }, "auth_ref": { "cl:OtherIncomeExpenseNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherIncomeExpenseNetMember", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "label": "Other (Income) Expense, Net [Member]", "documentation": "Other (Income) Expense, Net [Member]" } }, "auth_ref": { "cl:OtherIncomeExpenseNetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherIncomeExpenseNetTableTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationTables": { "lang": { "en-us": { "role": { "verboseLabel": "Other (income) expense, net", "label": "Other (income) expense, net [Table Text Block]", "documentation": "Other (income) expense, net [Table Text Block]" } }, "auth_ref": { "us-gaap:OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other finite life intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } }, "auth_ref": { "r993", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260" } }, "us-gaap:OtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesAbstract", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Other Liabilities [Abstract]" } }, "auth_ref": { "us-gaap:OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } }, "auth_ref": { "us-gaap:OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:Liabilities", "weight": 1.0, "order": 4.0 } }, "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "totalLabel": "Total Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } }, "auth_ref": { "r100" } }, "us-gaap:OtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesTableTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationTables": { "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Other Liabilities", "label": "Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other liabilities." } }, "auth_ref": { "cl:OtherNoncurrentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "OtherNoncurrentLiability", "crdr": "credit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": { "parentTag": "us-gaap:OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Noncurrent Liability", "documentation": "Obligations not otherwise itemized or previously categorized that are due beyond one year (or operating cycle, if longer) from the balance sheet date." } }, "auth_ref": { "us-gaap:OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap:OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other (income) expense, net", "negatedTotalLabel": "Total Other (income) expense, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } }, "auth_ref": { "ecd:OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } }, "auth_ref": { "r1130" } }, "us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueofPlanAssetsDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Retiree Benefit Plans", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } }, "auth_ref": { "r499", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r550", "r553", "r556", "r560", "r561", "r562", "r563", "r564",

"r565","r566","r567","r568","r569","r573","r574","r575","r1011","r1012","r1013","r1014","r1015"}}, {"us-gaap-OtherRestructuringMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": {"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails", "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesCumulativeToDateDetails"}}, {"lang": {"en-us": {"role": {"verboseLabel": "Other Charges", "terseLabel": "Other", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other."}}}}, {"auth_ref": {"r995", "r996", "r997", "r998"}}, {"ecd-OutstandingAggtErrCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount"}}, {"auth_ref": {"r1091", "r1102", "r1112", "r1145"}}, {"ecd-OutstandingRecoveryCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount"}}, {"auth_ref": {"r1094", "r1105", "r1148"}}, {"ecd-OutstandingRecoveryIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "Name", "label": "Outstanding Recovery, Individual Name"}}, {"auth_ref": {"r1094", "r1105", "r1148"}}, {"ecd-PayVsPerformanceDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": {"en-us": {"role": {"label": "Pay vs Performance Disclosure [Line Items]"}}, {"auth_ref": {"r1119"}}, {"us-gaap-PayablesAndAccrualsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "presentation": {"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Other accruals", "label": "Payables and Accruals [Abstract]"}}, {"auth_ref": {"us-gaap-PaymentsForProceedsFromOtherInvestingActivities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0}}}}, {"presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"negatedLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."}}}}, {"auth_ref": {"r1184", "r1209"}}, {"us-gaap-PaymentsForRepurchaseOfCommonStock": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0}}}}, {"presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails": "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows"}}, {"lang": {"en-us": {"role": {"negatedLabel": "Purchases of treasury shares", "terseLabel": "Repurchased stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period."}}}}, {"auth_ref": {"r1129"}}, {"us-gaap-PaymentsForRepurchaseOfEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfEquityAbstract", "presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Stock Repurchases [Abstract]", "label": "Payments for Repurchase of Equity [Abstract]"}}, {"auth_ref": {"us-gaap-PaymentsForRestructuring", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": {"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails"}}, {"lang": {"en-us": {"role": {"negatedTerseLabel": "Cash Payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."}}}}, {"auth_ref": {"r1423", "r1211"}}, {"us-gaap-PaymentsOfOrdinaryDividends": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfOrdinaryDividends", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0}}}}, {"presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends", "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings."}}}}, {"auth_ref": {"r1129"}}, {"us-gaap-PaymentsToAcquireBusinessesNetOfCashAcquired": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0}}}}, {"presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"negatedLabel": "Payment for acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."}}}}, {"auth_ref": {"r127"}}, {"us-gaap-PaymentsToAcquireMarketableSecurities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0}}}}, {"presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"negatedLabel": "Purchases of marketable securities and investments", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security."}}}}, {"auth_ref": {"r1235"}}, {"us-gaap-PaymentsToAcquireProductiveAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0}}}}, {"presentation": {"http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"negatedLabel": "Capital expenditures", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."}}}}, {"auth_ref": {"r1177", "r1332", "r1333", "r1334"}}, {"ecd-PeerGroupIssuersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]"}}, {"auth_ref": {"r1129"}}, {"ecd-PeerGroupTotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount"}}, {"auth_ref": {"r1129"}}, {"us-gaap-PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": {"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": {"parentTag": "us-gaap-OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0}}}}, {"presentation": {"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Pension and other retiree benefits", "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."}}}}, {"auth_ref": {"r149", "r50", "r100", "r149"}}, {"us-gaap-PensionAndOtherPostretirementBenefitExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitExpense", "crdr": "debit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"parentTag": null, "weight": null, "order": null, "root": true}}}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails": {"lang": {"en-us": {"role": {"totalLabel": "Total pension cost", "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)", "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."}}}}, {"auth_ref": {"us-gaap-PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefits"}}, {"lang": {"en-us": {"role": {"terseLabel": "Retirement Plans and Other Retiree Benefits", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits."}}}}, {"auth_ref": {"r498", "r523", "r525", "r531", "r549", "r551", "r552", "r553", "r554", "r555", "r570", "r571", "r573", "r1011"}}, {"us-gaap-PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"parentTag": "us-gaap-DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 2.0}}}}, {"http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails": {"parentTag": "us-gaap-OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0}}}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"lang": {"en-us": {"role": {"terseLabel": "Pension and other retiree benefits", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current."}}}}, {"auth_ref": {"r95", "r499", "r500", "r522", "r1011"}}, {"us-gaap-PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"parentTag": "us-gaap-DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 3.0}}}}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Noncurrent liabilities", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent."}}}}, {"auth_ref": {"r100", "r499", "r500", "r522", "r1011"}}, {"us-gaap-PensionPlansDefinedBenefitMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueofPlanAssetsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Pension Plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits."}}}}, {"auth_ref": {"r499", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r550", "r553", "r556", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r573", "r574", "r577", "r1011", "r1012", "r1016", "r1017", "r1018"}}, {"ecd-PeoActuallyPaidCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount"}}, {"auth_ref": {"r1121"}}, {"ecd-PeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "PEO", "label": "PEO [Member]"}}, {"auth_ref": {"r1138"}}, {"ecd-PeoName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "PEO Name", "label": "PEO Name"}}, {"auth_ref": {"r1131"}}, {"ecd-PeoTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": {"en-us": {"role": {"terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount"}}, {"auth_ref": {"r1120"}}, {"cl-PercentOfTotalRestructuringChargesRelatedToSegmentForThePeriod": {"xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "PercentOfTotalRestructuringChargesRelatedToSegmentForThePeriod", "presentation": {"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails": {"lang": {"en-us": {"role": {"terseLabel": "Percent of total restructuring charges related to segment", "label": "Percent Of Total Restructuring Charges Related To Segment For The Period", "documentation": "Percent

[illegible]

"terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": { "r203", "r204", "r205", "r206", "r207", "r208", "r228", "r363", "r748", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r966", "r1006", "r1047", "r1049", "r1050", "r1054", "r1055", "r1195", "r1274", "r1275", "r1283", "r1371", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402" } }, "c": "ProductRecallCosts", "f": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ProductRecallCosts", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product recall costs", "label": "Product Recall Costs", "documentation": "Product Recall Costs" } } }, "auth_ref": { "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402" } } }, "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.colgate.com/role/NatureOfOperationsDetails": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": { "r203", "r204", "r205", "r206", "r207", "r208", "r228", "r363", "r748", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r966", "r1006", "r1047", "r1049", "r1050", "r1054", "r1055", "r1195", "r1274", "r1275", "r1283", "r1371", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402" } } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows", "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity", "http://www.colgate.com/role/ConsolidatedStatementsofComprehensiveIncome": { "http://www.colgate.com/role/ConsolidatedStatementsofIncome": { "lang": { "en-us": { "role": { "totalLabel": "Net income including noncontrolling interests", "verboseLabel": "Net income including noncontrolling interests", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r234", "r265", "r268", "r281", "r288", "r297", "r303", "r306", "r307", "r371", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r670", "r673", "r674", "r677", "r678", "r693", "r709", "r787", "r802", "r851", "r905", "r922", "r923", "r1025", "r1026", "r1066", "r1206", "r1278" } } }, "c": "Program2022Member", "f": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "Program2022Member", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Program 2022", "label": "Program 2022 | Member", "documentation": "Program 2022" } } }, "auth_ref": { "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402" } } }, "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment [Abstract]", "documentation": "Property, plant and equipment, net." } } }, "auth_ref": { "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402" } } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment by Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r11", "r739" } } }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r140", "r239", "r799" } } }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r739" } } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets", "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r11", "r739", "r788", "r799", "r1038" } } }, "us-gaap_PropertyPlantAndEquipmentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentOther", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other equipment", "label": "Property, Plant and Equipment, Other, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": { "r11" } } }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { "r11", "r184", "r187", "r797" } } }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r11" } } }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r140", "r739" } } }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnTnHnMnS' format, for example, 'PY5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": { "r11", "r437", "r438", "r523", "r576", "r609", "r610", "r611", "r623", "r699", "r744", "r745", "r746", "r830", "r832", "r840", "r873", "r874", "r927", "r929", "r931", "r932", "r942", "r962", "r963", "r991", "r1003", "r1019", "r1032", "r1033", "r1034", "r1035", "r1049", "r1058", "r1267", "r1280", "r1342", "r1361", "r1362", "r1363", "r1364", "r1365" } } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://www.colgate.com/role/CommitmentsandContingenciesDetails": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails", "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangiblesDetails", "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": { "r194", "r196", "r198", "r199", "r201", "r229", "r230", "r435", "r436", "r437", "r438", "r523", "r576", "r609", "r610", "r611", "r623", "r699", "r744", "r745", "r746", "r830", "r832", "r840", "r873", "r874", "r927", "r929", "r931", "r932", "r942", "r962", "r963", "r991", "r1003", "r1019", "r1032", "r1033", "r1034", "r1035", "r1049", "r1058", "r1267", "r1280", "r1342", "r1361", "r1362", "r1363", "r1364", "r1365" } } }, "c": "RealEstateandOtherInvestmentsMember", "f": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "RealEstateandOtherInvestmentsMember", "presentation": { "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Real Estate and Other Investments [Member]", "documentation": "Real Estate and Other Investments" } } }, "auth_ref": { "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402" } } }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleofComprehensiveIncomeLineDetails": { "lang": { "en-us": { "role": {

"terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r273" } }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "calculation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleOfComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleOfComprehensiveIncomeLossDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification from AOCI, pretax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r25", "r272", "r712", "r717", "r718", "r805", "r1204" } }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": { "http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationScheduleOfComprehensiveIncomeLossDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": { "r273" } }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": { "http://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": { "r1086", "r1097", "r1107", "r1140" } }, "us-gaap_RepaymentsOfOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherDebt", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on debt", "label": "Repayments of Other Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other." } } }, "auth_ref": { "r130" } }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": { "http://www.colgate.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": { "r391", "r392", "r992" } }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": { "http://www.colgate.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit {Domain}", "label": "Reporting Unit {Domain}", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": { "r391", "r392", "r992" } }, "cl_ReportingUnitImpairmentAnalysisCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ReportingUnitImpairmentAnalysisCarryingAmount", "crdr": "debit", "presentation": { "http://www.colgate.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reporting unit impairment analysis carrying amount", "label": "Reporting Unit Impairment Analysis, Carrying Amount", "documentation": "Reporting Unit Impairment Analysis, Carrying Amount" } } }, "auth_ref": { "cl_ResearchAndDevelopmentAndAdvertisingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ResearchAndDevelopmentAndAdvertisingTableTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationTables": { "lang": { "en-us": { "role": { "verboseLabel": "Research and development and Advertising", "label": "Research And Development And Advertising [Table Text Block]", "documentation": "This element is used to disclose supplemental income statement information related to research and development and advertising expense." } } }, "auth_ref": { "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r625", "r964", "r986", "r1366" } }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]", "auth_ref": { "r1087", "r1098", "r1108", "r1141" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": { "r1088", "r1099", "r1109", "r1142" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]", "auth_ref": { "r1095", "r1106", "r1116", "r1149" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.colgate.com/role/EarningsPerShareNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]", "auth_ref": { "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationCharges": { "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Implementation Charges", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": { "r420", "r421", "r423", "r426", "r431" } }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostCostIncurredToDate", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Pretax charges related to the Restructuring Program to date", "label": "Restructuring and Related Cost, Cost Incurred to Date", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": { "r422", "r425", "r428", "r430" } }, "cl_RestructuringAndRelatedCostEstimatedToSettleThroughCashPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "RestructuringAndRelatedCostEstimatedToSettleThroughCashPercentage", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related Cost, estimated to settle through cash, percentage", "label": "Restructuring and Related Cost, Estimated to Settle Through Cash, Percentage", "documentation": "Restructuring and Related Cost, Estimated to Settle Through Cash, Percentage" } } }, "auth_ref": { "cl_RestructuringAndRelatedCostExpectedCostPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "RestructuringAndRelatedCostExpectedCostPercentage", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related cost, expected cost, percentage", "label": "Restructuring and Related Cost, Expected Cost, Percentage", "documentation": "Restructuring and Related Cost, Expected Cost, Percentage" } } }, "auth_ref": { "us-gaap_RestructuringAndRelatedCostCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostCostIncurredCost", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails": { "lang": { "en-us": { "role": { "netLabel": "Total 2022 Global Productivity Initiative charges, pretax", "verboseLabel": "Restructuring and related cost, incurred cost", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": { "r422", "r425", "r428", "r430" } }, "cl_RestructuringAndRelatedCostCostIncurredCostAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "RestructuringAndRelatedCostCostIncurredCostAfterTax", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total 2022 Global Productivity Initiative charges, aftertax", "label": "Restructuring And Related Cost, Incurred Cost, After Tax", "documentation": "Restructuring And Related Cost, Incurred Cost, After Tax" } } }, "auth_ref": { "cl_RestructuringAndRelatedCostCostIncurredCostPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "RestructuringAndRelatedCostCostIncurredCostPercent", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Program-to-date accumulated charges (percent)", "label": "Restructuring and Related Cost, Incurred Cost, Percent", "documentation": "Restructuring and Related Cost, Incurred Cost, Percent" } } }, "auth_ref": { "cl_RestructuringAndRelatedCostCostIncurredCostToDateAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "RestructuringAndRelatedCostCostIncurredCostToDateAfterTax", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related cost incurred cost to date after tax", "label": "Restructuring And Related Cost Incurred Cost To Date After Tax", "documentation": "Restructuring And Related Cost Incurred Cost To Date After Tax" } } }, "auth_ref": { "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r10", "r427", "r428", "r1268" } }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r422",


```

"r423","r424","r425","r428","r429","r430","1","us-gaap_RestructuringCosts","f","xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringCosts","crdr":"debit","calculation":"f","http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails","parentTag":"us-gaap_OtherOperatingIncomeExpenseNet","weight":"-1.0","order":"3.0"},"presentation":"f","http://www.colgate.com/role/SegmentInformationNarrativeDetails","http://www.colgate.com/role/SupplementalIncomeStatementInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring costs","verboseLabel":"2022 Global Productivity Initiative","label":"Restructuring Costs","documentation":"Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."}}},"auth_ref":{"r10"},"us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration":{"xbrltype":"enumerationSetItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"},"presentation":"f","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails","http://www.colgate.com/role/SegmentInformationNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]","label":"Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]","documentation":"Indicates line item in statement of income or comprehensive income that includes restructuring charges."}}},"auth_ref":{"r1182","r1183"},"cl_RestructuringNetOfCash":{"xbrltype":"monetaryItemType","nsuri":"http://www.colgate.com/20241231","localname":"RestructuringNetOfCash","crdr":"debit","calculation":"f","http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows","parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":"-1.0","order":"2.0"},"presentation":"f","http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring and termination benefits, net of cash","label":"Restructuring, net of cash","documentation":"The amount of noncash restructuring costs net of cash payments."}}},"auth_ref":{"1},"us-gaap_RestructuringPlanAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringPlanAxis","presentation":"f","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesCumulativeToDateDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails","http://www.colgate.com/role/SegmentInformationNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring Plan [Axis]","label":"Restructuring Plan [Axis]","documentation":"Information by individual restructuring plan."}}},"auth_ref":{"1},"us-gaap_RestructuringPlanDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringPlanDomain","presentation":"f","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesCumulativeToDateDetails","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails","http://www.colgate.com/role/SegmentInformationNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring Plan [Domain]","label":"Restructuring Plan [Domain]","documentation":"Identification of the individual restructuring plans."}}},"auth_ref":{"1},"us-gaap_RestructuringReserve":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringReserve","crdr":"credit","presentation":"f","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails"},"lang":{"en-us":{"role":{"periodStartLabel":"Beginning balance","periodEndLabel":"Ending balance","label":"Restructuring Reserve","documentation":"Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."}}},"auth_ref":{"r423","r429"},"cl_RestructuringReserveChargesAgainstAssets":{"xbrltype":"monetaryItemType","nsuri":"http://www.colgate.com/20241231","localname":"RestructuringReserveChargesAgainstAssets","crdr":"debit","presentation":"f","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Charges against assets","label":"Restructuring Reserve, Charges Against Assets","documentation":"Restructuring Reserve, Charges Against Assets"}}},"auth_ref":{"1},"us-gaap_RestructuringReserveCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringReserveCurrent","crdr":"credit","calculation":"f","http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails"},"parentTag":"us-gaap_OtherAccruedLiabilitiesCurrent","weight":"-1.0","order":"4.0"},"presentation":"f","http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherAccrualsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring accrual","label":"Restructuring Reserve, Current","documentation":"Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."}}},"auth_ref":{"r1201","r1269","r1270"},"us-gaap_RestructuringReserveNoncurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringReserveNoncurrent","crdr":"credit","calculation":"f","http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails"},"parentTag":"us-gaap_OtherLiabilitiesNoncurrent","weight":"-1.0","order":"4.0"},"presentation":"f","http://www.colgate.com/role/SupplementalBalanceSheetInformationScheduleofOtherLiabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring accrual","label":"Restructuring Reserve, Noncurrent","documentation":"Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."}}},"auth_ref":{"r1202","r1269","r1270"},"us-gaap_RestructuringReserveRollForward":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringReserveRollForward","presentation":"f","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restructuring Reserve [Roll Forward]","label":"Restructuring Reserve [Roll Forward]","documentation":"A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."}}},"auth_ref":{"1},"us-gaap_RestructuringReserveTranslationAdjustment":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringReserveTranslationAdjustment","crdr":"credit","presentation":"f","http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Foreign exchange","label":"Restructuring Reserve, Foreign Currency Translation Gain (Loss)","documentation":"Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve."}}},"auth_ref":{"r1269","r1270"},"us-gaap_RetainedEarningsAccumulatedDeficit":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsAccumulatedDeficit","crdr":"credit","calculation":"f","http://www.colgate.com/role/ConsolidatedBalanceSheets"},"parentTag":"us-gaap_StockholdersEquity","weight":"1.0","order":"3.0"},"presentation":"f","http://www.colgate.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Retained earnings","label":"Retained Earnings (Accumulated Deficit)","documentation":"Amount of accumulated undistributed earnings (deficit)."}}},"auth_ref":{"r108","r148","r794","r837","r839","r848","r885","r1038"},"us-gaap_RetainedEarningsMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsMember","presentation":"f","http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"},"lang":{"en-us":{"role":{"terseLabel":"Retained Earnings","label":"Retained Earnings [Member]","documentation":"Accumulated undistributed earnings (deficit)."}}},"auth_ref":{"r231","r294","r295","r296","r298","r303","r305","r307","r372","r373","r407","r657","r658","r667","r668","r669","r671","r672","r673","r685","r687","r688","r690","r691","r721","r724","r834","r836","r852","r1406"},"us-gaap_RetirementPlanSponsorLocationAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetirementPlanSponsorLocationAxis","presentation":"f","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Retirement Plan Sponsor Location [Axis]","label":"Retirement Plan Sponsor Location [Axis]","documentation":"Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."}}},"auth_ref":{"r502","r503","r504","r505","r506","r507","r508","r509","r510","r511","r512","r513","r514","r515","r516","r517","r518","r519","r520","r521","r522","r523","r524","r526","r527","r528","r529","r530","r531","r532","r533","r534","r535","r536","r537","r538","r539","r540","r541","r542","r543","r544","r545","r546","r547","r548","r550","r553","r557","r558","r559","r560","r561","r562","r563","r564","r565","r566","r567","r568","r569","r1291","r1292","r1293"},"us-gaap_RetirementPlanTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetirementPlanTypeAxis","presentation":"f","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueofPlanAssetsDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails","http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetails"},"lang":{"en-us":{"role":{"terseLabel":"Retirement Plan Type [Axis]","label":"Retirement Plan Type [Axis]","documentation":"Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."}}},"auth_ref":{"r499","r502","r503","r504","r505","r506","r507","r508","r509","r510","r511","r512","r513","r514","r515","r516","r517","r518","r519","r520","r521","r522","r523","r524","r526","r527","r528","r529","r530","r531","r532","r533","r534","r535","r536","r537","r538","r539","r540","r541","r542","r543","r544","r545","r546","r547","r548","r550","r553","r557","r558","r559","r560","r561","r562","r563","r564","r565
```

```

http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails",
"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails",
"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails",
"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails",
"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Retirement Plan Type {Domain}", "label": "Retirement Plan Type {Domain}", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." }}, "auth_ref": {"r499", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r550", "r553", "r556", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r573", "r574", "r575", "r577", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018"}}, "us-gaap": "RevenueFromContractWithCustomerExcludingAssessedTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": "http://www.colgate.com/role/ConsolidatedStatementsOfIncome", {"parentTag": "us-gaap:GrossProfit", "weight": 1.0, "order": 1.0}, "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails", {"parentTag": "us-gaap:OperatingIncomeLoss", "weight": 1.0, "order": 1.0}, "presentation": "http://www.colgate.com/role/ConsolidatedStatementsOfIncome", "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}], "lang": {"en-us": {"role": {"verboseLabel": "Net sales", "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." }}, "auth_ref": {"r173", "r174", "r330", "r339", "r340", "r354", "r360", "r363", "r365", "r367", "r496", "r497", "r748"}}, "us-gaap": "RevenueFromContractWithCustomerPolicyTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": {"http://www.colgate.com/role/SummaryofSignificantAccountingPolicies", {"lang": {"en-us": {"role": {"terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." }}, "auth_ref": {"r191", "r486", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r965"}}, "us-gaap": "RevolvingCreditFacilityMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": {"http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails", {"lang": {"en-us": {"role": {"terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." }}, "auth_ref": {"r11", "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": {"http://www.colgate.com/role/LeasesNarrativeDetails", {"lang": {"en-us": {"role": {"terseLabel": "Right-of-use asset obtained in exchange for operating lease liability", "label": "Right-of-use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." }}, "auth_ref": {"r735", "r1037"}}, "ecd_Rule10b51ArrAdoptedFlag", {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", {"lang": {"en-us": {"role": {"terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": {"r1158"}}, "ecd_Rule10b51ArrTerminatedFlag", {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTerminatedFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", {"lang": {"en-us": {"role": {"terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": {"r1158"}}, "us-gaap:SalesRevenueNetMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": {"http://www.colgate.com/role/NatureofOperationsDetails", "http://www.colgate.com/role/SegmentInformationNarrativeDetails", {"lang": {"en-us": {"role": {"terseLabel": "Sales Revenue, Net", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." }}, "auth_ref": {"r367", "r1186"}}, "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsTables", {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets." }}, "auth_ref": {"r1011", "r1288", "r1289"}}, "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsTables", {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Allocation of Plan Assets", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." }}, "auth_ref": {"r150"}}, "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": {"http://www.colgate.com/role/EarningsPerShareNarrativeDetails", {"lang": {"en-us": {"role": {"terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." }}, "auth_ref": {"r32"}}, "cl:ScheduleOfCommonAndTreasuryStockActivityTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ScheduleOfCommonAndTreasuryStockActivityTableTextBlock", "presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansTables", {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Common and Treasury Stock Activity", "label": "Schedule of Common and Treasury Stock Activity [Table Text Block]", "documentation": "Schedule of Common and Treasury Stock Activity [Table Text Block]", "auth_ref": {"r11", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "presentation": {"http://www.colgate.com/role/SupplementalOtherComprehensiveIncomeLossInformationTables", {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans." }}, "auth_ref": {"r116"}}, "us-gaap:ScheduleOfDebtInstrumentsTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": {"http://www.colgate.com/role/LongTermDebtandCreditFacilitiesTables", {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." }}, "auth_ref": {"r22", "r45", "r46", "r90", "r146", "r147", "r1001", "r1003", "r1219", "r1354"}}, "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": {"http://www.colgate.com/role/IncomeTaxesTables", {"lang": {"en-us": {"role": {"verboseLabel": "Schedule of Components of Deferred Tax Assets (Liabilities)", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." }}, "auth_ref": {"r1327"}}, "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTable", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationofPlanAssetsandLevelofValuationInPutbyMajorAssetCategoryDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsBenefitObligationExceedsFairValueofPlanAssetsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails", "http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofOtherRetireeBenefitPlansDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Defined Benefit Plan [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."}}, "auth_ref": {"r13", "r51", "r52", "r53", "r54"}}, "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsTables", {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Defined Benefit
```

gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTableBlock", "presentation": {
"http://www.colgate.com/role/NatureOfOperationsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Percentage of Worldwide Sales", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": {
"r41": {
"us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": {
"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Expected Benefit Payments", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": {
"r151": {
"cl_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
"xbrltype": "stringItemType", "nsuri":
"http://www.colgate.com/20241231", "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "presentation": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryOfOtherIntangibleAssetsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule Of Finite And Indefinite Lived Intangible Assets By Major Class [Table]", "label": "Schedule Of Finite And Indefinite Lived Intangible Assets By Major Class [Table]", "documentation": "Disclosure of the carrying value of amortizable intangible assets by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Disclosure of the details of intangible assets not subject to amortization, excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": {
"cl_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "presentation": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Finite and Indefinite Lived Intangible Assets By Major Class", "label": "Schedule Of Finite And Indefinite Lived Intangible Assets By Major Class [Table Text Block]", "documentation": "Disclosure of amortizable intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization. Disclosure of the carrying value of intangible assets not subject to amortization, excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": {
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
"xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": {
"http://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesGoodwillandOtherIntangibleAssets": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": {
"r393", "r400", "r404", "r405", "r406", "r749", "r964", "r993": {
"us-gaap_ScheduleOfGoodwillTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleOfGoodwillDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": {
"r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r992": {
"us-gaap_ScheduleOfGoodwillTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfGoodwillTableTextBlock", "presentation": {
"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Goodwill by Segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": {
"r992", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249": {
"us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": {
"http://www.colgate.com/role/IncomeTaxesTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Components of Income Before Income Taxes", "label": "Schedule of Income Before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": {
"r1217": {
"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfInventoryCurrentTableTextBlock", "presentation": {
"http://www.colgate.com/role/SupplementalBalanceSheetInformationTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Inventories by Major Class", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": {
"r23", "r112", "r113", "r114": {
"us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": {
"http://www.colgate.com/role/LongTermDebtandCreditFacilitiesTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": {
"r12": {
"us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfNetBenefitCostsTableTextBlock", "presentation": {
"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Net Benefit Costs", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": {
"r152": {
"us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": {
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period." } } }, "auth_ref": {
"r1337": {
"us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": {
"http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": {
"r72": {
"us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": {
"http://www.colgate.com/role/SupplementalBalanceSheetInformationTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": {
"cl_ScheduleOfPercentOfTotalRestructuringChargesRelatedToSegmentForThePeriodTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri":
"http://www.colgate.com/20241231", "localname": "ScheduleOfPercentOfTotalRestructuringChargesRelatedToSegmentForThePeriodTableTextBlock", "presentation": {
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Percent of Total Restructuring Charges Related To Segment for the period", "label": "Schedule Of Percent Of Total Restructuring Charges Related To Segment For The Period [Table Text Block]", "documentation": "Schedule of Percent Of Total Restructuring Charges Related To Segment for the period" } } }, "auth_ref": {
"us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfPropertyPlantAndEquipmentTable", "presentation": {
"http://www.colgate.com/role/SummaryOfSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": {
"r11", "r739": {
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRestructuringAndRelatedCostsTable", "presentation": {
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringActivityandRelatedAccrualsDetails": {
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredBySegmentDetails": {
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryOfRestructuringChargesCumulativeToDateDetails": {
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryOfRestructuringandRelatedCostsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Restructuring Cost [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": {
"r422", "r423", "r424", "r425", "r428", "r429", "r430": {
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTableTextBlock", "presentation": {
"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": {
"r43", "r441", "r442": {
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": {
"http://www.colgate.com/role/SegmentInformationScheduleOfSegmentInformationDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": {
"r38", "r39", "r40": {
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "presentation": {
"http://www.colgate.com/role/SegmentInformationTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Net Sales and Operating Profit by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": {
"r38", "r39", "r40": {
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": {
"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails": {
"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryOfPerformanceRestrictedStockActivityDetails": {
"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryOfRestrictedStockActivityDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": {
"r579", "r581", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r612": {
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": {
"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": {
"r17", "r18", "r153": {
"us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",

"presentation": {"f": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansTables"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions"}, {"label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."}}}, {"auth_ref": {"f": "r155"}}, {"us_gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {"f": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"}, {"presentation": {"f": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansTables"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Schedule of Share-based Compensation, Performance Restricted Stock and Time-based Restricted Stock Units Activity"}, {"label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."}}}, {"auth_ref": {"f": "r155"}}, {"us_gaap_ScheduleOfShortTermDebtTextBlock": {"f": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTextBlock"}, {"presentation": {"f": "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesTables"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Schedule of Short-Term Debt"}, {"label": "Schedule of Short-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."}}}, {"auth_ref": {"f": "r94"}}, {"us_gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {"f": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"}, {"presentation": {"f": "http://www.colgate.com/role/IncomeTaxesTables"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Schedule of Unrecognized Tax Benefits Activity"}, {"label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits."}}}, {"auth_ref": {"f": "r643", "r1023"}}, {"c_ScheduleOfComponentsOfDeferredIncomeTaxBenefitProvisionTableTextBlock": {"f": "xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ScheduleOfComponentsOfDeferredIncomeTaxBenefitProvisionTableTextBlock"}, {"presentation": {"f": "http://www.colgate.com/role/IncomeTaxesTables"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Schedule of Components of Deferred Income Tax Benefit"}, {"label": "Schedule of Components of Deferred Income Tax Benefit (Provision) [Table Text Block]", "documentation": "Disclosure of the temporary differences between accounting for financial statement purposes and accounting for tax purposes that result in the current provision for taxes being higher (lower) than the total provision for income taxes."}}}, {"auth_ref": {"f": "dei_Security12bTitle"}, {"f": "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle"}, {"presentation": {"f": "http://www.colgate.com/role/Cover"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Title of 12(b) Security"}, {"label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security."}}}, {"auth_ref": {"f": "r1068"}}, {"dei_SecurityExchangeName": {"f": "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName"}, {"presentation": {"f": "http://www.colgate.com/role/Cover"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Security Exchange Name"}, {"label": "Security Exchange Name", "documentation": "Name of the exchange on which a security is registered."}}}, {"auth_ref": {"f": "r1071"}}, {"us_gaap_SegmentDomain": {"f": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain"}, {"presentation": {"f": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails"}, {"f": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails"}, {"f": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails"}, {"f": "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."}}}, {"auth_ref": {"f": "r173", "r174", "r175", "r176", "r330", "r335", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r367", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r406", "r425", "r430", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r983", "r986", "r987", "r992", "r1052", "r1371", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402"}}, {"us_gaap_SegmentExpenditureAdditionToLongLivedAssets": {"f": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentExpenditureAdditionToLongLivedAssets"}, {"presentation": {"f": "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Capital expenditures"}, {"label": "Segment, Expenditure, Addition to Long-Lived Assets", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."}}}, {"auth_ref": {"f": "r330", "r349", "r360", "r986", "r987"}}, {"srt_SegmentGeographicalDomain": {"f": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain"}, {"presentation": {"f": "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails"}, {"f": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails"}, {"f": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails"}, {"f": "http://www.colgate.com/role/SegmentInformationNarrativeDetails"}, {"f": "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area."}}}, {"auth_ref": {"f": "r195", "r197", "r200", "r202", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r365", "r366", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r866", "r869", "r871", "r928", "r930", "r933", "r943", "r950", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r967", "r1400", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1051", "r1058", "r1283", "r1371", "r1375", "r1376", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402"}}, {"us_gaap_SegmentReportingAbstract": {"f": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]"}, {"auth_ref": {"f": "r176", "r330", "r334", "r335", "r336", "r337", "r338", "r350", "r352", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r982", "r984", "r985", "r986", "r988", "r989"}}, {"us_gaap_SegmentReportingInformationLineItems": {"f": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems"}, {"presentation": {"f": "http://www.colgate.com/role/SegmentInformationNarrativeDetails"}, {"f": "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, {"auth_ref": {"f": "r176", "r330", "r334", "r335", "r336", "r337", "r338", "r350", "r352", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r982", "r984", "r985", "r986", "r988", "r989"}}, {"us_gaap_SellingGeneralAndAdministrativeExpense": {"f": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense"}, {"presentation": {"f": "http://www.colgate.com/role/ConsolidatedStatementsOfIncome"}, {"parentTag": {"f": "us_gaap_OperatingIncomeLoss", "weight": {"f": "1.0", "order": {"f": "1.0"}}, {"f": "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}, {"parentTag": {"f": "us_gaap_OperatingIncomeLoss", "weight": {"f": "1.0", "order": {"f": "3.0"}}, {"presentation": {"f": "http://www.colgate.com/role/ConsolidatedStatementOfIncome"}, {"f": "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}, {"f": "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Selling, general and administrative expenses"}, {"verboseLabel": "Selling, general and administrative expenses"}, {"label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."}}}, {"auth_ref": {"f": "r127"}}, {"us_gaap_SellingGeneralAndAdministrativeExpensesMember": {"f": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember"}, {"presentation": {"f": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails"}, {"f": "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringandRelatedCostsDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Selling, general and administrative expenses"}, {"label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."}}}, {"auth_ref": {"f": "r127"}}, {"us_gaap_ShareBasedCompensation": {"f": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation"}, {"calculation": {"f": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows"}, {"parentTag": {"f": "us_gaap_NetCashProvidedByUsedInOperatingActivities", "weight": {"f": "1.0", "order": {"f": "7.0"}}, {"presentation": {"f": "http://www.colgate.com/role/ConsolidatedStatementsOfCashFlows"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Stock-based compensation expense"}, {"label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement."}}}, {"auth_ref": {"f": "r9"}}, {"us_gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {"f": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"}, {"presentation": {"f": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Stock-Based Compensation [Abstract]", "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"}, {"auth_ref": {"f": "r176", "r330", "r334", "r335", "r336", "r337", "r338", "r350", "r352", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r982", "r984", "r985", "r986", "r988", "r989"}}, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {"f": "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"}, {"presentation": {"f": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Vesting period (in years)"}, {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnFnMnSn' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."}}}, {"auth_ref": {"f": "r1020"}}, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {"f": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"}, {"presentation": {"f": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Additional disclosures pertaining to stock-based compensation [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"}, {"auth_ref": {"f": "r176", "r330", "r334", "r335", "r336", "r337", "r338", "r350", "r352", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r982", "r984", "r985", "r986", "r988", "r989"}}, {"c_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeWeightedAverageGrantDateFairValue": {"f": "xbrltype": "perShareItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsChangeWeightedAverageGrantDateFairValue"}, {"presentation": {"f": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}, {"lang": {"f": "en-us"}, {"role": {"f": "terseLabel": "Change due to performance and/or market condition achievement (in dollars per share)"}, {"label": "Share-Based Compensation Arrangement by Share-Based

Payment Award, Equity Instruments Other than Options, Change, Weighted Average Grant Date Fair Value, "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Change, Weighted Average Grant Date Fair Value" } } }, {"auth_ref": "I"}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited In Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, {"auth_ref": "I"}, {"r601"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "terseLabel": "Restricted stock awards - shares forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, {"auth_ref": "I"}, {"r601"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants In Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, {"auth_ref": "I"}, {"r599"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "terseLabel": "Restricted stock awards - shares granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants In Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, {"auth_ref": "I"}, {"r599"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "periodStartLabel": "Restricted stock awards - beginning balance (in shares)", "periodEndLabel": "Restricted stock awards - ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, {"auth_ref": "I"}, {"r596", "r597"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "terseLabel": "Shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares (Roll Forward)", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, {"auth_ref": "I"}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "terseLabel": "Shares (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares (Roll Forward)", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, {"auth_ref": "I"}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "terseLabel": "Weighted Average Grant Date Fair Value Per Award", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value {Abstract}", "auth_ref": "I"}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease", {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "terseLabel": "Change due to performance and/or market condition achievement (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)", "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period." } } }, {"auth_ref": "I"}, {"r1307"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested In Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, {"auth_ref": "I"}, {"r600"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crd": "debit", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}], {"lang": "en-us", "role": "terseLabel": "Total fair value of shares vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested In Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments or cash." } } }, {"auth_ref": "I"}, {"r603"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}], {"lang": "en-us", "role": "terseLabel": "Restricted stock awards - shares vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested In Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, {"auth_ref": "I"}, {"r600"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails"}], {"lang": "en-us", "role": "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, {"auth_ref": "I"}, {"r610"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails"}], {"lang": "en-us", "role": "terseLabel": "Expected volatility rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, {"auth_ref": "I"}, {"r609"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails"}], {"lang": "en-us", "role": "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk-Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, {"auth_ref": "I"}, {"r611"}], {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails"}]

"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r579", "r581", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r612" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": { "r55" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r590" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options exercisable - end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r590" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": { "r603" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": { "r595" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r594" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": { "r301" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted-average estimated fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": { "r602" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of unexercised in-the-money options, options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r55" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "periodStartLabel": "Options - beginning balance (in shares)", "periodEndLabel": "Options - ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r586", "r589" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "r594" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "periodStartLabel": "Options - beginning of period (in dollars per share)", "periodEndLabel": "Options - end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r588", "r589" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": { "r594" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofPerformanceRestrictedStockActivityDetails", "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r612" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options - shares exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r593" } } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options - shares expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": { "r595" } } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options - shares forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r594" } } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options - shares granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r592" } } } }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting

policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": { "r578": "r578", "r606": "r606", "r607": "r607", "r608": "r608", "r609": "r609", "r612": "r612", "r618": "r618", "r619": "r619", "r620": "r620", "r621": "r621" } } }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": { "r1282": "r1282" } }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": { "r1282": "r1282" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contractual term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r1021": "r1021" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansFairValueAssumptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Expected term of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r608": "r608" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of unexercised in-the-money options, options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": { "r55": "r55" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life, options exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r55": "r55" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life, options outstanding (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r154": "r154" } }, "cl_ShippingAndHandlingCostsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ShippingAndHandlingCostsPolicyPolicyTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling Costs", "label": "Shipping and Handling Costs Policy [Policy Text Block]", "documentation": "Shipping And Handling Costs Policy [Policy Text Block]" } } }, "auth_ref": { "r1": "r1" } }, "us-gaap_ShippingAndHandlingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShippingAndHandlingMember", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsPropertyPlantandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling", "label": "Shipping and Handling [Member]", "documentation": "Packing and transport of product." } } }, "auth_ref": { "r1284": "r1284" } }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBankLoansAndNotesPayable", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "http://www.colgate.com/role/LongTermDebtandCreditFacilitiesDebtPayablewithinOneYearDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt payable within one year", "totalLabel": "Debt payable within one year", "label": "Short-Term Bank Loans and Notes Payable", "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer." } } }, "auth_ref": { "r91": "r91", "r879": "r879", "r1369": "r1369" } }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": { "r731": "r731", "r1037": "r1037" } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://www.colgate.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r135": "r135", "r286": "r286" } }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": { "http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillDetails": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails": { "http://www.colgate.com/role/RestructuringandRelatedImplementationChargesRestructuringChargesIncurredbySegmentDetails": { "http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": { "r173": "r173", "r174": "r174", "r175": "r175", "r176": "r176", "r233": "r233", "r330": "r330", "r335": "r335", "r338": "r338", "r339": "r339", "r340": "r340", "r341": "r341", "r342": "r342", "r343": "r343", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r349": "r349", "r351": "r351", "r352": "r352", "r353": "r353", "r354": "r354", "r355": "r355", "r356": "r356", "r357": "r357", "r358": "r358", "r360": "r360", "r361": "r361", "r362": "r362", "r367": "r367", "r382": "r382", "r383": "r383", "r384": "r384", "r385": "r385", "r386": "r386", "r387": "r387", "r388": "r388", "r389": "r389", "r390": "r390", "r406": "r406", "r409": "r409", "r425": "r425", "r430": "r430", "r812": "r812", "r813": "r813", "r814": "r814", "r815": "r815", "r816": "r816", "r817": "r817", "r818": "r818", "r819": "r819", "r820": "r820", "r821": "r821", "r822": "r822", "r83": "r83", "r86": "r86", "r87": "r87", "r88": "r88", "r89": "r89", "r90": "r90", "r91": "r91", "r92": "r92", "r93": "r93", "r94": "r94", "r95": "r95", "r96": "r96", "r97": "r97", "r98": "r98", "r99": "r99", "r100": "r100", "r101": "r101", "r102": "r102", "r103": "r103", "r104": "r104", "r105": "r105", "r106": "r106", "r107": "r107", "r108": "r108", "r109": "r109", "r110": "r110", "r111": "r111", "r112": "r112", "r113": "r113", "r114": "r114", "r115": "r115", "r116": "r116", "r117": "r117", "r118": "r118", "r119": "r119", "r120": "r120", "r121": "r121", "r122": "r122", "r123": "r123", "r124": "r124", "r125": "r125", "r126": "r126", "r127": "r127", "r128": "r128", "r129": "r129", "r130": "r130", "r131": "r131", "r132": "r132", "r133": "r133", "r134": "r134", "r135": "r135", "r136": "r136", "r137": "r137", "r138": "r138", "r139": "r139", "r140": "r140", "r141": "r141", "r142": "r142", "r143": "r143", "r144": "r144", "r145": "r145", "r146": "r146", "r147": "r147", "r148": "r148", "r149": "r149", "r150": "r150", "r151": "r151", "r152": "r152", "r153": "r153", "r154": "r154", "r155": "r155", "r156": "r156", "r157": "r157", "r158": "r158", "r159": "r159", "r160": "r160", "r161": "r161", "r162": "r162", "r163": "r163", "r164": "r164", "r165": "r165", "r166": "r166", "r167": "r167", "r168": "r168", "r169": "r169", "r170": "r170", "r171": "r171", "r172": "r172", "r173": "r173", "r174": "r174", "r175": "r175", "r176": "r176", "r177": "r177", "r178": "r178", "r179": "r179", "r180": "r180", "r181": "r181", "r182": "r182", "r183": "r183", "r184": "r184", "r185": "r185", "r186": "r186", "r187": "r187", "r188": "r188", "r189": "r189", "r190": "r190", "r191": "r191", "r192": "r192", "r193": "r193", "r194": "r194", "r195": "r195", "r196": "r196", "r197": "r197", "r198": "r198", "r199": "r199", "r200": "r200", "r201": "r201", "r202": "r202", "r203": "r203", "r204": "r204", "r205": "r205", "r206": "r206", "r207": "r207", "r208": "r208", "r209": "r209", "r210": "r210", "r211": "r211", "r212": "r212", "r213": "r213", "r214": "r214", "r215": "r215", "r216": "r216", "r217": "r217", "r218": "r218", "r219": "r219", "r220": "r220", "r221": "r221", "r222": "r222", "r223": "r223", "r224": "r224", "r225": "r225", "r226": "r226", "r227": "r227", "r228": "r228", "r229": "r229", "r230": "r230", "r231": "r231", "r232": "r232", "r233": "r233", "r234": "r234", "r235": "r235", "r236": "r236", "r237": "r237", "r238": "r238", "r239": "r239", "r240": "r240", "r241": "r241", "r242": "r242", "r243": "r243", "r244": "r244", "r245": "r245", "r246": "r246", "r247": "r247", "r248": "r248", "r249": "r249", "r250": "r250", "r251": "r251", "r252": "r252", "r253": "r253", "r254": "r254", "r255": "r255", "r256": "r256", "r257": "r257", "r258": "r258", "r259": "r259", "r260": "r260", "r261": "r261", "r262": "r262", "r263": "r263", "r264": "r264", "r265": "r265", "r266": "r266", "r267": "r267", "r268": "r268", "r269": "r269", "r270": "r270", "r271": "r271", "r272": "r272", "r273": "r273", "r274": "r274", "r275": "r275", "r276": "r276", "r277": "r277", "r278": "r278", "r279": "r279", "r280": "r280", "r281": "r281", "r282": "r282", "r283": "r283", "r284": "r284", "r285": "r285", "r286": "r286", "r287": "r287", "r288": "r288", "r289": "r289", "r290": "r290", "r291": "r291", "r292": "r292", "r293": "r293", "r294": "r294", "r295": "r295", "r296": "r296", "r297": "r297", "r298": "r298", "r299": "r299", "r300": "r300", "r301": "r301", "r302": "r302", "r303": "r303", "r304": "r304", "r305": "r305", "r306": "r306", "r307": "r307", "r308": "r308", "r309": "r309", "r310": "r310", "r311": "r311", "r312": "r312", "r313": "r313", "r314": "r314", "r315": "r315", "r316": "r316", "r317": "r317", "r318": "r318", "r319": "r319", "r320": "r320", "r321": "r321", "r322": "r322", "r323": "r323", "r324": "r324", "r325": "r325", "r326": "r326", "r327": "r327", "r328": "r328", "r329": "r329", "r330": "r330", "r331": "r331", "r332": "r332", "r333": "r333", "r334": "r334", "r335": "r335", "r336": "r336", "r337": "r337", "r338": "r338", "r339": "r339", "r340": "r340", "r341": "r341", "r342": "r342", "r343": "r343", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r349": "r349", "r350": "r350", "r351": "r351", "r352": "r352", "r353": "r353", "r354": "r354", "r355": "r355", "r356": "r356", "r357": "r357", "r358": "r358", "r359": "r359", "r360": "r360", "r361": "r361", "r362": "r362", "r363": "r363", "r364": "r364", "r365": "r365", "r366": "r366", "r367": "r367", "r368": "r368", "r369": "r369", "r370": "r370", "r371": "r371", "r372": "r372", "r373": "r373", "r374": "r374", "r375": "r375", "r376": "r376", "r377": "r377", "r378": "r378", "r379": "r379", "r380": "r380", "r381": "r381", "r382": "r382", "r383": "r383", "r384": "r384", "r385": "r385", "r386": "r386", "r387": "r387", "r388": "r388", "r389": "r389", "r390": "r390", "r391": "r391", "r392": "r392", "r393": "r393", "r394": "r394", "r395": "r395", "r396": "r396", "r397": "r397", "r398": "r398", "r399": "r399", "r400": "r400", "r401": "r401", "r402": "r402", "r403": "r403", "r404": "r404", "r405": "r405", "r406": "r406", "r407": "r407", "r408": "r408", "r409": "r409", "r410": "r410", "r411": "r411", "r412": "r412", "r413": "r413", "r414": "r414", "r415": "r415", "r416": "r416", "r417": "r417", "r418": "r418", "r419": "r419", "r420": "r420", "r421": "r421", "r422": "r422", "r423": "r423", "r424": "r424", "r425": "r425", "r426": "r426", "r427": "r427", "r428": "r428", "r429": "r429", "r430": "r430", "r431": "r431", "r432": "r432", "r433": "r433", "r434": "r434", "r435": "r435", "r436": "r436", "r437": "r437", "r438": "r438", "r439": "r439", "r440": "r440", "r441": "r441", "r442": "r442", "r443": "r443", "r444": "r444", "r445": "r445", "r446": "r446", "r447": "r447", "r448": "r448", "r449": "r449", "r450": "r450", "r451": "r451", "r452": "r452", "r453": "r453", "r454": "r454", "r455": "r455", "r456": "r456", "r457": "r457", "r458": "r458", "r459": "r459", "r460": "r460", "r461": "r461", "r462": "r462", "r463": "r463", "r464": "r464", "r465": "r465", "r466": "r466", "r467": "r467", "r468": "r468", "r469": "r469", "r470": "r470", "r471": "r471", "r472": "r472", "r473": "r473", "r474": "r474", "r475": "r475", "r476": "r476", "r477": "r477", "r478": "r478", "r479": "r479", "r480": "r480", "r481": "r481", "r482": "r482", "r483": "r483", "r484": "r484", "r485": "r485", "r486": "r486", "r487": "r487", "r488": "r488", "r489": "r489", "r490": "r490", "r491": "r491", "r492": "r492", "r493": "r493", "r494": "r494", "r495": "r495", "r496": "r496", "r497": "r497", "r498": "r498", "r499": "r499", "r500": "r500", "r501": "r501", "r502": "r502", "r503": "r503", "r504": "r504", "r505": "r505", "r506": "r506", "r507": "r507", "r508": "r508", "r509": "r509", "r510": "r510", "r511": "r511", "r512": "r512", "r513": "r513", "r514": "r514", "r515": "r515", "r516": "r516", "r517": "r517", "r518": "r518", "r519": "r519", "r520": "r520", "r521": "r521", "r522": "r522", "r523": "r523", "r524": "r524", "r525": "r525", "r526": "r526", "r527": "r527", "r528": "r528", "r529": "r529", "r530": "r530", "r531": "r531", "r532": "r532", "r533": "r533", "r534": "r534", "r535": "r535", "r536": "r536", "r537": "r537", "r538": "r538", "r539": "r539", "r540": "r540", "r541": "r541", "r542": "r542", "r543": "r543", "r544": "r544", "r545": "r545", "r546": "r546", "r547": "r547", "r548": "r548", "r549": "r549", "r550": "r550", "r551": "r551", "r552": "r552", "r553": "r553", "r554": "r554", "r555": "r555", "r556": "r556", "r557": "r557", "r558": "r558", "r559": "r559", "r560": "r560", "r561": "r561", "r562": "r562", "r563": "r563", "r564": "r564", "r565": "r565", "r566": "r566", "r567": "r567", "r568": "r568", "r569": "r569", "r570": "r570", "r571": "r571", "r572": "r572", "r573": "r573", "r574": "r574", "r575": "r575", "r576": "r576", "r577": "r577", "r578": "r578", "r579": "r579", "r580": "r580", "r581": "r581", "r582": "r582", "r583": "r583", "r584": "r584", "r585": "r585", "r586": "r586", "r587": "r587", "r588": "r588", "r589": "r589", "r590": "r590", "r591": "r591", "r592": "r592", "r593": "r593", "r594": "r594", "r595": "r595", "r596": "r596", "r597": "r597", "r598": "r598", "r599": "r599", "r600": "r600", "r601": "r601", "r602": "r602", "r603": "r603", "r604": "r604", "r605": "r605", "r606": "r606", "r607": "r607", "r608": "r608", "r609": "r609", "r610": "r610", "r611": "r611", "r612": "r612", "r613": "r613", "r614": "r614", "r615": "r615", "r616": "r616", "r617": "r617", "r618": "r618", "r619": "r619", "r620": "r620", "r621": "r621", "r622": "r622", "r623": "r623", "r624": "r624", "r625": "r625", "r626": "r626", "r627": "r627", "r628": "r628", "r629": "r629", "r630": "r630", "r631": "r631", "r632": "r632", "r633": "r633", "r634": "r634", "r635": "r635", "r636": "r636", "r637": "r637", "r638": "r638", "r639": "r639", "r640": "r640", "r641": "r641", "r642": "r642", "r643": "r643", "r644": "r644", "r645": "r645", "r646": "r646", "r647": "r647", "r648": "r648", "r649": "r649", "r650": "r650", "r651": "r651", "r652": "r652", "r653": "r653", "r654": "r654", "r655": "r655", "r656": "r656", "r657": "r657", "r658": "r658", "r659": "r659", "r660": "r660", "r661": "r661", "r662": "r662", "r663": "r663", "r664": "r664", "r665": "r665", "r666": "r666", "r667": "r667", "r668": "r668", "r669": "r669", "r670": "r670", "r671": "r671", "r672": "r672", "r673": "r673", "r674": "r674", "r675": "r675", "r676": "r676", "r677": "r677", "r678": "r678", "r679": "r679", "r680": "r680", "r681": "r681", "r682": "r682", "r683": "r683", "r684": "r684", "r685": "r685", "r686": "r686", "r687": "r687", "r688": "r688", "r689": "r689", "r690": "r690", "r691": "r691", "r692": "r692", "r693": "r693", "r694": "r694", "r695": "r695", "r696": "r696", "r697": "r697", "r698": "r698", "r699": "r699", "r700": "r700", "r701": "r701", "r702": "r702", "r703": "r703", "r704": "r704", "r705": "r705", "r706": "r706", "r707": "r707", "r708": "r708", "r709": "r709", "r710": "r710", "r711": "r711", "r712": "r712", "r713": "r713", "r714": "r714", "r715": "r715", "r716": "r716", "r717": "r717", "r718": "r718", "r719": "r719", "r720": "r720", "r721": "r721", "r722": "r722", "r723": "r723", "r724": "r724", "r725": "r725", "r726": "r726", "r727": "r727", "r728": "r728", "r729": "r729", "r730": "r730", "r731": "r731", "r732": "r732", "r733": "r733", "r734": "r734", "r735": "r735", "r736": "r736", "r737": "r737", "r738": "r738", "r739": "r739", "r740": "r740", "r741": "r741", "r742": "r742", "r743": "r743", "r744": "r744", "r745": "r745", "r746": "r746", "r747": "r747", "r748": "r748", "r749": "r749", "r750": "r750", "r751": "r751", "r752": "r752", "r753": "r753", "r754": "r754", "r755": "r755", "r756": "r756", "r757": "r757", "r758": "r758", "r759": "r759", "r760": "r760", "r761": "r761", "r762": "r762", "r763": "r763", "r764": "r764", "r765": "r765", "r766": "r766", "r767": "r767", "r768": "r768", "r769": "r769", "r770": "r770", "r771": "r771", "r772": "r772", "r773": "r773", "r774": "r774", "r775": "r775", "r776": "r776", "r777": "r777", "r778": "r778", "r779": "r779", "r780": "r780", "r781": "r781", "r782": "r782", "r783": "r783", "r784": "r784", "r785": "r785", "r786": "r786", "r787": "r787", "r788": "r788", "r789": "r789", "r790": "r790", "r791": "r791", "r792": "r792", "r793": "r793", "r794": "r794", "r795": "r795", "r796": "r796", "r797": "r797", "r798": "r798", "r799": "r799", "r800": "r800", "r801": "r801", "r802": "r802", "r803": "r803", "r804": "r804", "r805": "r805", "r806": "r806", "r807": "r807", "r808": "r808", "r809": "r809", "r810": "r810", "r811": "r811", "r812": "r812", "r813": "r813", "r814": "r814", "

"StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": { } }, "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares issued for restricted stock and other (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": { "r15": "r105", "r106": "r148" } }, "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares issued for stock options (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": { "r15": "r105", "r106": "r148" } }, "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": { "r15": "r105", "r106": "r148", "r593" } }, "us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures", "crdr": "credit", "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" }, "lang": { "en-us": { "role": { "terseLabel": "Shares issued for restricted stock awards", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": { "r15": "r148" } }, "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" }, "lang": { "en-us": { "role": { "terseLabel": "Shares issued for stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": { "r15": "r106", "r109": "r110", "r148" } }, "cl:StockOptionPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "StockOptionPlansMember", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Stock Option Plans", "label": "Stock Option Plans Member", "documentation": "The Company's stock option plans provide for the issuance to directors, officers and other employees of non-qualified stock options that generally have a contractual term of six years and vest over three years." } } }, "auth_ref": { } }, "srt:StockRepurchaseProgramAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount", "crdr": "credit", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": { "r128" } }, "us-gaap:StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "totalLabel": "Total Colgate-Palmolive Company shareholders' 2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r106": "r109", "r110": "r138", "r886": "r903", "r925": "r926", "r1038": "r1067", "r1216": "r1237", "r1353", "r1406" } }, "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets" }, "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" }, "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": { "r63": "r64", "r67", "r231", "r232", "r272", "r294", "r295", "r296", "r298", "r303", "r305", "r372", "r373", "r407", "r487", "r657", "r658", "r667", "r668", "r669", "r671", "r672", "r673", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r712", "r714", "r718", "r722", "r740", "r835", "r836", "r850", "r886", "r903", "r925", "r926", "r949", "r1066", "r1216", "r1237", "r1353", "r1406" } }, "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": { "http://www.colgate.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Shareholders' 2019 Equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": { } }, "us-gaap:StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofChangesinShareholdersEquity" }, "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": { } }, "us-gaap:SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.colgate.com/role/LeasesScheduleofLeaseCostDetails": { "parentTag": "us-gaap:LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleofLeaseCostDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Sublease Income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": { "r733": "r1037" } }, "cl:SummaryOfCommonStockActivityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "SummaryOfCommonStockActivityRollForward", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Common Stock Outstanding", "label": "Summary Of Common Stock Activity [Roll Forward]", "documentation": "Summary Of Common Stock Activity [Roll Forward]" } } }, "auth_ref": { } }, "us-gaap:SummaryOfDerivativeInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfDerivativeInstrumentsAbstract", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsFairValueofDerivativeInstrumentsandOtherFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "role": { "terseLabel": "Designated derivative instruments", "label": "Summary of Derivative Instruments [Abstract]" } } }, "auth_ref": { } }, "us-gaap:SummaryOfNetInvestmentHedgeActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfNetInvestmentHedgeActivityAbstract", "presentation": { "http://www.colgate.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofGainLossIncludedinOCIDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net investment hedges [Abstract]", "label": "Summary of Net Investment Hedge Activity [Abstract]" } } }, "auth_ref": { } }, "cl:SummaryOfTreasuryStockActivityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "SummaryOfTreasuryStockActivityRollForward", "presentation": { "http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Summary Of Treasury Stock Activity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "cl:SupplementalBalanceSheetInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "SupplementalBalanceSheetInformationTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalBalanceSheetInformationTextBlock", "lang": { "en-us": { "role": { "verboseLabel": "Supplemental Balance Sheet Information", "label": "Supplemental Balance Sheet Information [Text Block]", "documentation": "This element is used to disclose supplemental balance sheet information for the periods disclosed." } } }, "auth_ref": { } }, "us-gaap:SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.colgate.com/role/ConsolidatedStatementsofCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": { } }, "us-gaap:SupplementalIncomeStatementElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalIncomeStatementElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Income Statement Elements [Abstract]", "label": "Supplemental Income Statement Elements [Abstract]" } } }, "auth_ref": { } }, "cl:SupplementalIncomeStatementInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "SupplementalIncomeStatementInformationTextBlock", "presentation": { "http://www.colgate.com/role/SupplementalIncomeStatementInformationTextBlock", "lang": { "en-us": { "role": { "verboseLabel": "Supplemental Income Statement Information", "label": "Supplemental Income Statement Information [Text Block]", "documentation": "This element is used to disclose supplemental income statement information for the periods disclosed." } } }, "auth_ref": { } }, "us-gaap:SupplierFinanceProgramTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramTextBlock", "presentation": { "http://www.colgate.com/role/SupplierFinanceProgramTextBlock", "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program", "label": "Supplier Finance Program [Text Block]", "documentation": "The entire disclosure for supplier finance program." } } }, "auth_ref": { "r416": "r417", "r418": "r419", "r994" } }, "ecd:TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Tabular List Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": { "r1137" } }, "cl:TaxAssessmentsWithInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TaxAssessmentsWithInterest", "crdr": "debit", "presentation": { "http://www.colgate.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Brazilian internal revenue authority, matter 1", "label": "Tax Assessments With Interest", "documentation": "The amount of tax assessment with estimated interest accrued as of the balance sheet date arising from income tax examinations related to an acquisition." } } }, "auth_ref": { } }, "cl:TaxAssessmentsWithInterestAndPenalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TaxAssessmentsWithInterestAndPenalties", "crdr": "debit", "presentation": { "http://www.colgate.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Brazilian internal revenue authority, matter 2", "label": "Tax Assessments With Interest And Penalties", "documentation": "The amount of tax assessment with estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations related to investments held by a foreign subsidiary." } } }, "auth_ref": { } }, "us-gaap:TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": { "http://www.colgate.com/role/IncomeTaxesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": { "r655" } }, "cl:TaxCreditCarryforwardNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TaxCreditCarryforwardNotSubjectToExpiration", "crdr": "debit", "presentation": { "http://www.colgate.com/role/IncomeTaxesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward, not subject to expiration", "label": "Tax Credit Carryforward, Not Subject to Expiration", "documentation": "Tax Credit Carryforward, Not Subject to Expiration" } } }, "auth_ref": { } }, "cl:TaxCreditCarryforwardSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TaxCreditCarryforwardSubjectToExpiration", "crdr": "debit", "presentation": { "http://www.colgate.com/role/IncomeTaxesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward, subject to expiration", "label": "Tax Credit Carryforward, Subject to Expiration", "documentation": "Tax Credit Carryforward, Subject to Expiration" } } }, "auth_ref": { } }, "us-gaap:TaxCreditCarryforwardValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardValuationAllowance", "crdr": "credit", "presentation": { "http://www.colgate.com/role/IncomeTaxesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "tax credit carryforward, valuation allowance", "label": "Tax Credit Carryforward, Valuation Allowance", "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": { "r1328" } }, "cl:TenYearNotesAt3250PercentNumberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TenYearNotesAt3250PercentNumberMember", "presentation": {

"http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Ten year notes at 3.250 percent number", "label": "Ten Year Notes at 3.250 Percent Number [Member]", "documentation": "Ten Year Notes at 3.250 Percent Number"} } }}, {"auth_ref": "11"}, {"cl_TenYearNotesAt460PercentNumberMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TenYearNotesAt460PercentNumberMember"}, {"presentation": {"http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Ten Year Notes at 4.600 Percent Number", "label": "Ten Year Notes at 4.60 Percent Number [Member]", "documentation": "Ten Year Notes at 4.60 Percent Number"} } }}, {"auth_ref": "11"}, {"cl_ThreeYearNotesAt480PercentNumberMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "ThreeYearNotesAt480PercentNumberMember"}, {"presentation": {"http://www.colgate.com/role/LongTermDebtandCreditFacilitiesNarrativeDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Three Year Notes at 4.800 Percent Number", "label": "Three Year Notes at 4.80 Percent Number [Member]", "documentation": "Three Year Notes at 4.80 Percent Number"} } }}, {"auth_ref": "11"}, {"cl_TimeVestedRestrictedStockUnitsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TimeVestedRestrictedStockUnitsMember"}, {"presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansNarrativeDetails"}, {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofRestrictedStockActivityDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Time-Vested Stock", "label": "Time-Vested Restricted Stock Units [Member]", "documentation": "Time-Vested Restricted Stock Units [Member]"} } }}, {"auth_ref": "11"}, {"cl_TotalLongLivedAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "TotalLongLivedAssets", "crdr": "debit", "presentation": {"http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Total long lived assets", "label": "Total Long Lived Assets", "documentation": "Amount of total long-lived assets, primarily property, plant and equipment and goodwill and other intangibles." } } }}, {"auth_ref": "11"}, {"ecd_TotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}-{"lang": {"en-us": {"role": {"terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount"} } }}, {"auth_ref": "r1129"}, {"ecd_TotalShareholderRtnVsPeerGroupTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}-{"lang": {"en-us": {"role": {"terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]"} } }}, {"auth_ref": "r1136"}, {"us-gaap_TrademarksMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember"}, {"presentation": {"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"}, {"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }}, {"auth_ref": "r62"}, {"r993"}, {"r1251"}, {"r1252"}, {"r1253"}, {"r1254"}, {"r1255"}, {"r1256"}, {"r1257"}, {"r1258"}, {"r1259"}, {"r1260"}, {"ecd_TradingArrAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]"} } }}, {"auth_ref": "r1157"}, {"ecd_TradingArrByIndTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]"} } }}, {"auth_ref": "r1159"}, {"dei_TradingSymbol": {"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol"}, {"presentation": {"http://www.colgate.com/role/Cover"}-{"lang": {"en-us": {"role": {"terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }}, {"auth_ref": "11"}, {"ecd_TrdArrAdoptionDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date"} } }}, {"auth_ref": "r1160"}, {"ecd_TrdArrDuration": {"xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration"} } }}, {"auth_ref": "r1161"}, {"ecd_TrdArrExpirationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date"} } }}, {"auth_ref": "r1161"}, {"ecd_TrdArrIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Name", "label": "Trading Arrangement, Individual Name"} } }}, {"auth_ref": "r1159"}, {"ecd_TrdArrIndTitle": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Title", "label": "Trading Arrangement, Individual Title"} } }}, {"auth_ref": "r1159"}, {"ecd_TrdArrSecuritiesAggAvailAmt": {"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount"} } }}, {"auth_ref": "r1162"}, {"ecd_TrdArrTerminationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}-{"lang": {"en-us": {"role": {"terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date"} } }}, {"auth_ref": "r1160"}, {"us-gaap_TreasuryStockCommonMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember"}, {"presentation": {"http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"}-{"lang": {"en-us": {"role": {"terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }}, {"auth_ref": "r147"}, {"us-gaap_TreasuryStockCommonShares": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares"}, {"presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails"}-{"lang": {"en-us": {"role": {"periodStartLabel": "Treasury stock balance, January 1 (in shares)", "periodEndLabel": "Treasury stock balance, December 31 (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }}, {"auth_ref": "r47"}, {"us-gaap_TreasuryStockCommonValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": {"http://www.colgate.com/role/ConsolidatedBalanceSheets"}-{"parentTag": "us-gaap_StockholdersEquity", "weight": "1.0", "order": "5.0"}, {"presentation": {"http://www.colgate.com/role/ConsolidatedBalanceSheets"}-{"lang": {"en-us": {"role": {"negatedLabel": "Treasury stock, at cost", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }}, {"auth_ref": "r47"}, {"r48"}, {"r109"}, {"us-gaap_TreasuryStockSharesAcquired": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired"}, {"presentation": {"http://www.colgate.com/role/CapitalStockandStockBasedCompensationPlansSummaryofCommonStockandTreasuryStockActivityDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Common stock acquired (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }}, {"auth_ref": "r15"}, {"r106"}, {"r148"}, {"us-gaap_TreasuryStockValueAcquiredCostMethod": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": {"http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"}-{"lang": {"en-us": {"role": {"negatedLabel": "Treasury stock acquired", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }}, {"auth_ref": "r15"}, {"r47"}, {"r148"}, {"us-gaap_TypeOfRestructuringDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain"}, {"presentation": {"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesNarrativeDetails"}, {"http://www.colgate.com/role/RestructuringandRelatedImplementationChargesSummaryofRestructuringChargesCumulativeToDateDetails"}, {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }}, {"auth_ref": "r422"}, {"r423"}, {"r428"}, {"r429"}, {"country_US": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US"}, {"presentation": {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsAllocationOfPlanAssetsandLevelofValuationInputbyMajorAssetCategoryDetails"}, {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsExpectedContributionsandBenefitPaymentsDetails"}, {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsNarrativeDetails"}, {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsScheduleofTargetAssetAllocationDetails"}, {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofDefinedBenefitandOtherRetireeBenefitPlansDetails"}, {"http://www.colgate.com/role/RetirementPlansandOtherRetireeBenefitsSummaryofNetPeriodicBenefitCostsDetails"}, {"http://www.colgate.com/role/SegmentInformationScheduleofSegmentInformationDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "United States", "label": "UNITED STATES"} } }}, {"auth_ref": "11"}, {"us-gaap_UnclassifiedIndefiniteLivedIntangibleAssetsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnclassifiedIndefiniteLivedIntangibleAssetsMember"}, {"presentation": {"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"}, {"http://www.colgate.com/role/GoodwillandOtherIntangibleAssetsSummaryofOtherIntangibleAssetsDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Indefinite life intangible assets", "label": "Unclassified Indefinite Lived Intangible Assets [Member]", "documentation": "Costs of contractual or legal rights meeting the criteria for capitalization as intangible assets apart from goodwill, which have indefinite life and that are not otherwise specified in the taxonomy." } } }}, {"auth_ref": "r1251"}, {"r1255"}, {"r1258"}, {"ecd_UndrlygSecurityMktPriceChngPct": {"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct"}, {"presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}-{"lang": {"en-us": {"role": {"terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent"} } }}, {"auth_ref": "r1156"}, {"cl_UnearnedCompensationMember": {"xbrltype": "domainItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "UnearnedCompensationMember"}, {"presentation": {"http://www.colgate.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"}-{"lang": {"en-us": {"role": {"terseLabel": "Unearned Compensation", "label": "Unearned Compensation [Member]", "documentation": "Amount corresponds to the amount of leveraged ESOP debt guaranteed by the company. When the debt is recorded on the company's books, the equity reserve for unearned compensation is also recorded." } } }}, {"auth_ref": "11"}, {"us-gaap_UnrecognizedTaxBenefits": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": {"http://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"}-{"lang": {"en-us": {"role": {"periodStartLabel": "Balance, January 1", "periodEndLabel": "Balance, December 31", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }}, {"auth_ref": "r627"}, {"r643"}, {"r1023"}, {"cl_UnrecognizedTaxBenefitsCumulativeEffectOfChangeInTaxPosition": {"xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "UnrecognizedTaxBenefitsCumulativeEffectOfChangeInTaxPosition", "crdr": "debit", "presentation": {"http://www.colgate.com/role/IncomeTaxesNarrativeDetails"}-{"lang": {"en-us": {"role": {"terseLabel": "Cumulative effect of change in tax position", "label": "Unrecognized Tax Benefits, Cumulative Effect of change in Tax Position", "documentation": "Unrecognized Tax Benefits, Cumulative Effect of change in Tax Position"} } }}, {"auth_ref": "11"}, {"us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "crdr": "debit", "presentation": {"http://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"}-{"lang": {"en-us": {"role": {"negatedLabel": "Effect of foreign currency rate movements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation." } } }}, {"auth_ref": "r1326"}, {"us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": {"http://www.colgate.com/role/IncomeTaxesNarrativeDetails"}, {"http://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"}-{"lang": {"en-us": {"role": {"negatedLabel": "Decreases of tax positions taken during prior years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }}, {"auth_ref": "r644"}, {"r1023"}, {"cl_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthoritiesAndLapseOfApplicableStatuteOfLimitations": {"xbrltype": "monetaryItemType", "nsuri": "http://www.colgate.com/20241231", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthoritiesAndLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": {"http://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"}-{"lang": {"en-us": {"role": {"negatedLabel": "Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations", "label": "Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities And Lapse Of

Applicable Statute Of Limitations, "documentation": "The gross amount of decreases in unrecognized tax benefits resulting from settlements with taxing authorities and lapses of the applicable statutes of limitations." } } }, "auth_ref": { "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": { "http://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Increases as a result of tax positions taken during the current year", "label": "Unrecognized Tax Benefits, Increase Resulting From Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": { "r645", "r1023" } } }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": { "http://www.colgate.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Increases of tax positions taken during prior years", "label": "Unrecognized Tax Benefits, Increase Resulting From Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": { "r644", "r1023" } } }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "debit", "presentation": { "http://www.colgate.com/role/IncomeTaxesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest (income) expense recognized related to unrecognized tax benefits", "label": "Unrecognized Tax Benefits, Interest On Income Taxes Expense", "documentation": "Amount of interest expense for an underpayment of income taxes." } } }, "auth_ref": { "r1324" } } }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "debit", "presentation": { "http://www.colgate.com/role/IncomeTaxesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": { "r646", "r1023" } } }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.colgate.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r35", "r36", "r37", "r182", "r183", "r185", "r186" } } }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "presentation": { "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceForDeferredTaxAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance by Deferred Tax Asset Axis", "label": "Valuation Allowance by Deferred Tax Asset Axis", "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences." } } }, "auth_ref": { "r1328" } } }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": { "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceForDeferredTaxAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance, deferred tax asset, additions (deductions)", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": { "r649" } } }, "us-gaap_ValuationAllowanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceLineItems", "presentation": { "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceForDeferredTaxAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance Line Items", "label": "Valuation Allowance Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_ValuationAllowanceTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceTable", "presentation": { "http://www.colgate.com/role/IncomeTaxesChangeInValuationAllowanceForDeferredTaxAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset, Valuation Allowance Table", "label": "Deferred Tax Asset, Valuation Allowance Table", "documentation": "Disclosure of information about valuation allowance representing portion of deferred tax asset for which it is more likely than not that tax benefit will not be realized." } } }, "auth_ref": { "r1328" } } }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.colgate.com/role/LeasesScheduleOfLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.colgate.com/role/LeasesScheduleOfLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": { "r732", "r1037" } } }, "ecd_VstngDtFrValOffQtyAwrdGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOffQtyAwrdGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "documentation": "Walmart Inc. Member", "presentation": { "http://www.colgate.com/role/SegmentInformationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Walmart, Inc.", "label": "Walmart, Inc. Member", "documentation": "Walmart, Inc.", "auth_ref": { "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.colgate.com/role/EarningsPerShareScheduleOfEarningsPerShareBasicandDilutedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": { "http://www.colgate.com/role/EarningsPerShareScheduleOfEarningsPerShareBasicandDilutedDetails": { "lang": { "en-us": { "role": { "totalLabel": "Diluted EPS (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPSU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": { "r311", "r325" } } }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": { "http://www.colgate.com/role/EarningsPerShareScheduleOfEarningsPerShareBasicandDilutedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Shares (millions)", "label": "Weighted Average Number of Shares Outstanding, Diluted Abstract", "documentation": "Weighted Average Number of Shares Outstanding Basic", "calculation": { "http://www.colgate.com/role/EarningsPerShareScheduleOfEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.colgate.com/role/EarningsPerShareScheduleOfEarningsPerShareBasicandDilutedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Basic EPS (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of basic shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r309", "r325" } } }, "ecd_YrEndFrValOffQtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOffQtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "documentation": "Walmart Inc. Member", "auth_ref": { "r1123" } } } }, "std_ref": { "r0", "r10", "r11", "r12", "r13", "r14", "r15", "r16", "r17", "r18", "r19", "r20", "r21", "r22", "r23", "r24", "r25", "r26", "r27", "r28", "r29", "r30", "r31", "r32", "r33", "r34", "r35", "r36", "r37", "r38", "r39", "r40", "r41", "r42", "r43", "r44", "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

E336H*0K*RI#F#9YL1#.#PIZNLKZ6S.#825:8/8817>/B*4.M2*5M71<YHU5.4FX.UC2J.MG3H.9.K&>ZLD<Z1<IEJ2MXF=>+WGGI(S<=>MMGOD*OK#E.HJGPV
 51BP*TP>/K6/QMX/%<S=ESD8+H/LI.8*1HSK1C=>M2B37C/E.6/M6+>0P91>J38+I=>=..IR*W3L#.#>P1TJG5<JG>+3ZAS<+4#E.&IATKY&A:QSN.3*TX3R3N
 QH&49S.#A#B1E0KBCRLY*0..1#H.M1HC#2C:<@KTXA5N12>+2>P2>ASXTK#H/LFV.T89YG5Y5M&I?0<=>BVX<L4#E.2#H<K*OGN>
 <=3.17>#ARS&9(5LH&Q0118>L.00M53D0B37K&C&PHZ<68776?>L.451Y23R&S025<=>6#G7<=>6..XLA4W6.M0DQ. BV6GM<
 I+H2>0Y<#U.F09XZQ0117R.XE2)TDC20>/WFSN2PK69>.M&85<+1J.30L<#U.WUW&P.L#L8P&S&KDN&LAE61H)9PL56M?>7V.TGHW-M
 (I-L9@0.6P.#H@5X&RME#H<+L/Z@OGKI=KW3>X1Y.7MIH.7AIOGHIM.MC4.M&5>+7.HQ.<=>S.A1.S<=>.LNF7IZH<L03UIKPSVBKBDI4UR.
 MOWW3NGN<=>=5KJ.0*1*B2.U@WPLRE7H/#Q<=>9QN8M8AMC.Y.MH>T>V@>0*P*HKM<@INSEMN4)VB6<62NT.K&8T6Q0D14U%EDP*TFPCL
 M#W>TC<+I.EVVKO.3D#H.9.F&S.SPD86:(GH>=HAI= STEFH(LV>XIA@C(M500G64Y.P2J.G?5.R=>I4M2.1.F?P&ME#H/LF.0-KGGJ&=(53)VE3
 MU*F28SF3QH/L9K.A#<#>D3.P-@<#K#M18=H00S2P2.ZZSO#<A*1.MNIVR&ZJL@WMEHTH9Q4H<2.1\$M.#H.0EK&S<=>ISW4W-FFU9K70F1P>+K&AA.MM?<
 HUS(CMU0B614MH1ZYESD01<@<XV+BI>Z>=>I48Q.2LVB0&D263K#1M)MZRI\$S<4&8A<S&SIEGLA#1#1#Z&W#<3CM0LUF8G<2>I)F2OFGPNGO.M<YMWIX#L.Q?
 A<FD2.PW>P.J5HJ93.2>=>SF<682BUBEF.9P.<#>J2B-.M5083BIAF<P.2E.9XK<SMAIN>U+I#>.OWP2/F#<0.61<=>I0Q3<=>52V&Y4QO.M*6<L33Z3&JRE4IOLOXXM&0=Y#<
 BHF#M#<3&FDY1T&BE443P23OYT<MHI(5#<K&K.I/K<..ONI>A9)I#4ZW>X<I">=>4?<=>#<#>H.NI?>P0>..ME#?>X1Q70Y4U&.&I.NW+>E6L5YL.T881I?DEZL1OQ9XB
 26Z&M#MUR#M.QM35F1415EJPHJ4F5C<+G3+6>Q1*F79JA@.0U.K02G<LCOICB)V7>42.M15P<I<L6>+>+7.F.1T1.707KHQJOL<.&I19>=>6SIO%MOIK.A7N1.M7FF<
 I7&.&4#12P32C10P37T0QKXMY#H0W.ULV6<+<8>U.<=>S.5C.&S.6GVNY3<=>MU7WD)>+<#>+1+BV903C0Z<=>M-Z#<L4&28>327YR1O1=I.4242(F@I>P.M0E@QG>
 ?K@<=>S61A3A3Q1J1>I-4)I#BAE)RBO&MF8K.F4X1I=>#OSPL&B.M3.3HK9XN31<CJX<3SF1UF262..WV>XF@<1*00I2(I.PN+>E5HJ.GU2K2
 M<=>FXM1ZD8CGU<2>3.HT13N2X#M28P03V<I.JN72.D17R.VXJ58IA.M164D0KPYM5L.D.<#>A*VL6<I#N#HINKMHL.5H8JCGFMMI
 M#>7<9U>+>3VCS44X+KPIHGWJZY>3.8E9A-7*B=PE?>Y4>70.6=EK.MU.FL6E+I.FICI>+5>#>W?N2P4)23P&I?>SPHD9.M*9>2J6W9U>DH#<+>LJ&W<+>J0MYTU.2
 DPEI9GHOH0W9K<=>I5AVV.GV.N.MN5+0.#4#<1.L.WHNT<#>8(KOGM5660Y>..OH+SIHJ426VYH@<+>1OR21MMNGLTZ>#>25>12..7B)I\$ZVDF(L?<
 B.UHRCGZ>+>X>W5DMK.LYB32.MC<+55D.AN7CAI3AT(EG6B#>MOYF0G.10.<6D>#<6@3&1*2UFK&R4&SHW-VW.MY9>X7I.FK1+K.4041
 TIX)T.HN)U=>O#0B#M9.S10.YGISSN.#EJNISN13X#<+I.M.03W#87.2Y4V0.2>=>9.F05.A<L.57QWMX3EISG1<I>H.L4&S&45X6G5J>ZTIZI>X6.RG00?<
 5MOU<HLL<I>Y3B.<#>Q.M.FP.V5<U(ZMR.13<+>K+I+9>W1JIG&WAMR7C.D&F.D<=>0FTH.I4X3Q3.M.V<+>L%>E&U&A19OH@Y?>Q01.128V1?3#X8.FE(Q'@MGG(CQ?<
 95&X5R0)YM2.<+>PYOKT(I25.MN)V.FUW+I3=D6.46<=>HIOQ*CG77+88Z.T+<+>BVZ.83JPOR.IUX+>I04#<M.HM51VRSHF&V<N95.M@<V<
 +>@F@<K%LVOJPF1G/7TJ.PAJGX=>F..GYB<LI3.P2.T<0>=>#>/M1#9F6.X6UC177ZT1Q108ABPTGFQM*0>F%GPW*DX4K.MD88C*VHCRRM=>#<=>3IM8#)VFFI-L
 WFO1G<+>=>GK>=>E.GABIES#>#>M.MYMIH1+QX33*W0A3KTX?>V>+>DU6T@<I8T65N)1033AW.A.MK.G.E5BH.(HLYB4LLV#P1QI3J.6U.H+>9+50HET+H+E>
 I?QOIBNVIR&25..Q58.9CA.EMGJ34C.C7JG.MN.FSR.2I.H1.70&1=4K3J.P.NR3.M4@<PJCJW83V7/4ZJ46.UVA@>U#>MZ6J*VWXHJ9>=>TGDUDY=I53ZQWE?<
 CA<=>PQJ6G.0E.MMMCG9BVD&5V>=>I>PCR1)S<=>P03YR<P>U>=Z7F9B1I<=>Q&O&FZ+3*AX.VM.0VNB9D<NU8<+>I+I1L7VL&S92<=>@<94Y5.T.O.MT73<=>V
 M4>V3TJL+Q.D5T3Z=ZM7.IP16&QIV#S7&KJ1YH#>#>K6.CP.K0(M4EO)<I)OBN0I&P.MV0>2590PVRV1Z5/6<L6L.<I8E5<=>LTFV#<G54.M.#.H97>
 I+U+9C)LEH+I.HOMO58<=>WGDN)ZM65.HCM.33M.6LVC&SRK.MWY7T7UJ3G%<R+<GMA?<V\$<I#HT@T7?>#>3>..SUH16NVY74K#DSE=L4.M26M>N8T>7V1+I!<
 I7YM(XKXA<60IPF5H1C<M<XV+>A7<=>IAG<=>U&I#N3N.9R.L+>I7L7GG<+>+VY(T.M.PQ.MJMY9#<2L+>EP<=>PXIKY&M.30EU.VW.KJ9GL8MPPQ.JUZN<^5TY
 M16#8<C)3A=>593P<E>Z>L.VK96.E2.H3.8LGD&3.&82#H15<IENLEI.MKZTFE#P1VZ569ICB7P7CGS<=>.<V3>25NM.P58N.W33KE7E13@<#>Q0>32?<OHLX5.9
 I<=>RPT57V01S1G607P.9X1<@<JFUSL<VHJ.W.F<=>A<=>=>I.M2.WY+>+IS.LTE.Y91#K1.QP<=>845?<IAR.UPIOC<5B&CFI<+>3VQPD(PI.M+>12.MB.A6<=>E
 <PD3<=>HY47BK13CYN+TUAU.0J@<=>VW4.V7W7>F.FE0VJ&K.M2.WY.<=>IS&C9M1M6Y.<=>QI7.0Q<=>B2Z8L350V<V.H8V1Q=<=>S&W&H7GSM&A(F&X&R.E2OIH.AU6E=Z
 M2<I<GWDQT.QI2>=>2.C<(<?<I).U2&HMOZ@<=>I@3SNH@3..M(I<V.7OP.UAFN+P6+N<3YR(GX?6XIP)/MVQC.Z456\$S8S/JAI#ZT*U;U!>TEK?2UI(%<X+G2H"XO.<=>OX.<?
 <I>GYR<+>G1V>2&S..9H1<=>N.P&B&W.P<#>R0+3.1BOG&CSGS?OZA.L@P7P7.M2K<K9Q(HH#<

[illegible]

[illegible]

[illegible]

[The following text contains extremely noisy and illegible characters, likely representing corrupted data or a heavily distorted document. It appears to be a mix of random alphanumeric strings and some recognizable words like "MAY", "JUNE", "JULY", "AUGUST", "SEPTEMBER", "OCTOBER", "NOVEMBER", "DECEMBER".]

Q:BF%:12%Q:GANGRCARO.W:WXU821/105IMHFXF1#073.51.ML1.T:P320HW%OB1.A)1L1.BHX"1.X#:#0Y3MPI=4M34-K-2SURTSIV8XC=1.MRB?>YFWQ+1.ZEY=ND?+>S+1J+GDW6E1&.RI@Q5=5>CJ+>@W.U.YYZOY6.M#:=E@00G0S1.TQ.OV>ZH9PI:TFE:RE?>N@:VOKG&47+FOY&+DV8EL@P11.M5.A4M6#<\$TFI8M?>FN:5\$.4\$6V08G.QJH:~W78AL@76H6Q.0GCV>G\$.MIG>#<3&XTIM.N.LZ%+>.D86VG=PI6C?FACF91TL#FBEG9QFBZPFRG&17+V.GVU/2-1.H5.M416H0B@P13/7:FNCAU? JH6H7PQNBH1&FFJFVW4+1+91+U#ZH2A.MSPOR7G&A>A%>5TJZG>X^1C5\$&41X8M%<XUY6%>N24H1ZQWHRZGKRS74.1.MKK>+4%06T47.KKCI23.WJ01.HLL.W" MUJ>+Z+91L=ZRG>=W.JYXGHBZ.91.BZV.M89.VCX.FGR%TFLH6.MNUGG37U2JUHNL+7HXA."Q^1Q(CS=07Q^10.M5+HWX\$@Y9140EB85D2&K1K7+T4VZR.IP^1.Y VIN>1.HJV.Y1PQX.M@CFIXE^P.J9K9\$QIBRR^=2#Y<#>J1H.HD/1\$1<#>Y2:CUA#\$\$S19FW^9.MQH.^70^9.X5H58GH>+03.&5D29H.3ZJ1J9)ANGI+@%697ID&=fT9Z^Y.M/G&M:~ (^2.X^<CV37)T/71.W5+SPFV^P879@<#>C@Q2@>L>P.ML:CF07?>D6.M?X6%Z0@MXVUDGAIB9.%N+>.&SUS1^Y.NE/X^Z4@7%V5ED&.6F0.6Z.M&.~C1J1VHNHXS.70T^1.V6MFSV^N=6#F0G:10B@F+>7@J3+ALB1M%>4@.OY>YSWY^ZS.S59W^96GVIN.M.^X5124V1@UR<&KHICLH7P.H8.M/MT^1DG%>J2 @26^Z1C919.P16\$@<RE4Q.101LBRT^1F16M@45.M/LK^3017+118U4DMQPKD8W13.1%.5MEH.C>@SHTCX.M/LG^14UE=N1879<65VYXLM(C>..HXA<^15RFH:~>HN^YCLSPH5)P2=1Q38-1.M5T+@<WZOH4@.ML^1L2-1.RXJ13CJL32<0<+UOSS09V.M4\$U1/DH:1C3\$PH=KZ.A.VKOUX.S=2@2T^1Y(1+123L6M. QUATKNIHY#Q:25@D^1Q(ASFXY.YT.MKJFZP^H&ABW^SQIR0@<U.H.UB#LC2^IKTRWJ.H=FP.IXG1L&M00.M2>+180<<^F2^4+>^CB.W1^1AJGG.K#E56L17>+3PIANB.M6N=6C3 M+T#26&>8LO3/SCH.P16CD<=1A1HBDOQ#?#<#&?N(NK%KWX^F&BD3@%12.M5H5\$DXS4>^F.BY<+>@FM3XW\$S1=O.UH1/TNWIMX<+1.N1@<F.M1^7.9.N.1301\$ #P.ROP5U.5J1RJB.F880NQG.=&#ZAN(KV+Z@72^1.M#0#1N1F107^21C2P0&.01@ZP^2D5H1J8M.2HN.M#T#M=OG:~ 1.681C2Q2O.3THNT@f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

W3018V2R2ZNC&NAIA X1(5T<1LG>?2Q21?8G) M*9FIJH6PM9T3>+s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f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

IOFH/0N;+MDXHIO-ZNR0@AV=IU>80I5YY^R@R:(EKW)BROZVOYVH^2NL3VTA+2^0C\$W^W^IHKF0K4I7L;DL;CRIU7WHI;DKF^SOCE8.NF.=?^M<7A%#/-=5WJ15\$5^NK1800Q0@K7JISZTPE.^4A(BZD)A(=,8FI^*0M\$7=-2,@QY0NHY^JHR^DVXZ^\$XMZ277HDM8NJBDJ0FV(C^2.6)F\$^c^IP+M=IK593Z2UPPGNAEML-1MUM2V-16UWV+00Y>D^CVA;T,KH;+>.^U7^75A^B^ME^?91CYVK;L\$>>#3.85.WEMD.HL.FLTG.\$7MB84G2/PHYS^5581LHN24IHXV;8I6<D-5^\$4J5-5Y2^K6H.MU+)=0E9I7R^EJSUML;I&6<-<M?^?01X2^4Y6V.R.GI9JZ.^0K^+P3@H.FGUG7C\$OXT^91/15?E@AWI+Y@.^*M%TIL&RLAI^c.OB=MCOS7NYH_@)##-..?M?1E,^0VD#D@+^/6\$S!^8G@FYM\$%MDAS9M-2QF#H65Y&@&R-W>ILC5\$1&C;CW.EA<4#BF+Y1Y5I2\$>@.HOZ(F2)=M-#.^16WFS1=-\$+FR#M4@F4U.N+BOE>+^/Q<0.YDG#1>I^S^JELLS-MI^I\$4FO@+V2I\$5JO.K^/UBMH;1FUW=2)KVRINSN3^E^IA.DS^J7H2K.M2^4(GID^X^Y^..1QJHd@P2^..9=&&4^c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

[illegible]

<2;_CR@B|TZM#IU3IH5PM8ZK(6TYDK<COF'2'3.ZO3\$S<-MND\$CSU>NCSI0.\$4<+JHN\$SS5R15@Z6NZ;8;OF:32"G<{5I::@VB)DD%YI_M7A-W<>?7RL#E-W~7@L) ...

Q277 WJHJ /ANA<DC44_N.22WJ/255A2D.MOLN0D./3XMKK.G-4K1X4.TH.1.117/1.1.(BR513R1AAXT.42&JQ<?>M-BW@.B3.Z1=Y^LN.=/UO*F=Q-AWG=IGHAT.6GHF:6YU/H/MSX/AY/2C1SBOOO=HELM&1LE5U/ZPOD?>=W/O3)P/R MBOSGIL/ETV.8^17%Y:O/M/R/Y/1=9#B=W19%0WC.
HKU>6Y<0^2Y2R0/4K1<U87Y4K.S1TKK031/HW.MOQQR/G=1Y1YH./%JfM%>?>B3@<?>1Y/Y=6%:P12>2/27^%X.25X.M.1+1^F5C^A(R7Q)S.&O'Z=?
J2G. %>0%4K182N.2DD2?22F2N/58TR0./E.Y.MC.F1&3H.M.G%52M+Q/560Q/UT34.JG1%J2ZW%W<-T2.FU6<?7IG7/LIN>M-V/L.6TALDM/22PIC.4H2IC4+>M1S1.CF.L<
<O4OBJE%OOGF=1+@MPUE.MG^N90F1EB.V77PBSE1/Q1QVJ/ITKH=CG.7E>+?5BZ^C^5D1N03A.M^C.R#1@F0BDP^C7G(C)1>2TN.1?>
JZ>=>D%>R8KJY/SHPY/@FFH/HI<-MGFO493=NIWW(C)W&1SG<3P+7ZPK1^=W3O^S^L^\$S\$U8VCZ>S>D-Z9KVNHI.MA1S^&X5TDFDP0D10.A8(R7-P1\$1/5N.8FR2>R.R#Y7439Q
Y4Y>9?3TO.M)=/4=>8IC0J/2LKJQJUL^GOHD4GXU/J2?5=67030B69^68.D1W0?7BR.M=G)H-CUNCF.RZ2=>82N)709EY#D41^A4FG3.2.C(8N4N@L^H^<=>+
M4EYNP>?>S1M^O>7UT.OQ3X.IK1Y1L>274%=>D4HG^6%>T0J<84CPE.1>MOA^*V.(U/W/H/4)X^DHI^NMY>Z^TAF^6FE5F^S#E8B5U(RVAEHUU).
M>UBRU1%>2.2M91/PTB2V.DA#6M4<8Y5D4M>R>92+0>K009<ZQ5V9Y.11M.6T^2>1.2MHPW>9>1CIU/U/1^FN8WCQ6R1R>W^2>TMJ#C10=>M-5=>M-5=>44FE5.
T22S.C>4.26FSPB94WGH2Z^T9U5VM1NWXVE.9Z.1^F623B97.M1^Q5YAT12LM)U3%<@>@>1JLHPUXZ>8Y.N.L+LZ\$55&10C^>@>O.MHWG^7HIEG^TPQ>@>FNOJ#BSRG0+
^/T^H%>JRX^Q<1@>P9N>74<=>Q^M1.M0S0ISGD0P0E^*K0+L.O.G.M=21J/131T.GN.QQ^<=>0EBU>X^B^HY.BT.HRTPGAG(RT^<D^W53D4RW^W9
MSZ1/HIG0NL>HGQ(K=FV>3>3)W1K1H@>D^TK.F6P0E(C)E.VL.M.(OF=HY)Y.L^J23.MOAG3+<G+L/TSIF9T(6Y\$IE+Y^>9C)Y=THV3G50HE>(R1<W^WY>+>H
M#41DKVB7W(H@<E6Z4>0^0^D^D^M@<=>K^5#P^3RPV1J@<49%MTF>0>=>5K>#>W.GZ.736G<0410>8B5D^66D(M5A.E1J4@<Y0VUKUO/\$D=>R+Q&NX7.O8?>
1^1FMS(NPH218IS/L1>2>1@H7^75N%>WZ>Z^<SJM.P9IO8S@=>MXA^0.2+>7^708^56SAH2V0/TVV31N.WDF=Q>?&AKWBFMR=J7K^33C1F.M91.203&MKRE210DF
F+1+K1R59Q5Y6.J1>DWSN4.IAMS^WZSSP.M.21>5WO.H41^BBOYU.O@Q\$1.VA.G99D.040Z1V0/LA#85LD5D>L^C.M3Y1M1L=0WN^<3>5>?>7&P7.ELF1V2
R=>A^ZN.\$@<A^DVCV.@1081K<2IU&5.MD3S^M^MCGGP<P^PAS^T.8E1Z>?>O+1&8J2L9CBZD<50%11AJVOX7(4450^K.M13C/R=SS(T^E1J4)F0W5.Y.LH&C.M7BT6<85R.ON22
<87>F.XD3DGGP^M.M6-1^5Q1^S1Z.NM3=E+NYO@H01GPGD^T.IA05^<KGA0.1%CB=73M3UKA4.MH@<?>C@J@<?>13C@XIU7OH3^KIZOC60/091+PHH<0^Q>T.E+L^<3S^Z6).
MRYO/S3D3CB5@4P/LA6Y2>S4L^B<3P<DULB4BZ/HG0NSN@EQ#1%AJTL.MOYSG4OX9J1.L.8Z1H/L^F(6+1B%1SA1)=D42VE.M1/J.O.B1Q1&L+WBFFB7VXB#>
Q>=>+19Y0EBNHH65C7L+U7Q&M500CK^Q<1@>X93>SEY.MR5^<P^RSDS3B2EG21^%>VH.(391Y=>FDOU1<4^BL.O.L0&ZQ9U4Y>2>2(LR6&-PV)61M00C42
QUZJ/L^FLT3F.HPB02.9/2U17)1HKK9^Q10H6L4)ISN^1.0UE#8(C^M1VZ2.1^\$1R.W^HKKH^<P^LH(CU2P@>S62>P@>1)1Z.M78/HF#<3OHMV.M.MC1YQOBE_5_Y
MYXE@ED@<1B105>40IM1^PC2M2QY.PD+7^0L2>?>2^175<OBYNO>2>P^F7O.MJXKTSRQ(020R^Rf@<=>A^UEYEE^>15X^GSR^<10ZJ2IXFEW>5T>4.S.M51Z
B44.DC.0TZJ4.V8^7>7.MMLF/H.MMXZ>=>6^F64-U7M%UUX0+12\$M55U.DQ1F<@>EHL.G^<1^H^5>8Y^X.W4>1%YKXG3RENPMO#8U7>1^>26>M.CF/W.N.CJ93>C65
YVZ>Y^AIVEYN.RDF4F2ZORTW1^>1)1DL=1@>O.M0NW^D1^<4=>K<S^B.&JGGH^P6B5^<U08H^NE>M^HV67^J0R3G^>51.AZ&BDD/R.G21.8R^7(P3HQN^U1D&ZL#>BYB
M+1/HVKQ<0487K12295N^U@O6(YV>=>352.F4#4U)U1+>=>V2=GLAI7U(23^49...5-WT^<4J@<V1914Q03N@AID(ZMA.SF15701XK.M^>KBPX2CWI0%>6M%>?>TZ87VL#>MXN?21
L=7X&22.7>@>AKIG74XDG^>1R0IS2T83&K^<FZFH08)NMVU^O)MOMDDH16V4.71^06JHEW&S(3^C&21-E^20&HRN^B-EE^2GH952CWI^>1^M3<-FZ^MEOEAE6^>3>
2NY&NMNMXK^>XH8W5@>U/YJ4.MZ01.G.YC23)32M.M^<8&5Z.K.2.M@>07L7510V6^ZAS17^/BXOT^5BF^1H7Z&4DQ2Z0=QC(MR4G/EKTV/ELKOPOQ)
VIO^ISR^KYIE31B.M.9)KRO\$17P^5C@<N0124TZ1^7H1+GE(182750V/QEWNFAWQ><1^7IAH.MV)=M1?3U=>3B0M^HF/RVK.^%1<88N^V>A1@>1E>?>2#<4\$3(1)^%T>3^
M.H^<EC>3^>8C23+<=>BMLD^2U3.L.YIO.OKKT6NYX^11%>GLSPELZT.M1^9KTY^4M7+P&M.X^PG)3VXE@>1T0+<6&167H
M26V1L.T27RQFHW^Q1^6H1U.9CTK&BMT73W^K51+<A@>JFY4>XJRJSQVKS.M=XM(MT^O+UJ/B/HM^JLIM^L&0M.C&1B1^F^F3Q)QVU.^12F1L^+AGH
M1^6BL1^92GUVG/TZ>QK94&F7E^99XJ.RR^<6A(U1M.8Z3^6^>1^>S^<C1A^TW81M^SUFU53@3A1(C)>9+FM1^X^F9P+EG.M6^RI9E>=>S&B1Z0+21X.O21^FF^H1?>
SUH2D>=<YW^<V^<6-1)ANB.HN.MJULM/H^<=>WF80S^RWR^SS1.HKYL6GL781CZ>D^O>1(9^XQ^G04PKR(H.M.2<@>B0.TK)P7.6H
TJ>1>60146\$&.&H>2605025Q>S.NDM82ZQ+1^M.BC>=>?1+I+USR+(UKFB81Y^CHG00.@U)T1+O(S^3W0)71^Y+R?1^YVZV2
MG/40>@>1MR8&6.CN^P1K.72WJ6Q0^/JN31XH)BC.CF1=6.&^ADQ.1^M=9#(1&22V171>1@>K4K1^390>1MC2@>7%00M)7&9>HS(WUM)B6-Y.SY4R4<U.3N>=>1#L?FCIK-1
ML^7.10<9KAHPD0.VZ.N.PE3IRRK-1>P^>F9&3XGT3RWYU>U>2S^W^2AGCIVPNQOE.Z01A.M.WM1INH+M.8M)NO>+Y1=>X&UHK9PICB4=>P1.RK+38^FW2421P1.W7=Z.
M8R%W-8.1.MU02P&K^Y1Y.(21HHU>35ZN>9&1O7^2J3J>D>916^GHK^J1JH(4-9A.MO.A1T3&OJFL50.FQ10158H^#BF@1L7.S6^M1^>2^7E1&MT^U54FR#>
MKZ=>1^T1A1.SIDL.JDN

[illegible]

[illegible]

[illegible]

01-PXU082%XX:Y5G:1.EHDXV@YU%AXU:A=5=59/K%CB5W:81.M7113:1=1V=0%JXE<06<N2P.W9Z.E30^X1VG@L=5>EDD>S(D72P2R
MN83WAI7P<66E9L5P+DQ.X1L+MQ>2AB=73D9.LP@A.8T9TRF+4H3URIA.MOOG6P@OQ=5^+QNJ16GDY2PAUEF:TRN?IE4+((@.IL^VS1NF.@.Y:~DQ-Z
MB5YGV05YUHT81G^AT&:~@Q9+1+R6MOQLID7N1N5\$LSA4+6BG+AWU:DBP@+MY9.6N(4^321WKWUJ:~^EJ0TRFEEEMZ&Z45M5P/MU:1(7ZH01P4D&733/R&EFT:C
G:20WCW^H^~L9:~8RSBS=>1+9Y31#PI9.MFIEDA10%YF2573V1U-M^ME2~.M^W^S:9JHN.WOY15P^1OL@G-NK2G:~K3731V>P^L5>~H5731ZK:~#>5
MODV((~0HKK&0H8K^1+10D05K^2+P66G2M+2/7^0R10^1+6%5=PC5>0UDYWO&F^T.M^XNA<A^1.S)E==+T^81H+V+160%5N3D5PETFZW.H.M7:G.8DN=>UB.MAR1Z7
5<205/TB+HE5(OY1>10^Y.M.GXU)5L.BDKM+7L5M5V^VE21YJ@.B4+1/25201^#K.C/6&W^50@PX^12^MP&N9.8^1HYCA4=(C@C3)ZIG#=#<F^7C@06W^H4X.S8
~ERV==+8^K.JSU:~.0077H-191^L=IG&D9E13^IF<21SIV.W<=>E^J~.MC0&CD&A#7&ZLVWUAY~9^W.H3Z2^G>K^QF.3UX%00@<1H96<9%F=LV34DT.MC
W#4H4Z:~#BOG=A6MD26K14^G:0027YXX~WAY3W^J:K9G2:T.M^A+3T^M+M^K1A^4+7^WTS^=PHD@I0<X^P>=790>V?=<=>4LWBXK(H60>~891.53(3.MAKW
9D+T7.Z9M+H8&2L7Z+H2P2E2K^V.1/@MB+X^1613.KU2HY.W95.M=WT@J&X&W^A^G&IVGN&D.SOZSY&G&FLJGIZYU=>MH-K&+13(87G08+9L.M&G#6~"K&5ULC6D1
2Q55YVM.K~387+7+D8H/M5/55WA0Z>P1:51.0)~ML58.#029B&B^UJ0~(1^)(4Y&C1@QPWUSIMTU(1^1^4N&L(VW76.MY^H~1R/F551@S4C>KAVAR+1K7#~.0>?
(B62&K<5.K1A4^/TGUWQ@M.M-JV+2^Y<~KZFLYH(C^YG:2.B01+6TWEU&W&R>W/GP^7S0QW11^5(S.MS1A^ZT2&RD~^4UFLR0+V10RMD
UJ>8H76PFLW+V9<8NQ.1KE.17.M3519.GD.D4V10QK^W1~>82%1%50<4L57-T^L+L^H.YJ~8L5%>1^MCQ:5^EDR^G^A0.K1C<0FH+P9RG0Q1^7\$A3C:
^3J2T1H33(N1P.)+^8Z1QO=XE#JE#>1^\$HRXQXV(T6.1^V.7G+1~M9FYF7HJQ.WIADFOVQJHO1.ZJ^JA(FT=GPZW=C^Y^N1Z&K53&89;IH:MI.MLGCYH5)
WMX&G(8.JAEMQ&5A&B&K.C.FSW9A+M.J1A4F&K&H&W7H(UY:0)~NP&N^F+L+15^152^1^XF021^L6^>X.M^Y^2UX7H~(=<S
~8VY15Y76%7)7OUBYD1&A1F2K~OTILHT.ML.CIL.W:~AS=^HJAMO~P72.MV1+Z^2O46IRGRMD1.(1R8.LK@3012Q2LM)PKY.M+^#D:<0^C<1TYT^IB^8LXY)5?
TA@<J^MP#1M267FURP~73Q3I&H.M.MO:G+V+H=H^&KOLRU#0HA010.VPM^RR01^>3J3L.N.H#8^MIB3(M~RQ80&K^C.X1.H7YA9E26>~716F^MF3>G5H4^GQ1979.^1W
M<5>@~HJ83.68H81=9B.W-OZB7.M3WO&P&E&E5:91P7Q&S&BM.F1+U&C1FCA@D^T9ZIE21>(C1^WZ77WCN<KX7^G10+^C+<37^H2W2PYVS8U=U.1>B^~.1H>N<C
V2HJ1+1A.MVBG.3V.5X.53L~<=>31^PZQ1=NMCC6.^@8M&41FFTM7^13^s08.M.A~.1^<#Z@EJ3&S.G2:9~"DVPHH8Y.NJFC7^~W=5.ZWK&FTY+V
M^Q9MK1^875^3^<0%6LDTCC^3REH89P^FL6G(C1GJH<5=<F^PH1Y1M)MB=ONIAKI.U.(T92U1L)Q04FZ71^21E1=LDA~X0.4K.^QE^HWCH.M1P
@12^DBOQZ37^X50^31E&F^S1FK2P3H1M^7X1Q1~.22^M.16FF1E^<=>1^7Q^SEFV3Z1J91^RMH^D9WKA4H^/9.M^69\$4&8&1413.P.MQ=H2SK&UJ0+@<=>1YF@KX1-5X57~
~^D^H^#B.B.M@~.OK1A=A-W20=C3>4W1+U^2RD<6^MI<L.B3A^C1E^X9^4J^1F&S.KB0LH.M#2+14NHWOX7X^U^CJH0IWO-P^+K>08.S.91T6W0Y9J9Y~7U7^N5-JM
M^IKZYV.C1@L5X4.OA7R2T@M.N.2.S.494.MG6+K67978H^H&K.AOE9+I0.E+~N17P@f\$K&D=I.G)~V-R^74.U=C^2<7^M=02UG=H/U42^M
(EJVS6FUV.V^ARKR52727~.6W6UW^NW.FH<=<6GR>U3F131^>YVB(K=2^M^%K&30F^N3RXM.NGN>C8^95H526.UC28=GZE6D+M^0ZV^F9.T.U:7^MZ.30
JPE6S5V56QM7F&E1XFFH1L@IF6Q.E7G5R<0N1E)X.A:IND>P.V^MHLHBBH.C.7#293Q40+HMD4.PLH41BV.8T8=9U6.LY1Y5H477(GS1)~MYBHRZ10^<?Q7^39W?
MDIB@M+13P.MWN.M56PYU+>33DYA1@.97PBU3(CMU^7EK1.OF2&KQ1.D.G>Z8=F.NYV^2195BVEF^WGS.W69\$1&MS+2^UOR.M4.KGFIUBG89JHJ9Z~
DIBK<4Y4&Z7Y.M.Q:URY.OWW&E9458F1H559.255W5&A#1072^516<=>T1L8GE3BA.JV.MJH2K2>~27.01^T3^6EGC9L&MZJ2&H3.7.#4^N1<~H4MES<>G^H^K.Y.M^E)
(IRC+YK17&Z1^4REF1^22L91^#M16K4B2>08ZH.L)BXL1A4M102^51F&V9F20.BB.T.907<10^5N10Y.M.LH5YTP182(CX1X=<?
5%XL)1^4EF3^D^1G<F&FTV^VLB%W<8FV1H9>~.M^5QN4K5A^ZL<7P.B109G13&0(RW>~74EQO=<^VUM@/B08)R+7FPIJ^/=1^G0
MX0&+2U(ZX483.U.LZ.G8=>YHTHD^R35B2D2N7TJGT^AC.M<=>.(4G&PM/1^<6=8@U1Y7Q6AEADP1^15L&5ZK^8~.EN44=6C&F^M.M=GQ@^TH5^KJO&KT3^AKE5&KS<F-
D^AX9H<F^X5510D33^#1=>1^GTC@G^KJ^P^7^XZT^0.M29S3ZG000L^P+^<X>=>166.UA+~NKQ^W1^Z.SB<=>16Y30&SR5W1+MC41.MHB(S.31VH8^=<4^8Q?
0.L)HLXC1H331=94LU26^15NF9S.3^#B^8HN39Y>+56L^E.GGGW@1.LHRPNQO@V1.PR&O&7F1OQYLR18^P^E1OFT7GF^E&X7Z.MK@JF1^U.F^Q1>1
F.T.M.3^12B.2&41^4REF1^22L91^#M16K4B2>08ZH.L)BXL1A4M102^51F&V9F20.BB.T.907<10^5N10Y.M.LH5YTP182(CX1X=<?
3L(Q^Q=0.5(IX^MQ>3#E(U^8NXH8T.P3IYVCO15.MV1^02L^\$PFESHU^?SE.Y:~2^5J166^QYYS.DN?P?279~.NV?19^0^2.MLA5N^4LCK~.T4>1R@?T7C^HV?RF&76^EQH5XL5>N-
F<R^1^1S1@M.M^BZGT18^0Q0>V07L^M1<1V73L1YFIBYB~.4B&81B^M=>HE7<6WP<5.1>~X1.MA1H@FC.6HOS:~J5>5BX<~L&D8E1G^MCA1HJ04^UG705)Z>45^%Z^QJQ.F.T.F-
C12.C4603DSM7.FN^X&83.M4.ZG+V&W^XW1^4MB&(80^D3X0B1^>VZH&B7^EG+LH^UJHE1.ZL.M^M^EP8R^0>20>10U.1^10U.1^2H14?
@K^~2^G5Y&219+Y&Y7U.M=1A73QAO10H&<45571Z>K<~7^4YVRH(6^YXO3.K.IE3(2V7-2H-D3?T~INET^Q2V^9SE1E+U0A75G
ML:W59H9Q72F6YU1+WRNA3CT.MF1QURUA.48@27-3G4W^5YB1B^W~G=BO.M2.IEJ>1^GV+1E@VX17.N5P@8s2.2.171@1+10GBN=T^&TNSE^V(Y9.F&W)UT9&#DDT^
~0(R^WZUJR.M2)1+VQ~19=QY.%T^>61315~>Z^BN4HHZ@:70XMS1

[illegible]

M=6%#R06JH(D3VN/IS)~.LM8UHDY(L&JLWGLI.NK56:QVTAO<FW.(XFG(44 M:4//RPR1,2FTTG.HJL.VOSH^CMZ5J9D^L3,^9BKXPEW(4#3XDUCO>#IGPJ.M2FSU<P.8H^83NQ-JKc976HIS>Q.H?P<#&XHX.ZI+7U>D1@SR<O=@G.&3G)WB9 M=26FY<+W9FFT=+1440.KK0KE.W2 MAY3=JAY^3R7R<#H?X.WFEF=GOKB)& MW9@HJ^LDDBDNU^ABYU%L. LE^X&M>+J53HJR7FFH# 89BP2PUO(0^).35/F M.=209BFF<#P(G&X#P#6%70X5.QUOUBI.LNMA=E^Q(=QU>NU^RIDWGDISO>L M_3#7H9-PS.CY.6JH^~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s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~N471GK5923DNJ.Z(1+7)324DRU9A7YIHTFRZ764+D32\$<P M=9AIE5>~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s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~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~/M?>P2U?>H&7?>1?>1?>HUU?>0&5&V&O&A&N?>J&S?>=>+1&12?>+WJ02?>4&5&E?>H&X?>P&1?>1?>P&CH?>V&W?>=>E?>=>I&8&C&P&+3&S&R&Z&T&5&E&M&F&R3?>9&67D602?>1&AVZ1?>I&5&S.MUP?>4TY?>Q?>^?>Q?>@>T/?>6%>1?>2&X&M&4&K?>+K?>+9.5?>2&S?>=>H&G&N6?>?>J&T?>=>=>M&H&S?>A&H&9?>T?>H&K&L&M&7&5&E&S?>O?>=>S?>?>X>?>Z&6H&A&M?>2L&U?>1&N&D&R5.90&D&R?>M&Q&99.8H2?>O?>=>C&E?>=>M?>=>K&9Z&K&S?>M1?>T?>T10&?>+U&H?>4&S?>I&B3&4B&H9?>PC&5H&M&340?>+>C7?>U1Y?>F3&1&X&T&S?>O?>I&MED&R&D?>6&S2&E&2&G&H&8?>M&H&O?>+>+>J&292T07H1&L?>N&W&E&9&B&S?>C?>9?>E&I&S1&L0.QV&E&R?>8&X9?>+>Y&G?>B5Q?>M&K?>O&X&F&G&U?>M&2&7&B?>=>H?>C?>H?>P?>W?>G?>Y?>=>F&N&F&B?>S&N1P?>5&W?>+3<=>3<=>K&Y&C&G?>#?>T&4U?>S?>M&E&N&D?>H?>M&V2Z?>1&K?>1&A?>9&B?>K?>F?>7&W&N?>V&4&B&F&M?>4?>B?>2&Q?>M0?>@>9&P?>N&S&M20U9V?>=>J&S&H?>G&H&E&K&Q10?>=>O?>=>6&R&2&D?>8&Z&E&X?>P?>C&C?>W?>L?>4?>1&6?>F&S1&S?>4?>F?>=>Y&V&D?>L&S&87291&R&4?>S?>I&T?>R&S1?>M&S4.I?>G?>=>Y&ZV?>M&S?>H&C&Q3C?>#?>+1&S?>62?>1&20?>=>1&H&O?>=>4?>=>C?>K&65?>W&+61&3&Z&8?>I&A.M?>L&S1?>1&O1H3?>=>P&S&N1&E2O&P&E1&J&K&1?>B?>7&X?>O?>E&S&R&4.50?>+>M&O&Y&3&E&D&8?>Z&N?>L?>1&5&Q&N&M&S?>I&S?>K&2&P971&C3&T&0?>H&0?>#?>+>Z?>=>L?>=>K&2?>G?>=>M?>R&O&L&G?>=>K&9?>E&U?>O?>=>9?>5&H?>+>U&X?>I?>+>H&B?>=>S&X&P&E?>?>P?>G?>I&A&B&A?>T&K&1&9&M&2?>G&H?>U?>=>=>2&X&K?>=>R&Y&H?>75?>=>M?>M&Y&X&R&C?>W&L&S?>I?>H?>T&V?>=>R?>27?>1&5?>O&H&K&O?>P&S&S?>#?>H?>=>Z?>M?>=>1&X&M&S&A?>6&2&S&4.N?>R&T&C&V&D&amp

[illegible]

[illegible]

X:T 6RI&Q1ASS@H M 28 P.T7S/LU/XK#JXKN80/S*75&D\$F ID\$ (T#i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{JRS}.H#>E.A:RUD/M2UJY7V.2(4N2P5CQKJ@>O-D/L\$M(CMW+^/TO%-UL15^?>Y#M^K^<@D=L+800X\$Y67LRM.Z1E+P07C4Z1E+?>80.8HUY88WYVGD05A.R5 XH MH.5YH 1R.(3A-#Z2E2A53NU.M4/-R DZ%U4Y1&LEF7YUKUJ.3N28BC651PF 2^95.9/V08-A^OXH/CVL MHS1>10)OID NFHUNP OG'Z04 Z250T 3J@V5T5/10X2A1*%<^YAHE4M.C9&K+JLX82M.J>OZAOPH0K566312 MNI:#MT5RAR:7RQOHD7 6**RB2?1>C^*MOYMNIS15^MHIG057R.VABT&C30HES=AHV;C.ML.PYO>+71-O13A?>P1312HEE.M'3.P6%2L 2@214AIN9.7? W7>0^F&O#JH@>YKOA0.P6\$HF^Y\$WBQA472B MTSIQ6 0\$OFIC?H=+^U2R80T6F&IUV817K.XV+2,\$Y9\$TP(I4TXVP1UR1.MO\$.VGHY%-OQFKAL:&X; O6.>(I9N4)1L7WKJT=>S4PT42?2P.DP+P=C^K^8M.M#J^B4DBH?>D .9R@>O ZG^T^MHPVYK>6N8A0B^&Z-WYNMPPKEX=-0F1K2M M3S?H1>^*C^D9E62>9C\$ZERH3^1? RG?76 MDYB/ET -Y5;8@.W@<C^G.Y8F+G=JLH M55ZSNP<90S6E1JZ2GE&+LFTON M(2.9A=8R44 M%CK(MK+^%#XLTB72Z2QOK@>C^JY19KJAP'DE M1/QA_-D+## P2=M-8J.ZZHAU@<-FD.LJL@YI*U#<#L=8SESPVOI'POT'Y9P MB7C+K MZL^L=EW?7 V#1WTFP.S^T2 14B(80G<+L/2138.O1M3AX141V+2^>GK MLK2T.6H.KR.KR.DH+X@<@P0Z&O(0094U.MRK^11BF>@U55\$UXK MZ3/M+T1213B4.M5RM+M92U1P0RHKTB.K@WIS;P+2+MCG5BT*0G(I2P2G-N'WBYH85B^6@>SR W6E3T70JF=4\$;?>L 6@)DDYBNN9 M'W#Y+P%Q?W7GBZY@+F219WW2C^M^>?5VA2YI#(#0XC<=-K% L6<0>=M(C@8I9-GG+D<S.0I^<6@>I2@>A0@Q%KN/I^<BLV>=>L C^U=P#B.Q1Y16Z+1%KF+T MBS\$X4M3A69130DD>0^#DEF<P4CQ>MFI+AAE{JRS}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{JRS}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{JRS}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{JRS}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{JRS}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{JRS}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{JRS}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{JRS}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{JRS}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{JRS}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

[illegible]

[illegible]

[illegible]

12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182838485868788899091929394959697989910010110210310410510610710810911011111211311411511611711811912012112212312412512612712812913013113213313413513613713813914014114214314414514614714814915015115215315415515615715815916016116216316416516616716816917017117217317417517617717817918018118218318418518618718818919019119219319419519619719819920020120220320420520620720820921021121221321421521621721821922022122222322422522622722822923023123223323423523623723823924024124224324424524624724824925025125225325425525625725825926026126226326426526626726826927027127227327427527627727827928028128228328428528628728828929029129229329429529629729829930030130230330430530630730830931031131231331431531631731831932032132232332432532632732832933033133233333433533633733833934034134234334434534634734834935035135235335435535635735835936036136236336436536636736836937037137237337437537637737837938038138238338438538638738838939039139239339439539639739839940040140240340440540640740840941041141241341441541641741841942042142242342442542642742842943043143243343443543643743843944044144244344444544644744844945045145245345445545645745845946046146246346446546646746846947047147247347447547647747847948048148248348448548648748848949049149249349449549649749849950050150250350450550650750850951051151251351451551651751851952052152252352452552652752852953053153253353453553653753853954054154254354454554654754854955055155255355455555655755855956056156256356456556656756856957057157257357457557657757857958058158258358458558658758858959059159259359459559659759859960060160260360460560660760860961061161261361461561661761861962062162262362462562662762862963063163263363463563663763863964064164264364464564664764864965065165265365465565665765865966066166266366466566666766866967067167267367467567667767867968068168268368468568668768868969069169269369469569669769869970070170270370470570670770870971071171271371471571671771871972072172272372472572672772872973073173273373473573673773873974074174274374474574674774874975075175275375475575675775875976076176276376476576676776876977077177277377477577677777877978078178278378478578678778878979079179279379479579679779879980080180280380480580680780880981081181281381481581681781881982082182282382482582682782882983083183283383483583683783883984084184284384484584684784884985085185285385485585685785885986086186286386486586686786886987087187287387487587687787887988088188288388488588688788888989089189289389489589689789889990090190290390490590690790890991091191291391491591691791891992092192292392492592692792892993093193293393493593693793893994094194294394494594694794894995095195295395495595695795895996096196296396496596696796896997097197297397497597697797897998098198298398498598698798898999099199299399499599699799899910001001100210031004100510061007100810091010101110121013101410151016101710181019102010211022102310241025102610271028102910301031103210331034103510361037103810391040104110421043104410451046104710481049105010511052105310541055105610571058105910601061106210631064106510661067106810691070107110721073107410751076107710781079108010811082108310841085108610871088108910901091109210931094109510961097109810991100110111021103110411051106110711081109111011111121113111411151116111711181119112011211122112311241125112611271128112911301131113211331134113511361137113811391140114111421143114411451146114711481149115011511152115311541155115611571158115911601161116211631164116511661167116811691170117111721173117411751176117711781179118011811182118311841185118611871188118911901191119211931194119511961197119811992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343

A&+/'P'0@/M3H1@Z-EY\$J29'LKF\$W8N'*.J/1P6.6\$@XDD0/LFZE.)V7>IVF T?EL9;MG-MAZFZ?2==4M7S32;R9f2E%K0Hf7VZCOS,EF8K.0(FFIM@1^6-AG;M4ID^89
M1+0FC6=0%7LH@15IDQ6@C@P@Q@&1^CV6@6@YBK9C^D67H=*<3^@/TRfZ32VFGKN-MZ=0/VU.36:X9.1^*0f(JE0Y
M-)02G02M@H=H06@5@9U/RP^CE^A064H.N\$H1L=K+>P/M+0;0OHzRPK<MV4PZ0MXXZ^H+B>?4L\$*fM925F^43AF&G7V3YA7HWU199
MRDL&FZE='TX00%YGM/LA^FO@E=P^27RT;1^HV5%&@t+H-VD-))3US<0%_MY=W\$1..36H/L=VfRI-6@8IH^TPVQ?EOHH%?E\$>OH.K%5ZC7R^M1O258N-
>7M7N29V6F>FC(45/2.8;M^PBO@82V.C-BU38&B.PKR.Bf772-M2=?6FG8@^5DH=;T3XQfH3QVB&N%\$A8IR-U.ZQ^K(USIDKN<#<.%M^P\$H=1\$^#2AM8R^H./G/U
UT4<037FE?SOIVDMfDC.GG.\$^CYA MU=;2^Xf<+RY+6Z)56.KNfHfTOB3C\$=633 K36<.69T3^7RAB+Df MI CIOf (EGf7fZf7fNOA033Uf7>7f19\$N2>U\$=(Z@8Q3M/V
C@7B>2.685 M.3.CM=;P788Z32H1Q666.7J2D>2^6X<4BW>=NW=;@.0V75>T0AP<..MXYKZ7C2R@P-M9ZX@H7f7@7\$4LHSJ3>IRV?7G(SV0/BNCWf=Q5f>C50K0
M/W\$5X46f?>=0+M^M1^DGfMOYf108-DD\$W4@10<0^E7L\$&&+Rf-M082fHfWMfMRK5N?>?>+H+A f\$Sf-URE7HfGfUfHfG<6<MXXRZ2C0TNC\$

#ZHH#TNP14T@<V3>Y3+>+RE/LJH13/276+4*+T+<+0=&H:7H151BMB4>[JUBB#M]LA=BTIG=<Q>.:<T1
 M,M2P4~WM1<+>+>+7ECC190R=RN.LJH7)9=<N@T=T-YLVS&FIO<QDFD~8M<HK_MKFN<F>S-0X.FPG=>VSI2FU:XCY3*TR+7C125.KQ)E(VVY.S+<G<19-M9HYL-JD<=>Z8
 E#B6P2P~(T10M2Q0#>4YCOQE.A6>F577HW33<HLM.VK#>M9JFF6M2M1+8N]5A.<FQ.MJ]ZL.3ZKL#18A51X1+IUGZ<R:Q?D-302+>J?Q_M@YN<?>B8B51<EUAATGFO?I54E:
 SY3E1%1L EDD>.<#1.L>B>HJ@>FH2U~MT25T1M~KTHYVMT#P0+J-#>7L31=>H-#>C3QJ0U_0>_CHQF07~>3F>:FHCYMIN(35810=<650DBH4A3>E.WX.A6/N%<A1G-IE49P)G-
 "N1">3<N5>91<00;AZ(7)YQGW.W.EKPL1\$Z1=ZYNRZY#MJYAZ5Y45U.A.MM.DC1J1<=>=>2813Z9C"CVVZ0#>2P<0+7>ES31-3&7>0<0.D.U.LU#7Z
 M=>1J#>0<1<3AL=>U2V?82~R.5+4U9~T126JG<44Y1.Q>#>Q016U>SU-Z&K.M=>EFW.7=>#(Q0DMB<RFHK"MOZK.TL.M6+>
 MQ_OE1Q~1)2#1#>FOL%<3.AB5A04G&8"398.SJ51=>#<K1"BA1290#>QW<=>=>GC.M+532.:@BIK"FP>#>L:LAUUAHK#>1%>1H6A=>KS<=>
 MDY1E<5FQ?2@<K6+V1(BWZ?P.HC@G60IAsC198~8.MDZY>3>5Y0571#X-4L<200AT0_>:@KOLEY1#>#>R3>50;009M.R0X-(>
 MAE">3&K2J1#>0OC2X+JM7+8"080.82SU8.Q.O.LL1D.FL1<GX+>2F20..MO91&GZ..%>YBSHAN1+MP>9=>2FHFWM-01ZCCX<QFKNQ+OKD5RW#6D6CIG
 M3MYN@OREP&ZAK1<7Z#D?74;W\$>R5O1TF10=DC8C5.8RP<23>B+EIQ%MA4(OQES1~>27;S&2A#F.IX
 M%>4T1.44L3KLR1N~J2Z<31)JIBXO<=>H%>+>Z.6%>H15\$SRHUN~%>GLX1LZ68.M%>G8M41Z+RRAP@R:(4WIV+I5C<LHWCFL9IV<0E/1X1+A"X+L=>Y.M89%<C7<=>J"~>J0A5
 M6D&8BM1-I22ZMRT0VR\$>#F~HJHHS>@<P"9>=X1"SI2XK<=>E391JH~HMT_K+M+L6<=>+76&TMC#36C<21G.M.ZPD@H?>+>@.OKCRN0:J2.\$NC399RPW<=>C\$S\$
 MP&YFQPM(RJON@CXT)~VJ<=>16;8"YN<SV>D=>6%ZG0-E.OMG;IMJ.MY9XVF=FO5.P.D3JHK.<11-50D1P216V(C75)7>M.IVYMU<KV6ROV&T
 MWH<7H1U:P.VH6V1E7A~VZ#IMC9QZ<=>7F.V1V44@<S>#>@<HJE<=>1#>M2H>0<LFMD>UOWOQ21L.AHGXFU<F>3>64Y014.V0A1FJN(DIYIV-EJW==
 M#<60Z>~DXH1U1R1JL0IW<=>8&8YK~V.A57.R.ZHJ@<V~Y+4&R~RUK1-MVIG@Z55H10<@<FTW~UYP=>E"U~Y2LH41XB&4(F)3>S91R~TJ3QY<YOG0~YMF7MNA=B?2
 GFT13GHC<S9D83JRP@00R>@EH6TK<GGRVC_Y~M\$>JHBE>1LMB\$<S>H5T51<10UBD#3WQ>?>PQ0MD0P&ZY7W.XEROB4D6ED1N"R#>
 M+FM66(B1Y~T2YHIGEG<1<7FPK10<@<LH48>@<8J2)EOX?1>=>6C%<XO91>=>M94=14>J00+>S5I0F0K8D7B1R.BG@J6+UEOA=<T70I2G8H0EHTHC\$9_M@CP3Y0RB30+K-
 IF#>=>36LPV9.IDB01G>7>V1(1SUFE62LLPROQHKO.M?D>=>30?V>32761AY+>#AY(E<?<7)PVC.M5V;FYM<IN<=>7WIOCZ?>ODTFS~UW1X5%<MD>5<=>BHL1~T75@<9DFT
 5DIGM.MOMN1L35L1NU<K%>=>1&C5<3NM9&?>@PE@S&=>9.MQJ640QXVTB62(F&D)C1~%M65C~>Z(C2?Z%<C1.MSKP&ABRTUONB.VWIT<U1&L.MB;L.P-
 S5d1FIR51&JHH(F0G@>UW6XJA."9D)M_@<OQ.0~>JFSV1W19W~WMZ?Y#MBA&5&F&HGH@NL:8H1L&K@<S>0F8D>2#&1&JRNKKG81G&=<G#750T.MT
 DHUNM9JZG<6"6KU10%<5>2>557Y.41OIS0S@U>~>L_K19R2U.GX8E~M3<5LAH12=>JZRON1S10MD<(<F"2~>0J>BQ\$V>2HD7MYAR.VS~PS.L10=>YMG<Q.O<X1%=>X3J<=>ZH
 H@N<00:ISGL2SSX&S80.M6X716X=AH.&8@<V.EC%>JWN\$D&S2T&M;ZOJ15RSU2XDDE&=>U%>5-K@<DD5Y514~M742*2\$MN<PAR1?>E-SGS6D
 M1.E+>P87J?P.PHK4%L.MW6X(9T*G<X&Z~NT~V91IMVBNYFFE/KC#G+>M\$IN8020AT~S5YH9)DP.M+BV+>85<=>SRL~D6%NO4K57@>=>VME8E
 PBB15.ZAO~NF6Y1K<X&WP1M~>M4&84P2PR1E@<~2VH7>22:FD.D.MTGH1M12E<XH.X741NPT~>0)MCF<C2>T8<=>K&E;CU.P53&IM406B?>
 >=>6&SDOYELID78EYA.#S3S~Z&K.M28.Q&P<D+>Y1JH78.DV@C401.M=>R.FO~\$95U4XQ4~<=>OCZBD>D9S>=>MH9.91L
 7.6H<1~>TFL1>=>DQRN1L.E3G.FT84IU4~E.6<G&1C4~>4D8~>N.O>RZ.M4JG6M08Y1TMS?~>3E\$HJA=>S1TT?P.A.OLK1ZM(D1B.0@<51+>(MG<1PR2
 M(WA~>4P6B19N>X.4%T?~3&9S<=>C\$5.HL4O.Z&RC9%>=>R21FLA12KU.M1?>PZRWWYWG&DK1KG6WH1+>H.H2Z=P(A817JH2H1023M.#4P258G1WAL~M/LH15JHP
 G6V<5K)9.<6S-0CZ/M=CZ1#1~>@R1P4YXO%G61@<YU~>1R1CAV~@UYP5L8+1881.3X.A(4~>MIA"A'O(6N~>KZ%>73#>XW)G5.HH<=>3NOKT"K.O1P%<L1~>FY.W%>V&6V
 M9J7>1>B+L1W1"TH=EQ&8&8B34C29J>+>7JHJQYQ180HW62~9.M32~1&8Q9>VW7>27>90E<=>U~>2@4T2.AW2X1H1UAJLK#~TTBQF<FU.CG~>1M&=>
 C#YB9T>F&K&QPOH18.321A74&L~>H#>=>U010?ITTGHHJFOJ.M)D>5D?0.10PZQ6WT(2)5N13916G\$>R1+>Z&6T<=>P~>X7J.1E1E
 M.#3DU.FHOXY<M~>MR@<S.O1X~>JNTL<3>3D0R0~H&G/G#16ON&S~>X&A1<GZ.M&#>S&E1L~>JEN<K~>HLZ~>H1~>190>0CLMWB8F1B1JPL&EY+<F~>AN@<7PG.M18+1&WEN?2
 5W.9CW2ALZJG#1WUCG1J4VACZE~<6(A2Z2P&NCWUNY6;JA.MA.TX&610(H81=>8H=>E.C.Q2MXS91VE1612~>1?Q0U~W1=>1&H&S#6>86<=>M=C&E&S.Q1R#<@<31~>?>
 +>V0WP>+>RAH#1~>1>1<3%>BWA#GZN~>VT*4QH<3)3L.DU)M\$<@<R1THVA;190<NLP&I&MD7D)73<3Z~>JU"5CG.&1G1"2~>E=1@<P7Y9W~UU.MQ9TAKK6L52\$>1WXYWG<?
 B0~>L1.D>7G1A>OUD5H1V1CLF1L.BKV~>M&ZVPM~>ZLN23;9+UE1I.MG&#&

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

8U9L7N-YK\$TKEISB7@2J0I-U(WH)SIS"P6AA-ELJH":V-5VB(IF-H)-MVB:B-RJ3JH5-IV@IT1-WZZ@8%OVK^#XCHOZ:ZA+IG0HH@7%A-2Z8<-4\$%%PI(A)3Y3"IF2?I MBN(0)1BN^A@D?OWG^JC%-Y3P#@<=3&S&BCVCX-876Y?:V6^@=HF4CCKM=M5XDZPKQB6A?5P-R\$R^K^BMK(OP^NTOTSYBC^U=NUS^%#L^IEDHV6ZF4R2S(M<MPBP^Z"/VN%)8S4SO5-2V63>=>Z&S-5-9B^<P^DFTFMBSG->149BPZ^QF0AOA^G-MVF4EHL-E3-R-DZDDH-F-&+EN#7^<HG3&+A^>=>OGG
M%<GN128BK.Y)YB<M%POPHMHMC.O5VVW>=2YWYO+G=M4BR1IA[AO6FZI]^<#G19.M1HBM-OAK.ZD^<L-P-8ELBW)<X&XEED1^HF.H=5^EK%^40Y#1:-NYK.K6.M%2-
550.OP/MZ">ML0321K6GXH7Y.U.M5G3">7PY1TN.N.XTT<+!OUEF7H^<Y&HYHLVB-MJDSE6A=-ES(SWT+K-MTHHV6OR^>=>M(A(D,R:IWHVP2R2-6G34W0\$00574A8^5K%-
%<Z<(N/(M3SA4XLPEZ74A+NMMEUDUGRO^#JWSIR94ZK7XBDA0*M(N9CU(SH^%(A)^%SN1^M+6255^VDI@9%#S+JUM5.XD.E(H?2.P%<HQ5-6A-B.(WM.Q19.^#0(092X
M3^NTN^#IH4BDC@1^<SMXT^HF\$OR^>+7HJM.R.C:5JGB<1^C(U.L.WP+LA+N,O4ZEHT2-V.H.M-(8MSO\$12D^H(L@8FY^HA5.<=<EVD^BD12:EHL/U018+>+4HU\$=3.2+M&C
XH70<=>2&H#1^<P^DWJHS^<="U^Z20/6B^AD1DK319YGRF^C.I3Z4I^<M^LF2U^<H^<XAY12IK4142LE^GVG(GA.G)MM\$4I1^<A&4548Z&JBD.MZLV@?>
C)>AE^PP&H4K^R4P.I6-OH^<P^DH182C(Q+L+IDH8<=>+6MVQO^<A^L^WA4-D^7=C9%OHNNK.M+6B)1XAANWRE^6.3K3M^PIYZG.M.Q8.5F(%<+#S2F+^<+3^J(A)R^4X#1^=" M(ML^URHM5M172P^HAN7L-B^CAQ^H1^<E^TE21A466@-8AL16HMR.MH+LQS54YA4HKJG-Z=P^M3O3<1^21JXL\$5FODSFGR^OXLO^<Q.KL5.^<1^JMAOKDRFA-
1GEUFVZK\$5^CARVANJ^<DBNB^>|<=HO\$-W4.M6.BD93.J.A<=3%3^HHHVGU/LH.HGDAREYD58(N3Z&JP^O1^<G@=%<@2.MZ/^S<+<HP_EMF(^4R^>^FEH_JV^<+FEHK?
=<8UTGJ^#2J8YLEJ8N>+IP.M1@<C&.6&=<WB6(PDH6V6^18WK.KNEG<CD\$>2^<MGZ^>YDZAV.^<3A5M^SLZB^M9K.7:GNH."2IP>+2ABU4I4Z^2519IDR4A^W0JP
QWY=HJ^5LPBBU_48IZ>=2.M8&A(FM)H0-(OK^<T&8727.F1&W240Q+\$3V9YEI2LS^%M%15LT>+6:7HN8~3A%5HO^55%5NI)MU>L.25A2.52T^L2&B5
M.H1640U&ZL^IP30+I(E&MS(E14.32:<+B4.C4^<Q731QJLN2D^M.M^M3A102+M+LKJMTD5H^K9EUJ.B(EV^QA.S^<@H6JG<=<-W7K9OUX^<MY>K&R^FHJ\$2-
=(W+FLJOPLE^EC%95H+W659IERE.OBW.DLI(K<=<LUU.MJ6(K210HFO^FUY)LINNM^<#JFXQO.N^1+<@<T^3M7HWAYNC^<%<Y|
MM6E^UD=36^6PK-6ADRE1^<MRYA6^<GIO.21Z^55>>QH\$5^YZV.BH.^9(E^<MA.CI3YVL^NVUU&ZY9:D&8QT&72@<MNJK@f(LWA^-PL4XYDO^0/+<2.6X%
MVY5IOQ3N+5B.5FTMNQ(I<+&=<B4T4ZE.SW^%1NX^<JGX7905DFU<T^<M=82;IZ(BK<-J.J.(2%80%<GDL@f(WTK9T08F^GP.R8^<F7PSB^VAVL.DY^<LO
MNZA^#41\$UI962DA.V52^8+M+Y2SW@(<5.H^U2^<@<P7LJ4J4D5>=<S2UL91.MI53.@RFV.<@<OB.95AQ^<SH)AEWF(^%Y6GA9A^<YXFMW^K+YCI=B5X%
MW&A+I7\$E&B.M3(HOMO)8LJ6K^<M%/26A^<NYS^<F..EP_EJJ9Q^<9JOY^<9H7+10VOI@IP^<A^<8N^X^TSI^C9JRGJ+5SUT469PV+L.TEW2IJ.M+NQ^<Z\$P^JEY|^<PD2^B^J@<x>58+!
^<+5AS^<QOJS|^<LUUNJHJ^<J.MP^<S^<DXY^<7P2^<F..OF=JB.3.^<SDI25(X\$^<KXJUUB0B(HAAD,B)^<9K9
MX@<018MB0131<GP.NYAWA^<\$>KW>=<WXG=<USSH@<BM^<X^<X%<@U.PI.M^<URBG1^<Y^<1\$>3^<5RM^<20FPS^<#IG2.VI(RB)LEV7Q^<6I.O#2I2+M1RH\$M^<DG^<QA\$H
(OI&K^<7Y^<2DX6^<Q3I^<=<HAJK6AU@<OKC.M^>|>|>DK3YEE3^<FEBOURH3.J%<(<+<@<1^K^<M\$ZHII\$^<HIA-ID8+A6T^<Q^<XK.PYZAL^<Q9>=HOS^<WiTO@<NS1:O
M7TAOKI^<Y|^<2CGMIA^<AOXA=?</@0%\$<#H^<_9=<SUZ.3^<q=<MG^<F8-WD5MX^<316&PTCWWO^<M7TM^<2PB^<EH.3-<K@<5W^<PB3^<?<IOFX^<OOHX^<DGA.V3W-
O^<DPO^<O.M6S^<H^<2JWWH34G7Y^<U@<B.B^<H3.EE>=<K^<LZ4+<+<C0PZR^<YSR3.F^<O.D.QG.MDOLQ^<4^<=<EQO.<+8WYI^<@IX^<VGGDXABJ^<6.XX\$5>=<W^<AK;ZI<=<
MOCVY.N.8L>+<=<FKC5MM^<OACV^<HBT^<+<P^<J^<PMN.NV.GIMA.MZYLH^<AHGYVIGKI^<JOM3K^<IU^<WVYV^<GHZY^<@)MMM.K^<MOOMN^<XS^<BWMW^<A2^<W36Z03P
M\$YVQ.TG^<6^<P^<HIG-KPPM-WPA.<O2P7Y^<^<DTY>=<57KY^<W7^<FR+L^<ME2^<JLBOYKL1G5GIH^<=<NNJKX&K7IUZL.OV2SY.GW+<WXPX^<BDM>7K&MZU^<8GT^<MWB.N2
>G4.6LY\$Y^<T0\$C8.3^<E.GT+IG.#UJH6^<EVRI^<2SF2.MXGL@<LNS9SA.H04LO>=<@BWK^<HAE.VK2^<YENE+IMUOL>=<K7>=5WWW.^<6S.MK^<NE^<C^<W57C_QO^<^<JGX^<V7
%N\$>=<TOH<+<SRV.Z^<7PL/G=MWSO+<GXSHI&!=<XQU?>=<67^<7I.^<C@>=<TU?+<SZU|6F^<QZ6.42<=<DM.6Z>=>|>5:1@<O-M>P^<HXA47O^<O^<C.6I?
OK\$^<WTO>26=<UUA3>+YASI+<KG6KH.Y2-P+<19OX-MVR9?>L.66GZO^<AWMH4IAYXV.55ZIO27^<MLZ^<3^<SQFQ6^<Q2RZUR3.PMO^<M^<HJZCP.
7-H^<3YI.LGW+7B^<#Q8.^<FELOSU@<80ZMHIRIC^<CCAO|<NYS.V^<MX=2FW+1&AFVNS^<POOQC6UV^<V7Q^<9=4H^<ER.O.O0|<MY2+OIS^<JH7^<ZAWYBJWY>+J^<MIKU?
ALYHJA+EAOVX^<OW1^<H^<U+|<WWEK^<T.MM^<^<8W+90|>=>WYORX^<YFBO>HH^<8N9.^<Z^<E9V.I^<U+M^<M^<UXZXZ^<GWZ+<Y^<EQ7^<GR18^<ROFI^<^<HO^<UP^<CID3
^<MSOGW^<C^<GM^<OGQM^<KG.M9L^<4SKEM^<IV^<Y^<SP9>O.MI2UC^<WPVNL>@<I^<WG+K^<J^<SUA5^<N^<R^<M9HP12+<5&YPTXBZ^<F^<EOIHB^<77G>S_|<MO>:
JU(A2^<ZD_IHCW|<5.J^<O?=>=76CD0^<JL9J.NJV.XE.9JR^<M^<YKOX=IAQV1D3^<AO.G^<GLV^<O^<OW.^<\$Y^<I|=55PVIFYGUOC5YR4BIY.M2VJ17)P.
HO75ZN\$N.LWZY^<K=IMEFYUW<6.D9IY02GT^<DS^<E^<F8+L^&


```

=7X<125>YB/D8C=0%>5J=^<^IB05E57.KUG6U<CND<LH%56745<LJ_1A<GQKA<R6P<A5L5A<1HG.V+2.2A3><9%2S=>4.1.M#AL+2?XL<5H<G3K9R<FPD417A?
1X<KDJG>Y644GDLH<@<E6BKMB525.M7<5DDPV=C.NJ=^Y6_Z_<TGI>J39%<G@<I0%3PR<IN#M<GSKJZ<M4OG<^F<M<ENI5G<DHO2MQ0<U<5KN8K5<S<^1?7F%<IG7?
X9Y8K5242?>BYVFG<ME6KSKFI<N<YD<^Y<A<0.<I<VPT<?>7HJ3J97<5HN2L99JRH19?>P<XRN5<U<MQ<Z<=W4N9.P7B<.<.<GD6W0<.<PGI0<WT<07#>?E6<C<H<_<.<IQ<
MMY2V6K0RS6<O<O<SHFAS19G?>E9<N<30G.V%>..JH7.3<4X<M3<M<A/>..<7.<F51<+N7Z?>C72MYH0<X&X<X1#>UD.PHP7BRN0UQ09C5G<MXTCA?>H1B/C1<IO<S0PVI<Z<2H
12>61>R<IO<Y6<EY>?>U<PGE<CG21<L.MOIC0.12<P>A81<+>8B5J<B1H<96B?>5172RC9R?>X<X<TEJML<10RD?>U<17<8WDSU9P1<ICGVYH?>0<OK<R<CK#<0<D
MCB?>=HVIR/8P<?>8<+<C5>S2RLG62>A<G<NKGPA<H53OT?>S5859<MG?>D5H1W7313<1?W5N5<Q05IDC95<F<F91<+<IGB<=A<I<PQI<+<WW<NP6.ZE<MMB<XMXK<=CU<Q45?
7/DQ6?>STC<=IN<SNKN0H1<MS<1<GJZ>BD0.NQ<+J5.V2%<QIC3Y1<TG?>ZB5E4H4FEW<GAGIO<+<I0RNB<ME<@<W4Y<R84V<6M9<R<1N<ALZ<5Z<=>XSF2E0INEP<UKU?
FHYA<J3M<+<H3HFM<M<W<A<S<Y<J8X<+<6DK8?>1<+<WICVY<ZM<BEC?>2OY<S5D1<K5TD1<MZ<Q0<.<N%>V<?>XBY<D<IHC<Q&ZZOF<K<T?>M49ASNW<D9P<YXID<+2H<A<R?
M?>7C<A<JQ<RZHQ<SXR<FLFZQ.ZY%>..9CN<+<KJ2<YHXHRO?>K17<LMOQV<BE4<F5+38L<L3WZ?>+<ISO<+<BVDS<+S<6%<CL<G8F3<+<PD6Y<K<+<MO<M<
C<K31<81875H1412?>M<+<H4V2R<92<+<WY3<+<OZHJG19Y<M<+<HK3P<I<N67P5<I8<W5<Y15<?>HTKJIKL<KZ<RZUP4<UO<N<M<K3Z5<M<Z<F8C4H5W<80106YU<P<IDA07<
+<TV<AYZE<6K93FHC7W>=ID<FV<4I6U<+<MRB<R7BET?>I2B<?>GEAG<F7H<Z48CAJUCXW404BB?>+<LM.W7U<L<Z4<+566.>N1<MM<@<+<30<YV<S6K<97<J9A2IC6A?>+<LMLUW<KZYKA?
+<6H<+<@<7P<M<+<HJG<7W1<7.V5255D<=I55<MM<M<K<FNUFK<Z<D683?>F<F<WL<HH4<H3<+<0<+<L?>IP<ZH?>+<DIGN?>+<H88<M<8B?>YBFBM<
7?>+<FJKOG96<+<BYE<M4V<M4<E55W<=GASD5U>+<RB6OP6<+<66<MBPP<MLD1BCEB1<+<JL<45?>J51C9<+<6V.A93<.<9JTL2M<?>7YAGV<P9ET<P<Q<C<MYXS<T<E.MZ1<T#<+<@<=>#E9U<
H3OV<P2.2M<S<0<IE<1GUCU<P4S<=I<J<M<L<54<=..>N%>+<Y<28<I<C2<+<9GFFD5P<?>7IZ&F<=42RV?>D<R<S<P1<+<2<C<MYU<Y8.U<D17?>SDNK5<I7W<K7<3T?>0
M?>3M<MOIS<5<6P<3R4<M<P4K1<N<+<N<H<+<V<H<35KY<+<#<6<42?>HD<B<R<M<TAK1<+<..<K2<J4<Y<S<P52?>+<Y<+<MG<JB<+<C<YU<Y1W<LO&A031<F<E<E<B<M<+<3<G<D1<1HE<G
S4790<0Y<KTG4>+<J8<+<ANGFY<Z<E<Q020<+<X<+<..<HYX<M<FEZ<I<Q<H<H<VU?>..DVI<+<WAM8D<L<Z2PH<K62U<U4O<KZ?>2<5<K<Y5ZEW<M<GL6Q<MSYHBFW<+<6S<+<B<VY<X<
+<I<O<8IZZ<=>5<2KJ4X<+<YFC2I2<+<41<O>2<#<3SGU<V<MNHJB<+<UV<+<HO?<+<WIG<R<+<1?>VIEOLA5L<G<HZA2VR0E?>+<LQ5B<RRR?>J<M<K<
QXX7H?>+<DMA<B1PP<GIZ?>GBLKC<=BYNC<Q<+<K&FOB<XISHE7?>+<B<S<NFPMGIO<?>XID<S<MWITX5F1Q75?>..M<T>N9<97?>VIGITEN7<+<600.01<+<H<Y<79<+<@<KA<S<W<SIX?
UW<H7H<S1I<M<+<Y1S>+<..<B<G<1%<GSV1<E2<+<1VXH1%<2M2M475>+<@<H1<L<P<MWJ?>+<+<W&Y<M?>..Y1LEY<+<A<M<+<BWT<F<M1W3<P1<8?>+<RXI<+<Q&O30AK<SIXY?>+<IR6Q<@>
M<+<L5PHZ<+<A<IRA40<Z3RP<K<CNC<E<H8108K1W<D<N<+<M<+<+<JOT&C<P<..08<N81<XJZ<+<ZV<+<5<6<8EE?>47C<+<1<MG<0B1Q5<B<S?>+<T1<C<WQT?>+<VH10<S<3M<LIE?
<K<Y<+<Z1<4W1BAGH<85<GWCX<Y<CGL<MR<=8Y<+<S<+<VQI<V?>..W<+<0+<1<32<Q1W<Z<=..V<0%>Q<F<E59>+<@<T1<U<OCD<N<MKMH<SU<AG<2IH<..TY<S<+<L4XF0<E<F<4IR7<+<320A<
H1<HP<+<O&T4Y8N<+<1<M<D<J98<Z<WY5<U<WAL<QCSYN8G?>M<S1<HETD1W6?>2?>TTS<FAAR<E6?>H<R<D8?>K?>U<O<M<+<5<6<ZWY71<..CH<E<72<=ZHY?>2A?>P7LZ<52<=Q<L<M
AJMBU<I<OXIL<U<7%<H<OVSQ<NZ%>74&1<+<C<HDF8<M1&A?>M?>..I<B<+<4YCWME<+<+<FWV<VY?>Z<S<..I<=DU?>Q<NPD?>HJ4<A<H<DBZNSW?>+<M5F<M?>+<79C21<SPTI<=XU?>TJ401?>
+<1<3B7D5<+<M1<84R<G9<+<51B<K&S<+<@<R?>U<M?>+<SV4<M?>+<ZVY<+<3KEI<U<+<J8<+<?>+<U<+<6<U?>E<G?>E<H<MHP<P<S<E2<C<R48<YD<+<VOXAQ80<..HA<S<+<9RN<+<1<6A<+<1<C<+<Z1Q<Q<SV13?
MZK<G<JOM<J<GL5<M7?>6<F
```

ASD2D2T.W.44<J935236<^LXDCIB.MG.SJ9J.TJ.NQ2Z7F7<^M3YR1BQ.E IE MB4<SC^M5ZJ.LDSHJ.HY4Z'Z.GPEE%7(C.LN9R^..GSZ(<5D)BE06)>,\$
M5JL5B1K+U.17P1Z<^JMAI^N)NKTFFBZP.NI.MIYKFAA^>8..#V\$+K+Q^*EGX9RQE@MJQGE17.5=,X3>+^MC2.9&19FFI.PvU.9 MW1P<
+DPP+L2Y1Z4U48A+V1&H5U5B1LGE=>.2.EWBK1C1+<^26B1KL M57.WZQ^SCN9.0^W+M^M1D&Z.0^W+<^>8\$0-01^>KX? MJBO<
<SKVY(A-B+>YDPK1642<^L>2>P8V^PKB5P=U.9WZ.03R.L0X1U+Q..M4<4Z(C@MGB5%1HM04@BM7U6U1^4Y&6W1FGZ29^A).R^GFFTR1<3UP4D7)M.M.E2<
\$8.3.KNH195D18V3W1Z<^L>5.9A:B4:BE^F<B5<C^R=>0W6G=>+MK>+3SWHUPB4P7W^N^T^P^>2BYQUL@:GYX^#EWO<0.5H.0.HIAG>=V\$
MS01008.0^RW.Y1\$W/MP\$9H0.0V3@:(U<^UYU)UE<^JHE_MM.5N^28.N<^C1^QOEVL.GHFKP#++>W15^R/5Q%1^K&ITW3.X:U@74@.M@C.6GV1=2\$?&ZU7X<
9Z>/A@DK<R3#\$.536UTB38N4A<^G2Q0?7^MLE<7^ME8.@(4C13N^T^YH<8L03>_57^M^>P.T.UQ>0@NBL71^H#759SJH<
MK1?M70^#U8T=>+^9WY.1=>ZG90AP9^F070)J&R12Z^PWPXSY^YJC49Z0+<+>=C1P.M03P2D.V4AW^W2512H&H.D12-0F17LB5<^C0ZBX(R.W6+NX6>MH<^/%
HSD(5LU2<C^Q^Q^H.C.H1<Q2G?>@.ID3L97^AY.EH1ZQ.DU@:(U<XK6%77-6W9D13177^>+^FOIWFCTREI@FRJ53 MX^C+&U+<^OJ5.0S9^<+&6-MI61^QV127?<
MH5.900.1ZEMUZHHDGOI<=>2 MK0K01Q35@F.YH.H<^&GFEH4^#8T+DZK7JH1^W^V+U^KABC+<+>=SS^X830^IXU^>T1.IR8IA66&M.M2-51L75DDWBD^BT^YFI<
+P0#3.EF>Y8=5B58W2=WCHPFI3+5HR<^GLW^GZV.U<^JQ03LFEBY0.MM^GL^WS^>CB\$1P0H^W1010%<^F^W+DLZZ34W<Y.B>V^%8U61=>71K@P.MC>91<
(34G002+<165.Y3 V1=>+N>B+P^G&S^#XU301%<^Q.U0125_34G MD9Q06@P3\$509-DGV1@P&QYH9N.6A>F^W58T^M9&<+&G4BJ01969\$X803P^#>#00Z1Q6<^ED1:SV<
Z118^B@Q.A1Y3 H@RDJ.MOQMOEVSFV70L\$Y2H.K#E2P1#G7/CU<^UYH3\$3>30HUQKALATOL.MI6.(5TJ.N<9<^R0.70T1Z5.4F7L6^X103.54P MB5VY.741^<
C31.3E\$N/UH<^Q.W8CRIMO>4>2.29F7Y4@D.3U5-64F-H..J=3N1NO4A<+<VQR2>^%IX7&A5J1@N88.MW^>^V3FQAGEJ(Q2W><C<L<
G8L&U01<1&DG74C1Z3/17MUSH3P2<6XK1.M^G.W^U<V1YKX&N1.MH.L2>1Y8.Z<^J@H1.5^U1U1^R@E9Y<36V7\$VNVY<X022K15+TK+VCYM>_M#-(P^=O/&<
9EDUW9.4L7Z0R0Q1.3L0.MWU^K<W3-JOS<^LMUT<9#12G1G<^&K1L<^J#<J4JK^QZ1^AN5J14&87^U^X@1^I#&B&N1^<^JNP^8K<_M6D1FY(%E6=<^U.WZ<
(U<^4MC+9.V6MR^..WK3HT<3.MCV-IPA(U75Y7^WJQJ&F0V107.44Q2^<=I00@+<^A^<+<^S1BM9LPD10V^>M^<
M1^4VY9H1^T^Y20>KQURIMT1WBLEF&MM1.93E1T0^XWED>1R5(S.F.U.M3^24OEB19U^RZ.ID.H1^6WHNYK47KUCI9^5BY.7.U6)RBY\$CO^P4Z&^9T\$>OZIOYB\$JHS<
M5H)D<^@IS4<@QRIH10K2Z^@>^BBYU12>D\$&^#Y1@OZIE.KD8+5+3C9R.E1JPN101.M=M5X215I8YU818PU7R9U.O>6>IR.K8HOH<^<XWTRR8<6XK1^<
M1PN.8C(BKUSTE)^>X0C.G^>+L7^Q(C7H1D^9^X1Y.U.F2^D1V21G011.M.L0^71GFEH>@<^HHVNH1+ W.B<^VJHE<^<IN^L1Z5IFETBLD472P.X.M@GS%8101.5^YQI>1<
1^1U.SC.L3<C^WSME.R40<^K15Y^6W1G1(CBZ^E#ZFW TKJD.N.9^>1<8L^>E=N^<=U.MKG V1H8.8Q^M6FE&RM3^<Q)9EZFZ<C.L^>@W03L.Y^NCZ^0EFH^JMP<
MK2^COQ12T91&U.LS>1<M.M(65^BGW4.YJR<6.8^>=>R4\$<+<MGP1HHEKYE.UK6<^44@FGV6C.3)M1O.UKFN OG +NYP@<VX=GTN>I9ZVAFB7D1Z=>4AV.CRN<
X7P2.012.105.M0176YLM.R6LOEMI.FX27^9+<C@FQV.&S1HSR^BG1<681Q^OQ^#1796.M>V>9ACG1ZV>^Q02=>@0@F.OVPPYOC17^HOB^M5SC18-1NSH=1^#1^2<
MP669P12P2H07K7NK1KBQ.N22<QOX<^<L>V4^>767507^INSID0.U(HHN<L^M^>Q<=<D^>W&716Q03.SH.3L29H.HU2@GZ.H16G.OK9H9>+>M0&6^OF<^@P/PTI.M0B+E^G<
M(6L.2.60P1.M3P06^4XDC@JWE.M.AX9-P1.95>ANJ4<^>1^IEGR><^M.L.N^0.9^V1^GZ6TOL<I3.(26L1M/HB0JY3<1^K<0+<QOE65V^<
M2^@P8X)Y4RW2^6E^&F9MGLXN8X7F0\$M.R0V1U^31.L00@W^>N.I8^<^F1U=>#0>Q.X1Q1B^17>+NM@KWB.Q^>M2^<^%1=U.OUKP6.O^>S.Q<K7\$225KMN<
M1U102@+1^I0K=9)UQ9FWVZ1(S^<=KC<H1=5^VT<1^&V19P9MC.MPFLX1^1 MX<^H1V0^>H4+PDV194Y4<^XCI>86>S<=>.ORDWUZ5H1^X18T>^2F61G12F+ MY9YD=7M5<
XLO+9C.W1>+<S5MU90.7C@<GQ4@ERW.DE&M64.<M81.HD1+P.W^W1+TSO6>7% HH GCN4>+<=812H2>W^>V1V2Q2980W<1Q1L.M^<
M1^>Q>1FL<^1Y3Y^W.FHN0+Y<C1D181218W=9C1/SEVS.6U^VW<^<31Q037.32PMR5YX30^ZB^W17^7CHB9J1KQ@J11^>^QN2<X1YD1Y6K1XTAM^#>^OWC<@&D27D1\$A7Q1<
B1@<=9+<5B52^BE4^<11N9PE%>552JL.M<^@WTM74V55-H1P.S4DL.W2CWMZP.(5R1^9933^W1T^CYX1<H.M1S9F5Z<6LE6T.%FMR<
IS.K<3\$P\$5.14.OG^91BXV^0P1Y+<15.13L1^<^<QO^US0A.M292197.L^0H<^<DV6<^AR^<^#FGFC&JZ>=TLMGV4.=IRU1L5.MZ<^D1^<^Y1ET<1^T^<^#YC4SW<^CFB<
YHURD88LP.SF18(29W\$ASBOQ^PD<=>^#HRF3^R>T=>+<402>+>P.MF6Y.61G>+>+>=IGKK>L6^M.PDB1^JL.H5F.UOV+<^&UYO18L41(INH116?<
>YNUDL41&XLM>41)6M.MK<^QBZ33^>=GC1V118/EDK16V7%TJNFH\$76>(P1+01/O2T48.M.81K.MY^16442^E7^YH202.>#MDBXK<@F1K>5IUO&.KB<+<16Y.Z^#1^>EDK<
M.C1U1B5>3^F.BT8813UH&UK&QEL\$7G^>T^<K1H1&EMD=J1T024PH@.M1M61^801D1T^&M<
M.C1U1B5>3^F.BT8813UH&UK&QEL\$7G^>T^<K1H1&EMD=J1T024PH@.M1M61^801D1T^&M<
M.C1U1B5>3^F.BT8813UH&UK&QEL\$7G^>T^<K1H1&EMD=J1T024PH@.M1M61^801D1T^&M<
M.C1U1B5>3^F.BT8813UH&UK&QEL\$

[illegible]

RASTTIO-SK:M8!WGYUUS-E'FHHJ>SV8M-O'F<|Y'G'GNS8H8<)&BSWMT7L;DL-KH8R5|^-M0ZC'MQIQT'X|-4.#;>O6<@RP%3HI-O-6^-J26V>%-NNHC'S<|D%M<DM*
M0Z&L<B6%O>O.C|S\$G&P#YMS-AUK-(23UC00T9CS9P,-('B9U'L;Y75!5-M?^<60E'W>W<|63!\$%#U1Z8H-O-S-M-L&X7Y'IM!A0Q?4;SF-L6&R9/T\$.K=<';?IAB66QO<X^<-B
M^+|W<~<|Y%SOH^+|CAH|HJ!2V8G!AMR5DPR<|G1Y<~'G|HKH5E.0!V|>|T|M/\$>4<-(WOPI<+|X+9S!6E3GD9P>@?^EC'M!V8>+
>@C<~7V<~&#U<~(V78)>26Y+EMEL83H<G|SV1RO>@L0V?2!0+<ZT-M^>N-5V>W>|TQ-O-W.M.50HA-O3&ZL1K74+!BQ32<@&W~<(|.PTL!AOH=<4-..MXY>^>?^C'XAMN!..KFY
MS4H!V576M2-14FH!W66.110<EMR9KIR6H!T0L6!U5!Y%573N8>+3+N-M.CQNO-155!<3D2A.O3&Z!7H!3352E#6ULL<~7-6SD>57RPN24!<-
M.55KFGY!J&7-5%P2%F4!2<X^<-8'02323X.M.0!2<5X!|5Y'R-8'F-E-M-EY7&+0*H0<|KMXAKEA-I0'HKI?>T<|<GJ\$-FV!B2D>^UN^<3YC<~.W>04-MD=L5&C&D?R3KT&E!S-
G!8U<R?G-B0!GB<@LW?B<~!TQ<-EJ!<-N!RM!4!4-MO!M2-YHFG?~!R3P2H!T>2G%GLBAKH^C<3B^IMEI^<4NRMD2!X<+5=74DR-M5K7?2-O-!U-FF&4^EL%NB?>
MWU-QZ%G!WB62-W?Y4M<~W>~>XVYDAFJ!#~M<~+!M!F!L<~>CQ6\$8>+|MBK6!-9FOM(XJ5>5^E4F=>~>YU!0!U!UWOUWB/OCH?7'M-!X!P8!>#5%MB!FRON&^R-JO-
6!Y7K!TAFZ!L!BU!3!-UFIS<EN!<SV272!<@&K5BO!K!M!>|>B!QY!2900U!U!H-!>XQWU&CP<@05?>+>|A!<3S206-4435!&1P-MT!M!996?2!U<U<<>?5!Z4F4!>I64+M.
3!U<Z!W>2!>E.O2+!L!W#-!W\$W-WIO-MX-M966CND!W&O?62<#7-5!B!W!MP!>+GK6!H4E!HVB!BK04S0<-X>R!M8-EJPHN<~5>+9KK>?Y~?2D!+>+9=+MWZ9RR?>
Y!<+8&8V2B!>2BM<-9!T+<S\$D>2-20G5!F!R-B6D5!<-&L^AOGN!AHP!M!|!H^<V^>9=+~!WF!0!P7Q.6M<-6X-4-MD4!<+R-24K>+3>A2!>
!ORS!PYM!<@E!JD90!Y!MO!E4N!X3R!H!N!X5!Y!MURSC!Z5!>4Y^<#E!VET9-~>CHEV!MTK!GECY6CM!NO!NESZ!57!<-9+DX>+>#E!<M!5+!A!W!O!E!W!<B!<8!<+X\$?>
Q9WA=7Z&GP.OX!+<K'FHHJN%2:77!RV8Y!L6!M\$<~M2&?H!<H6YF^!FX^~|<F=>N>?7:~#%(<|N:UW-3ME~|<VOS<(<#8!B-MF.S&W7R5V^!F!3GK!1MX&JVZ!7-AR!T?MO-MFE3+?>
DTW?>@!H8^K7RV90<~<|<Z!BY8!<K!<@3C!U4!<JV2BD!M!W!B.#.#>+BPAN?Z<=>5?T?Q3!FU!5L2R!5JTK~8N!H!64-OF!X!A4G-MN?7?P2D<~M7C
\$N"PU!KE!XZDY<3PO-~>BU?5!4HT^!AC!P2363!3RH!E!V!Z6U!A!XW!B~M9!C=EWA-\$S=^YU9@=5L&M\$S:S?G5Y=^P\$3!6L!O!O!M?7!<|<~R36<Z\$
M-!U!Y0?>+C!<2>...>2!B<~<#0!P#>2!<9\$<N!Z7R?7!0!M^<3!<+!1J!<9-9!P!A?D-U-E+8X<23XT!<P!<A0!<4!<Q!SWSZ<-Q^W!P!<X!<MO-MRVDT5<W!DG&4!<J!G5O!H!<D#B5!HM-?
!(BA6!2-5750!O<-5!M&Q!S&E.MN^DTCM2<~?YQ94D-1-S83Z!>|VEV!<|7-7E!8P!1-!<2!<A44K\$A!<M-2M!K3F7GR0-!Z?>+!<4!<FENC~!>Y!X!OU<Z!<3!H?>
&X~>?<FU.P!>MND\$SAK!5G?17~5<+>HP&!S!U3!<3K30>+>C<~<3!G>~Y6!<C8-EZ+K!57~!8TT-M!6!<@H!F!FZY<9V&9WN^<~\$<QY!<L9?G33#6<+!<Q9-?/!<%K86!^!U3D\$
M!C!U!ANK!<1ZF=<6<-V83!F75<~\$<-<O-2U9!5H<~\$<U^<B6F4GGN>Y6<-<MKN!C!OOR?<K2-5^<C?>@0-OQ^N!<4A!3R7C@~<@K!U^<VN!P!8H!>H!<L!<Q?C-M!
<Y!<Y!AAK!KPU!<72N!<4PSQ!7!%5-1<P!VPA!>5-26R!TH!>

[illegible]

[illegible]

[illegible]

NYDL&INTF%Q:VJL624G2+V=-M=FCG51V=V%18T#%GC4."R76%-6:1FY&H#1+D1H1V>0.0?G1@ZS=8YXG1QJ.C=GEV5M5.E^<#7-LEZ/RCYV7Z).M^DSC4H.%1%ZV5*1B2SEZ.70SW94JL(7K+Y+6.D/SRS>H91=9.R2F.9M5JIPVQ.9S031P1K&0L@+A.0D99J+<+181VED-PJL=69U^CAX9Z?JIOA
=PKB17H7F3%<5R9HZ)AW8+6&Q2K%ZV2V=-.USZRT+T3XG1J@.IK-M2KJ71%72V531<+4LW)CL(3+P-B.0BW7J3V1H)M+H6TH&YVH5X%W2L>L)KIN0NN+WE)=
-1M7+V2P%2AFF8FD+<PDD*8>=1P5^>YQ09.M50X9477M1DA7CVXK.YV.-8>76ZP=6DH3Y1="SS8A.6*5YX%G&M2?0H5=<+C8-M^AN9YK->?U0<E=BO1P%2
@TJ-E1V2PJWU-S2IG<+<ODD>@.04LM=PCUB+&NPE.M2X)H1.8H1H7431P1M2@E5+T&C>S.S.C7WN3B6Z0P<=<8F3P851M8A?2A?H7Z7H78D>L>Y?PTLC6MD=

1PJOI=D21@C2N2OE#3M.MA1.0GW.%SLN^XMG@%>7B>>65:SHR1PJO8.T.ZK=1Y3YHAT10.7ZXG4.MO/IK&Z>UZN=20W>|Z91_Y.S=V5URL(0X?F=EMI+L)ZQ=R7+
Y.0RZLMPD-2M1(C7PS5E^N^X%OB1905@=R-KPO1P)VJ501.NJKO&B&^YXOML.M.9V>IK^>?@8?>1MJ20.B(SL^HKT-MHL-6P2P)S>D.WW<12H^&J70U7V
K1=RS17YMPD=7Z3X<>UY5^=<IRIT.UIF<5%1PNT5%1.MXJYF4WBT9.71H%8&ADDB.M(BL^EN5N2P71Z1B\$G.6N:SEZY.&MAHX4TQJG/G741F/U19>DE^UVA
+40LKPVCV+L=X1FB.O_1Y^DK_1.G1-MR2L.DVYNIC=<NK.WNIFHCL1JX2P7Z>14KZ&XVM9U8-6U>_M1G<_<1D
RVRKPA>1Q(OJ9A)4L8H1R.DV29ENBTFWZP>5PDW2.M.M<94141<1\$81.92371@.W-BH5XS@S^T.M20.2G<0KM0VX%>ZEAT?OCH=-&Q
B/BX.C+WXGHR.%E%58R10IX&H&V5NPBQX=<MBU).PB^784V.NXGK).U^<121@G.1Q9A371H1USYX^MOJ.DB-SZ.&P+\$M.MG210H^E.M6?
2DGC1406.%C5<E%YA+QW&@>1B^14K.%C-C7D.JP=N50EB>PUUN%MX^GPCNMX6N>K.LLD46IKR.DIVABM1H1H%K&K%13>1T6.IB%MJ8(5B^<BHQ#G.M&PS
%E^O7YV6K.7S01R9V1&=W.C.4F5M1).MIX&K2Z36?/C/1P1ST2TU+CBZ.S71A.CS3X<5KN.69ICEH0&0-MTZH8G1A1<+L10)BT(Y<5JF.7P5%G3:<@0&F7-E9&Y
YVVKTV55714H.M8RO=<L1%>10(092.%C3ZG.604S&Z2%55UOOPQ?MRW.H5UQ.M20IQ.G9P^E.ZR/>1A.Y3UUS<C=SAU.FOEE?IQ40L87D>9F2%\$99
%42P.D1D86JMD-LFMF(C.TH1K^>W1S3+M17N2CDI(ZYL)H#VQ1VE3119LHXGMHWO-1.O&N7S>=U&UF411&O1S.
@GDH\$(J\$A8@&QD1\$6.6A7<7F.CE&8Y&ONY@>51HK0.8.K0P1@>1.M70.M2=X1MJ1M1%<=SDP^YV4G7>Z>SZ>)%/Y&IZ^PH(GR^*80Y2S.A8<=S1.O1Y3.M<99.%5YM
YIN36B.8S072G&FA5^<F8E>Z>S\$MX=<OX.R1^UW71>RG.M5PCS8>^ONH>1E7WMB<Z+4G7?9)1J93&=JSAQZIOH0+MAZ9N9@<BN76G@<?>
JES314HVOR\$%XI@&L.FLMYXQ7D+YFQ+G2M6G.X2XIO?<0LLW)@<07005.X11=<EN.L%1.A5H1.P%PAHB=Y^M2M^?WCM+CI+KOIG-/Y00I007Y.Y\$-7GU1^1?%)U+
%R&R^RU^F)H59W%TKW+1J=8P.KH(XXLLUBG2N.MR)=T5X^F#1+<2MHMA.0.R.PQ&TGM1Z>1VDVUC10Q.HS2J^&K^<=<1P2421S@<1K519C8D0G^YBXH(
%QKR@D&7RC6&BHL.M829DJ9U7T>Z9&OQGVYH^SKV^D6<K&H16V96G4^G1M2<1JW69^81T85SDC>=>1E3M+K1U7^71<=<S13F%1^D11<L5M04P2(+M.DAP)AG7
17LWY+>B<17T6N@>1.Y8TW1Z.YD1.^1Q&K&23T@>1^1(59@.M8&8&8TZE5(DD23XBBDDU>Q+V6KKGN.ZKQ=Q9@D&4Q(1\$1ST@P6E>0L^
1XVUIX.VNM)W^C>ALZKVD.FEEKWJOL(3UXS(819^<MK8.HO64^MYT^V^JOS.UB>=>1XG+1@>R2Y.Y@QN(A^DK48003&#.P#R&E=\$GB.M(LP3JH&
1CUGJIA3^>P&KO.C/>.&9C^E1P7DITR&2Y&41N^M0A9C<V^M>G.#1+771B>M.U1.VE.7^1U1+>S.M@<_0W.(HH1S%0821P^@0G\$=<01&4@=<Q1^"VZEDOHJSEZ+Q1&>?
R.M9^@<0T70.P+1V44CKR&1L5H(SYC^B95D+1E>1^<1K1BHX8728G6SF1X^M215XZ1Q>5#J1H76Q.D2PYHN4G9/WLXW067@31^>1O7WMD1^<5YVFE4.<
1FW2R1OMCY4N4Q:0.P@BBB1B<=<MYB1B.DRQ+L>1252&C+S.14X.X1XVEU4<70?01JZHW6.YSDQ)1%P.M.9318.D1.OXQUJHE701^<1DR+17H1^<1YSZ=1D
3E1^>7Z.VEL.O7YV.CL3>HBA^E.G1L&1&E7.0X1VY+JG>Y%YXO1Q72.MG<39.OXJ1U^>5F>=<GO1>=<S.V1.L3YR&R4T3X&B08942AM.RJ
1AMWK&9N1H.V1.)7Z.ML3P1@=<V1.O>VAA07Y1.KO1=<CTH.Y08^<9.MB%.(BB^>9P&S<2R-666R)(O161)O9HT7Z>=<6(6:01%ZS=<3170S?N.MK?#1H0^#?
1MB^KF=V1^<C.SY1Q1PYY15KWN7ZGU^Q.M2K7&1FHRN#)PYL.MN1JN2.JXSU?B&>@.9.HN^/IK^SY%G)01+NTFY=<9CG9\$V^CTY=<MIX.S'GU:15JN>9@<K^M-
D29P+<+2J231HTM.1VYV6QML+M.C.M5#1+1#U.OE.CPCN<=<848&8W1+1YRX15PMW1.8BH1+>P.C7QOI=W1RL.MB1%5G<C)(Q1B1)<0+1D.Q0H17D09D4FI
AT^>2.W>1PJKRTY6WCA1QO.M1A.%1P%17&1M&S\$25.P5%<XORA.^G=<@KJW&ER32P.1571M^P.C26S.MC1X.2>K&GR1&6CD3-B08@=<E1D85R2ALK16=<K(
P571Y51CT.8%\$M.E9AE1^1J1V.^@U26R\$7M9LHHN.11=9R>1UGD.RP.UELN^5F+<1HWD6>M2S3^T=C>=>FO.1Q^B1OX(C.MY31D9E<U3.5>.DM>2^S>DD>1Z8K1KJ7
1E&E&K0ZB1A.PHSD91=<1P.M1C^1CC&T1S.1M@R7K1F.^0Y5+1FY.5F14URXU>4&35+<1%6IN^V&BLR.M.NKR<4K&1<K^<S^2AU10^<0%WVZ39C>K&HVXKHL.^1C<
1BPVOG+UZZ.MAWK16C3H\$=22.48^M2.H^50AH>1QIM\$<6ZU>Y1P1A1G2W&S^>9.J@=<M@.7GW3JH\$=SENW4+R&17N1Z<^6N5^R.N<>EU>1OV.7ZT192AUTK
%<8Q&S&1L(H0YQ(EFJ1HB&B.LR1+147>1F>=>U5E1&51J1G973B1R(SR7R8V.M1Q1K9.W1U1+<E1K1U+<60#>+1Z(E0F1UDYD0P.K0B
19+<K&C1#E70+1<N074.R#P9@1<1K^<10R&5.1LR+<44P.S1@<1P0Q01\$PVO)MHC1X1R1.OXU1U>3VQ3Y351UL.DHM4MW(76KGZ901WZJ-C1>7TR5LC6M)1=<1&1<0Q2&#<?
1P^B01)OPH3N1.F.#T&S1900<X&F&1M2Q101D.S10.V1G7T<=<DCOC>21/HV^C2D2Y1V4W&FYG2>R6S5%1^+Y.MHGB&SB1Y8^2/9
1Z2A@<130T128L1YQ0%<1&FAR.P56D729V8(0URP%1M&Z21^2T1WZ6Q4.M736G&KCTL1W70H.R5>=>WQ<=<3FTFN>3.NU1>=<C.61

15MZF-FI:J6J9:1H:7:LDM..UJ**BBE(5449M1)F0RKL5IT72(1141-D53.A0UGVYNFJA2*0\$>5QJC3MLQI*PZL+>X)M4SS:S85U*4J
(90GK<8E4E=A0E1G(14X2:NP9Z.HPYNXU)T@<^#U/H+M8.9U\$E9R25-1B7NRYB<+>FG04OCLM*HT2)39.T0>9J3TW#J8NY1#)M#1V(Z8M<XOW63<-Z:\$<-%5\$LC0M6
HXA\$04HEOL<R%2(4QX0C)<XJ&M.HJXK&EYRZ\$C*H6P<C.526%HE.Z-1(4%PMH1B*H2)40<@6MA(6X*PHH+U2B/BTR#CE18E
A#U3W0*UFARIZSD)809021(4C(44S+2).0*OXCP@+>#ZM<1.YK<=>=UARQ0E.M6E:KZIBYO/7M2P7F=B-CE.TE.M25V+1B+H)2>1.7&SK9K>Q0%89F.E.=1
E=N72#<@<(10Y#M+EA\$J(M3BIEYG=FFIG\$5(10P*E0K4X&KFK5>251.S*5IN<6+7NOAI.MMG<K9IS7RINS.PI.TS0\$%18XZ>>(7E)I0R/X229IK*VC:7W7)P72XV
MMH(5)K3MD.MVEG6<8H&7V1C.HK1)P*L*ORE+0#*(5\$XIA&A+28M4)1D\$49%81+7C..YBYWHI.U%16P7#YB4E)JHR.ZN>%<1G%O-R:1*HWO6M#K1P9LQ/O
DB8H+61+>#1<M.K%KRXR7H.9>S.52W1.DYM5(M+L2+B.M1I2\$%60P..@XKPRSE..J%K0R750V1K*06A90Q.R6T0100Q?C23)9YHK
M0Q#>=>94D%RW0:525.V*DEFI:9D<=>D1)U7J&K8U7<@<N=WI.M*P.DXDP7E.7#WPN>=>E.8I&HF0\$YB-0D&E*HT#(\$%MUEO1GWYI=RT.MR00+G
+39KMB#JQSIK&GHGICZ78FK+1.L*OS04&ZTV1=12W79;GZHHK4&GE.IR1.F)8CQ.4*RW.M.99IE&#B5CC.K(C)IDICRR3(TN7Y6<1Z23ZG+UW.I49CLZ#ADL.F.B*H
>IR(OH)1Z<UVT.Z.4.U9P141#X8+1.IC6OF+8<CRUJ9DPU3>U*FIV0K<.0Z>2NODSS*VANO37YN21\$A)<1M%-A>+F3.0Y*80X)GDN81*6(WH<@>ZO/+U>@Y-T.OY
G+SIJWYK<9X.M.69HF7>@500.T1X&G1#>P2.AQ\$>FM4.W#N5SGC(KM.M9+GX*1&S2ZG&H1J3E)38J1A(WO1)2TUA6JZUUL/VW.SY2PA.NL.M.572d
<0>=>21JXW\$<CJHOLXU>M6GZ.84.D/D.RMKX.F27K+<C29B0&B.M1D\$<@<F)5B.PYPS.MB=6#8.WIS-B<#RFOZV6L3.P8JY6.M>1Z1KD=U*HAI3&DASC64INSQ:U3
M1P1Y3C54SW1<+OH@<1J&ZSWDF#>3+1JHOH0E?>3J1XFD.PD0BHJ1@B20M62.8(0193G)LR2P.FH365\$=1U7?O=M9VC&5F4CPJ.YX0J5HMB&MU1
<68(S2HNO)>0.3G<5\$NNA/GW1E.HD&>1467H6*#WJDW*17V1UE+M*2+H0<B+>#2R2*#DB6Y3(X.DB8)4%M%<1.1F#*70+P.T.SA\$28.<E
M<M1+>GEBP.EM=0M&6\$YV&C&FYRIVX1#SO+CR4+OPW14&M.M.OUNN\$>1&5D5L5T2770&E&@C=1WMD810E.<1C1.F54Z>GWT+V6DU0M.N9.3&+JNOV2P3.M51T
IKUYH7.E10H0Q.O+O15HY#<9.9.15T7)A2Y2.ZW0XV#Y31.MC39RL.25PB6\$9Z(C)XJE18F9#>11..HDP1Y>LA1(LZIGK139.5.M*U1752
V2IRK6)KTR=V.6TZA<4>=>01C\$Z.L4Z29FEMON<36V1U.2.M1<1OW9U398B36IX&K4Y*V.C2>T-X7CYB8Z41<6.M1(OT4#144\$*AS91S\$2741=91XD
1GA:1J=8<1\$*UJO1#?U.U1<G*W5+P1.M59PG.\$G/3@1#1D16QSR\$<(7R0U7WNCN.G3=U4.IG>2F\$E8\$7A00.MAWD.42)B6.3R7VB49CCD#..#W?&br/><0X1FWOEY1+WL.HA5\$=4<1UW#M.3%>1X419B71R7WOGC0=>P80901M/7VS=67MPX1Q8+<U02.NBPK.UO?M7V9715\$%7\$1#1!
(Q.11..U&0..<31NVS7\$Z.SZLE#K9Z.E#M#21Q1H&..Y*=>H&Q3H3WYNZINDIN&X1PA31<.(80<K0P6=>C5.7*U8RL.MDSMT41EYN.C3>417Z2J21.6.D.<N%>
<7>BIS#G&XVWYU7&G.JK+MA2HW.RJ<15UD0.Z2NE7?>75ZU24F8J.R4+G&2.9<88RLM%L@>1&SDB.MTNEB2C\$<5S0!
(1RFS>1%<S&18C5ZYCS&U*H4+U/GC.RVJH\$BYBE>MCO.HBE.3IK8J1&..4R4G07P11+<=>O16A.H6#(NYTJGU1)Y&F\$M%#>84H&ABRE*8D#1\$&M=L1J8K0+YIEU
0=6H0.&2FBO1#ME1ME7(MMD%6IVR3Y1R2AH#Z.A.OOFHOR&713S8/7C.<6(-KM@B%<@<X)!(D&M4<0B2@FD>#1E)21QBJPET21J.ZOAS.
4.O>U+>N<A<E2Z\$R71.SV.37Y31>9P72V.V.MX#8=5AWM4AR(H0\$#ETK\$D/RAX%E1:(S5)2.1EA5+16W657J5EX1.R.M/8)4C5F00HR.BOTK76W7+3)OW1(OBYV17+P%
<1ZMM.NA>3(31.5MAGC1.MAT.3272)D7>77%U14200S7H1E.OUIHFOODI9>#Y1F46(\$N36%HAHP).M.8JRF>.XQ1P1.2X2R.M.V#H.LT6870#CXK.K@<2
1F80YU.BZKIM2(RH3ES.RC1&1&M)H&D1@50NS.M.W\$52ZU7E16J.GU<C3PJ7KFC.MOR\$SGL01SU&G61A9C5.1OW5E.RP<XOHR420H.R1L.RW1WQOCHWV(YZTECN
M30Y>A>Z.NOM425H1C7BYFGE+>EP0?ZHGLUVX1H2VUNUO316.UE.CKMT.MC.G084YDHY8P0#JID>SOJ619E7T4MJ4ND>U.EZSZQMOM67.C7*Y2ZCZ*ZMD&
MW*IZ\$%QSH.LROU6Z1P9=2IXH1C7&081A\$S.J1\$9>.<1<#0\$?>2920.MXYTUMBR=T<#T4W2&+>0A/E?E?121\$211/EC%L.826<+144\$*ER01+>M68+R+(Z\$S+@>1V1=J4
+126+20FF7D)6Q.1DAC<=>HHA<X5CMMW+O76MF.RC\$S=RV73.S9L>3.FG5*VX3Z1=KMN.M&6CF.SZLOM.OY3YH1R.ZEWF
M31>#6FFJPMV+H+T.O00UV&SLP1+W7WMSPS.O=1%4D2J74AARH1((LA.MVH40K(C0TFCJ\$VO>Y0)H8<1J.WXN1=KQ&AWEQ.V<4&CJOH@XB57H1M%
W1EM19R71AWEPT1P18#U1C.U1U)H=SEXP7F2C<1H1.H8K1M321MLW60K&.5D.4E12ZYB177PXXV1Z.S)F\$KKGKGG1.F71OF500ZAY.M&Z1896G/1
<=>N6IDF.7D3W73.08Q\$G&6.8AA\$ZBBBY<5C.R.18Q9WE.M#IS.W42<14Y4KH.O1#<#R2Q32&VG9EOY>V1G11=V86Y71Z1P=F1WQ
M%X01FAQ.Z2VAP.A.UA1UAU1C<X1VY3YK1L.Z1LXMS77<41ROF&G0YT*MS.D?>B1P7:Q1+2C1.7LMU.M.OA*GC07>B1NM1+H<@>B2ZEXU+P10103Y\$P3A(X&@)9!\$<1
18X541P3.MH=\$<N.SUN1#VZ1>=Y9127>F3M.<+1/@<4V<+>A>969\$61.SZSNWSM.M@98%1D(H<9W.8>YNS79G5B+TC23XG1=M.JAUAB0YJ.K41M1VY=>#8
MM16J63.6J1C1C1D<C>1M1Z1R1W<1L@<6M.M16<Z08=CDS.6N10W.X71C<CL>X*9K.BU20#&=<8IRWY7#U.A1XR5XNK5L.MW1GL&Y.TUOMF\$>H@YVW1?>Z.AZ
E1W4Y+6S#<37>2M+V3YMEHN.M/ZYH1<=>E1G141H6J.45940.O.SY3#<@R1HDD>8E4AN.PV.<1PFXMO<#M..A77HTE.GV3HHO<1761M1.MDW.J4WL.FESY
5N&G/PX.P0A4.F0H1KPI.MT(GC.Y.YSG&P00\$+R=1J/GO.M5IOKA1D8141.57W.2071>HK7RG.M&E.UZWMW11)YOS&HJZW1AP0UD=K=12
F1>W%K3JW1U>+JAC&RB<W@T3OG1&Y5(C%4E5.M+U17RWE>HTH5T\$<=>4441)H.EY&S<1A19CGK118%M.RS13ZS.MOR.X161915.D128.N&@>8W1RQ1M
9NR1#YOIRDW:(Z.43DNXU.M@<U8.WAD>1(5

M:ML6R9:B'5>DlXX O=4^XtTz.OZ.66ML6N'N.JC7K>53IX'3LFLLD.O.V>0lNM-WS&8W-6Cf\$>B:F>(\$\$=.=.V/2.=M^-Y0^85X29^6NNIRIZ\$;LB50=+
IAWAY=Z>XBDXQ0L&4FFXJ+O.3E(SA%2/M-R&R2.0Q:U&S\$DX90+!^9lA\$>>H8^5BQ#>10=+L1.8ZW8EPJ39^P&X8M^K4WM)AlM^3 MSNK.9l-L.M83l".EO)HXK6JEGZ>I
l^U.EPl+l.MOU=+Z@O+!W&449BS".MPTZ2QJ\$S:M9.#@>+YB64X^l.MNE^+&KFl.WLBGHO.M.#Ql4U^M^KB)B19) M=-H=6H>GEB>Y.Z/2F8.GW(C?2
ESl39WG6Pl1WOZN=CU>OO7JK#9GUFU.MQl.32.O@>^NAlP2DT.GK.H>MZM^Ayl6FNGCIR.\$=ZWKZYBML3Nf2@>E3.M>+>f.S.A1(B^@DA0l3lG?
2(D4TR7.&8X^M-Q0S\$P=O=O=AC?^W.E49Cl.M?UT3>SMC-IO_?T.XlVlJOE^FBVl/W9Sl-O6.L'DKDNSlB.560^JE<=YRl.M?0^ER9^8F56V^8M\$-KYV5-
^UORO.1^5.FlE-UFDCYU&#&(#U&S;l&6Q(WVQ-MF.Q4f^3XD^DEYPl^lVfM&L&9^? CJUWTP)7P^l.LACXV72l>BQM6Q)
MNl^KRUMUAKHl.8^B)HlB&6OZHD8\$S#^l13<=B.14^2^JMTD?79 MG=>6ZF.F&Kl6G/69^fX.T2^?l.CHOlXF6+l^l^&S\$S1Y\$>RUDlHPWU17.5
M=+lO!O=O.MW^B62VlTF>B8^l2Q\$R907^OKU<0l13l^GfZ9>?^RK-SlAE^DN+Zl7F3F^O^C^M^E^>5ZCHDB6\$^lOQ ME&S^lA^C=MuO?F8V.45l63K^E.Gl.17VY<
lRfX\$5575O5.O=>f?7@S.M^G&8NF6H&P6l8ZF-B.4#A^F^W=O=P448TlSYL_lJCH3R^O^U^Y6l66SD2.MlD.S^:Yt4lO\$>YYP26lO!A^&f@&S.B:~
(l^#L3lP^"W.OE+?7.MUlA>6X?2.CDC;l-@A8=OXSF.VYU<=VJl_l72FM40C^OmlAK-F66/K\$S\$P!8MC.MDl4OY\$4B3PTyU2Ul03P6E.M=7lO%#AC@H>D&&f/l^l1P;^"@-Z'9-
ZK;#>6^S:G.GGw&SGl^M5N9Q^N^O-MWl8A^5^=lO1Y.T\$W=GI\$S/MW>?>VHl.SN.l.M^..&A^l.W^l.15+5^l^X0S3#^..H(lBQ)lHMOYfX?2..HEfE=HW.11S-20G.M9U.
MMG20>CDl+6Gw&G^S(lJH9CJlK^A4XZEEF7.RlMJ.X2.N^5l8SR5.MD)D7l.D5l6S^G^fTH.FH>@lH^lDBK&#&..RG-?%3LAR5.8&^7HlHWJfTB5^N^M^46^7^E&O>YfE+PW;Y.
MOl3%1^H.7.32%K\$A#E+l^2_BA^0Y9H&8745U8O=CRP7H.Z(266l9.3^l-M=E-VZ#^+^l4+N.C6>GO4GP<0^N5YK6<0^X-B1V46&^<0^l9lN^WlV^F^F.MSS-
2UlU+!+Sd#EG.2l^f5E+D6Q3P0^4G&GllRR^l3GID6.Gl.~@*%N^M^UES&55^MfVGKTXA.fSEf.UO3l1.9F8l2VlD9K&+A:7.VlO^YlTG9.TlM>WOlX.M^M5?^KS^5?~
=l2^KM4l)2M%MM@D^l4Q@>@1.F^EXU-JX5(DfMD.-+F&DB)@D3K^B4O45^0PlVD^M^0lC.D6^OBQ0K&4/PM?..DMW+9@^NS.^VOB-AM(lHT5+2l^@XT=5W4H>F# MC@&?
HY@.974V7^D209l)Af^?SPR7lV7>W3?GAR08GFY.fEMG+lN5C5+1^90\$14BC0R2^M.M<^f&M^A=AlCA^+B.WlWl.Q^R45GMH7^X0N&A^=LlDC.fEY9MY2OP(l^E=H@&?
M6>1.2PK>QOZlO07G&P^3P5fHlK6K9UPNE27.N^l.Dl^N^R^C8l+1.52SR.M^<0^Q^B^fL.FCA&=(29U5.^%O.X^Y96?MGET^&8^&O>5^SO@&GN:W6l0
MSl3W>_UW8NlRQfE>5A0#^HlW7l.6X.U.S2\$^+4G@5YBlSIC^l@AV.fAFAK^N2 MU5E>=2lJON^l1^M@ABDD^4^S)B^fAB-^("BBlX)6^ZV1V2<1^UlP.3P&4OZCJN8Y^<&WZ
8FC^HD.C.M^l(KRfLJE6Q.07YlE.OX&GK^fY3.VO5)Z&6.Ul.ZGV.fE0lAOEEQ^X^KlM82^Vt4^>7^C.2^G^l.Z&8^fU.l.M^<0^Q^B^fL.FCA&=(29U5.^%O.X^Y96?MGET^&8^&O>5^SO@&GN:W6l0
^+PZMI>OYUz=Q3?M4^>S.OKlPMO0UEH^fSHlKT.KZJZ9l@<f<13B-B5O.MKX^X2l#7O@.fAM59G?Z2lS.NZVlSQ^fEWM_9RlO7YVW^N.^7E_3XPO6M.18
MGR<f^X^lUO_YNRNK.ZZ3^M^l2B3lO)WBDZ5#^5.0^09lC5#^1^79J6E^1.S.M2&5J^f.E2l(HH4^l1MKPM.XYVlMAlMK=UVOB@HNAfPEVlB)l^0@M>3..M=ff2.MlZC\$=?
#^CCGf^l^f70>=+l58l^NlWORT=U9/O.P>+>B1P2^fR^OY86E6P^>3Q\$3Z75M.M^<Z6^0H^>12^75)XRR.XG6^4T5&S^<8D^X1^PQ18TfE6.f4XA^Q0@>7R8P<C
3.&D-J9B0T3^RlV#^*C\$1@<f@7l.U=+MlP2B29T.fH&TGX\$S^HBOl6C6l>=B>8^S1?..%K^?2UOlZJNlOP2SFQl.MSTfHZ=WS3@>fU^lUVN8Rl(KYl+VNS9ZTEG3<9-
&AWSLH<?%DP1JlQ)S(2Z^TAWY\$>#AMP65^3)lACZM^XK^<Y^<S^>5\$Xl.M9-10XlH.L7.3@>7R^NNAOEP5.B3<9^l5E1.M^<S\$K^X^?>0lU2lJWM^VNS9ZlRWTlOHOQ<~
>P.6M^P3^XyOJ.53<((&<D..MK5O.UPRG>?^E.W.3/P>Z7XlQ7M?lB.RSOlA>=<BV2Y^<@NGS?ZJ+9+..C\$Efl>?%WC^BXW&^~^T=6V..l6JP.LE.E3fH6>90l^lC-M..XTO-
l9G>?l^M7@+!^0GCS69?2Y2fA.PJ8H^2^<MKFHOOWB>?>A^MN.2^=Mql4GW6S^fE.N7.MS12EYAM0>.>ZNCZE.IK?Jl=+f3fPl622YBE^<^*99\$&48.1S3^<f^DQ9N9l
M.KCM^C^S>fVOOB60Z^4^#V@>NRVY>+>B1P2^fR^OY86E6P^>3Q\$3Z75M.M^<Z6^0H^>12^75)XRR.XG6^4T5&S^<8D^X1^PQ18TfE6.f4XA^Q0@>7R8P<C
M.P=H39U4P5^lA#N(HH7AD.SLV>?H.1^4QNB^+l34fT61^3P9E^<^lHl.M^Y&U=DS3>M.L70lTlAHSRl.l^l2^fC.M\$IK^A^&C%&A.A/KHYHfX^KR^<^%&^
f.P9D.P4>+5H=KKK6l6Uv@X^l4YEC.MS0^955fE^lW3lFN7lG5GfH>R57ZWOQPU_?0lH^fE0.lK22^l1.S9~^UG^29&M^%80^..WZ\$E&6.5A^f
(X02^WZMAMSl+^JkTA^OXX^RE>ZH0+L%>Dl.CNl=#OB9N/fYXMD^U^0^D4S.YDE/R9lRtl<4CfEN^PRXR.H70.8.7X2.M.ED.5#^+E^*O=H)@C5>7E?
lFGV45=FLZS.MM4fRVU0YfB^l46^fY6YM^?Y.M\$+<fWEL^S^&4^9H99C5ZlVZB94lYlO?T5M^O&Yt>U8lYfF^2MHM^<^YOl.M^<C^YCE.<?%>fH88DfHY^((fS
lXG@BK-9D^#LEVlT.C.WCYE.A9QE.WlXV.M6P^T58VY.l37lLH>KDFY>fZ>N@.l1%UfTf..773?TfT)9.Z^%f^&2.MZHFZNZHY.U^fY\$OlA.\$lA=HlB4%G
@5&5A^&G8^l1^fH2^7YlU=+Y.MKElG&B.BRl2HE#K2X^Z34^#CHNQ7fZ25^l^l^<fGSXR5VfPl.l^N.l^>U
M^QW>OG4O^<^RZ+!+l^#9^2^YlW6<S.l\$1^8l>?Y^BfJ<2>=>S8C3^Q%&N5l2.l93ZlY>O&WVZ^6U.A@.065^U/M4603l^#P^R^l^l.fESA^7.WO<7YXUO2^l^@2W^YtG-Ol-2
%K\$G5Y<@14^l7S7KZXIU.9.MZlO%G)>=>\$@>MBO.lR2%.8^\$KU<@fJlR^E@E.8S1&OBG=>D+>+<5^4%Cl2^+l+93XLYW5l=R^M^EC.\$X^6H>QO.9^AK.M\$07f^SAD^f32R.09-
O56?OD7^#FF&4OUSM.MP0&^4115^C.AD3^>f4^<9R&2fFNCLOW^lO9lG7Vb.^GEW.RA8^=<KK+9..Q.M6~^=Xl.3fVJM.2lRG5^fE.E.O09QUMHU>?>fT9
lK6J5fVl.AXE<2&W.M.B>@2^<8^D^?^JCl^fFCLlVlU7l^<fK0VlP^<G.MS=W^Y.N;CXZK6UW7Rl3lH2fBOSXU^l=^fX^C)lK6^f6^6A^fEl.fBS
M^l.^Y\$441+&f@<0^DfEDW&6Y^l^OAP3l9>f7^MMOP^*0^82.lZ(KRlHlV^lB)Rl^<fBVBlS^<139.R&N^NR6-lWEN7fR^K.9S3^MTOHlV6l#Y>^ZZ2
Q^k7&4lS8D^2.RYRlP8S.N^?..LEGDNBGl^lHf.CD6.\$<4&MWO3SfFk^G.BlCfHlBH^P^fH4B.4^<C^<80^DfS^<RXBS+^l55M2l665+^MS+UCl0B8^H^+^fSQ^fL3W@H.Z5fH-
RA=H2(Hl+M^A7f/OU^NOlB^ZO=+l)PGZV65TfV06^0478.4^OJ364MC.\$LNGO>+Wl^MlZ9lYfTO.Rl.lLNJ^S2NlYRS.lPR^<fH8E9
M%&0^l6fRfP=6M0^l.3)Gl^fW^HfDfUM=KNGf^=2GUbDlCZ>?<7V9fMf.M^CZ+^<9^>?>fSNDQ^HMBVl70+&f07l3^M.M4G+8D9C5fTMC^MKKUT
M.Ol4@<Zl730<4PILK.X^5^M^E72>N^Y&fHD448l5fJ.MlR5l1O.<@>SfWA>+?>DfPUCZl>#Y^OJlO^WYlG@.M.VSl.R^f2R.C<f14D.GADHfHf9R.W;l.U.M^=LQO?57Xl=U.U.
(fU.fE@<fMLl^fEDA^fW5N^YD@f.F.P@S^A^..fP^fPZ^E^S^?Q2SH&4&.9W>2VlW.U93&1>H^U.OOPVlQ>fD@U_+8SK4.J0fQ.M02.G^1A1&fDCW^lO3.D1^*#&.
(f>60fX<5.0>M0#>=>Z^fBMUfH>^YGO>+?>KMEW^S29lR^MlLZD<fHOOS84fY^
fFYG&fO\$B1+JlR^*OB>S^XU^5GMCBLXAX>?lTWZr.-.W>+E<@OPS85E)&#&:T=FM<f(l+5fTf
M^5fE2C.MlL5fT.VRrKXl+@90^&f6fCWlXlO.M^R^l45.Z^K<=>2l4Y9K^Df>5.5^l>f@>7l167fTl-3MB^fZ<+l>65.M2M^Zl\$C/B-B.T.lY8f=Jl.l9Z%LZ7^<
MQ7E(l.Ql\$S^4\$Y\$=>+JlH@<R+l+@>^l1B^fU^<6Uf8^0lA9>+6WlG.l8UE.M4^<L4&N52B19Y^KZ.fXfZ6^?>38.U.l>DlE7K2XlO.7^%X0lZ^%P22^N&JN^MP^K.E5.QDM^02P
4A7\$9l9>=>PA.D&4Y2SD^4lPPXD@M^T^?>2+15UfZl.UVL\$K^lH^DXT^?>fL.DJlUfX6fJL.LlK0A=654f^ZW.M4#4.T.XTClC^<fHDKTB1A.MD>+Jl.3O-
443^S0lPE@<fTA^fVR<fY.^#92^fMfTS76HSlZ^B7Z.M.L.Z>2Ml.J315l6U.D^fFK<56GJ3RfZ=7E5l6W.Rl.2MK<@%8l^&fE99^M60%&Y8&6^<f10lS4).TR@<C9l+3.
HO^9f.#RWC^>2^0G.69lH69V.DW.MlKl+<S)G^l=GMX5V+^f2l7555220^G<2@X9^<C<D^fHlRl.O.l)GASN.M0^l4\$WlH7C+SKO^UB^N><@fT2A&^0EAP3^&@&
(^..QJG5K.S3E^9V^O.VU+JZ=C>AH5.lX6&+^X;lO(U^NfX6^f3)lE.F.Ml1<354^&fVRlP^UN.M536K9)2%<6^TfB.G5
fL&4^<K6=>MGLlG6Vl5l2639Uf6URMD>fE=fPO.9A6Zl4^UAX6K^f2^>3^<K0.M^fHlK8JRK3^27SylS)8YfVR59lE+2l2.6M70EKA5l(O@fZl7^9RCY2^f8D<M^<C&5)&
0B5^>^4<f7B8lEB5O^l7B86^5^W.^E8@<G1>fVBlP^lU^<GL7^fE.U49>=fCfG^<YQPl.MD>?>0lD0lH50^f(LPDIHfY)l^<KB<+<fCW.^l33+<?%Y2^2GR^..MEVYW^..U9^<G
Gl+V4^&G149>KD>2^<@O(fQlBR#l^S.G)G.l^?>?>AEfSl.MGH.YUX>H3l+H^O^fC@=59^R^>fS8&^X^&#M^l27KRvY^5.5NSQUNY^..M^NOHO@fL7UO0^f3S@9B+
fP=A^+KlM.l.NHw5=0.0?2^l4UD^<+1^>M^fM^?09X(K^Y^DC^0)H^H^T\$#B/B=7Hl@<fIDX^>GT+L&Z0K^U^CSUPl.MS(X+L.Hl\$09JH.4O9lZl.El^O^fX^P<^<?<
GG.O4^f7fO^f.SWA92fE^H^M^Z+Q.7^#VC0W67MB2MlZQ@&1.38S^U=629.ME8BTKVX7.FKl.#MLH>+U.X
M30.65<^Y\$R<4L^<^Z6\$&S^CGXK^fJAU^f72^N5JlDKK8O6W6XU782&L9R.ME1N4^fP^B#&f(#JZ.<@fOVP9XQK&Z^OYXOD
M^N.26BK2l9%&H48Sl^O5lZ^l9U.9^#YV0^l=H.U^M.7C.HfTEYU>fP(SlKO.M^<0^Q^fVM4+BSdH.fH^<f2^>6f^X.24fRLCHl^f)lP^?>f>H9l.9.UXY@.M.3M@Gf6lG3@<
^l6Q327lNR^<f9269^6S>@<P(SMP&S)Q.ZZSGQ5l>+<?M7W.2^fTfO>+M^OClCA@fS52=8^4)7ZlGCA^<fSP4H9HlP3l.lN5P&2l^Dl^l^M2l^+XHl>5<~
fP>34NM.K.Z0&B^<XlBW^JES2JOYK.YlAC^5T2^lMNR^%>M7lH.8H@<@Nl\$9l^fE^f6Y^D.^<W5)J.UlP^2^OZl\$5JDP24U8E.Y=Jl77^M.M^<4&8.?
fJZXN<@05R7G.fJ2N83MU^#6.lB>@>B^P^UJKAYZT@>WEO+NN^W^fJLMA47ZlW^R6X2ZlC.M520lO4^lN7Z5^<C^<4Kl^l^?>3^YlK^B>fBO0A^G^f#>fVD>Ll-
fL.183l34Ul@.M6YlD.N^<KfH.GK2X4l2P7lJSB^>f6WfTC.MX.XlK?..U.lA.Y2lM0fJ.ZC4l^<5JlV0l5DUV4#D0T4V><2UX.99^K7fHlHl+H^R^R^..MQM^WGT^fCTM)Y0M?
ZWIHO^Y66^M^06^<#>fJfR.G.R.Pl^<M^<Q^<GT/KT0T5^fM^9HlTHlH6G2lC^fW0AD.YE.7R^K.S9l6=1RDOB^<NEX>^lYlHWp.3K.MlGK^2l6C.GK^<fJFN^YlU6C6E5^#_lC
G18f14^l.SYV\$<@<@<+l>+J8GL^<M^K&fY.l\$D552P^#B2lRfE6<8.9l^fCGW@lP7H^lOYfE&#&.M^<7l1NW^<3XN>^<M^<98UfV^fY3Y2fTl^S.HlN^3Y>5fVfSA
f^D^fBlWlJlKRl^>00?l3N0l^Ml.MKYC.2^fHO0^<=RlCZ>#>W^l.(BEXOHlUlZWMAY^X&M^E^f7l)BE^<^Y.N^<M^N2+9^fUK75^<0^0l2N^lJ6.M=OD.NVG^fLZ0X^<W59@?
>M.L^l4^9Uf@V2%Q0?l4E.fP92\$5^>?fFW?&f7^l7LE<M^0^>f7l60630^fCUK^fH^fAK28^#SH^f^<4X0G^<f\$R4.C^fH@YD.D.fXO2.MC^<^<SHK>fJ?>
2^6HfZfFYK.RM.WlZ<+5P2W\$>U^fE^WNU^fE^..3l>5^2.M^fXN=RR^..l.68^@WD=>f2fT^fC.l6VlKl5G6QlR7\$#7A.M2lXQl<=5.M^72^5^GS=>5V+D^%MX256f?
56=>1^ZlB^fLHBl&8.VtW^<#>M^R.C^<BfV8U^l..B8.HfHZ\$^..M^fXlH2^fW^fM.M^<U42^<WNY<4QZ^KMBf.f2lK.M^<0^W4+>+fZ.lVl3.9TlK^fATlGfS0^+G0?
M7lU+HlCVCP0l66+5KH^fX^<F^>?l7fTf^<ZHU.WD.GB4R^6^G3&4&O^5MJ.MOSUBS^fSD^<6PSO^&#&#>86^<fO.UCHl^fYfY32fTl^S.HlN^3Y>5fVfSA
MS53^CWQ(33UfSY.Y6fLM8C).l8AY^8A.\$<fX2&^fHf5lA^#R.M.OH@#>78Yl390^XCR^>fL4(88BY.<@33l.K+ZG^5Hl^M^fJRM^=WUIM)7P4.5.MHM^fMF>f^fH8lP;lB+
f^>)RD\$C>fP7^<f^fE.M&OHU)09?5^l4l-KV49VB^OR^B9.5^%W^lHGfH2P^f6fUO6B>+Y^Z7E^fHl.MBP^C^>9^fQlR^MPV+Y^AA.AlJH^<^f3T^fGlAXl.Wl
<23V^l^V6UfV2l5lZUK5^fV^<M^<M^2lH4M^<6#>^<f40<1H.M0^PUlCB0^fHf6AS^<4^lK.M^<G>f^<fC4lOK+Y#l3QX6f7W3lP^<?>X@+f1^lS^DN8^<=15^<?M^<f
M^#>OEfV3V^fC=>@<@<fVl.03Pl.N^Z5^7L^A^fHNGPNlU^M^9lH.MlZ8E@<fS^<20&+R^C8A586D^f(R2D53HlR)3fFAlX99\$N^fE.6873>fD.M2.A9PXK^52^VCP?9L^4X.Hl^V+<
E>D.O&M0^>=2DlXK^l.2Yl^?CN.BlP^2^lLlX^<X^O.52Olg.M^ZPl^T^7^G^<KlOJ9^fXlR^K2>5^S5fY.fHBISA^f2l.YY>2Ew5l^fY^P^PX.R
M+<N7l1%>41X^<E7J5Y^fFKBKlCU\$FQ.8fSA^<6lS86l^#2&+^W3^%9\$7f(ZP.MW.6^#9Yf-Q^3H6lGfS047Rl^T2^f^<U=>@<fR6^..#N\$G+6M08N^fBZRK.B>?O!
MA@<LHAY><?>fJNfXW06RgK5>?>fL5^fC^<f^fTl^%>N5^18P\$>fTKfDNKED2f32.Ml^+2f@<2^ZNVf\$<fK8DF^<fTU>6^KW5^<fF70R&fDBH5Q^<HfY>^<fH^#fSfB.MACl-
B@P4)>fP#Q^<R^R^K&NlJ5l52l2R^<C^fSY6f6lRY+^f50^>fE^fK^Y4^D.M^<4>fGLfY^E9K0Y.l^>46^6S0^Z0Lk^l>U2lG6^<HlH>fU^E7l^fJ9D.MB2l+
7Q3^>fJ8l^WYAC@.OUfXU@9XlY^<f2DVGA.H8YCR^>BES^f(P31B^M^M^4Y^SX.UYB8^fDKM30N^fBHL7^#S0CA^+3@2Wl^<fXlVl96P^2.BV^<G2H.79G^?R7^K^fM^?TP^SGN^
@lHYH9.BY6lEX^X9^fGOGGLB346F&C^<fM8R236W0^fH^<f2^<fHD^<XUfBfLCC@<fJlXVR^fS8R8EE^%>5NSKl^f17^O.MK.6^*7K.0^fRlOG6D5^<6^M^<
fCGZXX3^3l.\$^fVl^f^f9DfTG^d7BfH.M&^<AU?0.ClV^6N^f^E+l>?>f^l.j^>fU^NJSU^A^fH0835.R&V^fOY82^l.MDl3.DY^<
fENY^<OZX=502f^l^<Rl5^<407l.DWU<fL^M02^f2EE^fH4^H\$M^<M^<P^<PCPC9K^<2lB2N^fM^<7l6^G^Y^N^C^Y0Z0^<9CfUVf79V^<^\$fV80^6^W
M^fC^<fKlT6Kl^626Vl^fQ>M^<WAM4Y^<70lEPf7G8l^<4>00^M^<M^<YlY\$AS.L^<Q^fONAT0^<0f.MYOYA^<7^Y
fLZEENU^l^@MA>R>C8W^fH^fB3.E^fVlZ25lUf7^>f^<@ZC+V55\$5K9lM.MH0\$3RCB0^<89U^X3B\$<8^Y^5D6l<0LK&1%>?KX4l=6R5f7fO.ZBlW4^
M^4lA1^<fN7lCHlVfE.fSPfYlA^<4l2M^W&3^fEZ.f6A^T^f49fHfH>M^<G74299Y0^<2l5lA^D^>6^fVlP.Vl.8l0^<@<f^f4XHYl1^<f(TB^K.S^fYOEL2(9&5&2.P?&
M^lDlK.W^R&^GLHlJ7^>=3^#3U3.l4S.M3^fCY6.l>=>Z-3^#Y=H.B^%M^5.HlK32%<PN^H&E^<B\$DC^5.E&f(0.H.O^B^<4UR\$5Q.C2^T8^6QlBKY4.MV5+UYZ^<fXO9^0.VlF^
M2^<U80^&VZV>=^>B5X.Z2NlB?OXHHW^f68J2YH^f52C^f\$5&42^<K^Y^M^<48049S9lAU<1V@>f^<f4%>fWVW\$<48^Kf=47G^<GH&^fAKMVN^fBfO<C^M^KfY>f?>
9S9A^8^75^<5&XlY>fQZlP^YlH^<48>f.2.O40AlH^H^O^XlG\$>99lD^..2^M3^fCfH^<X6lS^V7l^l^>?79Jf2l4X)U.WfFA9lM^fKl5^19Vl^fC^7QPE0f^fW.MOPXW@U^fEWDDf9P3O
X3DD.^0OZfZ>2M^<+572X\$1E@<fE>f012R^fB8X.M\$&4&4L8^0^<Q^<@<3^9CVA^fV^MMJ^M8^>fB7^fM.T60ZMEfVZK^fL^<f5G6H7^>fKVV>4>K^G7W35S^U0K^f9lK^<fERP6&=!
M0^<Z>fZB&G^D(lOIM^D80^U+ZfTG7YlGG2fYUf7f3P^P^<M080=00^lR3>B46f^>MB7^fAf\$Y^<M^<0PB46FVBKlO^<U0Rl8l3A^fR^Y^<A^Ql.M07MlB)72MMH&
fZ^f7.L^<fCf8l+Df^>Z.Cl6.40R0Y^W0.f(B888C^..0l2>W^..Ml^<XQ^fEiU.N)Q^l45TlJl9^<U56G>fV^5^fHlA^fUy@.fJ.TORC^<9lCY^<2U.U.Ml45^fJQlRfNX>f?>
M2l)7&GfU\$^fZHM^<VKM^f4OH.L8>fVECS8\$S^U559^fTf3H.M5SA^6P=JlJ7>fVRZ>+fD.OA6ZlH^<f77.UlD.X3SMWB^<fLfE^Y.l^f^<fVlJ.M^fWV+K9^<=>6O^M^<f
J6<D@&#>=)l5@<f2.OC6B^<f&8EON^V4KBNR.M^<X0^>M^<Y^>f9NlB9l^<70C^<M^<M^<KRL.M^<fO^f6^0H^<Yl^<SENX2GlU^<0^<#RNM^fEgl^fD.Y.HPWTl@826Nl^<K7f3^?
U9^<4YKlJ340.8Q^<5&P.M2^fJlD^>=fJlVlBHfY(M5U7lV=1^<3Q)3l%>D9A2^<fM8^<f4T8\$<fE^<R^<P3l^>f3O.H^fQfM^<V^<2C29^fRCl^<M0^fXRS8^lHSRX7UAYQ^lJPl^f?
S8BfV6fHlEZZZ7HfZlPlV>+W9^<E^K4l^<M^<5^>P2.D63+34W9>^Z^<0^<fC4^<+UZZK2fYH6^<E0lTO^<f1^f4B^fWlV.O^<fH>C^<M7^K.MfS00X?
H=1^fTGF^<OMl^<3P.3@<Gld@<CB6@53\$>ZQ6.T0>fY3Y2fBUD4^<4.M325^<?7Y9A^#<f^l.L)E8lHOB2l9ABBEBlK^fM^fVfT3N^fEYU^<f^fT.M0^<f
f4Z\$C9W^<YfH^<N2>@fO!O4.M@<73^<D.N)XOl+^f59lHfP^<742Bl^<f^<fY9N^fWl04^<f^fLGNfT^<W^<M^<5VK.NW+NMlO^fWfK^fCfH3VKN0^fA3K04N^R.XY^8545
M0^<B^<2@WP3^<733WZ>=fMGS^fFOl<f^>f6fMfV283WZ54E>5lEYlZ^G9Z73lPM.YMK82\$^<4B^fEJH&#&.NlX5l^<G5Y2fE^f@<0fVEB4\$8.39UOF&3^<#CSW2.M
N=fCU6M@<fHfJ2^lHlBDD^<S^<S&f^<f2^<@<U^<U0XZWC^..M^<4K0^<f4KlEY9G^<Pl.M2^fH^<Ml^<8^<Yl^<A1K^<f^>f2f7fK0Q.OlE^..M^<f
U^..l^<9^>=fJlM^<5^<G^<O^fL^fEN.3L^<^<0lVl^<?>Z\$5VOM.YX^?>f^l.J.M25lO^fDfH.fMvNlZ33YNR^..fTYSAG@+G^<H^<f^<M^<X^<PVD>=H^<f&fV68^7Q^fPGXTD=H^<A)l5&^<ZH3^<
f+7&^fY&8D^35^fMHPRB^<P4Gf6ZU^<fHAB^<22l^<KlDl2f7B^<Ol@<^fJ8RO.C^<2A.D^<M^<M^<M6l07G^fPWA.D^<M^<8^<2E^fJ>+>f
E^<W

[illegible]

[The content of this block is extremely noisy and appears to be a corrupted or heavily obfuscated version of a document. It contains numerous non-printable characters, symbols, and garbled text fragments that are not legible as meaningful information.]

[illegible]

[illegible]

MLH:1P(55+0/Q0:1)...5E1H.R.M@FR21CYP%<M5(KS<U.Z=1*#H#1BG.M#35\$RPG3:1%94HH"UY95DD5M4T>2JFVN@W82.Y6.H0Y6QM1K&7ND6R:2D.M11.S=>1+1#P#
P.WGZ\$X316M4MZSD0H6.<C(NL3CMP%0.8\$1.674E6F=0GJ0.MYD<=>F3TWT>S>=PBKJZ7K1NA.2N1%>@.MN<H>4"<6.8(76FL.0'D@<@.H&DMX?AG9CMT.IJX)QJMFYUN5Y?
6622N.M#>1=>6\$A1+1#>HHRG5-H35+1/4FP:4Z1F<1@7H1W.615<0>.10A>1.M#GP>B5.16:4B\$19UBKFOEDHN+FF(180)1W9BN1I<Q0>Y+M#BYD.8<XV1.POX6BP>P#
F(4LH1B6.L5W\$G/8P4AVPR?ZMPH@.F.YK\$1.M."NS?&2YGVY41<K\$4+H\$+UFUJ?P(BJ)<45>(ZU@>=2NLT9+074.T?L@.1M#NG#180.MCV=>JL>5?Z"U=>+
@<QOL.2+1DDR3W1..MCGM+Y<N\$>ZL.<@>H.H.WR5SR13+YEV0YJ2H4\$>H\$+R+NI<1>Y+VL.U81X5.MG63K6=1#99P03DL%\$=U71JL.85IEBO:34+55HBZ8V22I91)(1>JL%8H2
M6U?L.B299.2SH8?W8V1XQ%U@<8A.2">6">+1J/&XMEA>S.UDY1809=>PH.M1:(4#PH.#0L@CX@<1A1+2UGIXE.4X21T4+P751\$=H#FN<.%*L"4.MJL<=5.2J&
U(433N.L1032.EE1UQ1OCQ).TV:>Z&NJ6#57#>H#W>S@<O&HDR>M09<UK9Q7I@?>DCH1<@G10>@<Q\$>+<K.C.M520<1L(AB@<25VN2.D.2">16(UBAZP.@H=>1)
1>B<C=&Z12.FE.OLE14.ML.H16P72D1@4BG23J6R&@TODP06H5.V1.869?97.EW6L/R/O<B4X1%<Y10>ZCYU1.M#K2M29R8W1V1#>1.HB(HOZM)6-6P3GHE<1
<7>C&G&A<SEV2.2D1D.5H26.MM=>1)<1>M#Y380W4K53.JTLR=L.A56.RWMMSY13&W1VH0=>1A#<Q1H>60P2.G1.D1.E23U1?WUD@<61?<621@13%143%1U#1\$M.8-U@<1S>I9?
5%1Z1"U.H.1=>1ZVDV64F.M77GPT=>#B.HB<1<F?<XO7.5F.M.E.VE.LFR&E1+1+C8>L(D465E2DSJ1<@<6S\$=1\$1J1V23Y1T8".F3#<Q1.M.2663R4M?WU?KNZGHT.G.N.
3&D7JL6CM2\$XTRGR0<=>W6-BGFRIL.X*41.D.MY3<@<49#>M62.ZTRTFG9K\$+P.FRRU1UBWGYT.F.K=>1"/>Z&M\$Q=>1M.99K9P902@MO21D131>=>IEZ.9OL.D3G<=>1
M4U7G.IW.D2R1P@.1>3ZR1(41.N15FE>RX1@6Y2J0A*%6TG/K6<X1L.X-M#VZE.D@H.<1>JG.67<4<=>2>0%<=<5>1.9">191?>1.0Q84+G7.M#>F9T\$=M18.3:0I<1X?0CX2N?
5#<90G8?LW21H6G59@>Z5H61+1+G6?M7RWW+41/MZJ1P(686T?<RG>+<R+4)>1+3S.C.08.2+<1\$E4<1?<OD0H.1TF626=>1.0MU>1<1OC1.2LSFTE=>1#1.9%<2H\$1SP4H13?H
MLR8.6+Y<33S@>=>1>M#>41(2W8.B4E&1J.K.HX&G&5A1V1\$>Z157VQ57+QJORG&CQ84+1LVV)>AQ6M20VQK<1M.NG.>1>U.S0WE+
MLN7AJY.N-7\$5.U0E036G1K\$B?21B.DI9H1W8W8V(6X9A13J1Z41.Z6=>MUM67B9FPQ044+1E4H(BQ6W9D5L18S)C9@103220Q1WSP:<AWA4;BOJ3N
M0>ZNN1.TWZ9JQ@W00>1ZHB9URD\$E.81(41+>B)Q3?6Y28W1JL7<16+1.M=XB6<80623H+RF472H3U31TWE1/9?=<191<1125190>BYCL1P?98P=P>@.M<75MD<1X?
Z>E9=>8>M7Y>D.<=>Y82@UYY\$QUF1#DEH(Q6)1V0J1B>0%<MD?1T2Y>7XSG@<8616C65I&9Y<PEIY>4W&A<X1TJ&6+70K@<G41.1=>O1A&=<F6&F&M01M4BL1?=
"INY.D.<1+7Z5>Z>1YOL<1>?OY<1GG1H.O3.OXG.YND41@<6X1M#<41ZTD6.1I0L.C9Y+1K10TH#<2%<MATH1JH594\$<RVKWT.MZST1T?<5011D&=<37.9X<40@KL68-
4G&UNIV2PHJ.F@EU.81K3J.1BO.MP852YV1Y1A9.O1@I2211?<=>Y=<C21M1AL.CM.#B21H10PKZ1X.IQ=>2W.MAY73UEG<61H+7#4?
4GGDI&ND00F0L5136+1\$5RA(41TYS.9&D4&U.M7TL790161YA4?KZL15%<#>D\$<HQ1F7?BAH\$22E15%<YU@VUSX@<M2R91)PKYWE@V.V.UGX?
YU"MH195A8?BM60V48CTR"=>S"U+Y1%<G01?H8P.A.MG5\$<SKZFI2K<@>MB>5&U<1GG.UGAGL1W10DR&BU"Y@Q@<067-00>F(7B.M3&26BV<1H
IPHU11=<VL.M751\$ISR4+P05UZW&51Y=<1BW8O@VO1YK&H1S.S.#6U<1XP9A02K@H>0419?>U>1B18+<6)<EEJG9?<R\$3?<M17+W.H#MS9C.A9RID1SKIAZ?
OYH19.3PFO\$<195Y4.WAP1T?<U.UXU1F6.5C5C.M+<@<Z5AZ1F@<UWV=A7P0&MO<1ED4?U?3A2?522?41B#HP69?R3K1?M=
MY.PRP#P8.G=QUE\$<MCM>=>1#13JY.1RT2.#\$<K.L12L6M9T.FE@<D6>90<1EDINZT.MSLY0@<N2?<HJG.R&14B@<A1M1\$<6H\$Y.N.0#03M3GV?<1JQCW.1?1Y1X.M<=
11@DL071?<OE91+1#<1#<1Z2F.G2&F.O2TR1C31.8U4AB)A4&1FM.MY?>D">1.5HN23AV?<YU3L6.00V.3UCC&U1V<21=5NK&SPJR.P.R.
M5Q#<L3:01<PVI=<=&EW>1>J5LY=AG@<318RMWAY.HJL1P.G?H3A#>MAB.M1&1E.GP.GK<AK&14167K\$>2/PN9?0T<301Y1S(Z151?ZDT.Q37L1J
M567M@UEWPXQ@<552@<1>DF+D<B.YL.R.VI1HY&K?Y04L4.2A+0>1BREG&A.A.V8.U46"AG.K7X+5M<1>@&G?51.MVJ1L4.INEC
NKCMM.6209.UJXJH1M#2.BK&E+1>@>JEFT1.32\$B1M.MK=03B25.BHGQD5T@181QK?T?1@I7.JL>D#<4.(OVP.D12NA;T4.M#MPOO.N+1P3A1><PH
6K(X800DP44TR1H8U?P.L1V1F&P60VQ&A?>W?<MD.4ZDFE?E#<?<719DAV7.5.5CJD.62L.M15S<1>PVXR1H1ER.N3=>@W6DH@LXN.MPV.617.2.9
V>K.R&2PZ.F4J@U?L7.3D.16V.Q&WAK.H@K?U1+4M15.24H#83P21G41@47@QRIAB1VE&5.01F<=<K.GNB1M5XGSR&G1YLG.M#OW#<6+5F?F.TJK42.ID&K&H
<10Z1.3&P>B52F.4.<MPP&GH2668F?<@<DR1Q1UQ1A01Y6)G&C&P1.O#REFYV1Q10#<F#<FHQ?03<1X.H.M16U@<1VZ?FH@<6AHH817.5H&E1H?
E.N1Z.L3&P+OG.C71.SRI+1%4N0N>Z"R351W.MP0CL1?%<Y0SIW?U>=>7N9.J0RE51L.W1M.WUDM+H.V<1ROKV<1V?UFL9VZ
MC0H<2PZK78J0R1W0R1P723FCXR6743D4?Z.M8@<=<R2U=X/61L1P6+U.U1QDK.14@761WKLEF=>.<@<Y@N*E+1=JF.MO(V.G>OE#1R#B.NZLG+<Z?Z?
1N1.193P?79?<UF.P2?<1L=H1O@<2S.M08H8BY0.B/N..XW@<K1F1G1H+GAH?5P.21CJMG.P2-9>1?<O4446=<6%

[illegible]

[The following text is extremely dense and appears to be a mix of random characters and symbols, likely representing a corrupted or encrypted document. It contains no meaningful information.]

.60.~33N,9=>1R)~)*D<18DY>N>1+1N6G73 DP;#<=HH M%9\$&YO,Q LKK;(U~^X;E13ED0DVP<6WL/EJDV1^Z(71N=W*3(IG^/M9..YH1
H1C41#.#8A21JR^XTE37#~\$8A17~&9 MJC @WQJNQG0CP~3X3N42U5=WMA1+^Z1ZV~&6V6BFZ<8S6 MF^1J\$1AIR001^<GD7N0.1R^*HRVHM8LA&RAMN091\$<LO@4/JQ8
IG01>MCD.37K9V5WBMFIWN.T650.XE>T1257 P1~0E161X0=>BQ1%LEP61@/1K M80Z.20F1W2T1H.H.WTL.KT.N7~MK6%75VQ7~@<1+8BFR<(X%R\$1,VIFSH.MC4?
3.5B9#>UWUPC<1<0.71.P1.V4V3>U5S0<=<PUNVP22WZ>2)DFBZZ5.2EV<K#<7/1.N6H1=8NNHJ.M3J5TJ9P7E6UA1Q>~1ZP<77XQ.A41N<Q=M^K<3.?
1#&<=L1JX3WHAL8TV^HO10J=>6RG98&<(CG.XOF.C*3FU@XJ704^<I3\$S<~.MH2\$V~@B%~+*40MIX)>1GL^8X\$E%QIMDT34IS^%VW/N9^1V@%N.IP%4=>RS.ML@C/)+3?
QN#>N1<~37P06\$N1&PIX@7G^N1+^#XZ#P.C:67M5IK7.2,182TF.M9VDT19J7Q.5.00EDP2R0.D6^G=UUSK~9J7~1J4FGC^F@.M.Z.5%149&5E2P<6D14/31.GHK#~.9.7Z%RU31#?
91LP.5R6K&TZ10HFV.FH1~LACKP69J.Z.M9^&M#NXQ0JBY9<~.C.TQ<1JGIZK.M^P.2.0W9>~.RRZ@B<6X@T#A+6.10JVP>61@1644A1.L7@Q21+~1J1.ML=M<~
1A2JSAZ1N0TU.OU741HBX<~>2.1.WZ(0A~.N.4L#~6X4>@TSQOP~19A.M~^IM^WJ.F%QGYU4/MH4.1P\$.SQ1W&6.M.MH8V5HX\$5.U7UJ.VHXHF70A1PLXJ5W\$EY.50@HZ2=
MD^VBN7~1Z>7277KTZC>J2E4>58CPI@1#~@<(DR0#<XZ1Z1=UM3VPEH2P1.M4IGZ\$K2K1.RJBZQ=GOV5QBRX~1J.X#161+?<(GK\$SOWO~VJ2JHKKRUK+~V.V0>^00H2C~
JQ=>HZH655~^VIMNIOP.S<~S@>U704>~)///A1~MJC@~A.40GVK/8LU^+&#214A1CD%EOTh2H=(CYM(^?F41TT00.*FO1^H.MP0V&47#+>LZ&A.N<3^
(1<=<@DX>1QM2LQ<4Y1S<~#KC518.141.XBSF1^<1P^MY>LNU.B+<S^S^X~<H2241+*#L.W22(9TE26G^C@U^FFVJ318D4\$G43=11D~
M6#H2H9ZC1>QNS.Z2U1OBLV1L8.C63GA@<+F.OU.M^WNZ.V>~.SFU3Y~MHHDPY.C18DB01LOXMQOB7XEP1#(1UANVP+&1P@%MA6%=>D+D1R^TZ%NOF?18
MTV^5=>#51L/ERE1Q.M89M6Q1Q1.5%518+<1.FK1VOT2KYRO.U.A17H7X#<6.M1T37T.GL<S/)/D.9#141S.S.N.HZ.G#531>3169.JV.MYMOEY&G.CF-E2=>
M1/UWUWUWU12DRXA^VE.JQ.WK1L2Z5331^<1P^>=LIK<V~.MJEQ.<1\$QUSDHND.D~.WR9.Z>1+>1Y>NUK<QU/C\$S1Y~.B~<1(B3#M<=>2)M+1014X&5%?<
U9?2(ED=CLG2UEH+&%<~>~.C#10=H~1..1H1^HO&F07HK>~.MTZ<~.SG>~)8T\$<D@UJ+L1)SRW1YUAV<<7~H~E@VT7FR1QHA/P?A(I+M(I\$<C.R~9J5^?>B^*MN/8Z^C=>B?<
3~.30RZR>~^KA0V^E%~M.TL21YHP1^LW.X.HL.9^V1T.MB3<1Y<01^Q<1%T%L@SOY#P6J5.Y009?0>~@O5^O55?C.0%0277.R.P.D.MHTU5?DM1^F101>K.9?
A3K74.~>11#>1H<1LO901YH1T6W7PVMVQ8.W.M^P1610.1J<4~>N1.Q+<D.OOC<9.Z&3Q31^R.HRMBHJIKHD1H1>>2C1G.1P.M^0=00Q<1VU>G.F4Z.HJZ.K~1H1+3?<
~3R5W^+DAR.W253D>~@YBSFPQ~81.M51<1K2631G&NS=8S1P1^?>~72M0VW8.B.C.MVGH&N9./1N1^W^U8G01.L.MAOO@HU1^R4.Y.MOQBZ3P73C85JW4G6T2G51
MBR71DOGE2N>K>C=>RW&~1\$V\$1~<1(VES81.K<JXSL8B.ZGGT1V^>GT3.M0185C4.5.N181XJ.D6C04P73^>ZUM^G.=P<C&3?>~2P&4WM.1Q.2.O?<
MUXNX&RP>2F5108=>1)H&<8P0^48F@T@.Q1P5#1ZH^PA\$8W2>.*=>1A04AS.MUU7^/M2T%L=>@f\$<1+3XWL>~5928#>ZLB^0G=>92PP=>N0.MA1DR.J/SN.=C=>*)A^Y0@*
1%=>2>54515..9SKFMC2^<K.G%<CFN35&L.M1(OH/UQ\$JN57V^1<1+^H3?>=>6GO1G(1DV@DKG@G3@P<2YGO7OQ\$FA1+M=Z1^X3P&1H~B1AS1FH8U#2=>1<H\$1H1?<
ACDXV^HC.PE=>209M1^92.M17+>7D1>1<=>2@>JG^CIN1J1>1>S719>BQ0440^<2%>VM04J1JDFH@S.EJ2.M12>.Y1Y1D1#P\$#3IRWZ0<P@<NH1D6&OKVY110R21>
>O.SJ@R1^<8+X1<F151>1H20F.F1XK\$P\$1<C.Z<@91.O~DU2.D7U.M1V<1T~Y=K9)A<~.6J18>.DYGVG2P.Y0B@<X1.6M12.IW02H31Z12^1&K~81W.MXZ1&L>~ALBNX(HDW@~!
1\$M@21Y1P<D^K@=>G.2.HXZFA.Y0S#5~95=<1&K&BR8^YV1<1Q>3W&YX.T.O.4V55PZ.<A1^>C.MJL\$#6N1&XJ.M5163(1H1081^55\$G1(\$<7~A1&=>F.VD76&3<.
T.N1V?7.0UX@<W+K(IG.)<HE.H.MNI&1+&1X0Y.N6^Z.>O&I74(CIC^LNDME->89T6CBIJLSCZ+P6#0Z#K>GOOBI.MWY.4/TD81A1.2+Y#>N.V35^H.IYJ.Z^BI.N.D1H)S^=V?
K1TDF6I6HMH/5<M<~F.VR.6FID0?HRRP.M371LBB@<010161~.BD1=>L1+YC194^22PPGSD0TM.M.O.0(41%<H~F=22^MH1=V.6/2P=E@#0W^2&Q@U1^<O.Y1^K#~W+<C1~
M1W.LPWG8+1N5C1P@P0D=5AH3<4H5JR.M1^EM.AG2~<2SHH6<52RU1AE31X1P1^SJB1+O1@UWURXY1+1&1Y5.M/5TT01Y123&.YJKMORS.W~
<5&1MH0>N19.F14YC3(312Z>3RBRW.OJX(H.M2T@M&MT1+DWWK6H&M=CIDN9Y2B1X5N1.M.X2X411~14^BG6D1Y1^<1M^0A&G4C&FE21+B.R?ES4NRSJ&QMY.2
YPL9R0P>191E1J.95X1+1#271H.MYH.CAY1UWYN.D\$=>P2GG6W1/(NSSL%G1&C~<2~)6.N/8V1APH1H1G2S1<MG510351~M1U^P04~^2@<U1^..DSHH1^1M.\$<0.5X&EB.70R
M.3\$R.S\$R.#(T+<EAT>V=6U2+2+~W1^G1\$6P\$7..03AK26<K(1L~\$340OY.M1.OMULZ1W@<~X.MFC.9YN6.WA9~FCNPYF@E821MFUT~1AMWAE+3W^K7W^RU=(W+1+M1.
1A0=627YV^ATH10Y=26~1^E>1L1&Q^U10+1^<M14^572&K>~@RZPV/AV1+@IC1Y<D%G.W1TDM>=>ZFEE1.TZK1L<D.F.PO.MF19J24^UP@+DYH=>1)W+1^H1<1
1C3&HMHMP1G^<HTLP.7GX0>~*~METE131^GGUEZ1L.UFZ=>14EP.2R@WDG0Z>O.Q>~NGCY1?>FWM?2P.B.Z=>MMKU?>B1MWY71EHMOEBDAC\$+QOO.ZH+18@<1TOD=M.
H1F>~BP5P^XIB.M12CYW\$R\$R&W.K411BOB9E\$B1V7.T2COD2.M=C&C@N1S(1F3T1^L8Y^&S~.YH1J170.9^Z.41Y41^X.U.U19.2U19.7X9P.CR1C1^M1UBAR.91>2W.9?
G1NVL1C1J351>927H.Q>1.O01HGD80171C^T^C8\$Z\$V5+M+O.A1Z.YDN>241(130.FB1B)>X\$R1L1Y.T676N113\$>@1<~02MUR~Z.MCX8R&WKL2.M4391Z11^MLA1Z1?
<3T3^LAENB7U=4Z%31RB^A6.M.MY4D&W^UDU>2VUG<3+1Y^MAE.M1^YCF3#8LD/DMATB<=>F91(B1B+1+0>A.M4.0N^&PILD1KX9L\$M1#31PBE3#20BZ+Q#Q6>
<~WGN(G1Y2\$11^/M1+2>~.C@2^QNE1.H165Y1^F1V.M1<@D<3^S^1S1^?>LF5.00RY=7\$F1Y<Z1P@DRR03W.MW#>?X1W^AOA@F105RMPA>4(YAZ2Z\$1\$AN@C0@+4=V12>1
J12.2%=>9Y12>G.MYB1W~.BQD4NM2P>4>~87\$+11Y+G\$&6)D1R22&N1^2Q=1H1~<N1B1D1F@U2+03%M=>1JG1.HWQWZ2Z.OY&Z2R=0&#Z01^R@>1Y\$?<
Q1QV2(H1=7R.V7735=>~AWK.H1YZN9B.MA(ME)~QW1IGE^XG.&133\$%1@QJOYV~1Z1B21Q1N\$NSEJY?G>=>?291J1U<1R.M1K^F+DYW1F52SA671~
W51311\$~UR1>E1@I4Q3Z2>~A1G&81Z1Y1YH61M.M.P1P^<@M1Y100&Y1P1KEN18X3Y1Z1W9=KZST^HB.M01C<1H^?Z52^AXOC\$?>C7N0.R4M31Z1^AKK\$<F.Z1.#@218?2Q~
~W>1&K13H\$1Y%91D01ASL13F^LW\$V.8\$M2^?>Q10>Y1@31B.E44DE1EJZ1#>4ZGM.N40YQ^41PEZX5.0.27L@SRI.M^&C66ASAF4(J1D^H1KP.&3SW4<0U1)1.0.81V^90R
5F1TH61611U1M@B.E8NT<1^FRTQ31^#NA803.MA.0471<1%1F.M1Y.E576Y/F06.SIR@BG&G00<31XRZQK^N4A1^U1J^08T1=M1YEE^BL0^B\$1+V\$1+4+8X.YU
~SURRB>=>E.CM^~ABA\$55106132E#12N6.MA3&6(5^1J1Z>)>46+2RN8Y131J1AA@~A1E.H571TQ1U<Y1A>6D.M1Z20%4D1L1214YQ32154YR1R.YB9N1Z.RGF-ID.
7#31Q4W^LD1SGH/4.M=E1C79G.A1U1Y~R^0#Q1G&631Y1V.RQEP.E5=>52.2KBX.M32GDB>TVPBG1K
M.PW55.Q19>3T6F1E2.F7Y@QSG2&FW1+1\$~45W^1N1N1CNB1MPLB1FH.K5U^A1H41=HP9B1B1M&H1R.HG1F68E=>1W43MXZF+31~24Y6L2MX1F@B2Y1U%
&1SFE.U^P^NU=#C.E721.10CQY&R.\$?\$>MxA3R>PU21Z(I.X0.X&XW~.K+?21=)O1ME.RUO1%1%1.LAMA+G#49M6Y7X~
MSH3C1.5HF6G(T33F.W1(3=>5#MA1RD28NU51M@<~16R22+G1%4A1M.M.B91PB#12=>9.W1BA&N1F1W^411\$5>~8CT&GR=&GL1U11.KK.X=735=>66.MK1
<1T@V1&=>S8V&KFTFQ310101M1L1331~10.T0256J9U1H141SK191<EG>M&P=&87B@R1H17151GLX1S1#GSA6?F51SL6CC1A1A1P4TAT?FE4.MPY1Q1L8=ZT~
K31^1P&X9Q2ZG3D1H1^51VTR@<#21J2+1TBR1)(ZK%1H.W6L0VRT.L1BL83Q.O>Y>1>1\$1L1K1D1TYR1M^FN1S1F30Z7+~76J31QPC>=<<1~75781GL1411.81S1B1E34M^W9~^ZI
MN1(G=>51S32X1#BVT22Q10\$%Y6>=>2G44.Z1BTMG1N1@SMET.FVPG+YB7<2#&6M1J01Q3S0?>R1F^UHX1U.OQ.%<=<8U1F0U\$P1^F1Y9X1L.G2.6.V1N61.M24IK1
40113C6>N1@0(F15N^3.KPV%1X1~>9.R163^X11D)CM\$#TW&XY.MS1+&(S+<DRI.F.N)@Z30SGA^<1LVG1M1^PX0^VPI10.<100^M2FQ30^4IH.(44FE=<1EAVV1%+Z1^P<~HRE~
PIA1@<~.GOTCBZU3>~WB1J1#13A029F9%2=>N4>1T.V7FEQ21R.S5BX&1JX#M.M.17%20Z1K^~99T=1A2M8AR>@>9+1+W+D1L&#<6@L21.FE8H^PF&71=1
M1@<~1)W1RMSQPI1+&XWT20>QOWZ9\$<5Q1U14G1AL1Q0<1%G1?56?2.5G.7Y1G1A.H@YRM1^1>~81=>11C2%#T1L>0OX1Y.N1M6Q1^<0N1M1M>1E1MFXQJS
N7&@Q1Y1M1P&G&K^F=0&@6PF(AN1).MOLBT1L<~.R70\$1H1J1DTY\$12^NP51L10.O1O21G=C1DU21%#7^4Z0CHH1=ZC1F<4FF3^WK1J&E&1F1~RN1P18.4MDA1HDY.M60^17Q@41

1R1B=&891C_1MDH=8L03GZ>D8D@31.VYHUEA1/(O1-BL=>P1^R0Z90F8^AEWU1^1^KJ%1^M#10=>1F1H1OR.V5@J@X%9Q1D=T0.F1(L1.H6U1U>1WU1+24#_ZM3P&GN.MCD+G7H

B1L1T^OGPN1+1H1>W1&=DC^<5YL&A>1A10130@.QC13%Y1T^ZSQ^FW1N=C.M.S^MSO.G1MY4^14>11(80FBWX0Y15LE1^%7GWOY19@J11>SH\$35A^A.3D12<9T3>^A1LDX
1Z1FO1NR)&M0G&IEEE43SL1A1PB7AD\$7G.1L>H71FEQ121/>1R^U1C1F@V.F1TH^0.Y1%N1M^4^11^H^HAH0L^>1Z17(OY>VHXU>UW~11G.MU&W.HZY.EJ1+1#>
>96Q6^98G143U1^W&P&B17P1913.11N1=0YN/O1+M.Z\$KFC<~2A1N1&Q5C1L6%1Q1Z>B71V>1M100<1Z>61V1~M1=UWA#1EY.V~
E1EUS^XOCL1^VTCL.H1%<121QK1H1&1P>#~A17ABB1+9.MR\$731Q.(G+<17^#93>+6E.B9#Q.Z1J1H11B1U\$#(A1D1S2P56L19.^PZ1L+MK1^1
V3^S3L1R1Y2U1E1+^CMTA1Z1D1TVEY3&1S>HC.MDPTF&G=#K63+36?2.3H1F1>Q1?25V.FN1W4\$1^OOF.K\$=1G.V.MV14E~
Y5C8Q0.SV4K1Z1>HE1^X2Q.Y1(1S%1%FN1G1K3=61F3G9Y1MMR60.M+1H1R13+1+188.3^PNOQ511H@<B1Y1#1L%O1YVW=WFN1H=Z%1D1M&A18FET.C00.C.Q.C.R~
^YH=&W&M&G13VS@0P~O4^A@<KGU1A2.DG^M#11TH1%<1@<F1N3\$>R+<N0R80B+1EN^N19GFB01<2G71KVE1KB1V7903F>M^<Q9?1A7N13H5X~M.VM^V^AO~
1YMC.YPZ7.RUNFZ51&116H^K<7M31D1Y9Y6\$B+W\$1NM1KVR.MT40.N1#515J1>2^1614XHA8V1~00WA9B1H09=F1~81F7(FK115A16^
MC\$2JK5=>71N6E\$1#A042.S@=>1DE71F4RH1^<25S.BR9HF08V1~1M3JH.MYS1V14W08SL1J1N^41M1L1Q1LERO1N.W21.7=(R1+U1C1D1ATVDZL6=41O1M1^21V1P.POO^13(OD1
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<
=>N\$SPDH=G<=&A841A=9^KJ3<1T4N&1@VT1611^14U5X1)4M2AE97@.O1^1JK1Q3&4Q7%1Z>1%>2%>6JH1U1KZ%61J1L1V1~M8.OFD.M7\$DSUM<.\$5A1Y^6S8
AG1EN1VB0M1D4KB>1>1UC4HCLY6\$M8P1F1UKK61>=>1U1+V0S12101N1G1S1TZ1AY=KYD+>22JCYND1T1?>1>1T.MV477M1%>9^1<~
X.8C1L=>1Y^N01A856D^Y1@11Y1W1G1K+<6EWRX1O1K.MWYQK^<6E1GX1K1N1ZW1AYWTO>A90&759<7D1C1Q1)8ZT1T1FCTPEP.MN0CP1%
MS2Y<Q8)LS1F1>O#0U179UZA1Y>4Y%11%1%RM.T137361J1U1M@<1L1H541Y5D\$3E/K^<4Y+O&L1Q1LE33H1MH1E1U1D1>9G1^71M1W1V9.R#=>12N1
#QOR.P94DM.U.W121.16+1KJ3>@S1@B312P<Q1A1B1.M1&15K+11^PSFT1P0H1).X%Q0R\$#F11=H+T\$1%1^M1=1@OG1<Y1NZ15^MM01>1HH^RQ>Y31<137GP.M8&<Z^?<<

[illegible]

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

12-31-0000021665 us-gaap:OtherRestructuringMembercl:GlobalProductivityInitiativeMember 2022-12-31-0000021665 cl:GlobalProductivityInitiativeMember 2022-12-31-0000021665 us-gaap:OneTimeTerminationBenefitsMembercl:GlobalProductivityInitiativeMember 2023-01-012023-12-31-0000021665 cl:IncrementalDepreciationMembercl:GlobalProductivityInitiativeMember 2023-01-012023-12-31-0000021665 cl:AssetImpairmentMembercl:GlobalProductivityInitiativeMember 2023-01-012023-12-31-0000021665 us-gaap:OtherRestructuringMembercl:GlobalProductivityInitiativeMember 2023-01-012023-12-31-0000021665 us-gaap:OneTimeTerminationBenefitsMembercl:GlobalProductivityInitiativeMember 2023-12-31-0000021665 cl:IncrementalDepreciationMembercl:GlobalProductivityInitiativeMember 2023-12-31-0000021665 cl:AssetImpairmentMembercl:GlobalProductivityInitiativeMember 2023-12-31-0000021665 us-gaap:OtherRestructuringMembercl:GlobalProductivityInitiativeMember 2023-12-31-0000021665 cl:IncrementalDepreciationMembercl:GlobalProductivityInitiativeMember 2023-12-31-0000021665 cl:AssetImpairmentMembercl:GlobalProductivityInitiativeMember 2023-12-31-0000021665 us-gaap:OneTimeTerminationBenefitsMembercl:GlobalProductivityInitiativeMember 2023-12-31-0000021665 cl:IncrementalDepreciationMembercl:GlobalProductivityInitiativeMember 2024-01-012024-12-31-0000021665 cl:AssetImpairmentMembercl:GlobalProductivityInitiativeMember 2024-01-012024-12-31-0000021665 us-gaap:OtherRestructuringMembercl:GlobalProductivityInitiativeMember 2024-01-012024-12-31-0000021665 us-gaap:OneTimeTerminationBenefitsMembercl:GlobalProductivityInitiativeMember 2024-12-31-0000021665 cl:IncrementalDepreciationMembercl:GlobalProductivityInitiativeMember 2024-12-31-0000021665 cl:AssetImpairmentMembercl:GlobalProductivityInitiativeMember 2024-12-31-0000021665 us-gaap:OtherRestructuringMembercl:GlobalProductivityInitiativeMember 2024-12-31-0000021665 srt:NorthAmericaMembercl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 srt:NorthAmericaMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31-0000021665 srt:NorthAmericaMembercl:OralPersonalAndHomeCareMember 2023-12-31-0000021665 srt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 srt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31-0000021665 srt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31-0000021665 srt:EuropeMembercl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 srt:EuropeMembercl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 srt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 srt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31-0000021665 srt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2023-12-31-0000021665 cl:AfricaEurasiaMembercl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 cl:AfricaEurasiaMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31-0000021665 cl:AfricaEurasiaMembercl:OralPersonalAndHomeCareMember 2023-12-31-0000021665 cl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 cl:OralPersonalAndHomeCareMember 2022-12-31-0000021665 cl:PetNutritionMember 2022-12-31-0000021665 cl:PetNutritionMember 2023-01-012023-12-31-0000021665 srt:NorthAmericaMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31-0000021665 srt:NorthAmericaMembercl:OralPersonalAndHomeCareMember 2024-12-31-0000021665 srt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31-0000021665 srt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2024-12-31-0000021665 srt:EuropeMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31-0000021665 srt:EuropeMembercl:OralPersonalAndHomeCareMember 2024-12-31-0000021665 srt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31-0000021665 srt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2024-12-31-0000021665 cl:AfricaEurasiaMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31-0000021665 cl:AfricaEurasiaMembercl:OralPersonalAndHomeCareMember 2024-12-31-0000021665 cl:OralPersonalAndHomeCareMember 2024-01-012024-12-31-0000021665 cl:OralPersonalAndHomeCareMember 2024-12-31-0000021665 cl:PetNutritionMember 2024-01-012024-12-31-0000021665 cl:PetNutritionMember 2024-12-31-0000021665 us-gaap:TrademarksMember 2024-12-31-0000021665 us-gaap:TrademarksMember 2024-12-31-0000021665 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2024-12-31-0000021665 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2023-12-31-0000021665 us-gaap:TrademarksMember 2024-12-31-0000021665 us-gaap:TrademarksMembercl:FilorgaReportingUnitMember 2024-12-31-0000021665 us-gaap:NotesPayableOtherPayablesMember 2024-12-31-0000021665 us-gaap:NotesPayableOtherPayablesMember 2023-12-31-0000021665 us-gaap:CommercialPaperMember 2024-12-31-0000021665 us-gaap:CommercialPaperMember 2023-12-31-0000021665 cl:FinanceLeaseObligationMember 2024-12-31-0000021665 cl:FinanceLeaseObligationMember 2023-12-31-0000021665 cl:TenYearNotesAt3250PercentNumberMember 2024-12-31-0000021665 cl:TenYearNotesAt3250PercentNumberMember 2024-01-012024-12-31-0000021665 cl:ThreeYearNotesAt480PercentNumberMember 2023-03-31-0000021665 cl:ThreeYearNotesAt480PercentNumberMember 2023-03-012023-03-31-0000021665 cl:FiveYearNotesAt460PercentNumberMember 2023-03-31-0000021665 cl:FiveYearNotesAt460PercentNumberMember 2023-03-012023-03-31-0000021665 cl:TenYearNotesAt460PercentNumberMember 2023-03-31-0000021665 cl:TenYearNotesAt460PercentNumberMember 2023-03-012023-03-31-0000021665 us-gaap:RevolvingCreditFacilityMember 2024-12-31-0000021665 cl:AmendedDomesticRevolvingCreditFacility3000MillionCapacityMember 2022-11-30-0000021665 cl:AmendedDomesticRevolvingCreditFacility3000MillionCapacityMember 2022-11-012022-11-30-0000021665 us-gaap:ForeignExchangeContractMember 2024-12-31-0000021665 us-gaap:ForeignExchangeContractMember 2024-12-31-0000021665 us-gaap:CommodityContractMember 2024-12-31-0000021665 us-gaap:CommodityContractMember 2023-12-31-0000021665 us-gaap:OtherCurrentAssetsMember 2024-12-31-0000021665 us-gaap:OtherCurrentAssetsMember 2023-12-31-0000021665 us-gaap:FairValueInputsLevel2Member 2024-12-31-0000021665 us-gaap:FairValueInputsLevel2Member 2023-12-31-0000021665 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31-0000021665 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31-0000021665 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember 2024-12-31-0000021665 us-gaap:DebtMemberus-gaap:FairValueHedgingMember 2024-12-31-0000021665 us-gaap:CommodityContractMemberus-gaap:FairValueHedgingMember 2024-12-31-0000021665 us-gaap:FairValueHedgingMember 2024-12-31-0000021665 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2024-12-31-0000021665 us-gaap:DebtMemberus-gaap:CashFlowHedgingMember 2024-12-31-0000021665 us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember 2024-12-31-0000021665 us-gaap:CashFlowHedgingMember 2024-12-31-0000021665 us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember 2024-12-31-0000021665 us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember 2024-12-31-0000021665 us-gaap:CommodityContractMemberus-gaap:NetInvestmentHedgingMember 2024-12-31-0000021665 us-gaap:NetInvestmentHedgingMember 2024-12-31-0000021665 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember 2023-12-31-0000021665 us-gaap:DebtMemberus-gaap:FairValueHedgingMember 2023-12-31-0000021665 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2023-12-31-0000021665 us-gaap:DebtMemberus-gaap:CashFlowHedgingMember 2023-12-31-0000021665 us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember 2023-12-31-0000021665 us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember 2023-12-31-0000021665 us-gaap:ForeignExchangeContractMember 2024-01-012024-12-31-0000021665 us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember 2023-01-012023-12-31-0000021665 us-g

gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 00000021665 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 00000021665 cl:DefinedBenefitPlanUSCommonStocksMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanUSCommonStocksMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanInternationalCommonStockMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanInternationalCommonStockMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanPooledFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanPooledFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Membercountry:USus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanGuaranteedInvestmentContractsMemberus-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanGuaranteedInvestmentContractsMemberus-gaap:FairValueInputsLevel2Membercountry:USus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 us-gaap:FairValueInputsLevel12And3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanDomesticDevelopedandEmergingMarketsEquityFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanFixedIncomeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanHedgeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanHedgeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:DefinedBenefitPlanMultiAssetFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 us-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 us-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:OtherAssetsandLiabilitiesNetMembercountry:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 cl:OtherAssetsandLiabilitiesNetMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 country:USus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000021665 srt:MinimumMember 2024-01-012024-12-31 0000021665 srt:MaximumMember 2024-01-012024-12-31 0000021665 country:USus-gaap:PensionPlansDefinedBenefitMember 2023-01-012023-12-31 0000021665 country:USus-gaap:PensionPlansDefinedBenefitMember 2024-01-012024-12-31 0000021665 country:USus-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000021665 us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000021665 us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2024-01-012024-12-31 0000021665 us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2023-01-012023-12-31 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-012023-12-31 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000021665 us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000021665 us-gaap:PensionPlansDefinedBenefitMember 2022-01-012022-12-31 0000021665 us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember 2022-01-012022-12-31 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-012022-12-31 0000021665 cl:ChargedToCostsAndExpensesMember 2024-01-012024-12-31 0000021665 cl:ChargedToCostsAndExpensesMember 2023-01-012023-12-31 0000021665 cl:DeductionsMember 2022-01-012022-12-31 0000021665 cl:DeductionsMember 2024-01-012024-12-31 0000021665 cl:DeductionsMember 2023-01-012023-12-31 0000021665 cl:DeductionsMember 2022-01-012022-12-31 0000021665 2024-04-012024-06-30 0000021665 2022-12-15 0000021665 us-gaap:EmployeeStockOptionMember 2024-01-012024-12-31 0000021665 us-gaap:EmployeeStockOptionMember 2023-01-012023-12-31 0000021665 us-gaap:EmployeeStockOptionMember 2022-01-012022-12-31 0000021665 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-12-31 0000021665 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-12-31 0000021665 us-gaap:RestrictedStockUnitsRSUMember 2022-01-012022-12-31 0000021665 srt:MinimumMember 2024-12-31 0000021665 srt:MaximumMember 2024-12-31 0000021665 2023-11-012023-11-30 0000021665 2024-08-012024-08-31 0000021665 2005-12-31 0000021665 2024-01-012024-03-31 0000021665 us-gaap:SalesRevenueNetMember 2024-12-31 0000021665 cl:WalmartIncMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2024-01-012024-12-31 0000021665 us-gaap:CorporateNonSegmentMemberus-gaap:OperatingIncomeLossMembercl:GlobalProductivityInitiativeMember 2024-01-012024-12-31 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2023-01-012023-12-31 0000021665 us-gaap:OperatingIncomeLossMembercl:GlobalProductivityInitiativeMember 2022-01-012022-12-31 0000021665 us-gaap:CorporateNonSegmentMember 2022-01-012022-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:NorthAmericaMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:EuropeMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2024-01-012024-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:EuropeMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:EuropeMembercl:OralPersonalAndHomeCareMember 2023-01-012023-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2022-01-012022-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2022-01-012022-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:EuropeMembercl:OralPersonalAndHomeCareMember 2022-01-012022-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:AsiaPacificMembercl:OralPersonalAndHomeCareMember 2022-01-012022-12-31 0000021665 us-gaap:OperatingSegmentsMembersrt:LatinAmericaMembercl:OralPersonalAndHomeCareMember 2022-01-012022-12-31 0000021665 country:US 2024-12-31 000002

and includes our Chief Financial Officer, Chief Legal Officer, Chief Information Officer and other members of senior management. The ERM Committee monitors both current and emerging risks facing the Company and meets at least quarterly to review the prioritization of identified risks. The ERM Committee has identified cybersecurity as a critical risk facing the Company. Each of the most critical risks identified is assigned to a member of senior management who oversees the management, mitigation and presentation of the risk to the senior leadership team and throughout the year to our Board of Directors. The risks relating to information technology, including cybersecurity, are overseen by our Chief Information Officer. Our Chief Information Officer then assigns the risks within the Information Technology risk category to others on his team. The cybersecurity risk is managed and overseen by our Chief Information Security Officer ("CISO"), who reports to our Chief Information Officer. Cybersecurity as a risk is presented to the full ERM Committee annually or more frequently as needed.

Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company's systems and information.

Our CISO joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.

The Company's information security organization seeks to employ cybersecurity best practices, including implementing new technologies to proactively identify and monitor new vulnerabilities and reduce risk, conducting due diligence of third-party vendors' information security programs, maintaining security policies and standards and regularly updating and testing our response planning and protocols. The information security organization also works in partnership with our Internal Audit function to identify cybersecurity risks and review cybersecurity-related internal controls with third parties as part of the overall internal controls process. The information security organization also gains valuable information to improve our threat and risk awareness capabilities as a member of an industry information sharing and analysis organization, which provides strategic and tactical information sharing channels. Additionally, employees are provided mandatory cybersecurity awareness training on an annual basis, which includes information about how to identify and report cybersecurity concerns and incidents. The information security organization also conducts phishing simulations and testing scenarios through tabletop exercises and assessment activities, to help ensure compliance with our cyber policies and procedures. We maintain a cybersecurity insurance policy and have retained relevant incident response services. Additionally, we maintain an offensive security team that

We maintain a Data Security Incident Response Plan (the "Plan"), which outlines the processes and procedures that we should follow to respond to, remediate and resolve a security incident involving a potential or actual compromise of our proprietary information and/or personal information. It also describes the structure, roles and responsibilities of personnel involved in responding to such incidents and provides a process for alerting senior management of such incidents. The Plan is reviewed on an annual basis and revised as necessary.

Our dedicated information security organization leverages various frameworks for managing cybersecurity risks, including the National Institute of Standards and Technology ("NIST") framework. The key pillars of the NIST framework are to (i) develop an organizational understanding to manage cybersecurity risk to systems, people, assets, data and capabilities; (ii) develop and implement appropriate safeguards to ensure delivery of critical services; (iii) develop and implement appropriate activities to identify the occurrence of a cybersecurity event; (iv) develop and implement appropriate activities to maintain plans for resilience and to restore any capabilities or services that were impaired due to a cybersecurity incident; and (v) develop appropriate activities to action an incident.

We have a comprehensive third party cybersecurity risk review process, which prioritizes, monitors and assesses the risks associated with our third party service provider interactions. The third party service provider assessment framework follows industry standard practices and allows us to properly understand the risk associated with the services provided which are key to our company's daily operations.

For additional information regarding risks faced by the Company from cybersecurity threats, see Item 1A, "Risk Factors - A cybersecurity incident, data breach or a failure of key technology systems could adversely impact our business."

We have a systematic and thorough risk management process, which is designed to identify, assess, prioritize, mitigate and manage the risks that could negatively impact achievement of our strategic and operating objectives. A key component of this process is our Enterprise Risk Management ("ERM") Committee, which is led by our Chairman, President and Chief Executive Officer, and includes our Chief Financial Officer, Chief Legal Officer, Chief Information Officer and other members of senior management.

We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats. Our Chief Information Officer reports to our Group President, Growth and Strategy, a member of our senior leadership team who reports to our Chairman of the Board, President and Chief Executive Officer.

Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company's systems and information.

Our CISO joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.

We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats.

Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company's systems and information.

Our CISO joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.

Our Board of Directors is focused on cybersecurity. Specific responsibility for cybersecurity oversight is delegated to the Audit Committee. The Board oversees our risk management process to ensure it is properly designed, well-functioning and consistent with our overall corporate strategy. Our Audit Committee oversees the ERM process and the implementation of appropriate risk monitoring and management systems, though all Board members attend Audit Committee meetings and participate in risk management discussions.

Our Board of Directors has adopted a written statement, known as the Independent Board Candidate Qualifications and made available on our website, outlining the qualities sought in our directors. This statement, which is refreshed periodically, is used by the Nominating, Governance and Corporate Responsibility Committee ("NGCR Committee") to evaluate individual director candidates. The NGCR Committee has identified experience with overseeing and managing risk management processes, including with respect to cybersecurity, as being important to creating an effective, well-rounded and diverse Board. Directors with experience overseeing and managing risk management processes play a critical role in the Board's oversight of our enterprise risk management process.

Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.

Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.

[illegible]

[illegible]

impairment, the Company performs either a quantitative or a qualitative analysis. </div><div style="text-indent:36pt">
</div><div style="text-indent:18pt">Determining the fair value of the Company's reporting units for goodwill and the fair value of its intangible assets requires significant estimates and judgments by management. When a quantitative analysis is performed, the Company generally uses the income approach, which requires several estimates, including future cash flows consistent with management's strategic plans, sales growth rates and the selection of royalty rates and discount rates. The Company generally engages a third-party valuation firm to assist in determining the fair value of intangible assets acquired in business combinations. </div><div>
</div><div style="text-indent:18pt">As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reporting structure realignment, the Company completed an assessment indicating no goodwill impairment was required. Refer to Note 13, Segment Information for additional information. </div><div>
</div></div><div style="text-indent:18pt">Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit. </div><div>Income Taxes</div><div>
</div><div>The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. </div><div>
</div><div style="text-indent:18pt">The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes. </div><div style="text-indent:18pt">
</div><div>Financial Instruments</div><div>
</div><div style="text-indent:18pt">Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company's derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company's derivative instruments and other financial instruments are more fully described in Note 6, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations. </div><div>
</div><div>Stock-Based Compensation</div><div>
</div><div style="text-indent:18pt">The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period. The Company uses the Black-Scholes-Merton </div><div>Black-Scholes</div><div>option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company's stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans. </div><div>
</div><div style="text-indent:18pt">Currency Translation</div><div>
</div><div style="text-indent:18pt">The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders' equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">For subsidiaries operating in highly inflationary environments, local currency-denominated non-monetary assets, including inventories, goodwill and property, plant and equipment, are remeasured at their historical exchange rates, while local currency-denominated monetary assets and liabilities are remeasured at year-end exchange rates. Remeasurement adjustments for these operations are included in Net income attributable to Colgate-Palmolive Company. </div><div>
</div><div style="text-indent:18pt">Recent Accounting Pronouncements and Disclosure Rules</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In November 2024, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments." This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrants' registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">In December 2023, the FASB issued ASU No. 2023-08, "Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets." This ASU improves the accounting for certain crypto assets by requiring companies to measure them at fair value for each reporting period with changes in fair value recognized in net income. This guidance is effective for the Company for fiscal years beginning after December 15, 2024 and is not expected to have an impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information for additional information. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In October 2023, the FASB issued ASU No. 2023-06, "Disclosure Improvements—Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative." This ASU modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC's regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In August 2023, the FASB issued ASU No. 2023-05, "Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement." This ASU requires a joint venture to initially measure all contributions received upon its formation at fair value. This guidance is applicable to joint ventures with a formation date on or after January 1, 2025 and is not expected to have a material impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">In March 2023, the FASB issued ASU No. 2023-01, "Leases (Topic 842): Common Control Arrangements." This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Company's Consolidated Financial Statements. </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In September 2022, the FASB issued ASU No. 2022-04, "Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations." This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programs' key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated roll-forward information. The Company adopted the guidance beginning on January 1, 2023, and with respect to the roll-forward information disclosure, beginning on January 1, 2024. See Note 15, Supplier Finance Programs for additional information. </div><div style="text-indent:18pt">
</div><div style="text-align:justify">Reclassifications</div><div>
</div><div style="text-indent:18pt">Principles of Consolidation</div><div>
</div><div style="text-indent:18pt">The Consolidated Financial Statements include the accounts of Colgate-Palmolive Company and its majority-owned or controlled subsidiaries. Intercompany transactions and balances have been eliminated. The Company's investments in consumer products companies with interests ranging between 20% and 50%, where the Company has significant influence over the investee, are accounted for using the equity method. Net income (loss) from such investments is recorded in Other (income) expense, net in the Consolidated Statements of Income. As of December 31, 2024 and 2023, equity method investments included in Other assets in the Consolidated Balance Sheets were \$81 and \$83, respectively. Unrelated third parties hold the remaining ownership interests in these investments. Investments with less than a 20% interest are recorded at cost and periodically adjusted based on observable price changes or quoted market prices in active markets, if applicable. 0.200.50810000000830000000.20 </div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">Use of Estimates</div><div>
</div><div style="text-indent:18pt">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported

amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Company's assumptions and estimates involved in preparing the financial statements includes pension and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. Additionally, the Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments and retirement plan assets. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. Actual results could ultimately differ from those estimates.

Revenue Recognition—The Company's revenue contracts represent a single performance obligation to sell its products to trade customers. Sales are recorded at the time control of the products is transferred to trade customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for the products. Control is the ability of trade customers to "direct the use of" and "obtain the benefit from" our products. In evaluating the timing of the transfer of control of products to trade customers, the Company considers several control indicators, including significant risks and rewards of products, the Company's right to payment and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to trade customers.

Shipping and Handling Costs—Net sales reflect the transaction prices for contracts, which include units shipped at selling list prices reduced by variable consideration. Variable consideration includes expected sales returns and the cost of current and continuing promotional programs. Current promotional programs primarily include product listing allowances and co-operative advertising arrangements. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements. The cost of promotional programs is estimated using the expected value method considering all reasonably available information, including the Company's historical experience and its current expectations, and is reflected in the transaction price when sales are recorded. Adjustments to the cost of promotional programs in subsequent periods are generally not material, as the Company's promotional programs are typically of short duration, thereby reducing the uncertainty inherent in such estimates.

Marketing Costs—The Company markets its products through advertising and other promotional activities. Advertising costs are included in Selling, general and administrative expenses and are expensed as incurred. Certain consumer and trade promotional programs, such as consumer coupons, are recorded as a reduction of sales.

Cash and Cash Equivalents—The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

Inventories—Inventories are classified as Selling, general and administrative expenses and were \$1,777, \$1,771 and \$1,874 for the years ended December 31, 2024, 2023 and 2022, respectively.

Land, buildings and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over the estimated useful lives ranging from 3 to 15 years for machinery and equipment and up to 40 years for buildings. Depreciation attributable to manufacturing operations is included in Cost of sales. The remaining component of depreciation is included in Selling, general and administrative expenses.

Goodwill and Other Intangibles—Goodwill and indefinite-life intangible assets, such as the Company's global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate that an asset may be impaired. In assessing impairment, the Company performs either a quantitative or a qualitative analysis.

Determining the fair value of the Company's reporting units for goodwill and the fair value of its intangible assets requires significant estimates and judgments by management. When a quantitative analysis is performed, the Company generally uses the income approach, which requires several estimates, including future cash flows consistent with management's strategic plans, sales growth rates and the selection of royalty rates and discount rates. The Company generally engages a third-party valuation firm to assist in determining the fair value of intangible assets acquired in business combinations.

As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reporting structure realignment, the Company completed an assessment indicating no goodwill impairment was required. Refer to Note 13, Segment Information for additional information.

Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit.

Income Taxes—The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes.

Financial Instruments—Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company's derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows.

Stock-Based Compensation—The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company's derivative instruments and other financial instruments are more fully described in Note 6, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations.

Black-Scholes—The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company's stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans.

Currency Translation—The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders' equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year.

For subsidiaries operating in highly inflationary environments, local currency-denominated non-monetary assets, including inventories, goodwill and property, plant and equipment, are remeasured at their historical exchange rates, while local currency-denominated monetary assets and liabilities are remeasured at year-end exchange rates. Remeasurement adjustments for these operations are included in Net income attributable to Colgate-Palmolive Company.

Recent Accounting Pronouncements and Disclosure Rules—In November 2024, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments." This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Company's Consolidated Financial Statements.

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements.

In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrants'

registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements.

In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements.

In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information for additional information.

In October 2023, the FASB issued ASU No. 2023-06, "Disclosure Improvements—Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative." This ASU modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC's regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company's Consolidated Financial Statements.

In March 2023, the FASB issued ASU No. 2023-01, "Leases (Topic 842): Common Control Arrangements." This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Company's Consolidated Financial Statements.

In September 2022, the FASB issued ASU No. 2022-04, "Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations." This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programs' key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated roll-forward information. The Company adopted the guidance beginning on January 1, 2023, and with respect to the roll-forward information disclosure, beginning on January 1, 2024.

Certain prior year amounts have been reclassified to conform to the current year presentation. Restructuring and Related Implementation Charges

On January 27, 2022, the Board approved a targeted productivity program (the "2022 Global Productivity Initiative"). All initiatives have been implemented and the program concluded on December 31, 2024. The 2022 Global Productivity Initiative resulted in the reallocation of resources towards the Company's strategic priorities and faster growth businesses, efficiencies in the Company's operations and the streamlining of its supply chain to reduce structural costs.

Over the course of the 2022 Global Productivity Initiative, the Company incurred total pretax charges of \$228 (\$166 after tax) in connection with the implementation of various projects as follows:

Total Program Charges	
Employee-Related Costs	
Asset Impairments	
Incremental Depreciation	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

color:#fffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance at December 31, 2023</div></td><td colspan="3"><div>Charges</div></td><td colspan="2"><div>Charges against assets</div></td><td colspan="3"><div>Cash Payments</div></td><td colspan="2"><div>Foreign exchange</div></td><td colspan="3"><div>Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments:</div></td></tr></table>

Total Program Charges

Region	Charges
North America	\$120,000,000
Latin America	\$15,000,000
Europe	\$20,000,000
Asia Pacific	\$20,000,000
Hill's Pet Nutrition	\$6,000,000
FarmVet	\$20,000,000
Africa/Eurasia	\$5,000,000
Corporate	\$2,000,000
Total	\$204,000,000

The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. See Note 13. Segment Information for additional details.

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Common stock acquired</p><table border="1"><tr><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Common stock acquired</div></td><td colspan="3"><div style="background-color:#ffffff;padding:0 1pt"><div style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,735,909)</div></div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">14,735,909</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">14,735,909</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">14,735,909</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">14,735,909</div></td></tr><tr><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Shares issued for stock options</div></td><td colspan="3"><div style="background-color:#ffffff;padding:0 1pt"><div style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,318,430</div></div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">5,318,430</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">5,318,430</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">5,318,430</div></td></tr><tr><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Shares issued for restricted stock units and other</div></td><td colspan="3"><div style="background-color:#ffffff;padding:0 1pt"><div style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">617,642</div></div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">617,642</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">617,642</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">617,642</div></td></tr><tr><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</div></td><td colspan="3"><div style="background-color:#ffffff;padding:0 1pt"><div style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">821,412,769</div></div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">821,412,769</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">821,412,769</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">821,412,769</div></td></tr><tr><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Shares issued for restricted stock units and other</div></td><td colspan="3"><div style="background-color:#ffffff;padding:0 1pt"><div style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">860,669</div></div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">860,669</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">860,669</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">860,669</div></td></tr><tr><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units, based on the fair value of those awards at the date of grant. The fair value of restricted stock units, generally based on market price, is amortized ratably over the requisite service period. The estimated fair value of stock options on the date of grant, based on the Black-Scholes value described below, is amortized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company accounts for forfeitures as they occur. Awards to employees eligible for retirement prior to the award becoming fully vested are recognized as compensation cost from the grant date through the date that the employee first becomes eligible to retire and is no longer required to provide service to earn the award.</div><div style="text-indent:18pt"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">The Company has one incentive compensation plan pursuant to which it issues restricted stock units (both performance-based and time-vested) and stock options to employees and shares of common stock and stock options to non-employee directors. The Personnel and Organization Committee of the Board, which is comprised entirely of independent directors, administers the incentive compensation plan. The total stock-based compensation expense charged against pretax income for this plan was \$135, \$122 and \$125 for the years ended December 31, 2024, 2023 and 2022, respectively. The total income tax benefit recognized on stock-based compensation, excluding excess tax benefits, was approximately \$26, \$22 and \$25 for the years ended December 31, 2024, 2023 and 2022, respectively.</div><div style="text-indent:18pt"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Stock-based compensation expense is recorded within Selling, general and administrative expenses in the Corporate segment as these amounts are not included in internal measures of segment operating performance.</div><div style="text-indent:18pt"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The weighted-average fair value assumptions are summarized in the following table:</div><table border="1"><tr><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Expected volatility rate</div></td><td colspan="3"><div style="background-color:#ffffff;padding:2px 1pt 2px 7.5pt;text-align:left;vertical-align:bottom">Expected volatility rate</div></td><td colspan="3"><div style

Weighted Average Expected Term of Options

The weighted-average expected term of options granted each year was determined with reference to historical exercise and post-vesting cancellation experience, the vesting period of the awards and the contractual term of the awards, among other factors. Expected volatility incorporates implied share-price volatility derived from exchange traded options on the Company's common stock. The risk-free interest rate for the expected term of the option is based on the yield of a zero-coupon U.S. Treasury bond with a maturity period equal to the option's expected term.

Stock Options

The Company issues non-qualified stock options to non-employee directors, officers and other key employees. Stock options have a contractual term of eight years and generally vest ratably over three years. As of December 31, 2024, approximately 19,248,078 shares of common stock were available for future stock option grants.

Summary of Stock Option Activity during 2024

	Weighted Average Expected Term (Years)	Weighted Average Exercise Price (\$)
Granted	7.5	955
Forfeited	7.4	106
Expired	7.4	106
Exercised	7.3	76

Options outstanding, January 1, 2024

	Weighted Average Expected Term (Years)	Weighted Average Exercise Price (\$)
Options outstanding	7.5	955

Options outstanding, December 31, 2024

	Weighted Average Expected Term (Years)	Weighted Average Exercise Price (\$)
Options outstanding	7.5	955

[illegible]

[illegible]

[illegible]

option activity during 2024 is presented below:

Symbol	Underlying Price	Option Type	Strike Price	Expiration Date	Volume	Open Interest	Implied Volatility	Delta	Gamma	Rho	Theta	Price
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	100,000	0.557%	-0.10	0.01	-0.10	0.01	10.00
SPY	450.00	Call	450.00	12/31/2024	100,000	100,000	0.557%	0.10	0.01	0.10	-0.01	10.00
SPY	450.00	Put	450.00	12/31/2024	100,000	1						

[illegible]

[illegible]

[illegible]

[illegible]

bottom

Investments valued using NAV per share

Domestic, developed and emerging markets equity funds

Hedge funds

Real estate funds

Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities.

The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2. As of December 31, 2024 and December 31, 2023, approximately 30% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds.

Total Investments

The guaranteed investment contracts ("GICs") represent contracts with insurance companies measured at the cash surrender value of each contract. The Level 2 valuation reflects that the cash surrender value is based principally on a

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table>
 <tr>
 <td colspan=`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

#<td colspan=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table border=`

[illegible]

[illegible]

[illegible]

style="background-color:#c00000;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt">As of December 31, 2024, the Company had net operating losses ("NOLs") and capital loss carryforwards of \$37. Of this amount, capital loss and NOL carryforwards of \$6 will begin to expire in 2025 and NOLs of \$13 can be carried forward indefinitely. The Company believes that it will be able to utilize these capital loss and NOL carryforwards. There is an additional NOL of \$18 which has a full valuation allowance.</div><div style="text-indent:18pt">As of December 31, 2024, the Company has \$393 of tax credits, of which \$66 will begin to expire in 2030 and \$17 can be carried forward indefinitely. The Company believes that it will be able to utilize these tax credits. The remaining credits of \$310 have a full valuation allowance.</div><div>
</div><div style="text-indent:18pt">Applicable U.S. income and foreign withholding taxes have been provided on substantially all of the Company's accumulated earnings of foreign subsidiaries.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">Net tax expense of \$55, net tax benefit of \$19 and net tax expense of \$164 were recorded directly through equity in 2024, 2023 and 2022 respectively. The net tax expense or benefit in each year predominantly includes current and future tax impacts related to benefit plans and the impact of currency translation adjustments.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return.</div><div style="text-indent:18pt">Unrecognized tax benefits activity for the years ended December 31, 2024, 2023 and 2022 is summarized below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top; width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.72%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:7.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:center;vertical-align:bottom">2022</div></td></tr><tr><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom">Unrecognized tax benefits.</div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td></tr><tr><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td></tr><tr><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td></tr><tr><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td></tr><tr><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td></tr><tr><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"></div></td><td colspan="3"><div style="padding:0 1pt"></div></td><td colspan="3"><div style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:Times New Roman,sans

"text-indent:18pt">The Company recognized expenses of approximately \$22, \$10 and \$8 for interest and penalties related to the above unrecognized tax benefits within income tax expense in 2024, 2023 and 2022, respectively. The Company had accrued interest and penalties of approximately \$68, \$45 and \$40 as of December 31, 2024, 2023 and 2022, respectively.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">In the third quarter of 2023, the Internal Revenue Service (the "IRS") issued a notice giving taxpayers temporary relief from the effects of certain U.S. tax regulations that were issued in December 2021, which place greater restrictions on foreign taxes that are creditable against U.S. taxes on foreign-source income. This notice allowed taxpayers to defer the application of these new regulations through the end of 2023. In December 2023, the IRS issued further guidance modifying this temporary relief period to the date that a notice or other guidance withdrawing or modifying the temporary relief is issued. The Company will recognize the impact, if any, in the period in which the temporary relief is withdrawn or modified.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">During the quarter ended June 30, 2023, the Company reassessed with its legal and tax advisers certain tax deductions taken in prior years by one of our subsidiaries and concluded that it was more likely than not that the deductions would not be sustained by the courts in that jurisdiction. The value of the tax deductions was not material to the Company in any year in which they were taken. The cumulative effect of the change in tax position of \$148 was reflected as a discrete item in the quarter ended June 30, 2023 income tax expense, partially offset by the reversal of certain prior years' withholding tax reserves of \$22 that were no longer required. The tax liability was paid in the quarter ended September 30, 2023.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">On August 16, 2022, the Inflation Reduction Act of 2022 (the "IRA") was enacted, which among other things, implements a 15% minimum tax on book income of certain large corporations effective for years beginning after December 31, 2022. Based on the Company's analysis, as well as guidance published by the IRS, the IRA, and in particular the 15% minimum tax, did not have an impact on the Company's Consolidated Financial Statements. Subsequent to the aforementioned guidance published by the IRS, on September 12, 2024, the U.S. Treasury Department and IRS released proposed regulations relating to this 15% minimum tax. Based on the Company's analysis, these proposed regulations, if finalized in their current form, are not expected to have an impact on the Company's Consolidated Financial Statements. However, the Company will continue to evaluate any additional guidance and clarification that becomes available.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">Additionally, on December 15, 2022, the 27 member states of the European Union ("EU") reached an agreement on a minimum level of taxation for certain large corporations to pay a minimum corporate tax rate of 15% in every jurisdiction in which they operate. This agreement, which is known as the Minimum Tax Directive (part of the "Pillar II Model Rules"), was supposed to be transposed into the laws of all EU member states by December 31, 2023. Most member states complied, while some were granted extensions of time. In addition, many other jurisdictions outside the EU have implemented a similar minimum tax regime consistent with the policy of the Pillar II Model Rules. Detailed regulations of these minimum tax regimes are still being considered in certain countries and, in some cases, enactment and timing is still </div><div>uncertain. Based on current legislation and available guidance, apart from a significant additional compliance burden, Pillar II did not have a material impact as of December 31, 2024 and the Company does not believe it will have a material impact on its Consolidated Financial Statements. However, as these rules and related regulations are revised and implemented, the Company will evaluate the impact, if any, on its Consolidated Financial Statements.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">The Company has ongoing federal, state and international income tax audits in various jurisdictions and evaluates uncertain tax positions that may be challenged by local tax authorities and not fully sustained. All U.S. federal income tax returns through December 31, 2013 have been audited by the IRS and there are limited matters which the Company plans to appeal for years 2010 through 2013. One such matter relates to the IRS assessment of taxes on the Company by imputing income on certain activities within one of our international operations, which is also under audit for the years 2014 through 2018. There were U.S. Tax Court rulings during 2023 in favor of the IRS against unrelated third parties on similar matters. Despite the U.S. Tax Court rulings, the Company continues to believe that the tax assessment against the Company is without merit. While there can be no assurances, the Company believes this matter will ultimately be decided in favor of the Company. The amount of tax plus interest for the years 2010 through 2018 is estimated to be approximately \$153, which is not included in the Company's uncertain tax positions. In May 2024, the IRS initiated an audit for the years 2019 through 2021.</div><div style="text-indent:18pt">
</div><div style="text-indent:18pt">The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.</div><div style="margin-bottom:6pt;text-indent:18pt">The components of income before income taxes are as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:63.088%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

</div><td colspan=

```
solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"></td><td style="color:#000000;font-family:'Times New Roman','sans-serif';font-size:10pt;font-weight:400;line-height:100%;>4.951</td></td><td style="background-color:#ffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffff;padding:0 1pt"></td><td style="background-color:#ffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="6" style="color:#000000;font-family:'Times New Roman','sans-serif';font-size:10pt;font-weight:400;line-height:100%;">$</td><td style="background-color:#ffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman','sans-serif';font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"></span><br><span style="color:#000000;font-family:'Times New Roman','sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(f)</span> Long-lived assets include Property, plant and equipment, net and lease right-of-use  
assets. 250,450. 118,500,0000027000000025000000721000000950000004700000019000000 <div style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100%"><table border="1" style="width:1.0% "><tr><td style="width:37.081% "></td><td style="width:0.1% "></td><td style="width:1.0% "></td><td style="width:10.869% "></td><td style="width:0.1% "></td><td style="width:1.0% "></td><td style="width:1.021% "></td><td style="width:0.1% "></td><td style="width:1.0% "></td><td style="width:12.687% "></td><td style="width:0.1% "></td><td style="width:1.0% "></td><td style="width:11.172% "></td><td style="width:0.1% "></td><td style="width:1.0% "></td><td style="width:10.570% "></td><td style="width:0.1% "></td></tr><tr><td colspan="3" style="background-color:#ffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman','sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middl
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Supplemental cash flow information related to operating leases for the twelve months ended December 31, 2024 and 2023 was as follows:

	2024	2023
Payments against amounts included in the measurement of lease liabilities: \$132 and \$171, respectively	\$132	\$171
Lease assets obtained in exchange for lease liabilities: \$141 and \$139, respectively	\$141	\$139
Weighted-average remaining lease term for operating leases was 7 and 8 years, respectively, and the weighted-average discount rate for operating leases was 4.4% and 4.5%, respectively	7.0	8.0

The components of the Company's operating lease cost for the twelve months ended December 31, 2024 and 2023 were as follows:

	2024	2023
Operating lease expense	\$132	\$171
Short-term lease expense	\$141	\$139
Variable lease expense	\$141	\$139
Total lease expense	\$414	\$449

[illegible]

[illegible]

`<table border=`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]